

US Patent & Trademark Office

Patent Public Search | Text View

United States Patent Application Publication
Kind Code
Publication Date
Inventor(s)

20250250338
A1
August 07, 2025
BEIL; Christian et al.

TRISPECIFIC BINDING PROTEINS, METHODS, AND USES THEREOF

Abstract

Provided herein are trispecific and/or trivalent binding proteins comprising four polypeptide chains that form three antigen binding sites that specifically bind one or more target proteins, wherein a first pair of polypeptides forming the binding protein possess dual variable domains having a cross-over orientation, and wherein a second pair of polypeptides possess a single variable domain forming a single antigen binding site. In some embodiments, the binding proteins comprise a binding site that binds a CD28 polypeptide, a binding site that binds a CD3 polypeptide, and a binding site that binds a third polypeptide, such as a tumor target protein. In some embodiments, the binding proteins comprise four polypeptide chains that form three antigen binding sites that specifically bind one or more HIV target proteins. The disclosure also relates to methods for making trispecific and/or trivalent binding proteins and uses of such binding proteins.

Inventors: BEIL; Christian (Frankfurt am Main, DE), BENINGA; Jochen (Frankfurt am Main, DE), BIRKENFELD; Joerg (Frankfurt am Main, DE), NABEL; Gary J. (Cambridge, MA), QIU; Huawei (Westborough, MA), RAO; Ercole (Mörfelden-Walldorff, DE), REGULA; Joerg (Munich, DE), SEUNG; Edward (Cambridge, MA), WEI; Ronnie (Needham, MA), WU; Lan (Cambridge, MA), XING; Zhen (Cambridge, MA), XU; Ling (Cambridge, MA), YANG; Zhi-Yong (Cambridge, MA)

Applicant: Sanofi (Paris, FR)

Family ID: 74038192

Appl. No.: 19/012409

Filed: January 07, 2025

Foreign Application Priority Data

EP	19306261.9	Oct. 02, 2019
EP	19306312.0	Oct. 08, 2019

Related U.S. Application Data

parent US division 18183107 20230313 parent-grant-document US 12227573 child US 19012409
parent US division 16843792 20200408 parent-grant-document US 11613576 child US 18183107
us-provisional-application US 62831572 20190409
us-provisional-application US 62831415 20190409

Publication Classification

Int. Cl.: C07K16/28 (20060101); A61K39/395 (20060101); A61K45/06 (20060101); A61P35/00 (20060101); C07K16/32 (20060101); C07K16/46 (20060101); C12N15/63 (20060101)

U.S. Cl.:

CPC C07K16/2809 (20130101); A61K39/3955 (20130101); A61K39/39558 (20130101); A61K45/06 (20130101); A61P35/00 (20180101); C07K16/2818 (20130101); C07K16/2896 (20130101); C07K16/32 (20130101); C07K16/468 (20130101); C12N15/63 (20130101); C07K2317/31 (20130101); C07K2317/52 (20130101);

Background/Summary

CROSS REFERENCE TO RELATED APPLICATIONS [0001] This application claims priority to U.S. Provisional Application No. 62/831,572, filed Apr. 9, 2019; U.S. Provisional Application No. 62/831,415, filed Apr. 9, 2019; EP Application No. EP19306312.0, filed Oct. 8, 2019; and EP Application No. EP19306311.2, filed Oct. 8, 2019, the disclosures of each of which are incorporated herein by reference in their entirety.

SUBMISSION OF SEQUENCE LISTING ON ASCII TEXT FILE

[0002] The content of the following submission on ASCII text file is incorporated herein by reference in its entirety: a computer readable form (CRF) of the Sequence Listing (file name: 183952032000SEQLIST.TXT, date recorded: Apr. 8, 2020, size: 1,107 KB).

FIELD

[0003] The disclosure relates to trisppecific and/or trivalent binding proteins comprising four polypeptide chains that form three antigen binding sites that specifically bind one or more target proteins, wherein a first pair of polypeptides forming the binding protein possess dual variable domains having a cross-over orientation. The disclosure also relates to methods for making trisppecific and/or trivalent binding proteins and uses of such binding proteins.

BACKGROUND

[0004] Monoclonal antibody based biotherapeutics have become an important avenue for new drug development. Monoclonal antibody technology offers specific targeting, precise signaling delivery and/or payload to specific cell population, and provides long lasting biological effect through its Fc functions. Efforts in antibody engineering have allowed developing bispecific antibodies combining the specificities of two monoclonal antibodies for various biological applications, expanding the scope of antibody drug development. Newly discovered neutralizing antibodies with improved breadth and potency may provide more options for developing biotherapeutics to treat complexed diseases such as cancer, arthritis, and/or inflammatory disorders.

[0005] Immuno-oncology is a promising, emerging therapeutic approach to disease management in cancer. The immune system is the first line of defense against cancer development and progression. There is now large evidence that T cells are able to control tumor growth and prolong the survival of cancer patients in both early and late stages of disease. However, T cells specific for tumors can be limited in a number of ways preventing them from controlling the disease.

[0006] As part of the human adaptive immunity, T cell immunity plays crucial role in controlling viral infection and cancer, possibly eliminating infected cells and malignant cells which result in clearance of viral infection or cure of cancer. In chronic infectious diseases such as Herpes viral infection (HSV, CMV, EBV, etc.), HIV, and HBV, viruses establish their persistence in humans by various mechanisms including immune suppression, T cell exhaustion, and latency establishment. Nevertheless, viral infection generally induces viral antigen specific immunity including antigen specific CD8 T cells that can readily recognize infected cells for controlling or killing through cytokine release or cytotoxic T cell (CTL) mediated killing processes.

[0007] Thus, viral antigen specific T cell activation and/or amplification in vivo and/or ex vivo may provide therapeutic strategies against chronic viral infections.

[0008] Anti-retroviral therapy (ART) has been the standard of care for HIV/AIDS patients in the past decades. ART drugs target internal proteins such as reverse transcriptase (RT), integrase (IN), and viral protease (PI) by inhibiting reverse transcription of HIV-1 genome, integration of HIV-1 genome, and proteolytic cleavage of protein precursors that are necessary for the production of infectious viral particles. Treatment using ART or combination of different classes of ART results in inhibition of HIV-1 replication and subsequent reduction of viremia, often to undetectable level (aviremic status). Although ART greatly helps HIV patients in controlling their disease progression, and containing the global HIV epidemic, it does require patients taking daily medicines often following a strict regimen. About 10% patients fail therapy each year due to drug toxicity, suboptimal adherence and emerging drug resistance. As more HIV patients can live a normal life span (over 80 years), chronic complications are of particular concern, such as aging and drug-drug interaction, and cardiovascular/renal/bone toxicities. The economic burden treating HIV/AIDS has not subsided thus far.

[0009] HIV latently infects long-lived resting memory CD4⁺ T cells and others as a form of proviral DNA integrated into the host genome. The latently infected cells survive for decades and self-renew like stem cells via homeostatic proliferation, which is regarded as an HIV-1 reservoir. The HIV-1 reservoirs are neither affected by ART nor the host immune system as they do not express viral proteins. Yet, a small proportion of cells among the reservoirs are randomly reactivated by unknown mechanism(s), which are responsible for recurrence of viremia once ART is stopped.

[0010] Therefore, a need exists for developing HIV/AIDS treatments to target the HIV-1 reservoir(s), and ultimately eliminate them completely, achieving a cure, or long term remission of HIV without any further treatment. Any therapeutic strategy to eliminate the HIV-1 reservoir needs to activate the reservoir first, followed by elimination of the activated HIV-1 reservoir cells.

[0011] All references cited herein, including patent applications, patent publications, and UniProtKB/Swiss-Prot Accession numbers are herein incorporated by reference in their entirety, as if each individual reference were specifically and individually indicated to be incorporated by reference.

BRIEF SUMMARY

[0012] To meet these and other needs, provided herein are trispecific binding proteins (e.g., antibodies) that form three antigen binding sites. These binding proteins can specifically bind one, two, or three antigen targets or target proteins, such as CD28, CD3, and a tumor target protein. Some tumors express specific antigens. For example, HER2 amplification and overexpression can be found in molecular subtypes of breast cancer, and also in gastric, ovarian, lung and prostate carcinomas. Optimal activation of T cells requires two factors: 1. Antigen recognition and 2. Co-stimulation. Using the trispecific HER2/CD28xCD3 trispecific binding proteins described herein, Signal 1 is provided by an agonist anti-CD3 binding site, and Signal 2 is provided by an agonist anti-CD28 binding site. The trispecific binding protein recruits T cells to the tumor via HER2, CD38, or a binding site recognizing another tumor target protein and activates the engaged T cells via anti-CD3 and -CD28. The resulting activation induces the killing potential of the immune cells against the nearby tumor cells. In addition, anti-CD3 binding sites are described with high affinity binding to human CD3 polypeptides and potential manufacturing liabilities (e.g., deamidation sites) removed.

[0013] Further provided herein are anti-CD38/CD28xCD3 trispecific antibodies that were developed and evaluated for their potential in activating T cells, and subsequent proliferation and/or amplification of antigen specific T cells. These trispecific Abs can effectively expand CD4 and CD8 effector and memory populations, including antigen specific CD8 T central memory and effector memory cells in vitro. Specifically, in vitro expansion of CMV, EBV, HIV-1, Influenza specific CD8 central memory and effector memory cells were demonstrated. The anti-CD38/CD28xCD3 trispecific antibodies described herein exhibited novel properties by engaging CD3/CD28/CD38, providing signaling pathways to stimulate and expand T cells, which may offer an effective strategy treating chronic infectious diseases such as HSV, CMV, EBV, HIV-1, and HBV infections.

[0014] To meet these and other needs, provided herein are binding proteins that bind CD38 polypeptides (e.g., human and cynomolgus monkey CD38 polypeptides), including monospecific, bispecific, or trispecific binding proteins with at least one antigen binding site that binds a CD38 polypeptide. Advantageously, these binding proteins have the ability to recruit T cells to the proximity of cancer cells, subsequently to activate T cells and promote the activated T cells killing of adjacent cancer cells through a Granzyme/Perforin mechanism, providing a different mode of action for anti-tumor activity from anti-CD38 antibodies such as DARZALEX® (daratumumab). Moreover, the ability to bind both human and cynomolgus monkey CD38 polypeptides allows binding proteins to be readily tested in preclinical toxicological studies, e.g., to evaluate their safety profiles for later clinical use.

[0015] In some embodiments, provided herein are binding proteins comprising four polypeptide chains that form the three antigen binding sites, wherein a first polypeptide chain comprises a structure represented by the formula:

V.sub.L2-L.sub.1-V.sub.L1-L.sub.2-C.sub.L [I]

and a second polypeptide chain comprises a structure represented by the formula:

V.sub.H1-L.sub.3-V.sub.H2-L.sub.4-C.sub.H1-hinge-C.sub.H2-C.sub.H3 [II]

and a third polypeptide chain comprises a structure represented by the formula:

V.sub.H3-C.sub.H1-hinge-C.sub.H2-C.sub.H3 [III]

and a fourth polypeptide chain comprises a structure represented by the formula:

V.sub.L3-C.sub.L [IV] [0016] wherein: [0017] V.sub.L1 is a first immunoglobulin light chain variable domain; [0018] V.sub.L2 is a second immunoglobulin light chain variable domain; [0019] V.sub.L3 is a third immunoglobulin light chain variable domain; [0020] V.sub.H1 is a first immunoglobulin heavy chain variable domain; [0021] V.sub.H2 is a second immunoglobulin heavy chain variable domain; [0022] V.sub.H3 is a third immunoglobulin heavy chain variable domain; [0023] C.sub.L is an immunoglobulin light chain constant domain; [0024] C.sub.H1 is an immunoglobulin C.sub.H1 heavy chain constant domain; [0025] C.sub.H2 is an immunoglobulin C.sub.H2 heavy chain constant domain; [0026] C.sub.H3 is an immunoglobulin C.sub.H3 heavy chain constant domain; [0027] hinge is an immunoglobulin hinge region connecting the C.sub.H1 and C.sub.H2 domains; and [0028] L.sub.1, L.sub.2, L.sub.3 and L.sub.4 are amino acid linkers; [0029] wherein the polypeptide of formula I and the polypeptide of formula II form a cross-over light chain-heavy chain pair; and [0030] wherein V.sub.H1 and V.sub.L1 form a first antigen binding site; [0031] wherein V.sub.H2 and V.sub.L2 form a second antigen binding site that binds a CD3 polypeptide, [0032] wherein the V.sub.H2 domain comprises a CDR-H1 sequence comprising the amino acid sequence of GFTFTKAW (SEQ ID NO:55), a CDR-H2 sequence comprising the amino acid sequence of IKDKSNSYAT (SEQ ID NO:56), and a CDR-H3 sequence comprising the amino acid sequence of RGVYYALSPFDY (SEQ ID NO:57), and the V.sub.L2 domain comprises a CDR-L1 sequence comprising the amino acid sequence of QSLVHX.sub.1NX.sub.2X.sub.3TY, wherein X.sub.1 is E or Q, X.sub.2 is A or L, and X.sub.3 is Q, R, or F (SEQ ID NO:180), a CDR-L2 sequence comprising the amino acid sequence of KVS (SEQ ID NO:64), and a CDR-L3 sequence comprising the amino acid sequence of GQGTQYPFT (SEQ ID NO:65); and [0033] wherein V.sub.H3 and V.sub.L3 form a third antigen binding site.

[0034] In some embodiments, the first binding site binds a CD28 polypeptide. In some embodiments, the V.sub.H1 domain comprises a CDR-H1 sequence comprising the amino acid sequence of GYTFTSYY (SEQ ID NO:49), a CDR-H2 sequence comprising the amino acid sequence of IYPGNVNT (SEQ ID NO:50), and a CDR-H3 sequence comprising the amino acid sequence of TRSHYGLDWNFDV (SEQ ID NO:51), and the V.sub.L1 domain comprises a CDR-L1 sequence comprising the amino acid sequence of QNIYVW (SEQ ID NO:52), a CDR-L2 sequence comprising the amino acid sequence of KAS

(SEQ ID NO:53), and a CDR-L3 sequence comprising the amino acid sequence of QQGQTPY (SEQ ID NO:54). In some embodiments, the V.sub.H1 domain comprises the amino acid sequence of QVQLVQSGAEVVKPGASVKVCKASGYTFTSYIHVVRQAPGQGLEWIGSIYPGN VNTNYAQKFQGRATLTVDTSISTAYMELSRLSDDTAVYYCTRSHYGLDWNFDV WGKGTTVTVSS (SEQ ID NO:91), and/or the V.sub.L1 domain comprises the amino acid sequence of DIQMTQSPSSLSASVGDRVTITCQASQNIYVWLNWYQQKPGKAPKLLIYKASNLHT GVPSRFSGSGSGTDFTLTISLQPEDATYYCQQGQTPYTFGQGTKLEIK (SEQ ID NO:92).

[0035] In some embodiments, the CDR-L1 sequence of the V.sub.L2 domain comprises an amino acid sequence selected from the group consisting of QSLVHQNAQTY (SEQ ID NO:59), QSLVHENLQTY (SEQ ID NO:60), QSLVHENLFTY (SEQ ID NO:61), and QSLVHENLRTY (SEQ ID NO:62). In some embodiments, a binding protein of the present disclosure comprises an antigen binding site comprising: an antibody heavy chain variable (VH) domain comprising a CDR-H1 sequence comprising the amino acid sequence of GFTFTKAW (SEQ ID NO:55), a CDR-H2 sequence comprising the amino acid sequence of IKDKSNSYAT (SEQ ID NO:56), and a CDR-H3 sequence comprising the amino acid sequence of RGVYYALSPFDY (SEQ ID NO:57); and/or an antibody light chain variable (VL) domain comprising a CDR-L1 sequence comprising the amino acid sequence of QSLVHQNAQTY (SEQ ID NO:59), a CDR-L2 sequence comprising the amino acid sequence of KVS (SEQ ID NO:64), and a CDR-L3 sequence comprising the amino acid sequence of GQGTQYPFT (SEQ ID NO:65). In some embodiments, a binding protein of the present disclosure comprises an antigen binding site comprising: an antibody heavy chain variable (VH) domain comprising a CDR-H1 sequence comprising the amino acid sequence of GFTFTKAW (SEQ ID NO:55), a CDR-H2 sequence comprising the amino acid sequence of IKDKSNSYAT (SEQ ID NO:56), and a CDR-H3 sequence comprising the amino acid sequence of RGVYYALSPFDY (SEQ ID NO:57); and/or an antibody light chain variable (VL) domain comprising a CDR-L1 sequence comprising the amino acid sequence of QSLVHENLQTY (SEQ ID NO:60), a CDR-L2 sequence comprising the amino acid sequence of KVS (SEQ ID NO:64), and a CDR-L3 sequence comprising the amino acid sequence of GQGTQYPFT (SEQ ID NO:65). In some embodiments, a binding protein of the present disclosure comprises an antigen binding site comprising: an antibody heavy chain variable (VH) domain comprising a CDR-H1 sequence comprising the amino acid sequence of GFTFTKAW (SEQ ID NO:55), a CDR-H2 sequence comprising the amino acid sequence of IKDKSNSYAT (SEQ ID NO:56), and a CDR-H3 sequence comprising the amino acid sequence of RGVYYALSPFDY (SEQ ID NO:57); and/or an antibody light chain variable (VL) domain comprising a CDR-L1 sequence comprising the amino acid sequence of QSLVHENLFTY (SEQ ID NO:61), a CDR-L2 sequence comprising the amino acid sequence of KVS (SEQ ID NO:64), and a CDR-L3 sequence comprising the amino acid sequence of GQGTQYPFT (SEQ ID NO:65). In some embodiments, a binding protein of the present disclosure comprises an antigen binding site comprising: an antibody heavy chain variable (VH) domain comprising a CDR-H1 sequence comprising the amino acid sequence of GFTFTKAW (SEQ ID NO:55), a CDR-H2 sequence comprising the amino acid sequence of IKDKSNSYAT (SEQ ID NO:56), and a CDR-H3 sequence comprising the amino acid sequence of RGVYYALSPFDY (SEQ ID NO:57); and/or an antibody light chain variable (VL) domain comprising a CDR-L1 sequence comprising the amino acid sequence of QSLVHENLRTY (SEQ ID NO:62), a CDR-L2 sequence comprising the amino acid sequence of KVS (SEQ ID NO:64), and a CDR-L3 sequence comprising the amino acid sequence of GQGTQYPFT (SEQ ID NO:65). In some embodiments, the V.sub.H2 domain comprises the amino acid sequence of QVQLVESGGGVVQPGRSLRLSCAASGFTFTKAWMHVVRQAPGKQLEWVAQIKD KSNSYATYYADSVKGRFTISRDDSKNTLYLQMNSLRAEDTAVYYCRGVYYALSPF DYWGQGTTLTVSS (SEQ ID NO:93), and/or the V.sub.L2 domain comprises an amino acid sequence selected from the group consisting of DIVMTQTPLSLSVTPGQPASISCKSSQSLVHQNAQTYLSWYLQKPGQSPQSLIYKVS NRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCGQGTQYPFTFGSGTKVEIK (SEQ ID NO:95), DIVMTQTPLSLSVTPGQPASISCKSSQSLVHENLQTYLSWYLQKPGQSPQSLIYKVS NRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCGQGTQYPFTFGSGTKVEIK (SEQ ID NO:96), DIVMTQTPLSLSVTPGQPASISCKSSQSLVHENLFTYLSWYLQKPGQSPQSLIYKVS NRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCGQGTQYPFTFGSGTKVEIK (SEQ ID NO:97), and DIVMTQTPLSLSVTPGQPASISCKSSQSLVHENLRTYLSWYLQKPGQSPQSLIYKVS NRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCGQGTQYPFTFGSGTKVEIK (SEQ ID NO:98). In some embodiments, the V.sub.H2 domain comprises the amino acid sequence of QVQLVESGGGVVQPGRSLRLSCAASGFTFTKAWMHVVRQAPGKQLEWVAQIKD KSNSYATYYADSVKGRFTISRDDSKNTLYLQMNSLRAEDTAVYYCRGVYYALSPF DYWGQGTTLTVSS (SEQ ID NO:93) or QVQLVESGGGVVQPGRSLRLSCAASGFTFTKAWMHVVRQAPGKQLEWVAQIKD KSNSYATYYASSVKGRFTISRDDSKNTLYLQMNSLRAEDTAVYYCRGVYYALSPF DYWGQGTTLTVSS (SEQ ID NO:595), and/or the V.sub.L2 domain comprises an amino acid sequence selected from the group consisting of DIVMTQTPLSLSVTPGQPASISCKSSQSLVHQNAQTYLSWYLQKPGQSPQSLIYKVS NRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCGQGTQYPFTFGSGTKVEIK (SEQ ID NO:95), DIVMTQTPLSLSVTPGQPASISCKSSQSLVHENLQTYLSWYLQKPGQSPQSLIYKVS NRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCGQGTQYPFTFGSGTKVEIK (SEQ ID NO:96), DIVMTQTPLSLSVTPGQPASISCKSSQSLVHENLFTYLSWYLQKPGQSPQSLIYKVS NRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCGQGTQYPFTFGSGTKVEIK (SEQ ID NO:97), and DIVMTQTPLSLSVTPGQPASISCKSSQSLVHENLRTYLSWYLQKPGQSPQSLIYKVS NRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCGQGTQYPFTFGSGTKVEIK (SEQ ID NO:98). In some embodiments, a binding protein of the present disclosure comprises an antigen binding site comprising: an antibody heavy

chain variable (VH) domain comprising the amino acid sequence of SEQ ID NO:93, and/or an antibody light chain variable (VL) domain comprising the amino acid sequence of SEQ ID NO:95. In some embodiments, a binding protein of the present disclosure comprises an antigen binding site comprising: an antibody heavy chain variable (VH) domain comprising the amino acid sequence of SEQ ID NO:595, and/or an antibody light chain variable (VL) domain comprising the amino acid sequence of SEQ ID NO:95. In some embodiments, a binding protein of the present disclosure comprises an antigen binding site comprising: an antibody heavy chain variable (VH) domain comprising the amino acid sequence of SEQ ID NO:93, and/or an antibody light chain variable (VL) domain comprising the amino acid sequence of SEQ ID NO:96. In some embodiments, a binding protein of the present disclosure comprises an antigen binding site comprising: an antibody heavy chain variable (VH) domain comprising the amino acid sequence of SEQ ID NO:93, and/or an antibody light chain variable (VL) domain comprising the amino acid sequence of SEQ ID NO:97. In some embodiments, a binding protein of the present disclosure comprises an antigen binding site comprising: an antibody heavy chain variable (VH) domain comprising the amino acid sequence of SEQ ID NO:93, and/or an antibody light chain variable (VL) domain comprising the amino acid sequence of SEQ ID NO:98.

[0036] In some embodiments, the third antigen binding site binds a tumor target protein. In some embodiments, the tumor target protein is a CD38 polypeptide (e.g., a human CD38 polypeptide). In some embodiments, the tumor target protein is a HER2 polypeptide (e.g., a human HER2 polypeptide). In some embodiments, a tumor target protein of the present disclosure includes, without limitation, A2AR, APRIL, ATPDase, BAFF, BAFFR, BCMA, BlyS, BTK, BTLA, B7DC, B7H1, B7H4 (also known as VTCN1), B7H5, B7H6, B7H7, B7RP1, B7-4, C3, C5, CCL2 (also known as MCP-1), CCL3 (also known as MIP-1a), CCL4 (also known as MIP-1b), CCL5 (also known as RANTES), CCL7 (also known as MCP-3), CCL8 (also known as mcp-2), CCL11 (also known as eotaxin), CCL15 (also known as MIP-1d), CCL17 (also known as TARC), CCL19 (also known as MIP-3b), CCL20 (also known as MIP-3a), CCL21 (also known as MIP-2), CCL24 (also known as MPIF-2/eotaxin-2), CCL25 (also known as TECK), CCL26 (also known as eotaxin-3), CCR3, CCR4, CD3, CD19, CD20, CD23 (also known as FCER2, a receptor for IgE), CD24, CD27, CD28, CD38, CD39, CD40, CD70, CD80 (also known as B7-1), CD86 (also known as B7-2), CD122, CD137 (also known as 41BB), CD137L, CD152 (also known as CTLA4), CD154 (also known as CD40L), CD160, CD272, CD273 (also known as PDL2), CD274 (also known as PDL1), CD275 (also known as B7H2), CD276 (also known as B7H3), CD278 (also known as ICOS), CD279 (also known as PD-1), CDH1 (also known as E-cadherin), chitinase, CLEC9, CLEC91, CRTH2, CSF-1 (also known as M-CSF), CSF-2 (also known as GM-CSF), CSF-3 (also known as GCSF), CX3CL1 (also known as SCYD1), CXCL12 (also known as SDF1), CXCL13, CXCR3, DNGR-1, ectonucleoside triphosphate diphosphohydrolase 1, EGFR, ENTPD1, FCER1A, FCER1, FLAP, FOLH1, Gi24, GITR, GITRL, GM-CSF, Her2, HHLA2, HMGB1, HVEM, ICOSLG, IDO, IFN α , IgE, IGF1R, IL2Rbeta, IL1, IL1A, IL1B, IL1F10, IL2, IL4, IL4Ra, IL5, IL5R, IL6, IL7, IL7Ra, IL8, IL9, IL9R, IL10, rhIL10, IL12, IL13, IL13Ra1, IL13Ra2, IL15, IL17, IL17Rb (also known as a receptor for IL25), IL18, IL22, IL23, IL25, IL27, IL33, IL35, ITGB4 (also known as b4 integrin), ITK, KIR, LAG3, LAMP1, leptin, LPFS2, MHC class II, MUC-1, NCR3LG1, NKG2D, NTPDase-1, OX40, OX40L, PD-1H, platelet receptor, PROM1, S152, SISP1, SLC, SPG64, ST2 (also known as a receptor for IL33), STEAP2, Syk kinase, TACI, TDO, T14, TIGIT, TIM3, TLR, TLR2, TLR4, TLR5, TLR9, TMEF1, TNFa, TNFRSF7, Tp55, TREM1, TSLP (also known as a co-receptor for IL7Ra), TSLPR, TWEAK, VEGF, VISTA, Vstm3, WUCAM, and XCR1 (also known as GPR5/CCXCR1). In some embodiments, one or more of the above antigen targets are human antigen targets.

[0037] In some embodiments, the third antigen binding site binds a human CD38 polypeptide. In some embodiments, the V.sub.H3 domain comprises a CDR-H1 sequence comprising the amino acid sequence of GYTFTSYA (SEQ ID NO:13), a CDR-H2 sequence comprising the amino acid sequence of IYPGQGGT (SEQ ID NO:14), and a CDR-H3 sequence comprising the amino acid sequence of ARTGGLRRAYFTY (SEQ ID NO:15), and the V.sub.L3 domain comprises a CDR-L1 sequence comprising the amino acid sequence of QSVSSYGQGF (SEQ ID NO:16), a CDR-L2 sequence comprising the amino acid sequence of GAS (SEQ ID NO:17), and a CDR-L3 sequence comprising the amino acid sequence of QQNKEDPWT (SEQ ID NO:18). In some embodiments, the V.sub.H3 domain comprises a CDR-H1 sequence comprising the amino acid sequence of GYTLTEFS (SEQ ID NO:19), a CDR-H2 sequence comprising the amino acid sequence of FDPEDGET (SEQ ID NO:20), and a CDR-H3 sequence comprising the amino acid sequence of TTGRFFDWF (SEQ ID NO:21), and the V.sub.L3 domain comprises a CDR-L1 sequence comprising the amino acid sequence of QSVISRF (SEQ ID NO:22), a CDR-L2 sequence comprising the amino acid sequence of GAS (SEQ ID NO:23), and a CDR-L3 sequence comprising the amino acid sequence of QQDSNLPIT (SEQ ID NO:24). In some embodiments, the V.sub.H3 domain comprises a CDR-H1 sequence comprising the amino acid sequence of GYAFTTYL (SEQ ID NO:25), a CDR-H2 sequence comprising the amino acid sequence of INPGSGST (SEQ ID NO:26), and a CDR-H3 sequence comprising the amino acid sequence of ARYAYGY (SEQ ID NO:27), and the V.sub.L3 domain comprises a CDR-L1 sequence comprising the amino acid sequence of QNVGTA (SEQ ID NO:28), a CDR-L2 sequence comprising the amino acid sequence of SAS (SEQ ID NO:29), and a CDR-L3 sequence comprising the amino acid sequence of QQYSTYPFT (SEQ ID NO:30). In some embodiments, the V.sub.H3 domain comprises a CDR-H1 sequence comprising the amino acid sequence of GYSFTNYA (SEQ ID NO:31), a CDR-H2 sequence comprising the amino acid sequence of ISPYYGDT (SEQ ID NO:32), and a CDR-H3 sequence comprising the amino acid sequence of ARRFEGFYYSMDY (SEQ ID NO:33), and the V.sub.L3 domain comprises a CDR-L1 sequence comprising the amino acid sequence of QSLVHSNGNTY (SEQ ID NO:34), a CDR-L2 sequence comprising the amino acid sequence of KVS (SEQ ID NO:35), and a CDR-L3 sequence comprising the amino acid sequence of SQSTHVPLT (SEQ ID NO:36).

[0038] In some embodiments, the V.sub.H3 domain comprises a CDR-H1 sequence comprising the amino acid sequence of GFTFSSYG (SEQ ID NO:37), a CDR-H2 sequence comprising the amino acid sequence of IWYDGSNK (SEQ ID NO:38), and a CDR-H3 sequence comprising the amino acid sequence of ARDPGLRYFDGGMDV (SEQ ID NO:39), and the

V.sub.L3 domain comprising a CDR-L1 sequence comprising the amino acid sequence of QGISSY (SEQ ID NO:40), a CDR-L2 sequence comprising the amino acid sequence of AAS (SEQ ID NO:41), and a CDR-L3 sequence comprising the amino acid sequence of QQLNSFPYT (SEQ ID NO:42). In some embodiments, the V.sub.H3 domain comprises a CDR-H1 sequence comprising the amino acid sequence of GFTFSSYG (SEQ ID NO:43), a CDR-H2 sequence comprising the amino acid sequence of IWYDGSNK (SEQ ID NO:44), and a CDR-H3 sequence comprising the amino acid sequence of ARMFRGAFDY (SEQ ID NO:45), and the V.sub.L3 domain comprises a CDR-L1 sequence comprising the amino acid sequence of QGIRND (SEQ ID NO:46), a CDR-L2 sequence comprising the amino acid sequence of AAS (SEQ ID NO:47), and a CDR-L3 sequence comprising the amino acid sequence of LQDYIYYPT (SEQ ID NO:48). In some embodiments, the V.sub.H3 domain comprises the amino acid sequence of QVQLVQSGAEVVKPGASVKVSKASGYTFTSYAMHWVKEAPGQRLEWIGYIYPG QGGTNYNQKFQGRATLTADTSASTAYMELSSLRSED TAVYFCARTGGLRRAYFTY WGQGT LVT VSS (SEQ ID NO:79), and/or the V.sub.L3 domain comprises the amino acid sequence of DIVLTQSPATLSLSPGERATISCRASQSVSSYGQGMHWYQQKPGQPPRLLIYGASS RATGIPARFSGSGSGTDFTLTISP LEPEDFAVYYCQ QNKEDPWTFGGGTKLEIK (SEQ ID NO:80). In some embodiments, the V.sub.H3 domain comprises the amino acid sequence of QVQLVQSGAEVKKPGASVKVSKVSGYTLTEFSIHWVRQAPGQGLEWMGGFDPE DGETIYAQKFQGRVIMTEDTSTDTAYMEMNSLRSED TAIYYCTTGRFFDWFVGQG TLVT VSS (SEQ ID NO:81), and/or the V.sub.L3 domain comprises the amino acid sequence of EIILTQSPAILSLSPGERATLSRASQSVISRFLSWYQVKPGLAPRLLIYGASTRATGIP VRFSGSGSGTDFTSLTISSLQPEDCAVYYCQ QDSNLPITFGQGTRLEIK (SEQ ID NO:82). In some embodiments, the V.sub.H3 domain comprises the amino acid sequence of QVQLVQSGAEVKKPGASVKVSKASGYAFTTYLV EWIRQRP GQGLEWMGVINPG SGTSTNYAQKFQGRVTMTVDRSSTTAYMELSR LRSDDTAVYYCARYAYGYWGQG TLVT VSS (SEQ ID NO:83), and/or the V.sub.L3 domain comprises the amino acid sequence of DIQMTQSPSSLSASVGDRTITCRASQNVGTAVAWYQQKPGKSPKQLIYSASNRYT GVPSRFSGSGSGTDFTLTISLQPEDLATYYCQ QYSTYPFTFGQGTKLEIK (SEQ ID NO:84). In some embodiments, the V.sub.H3 domain comprises the amino acid sequence of QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGM YWVRQAPGKGLEWVAVIWYD GSNKYYADSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYHCARDPGLRYFDGG MDVWGQGT TTVTVSS (SEQ ID NO:87), and/or the V.sub.L3 domain comprises the amino acid sequence of DIQLTQSPSFLSASVGDRTITCRASQGISSYLA WYQQKPGKAPKLLIFAASTLHSG VPSRFSGSGSGTEFTLTISLQPEDFATYYCQQL NSFPYTFGQGTKLEIK (SEQ ID NO:88). In some embodiments, the V.sub.H3 domain comprises the amino acid sequence of QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGM HWVRQAPGKGLEWVAVIWYD GSNKYYADSVKGRFTISGDN SKNTLYLQMNSLRAEDTAVYYCARMFRGAFDYWG QGT LVT VSS (SEQ ID NO:89), and/or the V.sub.L3 domain comprises the amino acid sequence of AIQMTQSPSSLSASVGDRTITCRASQGIRNDLG WYQQKPGKAPKLLIYAASSLQS GVPSRFSGSGSGTDFTLTISGLQPEDSATYYCL QDYIYYPTFGQGTKVEIK (SEQ ID NO:90). In some embodiments, the V.sub.H3 domain comprises the amino acid sequence of QVQLVQSGAEVKKPGASVKVSKASGYSTNYAVH WVRQAPGQGLEWMGVISPY YGDTTYAQKFQGRVTMTVDKSSSTAYMELSR LRSDDTAVYYCARRFEGFYYSMD YWGQGT LVT VSS (SEQ ID NO:85), and/or the V.sub.L3 domain comprises the amino acid sequence of DVVMTQSPLSLPVTLGQPASISCRPSQSLVHSN GNTYLNWYQRP GQSPKLLIYKV SKRFSGV PDRFSGSGSGTDFTLKISRVEAEDVGVYYCSQSTHVPLTFGGGTKVEIK (SEQ ID NO:86).

[0039] In some embodiments, the first polypeptide chain comprises the amino acid sequence of SEQ ID NO:156 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:156; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO:157 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:157; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO:158 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:158; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO:159 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:159. In some embodiments, the first polypeptide chain comprises the amino acid sequence of SEQ ID NO:160 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:160; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO:161 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:161; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO:162 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:162; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO:163 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:163. In some embodiments, the first polypeptide chain comprises the amino acid sequence of SEQ ID NO:164 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:164; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO:165 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:165; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO:166 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:166; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO:167 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID

and a CDR-H3 sequence comprising the amino acid sequence of SRWGGEGFYAMDY (SEQ ID NO:7), and the V.sub.L3 domain comprises a CDR-L1 sequence comprising the amino acid sequence of QDVNTA (SEQ ID NO:9), a CDR-L2 sequence comprising the amino acid sequence of SAS (SEQ ID NO:11), and a CDR-L3 sequence comprising the amino acid sequence of QQHYTTP (SEQ ID NO:12). In some embodiments, the V.sub.H3 domain comprises a CDR-H1 sequence comprising the amino acid sequence of GFNIKDTY (SEQ ID NO:1), a CDR-H2 sequence comprising the amino acid sequence of IYPTNGYT (SEQ ID NO:3), and a CDR-H3 sequence comprising the amino acid sequence of SRWGGDGFYAMDY (SEQ ID NO:6), and the V.sub.L3 domain comprises a CDR-L1 sequence comprising the amino acid sequence of QDVQTA (SEQ ID NO:10), a CDR-L2 sequence comprising the amino acid sequence of SAS (SEQ ID NO:11), and a CDR-L3 sequence comprising the amino acid sequence of QQHYTTP (SEQ ID NO:12). In some embodiments, the V.sub.H3 domain comprises the amino acid sequence of

EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTN
GYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDY WGQGTLLTVSS (SEQ ID NO:72), EVQLVESGGGLVQPGGSLRLSCAASGFNIRDYIHWVRQAPGKGLEWVARIYPTQ
GYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGEGFYAMDY WGQGTLLTVSS (SEQ ID NO:73), EVQLVESGGGLVQPGGSLRLSCAASGFNIRDYIHWVRQAPGKGLEWVARIYPTQ
GYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGSGFYAMDY WGQGTLLTVSS (SEQ ID NO:74), EVQLVESGGGLVQPGGSLRLSCAASGFNIRDYIHWVRQAPGKGLEWVARIYPTN
AYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGSGFYAMDY WGQGTLLTVSS (SEQ ID NO:75), or EVQLVESGGGLVQPGGSLRLSCAASGFNIRDYIHWVRQAPGKGLEWVARIYPTN
AYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGEGFYAMDY WGQGTLLTVSS (SEQ ID NO:76), and/or the V.sub.L3 domain comprises the amino acid sequence of
DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYS
GVPSRFSGSRSGTDFTLTISLQPEDFATYYCQQHYTTPPTFGQGTKVEIK (SEQ ID NO:77) or
DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYS
GVPSRFSGSRSGTDFTLTISLQPEDFATYYCQQHYTTPPTFGQGTKVEIK (SEQ ID NO:78). In some embodiments, the V.sub.H3 domain comprises the amino acid sequence of
EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTN
GYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDY WGQGTLLTVSS (SEQ ID NO:72), and/or the V.sub.L3 domain comprises the amino acid sequence of
DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYS
GVPSRFSGSRSGTDFTLTISLQPEDFATYYCQQHYTTPPTFGQGTKVEIK (SEQ ID NO:77). In some embodiments, the V.sub.H3 domain comprises the amino acid sequence of
EVQLVESGGGLVQPGGSLRLSCAASGFNIRDYIHWVRQAPGKGLEWVARIYPTQ
GYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGEGFYAMDY WGQGTLLTVSS (SEQ ID NO:73), and/or the V.sub.L3 domain comprises the amino acid sequence of
DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYS
GVPSRFSGSRSGTDFTLTISLQPEDFATYYCQQHYTTPPTFGQGTKVEIK (SEQ ID NO:77). In some embodiments, the V.sub.H3 domain comprises the amino acid sequence of
EVQLVESGGGLVQPGGSLRLSCAASGFNIRDYIHWVRQAPGKGLEWVARIYPTN
AYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGSGFYAMDY WGQGTLLTVSS (SEQ ID NO:75), and/or the V.sub.L3 domain comprises the amino acid sequence of
DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYS
GVPSRFSGSRSGTDFTLTISLQPEDFATYYCQQHYTTPPTFGQGTKVEIK (SEQ ID NO:77). In some embodiments, the V.sub.H3 domain comprises the amino acid sequence of
EVQLVESGGGLVQPGGSLRLSCAASGFNIRDYIHWVRQAPGKGLEWVARIYPTQ
GYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGSGFYAMDY WGQGTLLTVSS (SEQ ID NO:74), and/or the V.sub.L3 domain comprises the amino acid sequence of
DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYS
GVPSRFSGSRSGTDFTLTISLQPEDFATYYCQQHYTTPPTFGQGTKVEIK (SEQ ID NO:77). In some embodiments, the V.sub.H3 domain comprises the amino acid sequence of
EVQLVESGGGLVQPGGSLRLSCAASGFNIRDYIHWVRQAPGKGLEWVARIYPTN
AYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGEGFYAMDY WGQGTLLTVSS (SEQ ID NO:76), and/or the V.sub.L3 domain comprises the amino acid sequence of
DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYS
GVPSRFSGSRSGTDFTLTISLQPEDFATYYCQQHYTTPPTFGQGTKVEIK (SEQ ID NO:77). In some embodiments, the V.sub.H3 domain comprises the amino acid sequence of
EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTN
GYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDY WGQGTLLTVSS (SEQ ID NO:72), and/or the V.sub.L3 domain comprises the amino acid sequence of
DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYS
GVPSRFSGSRSGTDFTLTISLQPEDFATYYCQQHYTTPPTFGQGTKVEIK (SEQ ID NO:78).

[0041] In some embodiments, the first polypeptide chain comprises the amino acid sequence of SEQ ID NO:100 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:100; the second polypeptide chain

[illegible]

of SEQ ID NO:144; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO:145 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:145; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO:146 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:146; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO:147 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:147. In some embodiments, the first polypeptide chain comprises the amino acid sequence of SEQ ID NO:148 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:148; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO:149 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:149; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO:150 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:150; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO:151 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:151. In some embodiments, the first polypeptide chain comprises the amino acid sequence of SEQ ID NO:152 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:152; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO:153 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:153; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO:154 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:154; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO:155 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:155. In some embodiments, the first polypeptide chain comprises the amino acid sequence of SEQ ID NO:286 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:286; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO:287 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:287; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO:288 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:288; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO:289 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:289. In some embodiments, the first polypeptide chain comprises the amino acid sequence of SEQ ID NO:290 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:290; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO:291 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:291; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO:292 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:292; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO:293 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:293. In some embodiments, the first polypeptide chain comprises the amino acid sequence of SEQ ID NO:294 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:294; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO:295 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:295; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO:296 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:296; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO:297 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:297. In some embodiments, the first polypeptide chain comprises the amino acid sequence of SEQ ID NO:298 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:298; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO:299 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:299; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO:300 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:300; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO:301 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:301.

[0042] In some embodiments that may be combined with any other embodiments described herein, at least one of L.sub.1, L.sub.2, L.sub.3 or L.sub.4 is independently 0 amino acids in length. In some embodiments, L.sub.1, L.sub.2, L.sub.3 and L.sub.4 each independently are zero amino acids in length or comprise a sequence selected from the group consisting of GGGGSGGGGS (SEQ ID NO:69), GGGGSGGGSGGGGS (SEQ ID NO:70), S, RT, TKGPS (SEQ ID NO:68), GQPKAAP (SEQ ID NO:67), and GSGSSGSGG (SEQ ID NO:71). In some embodiments, L.sub.1, L.sub.2, L.sub.3 and L.sub.4 each independently comprise a sequence selected from the group consisting of GGGGSGGGGS (SEQ ID NO:69), GGGGSGGGSGGGGS (SEQ ID NO:70), S, RT, TKGPS (SEQ ID NO:68), GQPKAAP (SEQ ID NO:67), and GSGSSGSGG (SEQ ID NO:71). In some embodiments, L.sub.1 comprises the sequence GQPKAAP (SEQ ID NO:67), L.sub.2 comprises the sequence TKGPS (SEQ ID NO:68), L.sub.3 comprises the sequence S, and L.sub.4 comprises the sequence RT. In some embodiments, at least one of L.sub.1, L.sub.2, L.sub.3 or L.sub.4 comprises the sequence DKTHT (SEQ ID NO:66). In some embodiments, L.sub.1, L.sub.2, L.sub.3 and L.sub.4 comprise the sequence DKTHT (SEQ ID NO:66).

[0043] In some embodiments that may be combined with any other embodiments described herein, the hinge-C.sub.H2-C.sub.H3 domains of the second and the third polypeptide chains are human IgG4 hinge-C.sub.H2-C.sub.H3 domains, and wherein the hinge-C.sub.H2-C.sub.H3 domains each comprise amino acid substitutions at positions corresponding to positions 234 and 235 of human IgG4 according to EU Index, wherein the amino acid substitutions are F234A and L235A. In some embodiments, the hinge-C.sub.H2-C.sub.H3 domains of the second and the third polypeptide chains are human IgG4 hinge-C.sub.H2-C.sub.H3 domains, and wherein the hinge-C.sub.H2-C.sub.H3 domains each comprise amino acid substitutions at positions corresponding to positions 233-236 of human IgG4 according to EU Index, wherein the amino acid substitutions are E233P, F234V, L235A, and a deletion at 236. In some embodiments, the hinge-C.sub.H2-C.sub.H3 domains

of the second and the third polypeptide chains are human IgG4 hinge-C.sub.H2-C.sub.H3 domains, and wherein the hinge-C.sub.H2-C.sub.H3 domains each comprise amino acid substitutions at positions corresponding to positions 228 and 409 of human IgG4 according to EU Index, wherein the amino acid substitutions are S228P and R409K. In some embodiments, the hinge-C.sub.H2-C.sub.H3 domains of the second and the third polypeptide chains are human IgG1 hinge-C.sub.H2-C.sub.H3 domains, and wherein the hinge-C.sub.H2-C.sub.H3 domains each comprise amino acid substitutions at positions corresponding to positions 234, 235, and 329 of human IgG1 according to EU Index, wherein the amino acid substitutions are L234A, L235A, and P329A. In some embodiments, the hinge-C.sub.H2-C.sub.H3 domains of the second and the third polypeptide chains are human IgG1 hinge-C.sub.H2-C.sub.H3 domains, and wherein the hinge-C.sub.H2-C.sub.H3 domains each comprise amino acid substitutions at positions corresponding to positions 298, 299, and 300 of human IgG1 according to EU Index, wherein the amino acid substitutions are S298N, T299A, and Y300S. In some embodiments, the hinge-C.sub.H2-C.sub.H3 domain of the second polypeptide chain comprises amino acid substitutions at positions corresponding to positions 349, 366, 368, and 407 of human IgG1 or IgG4 according to EU Index, wherein the amino acid substitutions are Y349C, T366S, L368A, and Y407V; and wherein the hinge-C.sub.H2-C.sub.H3 domain of the third polypeptide chain comprises amino acid substitutions at positions corresponding to positions 354 and 366 of human IgG1 or IgG4 according to EU Index, wherein the amino acid substitutions are S354C and T366W. In some embodiments, the hinge-C.sub.H2-C.sub.H3 domain of the second polypeptide chain comprises amino acid substitutions at positions corresponding to positions 354 and 366 of human IgG1 or IgG4 according to EU Index, wherein the amino acid substitutions are S354C and T366W; and wherein the hinge-C.sub.H2-C.sub.H3 domain of the third polypeptide chain comprises amino acid substitutions at positions corresponding to positions 349, 366, 368, and 407 of human IgG1 or IgG4 according to EU Index, wherein the amino acid substitutions are Y349C, T366S, L368A, and Y407V.

[0044] In some embodiments, provided herein are isolated nucleic acid molecules comprising a nucleotide sequence encoding the binding protein of any one of the above embodiments. In some embodiments, provided herein are expression vectors comprising the nucleic acid molecule of any one of the above embodiments. In some embodiments, provided herein are isolated host cells comprising the nucleic acid molecule of any one of the above embodiments or the expression vector of any one of the above embodiments. In some embodiments, the host cell is a mammalian or insect cell.

[0045] In some embodiments, provided herein are pharmaceutical compositions comprising the binding protein of any one of the above embodiments and a pharmaceutically acceptable carrier.

[0046] In some embodiments, provided herein are methods of preventing and/or treating cancer in a patient comprising administering to the patient a therapeutically effective amount of at least one binding protein or pharmaceutical composition of any one of the above embodiments. In some embodiments, provided herein is a binding protein or pharmaceutical composition according to any one of the above embodiments for use in a method of preventing and/or treating cancer in a patient, wherein the method comprises administering to the patient a therapeutically effective amount of the binding protein or pharmaceutical composition. In some embodiments, provided herein is a binding protein or pharmaceutical composition according to any one of the above embodiments for use in manufacturing a medicament for preventing and/or treating cancer in a patient.

[0047] In some embodiments, the at least one binding protein is co-administered with a chemotherapeutic agent. In some embodiments, the patient is a human.

[0048] In some embodiments, the third antigen binding site binds a human CD38 polypeptide, and wherein cancer cells from the individual or patient express CD38. In some embodiments, the cancer is multiple myeloma. In some embodiments, the cancer is acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), or a B cell lymphoma. In some embodiments, prior to administration of the binding protein, the patient has been treated with daratumumab without a wash-out period.

[0049] In some embodiments, the third antigen binding site binds a human HER2 polypeptide, and wherein cancer cells from the individual or patient express HER2. In some embodiments, the cancer is breast cancer, colorectal cancer, gastric cancer, or non-small cell lung cancer (NSCLC).

[0050] In some embodiments, provided herein is a method for expanding virus-specific memory T cells, comprising contacting a virus-specific memory T cell with a binding protein, wherein the binding protein comprises four polypeptide chains that form the three antigen binding sites, wherein a first polypeptide chain comprises a structure represented by the formula:

V.sub.L2-L.sub.1-V.sub.L1-L.sub.2-C.sub.L [I]

and a second polypeptide chain comprises a structure represented by the formula:

V.sub.H1-L.sub.3-V.sub.H2-L.sub.4-C.sub.H1-hinge-C.sub.H2-C.sub.H3 [II]

and a third polypeptide chain comprises a structure represented by the formula:

V.sub.H3-C.sub.H1-hinge-C.sub.H2-C.sub.H3 [III]

and a fourth polypeptide chain comprises a structure represented by the formula:

V.sub.L3-C.sub.L [IV] [0051] wherein: [0052] V.sub.L1 is a first immunoglobulin light chain variable domain; [0053] V.sub.L2 is a second immunoglobulin light chain variable domain; [0054] V.sub.L3 is a third immunoglobulin light chain variable domain; [0055] V.sub.H1 is a first immunoglobulin heavy chain variable domain; [0056] V.sub.H2 is a second immunoglobulin heavy chain variable domain; [0057] V.sub.H3 is a third immunoglobulin heavy chain variable domain;

[0058] C.sub.L is an immunoglobulin light chain constant domain; [0059] C.sub.H1 is an immunoglobulin C.sub.H1 heavy chain constant domain; [0060] C.sub.H2 is an immunoglobulin C.sub.H2 heavy chain constant domain; [0061] C.sub.H3 is an immunoglobulin C.sub.H3 heavy chain constant domain; [0062] hinge is an immunoglobulin hinge region connecting the C.sub.H1 and C.sub.H2 domains; and [0063] L.sub.1, L.sub.2, L.sub.3 and L.sub.4 are amino acid linkers; [0064] wherein the polypeptide of formula I and the polypeptide of formula II form a cross-over light chain-heavy chain pair; and [0065] wherein V.sub.H1 and V.sub.L1 form a first antigen binding site that binds a CD28 polypeptide, wherein V.sub.H2 and V.sub.L2 form a second antigen binding site that binds a CD3 polypeptide, wherein the V.sub.H2 domain comprises a CDR-H1 sequence comprising the amino acid sequence of GFTFTKAW (SEQ ID NO:55), a CDR-H2 sequence comprising the amino acid sequence of IKDKSNSYAT (SEQ ID NO:56), and a CDR-H3 sequence comprising the amino acid sequence of RGVYYALSPFDY (SEQ ID NO:57), and the V.sub.L2 domain comprises a CDR-L1 sequence comprising the amino acid sequence of QSLVHX.sub.1NX.sub.2X.sub.3TY, wherein X.sub.1 is E or Q, X.sub.2 is A or L, and X.sub.3 is Q, R, or F (SEQ ID NO:180), a CDR-L2 sequence comprising the amino acid sequence of KVS (SEQ ID NO:64), and a CDR-L3 sequence comprising the amino acid sequence of GQGTQYPFT (SEQ ID NO:65), and wherein V.sub.H3 and V.sub.L3 form a third antigen binding site that binds a CD38 polypeptide.

[0066] In some embodiments, provided herein is a binding protein that comprises four polypeptide chains that form the three antigen binding sites, wherein a first polypeptide chain comprises a structure represented by the formula:

V.sub.L2-L.sub.1-V.sub.L1-L.sub.2-C.sub.L [I]

and a second polypeptide chain comprises a structure represented by the formula:

V.sub.H1-L.sub.3-V.sub.H2-L.sub.4-C.sub.H1-hinge-C.sub.H2-C.sub.H3 [II]

and a third polypeptide chain comprises a structure represented by the formula:

V.sub.H3-C.sub.H1-hinge-C.sub.H2-C.sub.H3 [III]

and a fourth polypeptide chain comprises a structure represented by the formula:

V.sub.L3-C.sub.L [IV] [0067] wherein: [0068] V.sub.L1 is a first immunoglobulin light chain variable domain; [0069] V.sub.L2 is a second immunoglobulin light chain variable domain; [0070] V.sub.L3 is a third immunoglobulin light chain variable domain; [0071] V.sub.H1 is a first immunoglobulin heavy chain variable domain; [0072] V.sub.H2 is a second immunoglobulin heavy chain variable domain; [0073] V.sub.H3 is a third immunoglobulin heavy chain variable domain; [0074] C.sub.L is an immunoglobulin light chain constant domain; [0075] C.sub.H1 is an immunoglobulin C.sub.H1 heavy chain constant domain; [0076] C.sub.H2 is an immunoglobulin C.sub.H2 heavy chain constant domain; [0077] C.sub.H3 is an immunoglobulin C.sub.H3 heavy chain constant domain; [0078] hinge is an immunoglobulin hinge region connecting the C.sub.H1 and C.sub.H2 domains; and [0079] L.sub.1, L.sub.2, L.sub.3 and L.sub.4 are amino acid linkers; [0080] wherein the polypeptide of formula I and the polypeptide of formula II form a cross-over light chain-heavy chain pair; and [0081] wherein V.sub.H1 and V.sub.L1 form a first antigen binding site that binds a CD28 polypeptide, wherein V.sub.H2 and V.sub.L2 form a second antigen binding site that binds a CD3 polypeptide, wherein the V.sub.H2 domain comprises a CDR-H1 sequence comprising the amino acid sequence of GFTFTKAW (SEQ ID NO:55), a CDR-H2 sequence comprising the amino acid sequence of IKDKSNSYAT (SEQ ID NO:56), and a CDR-H3 sequence comprising the amino acid sequence of RGVYYALSPFDY (SEQ ID NO:57), and the V.sub.L2 domain comprises a CDR-L1 sequence comprising the amino acid sequence of QSLVHX.sub.1NX.sub.2X.sub.3TY, wherein X.sub.1 is E or Q, X.sub.2 is A or L, and X.sub.3 is Q, R, or F (SEQ ID NO:180), a CDR-L2 sequence comprising the amino acid sequence of KVS (SEQ ID NO:64), and a CDR-L3 sequence comprising the amino acid sequence of GQGTQYPFT (SEQ ID NO:65), and wherein V.sub.H3 and V.sub.L3 form a third antigen binding site that binds a CD38 polypeptide for use in expanding virus-specific memory T cells.

[0082] In some embodiments, the virus-specific memory T cell is contacted with the binding protein in vitro or ex vivo. In some embodiments, contacting the virus-specific memory T cell with the binding protein causes activation and/or proliferation of virus-specific memory T cells.

[0083] In some embodiments, provided herein is a method for expanding T cells, comprising contacting a T cell with a binding protein in vitro or ex vivo, wherein the binding protein comprises four polypeptide chains that form the three antigen binding sites, wherein a first polypeptide chain comprises a structure represented by the formula:

V.sub.L2-L.sub.1-V.sub.L1-L.sub.2-C.sub.L [I]

and a second polypeptide chain comprises a structure represented by the formula:

V.sub.H1-L.sub.3-V.sub.H2-L.sub.4-C.sub.H1-hinge-C.sub.H2-C.sub.H3 [II]

and a third polypeptide chain comprises a structure represented by the formula:

V.sub.H3-C.sub.H1-hinge-C.sub.H2-C.sub.H3 [III]

and a fourth polypeptide chain comprises a structure represented by the formula:

V.sub.L3-C.sub.L [IV] [0084] wherein: [0085] V.sub.L1 is a first immunoglobulin light chain variable domain; [0086] V.sub.L2 is a second immunoglobulin light chain variable domain; [0087] V.sub.L3 is a third immunoglobulin light chain variable domain; [0088] V.sub.H1 is a first immunoglobulin heavy chain variable domain; [0089] V.sub.H2 is a second

immunoglobulin heavy chain variable domain; [0090] V.sub.H3 is a third immunoglobulin heavy chain variable domain; [0091] C.sub.L is an immunoglobulin light chain constant domain; [0092] C.sub.H1 is an immunoglobulin C.sub.H1 heavy chain constant domain; [0093] C.sub.H2 is an immunoglobulin C.sub.H2 heavy chain constant domain; [0094] C.sub.H3 is an immunoglobulin C.sub.H3 heavy chain constant domain; [0095] hinge is an immunoglobulin hinge region connecting the C.sub.H1 and C.sub.H2 domains; and [0096] L.sub.1, L.sub.2, L.sub.3 and L.sub.4 are amino acid linkers; [0097] wherein the polypeptide of formula I and the polypeptide of formula II form a cross-over light chain-heavy chain pair; and [0098] wherein V.sub.H1 and V.sub.L1 form a first antigen binding site that binds a CD28 polypeptide, wherein V.sub.H2 and V.sub.L2 form a second antigen binding site that binds a CD3 polypeptide, wherein the V.sub.H2 domain comprises a CDR-H1 sequence comprising the amino acid sequence of GFTFTKAW (SEQ ID NO:55), a CDR-H2 sequence comprising the amino acid sequence of IKDKSNSYAT (SEQ ID NO:56), and a CDR-H3 sequence comprising the amino acid sequence of RGVYYALSPFDY (SEQ ID NO:57), and the V.sub.L2 domain comprises a CDR-L1 sequence comprising the amino acid sequence of QSLVHX.sub.1NX.sub.2X.sub.3TY, wherein X.sub.1 is E or Q, X.sub.2 is A or L, and X.sub.3 is Q, R, or F (SEQ ID NO:180), a CDR-L2 sequence comprising the amino acid sequence of KVS (SEQ ID NO:64), and a CDR-L3 sequence comprising the amino acid sequence of GQGTQYPFT (SEQ ID NO:65), and wherein V.sub.H3 and V.sub.L3 form a third antigen binding site that binds a CD38 polypeptide.

[0099] In some embodiments, provided herein is a binding protein that comprises four polypeptide chains that form the three antigen binding sites, wherein a first polypeptide chain comprises a structure represented by the formula:

V.sub.L2-L.sub.1-V.sub.L1-L.sub.2-C.sub.L [I]

and a second polypeptide chain comprises a structure represented by the formula:

V.sub.H1-L.sub.3-V.sub.H2-L.sub.4-C.sub.H1-hinge-C.sub.H2-C.sub.H3 [II]

and a third polypeptide chain comprises a structure represented by the formula:

V.sub.H3-C.sub.H1-hinge-C.sub.H2-C.sub.H3 [III]

and a fourth polypeptide chain comprises a structure represented by the formula:

V.sub.L3-C.sub.L [IV] [0100] wherein: [0101] V.sub.L1 is a first immunoglobulin light chain variable domain; [0102] V.sub.L2 is a second immunoglobulin light chain variable domain; [0103] V.sub.L3 is a third immunoglobulin light chain variable domain; [0104] V.sub.H1 is a first immunoglobulin heavy chain variable domain; [0105] V.sub.H2 is a second immunoglobulin heavy chain variable domain; [0106] V.sub.H3 is a third immunoglobulin heavy chain variable domain; [0107] C.sub.L is an immunoglobulin light chain constant domain; [0108] C.sub.H1 is an immunoglobulin C.sub.H1 heavy chain constant domain; [0109] C.sub.H2 is an immunoglobulin C.sub.H2 heavy chain constant domain; [0110] C.sub.H3 is an immunoglobulin C.sub.H3 heavy chain constant domain; [0111] hinge is an immunoglobulin hinge region connecting the C.sub.H1 and C.sub.H2 domains; and [0112] L.sub.1, L.sub.2, L.sub.3 and L.sub.4 are amino acid linkers; [0113] wherein the polypeptide of formula I and the polypeptide of formula II form a cross-over light chain-heavy chain pair; and [0114] wherein V.sub.H1 and V.sub.L1 form a first antigen binding site that binds a CD28 polypeptide, wherein V.sub.H2 and V.sub.L2 form a second antigen binding site that binds a CD3 polypeptide, wherein the V.sub.H2 domain comprises a CDR-H1 sequence comprising the amino acid sequence of GFTFTKAW (SEQ ID NO:55), a CDR-H2 sequence comprising the amino acid sequence of IKDKSNSYAT (SEQ ID NO:56), and a CDR-H3 sequence comprising the amino acid sequence of RGVYYALSPFDY (SEQ ID NO:57), and the V.sub.L2 domain comprises a CDR-L1 sequence comprising the amino acid sequence of QSLVHX.sub.1NX.sub.2X.sub.3TY, wherein X.sub.1 is E or Q, X.sub.2 is A or L, and X.sub.3 is Q, R, or F (SEQ ID NO:180), a CDR-L2 sequence comprising the amino acid sequence of KVS (SEQ ID NO:64), and a CDR-L3 sequence comprising the amino acid sequence of GQGTQYPFT (SEQ ID NO:65), and wherein V.sub.H3 and V.sub.L3 form a third antigen binding site that binds a CD38 polypeptide for use in a method for expanding T cells.

[0115] In some embodiments, the T cell is a memory T cell or an effector T cell. In some embodiments, the T cell expresses a chimeric antigen receptor (CAR) on its cell surface or comprises a polynucleotide encoding a CAR.

[0116] In some embodiments, provided herein is a method for treating chronic viral infection, comprising administering to an individual or patient in need thereof an effective amount of a binding protein, wherein the binding protein comprises four polypeptide chains that form the three antigen binding sites, wherein a first polypeptide chain comprises a structure represented by the formula:

V.sub.L2-L.sub.1-V.sub.L1-L.sub.2-C.sub.L [I]

and a second polypeptide chain comprises a structure represented by the formula:

V.sub.H1-L.sub.3-V.sub.H2-L.sub.4-C.sub.H1-hinge-C.sub.H2-C.sub.H3 [II]

and a third polypeptide chain comprises a structure represented by the formula:

V.sub.H3-C.sub.H1-hinge-C.sub.H2-C.sub.H3 [III]

and a fourth polypeptide chain comprises a structure represented by the formula:

V.sub.L3-C.sub.L [IV] [0117] wherein: [0118] V.sub.L1 is a first immunoglobulin light chain variable domain; [0119] V.sub.L2 is a second immunoglobulin light chain variable domain; [0120] V.sub.L3 is a third immunoglobulin light chain

variable domain; [0121] V.sub.H1 is a first immunoglobulin heavy chain variable domain; [0122] V.sub.H2 is a second immunoglobulin heavy chain variable domain; [0123] V.sub.H3 is a third immunoglobulin heavy chain variable domain; [0124] C.sub.L is an immunoglobulin light chain constant domain; [0125] C.sub.H1 is an immunoglobulin C.sub.H1 heavy chain constant domain; [0126] C.sub.H2 is an immunoglobulin C.sub.H2 heavy chain constant domain; [0127] C.sub.H3 is an immunoglobulin C.sub.H3 heavy chain constant domain; [0128] hinge is an immunoglobulin hinge region connecting the C.sub.H1 and C.sub.H2 domains; and [0129] L.sub.1, L.sub.2, L.sub.3 and L.sub.4 are amino acid linkers; [0130] wherein the polypeptide of formula I and the polypeptide of formula II form a cross-over light chain-heavy chain pair; and [0131] wherein V.sub.H1 and V.sub.L1 form a first antigen binding site that binds a CD28 polypeptide, wherein V.sub.H2 and V.sub.L2 form a second antigen binding site that binds a CD3 polypeptide, wherein the V.sub.H2 domain comprises a CDR-H1 sequence comprising the amino acid sequence of GFTFTKAW (SEQ ID NO:55), a CDR-H2 sequence comprising the amino acid sequence of IKDKSNSYAT (SEQ ID NO:56), and a CDR-H3 sequence comprising the amino acid sequence of RGVYYALSPFDY (SEQ ID NO:57), and the V.sub.L2 domain comprises a CDR-L1 sequence comprising the amino acid sequence of QSLVHX.sub.1NX.sub.2X.sub.3TY, wherein X.sub.1 is E or Q, X.sub.2 is A or L, and X.sub.3 is Q, R, or F (SEQ ID NO:180), a CDR-L2 sequence comprising the amino acid sequence of KVS (SEQ ID NO:64), and a CDR-L3 sequence comprising the amino acid sequence of GQGTQYPFT (SEQ ID NO:65), and wherein V.sub.H3 and V.sub.L3 form a third antigen binding site that binds a CD38 polypeptide.

[0132] In some embodiments, provided herein is a binding protein that comprises four polypeptide chains that form the three antigen binding sites, wherein a first polypeptide chain comprises a structure represented by the formula:

V.sub.L2-L.sub.1-V.sub.L1-L.sub.2-C.sub.L [I]

and a second polypeptide chain comprises a structure represented by the formula:

V.sub.H1-L.sub.3-V.sub.H2-L.sub.4-C.sub.H1-hinge-C.sub.H2-C.sub.H3 [II]

and a third polypeptide chain comprises a structure represented by the formula:

V.sub.H3-C.sub.H1-hinge-C.sub.H2-C.sub.H3 [III]

and a fourth polypeptide chain comprises a structure represented by the formula:

V.sub.L3-C.sub.L [IV] [0133] wherein: [0134] V.sub.L1 is a first immunoglobulin light chain variable domain; [0135] V.sub.L2 is a second immunoglobulin light chain variable domain; [0136] V.sub.L3 is a third immunoglobulin light chain variable domain; [0137] V.sub.H1 is a first immunoglobulin heavy chain variable domain; [0138] V.sub.H2 is a second immunoglobulin heavy chain variable domain; [0139] V.sub.H3 is a third immunoglobulin heavy chain variable domain; [0140] C.sub.L is an immunoglobulin light chain constant domain; [0141] C.sub.H1 is an immunoglobulin C.sub.H1 heavy chain constant domain; [0142] C.sub.H2 is an immunoglobulin C.sub.H2 heavy chain constant domain; [0143] C.sub.H3 is an immunoglobulin C.sub.H3 heavy chain constant domain; [0144] hinge is an immunoglobulin hinge region connecting the C.sub.H1 and C.sub.H2 domains; and [0145] L.sub.1, L.sub.2, L.sub.3 and L.sub.4 are amino acid linkers; [0146] wherein the polypeptide of formula I and the polypeptide of formula II form a cross-over light chain-heavy chain pair; and [0147] wherein V.sub.H1 and V.sub.L1 form a first antigen binding site that binds a CD28 polypeptide, wherein V.sub.H2 and V.sub.L2 form a second antigen binding site that binds a CD3 polypeptide, wherein the V.sub.H2 domain comprises a CDR-H1 sequence comprising the amino acid sequence of GFTFTKAW (SEQ ID NO:55), a CDR-H2 sequence comprising the amino acid sequence of IKDKSNSYAT (SEQ ID NO:56), and a CDR-H3 sequence comprising the amino acid sequence of RGVYYALSPFDY (SEQ ID NO:57), and the V.sub.L2 domain comprises a CDR-L1 sequence comprising the amino acid sequence of QSLVHX.sub.1NX.sub.2X.sub.3TY, wherein X.sub.1 is E or Q, X.sub.2 is A or L, and X.sub.3 is Q, R, or F (SEQ ID NO:180), a CDR-L2 sequence comprising the amino acid sequence of KVS (SEQ ID NO:64), and a CDR-L3 sequence comprising the amino acid sequence of GQGTQYPFT (SEQ ID NO:65), and wherein V.sub.H3 and V.sub.L3 form a third antigen binding site that binds a CD38 polypeptide for use in a method for treating chronic viral infection, wherein said method comprises administering to an individual or patient in need thereof an effective amount of the binding protein. [0148] In some embodiments, the individual or patient is a human. In some embodiments, the binding protein is administered to the individual or patient in pharmaceutical formulation comprising the binding protein and a pharmaceutically acceptable carrier. In some embodiments, administration of the binding protein results in activation and/or proliferation of virus-specific memory T cells in the individual or patient.

[0149] In some embodiments that may be combined with any other embodiments described herein, the memory T cells are CD8+ or CD4+ memory T cells. In some embodiments, the memory T cells are central memory T cells (T.sub.CM) or effector memory T cells (T.sub.EM).

[0150] In some embodiments that may be combined with any other embodiments described herein, the virus is a human immunodeficiency virus (HIV), influenza virus, cytomegalovirus (CMV), hepatitis B virus (HBV), human papillomavirus (HPV), Epstein-barr virus (EBV), human foamy virus (HFV), herpes simplex virus 1 (HSV-1), or herpes simplex virus 1 (HSV-2).

[0151] In some embodiments that may be combined with any other embodiments described herein, the CD28 polypeptide is a human CD28 polypeptide, wherein the CD3 polypeptide is a human CD3 polypeptide, and wherein the CD38 polypeptide is a human CD38 polypeptide.

[0152] In some embodiments, provided herein is a vector system comprising one or more vectors encoding a first, second, third, and fourth polypeptide chain of a binding protein of any one of the above embodiments. In some embodiments, the

comprising the polynucleotide sequence of SEQ ID NO:265, a second polynucleotide comprising the polynucleotide sequence of SEQ ID NO:266, a third polynucleotide comprising the polynucleotide sequence of SEQ ID NO:267, and a fourth polynucleotide comprising the polynucleotide sequence of SEQ ID NO:268; (u) a first polynucleotide comprising the polynucleotide sequence of SEQ ID NO:269, a second polynucleotide comprising the polynucleotide sequence of SEQ ID NO:270, a third polynucleotide comprising the polynucleotide sequence of SEQ ID NO:271, and a fourth polynucleotide comprising the polynucleotide sequence of SEQ ID NO:272; or (v) a first polynucleotide comprising the polynucleotide sequence of SEQ ID NO:273, a second polynucleotide comprising the polynucleotide sequence of SEQ ID NO:274, a third polynucleotide comprising the polynucleotide sequence of SEQ ID NO:275, and a fourth polynucleotide comprising the polynucleotide sequence of SEQ ID NO:276.

[0155] To meet these and other needs, further provided herein are multispecific binding proteins (e.g., antibodies) that form three antigen binding sites, e.g., binding proteins that bind one or more HIV target proteins and a CD3 polypeptide, or an HIV target protein, a CD28 polypeptide, and a CD3 polypeptide. The trispecific anti-HIV/CD28xCD3 T cell engager (TCE) concept disclosed herein is thought to be an effective eliminator of the HIV-1 reservoir through activation by anti-CD3, co-activation by anti-CD28, and subsequent killing of activated HIV-1 reservoir cells through anti-HIV/anti-CD28 by engaging activated CD8 T cells, providing a potential strategy for attacking the HIV-1 reservoir. In addition, anti-CD3 binding sites are described with high affinity binding to human CD3 polypeptides and potential manufacturing liabilities (e.g., deamidation sites) removed.

[0156] In some embodiments, provided herein are binding proteins comprising four polypeptide chains that form the three antigen binding sites that specifically bind one or more HIV target proteins, wherein a first polypeptide chain comprises a structure represented by the formula:

V.sub.L2-L.sub.1-V.sub.L1-L.sub.2-C.sub.L [I]

and a second polypeptide chain comprises a structure represented by the formula:

V.sub.H1-L.sub.3-V.sub.H2-L.sub.4-C.sub.H1-hinge-C.sub.H2-C.sub.H3 [II]

and a third polypeptide chain comprises a structure represented by the formula:

V.sub.H3-C.sub.H1-hinge-C.sub.H2-C.sub.H3 [III]

and a fourth polypeptide chain comprises a structure represented by the formula:

V.sub.L3-C.sub.L [IV] [0157] wherein: [0158] V.sub.L1 is a first immunoglobulin light chain variable domain; [0159] V.sub.L2 is a second immunoglobulin light chain variable domain; [0160] V.sub.L3 is a third immunoglobulin light chain variable domain; [0161] V.sub.H1 is a first immunoglobulin heavy chain variable domain; [0162] V.sub.H2 is a second immunoglobulin heavy chain variable domain; [0163] V.sub.H3 is a third immunoglobulin heavy chain variable domain; [0164] C.sub.L is an immunoglobulin light chain constant domain; [0165] C.sub.H1 is an immunoglobulin C.sub.H1 heavy chain constant domain; [0166] C.sub.H2 is an immunoglobulin C.sub.H2 heavy chain constant domain; [0167] C.sub.H3 is an immunoglobulin C.sub.H3 heavy chain constant domain; [0168] hinge is an immunoglobulin hinge region connecting the C.sub.H1 and C.sub.H2 domains; and [0169] L.sub.1, L.sub.2, L.sub.3 and L.sub.4 are amino acid linkers; [0170] wherein the polypeptide of formula I and the polypeptide of formula II form a cross-over light chain-heavy chain pair; [0171] wherein V.sub.H1 and V.sub.L1 form a first antigen binding site; [0172] wherein V.sub.H2 and V.sub.L2 form a second antigen binding site that binds a CD3 polypeptide, wherein the V.sub.H2 domain comprises a CDR-H1 sequence comprising the amino acid sequence of GFTFTKAW (SEQ ID NO:321), a CDR-H2 sequence comprising the amino acid sequence of IKDKSNSYAT (SEQ ID NO:322), and a CDR-H3 sequence comprising the amino acid sequence of RGVYYALSPFDY (SEQ ID NO:323), and the V.sub.L2 domain comprises a CDR-L.sub.1 sequence comprising the amino acid sequence of QSLVHX.sub.1NX.sub.2X.sub.3TY, wherein X.sub.1 is E or Q, X.sub.2 is A or L, and X.sub.3 is Q, R, or F (SEQ ID NO:594), a CDR-L2 sequence comprising the amino acid sequence of KVS (SEQ ID NO:330), and a CDR-L3 sequence comprising the amino acid sequence of GQGTYYPFT (SEQ ID NO:331); and [0173] wherein V.sub.H3 and V.sub.L3 form a third antigen binding site that binds an HIV target protein.

[0174] In some embodiments, the first binding site binds a CD28 polypeptide (e.g., a human CD28 polypeptide). In some embodiments, the V.sub.H1 domain comprises a CDR-H1 sequence comprising the amino acid sequence of GYTFTSY (SEQ ID NO:332), a CDR-H2 sequence comprising the amino acid sequence of IYPGNVNT (SEQ ID NO:333), and a CDR-H3 sequence comprising the amino acid sequence of TRSHYGLDWNFDV (SEQ ID NO:334), and the V.sub.L1 domain comprises a CDR-L1 sequence comprising the amino acid sequence of QNIYVW (SEQ ID NO:335), a CDR-L2 sequence comprising the amino acid sequence of KAS (SEQ ID NO:336), and a CDR-L3 sequence comprising the amino acid sequence of QQGQTYPY (SEQ ID NO:337). In some embodiments, the V.sub.H1 domain comprises the amino acid sequence of QVQLVQSGAEVVKPGASVKVSKASGYTFTSYIHWVRQAPGQGLEWIGSIYPGN VNTNYAQKFQGRATLTVDTSISTAYMELSRRLRSDDTAVYYCTRSHYGLDWNFDV WGKGTTVTVSS (SEQ ID NO:360), and/or the V.sub.L1 domain comprises the amino acid sequence of DIQMTQSPSSLSASVGRVTITCQASQNIYVWLNWYQKPGKAPKLLIYKASNLHT GVPSRFSGSGSGTDFTLTISSLQPEDIATYYCQQGQTYPYTFGQGKLEIK (SEQ ID NO:361).

[0175] In some embodiments, the CDR-L1 sequence of the V.sub.L2 domain comprises an amino acid sequence selected from the group consisting of QSLVHQNAQTY (SEQ ID NO:325), QSLVHENLQTY (SEQ ID NO:326), QSLVHENLFTY (SEQ ID NO:327), and QSLVHENLRTY (SEQ ID NO:328). In some embodiments, the V.sub.H2 domain comprises: an

antibody heavy chain variable (VH) domain comprising a CDR-H1 sequence comprising the amino acid sequence of GFTFTKAW (SEQ ID NO:321), a CDR-H2 sequence comprising the amino acid sequence of IKDKSNSYAT (SEQ ID NO:322), and a CDR-H3 sequence comprising the amino acid sequence of RGVYYALSPFDY (SEQ ID NO:323); and the V.sub.L2 domain comprises a CDR-L1 sequence comprising the amino acid sequence of QSLVHQNATY (SEQ ID NO:325), a CDR-L2 sequence comprising the amino acid sequence of KVS (SEQ ID NO:330), and a CDR-L3 sequence comprising the amino acid sequence of GQGTQYPFT (SEQ ID NO:331). In some embodiments, the V.sub.H2 domain comprises: a CDR-H1 sequence comprising the amino acid sequence of GFTFTKAW (SEQ ID NO:321), a CDR-H2 sequence comprising the amino acid sequence of IKDKSNSYAT (SEQ ID NO:322), and a CDR-H3 sequence comprising the amino acid sequence of RGVYYALSPFDY (SEQ ID NO:323); and the V.sub.L2 domain comprises a CDR-L1 sequence comprising the amino acid sequence of QSLVHENLQTY (SEQ ID NO:326), a CDR-L2 sequence comprising the amino acid sequence of KVS (SEQ ID NO:330), and a CDR-L3 sequence comprising the amino acid sequence of GQGTQYPFT (SEQ ID NO:331). In some embodiments, the V.sub.H2 domain comprises: a CDR-H1 sequence comprising the amino acid sequence of GFTFTKAW (SEQ ID NO:321), a CDR-H2 sequence comprising the amino acid sequence of IKDKSNSYAT (SEQ ID NO:322), and a CDR-H3 sequence comprising the amino acid sequence of RGVYYALSPFDY (SEQ ID NO:323); and the V.sub.L2 domain comprises a CDR-L1 sequence comprising the amino acid sequence of QSLVHENLFTY (SEQ ID NO:327), a CDR-L2 sequence comprising the amino acid sequence of KVS (SEQ ID NO:330), and a CDR-L3 sequence comprising the amino acid sequence of GQGTQYPFT (SEQ ID NO:331). In some embodiments, the V.sub.H2 domain comprises: a CDR-H1 sequence comprising the amino acid sequence of GFTFTKAW (SEQ ID NO:321), a CDR-H2 sequence comprising the amino acid sequence of IKDKSNSYAT (SEQ ID NO:322), and a CDR-H3 sequence comprising the amino acid sequence of RGVYYALSPFDY (SEQ ID NO:323); and the V.sub.L2 domain comprises a CDR-L1 sequence comprising the amino acid sequence of QSLVHENLRTY (SEQ ID NO:328), a CDR-L2 sequence comprising the amino acid sequence of KVS (SEQ ID NO:330), and a CDR-L3 sequence comprising the amino acid sequence of GQGTQYPFT (SEQ ID NO:331). In some embodiments, the V.sub.H2 domain comprises the amino acid sequence of QVQLVESGGGVVQPGKSLRLSQAASGFTFTKAWMHVVRQAPGKQLEWVAQIKDKSNSYATYYADSVKGRFTISRDDSKNTLYLQMNSLR AEDTAVYYCRGVYYALSPFDYWGQGTLVTVSS (SEQ ID NO:353), and/or the V.sub.L2 domain comprises an amino acid sequence selected from the group consisting of DIVMTQTPLSLSVTPGQPASISCKSSQSLVHQNATYLSWYLQKPGQSPQSLIYKVS NRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCGQGTQYPFTFGSGTKVEIK (SEQ ID NO:355), DIVMTQTPLSLSVTPGQPASISCKSSQSLVHENLQTYLSWYLQKPGQSPQSLIYKVS NRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCGQGTQYPFTFGSGTKVEIK (SEQ ID NO:356), DIVMTQTPLSLSVTPGQPASISCKSSQSLVHENLFTYLSWYLQKPGQSPQSLIYKVS NRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCGQGTQYPFTFGSGTKVEIK (SEQ ID NO:357), and DIVMTQTPLSLSVTPGQPASISCKSSQSLVHENLRTYLSWYLQKPGQSPQSLIYKVS NRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCGQGTQYPFTFGSGTKVEIK (SEQ ID NO:358). In some embodiments, a binding protein of the present disclosure comprises an antigen binding site comprising: an antibody heavy chain variable (VH) domain comprising the amino acid sequence of SEQ ID NO:353, and/or an antibody light chain variable (VL) domain comprising the amino acid sequence of SEQ ID NO:355. In some embodiments, a binding protein of the present disclosure comprises an antigen binding site comprising: an antibody heavy chain variable (VH) domain comprising the amino acid sequence of SEQ ID NO:353, and/or an antibody light chain variable (VL) domain comprising the amino acid sequence of SEQ ID NO:356. In some embodiments, a binding protein of the present disclosure comprises an antigen binding site comprising: an antibody heavy chain variable (VH) domain comprising the amino acid sequence of SEQ ID NO:353, and/or an antibody light chain variable (VL) domain comprising the amino acid sequence of SEQ ID NO:357. In some embodiments, a binding protein of the present disclosure comprises an antigen binding site comprising: an antibody heavy chain variable (VH) domain comprising the amino acid sequence of SEQ ID NO:353, and/or an antibody light chain variable (VL) domain comprising the amino acid sequence of SEQ ID NO:358.

[0176] In some embodiments, the third antigen binding site binds an HIV target protein selected from the group consisting of glycoprotein 120, glycoprotein 41 and glycoprotein 160. In some embodiments, the V.sub.H3 domain comprises a CDR-H1 sequence comprising the amino acid sequence of NCPIN (SEQ ID NO:302) a CDR-H2 sequence comprising the amino acid sequence of WMKPRHGA VSYARQLQG (SEQ ID NO:303), and a CDR-H3 sequence comprising the amino acid sequence of GKYCTARDYYNWDFEH (SEQ ID NO:304), and the V.sub.L3 domain comprises a CDR-L1 sequence comprising the amino acid sequence of RTSQYGLA (SEQ ID NO:305), a CDR-L2 sequence comprising the amino acid sequence of SGSTRAA (SEQ ID NO:306), and a CDR-L3 sequence comprising the amino acid sequence of QQYEF (SEQ ID NO:307). In some embodiments, the V.sub.H3 domain comprises a CDR-H1 sequence comprising the amino acid sequence of GYTFTAH (SEQ ID NO:308) a CDR-H2 sequence comprising the amino acid sequence of IKPQYGAV (SEQ ID NO:309) or IKPQYGAT (SEQ ID NO:310), and a CDR-H3 sequence comprising the amino acid sequence of DRSYGDSSWALDA (SEQ ID NO:311), and the V.sub.L3 domain comprises a CDR-L1 sequence comprising the amino acid sequence of QGVGSD (SEQ ID NO:312), a CDR-L2 sequence comprising the amino acid sequence of HTS (SEQ ID NO:313), and a CDR-L3 sequence comprising the amino acid sequence of CQVLQF (SEQ ID NO:314). In some embodiments, the V.sub.H3 domain comprises a CDR-H1 sequence comprising the amino acid sequence of DCTLN (SEQ ID NO:315) a CDR-H2 sequence comprising the amino acid sequence of WLKPRWGAVNYARPLQG (SEQ ID NO:316), and a CDR-H3 sequence comprising the amino acid sequence of GKNCDYNWDFEH (SEQ ID NO:317), and the V.sub.L3 domain comprises a CDR-L1 sequence comprising the amino acid sequence of RTSQYGLA (SEQ ID NO:318), a CDR-L2 sequence comprising the amino acid sequence of SGSTRAA (SEQ ID NO:319), and a CDR-L3 sequence comprising the amino acid sequence of

QYEF (SEQ ID NO:320). In some embodiments, the V.sub.H3 domain comprises the amino acid sequence of QVRLSQSGGQMKKPGDSMRISCRASGYEFINCPINWIRLAPGKRPEWMGWMKPRH GAVSYARQLQGRVTMTRDMYSETAFLELRSLTSDDTAVYFCTRGKYCTARDYYN WDFEHWGQGTPVTVSS (SEQ ID NO:344), and/or the V.sub.L3 domain comprises the amino acid sequence of SLTQSPGTLSSLPGETAIIISCRTSQYGSRAWYQQRPGQAPRLVIYSGSTRAAGIPDRF SGRWGPDPYNTISNLESGDFGVYYCQQYEFFGQGTKVQVDIK (SEQ ID NO:346). In some embodiments, the V.sub.H3 domain comprises the amino acid sequence of QVRLSQSGGQMKKPGDSMRISCRASGYEFINCPINWIRLAPGKRPEWMGWMKPRH GAVSYARQLQGRVTMTRQLSQDPDDPDWGTAFLERSLTSDDTAVYFCTRGKYC TARDYYNWDFEHWGQGTPVTVSS (SEQ ID NO:345), and/or the V.sub.L3 domain comprises the amino acid sequence of SLTQSPGTLSSLPGETAIIISCRTSQYGSRAWYQQRPGQAPRLVIYSGSTRAAGIPDRF SGRWGPDPYNTISNLESGDFGVYYCQQYEFFGQGTKVQVDIK (SEQ ID NO:346). In some embodiments, the V.sub.H3 domain comprises the amino acid sequence of RAHLVQSGTAMKKPGASVRVSCQTSGYTFTAHLFWFRQAPGRGLEWVGWIKPQ YGAVNFGGGFRDRVTLTRDVYREIAYMDIRGLKPDDTAVYYCARDRSYGDSSWA LDAWGQGTTVVSA (SEQ ID NO:347), and/or the V.sub.L3 domain comprises the amino acid sequence of YIHVTQSPSSLSVIGDRVITNCQTSQGVGSDLHWYQHKPGRAPKLLIHHTSSVEDG VPSRFGSGFHTSFNLTISDLQADDIATYYCQVLQFFGRGSRLHIK (SEQ ID NO:350). In some embodiments, the V.sub.H3 domain comprises the amino acid sequence of RAHLVQSGTAMKKPGASVRVSCQTSGYTFTAHLFWFRQAPGRGLEWVGWIKPQ YGATNFGGGFRDRVTLTRDVYREIAYMDIRGLKPDDTAVYYCARDRSYGDSSWA LDAWGQGTTVVSA (SEQ ID NO:348), and/or the V.sub.L3 domain comprises the amino acid sequence of YIHVTQSPSSLSVIGDRVITNCQTSQGVGSDLHWYQHKPGRAPKLLIHHTSSVEDG VPSRFGSGFHTSFNLTISDLQADDIATYYCQVLQFFGRGSRLHIK (SEQ ID NO:350). In some embodiments, the V.sub.H3 domain comprises the amino acid sequence of RAHLVQSGTAMKKPGASVRVSCQTSGYTFTAHLFWFRQAPGRGLEWVGWIKPQ YGAVNFGGGFRDRVTLTRQLSQDPDDPDWGIAIYMDIRGLKPDDTAVYYCARDRS YGDSSWALDAWGQGTTVVSA (SEQ ID NO:349), and/or the V.sub.L3 domain comprises the amino acid sequence of YIHVTQSPSSLSVIGDRVITNCQTSQGVGSDLHWYQHKPGRAPKLLIHHTSSVEDG VPSRFGSGFHTSFNLTISDLQADDIATYYCQVLQFFGRGSRLHIK (SEQ ID NO:350). In some embodiments, the V.sub.H3 domain comprises the amino acid sequence of QVQLVQSGGQMKKPGESMRISCRASGYEFIDCTLNWIRLAPGKRPEWMGWLKPR WGAVNYARPLQGRVTMTRQLSQDPDDPDWGTAFLERSLTVDDTAVYFCTRGKN CDYNWDFEHWGRGTPVIVSS (SEQ ID NO:351), and/or the V.sub.L3 domain comprises the amino acid sequence of LTQSPGTLSSLPGETAIIISCRTSQYGSRAWYQQRPGQAPRLVIYSGSTRAAGIPDRFS GSRWGPDPYNTISNLESGDFGVYYCQQYEFFGQGTKVQVDIK (SEQ ID NO:352).

[0177] In some embodiments that may be combined with any other embodiments described herein, at least one of L.sub.1, L.sub.2, L.sub.3 or L.sub.4 is independently 0 amino acids in length. In some embodiments, L.sub.1, L.sub.2, L.sub.3 and L.sub.4 each independently are zero amino acids in length or comprise a sequence selected from the group consisting of GGGGSGGGGS (SEQ ID NO:341), GGGGSGGGSGGGGS (SEQ ID NO:342), S, RT, TKGPS (SEQ ID NO:340), GQPKAAP (SEQ ID NO:339), and GSGSSSGSGG (SEQ ID NO:343). In some embodiments, L.sub.1, L.sub.2, L.sub.3 and L.sub.4 each independently comprise a sequence selected from the group consisting of GGGGSGGGGS (SEQ ID NO:341), GGGGSGGGSGGGGS (SEQ ID NO:342), S, RT, TKGPS (SEQ ID NO:340), GQPKAAP (SEQ ID NO:339), and GSGSSSGSGG (SEQ ID NO:343). In some embodiments, L.sub.1 comprises the sequence GQPKAAP (SEQ ID NO:339), L.sub.2 comprises the sequence TKGPS (SEQ ID NO:340), L.sub.3 comprises the sequence S, and L.sub.4 comprises the sequence RT. In some embodiments, at least one of L.sub.1, L.sub.2, L.sub.3 or L.sub.4 comprises the sequence DKTHT (SEQ ID NO:338). In some embodiments, L.sub.1, L.sub.2, L.sub.3 and L.sub.4 comprise the sequence DKTHT (SEQ ID NO:338).

[0178] In some embodiments that may be combined with any other embodiments described herein, the hinge-C.sub.H2-C.sub.H3 domains of the second and the third polypeptide chains are human IgG4 hinge-C.sub.H2-C.sub.H3 domains, and wherein the hinge-C.sub.H2-C.sub.H3 domains each comprise amino acid substitutions at positions corresponding to positions 234 and 235 of human IgG4 according to EU Index, wherein the amino acid substitutions are F234A and L235A. In some embodiments, the hinge-C.sub.H2-C.sub.H3 domains of the second and the third polypeptide chains are human IgG4 hinge-C.sub.H2-C.sub.H3 domains, and wherein the hinge-C.sub.H2-C.sub.H3 domains each comprise amino acid substitutions at positions corresponding to positions 233-236 of human IgG4 according to EU Index, wherein the amino acid substitutions are E233P, F234V, L235A, and a deletion at 236. In some embodiments, the hinge-C.sub.H2-C.sub.H3 domains of the second and the third polypeptide chains are human IgG4 hinge-C.sub.H2-C.sub.H3 domains, and wherein the hinge-C.sub.H2-C.sub.H3 domains each comprise amino acid substitutions at positions corresponding to positions 228 and 409 of human IgG4 according to EU Index, wherein the amino acid substitutions are S228P and R409K. In some embodiments, the hinge-C.sub.H2-C.sub.H3 domains of the second and the third polypeptide chains are human IgG1 hinge-C.sub.H2-C.sub.H3 domains, and wherein the hinge-C.sub.H2-C.sub.H3 domains each comprise amino acid substitutions at positions corresponding to positions 234, 235, and 329 of human IgG1 according to EU Index, wherein the amino acid substitutions are L234A, L235A, and P329A. In some embodiments, the hinge-C.sub.H2-C.sub.H3 domains of the second and the third

[illegible]

[illegible]

polypeptide chain comprises the amino acid sequence of SEQ ID NO:477 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:477.

[0180] In some embodiments, provided herein are isolated nucleic acid molecules comprising a nucleotide sequence encoding the binding protein of any one of the above embodiments. In some embodiments, provided herein are expression vectors comprising the nucleic acid molecule of any one of the above embodiments. In some embodiments, provided herein are isolated host cells comprising the nucleic acid molecule of any one of the above embodiments or the expression vector of any one of the above embodiments. In some embodiments, the host cell is a mammalian or insect cell.

[0181] In some embodiments, provided herein are pharmaceutical compositions comprising the binding protein of any one of the above embodiments and a pharmaceutically acceptable carrier.

[0182] In some embodiments, provided herein are methods of preventing and/or treating HIV infection in a patient comprising administering to the patient a therapeutically effective amount of at least one binding protein of any one of the above embodiments or the pharmaceutical composition of any one of the above embodiments. In some embodiments, the binding protein is co-administered with standard anti-retroviral therapy. In some embodiments, administration of the at least one binding protein results in the elimination of one or more latently and/or chronically HIV-infected cells in the patient. In some embodiments, the patient is a human.

[0183] In some embodiments, the binding protein or pharmaceutical composition of any one of the above embodiments is provided for the prevention and/or treatment of HIV infection in a patient. In some embodiments, the binding protein is to be co-administered with standard anti-retroviral therapy. In some embodiments, the binding protein causes the elimination of one or more latently and/or chronically HIV-infected cells in the patient. In some embodiments, the patient is a human.

[0184] In some embodiments, the binding protein or pharmaceutical composition of any one of the above embodiments is provided for use in the manufacture of a medicament for the prevention and/or treatment of HIV infection in a patient. In some embodiments, the binding protein is to be co-administered with standard anti-retroviral therapy. In some embodiments, the binding protein causes the elimination of one or more latently and/or chronically HIV-infected cells in the patient. In some embodiments, the patient is a human.

[0185] In some embodiments, provided herein is a vector system comprising one or more vectors encoding a first, second, third, and fourth polypeptide chain of a binding protein of any one of the above embodiments. In some embodiments, the vector system comprises a first vector encoding the first polypeptide chain of the binding protein, a second vector encoding the second polypeptide chain of the binding protein, a third vector encoding the third polypeptide chain of the binding protein, and a fourth vector encoding the fourth polypeptide chain of the binding protein.

[0186] In some embodiments, provided herein are kits comprising one, two, three, or four polypeptide chains of a binding protein according to any one of the above embodiments. In some embodiments, the kits further comprise instructions for using the polypeptide chain or binding protein according to any of the methods or uses described herein, e.g., supra.

[0187] In some embodiments, provided herein are kits comprising one, two, three, or four polynucleotides according to any one of the above embodiments. In some embodiments, provided herein are kits of polynucleotides comprising one, two, three, or four polynucleotides of a kit of polynucleotides comprising: (a) a first polynucleotide comprising the polynucleotide sequence of SEQ ID NO:478, a second polynucleotide comprising the polynucleotide sequence of SEQ ID NO:479, a third polynucleotide comprising the polynucleotide sequence of SEQ ID NO:480, and a fourth polynucleotide comprising the polynucleotide sequence of SEQ ID NO:481; (b) a first polynucleotide comprising the polynucleotide sequence of SEQ ID NO:482, a second polynucleotide comprising the polynucleotide sequence of SEQ ID NO:483, a third polynucleotide comprising the polynucleotide sequence of SEQ ID NO:484, and a fourth polynucleotide comprising the polynucleotide sequence of SEQ ID NO:485; (c) a first polynucleotide comprising the polynucleotide sequence of SEQ ID NO:486, a second polynucleotide comprising the polynucleotide sequence of SEQ ID NO:487, a third polynucleotide comprising the polynucleotide sequence of SEQ ID NO:488, and a fourth polynucleotide comprising the polynucleotide sequence of SEQ ID NO:489; (d) a first polynucleotide comprising the polynucleotide sequence of SEQ ID NO:490, a second polynucleotide comprising the polynucleotide sequence of SEQ ID NO:491, a third polynucleotide comprising the polynucleotide sequence of SEQ ID NO:492, and a fourth polynucleotide comprising the polynucleotide sequence of SEQ ID NO:493; (e) a first polynucleotide comprising the polynucleotide sequence of SEQ ID NO:494, a second polynucleotide comprising the polynucleotide sequence of SEQ ID NO:495, a third polynucleotide comprising the polynucleotide sequence of SEQ ID NO:496, and a fourth polynucleotide comprising the polynucleotide sequence of SEQ ID NO:497; (f) a first polynucleotide comprising the polynucleotide sequence of SEQ ID NO:498, a second polynucleotide comprising the polynucleotide sequence of SEQ ID NO:499, a third polynucleotide comprising the polynucleotide sequence of SEQ ID NO:500, and a fourth polynucleotide comprising the polynucleotide sequence of SEQ ID NO:501; (g) a first polynucleotide comprising the polynucleotide sequence of SEQ ID NO:502, a second polynucleotide comprising the polynucleotide sequence of SEQ ID NO:503, a third polynucleotide comprising the polynucleotide sequence of SEQ ID NO:504, and a fourth polynucleotide comprising the polynucleotide sequence of SEQ ID NO:505; (h) a first polynucleotide comprising the polynucleotide sequence of SEQ ID NO:506, a second polynucleotide comprising the polynucleotide sequence of SEQ ID NO:507, a third polynucleotide comprising the polynucleotide sequence of SEQ ID NO:508, and a fourth polynucleotide comprising the polynucleotide sequence of SEQ ID NO:509; (i) a first polynucleotide comprising the polynucleotide sequence of SEQ ID NO:510, a second polynucleotide comprising the polynucleotide sequence of SEQ ID NO:511, a third polynucleotide comprising the polynucleotide sequence of SEQ ID NO:512, and a fourth polynucleotide comprising the polynucleotide sequence of SEQ ID NO:513; (j) a first polynucleotide comprising the polynucleotide sequence of SEQ ID NO:514, a second polynucleotide comprising the polynucleotide sequence of SEQ ID NO:515, a third polynucleotide comprising the polynucleotide sequence of SEQ ID NO:516, and a fourth polynucleotide comprising the polynucleotide sequence of SEQ ID

[0188] It is to be understood that one, some, or all of the properties of the various embodiments described herein may be combined to form other embodiments of the present invention. These and other aspects of the invention will become apparent to one of skill in the art. These and other embodiments of the invention are further described by the detailed description that follows.

BRIEF DESCRIPTION OF THE DRAWINGS

[0189] FIG. 1A provides a schematic representation of a trispecific binding protein comprising four polypeptide chains that form three antigen binding sites that binds three target proteins: CD28, CD3, and HER2. A first pair of polypeptides possess dual variable domains having a cross-over orientation (VH1-VH2 and VL2-VL1) forming two antigen binding sites that recognize CD3 and CD28, and a second pair of polypeptides possess a single variable domain (VH3 and VL3) forming a single antigen binding site that recognizes HER2. The trispecific binding protein shown in FIG. 1A uses a constant region with a “knobs-into-holes” mutation, where the knob is on the second pair of polypeptides with a single variable domain.

[0190] FIG. 1B provides the fold change (vs. parental) in binding affinities of anti-CD28/CD3/HER2 trispecific antibody variants using the indicated anti-HER2, anti-CD3, and anti-CD28 binding domains. Mutations 3233QQ to QEQ (top to bottom) refer to mutations introduced into residues 32-35 of the VL domain of the anti-CD3 binding site (indicated by *); the remaining mutations were introduced into the VH or VL domain of the trastuzumab anti-HER2 binding site (indicated by #; numbering according to Kabat). For the mutations in the anti-HER2 binding site, mutation 30Q was introduced into the VL domain, and the remaining mutations were introduced into the VH domain. The binding affinities were measured by ELISA, and the values provided are relative to parental trispecific antibody.

[0191] FIG. 1C provides binding curves for the indicated trispecific antibodies binding to human HER2, human CD28, and CD3, as determined by ELISA.

[0192] FIG. 1D provides a proposed mechanism of action for HER2/CD28xCD3 trispecific antibody-mediated T cell activation and HER2+ cancer cell killing.

[0193] FIG. 2A provides a schematic representation of a trispecific binding protein comprising four polypeptide chains that form three antigen binding sites that binds three target proteins: CD28, CD3, and CD38. A first pair of polypeptides possess dual variable domains having a cross-over orientation (VH1-VH2 and VL2-VL1) forming two antigen binding sites that recognize CD3 and CD28, and a second pair of polypeptides possess a single variable domain (VH3 and VL3) forming a single antigen binding site that recognizes CD38. The trispecific binding protein shown in FIG. 2A uses an IgG4 constant region with a “knobs-into-holes” mutation, where the knob is on the second pair of polypeptides with a single variable domain.

[0194] FIGS. 2B-2E show the binding affinities, as measured by ELISA, of CD38/CD28sup x CD3mid_ENLQ DKTHT IgG4 FALA trispecific antibodies with the indicated anti-CD38 binding domains for the target antigens human CD38 (FIG. 2B), cynomolgus monkey CD38 (FIG. 2C), human CD3 (FIG. 2D), and human CD28 (FIG. 2E).

[0195] FIG. 3 shows SPR competition assays for binding to CD38 by Daratumumab and anti-CD38 monospecific antibodies with the indicated anti-CD38 binding domains. If an antibody recognized an epitope on CD38 which was different from that of Daratumumab, injection of the antibody resulted in an increased SPR signal. If an antibody recognized an overlapping epitope as Daratumumab, injection of the antibody did not increase SPR signal.

[0196] FIGS. 4A-4B show the in vitro cell killing activity of CD38/CD28sup x CD3mid_ENLQ DKTHT IgG4 FALA trispecific antibodies with the indicated anti-CD38 binding domains against human multiple myeloma NCI-H929 cells (CD38+/CD28+). The assays were carried out in the presence of 5 nM isotype control antibody (FIG. 4A) or Daratumumab (FIG. 4B). In the presence of daratumumab, the trispecific antibodies continued to exhibit cell killing activity.

[0197] FIGS. 5A-5B show the in vitro cell killing activity of CD38/CD28sup x CD3mid_ENLQ DKTHT IgG4 FALA trispecific antibodies with the indicated anti-CD38 binding domains against human lymphoma OCI-Ly19 cells (CD38+/CD28-). The assays were carried out in the presence of 5 nM isotype control antibody (FIG. 5A) or Daratumumab (FIG. 5B). Daratumumab caused a decrease in the cell killing activity of anti-CD38/CD28xCD3 trispecific antibodies.

[0198] FIGS. 6A-6J show the characterization of in vitro T cell subset expansion in PBMCs collected from CMV-infected Donor D in response to CD38/CD28sup x CD3mid_ENLQ DKTHT IgG4 FALA trispecific antibodies with the indicated alternative anti-CD38 binding domains. A trispecific antibody lacking the CD38VH1 anti-CD38 binding domain was used as a negative control (Δ CD38VH1/ Δ CD28sup x Δ CD3mid IgG4 FALA). T cell populations were measured at indicated time points (D3 refers to day 3; D7 refers to day 7). The indicated trispecific antibodies were tested at the indicated concentrations of 0.2 nM and 1 nM. Flow cytometry was used to quantify CMV-specific CD8+ T cells (FIGS. 6A-6B), CMV-specific T.sub.cm CD8+ cells (FIGS. 6C-6D), and CMV-specific T.sub.cm CD8+ cells (FIGS. 6E-6F). In addition, the percentages of CMV-specific T.sub.cm (FIGS. 6G-6H) and T.sub.cm (FIGS. 6I-6J) CD8+ cells were quantified at the indicated time points. All tested trispecific antibodies promoted the proliferation of CMV-specific memory CD8+ T cells with different potency and kinetics in a dose-responsive manner.

[0199] FIGS. 7A-7J show the characterization of in vitro T cell subset expansion in PBMCs collected from CMV-infected Donor E in response to CD38/CD28sup x CD3mid_ENLQ DKTHT IgG4 FALA trispecific antibodies with the indicated anti-CD38 binding domains. A trispecific antibody lacking the CD38VH1 anti-CD38 binding domain was used as a negative control (Δ CD38VH1/ Δ CD28sup x Δ CD3mid IgG4 FALA). Antibodies shown in legend from top to bottom are shown in the graphs from left to right. T cell populations were measured at indicated time points (D3 refers to day 3; D7 refers to day 7). The indicated trispecific antibodies were tested at the indicated concentrations of 0.2 nM, 1 nM, and 2 nM. Flow cytometry was used to quantify CMV-specific CD8+ T cells (FIGS. 7A-7B), CMV-specific T.sub.cm CD8+ cells (FIGS. 7C-7D), and CMV-specific T.sub.cm CD8+ cells (FIGS. 7E-7F). In addition, the percentages of CMV-specific T.sub.cm (FIGS. 7G-7H) and T.sub.cm (FIGS. 7I-7J) CD8+ cells were quantified at the indicated time points. All tested trispecific antibodies promoted the proliferation of CMV-specific memory CD8+ T cells with different potency and kinetics in dose response manner.

[0200] FIGS. 8A-8J show the characterization of in vitro T cell subset expansion in PBMCs collected from EBV-infected

Donor C in response to CD38/CD28sup x CD3mid_ENLQ DKTHT IgG4 FALA trispecific antibodies with the indicated alternative anti-CD38 binding domains. A trispecific antibody lacking the CD38VH1 anti-CD38 binding domain was used as a negative control (Δ CD38VH1/ Δ CD28sup x Δ CD3mid IgG4 FALA). T cell populations were measured at indicated time points (D3 refers to day 3; D7 refers to day 7). The indicated trispecific antibodies were tested at the indicated concentrations of 0.2 nM and 1 nM. Flow cytometry was used to quantify EBV-specific CD8⁺ T cells (FIGS. 8A-8B), CMV-specific T.sub.cm CD8⁺ cells (FIGS. 8C-8D), and CMV-specific T.sub.cm CD8⁺ cells (FIGS. 8E-8F). In addition, the percentages of EBV-specific T.sub.cm (FIGS. 8G-8H) and T.sub.cm (FIGS. 8I-8J) CD8⁺ cells were quantified at the indicated time points. All tested trispecific antibodies promoted the proliferation of CMV-specific memory CD8⁺ T cells with different potency and kinetics in dose response manner.

[0201] FIGS. 9A-12 show the characterization of in vitro T cell subset expansion in PBMCs collected from EBV-infected Donor D in response to CD38/CD28sup x CD3mid_ENLQ DKTHT IgG4 FALA trispecific antibodies with the indicated alternative anti-CD38 binding domains. A trispecific antibody lacking the CD38VH1 anti-CD38 binding domain was used as a negative control (Δ CD38VH1/ Δ CD28sup x Δ CD3mid IgG4 FALA). T cell populations were measured at indicated time points (D3 refers to day 3; D7 refers to day 7). The indicated trispecific antibodies were tested at the indicated concentrations of 0.2 nM and 1 nM. Flow cytometry was used to quantify EBV-specific CD8⁺ T cells (FIGS. 9A-9B), EBV-specific T.sub.cm CD8⁺ cells (FIGS. 9C-9D), and EBV-specific T.sub.cm CD8⁺ cells (FIGS. 9E-9F). In addition, the percentages of EBV-specific T.sub.cm (FIGS. 9G-10) and T.sub.cm (FIGS. 11-12) CD8⁺ cells were quantified at the indicated time points. All tested trispecific antibodies promoted the proliferation of EBV-specific memory CD8⁺ T cells with different potency and kinetics in dose response manner.

[0202] FIGS. 13A-13D show the change over time (days) in tumor volume (FIG. 13A) and body weight (FIG. 13B) in ZR-75-1 tumor bearing NSG mice engrafted with in vitro expanded human CD3⁺ T cells. Groups of 10 mice were either treated with vehicle or Her2/CD28 x CD3 trispecific antibody at the indicated dosages. Arrow heads indicate days of administration. Tumor volume is depicted as mean \pm SEM, mm.sup.3. Body weight change is depicted as % change, mean \pm SEM. X-axis shows days after implantation with ZR-75-1 cells. Tumor volume (mm.sup.3) over time for individual mice in each treatment group are shown in FIG. 13C. Tumor weight (mg) for each treatment group is shown in FIG. 13D. **= $p < 0.001$; ***= $p < 0.0003$ (two-way ANOVA, control vs. 100 & 10 μ g/kg).

[0203] FIGS. 14A-14C show the effect of Her2/CD28 x CD3 trispecific antibody treatment on T cells from whole blood. FIG. 14A shows the analysis of hCD45⁺, CD8⁺, CD4⁺, and mCD45⁺ cells by flow cytometry. FIG. 14B shows the effect of control or Her2/CD28 x CD3 trispecific antibody treatment (at the indicated doses) on hCD45⁺, CD8⁺, CD4⁺, and mCD45⁺ cell counts. FIG. 14C shows the effect of control or Her2/CD28 x CD3 trispecific antibody treatment (at the indicated doses) on human cell ratios (CD4⁺/CD45⁺ and CD8⁺/CD45⁺). For each x-axis parameter shown in FIGS. 14B & 14C, conditions are (left to right): control, 100 μ g/kg trispecific antibody, 10 μ g/kg trispecific antibody, 1 μ g/kg trispecific antibody, and 0.1 μ g/kg trispecific antibody. Percentages shown in FIGS. 14B & 14C are based on control sample vs. 100 μ g/kg.

[0204] FIGS. 15A-15C show the effect of Her2/CD28 x CD3 trispecific antibody treatment on tumor infiltrating lymphocytes (TILs), as examined by immunohistochemistry (IHC). Arrows indicate tumor infiltrating T cells identified in ZR-75-1 breast tumors. Upper images are at 1 \times magnification; lower images are at 20 \times magnification. In both sets of images, staining for human CD45, human CD4, and human CD8 are shown from left to right. Shown are tumors from mice treated with vehicle control (FIG. 15A), 100 μ g/kg trispecific antibody (FIG. 15B), or 0.1 μ g/kg trispecific antibody (FIG. 15C).

[0205] FIGS. 16A-16C show quantitation of the effect of Her2/CD28 x CD3 trispecific antibody treatment on TILs as measured by IHC. Each dot represents one tumor from an individual mouse; rectangles represent group means; and error bars indicate standard deviation. *= $p < 0.05$ compared to vehicle control group (ANOVA). Numbers of CD45⁺ (FIG. 16A), CD4⁺ (FIG. 16B), or CD8⁺ (FIG. 16C) cells are shown. In FIG. 16C, a \$ area quantitation approach was used for CD8⁺ cells instead of cell counting algorithm due to excessive non-specific signal in the CD8 IHC slide.

[0206] FIGS. 17A-17F show in vitro cell lysis of HER2⁺ breast cancer target cells in the presence of human CD8⁺ T cells by Her2/CD28 x CD3 trispecific antibody with wild-type trastuzumab antigen binding domain and an anti-CD3 antigen binding domain without 32/35 QQ mutations in the VL domain ("ctl") as compared to a Her2/CD28 x CD3 trispecific antibodies having mutations in the anti-HER2 arm and the VL domain of the anti-CD3 arm (numbering as shown in Table 1). Cell killing activities against cell lines with varying expression of HER2 are depicted: HCC1954 for high HER2 expression (FIG. 17A), BT20 for intermediate HER2 expression (FIG. 17C), and MDA-MD-231 for low HER2 expression (FIG. 17E). Graphs depicting cell killing as a function of antibody concentration against target cells HCC1954 (FIG. 17B), BT20 (FIG. 17D), and MDA-MD-231 (FIG. 17F) are shown, comparing binding protein #2 vs. ctl or binding protein #1 and #5 vs. ctl.

[0207] FIGS. 18A & 18B summarize the mean EC50 (pM) of in vitro cell killing by experimental or control Her2/CD28 x CD3 trispecific antibodies against the indicated breast cancer (FIG. 18A) or gastric cancer cell lines (FIG. 18B). Amino acid sequences of the indicated trispecific antibodies are provided in Table 1.

[0208] FIG. 19 provides a schematic representation of a trispecific binding protein comprising four polypeptide chains that form three antigen binding sites that binds three target proteins: CD28, CD3, and HIV Env. A first pair of polypeptides possess dual variable domains having a cross-over orientation (VH1-VH2 and VL2-VL1) forming two antigen binding sites (VH1 and VL1; VH2 and VL2) that recognize CD28 and CD3, respectively, and a second pair of polypeptides possess a single variable domain (VH3 and VL3) forming a single antigen binding site that recognizes HIV Env. The trispecific binding protein shown in FIG. 19 uses a constant region with a "knobs-into-holes" mutation, where the knob is on the second pair of polypeptides with a single variable domain

[0209] FIG. 20 shows a schematic representation of a trispecific T cell Engager (TCE) strategy for using the anti-HIV trispecific binding protein shown in FIG. 19 to target and eliminate the HIV reservoir.

DETAILED DESCRIPTION

[0210] The disclosure provides trispecific and/or trivalent binding proteins comprising four polypeptide chains that form three antigen binding sites that specifically bind to one or more target proteins, wherein a first pair of polypeptides forming the binding protein possess dual variable domains having a cross-over orientation.

[0211] The present disclosure further provides trispecific and/or trivalent binding proteins comprising four polypeptide chains that form three antigen binding sites that specifically bind to one or more human immunodeficiency virus (HIV) target proteins and/or one or more T-cell receptor target proteins, wherein a first pair of polypeptides forming the binding protein possess dual variable domains having a cross-over orientation, and wherein a second pair of polypeptides possess a single variable domain.

I. General Definitions

[0212] As utilized in accordance with the present disclosure, the following terms, unless otherwise indicated, shall be understood to have the following meanings. Unless otherwise required by context, singular terms shall include pluralities and plural terms shall include the singular.

[0213] It is understood that aspects and embodiments of the disclosure described herein include “comprising,” “consisting,” and “consisting essentially of” aspects and embodiments.

[0214] The term “polynucleotide” as used herein refers to single-stranded or double-stranded nucleic acid polymers of at least 10 nucleotides in length. In certain embodiments, the nucleotides comprising the polynucleotide can be ribonucleotides or deoxyribonucleotides or a modified form of either type of nucleotide. Such modifications include base modifications such as bromuridine, ribose modifications such as arabinoside and 2',3'-dideoxyribose, and internucleotide linkage modifications such as phosphorothioate, phosphorodithioate, phosphoroselenoate, phosphorodiselenoate, phosphoroanilothioate, phosphoraniladate and phosphoroamidate. The term “polynucleotide” specifically includes single-stranded and double-stranded forms of DNA.

[0215] An “isolated polynucleotide” is a polynucleotide of genomic, cDNA, or synthetic origin or some combination thereof, which: (1) is not associated with all or a portion of a polynucleotide in which the isolated polynucleotide is found in nature, (2) is linked to a polynucleotide to which it is not linked in nature, or (3) does not occur in nature as part of a larger sequence.

[0216] An “isolated polypeptide” is one that: (1) is free of at least some other polypeptides with which it would normally be found, (2) is essentially free of other polypeptides from the same source, e.g., from the same species, (3) is expressed by a cell from a different species, (4) has been separated from at least about 50 percent of polynucleotides, lipids, carbohydrates, or other materials with which it is associated in nature, (5) is not associated (by covalent or noncovalent interaction) with portions of a polypeptide with which the “isolated polypeptide” is associated in nature, (6) is operably associated (by covalent or noncovalent interaction) with a polypeptide with which it is not associated in nature, or (7) does not occur in nature. Such an isolated polypeptide can be encoded by genomic DNA, cDNA, mRNA or other RNA, of synthetic origin, or any combination thereof. Preferably, the isolated polypeptide is substantially free from polypeptides or other contaminants that are found in its natural environment that would interfere with its use (therapeutic, diagnostic, prophylactic, research or otherwise).

[0217] Naturally occurring antibodies typically comprise a tetramer. Each such tetramer is typically composed of two identical pairs of polypeptide chains, each pair having one full-length “light” chain (typically having a molecular weight of about 25 kDa) and one full-length “heavy” chain (typically having a molecular weight of about 50-70 kDa). The terms “heavy chain” and “light chain” as used herein refer to any immunoglobulin polypeptide having sufficient variable domain sequence to confer specificity for a target antigen. The amino-terminal portion of each light and heavy chain typically includes a variable domain of about 100 to 110 or more amino acids that typically is responsible for antigen recognition. The carboxy-terminal portion of each chain typically defines a constant domain responsible for effector function. Thus, in a naturally occurring antibody, a full-length heavy chain immunoglobulin polypeptide includes a variable domain (V.sub.H) and three constant domains (C.sub.H1, C.sub.H2, and C.sub.H3), wherein the V.sub.H domain is at the amino-terminus of the polypeptide and the C.sub.H3 domain is at the carboxyl-terminus, and a full-length light chain immunoglobulin polypeptide includes a variable domain (V.sub.L) and a constant domain (C.sub.L), wherein the V.sub.L domain is at the amino-terminus of the polypeptide and the C.sub.L domain is at the carboxyl-terminus.

[0218] Human light chains are typically classified as kappa and lambda light chains, and human heavy chains are typically classified as mu, delta, gamma, alpha, or epsilon, and define the antibody's isotype as IgM, IgD, IgG, IgA, and IgE, respectively. IgG has several subclasses, including, but not limited to, IgG1, IgG2, IgG3, and IgG4. IgM has subclasses including, but not limited to, IgM1 and IgM2. IgA is similarly subdivided into subclasses including, but not limited to, IgA1 and IgA2. Within full-length light and heavy chains, the variable and constant domains typically are joined by a “J” region of about 12 or more amino acids, with the heavy chain also including a “D” region of about 10 more amino acids. See, e.g., FUNDAMENTAL IMMUNOLOGY (Paul, W., ed., Raven Press, 2nd ed., 1989), which is incorporated by reference in its entirety for all purposes. The variable regions of each light/heavy chain pair typically form an antigen binding site. The variable domains of naturally occurring antibodies typically exhibit the same general structure of relatively conserved framework regions (FR) joined by three hypervariable regions, also called complementarity determining regions or CDRs. The CDRs from the two chains of each pair typically are aligned by the framework regions, which may enable binding to a specific epitope. From the amino-terminus to the carboxyl-terminus, both light and heavy chain variable domains typically comprise the domains FR1, CDR1, FR2, CDR2, FR3, CDR3, and FR4.

[0219] The term “CDR set” refers to a group of three CDRs that occur in a single variable region capable of binding the antigen. The exact boundaries of these CDRs have been defined differently according to different systems. The system described by Kabat (Kabat et al., SEQUENCES OF PROTEINS OF IMMUNOLOGICAL INTEREST (National Institutes of

Health, Bethesda, Md. (1987) and (1991)) not only provides an unambiguous residue numbering system applicable to any variable region of an antibody, but also provides precise residue boundaries defining the three CDRs. These CDRs may be referred to as Kabat CDRs. Chothia and coworkers (Chothia and Lesk, 1987, *J. Mol. Biol.* 196: 901-17; Chothia et al., 1989, *Nature* 342: 877-83) found that certain sub-portions within Kabat CDRs adopt nearly identical peptide backbone conformations, despite having great diversity at the level of amino acid sequence. These sub-portions were designated as L1, L2, and L3 or H1, H2, and H3 where the “L” and the “H” designates the light chain and the heavy chain regions, respectively. These regions may be referred to as Chothia CDRs, which have boundaries that overlap with Kabat CDRs. Other boundaries defining CDRs overlapping with the Kabat CDRs have been described by Padlan, 1995, *FASEB J.* 9: 133-39; MacCallum, 1996, *J. Mol. Biol.* 262(5): 732-45; and Lefranc, 2003, *Dev. Comp. Immunol.* 27: 55-77. Still other CDR boundary definitions may not strictly follow one of the herein systems, but will nonetheless overlap with the Kabat CDRs, although they may be shortened or lengthened in light of prediction or experimental findings that particular residues or groups of residues or even entire CDRs do not significantly impact antigen binding. The methods used herein may utilize CDRs defined according to any of these systems, although certain embodiments use Kabat or Chothia defined CDRs. Identification of predicted CDRs using the amino acid sequence is well known in the field, such as in Martin, A. C. “Protein sequence and structure analysis of antibody variable domains,” *In Antibody Engineering*, Vol. 2. Kontermann R., Dubel S., eds. Springer-Verlag, Berlin, p. 33-51 (2010). The amino acid sequence of the heavy and/or light chain variable domain may be also inspected to identify the sequences of the CDRs by other conventional methods, e.g., by comparison to known amino acid sequences of other heavy and light chain variable regions to determine the regions of sequence hypervariability. The numbered sequences may be aligned by eye, or by employing an alignment program such as one of the CLUSTAL suite of programs, as described in Thompson, 1994, *Nucleic Acids Res.* 22: 4673-80. Molecular models are conventionally used to correctly delineate framework and CDR regions and thus correct the sequence-based assignments.

[0220] The term “Fc” as used herein refers to a molecule comprising the sequence of a non-antigen-binding fragment resulting from digestion of an antibody or produced by other means, whether in monomeric or multimeric form, and can contain the hinge region. The original immunoglobulin source of the native Fc is preferably of human origin and can be any of the immunoglobulins, although IgG1 and IgG2 are preferred. Fc molecules are made up of monomeric polypeptides that can be linked into dimeric or multimeric forms by covalent (i.e., disulfide bonds) and non-covalent association. The number of intermolecular disulfide bonds between monomeric subunits of native Fc molecules ranges from 1 to 4 depending on class (e.g., IgG, IgA, and IgE) or subclass (e.g., IgG1, IgG2, IgG3, IgA1, and IgA2). One example of a Fc is a disulfide-bonded dimer resulting from papain digestion of an IgG. The term “native Fc” as used herein is generic to the monomeric, dimeric, and multimeric forms.

[0221] A F(ab) fragment typically includes one light chain and the V.sub.H and C.sub.H1 domains of one heavy chain, wherein the V.sub.H-C.sub.H1 heavy chain portion of the F(ab) fragment cannot form a disulfide bond with another heavy chain polypeptide. As used herein, a F(ab) fragment can also include one light chain containing two variable domains separated by an amino acid linker and one heavy chain containing two variable domains separated by an amino acid linker and a C.sub.H1 domain.

[0222] A F(ab') fragment typically includes one light chain and a portion of one heavy chain that contains more of the constant region (between the C.sub.H1 and C.sub.H2 domains), such that an interchain disulfide bond can be formed between two heavy chains to form a F(ab')₂ molecule.

[0223] The term “binding protein” as used herein refers to a non-naturally occurring (or recombinant or engineered) molecule that specifically binds to at least one target antigen. A trispecific binding protein of the present disclosure, unless otherwise specified, typically comprises four polypeptide chains that form at least three antigen binding sites, wherein a first polypeptide chain has a structure represented by the formula:

V.sub.L2-L.sub.1-V.sub.L1-L.sub.2-C.sub.L [I]

and a second polypeptide chain has a structure represented by the formula:

V.sub.H1-L.sub.3-V.sub.H2-L.sub.4-C.sub.H1-hinge-C.sub.H2-C.sub.H3 [II]

and a third polypeptide chain has a structure represented by the formula:

V.sub.H3-C.sub.H1 [III]

and a fourth polypeptide chain has a structure represented by the formula:

V.sub.L3-C.sub.L [IV] [0224] wherein: [0225] V.sub.L1 is a first immunoglobulin light chain variable domain; [0226] V.sub.L2 is a second immunoglobulin light chain variable domain; [0227] V.sub.L3 is a third immunoglobulin light chain variable domain; [0228] V.sub.H1 is a first immunoglobulin heavy chain variable domain; [0229] V.sub.H2 is a second immunoglobulin heavy chain variable domain; [0230] V.sub.H3 is a third immunoglobulin heavy chain variable domain; [0231] C.sub.L is an immunoglobulin light chain constant domain; [0232] C.sub.H1 is the immunoglobulin C.sub.H1 heavy chain constant domain; and [0233] hinge is an immunoglobulin hinge region connecting the C.sub.H1 and C.sub.H2 domains; [0234] L.sub.1, L.sub.2, L.sub.3 and L.sub.4 are amino acid linkers; [0235] and wherein the polypeptide of formula I and the polypeptide of formula II form a cross-over light chain-heavy chain pair.

[0236] A “recombinant” molecule is one that has been prepared, expressed, created, or isolated by recombinant means.

[0237] One embodiment of the disclosure provides binding proteins having biological and immunological specificity to between one and three target antigens. Another embodiment of the disclosure provides nucleic acid molecules comprising

nucleotide sequences encoding polypeptide chains that form such binding proteins. Another embodiment of the disclosure provides expression vectors comprising nucleic acid molecules comprising nucleotide sequences encoding polypeptide chains that form such binding proteins. Yet another embodiment of the disclosure provides host cells that express such binding proteins (i.e., comprising nucleic acid molecules or vectors encoding polypeptide chains that form such binding proteins).

[0238] The term “swapability” as used herein refers to the interchangeability of variable domains within the binding protein format and with retention of folding and ultimate binding affinity. “Full swapability” refers to the ability to swap the order of both V.sub.H1 and V.sub.H2 domains, and therefore the order of V.sub.L1 and V.sub.L2 domains, in the polypeptide chain of formula I or the polypeptide chain of formula II (i.e., to reverse the order) while maintaining full functionality of the binding protein as evidenced by the retention of binding affinity. Furthermore, it should be noted that the designations V.sub.H and V.sub.L refer only to the domain's location on a particular protein chain in the final format. For example, V.sub.H1 and V.sub.H2 could be derived from V.sub.L1 and V.sub.L2 domains in parent antibodies and placed into the V.sub.H1 and V.sub.H2 positions in the binding protein. Likewise, V.sub.L1 and V.sub.L2 could be derived from V.sub.H1 and V.sub.H2 domains in parent antibodies and placed in the V.sub.H1 and V.sub.H2 positions in the binding protein. Thus, the V.sub.H and V.sub.L designations refer to the present location and not the original location in a parent antibody. V.sub.H and V.sub.L domains are therefore “swappable.”

[0239] The term “antigen” or “target antigen” or “antigen target” as used herein refers to a molecule or a portion of a molecule that is capable of being bound by a binding protein, and additionally is capable of being used in an animal to produce antibodies capable of binding to an epitope of that antigen. A target antigen may have one or more epitopes. With respect to each target antigen recognized by a binding protein, the binding protein is capable of competing with an intact antibody that recognizes the target antigen.

[0240] The term “Her2” refers to human epidermal growth factor receptor 2 which is a member of the epidermal growth factor receptor family.

[0241] “CD3” is cluster of differentiation factor 3 polypeptide and is a T-cell surface protein that is typically part of the T cell receptor (TCR) complex.

[0242] “CD28” is cluster of differentiation 28 polypeptide and is a T-cell surface protein that provides co-stimulatory signals for T-cell activation and survival.

[0243] “CD38” is cluster of differentiation 38 polypeptide and is a glycoprotein found on the surface of many immune cells.

[0244] The term “monospecific binding protein” refers to a binding protein that specifically binds to one antigen target.

[0245] The term “monovalent binding protein” refers to a binding protein that has one antigen binding site.

[0246] The term “bispecific binding protein” refers to a binding protein that specifically binds to two different antigen targets.

[0247] The term “bivalent binding protein” refers to a binding protein that has two binding sites.

[0248] The term “trispecific binding protein” refers to a binding protein that specifically binds to three different antigen targets.

[0249] The term “trivalent binding protein” refers to a binding protein that has three binding sites. In particular embodiments the trivalent binding protein can bind to one antigen target. In other embodiments, the trivalent binding protein can bind to two antigen targets. In other embodiments, the trivalent binding protein can bind to three antigen targets.

[0250] An “isolated” binding protein is one that has been identified and separated and/or recovered from a component of its natural environment. Contaminant components of its natural environment are materials that would interfere with diagnostic or therapeutic uses for the binding protein, and may include enzymes, hormones, and other proteinaceous or non-proteinaceous solutes. In some embodiments, the binding protein will be purified: (1) to greater than 95% by weight of antibody as determined by the Lowry method, and most preferably more than 99% by weight, (2) to a degree sufficient to obtain at least 15 residues of N-terminal or internal amino acid sequence by use of a spinning cup sequenator, or (3) to homogeneity by SDS-PAGE under reducing or nonreducing conditions using Coomassie blue or, preferably, silver stain. Isolated binding proteins include the binding protein in situ within recombinant cells since at least one component of the binding protein's natural environment will not be present.

[0251] The terms “substantially pure” or “substantially purified” as used herein refer to a compound or species that is the predominant species present (i.e., on a molar basis it is more abundant than any other individual species in the composition). In some embodiments, a substantially purified fraction is a composition wherein the species comprises at least about 50% (on a molar basis) of all macromolecular species present. In other embodiments, a substantially pure composition will comprise more than about 80%, 85%, 90%, 95%, or 99% of all macromolecular species present in the composition. In still other embodiments, the species is purified to essential homogeneity (contaminant species cannot be detected in the composition by conventional detection methods) wherein the composition consists essentially of a single macromolecular species.

[0252] The term “epitope” includes any determinant, preferably a polypeptide determinant, capable of specifically binding to an immunoglobulin or T-cell receptor. In certain embodiments, epitope determinants include chemically active surface groupings of molecules such as amino acids, sugar side chains, phosphoryl groups, or sulfonyl groups, and, in certain embodiments, may have specific three-dimensional structural characteristics and/or specific charge characteristics. An epitope is a region of an antigen that is bound by an antibody or binding protein. In certain embodiments, a binding protein is said to specifically bind an antigen when it preferentially recognizes its target antigen in a complex mixture of proteins and/or macromolecules. In some embodiments, a binding protein is said to specifically bind an antigen when the equilibrium dissociation constant is $\leq 10^{-8}$ M, more preferably when the equilibrium dissociation constant is $\leq 10^{-9}$ M, and most preferably when the dissociation constant is $\leq 10^{-10}$ M.

[0253] The dissociation constant (K.sub.D) of a binding protein can be determined, for example, by surface plasmon resonance. Generally, surface plasmon resonance analysis measures real-time binding interactions between ligand (a target antigen on a biosensor matrix) and analyte (a binding protein in solution) by surface plasmon resonance (SPR) using the BIAcore system (Pharmacia Biosensor; Piscataway, NJ). Surface plasmon analysis can also be performed by immobilizing the analyte (binding protein on a biosensor matrix) and presenting the ligand (target antigen). The term “K.sub.D,” as used herein refers to the dissociation constant of the interaction between a particular binding protein and a target antigen.

[0254] The term “specifically binds” as used herein refers to the ability of a binding protein or an antigen-binding fragment thereof to bind to an antigen containing an epitope with an K_d of at least about 1×10⁻⁶ M, 1×10⁻⁷ M, 1×10⁻⁸ M, 1×10⁻⁹ M, 1×10⁻¹⁰ M, 1×10⁻¹¹ M, 1×10⁻¹² M, or more, and/or to bind to an epitope with an affinity that is at least two-fold greater than its affinity for a nonspecific antigen.

[0255] In some embodiments, an antigen binding domain and/or binding protein of the present disclosure “cross reacts” with human and cynomolgus monkey CD38 polypeptides, e.g., CD38 extracellular domains, human CD38 isoform A, human CD38 isoform E, and cynomolgus monkey CD38. A binding protein binding to antigen 1 (Ag1) is “cross-reactive” to antigen 2 (Ag2) when the EC₅₀s are in a similar range for both antigens. In the present application, a binding protein binding to Ag1 is cross-reactive to Ag2 when the ratio of affinity of Ag2 to affinity of Ag1 is equal or less than 20, affinities being measured with the same method for both antigens.

[0256] The term “linker” as used herein refers to one or more amino acid residues inserted between immunoglobulin domains to provide sufficient mobility for the domains of the light and heavy chains to fold into cross over dual variable region immunoglobulins. A linker is inserted at the transition between variable domains or between variable and constant domains, respectively, at the sequence level. The transition between domains can be identified because the approximate size of the immunoglobulin domains are well understood. The precise location of a domain transition can be determined by locating peptide stretches that do not form secondary structural elements such as beta-sheets or alpha-helices as demonstrated by experimental data or as can be assumed by techniques of modeling or secondary structure prediction. The linkers described herein are referred to as L.sub.1, which is located on the light chain between the C-terminus of the V.sub.L2 and the N-terminus of the V.sub.L1 domain; and L.sub.2, which is located on the light chain between the C-terminus of the V.sub.L1 and the N-terminus of the C.sub.L domain. The heavy chain linkers are known as L.sub.3, which is located between the C-terminus of the V.sub.H1 and the N-terminus of the V.sub.H2 domain; and L.sub.4, which is located between the C-terminus of the V.sub.H2 and the N-terminus of the C.sub.H1 domain.

[0257] The term “vector” as used herein refers to any molecule (e.g., nucleic acid, plasmid, or virus) that is used to transfer coding information to a host cell. The term “vector” includes a nucleic acid molecule that is capable of transporting another nucleic acid to which it has been linked. One type of vector is a “plasmid,” which refers to a circular double-stranded DNA molecule into which additional DNA segments may be inserted. Another type of vector is a viral vector, wherein additional DNA segments may be inserted into the viral genome. Certain vectors are capable of autonomous replication in a host cell into which they are introduced (e.g., bacterial vectors having a bacterial origin of replication and episomal mammalian vectors). Other vectors (e.g., non-episomal mammalian vectors) can be integrated into the genome of a host cell upon introduction into the host cell and thereby are replicated along with the host genome. In addition, certain vectors are capable of directing the expression of genes to which they are operatively linked. Such vectors are referred to herein as “recombinant expression vectors” (or simply, “expression vectors”). In general, expression vectors of utility in recombinant DNA techniques are often in the form of plasmids. The terms “plasmid” and “vector” may be used interchangeably herein, as a plasmid is the most commonly used form of vector. However, the disclosure is intended to include other forms of expression vectors, such as viral vectors (e.g., replication defective retroviruses, adenoviruses, and adeno-associated viruses), which serve equivalent functions.

[0258] The phrase “recombinant host cell” (or “host cell”) as used herein refers to a cell into which a recombinant expression vector has been introduced. A recombinant host cell or host cell is intended to refer not only to the particular subject cell, but also to the progeny of such a cell. Because certain modifications may occur in succeeding generations due to either mutation or environmental influences, such progeny may not, in fact, be identical to the parent cell, but such cells are still included within the scope of the term “host cell” as used herein. A wide variety of host cell expression systems can be used to express the binding proteins, including bacterial, yeast, baculoviral, and mammalian expression systems (as well as phage display expression systems). An example of a suitable bacterial expression vector is pUC19. To express a binding protein recombinantly, a host cell is transformed or transfected with one or more recombinant expression vectors carrying DNA fragments encoding the polypeptide chains of the binding protein such that the polypeptide chains are expressed in the host cell and, preferably, secreted into the medium in which the host cells are cultured, from which medium the binding protein can be recovered.

[0259] The term “transformation” as used herein refers to a change in a cell's genetic characteristics, and a cell has been transformed when it has been modified to contain a new DNA. For example, a cell is transformed where it is genetically modified from its native state. Following transformation, the transforming DNA may recombine with that of the cell by physically integrating into a chromosome of the cell, or may be maintained transiently as an episomal element without being replicated, or may replicate independently as a plasmid. A cell is considered to have been stably transformed when the DNA is replicated with the division of the cell. The term “transfection” as used herein refers to the uptake of foreign or exogenous DNA by a cell, and a cell has been “transfected” when the exogenous DNA has been introduced inside the cell membrane. A number of transfection techniques are well known in the art. Such techniques can be used to introduce one or more exogenous DNA molecules into suitable host cells.

[0260] The term “naturally occurring” as used herein and applied to an object refers to the fact that the object can be found in

nature and has not been manipulated by man. For example, a polynucleotide or polypeptide that is present in an organism (including viruses) that can be isolated from a source in nature and that has not been intentionally modified by man is naturally-occurring. Similarly, “non-naturally occurring” as used herein refers to an object that is not found in nature or that has been structurally modified or synthesized by man.

[0261] As used herein, the twenty conventional amino acids and their abbreviations follow conventional usage.

Stereoisomers (e.g., D-amino acids) of the twenty conventional amino acids; unnatural amino acids and analogs such as α -, α -disubstituted amino acids, N-alkyl amino acids, lactic acid, and other unconventional amino acids may also be suitable components for the polypeptide chains of the binding proteins. Examples of unconventional amino acids include: 4-hydroxyproline, γ -carboxyglutamate, ϵ -N,N,N-trimethyllysine, ϵ -N-acetyllysine, O-phosphoserine, N-acetylserine, N-formylmethionine, 3-methylhistidine, 5-hydroxylysine, σ -N-methylarginine, and other similar amino acids and imino acids (e.g., 4-hydroxyproline). In the polypeptide notation used herein, the left-hand direction is the amino terminal direction and the right-hand direction is the carboxyl-terminal direction, in accordance with standard usage and convention.

[0262] Naturally occurring residues may be divided into classes based on common side chain properties: [0263] (1)

hydrophobic: Met, Ala, Val, Leu, Ile, Phe, Trp, Tyr, Pro; [0264] (2) polar hydrophilic: Arg, Asn, Asp, Gln, Glu, His, Lys, Ser, Thr; [0265] (3) aliphatic: Ala, Gly, Ile, Leu, Val, Pro; [0266] (4) aliphatic hydrophobic: Ala, Ile, Leu, Val, Pro; [0267] (5) neutral hydrophilic: Cys, Ser, Thr, Asn, Gln; [0268] (6) acidic: Asp, Glu; [0269] (7) basic: His, Lys, Arg; [0270] (8) residues that influence chain orientation: Gly, Pro; [0271] (9) aromatic: His, Trp, Tyr, Phe; and [0272] (10) aromatic hydrophobic: Phe, Trp, Tyr.

[0273] Conservative amino acid substitutions may involve exchange of a member of one of these classes with another member of the same class. Non-conservative substitutions may involve the exchange of a member of one of these classes for a member from another class.

[0274] A skilled artisan will be able to determine suitable variants of the polypeptide chains of the binding proteins using well-known techniques. For example, one skilled in the art may identify suitable areas of a polypeptide chain that may be changed without destroying activity by targeting regions not believed to be important for activity. Alternatively, one skilled in the art can identify residues and portions of the molecules that are conserved among similar polypeptides. In addition, even areas that may be important for biological activity or for structure may be subject to conservative amino acid substitutions without destroying the biological activity or without adversely affecting the polypeptide structure.

[0275] The term “patient” as used herein includes human and animal subjects.

[0276] The terms “pharmaceutical composition” or “therapeutic composition” as used herein refer to a compound or composition capable of inducing a desired therapeutic effect when properly administered to a patient.

[0277] The term “pharmaceutically acceptable carrier” or “physiologically acceptable carrier” as used herein refers to one or more formulation materials suitable for accomplishing or enhancing the delivery of a binding protein.

[0278] The terms “effective amount” and “therapeutically effective amount” when used in reference to a pharmaceutical composition comprising one or more binding proteins refer to an amount or dosage sufficient to produce a desired therapeutic result. More specifically, a therapeutically effective amount is an amount of a binding protein sufficient to inhibit, for some period of time, one or more of the clinically defined pathological processes associated with the condition being treated. The effective amount may vary depending on the specific binding protein that is being used, and also depends on a variety of factors and conditions related to the patient being treated and the severity of the disorder. For example, if the binding protein is to be administered in vivo, factors such as the age, weight, and health of the patient as well as dose response curves and toxicity data obtained in preclinical animal work would be among those factors considered. The determination of an effective amount or therapeutically effective amount of a given pharmaceutical composition is well within the ability of those skilled in the art.

[0279] One embodiment of the disclosure provides a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a binding protein.

II. Trispecific and/or Trivalent Binding Proteins for Treating and/or Preventing Cancer

[0280] Certain aspects of the present disclosure relate to trispecific and/or trivalent binding proteins comprising four polypeptide chains that form three antigen binding sites that specifically bind to one or more target proteins, wherein a first pair of polypeptides forming the binding protein possess dual variable domains having a cross-over orientation and wherein a second pair of polypeptides forming the binding protein possess a single variable domain. Any of the CDRs or variable domains of any of the antigen binding proteins described herein may find use in a trispecific binding protein of the present disclosure.

[0281] In some embodiments, each of the three antigen binding sites binds a different target (e.g., polypeptide antigen). In some embodiments, the trispecific binding protein comprises four polypeptide chains that form the three antigen binding sites, wherein a first polypeptide chain comprises a structure represented by the formula:

V.sub.L2-L.sub.1-V.sub.L1-L.sub.2-C.sub.L [I]

and a second polypeptide chain comprises a structure represented by the formula:

V.sub.H1-L.sub.3-V.sub.H2-L.sub.4-C.sub.H1-hinge-C.sub.H2-C.sub.H3 [II]

and a third polypeptide chain comprises a structure represented by the formula:

V.sub.H3-C.sub.H1-hinge-C.sub.H2-C.sub.H3 [III]

and a fourth polypeptide chain comprises a structure represented by the formula:

V.sub.L3-C.sub.L [IV] [0282] wherein: [0283] V.sub.L1 is a first immunoglobulin light chain variable domain; [0284] V.sub.L2 is a second immunoglobulin light chain variable domain; [0285] V.sub.L3 is a third immunoglobulin light chain variable domain; [0286] V.sub.H1 is a first immunoglobulin heavy chain variable domain; [0287] V.sub.H2 is a second immunoglobulin heavy chain variable domain; [0288] V.sub.H3 is a third immunoglobulin heavy chain variable domain; [0289] C.sub.L is an immunoglobulin light chain constant domain; [0290] C.sub.H1 is an immunoglobulin C.sub.H1 heavy chain constant domain; [0291] C.sub.H2 is an immunoglobulin C.sub.H2 heavy chain constant domain; [0292] C.sub.H3 is an immunoglobulin C.sub.H3 heavy chain constant domain; [0293] hinge is an immunoglobulin hinge region connecting the C.sub.H1 and C.sub.H2 domains; and [0294] L.sub.1, L.sub.2, L.sub.3 and L.sub.4 are amino acid linkers; [0295] wherein the polypeptide of formula I and the polypeptide of formula II form a cross-over light chain-heavy chain pair.

[0296] In some embodiments, e.g., as used in reference to binding proteins of the present disclosure for treating and/or preventing cancer, the term “T-cell engager” refers to binding proteins directed to a host's immune system, more specifically the T cells' cytotoxic activity as well as directed to a tumor target protein.

[0297] In some embodiments, e.g., as used in reference to binding proteins of the present disclosure that target cancer, the terms “treatment” or “treat” as used herein refer to both therapeutic treatment and prophylactic or preventative measures. Those in need of treatment include those having a disorder as well as those prone to have the disorder or those in which the disorder is to be prevented. In particular embodiments, binding proteins can be used to treat humans with cancer, or humans susceptible to cancer, or ameliorate cancer in a human subject. The binding proteins can also be used to prevent cancer in a human patient. In particular embodiments, the cancer is multiple myeloma, acute lymphoblastic leukemia, chronic lymphocytic leukemia, acute myeloid leukemia, lymphoma, breast cancer such as Her2+ breast cancer, germinal center B-cell lymphoma or B-cell acute lymphoblastic leukemia. In other embodiments, the binding proteins can be used to treat humans with inflammatory disorders, or humans susceptible to inflammatory disorders, or ameliorate inflammatory disorders in a human subject.

[0298] It is contemplated that any of the antigen binding sites described herein may find use in a trispecific binding protein of the present disclosure, e.g., comprising four polypeptide chains having the structures described supra. For example, in some embodiments, a trispecific binding protein of the present disclosure comprises a V.sub.H1 and V.sub.L1 domain pair that form a first antigen binding site, a V.sub.H2 and V.sub.L2 domain pair that form a second antigen binding site that binds a CD3 polypeptide, and a V.sub.H3 and V.sub.L3 domain pair that form a third antigen binding site. In some embodiments, a trispecific binding protein of the present disclosure comprises a V.sub.H1 and V.sub.L1 domain pair that form a first antigen binding site that binds a CD28 polypeptide, a V.sub.H2 and V.sub.L2 domain pair that form a second antigen binding site that binds a CD3 polypeptide, and a V.sub.H3 and V.sub.L3 domain pair that form a third antigen binding site. In some embodiments, a trispecific binding protein of the present disclosure comprises a V.sub.H1 and V.sub.L1 domain pair that form a first antigen binding site, a V.sub.H2 and V.sub.L2 domain pair that form a second antigen binding site that binds a CD3 polypeptide, and a V.sub.H3 and V.sub.L3 domain pair that form a third antigen binding site that binds a tumor target protein. In some embodiments, a trispecific binding protein of the present disclosure comprises a V.sub.H1 and V.sub.L1 domain pair that form a first antigen binding site that binds a CD28 polypeptide, a V.sub.H2 and V.sub.L2 domain pair that form a second antigen binding site that binds a CD3 polypeptide, and a V.sub.H3 and V.sub.L3 domain pair that form a third antigen binding site that binds a tumor target protein. In some embodiments, a trispecific binding protein of the present disclosure comprises a V.sub.H1 and V.sub.L1 domain pair that form a first antigen binding site that binds a CD28 polypeptide, a V.sub.H2 and V.sub.L2 domain pair that form a second antigen binding site that binds a CD3 polypeptide, and a V.sub.H3 and V.sub.L3 domain pair that form a third antigen binding site that binds a CD38 polypeptide. In some embodiments, a trispecific binding protein of the present disclosure comprises a V.sub.H1 and V.sub.L1 domain pair that form a first antigen binding site that binds a CD28 polypeptide, a V.sub.H2 and V.sub.L2 domain pair that form a second antigen binding site that binds a CD3 polypeptide, and a V.sub.H3 and V.sub.L3 domain pair that form a third antigen binding site that binds a HER2 polypeptide.

[0299] In some embodiments, a binding protein of the present disclosure binds one or more tumor target proteins and one or more T cell target proteins. In some embodiments, the binding protein is capable of specifically binding one tumor target protein and two different epitopes on a single T cell target protein. In some embodiments, the binding protein is capable of specifically binding one tumor target protein and two different T cell target proteins (e.g., CD28 and CD3). In some embodiments, the first and second polypeptide chains of the binding protein form two antigen binding sites that specifically target two T cell target proteins, and the third and fourth polypeptide chains of the binding protein form an antigen binding site that specifically binds a tumor target protein. In some embodiments, the target protein is CD38 or HER2. Additional tumor target proteins are provided infra. In some embodiments, the one or more T cell target proteins are one or more of CD3 and CD28. Exemplary and non-limiting polypeptides that may find use in any of the trispecific binding proteins described herein are provided in Table 1.

[0300] In some embodiments, a binding protein of the present disclosure comprises four polypeptide chains that form three antigen binding sites, wherein the first polypeptide chain comprises the amino acid sequence of SEQ ID NO:156 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:156; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO:157 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:157; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO:158 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:158; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO:159 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:159.

amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:300; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO:301 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:301.

Anti-CD38 Binding Sites

[0325] Certain aspects of the present disclosure relate to binding proteins that comprise an antigen binding site that binds a CD38 polypeptide. In some embodiments, the CD38 polypeptide is a human CD38 polypeptide, also known as ADPRC1. Human CD38 polypeptides are known in the art and include, without limitation, the polypeptide represented by NCBI Accession Number NP_001766.2, or a polypeptide produced from NCBI Gene ID Number 952. In some embodiments, the antigen binding site binds a human CD38 polypeptide, a non-human primate (e.g., cynomolgus monkey) CD38 polypeptide, or a human CD38 polypeptide and a non-human primate (e.g., cynomolgus monkey) CD38 polypeptide. In some embodiments, a binding protein comprising an antigen binding site that binds a CD38 polypeptide is monospecific and/or monovalent, bispecific and/or bivalent, trispecific and/or trivalent, or multispecific and/or multivalent.

[0326] In some embodiments, any of the CDRs and/or variable domains of the anti-CD38 binding sites described below can be used in a monospecific antibody.

[0327] In other embodiments, any of the CDRs and/or variable domains of the anti-CD38 binding sites described below can be used in any binding site of a trispecific binding protein comprising four polypeptides that form three antigen binding sites, e.g., as described supra. In certain embodiments, a binding protein that comprises an antigen binding site that binds a CD38 polypeptide is a trispecific binding protein comprising four polypeptides that form three antigen binding sites as described supra, wherein the V.sub.H3 and V.sub.L3 domains pair and form a third antigen binding site that binds a CD38 polypeptide.

[0328] A variety of features of exemplary binding sites and binding proteins are described herein. For example, in some embodiments, an anti-CD38 binding site cross-reacts with human CD38 (e.g., a human CD38 isoform A and/or isoform E polypeptide) and cynomolgus monkey CD38. In some embodiments, a binding protein comprising an anti-CD38 binding site induces apoptosis of a CD38+ cell. In some embodiments, a binding protein comprising an anti-CD38 binding site recruits a T cell to a CD38+ cell and optionally activates the T cell (e.g., through TCR stimulation and/or costimulation).

[0329] In some embodiments, a binding site that binds CD38 comprises: an antibody heavy chain variable (VH) domain comprising a CDR-H1 sequence comprising the amino acid sequence of GYTFTSYA (SEQ ID NO:13), a CDR-H2 sequence comprising the amino acid sequence of IYPGQGGT (SEQ ID NO:14), and a CDR-H3 sequence comprising the amino acid sequence of ARTGGLRRAYFTY (SEQ ID NO:15); and/or an antibody light chain variable (VL) domain comprising a CDR-L1 sequence comprising the amino acid sequence of QSVSSYGQGF (SEQ ID NO:16), a CDR-L2 sequence comprising the amino acid sequence of GAS (SEQ ID NO:17), and a CDR-L3 sequence comprising the amino acid sequence of QQNKEDPWT (SEQ ID NO:18). In some embodiments, a binding site that binds CD38 comprises: an antibody heavy chain variable (VH) domain comprising a CDR-H1 sequence comprising the amino acid sequence of GYTFTSYA (SEQ ID NO:13), a CDR-H2 sequence comprising the amino acid sequence of IYPGQGGT (SEQ ID NO:14), and a CDR-H3 sequence comprising the amino acid sequence of ARTGGLRRAYFTY (SEQ ID NO:15); and an antibody light chain variable (VL) domain comprising a CDR-L1 sequence comprising the amino acid sequence of QSVSSYGQGF (SEQ ID NO:16), a CDR-L2 sequence comprising the amino acid sequence of GAS (SEQ ID NO:17), and a CDR-L3 sequence comprising the amino acid sequence of QQNKEDPWT (SEQ ID NO:18).

[0330] In some embodiments, a binding site that binds CD38 comprises: an antibody heavy chain variable (VH) domain comprising a CDR-H1 sequence comprising the amino acid sequence of GYTLTEFS (SEQ ID NO:19), a CDR-H2 sequence comprising the amino acid sequence of FDPEDGET (SEQ ID NO:20), and a CDR-H3 sequence comprising the amino acid sequence of TTGRFFDWF (SEQ ID NO:21); and/or an antibody light chain variable (VL) domain comprising a CDR-L1 sequence comprising the amino acid sequence of QSVISRF (SEQ ID NO:22), a CDR-L2 sequence comprising the amino acid sequence of GAS (SEQ ID NO:23), and a CDR-L3 sequence comprising the amino acid sequence of QQDSNLPIT (SEQ ID NO:24). In some embodiments, a binding site that binds CD38 comprises: an antibody heavy chain variable (VH) domain comprising a CDR-H1 sequence comprising the amino acid sequence of GYTLTEFS (SEQ ID NO:19), a CDR-H2 sequence comprising the amino acid sequence of FDPEDGET (SEQ ID NO:20), and a CDR-H3 sequence comprising the amino acid sequence of TTGRFFDWF (SEQ ID NO:21); and an antibody light chain variable (VL) domain comprising a CDR-L1 sequence comprising the amino acid sequence of QSVISRF (SEQ ID NO:22), a CDR-L2 sequence comprising the amino acid sequence of GAS (SEQ ID NO:23), and a CDR-L3 sequence comprising the amino acid sequence of QQDSNLPIT (SEQ ID NO:24).

[0331] In some embodiments, a binding site that binds CD38 comprises: an antibody heavy chain variable (VH) domain comprising a CDR-H1 sequence comprising the amino acid sequence of GYAFTTYL (SEQ ID NO:25), a CDR-H2 sequence comprising the amino acid sequence of INPGSGST (SEQ ID NO:26), and a CDR-H3 sequence comprising the amino acid sequence of ARYAYGY (SEQ ID NO:27); and/or an antibody light chain variable (VL) domain comprising a CDR-L1 sequence comprising the amino acid sequence of QNVGTA (SEQ ID NO:28), a CDR-L2 sequence comprising the amino acid sequence of SAS (SEQ ID NO:29), and a CDR-L3 sequence comprising the amino acid sequence of QQYSTYPFT (SEQ ID NO:30). In some embodiments, a binding site that binds CD38 comprises: an antibody heavy chain variable (VH) domain comprising a CDR-H1 sequence comprising the amino acid sequence of GYAFTTYL (SEQ ID NO:25), a CDR-H2 sequence comprising the amino acid sequence of INPGSGST (SEQ ID NO:26), and a CDR-H3 sequence comprising the amino acid sequence of ARYAYGY (SEQ ID NO:27); and an antibody light chain variable (VL) domain comprising a CDR-L1 sequence comprising the amino acid sequence of QNVGTA (SEQ ID NO:28), a CDR-L2 sequence comprising the amino acid sequence of SAS (SEQ ID NO:29), and a CDR-L3 sequence comprising the amino acid sequence of QQYSTYPFT (SEQ ID NO:30).

[0332] In some embodiments, a binding site that binds CD38 comprises: an antibody heavy chain variable (VH) domain comprising a CDR-H1 sequence comprising the amino acid sequence of GYSFTNYA (SEQ ID NO:31), a CDR-H2 sequence comprising the amino acid sequence of ISPYYGDT (SEQ ID NO:32), and a CDR-H3 sequence comprising the amino acid sequence of ARRFEGFYYSMDY (SEQ ID NO:33); and/or an antibody light chain variable (VL) domain comprising a CDR-L1 sequence comprising the amino acid sequence of QSLVHSNGNTY (SEQ ID NO:34), a CDR-L2 sequence comprising the amino acid sequence of KVS (SEQ ID NO:35), and a CDR-L3 sequence comprising the amino acid sequence of SQSTHVPLT (SEQ ID NO:36). In some embodiments, a binding site that binds CD38 comprises: an antibody heavy chain variable (VH) domain comprising a CDR-H1 sequence comprising the amino acid sequence of GYSFTNYA (SEQ ID NO:31), a CDR-H2 sequence comprising the amino acid sequence of ISPYYGDT (SEQ ID NO:32), and a CDR-H3 sequence comprising the amino acid sequence of ARRFEGFYYSMDY (SEQ ID NO:33); and an antibody light chain variable (VL) domain comprising a CDR-L1 sequence comprising the amino acid sequence of QSLVHSNGNTY (SEQ ID NO:34), a CDR-L2 sequence comprising the amino acid sequence of KVS (SEQ ID NO:35), and a CDR-L3 sequence comprising the amino acid sequence of SQSTHVPLT (SEQ ID NO:36).

[0333] In some embodiments, a binding site that binds CD38 comprises: an antibody heavy chain variable (VH) domain comprising a CDR-H1 sequence comprising the amino acid sequence of GFTFSSYG (SEQ ID NO:37), a CDR-H2 sequence comprising the amino acid sequence of IWYDGSNK (SEQ ID NO:38), and a CDR-H3 sequence comprising the amino acid sequence of ARDPGLRYFDGGMDV (SEQ ID NO:39); and/or an antibody light chain variable (VL) domain comprising a CDR-L1 sequence comprising the amino acid sequence of QGISSY (SEQ ID NO:40), a CDR-L2 sequence comprising the amino acid sequence of AAS (SEQ ID NO:41), and a CDR-L3 sequence comprising the amino acid sequence of QQLNSFPYT (SEQ ID NO:42). In some embodiments, a binding site that binds CD38 comprises: an antibody heavy chain variable (VH) domain comprising a CDR-H1 sequence comprising the amino acid sequence of GFTFSSYG (SEQ ID NO:37), a CDR-H2 sequence comprising the amino acid sequence of IWYDGSNK (SEQ ID NO:38), and a CDR-H3 sequence comprising the amino acid sequence of ARDPGLRYFDGGMDV (SEQ ID NO:39); and an antibody light chain variable (VL) domain comprising a CDR-L1 sequence comprising the amino acid sequence of QGISSY (SEQ ID NO:40), a CDR-L2 sequence comprising the amino acid sequence of AAS (SEQ ID NO:41), and a CDR-L3 sequence comprising the amino acid sequence of QQLNSFPYT (SEQ ID NO:42).

[0334] In some embodiments, a binding site that binds CD38 comprises: an antibody heavy chain variable (VH) domain comprising a CDR-H1 sequence comprising the amino acid sequence of GFTFSSYG (SEQ ID NO:43), a CDR-H2 sequence comprising the amino acid sequence of IWYDGSNK (SEQ ID NO:44), and a CDR-H3 sequence comprising the amino acid sequence of ARMFRGAFDY (SEQ ID NO:45); and/or an antibody light chain variable (VL) domain comprising a CDR-L1 sequence comprising the amino acid sequence of QGIRND (SEQ ID NO:46), a CDR-L2 sequence comprising the amino acid sequence of AAS (SEQ ID NO:47), and a CDR-L3 sequence comprising the amino acid sequence of LQDYIYYPT (SEQ ID NO:48). In some embodiments, a binding site that binds CD38 comprises: an antibody heavy chain variable (VH) domain comprising a CDR-H1 sequence comprising the amino acid sequence of GFTFSSYG (SEQ ID NO:43), a CDR-H2 sequence comprising the amino acid sequence of IWYDGSNK (SEQ ID NO:44), and a CDR-H3 sequence comprising the amino acid sequence of ARMFRGAFDY (SEQ ID NO:45); and an antibody light chain variable (VL) domain comprising a CDR-L1 sequence comprising the amino acid sequence of QGIRND (SEQ ID NO:46), a CDR-L2 sequence comprising the amino acid sequence of AAS (SEQ ID NO:47), and a CDR-L3 sequence comprising the amino acid sequence of LQDYIYYPT (SEQ ID NO:48).

[0335] In some embodiments, a binding site that binds CD38 comprises: an antibody heavy chain variable (VH) domain comprising an amino acid sequence that is at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of

QVQLVQSGAEVVKPGASVKVCKASGYTFTSYAMHWVKEAPGQRLEWIGYIYPGQ
GGTNYNQKFQGRATLTADTSASTAYMELSSLRSEDVAVYFCARTGGLRRAYFTYWG QGTLTVTVSS (SEQ ID NO:79), and/or an antibody light chain variable (VL) domain comprising an amino acid sequence that is at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of
DIVLTQSPATLSLSPGERATISCRASQSVSSYGQGFMHWYQQKPGQPPRLLIYGASSR
ATGIPARFSGSGSDFTLTISPLEPEDFAVYYCQQNKEDPWTFGGGKLEIK (SEQ ID NO:80). In some embodiments, a binding site that binds CD38 comprises: an antibody heavy chain variable (VH) domain comprising the amino acid sequence of SEQ ID NO:79, and/or an antibody light chain variable (VL) domain comprising the amino acid sequence of SEQ ID NO:80. In some embodiments, a binding site that binds CD38 comprises: an antibody heavy chain variable (VH) domain comprising the amino acid sequence of SEQ ID NO:79, and an antibody light chain variable (VL) domain comprising the amino acid sequence of SEQ ID NO:80.

[0336] In some embodiments, a binding site that binds CD38 comprises: an antibody heavy chain variable (VH) domain comprising an amino acid sequence that is at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of

QVQLVQSGAEVVKPGASVKVCKVSGYTLTEFSIHWRQAPGQGLEWMGGFDPED
GETIYAQKFQGRVIMTEDTSTDYMEMNSLRSEDTAIYYCTTGRFFDWFVGQGT LTVTVSS (SEQ ID NO:81), and/or an antibody light chain variable (VL) domain comprising an amino acid sequence that is at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least

96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of EIIILTQSPAILSLSPGERATLSCRASQSVISRFLSWYQVKPGLAPRLLIYGASTRATGIPV RFSGSGSGTDFSLTISLQPEDCAVYYCQQDSNLPITFGQGTRLEIK (SEQ ID NO:82). In some embodiments, a binding site that binds CD38 comprises: an antibody heavy chain variable (VH) domain comprising the amino acid sequence of SEQ ID NO:81, and/or an antibody light chain variable (VL) domain comprising the amino acid sequence of SEQ ID NO:82. In some embodiments, a binding site that binds CD38 comprises: an antibody heavy chain variable (VH) domain comprising the amino acid sequence of SEQ ID NO:81, and an antibody light chain variable (VL) domain comprising the amino acid sequence of SEQ ID NO:82.

[0337] In some embodiments, a binding site that binds CD38 comprises: an antibody heavy chain variable (VH) domain comprising an amino acid sequence that is at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of

QVQLVQSGAEVKKPGASVKVSCKASGYAFTTYLVEWIRQRPQGQGLEWMGVINPGS GSTNYAQKFQGRVTMTVDRSSTTAYMELSRLSDDTAVYYCARYAYGYWGQGTTL VTVSS (SEQ ID NO:83), and/or an antibody light chain variable (VL) domain comprising an amino acid sequence that is at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of

DIQMTQSPSSLSASVGDRVTITCRASQNVGTAVAWYQQKPGKSPKQLIYSASNRYTG VPSRFSGSGSGTDFTLTISLQPEDLATYYCQYSTYPFTFGQGTKLEIK (SEQ ID NO:84). In some embodiments, a binding site that binds CD38 comprises: an antibody heavy chain variable (VH) domain comprising the amino acid sequence of SEQ ID NO:83, and/or an antibody light chain variable (VL) domain comprising the amino acid sequence of SEQ ID NO:84. In some embodiments, a binding site that binds CD38 comprises: an antibody heavy chain variable (VH) domain comprising the amino acid sequence of SEQ ID NO:83, and an antibody light chain variable (VL) domain comprising the amino acid sequence of SEQ ID NO:84.

[0338] In some embodiments, a binding site that binds CD38 comprises: an antibody heavy chain variable (VH) domain comprising an amino acid sequence that is at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of

QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMWVRQAPGKGLEWVAVIWDYDGNKYYADSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYH CARDPGLRYFDGGMD VWGQGTTLTVTVSS (SEQ ID NO:87), and/or an antibody light chain variable (VL) domain comprising an amino acid sequence that is at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or 100% identical to the amino acid sequence of

DIQLTQSPSFLSASVGDRVTITCRASQGISSYLAWYQQKPGKAPKLLIFAASTLHSGVPSRFSGSGSGTEFTLTISLQPEDFATYYCQQLNSFPYTFGQGTKLEIK (SEQ ID NO:88). In some embodiments, a binding site that binds CD38 comprises: an antibody heavy chain variable (VH) domain comprising the amino acid sequence of SEQ ID NO:87, and/or an antibody light chain variable (VL) domain comprising the amino acid sequence of SEQ ID NO:88. In some embodiments, a binding site that binds CD38 comprises: an antibody heavy chain variable (VH) domain comprising the amino acid sequence of SEQ ID NO:87, and an antibody light chain variable (VL) domain comprising the amino acid sequence of SEQ ID NO:88.

[0339] In some embodiments, a binding site that binds CD38 comprises: an antibody heavy chain variable (VH) domain comprising an amino acid sequence that is at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of

QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVIWDYDGNKYYADSVKGRFTISGDNSKNTLYLQMNSLRAEDTAVYYCARMFRGAFDYWGQG TLTVTVSS (SEQ ID NO:89), and/or an antibody light chain variable (VL) domain comprising an amino acid sequence that is at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of

AIQMTQSPSSLSASVGDRVTITCRASQGIRNDLGWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISGLQPEDSATYYCLQDIYYPTFGQGTKVEIK (SEQ ID NO:90). In some embodiments, a binding site that binds CD38 comprises: an antibody heavy chain variable (VH) domain comprising the amino acid sequence of SEQ ID NO:89, and/or an antibody light chain variable (VL) domain comprising the amino acid sequence of SEQ ID NO:90. In some embodiments, a binding site that binds CD38 comprises: an antibody heavy chain variable (VH) domain comprising the amino acid sequence of SEQ ID NO:89, and an antibody light chain variable (VL) domain comprising the amino acid sequence of SEQ ID NO:90.

[0340] In some embodiments, a binding site that binds CD38 comprises: an antibody heavy chain variable (VH) domain comprising an amino acid sequence that is at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of

QVQLVQSGAEVKKPGASVKVSCKASGYSFTNYAVHWVRQAPGQGLEWMGVISPY YGDTTYAQKFQGRVTMTVDKSSSTAYMELSRLSDDTAVYYCARRFEGFYYSMDY WGQGTTLTVTVSS (SEQ ID NO:85), and/or an antibody light chain variable (VL) domain comprising an amino acid sequence that is at least 85%, at least

86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of DVVMTQSPLSLPVTLGQPASISCRPSQSLVHSNGNTYLNWYQQRPGQSPKLLIYKVS

KRFGSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCSQSTHVPLTFGGGTKEIK (SEQ ID NO:86). In some embodiments, a binding site that binds CD38 comprises: an antibody heavy chain variable (VH) domain comprising the amino acid sequence of SEQ ID NO:85, and/or an antibody light chain variable (VL) domain comprising the amino acid sequence of SEQ ID NO:86. In some embodiments, a binding site that binds CD38 comprises: an antibody heavy chain variable (VH) domain comprising the amino acid sequence of SEQ ID NO:85, and an antibody light chain variable (VL) domain comprising the amino acid sequence of SEQ ID NO:86.

[0341] In some embodiments, a binding site that binds CD38 comprises: an antibody heavy chain variable (VH) domain comprising an amino acid sequence that is at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of

QVQLQQSGPELVRPGTSVKVSCASGYAFTTYLVEWIKRPGQGLEWIGVINPGSGS

TNYNEKFKGKATLTVDRSSTTAYMHLSTGSDSAVYFCARYAYGYWGQGTTLTV SS (SEQ ID NO:277), and/or an antibody light chain variable (VL) domain comprising an amino acid sequence that is at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of

DIVMTQSQKFMASVGDRTSITCKASQNVGTAVAWYQQPGHSPKQLIYSASNRYT

GVPDRFTGSGAGTDFTLTISNIQSEDLADYFCQYSTYPFTFGSGTKLEIK (SEQ ID NO:278). In some embodiments, a binding site that binds CD38 comprises: an antibody heavy chain variable (VH) domain comprising the amino acid sequence of SEQ ID NO:277, and/or an antibody light chain variable (VL) domain comprising the amino acid sequence of SEQ ID NO:278. In some embodiments, a binding site that binds CD38 comprises: an antibody heavy chain variable (VH) domain comprising the amino acid sequence of SEQ ID NO:277, and an antibody light chain variable (VL) domain comprising the amino acid sequence of SEQ ID NO:278. In some embodiments, the VH and/or VL domains are humanized.

[0342] In some embodiments, a binding site that binds CD38 comprises: an antibody heavy chain variable (VH) domain comprising an amino acid sequence that is at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of

QVQLLQSGAELVRPGVSVKISCTGSGYSFTNYAVHWVKQSHVKSLEWIGVISPYG

TTYNQKFTGKATMTVDKSSSTAYMELARLTSEDSAIYFCARRFEGFYYSMDYWGQG TSVTVSS (SEQ ID NO:279), and/or an antibody light chain variable (VL) domain comprising an amino acid sequence that is at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of

DVVMITQPLSLPVSLGDQASISCRPSQSLVHSNGNTYLNWYLQRPQGSPKLLIYKVS

KRFGSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYLCQSTHVPLTFGSGTQLEIK (SEQ ID NO:280). In some embodiments, a binding site that binds CD38 comprises: an antibody heavy chain variable (VH) domain comprising the amino acid sequence of SEQ ID NO:279, and/or an antibody light chain variable (VL) domain comprising the amino acid sequence of SEQ ID NO:280. In some embodiments, a binding site that binds CD38 comprises: an antibody heavy chain variable (VH) domain comprising the amino acid sequence of SEQ ID NO:279, and an antibody light chain variable (VL) domain comprising the amino acid sequence of SEQ ID NO:280. In some embodiments, the VH and/or VL domains are humanized.

[0343] In some embodiments of any of the above embodiments, the binding protein is a trispecific binding protein. In some embodiments, the trispecific binding protein comprising an antigen binding site that binds a CD38 polypeptide, an antigen binding site that binds a CD28 polypeptide, and an antigen binding site that binds a CD3 polypeptide. In some embodiments, the binding protein is a trispecific binding protein comprising four polypeptides comprising three antigen binding sites, wherein the polypeptide of formula I and the polypeptide of formula II form a cross-over light chain-heavy chain pair (e.g., as described herein). In some embodiments, the VH and VL domains of any of the anti-CD38 antigen binding sites described above represent V.sub.H3 and V.sub.L3 and form a third antigen binding site that binds a CD38 polypeptide. In some embodiments, V.sub.H1 and V.sub.L1 form a first antigen binding site that binds a CD28 polypeptide, V.sub.H2 and V.sub.L2 form a second antigen binding site that binds a CD3 polypeptide, and the VH and VL domains of any of the anti-CD38 antigen binding sites described above and/or in Table 2 represent V.sub.H3 and V.sub.L3 and form a third antigen binding site that binds a CD38 polypeptide.

[0344] Sequences of exemplary anti-CD38 antigen binding sites are provided in Table 2. In some embodiments, a binding protein comprising an anti-CD38 antigen binding site of the present disclosure comprises 1, 2, 3, 4, 5, or all 6 CDR sequences of an anti-CD38 antibody described in Table 2. In some embodiments, a binding protein comprising an anti-CD38 antigen binding site of the present disclosure comprises a VH domain sequence and/or VL domain sequence of an anti-CD38 antibody described in Table 2.

TABLE-US-00001 TABLE 2 Anti-CD38 binding protein sequences. Se- SEQ quence Descrip- ID Type Molecule
tion NO Sequence CDR Anti-CD38 CDR-H1 13 GYTFTSYA (VH1) CDR-H2 14 IYPGQGGT CDR-H3 15

ARTGGLRRAYFTY CDR-L1 16 QSVSSYGQGF CDR-L2 17 GAS CDR-L3 18 QQNKEDPWT Anti-CD38 CDR-H1 19
GYTLTEFS (hh992) CDR-H2 20 FDPEDGET CDR-H3 21 TTGRFFDWF CDR-L1 22 QSVISRF CDR-L2 23 GAS CDR-
L3 24 QQDSNLPIT Anti-CD38 CDR-H1 25 GYAFTTYL (hyb5739) CDR-H2 26 INPGSGST CDR-H3 27 ARYAYGY

CDR-L1 28 QNVGTA CDR-L2 29 SAS CDR-L3 30 QQYSTYPT Anti-CD38 CDR-H1 31 GYSFTNYA (hyb6284) CDR-H2 32 ISPYGDT CDR-H3 33 ARREFGFYYSMDY CDR-L1 34 QSLVHSNGNTY CDR-L2 35 KVS CDR-L3 36 SQSTHVPLT Anti-CD38 CDR-H1 37 GFTFSSYG (hhy1195) CDR-H2 38 IWYDGSNK CDR-H3 39 ARDPGLRYFDGGMDV CDR-L1 40 QGISSY CDR-L2 41 AAS CDR-L3 42 QQLNSFPYT Anti-CD38 CDR-H1 43 GFTFSSYG (hhy1370) CDR-H2 44 IWYDGSNK CDR-H3 45 ARMFRGAFDY CDR-L1 46 QGIRND CDR-L2 47 AAS CDR-L3 48 LQDIYYPT Vari- CD38 VH 79 QVQLVQSGAEVVKPGASVKVCKASG able VH1 YTFTSYAMHWWKEAPGQRLEWIGYIYP domain GQGGTNYNQKFQGRATLTADTSASTA YMELSSLRSEDTAVYFCARTGGLRRAY FTYWGGQTLTVTVSS VL 80 DIVLTQSPATLSLSPGERATISCRASQSV SSYGQGFMHWYQQKPGQPPRLLIYGAS SRATGIPARFSGSGSGTDFTLTISPLED FAVYYCQQNKEDPWTFGGGKLEIK CD38 VH 81 QVQLVQSGAEVKKPGASVKVCKVSG hhy992 YTLTEFSIHWVRQAPGQGLEWMGGFDP EDGETIYAQKFQGRVIMTEDTSTDYAY MEMNSLRSEDTAIYYCTTGRFFDWFVG QGTLTVTVSS VL 82 EIILTQSPAILSLSPGERATLSCRASQSVI SRFLSWYQVKPGLAPRLLIYGASTRATG IPVRFSGSGSGTDFSLTISSLQPEDCAVY YCQQDSNLPITFGQGTRLEIK CD38 VH 83 QVQLVQSGAEVKKPGASVKVCKASG hu5739 YAFTTYLVEWIRQRPQGQGLEWMGVINP GSGSTNYAQKFQGRVTMTVDRSSTAY MELSRLRSDDTAVYYCARYAYGYWGQ GTLTVTVSS VL 84 DIQMTQSPSSLSASVGDRVTITCRASQN VGTAVAWYQQKPGKSPKQLIYSASNRY TGVPSRFSGSGSGTDFTLTISLQPEDLA TYCQQYSTYPTFTFGGKLEIK CD38 VH 85 QVQLVQSGAEVKKPGASVKVCKASG hu6284 YSFTNYAVHWVRQAPGQGLEWMGVIS PYYGDTTYAQKFQGRVTMTVDKSSSTA YMELSRLRSDDTAVYYCARRFEGFYYS MDYWGGQTLTVTVSS VL 86 DVVMTQSPLSLPVTLGQPASISCRPSQS LVHSNGNTYLNWYQQRPGQSPKLLIYK VSKRFSGVDPDRFSGSGSGTDFTLKISRVEAEDVGVYYCSQSTHVPLTFGGGKVE IK CD38 VH 87 QVQLVESGGGVVQPGRSLRLSCAASGF hhy1195 TFSSYGMWVRQAPGKGLEWVAVIYWG DGSNKYYADSVKGRFTISRDNKNTLY LQMNSLRSEDYAVYHCARDPGLRYFD GGMDVWGQGTITVTVSS VL 88 DIQLTQSPSFLSASVGDRVTITCRASQGI SSYLAWYQQKPGKAPKLLIFAASTLHS GVPSTRFSGSGSGTEFTLTISLQPEDFAT YYCQQLNSFPYTFGQGTLEIK CD38 VH 89 QVQLVESGGGVVQPGRSLRLSCAASGF hhy1370 TFSSYGMWVRQAPGKGLEWVAVIYWG DGSNKYYADSVKGRFTISRDNKNTLY LQMNSLRSEDYAVYCARMFRGAFDY WGQGTITVTVSS VL 90 AIQMTQSPSSLSASVGDRVTITCRASQGI RNDLGWYQQKPGKAPKLLIYAASLQS GVPSTRFSGSGSGTDFTLTISGLQPEDSAT YYCLQDIYYPTFTFGGKVEIK CD38 VH 277 QVQLQQSGPELVRPGTSVKVCKASGY hyb5739 AFTTYLVEWIKQRPQGQGLEWIGVINPGS GSTNYNEKFKGKATLTVDRSSTAYMH LSGLTSDSAVYFCARYAYGYWGQGT TLTVSS VL 278 DIVMTQSQKFMASAVGDRVSITCKASQ NVGTAVAWYQQQPGHSPKQLIYSASNR YTGVPDRFTGSGAGTDFTLTISNIQSEDL ADYFCQQYSTYPTFTFGSGTKLEIK CD38 VH 279 QVQLLQSGAELVRPGVSVKISCTGSGYS hyb6284 FTNYAVHWVKQSHVKSLEWIGVISPYG GDTTYNQKFTGKATMTVDKSSSTAYM ELARLTSEDSAIYFCARRFEGFYYSMDY WGQGTSTVTVSS VL 280 DVVMIQTPLSLPVSLGDQASISCRPSQSL VHSNGNTYLNWYLRPGQSPKLLIYKV SKRFSGVDPDRFSGSGSGTDFTLKISRVE AEDLGVYLCQSTHVPLTFGSGTQLEIK

[0345] Further provided herein are antibodies (e.g., monospecific antibodies) comprising any of the anti-CD38 CDRs and/or variable domains described supra.

[0346] In some embodiments, a binding protein of the present disclosure comprises an antigen binding site that binds an extracellular domain of a human CD38 polypeptide and an extracellular domain of a cynomolgus monkey CD38 polypeptide. Exemplary assays for determining whether an antigen binding site binds an antigen are described herein and known in the art, including (without limitation) ELISA, SPR, and flow cytometry assays.

Anti-HER2 Binding Sites

[0347] Certain aspects of the present disclosure relate to binding proteins that comprise an antigen binding site that binds a HER2 polypeptide. In some embodiments, the HER2 polypeptide is a human HER2 polypeptide, also known as NEU, NGL, ERBB2, TKR1, CD340, HER-2, MLN19, and HER-2/neu. Human HER2 polypeptides are known in the art and include, without limitation, the polypeptides represented by NCBI Accession Numbers XP_024306411.1, XP_024306410.1, XP_024306409.1, NP_001276867.1, NP_001276866.1, NP_001276865.1, NP_001005862.1, or NP_004439.2, or a polypeptide produced from NCBI Gene ID Number 2064. In some embodiments, a binding protein comprising an antigen binding site that binds a HER2 polypeptide is monospecific and/or monovalent, bispecific and/or bivalent, trispecific and/or trivalent, or multispecific and/or multivalent. In some embodiments, a binding protein that comprises an antigen binding site that binds a HER2 polypeptide is a trispecific binding protein comprising four polypeptides that form three antigen binding sites as described supra, wherein V.sub.H3 and V.sub.L3 domain pair that form a third antigen binding site that binds a HER2 polypeptide.

[0348] In some embodiments, a binding site that binds HER2 comprises: an antibody heavy chain variable (VH) domain comprising a CDR-H1 sequence comprising the amino acid sequence of GFNIKDTY (SEQ ID NO:1) or GFNIRDY (SEQ ID NO:2), a CDR-H2 sequence comprising the amino acid sequence of IYPTNGYT (SEQ ID NO:3), IYPTQGYT (SEQ ID NO:4), or IYPTNAYT (SEQ ID NO:5), and a CDR-H3 sequence comprising the amino acid sequence of SRWGGDGFYAMDY (SEQ ID NO:6), SRWGGEGFYAMDY (SEQ ID NO:7), or SRWGGSGFYAMDY (SEQ ID NO:8); and/or an antibody light chain variable (VL) domain comprising a CDR-L1 sequence comprising the amino acid sequence of QDVNTA (SEQ ID NO:9) or QDVQTA (SEQ ID NO:10), a CDR-L2 sequence comprising the amino acid sequence of SAS (SEQ ID NO:11), and a CDR-L3 sequence comprising the amino acid sequence of QQHYTTP (SEQ ID NO:12). In some

[0358] In some embodiments, a binding site that binds HER2 comprises: an antibody heavy chain variable (VH) domain comprising a CDR-H1 sequence comprising the amino acid sequence of GFNIRDY (SEQ ID NO:2), a CDR-H2 sequence comprising the amino acid sequence of IYPTNAYT (SEQ ID NO:5), and a CDR-H3 sequence comprising the amino acid sequence of SRWGGEGFYAMDY (SEQ ID NO:7); and/or an antibody light chain variable (VL) domain comprising a CDR-L1 sequence comprising the amino acid sequence of QDVQTA (SEQ ID NO:10), a CDR-L2 sequence comprising the amino acid sequence of SAS (SEQ ID NO:11), and a CDR-L3 sequence comprising the amino acid sequence of QQHYTTP (SEQ ID NO:12). In some embodiments, a binding site that binds HER2 comprises: an antibody heavy chain variable (VH) domain comprising a CDR-H1 sequence comprising the amino acid sequence of GFNIRDY (SEQ ID NO:2), a CDR-H2 sequence comprising the amino acid sequence of IYPTNAYT (SEQ ID NO:5), and a CDR-H3 sequence comprising the amino acid sequence of SRWGGEGFYAMDY (SEQ ID NO:7); and an antibody light chain variable (VL) domain comprising a CDR-L1 sequence comprising the amino acid sequence of QDVQTA (SEQ ID NO:10), a CDR-L2 sequence comprising the amino acid sequence of SAS (SEQ ID NO:11), and a CDR-L3 sequence comprising the amino acid sequence of QQHYTTP (SEQ ID NO:12).

EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNG
YTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGLTVTVSS (SEQ ID
NO:72), EVQLVESGGGLVQPGGSLRLSCAASGFNIRDYIHWVRQAPGKGLEWVARIYPTQG
YTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGEGFYAMDYWGQGLTVTVSS (SEQ ID NO:73),
EVQLVESGGGLVQPGGSLRLSCAASGFNIRDYIHWVRQAPGKGLEWVARIYPTQG
YTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGSGFYAMDYWGQGLTVTVSS (SEQ ID NO:74),
EVQLVESGGGLVQPGGSLRLSCAASGFNIRDYIHWVRQAPGKGLEWVARIYPTNA
YTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGSGFYAMDYWGQGLTVTVSS (SEQ ID NO:75),
or EVQLVESGGGLVQPGGSLRLSCAASGFNIRDYIHWVRQAPGKGLEWVARIYPTNA
YTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGEGFYAMDYWGQGLTVTVSS (SEQ ID
NO:76); and/or an antibody light chain variable (VL) domain comprising an amino acid sequence that is at least 85%, at least
86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least
95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of
DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSG
VPSRFGSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIK (SEQ ID NO:77) or
DIQMTQSPSSLSASVGDRVTITCRASQDVQTAFAWYQQKPGKAPKLLIYSASFLYSG
VPSRFGSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIK (SEQ ID NO:78). In some embodiments, a
binding site that binds HER2 comprises: an antibody heavy chain variable (VH) domain comprising the amino acid sequence
of SEQ ID NO:72, SEQ ID NO:73, SEQ ID NO:74, SEQ ID NO:75, or SEQ ID NO:76; and/or an antibody light chain
variable (VL) domain comprising the amino acid sequence of SEQ ID NO:77 or SEQ ID NO:78. In some embodiments, a
binding site that binds HER2 comprises: an antibody heavy chain variable (VH) domain comprising the amino acid sequence
of SEQ ID NO:72, SEQ ID NO:73, SEQ ID NO:74, SEQ ID NO:75, or SEQ ID NO:76; and an antibody light chain variable
(VL) domain comprising the amino acid sequence of SEQ ID NO:77 or SEQ ID NO:78.

EVQLVESGGGLVQPGGSLRLSCAASGFNIDQTYIHWRQAPGKGLEWVARIYPTNG
YTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGLTVTVSS (SEQ ID
NO:72), and/or an antibody light chain variable (VL) domain comprising an amino acid sequence that is at least 85%, at least
86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least
95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of
DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSG
VPSRFGSGRSGTDFTLTISLQPEDFATYYCQQHYTTPPTFGQGTKVEIK (SEQ ID NO:77). In some embodiments, a
binding site that binds HER2 comprises: an antibody heavy chain variable (VH) domain comprising the amino acid sequence
of SEQ ID NO:72, and/or an antibody light chain variable (VL) domain comprising the amino acid sequence of SEQ ID
NO:77. In some embodiments, a binding site that binds HER2 comprises: an antibody heavy chain variable (VH) domain
comprising the amino acid sequence of SEQ ID NO:72, and an antibody light chain variable (VL) domain comprising the
amino acid sequence of SEQ ID NO:77.

EVQLVESGGGLVQPGGSLRLSCAASGFINRDITYIHVVRQAPGKGLEWVARIYPTQG
YTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGEFGFYAMDYW GQGTLVTVSS (SEQ ID NO:73),

YTRYADSVKSGRSRGTDFLTITSLQPEDFATYYCQQHYTTTPPTFGQGGTKVEIK (SEQ ID NO:72), and/or an antibody light chain variable (VL) domain comprising an amino acid sequence that is at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of DIQMTQSPSSLSASVGDRTITCRASQDVQTAVAWYQQKPGKAPKLLIYSASFLYSG VPSRFGSGRSRGTDFLTITSLQPEDFATYYCQQHYTTTPPTFGQGGTKVEIK (SEQ ID NO:78). In some embodiments, a binding site that binds HER2 comprises: an antibody heavy chain variable (VH) domain comprising the amino acid sequence of SEQ ID NO:72, and/or an antibody light chain variable (VL) domain comprising the amino acid sequence of SEQ ID NO:78. In some embodiments, a binding site that binds HER2 comprises: an antibody heavy chain variable (VH) domain comprising the amino acid sequence of SEQ ID NO:72, and an antibody light chain variable (VL) domain comprising the amino acid sequence of SEQ ID NO:78.

[0366] In some embodiments, an anti-HER2 antigen binding site of the present disclosure comprises 1, 2, 3, 4, 5, or all 6 CDR sequences of anti-HER2 antibody trastuzumab, 30R/55Q/102E, 30R/56A/102S, 30R/55Q/102S, 30R/56A/102E, or 30Q. In some embodiments, an anti-HER2 antigen binding site of the present disclosure comprises a VH domain sequence and/or VL domain sequence of anti-HER2 antibody trastuzumab, 30R/55Q/102E, 30R/56A/102S, 30R/55Q/102S, 30R/56A/102E, or 30Q.

[0367] Sequences of exemplary anti-HER2 antigen binding sites are provided in Table 3. In some embodiments, an anti-HER2 antigen binding site of the present disclosure comprises 1, 2, 3, 4, 5, or all 6 CDR sequences of an anti-HER2 antibody described in Table 3. In some embodiments, an anti-HER2 antigen binding site of the present disclosure comprises a VH domain sequence and/or VL domain sequence of an anti-HER2 antibody described in Table 3.

TABLE-US-00002 TABLE 3 Anti-HER2 binding protein sequences. Sequence SEQ Type Molecule Description ID NO Sequence CDR Anti-Her2 CDR-H1 1 GFNIKDTY (trastuzumab) (original) Heavy chain CDR-H1 2 GFNIRDY CDRs 30R CDR-H2 3 IYPTNGYT (original) CDR-H2 4 IYPTQGYT 55Q CDR-H2 5 IYPTNAYT 56A CDR-H3 6 SRWGGDGFYAMDY (original) CDR-H3 7 SRWGGEGFYAMDY 102E CDR-H3 8 SRWGGSGFYAMDY 102S Anti-Her2 CDR-L1 9 QDVNTA (trastuzumab) (original) Light chain CDR-L1 10 QDVQTA CDRs 30Q CDR-L2 11 SAS (original) CDR-L3 12 QQHYTTP (original) Variable Anti-Her2 VH wt 72 EVQLVESGGGLVQPGGSLRLSCAASGF domain Trastuzumab NIKDTYIHWRQAPGKGLEWVARIYP and variant TNGYTRYADSVKGRFTISADTSKNTAYL VH LQMNSLRAEDTAVYYCSRWGGDGFY AMDYWGQGTSLVTVSS VH 73 EVQLVESGGGLVQPGGSLRLSCAASGF 30R/55Q/102E NIRDYIHWRQAPGKGLEWVARIYPT QGYTRYADSVKGRFTISADTSKNTAYL QMNSLRAEDTAVYYCSRWGGEGFYA MDYWGQGTSLVTVSS VH 74 EVQLVESGGGLVQPGGSLRLSCAASGF 30R/55Q/102S NIRDYIHWRQAPGKGLEWVARIYPT QGYTRYADSVKGRFTISADTSKNTAYL QMNSLRAEDTAVYYCSRWGGSGFYA MDYWGQGTSLVTVSS VH 75 EVQLVESGGGLVQPGGSLRLSCAASGF 30R/56A/102S NIRDYIHWRQAPGKGLEWVARIYPT NAYTRYADSVKGRFTISADTSKNTAYL QMNSLRAEDTAVYYCSRWGGSGFYA MDYWGQGTSLVTVSS VH 76 EVQLVESGGGLVQPGGSLRLSCAASGF 30R/56A/102E NIRDYIHWRQAPGKGLEWVARIYPT NAYTRYADSVKGRFTISADTSKNTAYL QMNSLRAEDTAVYYCSRWGGEGFYA MDYWGQGTSLVTVSS Anti-Her2 VL wt 77 DIQMTQSPSSLSASVGDRTITCRASQ Trastuzumab DVNTAVAWYQQKPGKAPKLLIYSASF and variant LYSGVPSRFGSGRSRGTDFLTITSLQPE VL DFATYYCQQHYTTTPPTFGQGGTKVEIK VL 30Q 78 DIQMTQSPSSLSASVGDRTITCRASQ DVQTAVAWYQQKPGKAPKLLIYSASF LYSGVPSRFGSGRSRGTDFLTITSLQPE DFATYYCQQHYTTTPPTFGQGGTKVEIK

Other Anti-Tumor Target Binding Sites

[0368] In some embodiments, a binding protein of the present disclosures comprises an antigen binding site that binds a tumor target protein. In some embodiments, the tumor target protein is a CD38 polypeptide (e.g., a human CD38 polypeptide). In some embodiments, the tumor target protein is a HER2 polypeptide (e.g., a human HER2 polypeptide). In some embodiments, a tumor target protein of the present disclosure includes, without limitation, A2AR, APRIL, ATPDase, BAFF, BAFFR, BCMA, BlyS, BTK, BTLA, B7DC, B7H1, B7H4 (also known as VTCN1), B7H5, B7H6, B7H7, B7RP1, B7-4, C3, C5, CCL2 (also known as MCP-1), CCL3 (also known as MIP-1a), CCL4 (also known as MIP-1b), CCL5 (also known as RANTES), CCL7 (also known as MCP-3), CCL8 (also known as mcp-2), CCL11 (also known as eotaxin), CCL15 (also known as MIP-1d), CCL17 (also known as TARC), CCL19 (also known as MIP-3b), CCL20 (also known as MIP-3a), CCL21 (also known as MIP-2), CCL24 (also known as MPIF-2/eotaxin-2), CCL25 (also known as TECK), CCL26 (also known as eotaxin-3), CCR3, CCR4, CD3, CD19, CD20, CD23 (also known as FCER2, a receptor for IgE), CD24, CD27, CD28, CD38, CD39, CD40, CD70, CD80 (also known as B7-1), CD86 (also known as B7-2), CD122, CD137 (also known as 41BB), CD137L, CD152 (also known as CTLA4), CD154 (also known as CD40L), CD160, CD272, CD273 (also known as PDL2), CD274 (also known as PDL1), CD275 (also known as B7H2), CD276 (also known as B7H3), CD278 (also known as ICOS), CD279 (also known as PD-1), CDH1 (also known as E-cadherin), chitinase, CLEC9, CLEC91, CRTH2, CSF-1 (also known as M-CSF), CSF-2 (also known as GM-CSF), CSF-3 (also known as GCSF), CX3CL1 (also known as SCYD1), CXCL12 (also known as SDF1), CXCL13, CXCR3, DNGR-1, ectonucleoside triphosphate diphosphohydrolase 1, EGFR, ENTPD1, FCER1A, FCER1, FLAP, FOLH1, Gi24, GITR, GITRL, GM-CSF, Her2, HHLA2, HMGB1, HVEM, ICOSLG, IDO, IFN α , IgE, IGF1R, IL2Rbeta, IL1, IL1A, IL1B, IL1F10, IL2, IL4, IL4Ra, IL5, IL5R, IL6, IL7, IL7Ra, IL8, IL9, IL9R, IL10, rhIL10, IL12, IL13, IL13Ra1, IL13Ra2, IL15, IL17, IL17Rb (also known as a receptor for IL25), IL18, IL22, IL23, IL25, IL27, IL33, IL35, ITGB4 (also known as b4 integrin), ITK, KIR, LAG3, LAMP1, leptin, LPFS2, MHC class II, MUC-1, NCR3LG1, NKG2D, NTPDase-1, OX40, OX40L, PD-1H, platelet receptor, PROM1, S152, SISP1, SLC, SPG64, ST2 (also known as a receptor for IL33), STEAP2, Syk kinase, TACI, TDO, T14, TIGIT, TIM3, TLR, TLR2, TLR4, TLR5,

TLR9, TNFRSF1, TNF α , TNFRSF7, Tp55, TNFRSF7 (also known as a co-receptor for IL7Ra), TSLPR, TWEAK, VEGF, VISTA, Vstm3, WUCAM, and XCR1 (also known as GPR5/CCXCR1). In some embodiments, one or more of the above antigen targets are human antigen targets.

Anti-CD28 Binding Sites

[0369] Certain aspects of the present disclosure relate to binding proteins that comprise an antigen binding site that binds a CD28 polypeptide. In some embodiments, the CD28 polypeptide is a human CD28 polypeptide, also known as Tp44. Human CD28 polypeptides are known in the art and include, without limitation, the polypeptides represented by NCBI Accession Numbers XP_011510499.1, XP_011510497.1, XP_011510496.1, NP_001230007.1, NP_001230006.1, or NP_006130.1, or a polypeptide produced from NCBI Gene ID Number 940. In some embodiments, a binding protein comprising an antigen binding site that binds a CD28 polypeptide is monospecific and/or monovalent, bispecific and/or bivalent, trispecific and/or trivalent, or multispecific and/or multivalent. In some embodiments, a binding protein that comprises an antigen binding site that binds a CD28 polypeptide is a trispecific binding protein comprising four polypeptides that form three antigen binding sites. In some embodiments, a binding protein that comprises an antigen binding site that binds a CD28 polypeptide is a trispecific binding protein comprising four polypeptides that form three antigen binding sites, one of which binds a CD28 polypeptide, and one of which binds a CD3 polypeptide. In some embodiments, a binding protein that comprises an antigen binding site that binds a CD3 polypeptide is a trispecific binding protein comprising four polypeptides that form three antigen binding sites, one of which binds a CD28 polypeptide, one of which binds a CD3 polypeptide, and one of which binds a CD38 polypeptide. In some embodiments, a binding protein that comprises an antigen binding site that binds a CD3 polypeptide is a trispecific binding protein comprising four polypeptides that form three antigen binding sites, one of which binds a CD28 polypeptide, one of which binds a CD3 polypeptide, and one of which binds a HER2 polypeptide. In some embodiments, a binding protein that comprises an antigen binding site that binds a CD3 polypeptide is a trispecific binding protein comprising four polypeptides that form three antigen binding sites, one of which binds a CD28 polypeptide, one of which binds a CD3 polypeptide, and one of which binds a tumor target protein.

[0370] In some embodiments, a binding site that binds CD28 comprises: an antibody heavy chain variable (VH) domain comprising a CDR-H1 sequence comprising the amino acid sequence of GYTFTSY (SEQ ID NO:49), a CDR-H2 sequence comprising the amino acid sequence of IYPGNVNT (SEQ ID NO:50), and a CDR-H3 sequence comprising the amino acid sequence of TRSHYGLDWNFDV (SEQ ID NO:51) and/or an antibody light chain variable (VL) domain comprising a CDR-L1 sequence comprising the amino acid sequence of QNIYVW (SEQ ID NO:52), a CDR-L2 sequence comprising the amino acid sequence of KAS (SEQ ID NO:53), and a CDR-L3 sequence comprising the amino acid sequence of QQGQTPY (SEQ ID NO:54). In some embodiments, a binding site that binds CD28 comprises: an antibody heavy chain variable (VH) domain comprising a CDR-H1 sequence comprising the amino acid sequence of GYTFTSY (SEQ ID NO:49), a CDR-H2 sequence comprising the amino acid sequence of IYPGNVNT (SEQ ID NO:50), and a CDR-H3 sequence comprising the amino acid sequence of TRSHYGLDWNFDV (SEQ ID NO:51); and an antibody light chain variable (VL) domain comprising a CDR-L1 sequence comprising the amino acid sequence of QNIYVW (SEQ ID NO:52), a CDR-L2 sequence comprising the amino acid sequence of KAS (SEQ ID NO:53), and a CDR-L3 sequence comprising the amino acid sequence of QQGQTPY (SEQ ID NO:54).

[0371] In some embodiments, a binding site that binds CD28 comprises: an antibody heavy chain variable (VH) domain comprising an amino acid sequence that is at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of

QVQLVQSGAEVVKPGASVKVSKASGYTFTSYIHVWRQAPGQGLEWIGSIYPGNV

NTNYAQKFQGRATLTVDTSISTAYMELSRLSDDTAVYYCTRSHYGLDWNFDVWG KGTTVTVSS (SEQ ID NO:91), and/or an antibody light chain variable (VL) domain comprising an amino acid sequence that is at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of

DIQMTQSPSSLSASVGRVTITCQASQNIYVWLNWYQKPGKAPKLLIYKASNLHTG

VPSRFGSGSGTDFLTISLQPEDATYYCQQGQTPYTFGQGTKLEIK (SEQ ID NO:92). In some embodiments, a binding site that binds CD28 comprises: an antibody heavy chain variable (VH) domain comprising the amino acid sequence of SEQ ID NO:91, and/or an antibody light chain variable (VL) domain comprising the amino acid sequence of SEQ ID NO:92. In some embodiments, a binding site that binds CD28 comprises: an antibody heavy chain variable (VH) domain comprising the amino acid sequence of SEQ ID NO:91, and an antibody light chain variable (VL) domain comprising the amino acid sequence of SEQ ID NO:92.

[0372] In some embodiments of any of the above embodiments, the binding protein is a trispecific binding protein. In some embodiments, the trispecific binding protein comprising an antigen binding site that binds a tumor target protein (including, without limitation, CD38 or HER2), an antigen binding site that binds a CD28 polypeptide, and an antigen binding site that binds a CD3 polypeptide. In some embodiments, the binding protein is a trispecific binding protein comprising four polypeptides comprising three antigen binding sites, wherein the polypeptide of formula I and the polypeptide of formula II form a cross-over light chain-heavy chain pair (e.g., as described herein). In some embodiments, the VH and VL domains of any of the anti-CD28 antigen binding sites described above represent V_{sub}.H1 and V_{sub}.L1 and form a first antigen binding site that binds a CD28 polypeptide. In some embodiments, the VH and VL domains of any of the anti-CD28 antigen binding sites described above and/or in Table 4 represent V_{sub}.H1 and V_{sub}.L1 and form a first antigen binding site that binds a CD28 polypeptide, V_{sub}.H2 and V_{sub}.L2 form a second antigen binding site that binds a CD3 polypeptide, and V_{sub}.H3 and V_{sub}.L3 and form a third antigen binding site that binds a tumor target protein (including, without limitation, CD38 or

HER2).

[0373] Sequences of exemplary anti-CD28 antigen binding sites are provided in Table 4. In some embodiments, an anti-CD28 antigen binding site of the present disclosure comprises 1, 2, 3, 4, 5, or all 6 CDR sequences of an anti-CD28 antibody described in Table 4. In some embodiments, an anti-CD28 antigen binding site of the present disclosure comprises a VH domain sequence and/or VL domain sequence of an anti-CD28 antibody described in Table 4.

TABLE-US-00003 TABLE 4 Anti-CD28 binding protein sequences. Sequence SEQ Type Molecule Description ID
NO Sequence CDR Anti-CD28 CDR-H1 49 GYTFSTYY (sup) CDR-H2 50 IYPGNVNT CDR-H3 51 TRSHYGLDWNFDV
CDR-L1 52 QNIYVW CDR-L2 53 KAS CDR-L3 54 QQGQTPY Variable Anti-CD28 VH 91
QVQLVQSGAEVVKPGASVKVCKASGYT domain (sup) FTSYYIHWVRQAPGQGLEWIGSIYPGNVN
TNYAQKFQGRATLTVDTSISTAYMELSRL RSDDTAVYYCTRSHYGLDWNFDVWGKG TTVTVSS VL 92
DIQMTQSPSSLSASVGDRTITCQASQNIY VWLNWYQQKPGKAPKLLIYKASNLTGTV
PSRFGSGSGTDFLTITSLQPEDIATYYCQ QGQTPYTFGQGTKLEIK

Anti-CD3 Binding Sites

[0374] Certain aspects of the present disclosure relate to binding proteins that comprise an antigen binding site that binds a CD3 polypeptide. In some embodiments, the CD3 polypeptide is a human CD3 polypeptide, including CD3-delta (also known as T3D, IMD19, and CD3-DELTA), CD3-epsilon (also known as T3E, IMD18, and TCRE), and CD3-gamma (also known as T3G, IMD17, and CD3-GAMMA). Human CD3 polypeptides are known in the art and include, without limitation, the polypeptides represented by NCBI Accession Numbers XP_006510029.1 or NP_031674.1, or a polypeptide produced from NCBI Gene ID Numbers 915, 916, or 917. In some embodiments, a binding protein comprising an antigen binding site that binds a CD3 polypeptide is monospecific and/or monovalent, bispecific and/or bivalent, trispecific and/or trivalent, or multispecific and/or multivalent. In some embodiments, a binding protein that comprises an antigen binding site that binds a CD3 polypeptide is a trispecific binding protein comprising four polypeptides that form three antigen binding sites. In some embodiments, a binding protein that comprises an antigen binding site that binds a CD3 polypeptide is a trispecific binding protein comprising four polypeptides that form three antigen binding sites, one of which binds a CD28 polypeptide, and one of which binds a CD3 polypeptide. In some embodiments, a binding protein that comprises an antigen binding site that binds a CD3 polypeptide is a trispecific binding protein comprising four polypeptides that form three antigen binding sites, one of which binds a CD28 polypeptide, one of which binds a CD3 polypeptide, and one of which binds a CD38 polypeptide. In some embodiments, a binding protein that comprises an antigen binding site that binds a CD3 polypeptide is a trispecific binding protein comprising four polypeptides that form three antigen binding sites, one of which binds a CD28 polypeptide, one of which binds a CD3 polypeptide, and one of which binds a HER2 polypeptide. In some embodiments, a binding protein that comprises an antigen binding site that binds a CD3 polypeptide is a trispecific binding protein comprising four polypeptides that form three antigen binding sites, one of which binds a CD28 polypeptide, one of which binds a CD3 polypeptide, and one of which binds a tumor target protein.

[0375] In some embodiments, a binding site that binds CD3 comprises: an antibody heavy chain variable (VH) domain comprising a CDR-H1 sequence comprising the amino acid sequence of GFTFTKAW (SEQ ID NO:55), a CDR-H2 sequence comprising the amino acid sequence of IKDKSNSYAT (SEQ ID NO:56), and a CDR-H3 sequence comprising the amino acid sequence of RGVYYALSPFDY (SEQ ID NO:57); and/or an antibody light chain variable (VL) domain comprising a CDR-L1 sequence comprising the amino acid sequence of QSLVHX.sub.1NX.sub.2X.sub.3TY, wherein X.sub.1 is E or Q, X.sub.2 is A or L, and X.sub.3 is Q, R, or F (SEQ ID NO:180), a CDR-L2 sequence comprising the amino acid sequence of KVS (SEQ ID NO:64), and a CDR-L3 sequence comprising the amino acid sequence of GQGTQYPFT (SEQ ID NO:65). In some embodiments, the CDR-L1 sequence of the V.sub.L2 domain comprises an amino acid sequence selected from the group consisting of QSLVHQNAQTY (SEQ ID NO:59), QSLVHENLQTY (SEQ ID NO:60), QSLVHENLFTY (SEQ ID NO:61), and QSLVHENLRTY (SEQ ID NO:62).

[0376] In some embodiments, a binding site that binds CD3 comprises: an antibody heavy chain variable (VH) domain comprising a CDR-H1 sequence comprising the amino acid sequence of GFTFTKAW (SEQ ID NO:55), a CDR-H2 sequence comprising the amino acid sequence of IKDKSNSYAT (SEQ ID NO:56), and a CDR-H3 sequence comprising the amino acid sequence of RGVYYALSPFDY (SEQ ID NO:57); and/or an antibody light chain variable (VL) domain comprising a CDR-L1 sequence comprising the amino acid sequence of QSLVHQNAQTY (SEQ ID NO:59), a CDR-L2 sequence comprising the amino acid sequence of KVS (SEQ ID NO:64), and a CDR-L3 sequence comprising the amino acid sequence of GQGTQYPFT (SEQ ID NO:65). In some embodiments, a binding site that binds CD3 comprises: an antibody heavy chain variable (VH) domain comprising a CDR-H1 sequence comprising the amino acid sequence of GFTFTKAW (SEQ ID NO:55), a CDR-H2 sequence comprising the amino acid sequence of IKDKSNSYAT (SEQ ID NO:56), and a CDR-H3 sequence comprising the amino acid sequence of RGVYYALSPFDY (SEQ ID NO:57); and an antibody light chain variable (VL) domain comprising a CDR-L1 sequence comprising the amino acid sequence of QSLVHQNAQTY (SEQ ID NO:59), a CDR-L2 sequence comprising the amino acid sequence of KVS (SEQ ID NO:64), and a CDR-L3 sequence comprising the amino acid sequence of GQGTQYPFT (SEQ ID NO:65).

[0377] In some embodiments, a binding site that binds CD3 comprises: an antibody heavy chain variable (VH) domain comprising a CDR-H1 sequence comprising the amino acid sequence of GFTFTKAW (SEQ ID NO:55), a CDR-H2 sequence comprising the amino acid sequence of IKDKSNSYAT (SEQ ID NO:56), and a CDR-H3 sequence comprising the amino acid sequence of RGVYYALSPFDY (SEQ ID NO:57); and/or an antibody light chain variable (VL) domain comprising a CDR-L1 sequence comprising the amino acid sequence of QSLVHENLQTY (SEQ ID NO:60), a CDR-L2 sequence comprising the amino acid sequence of KVS (SEQ ID NO:64), and a CDR-L3 sequence comprising the amino acid sequence of GQGTQYPFT (SEQ ID NO:65). In some embodiments, a binding site that binds CD3 comprises: an antibody heavy chain

variable (VH) domain comprising a CDR-H1 sequence comprising the amino acid sequence of GFTFTKAW (SEQ ID NO:55), a CDR-H2 sequence comprising the amino acid sequence of IKDKSNSYAT (SEQ ID NO:56), and a CDR-H3 sequence comprising the amino acid sequence of RGVYYALSPFDY (SEQ ID NO:57); and an antibody light chain variable (VL) domain comprising a CDR-L1 sequence comprising the amino acid sequence of QSLVHENLQTY (SEQ ID NO:60), a CDR-L2 sequence comprising the amino acid sequence of KVS (SEQ ID NO:64), and a CDR-L3 sequence comprising the amino acid sequence of GQGTQYPFT (SEQ ID NO:65).

[0378] In some embodiments, a binding site that binds CD3 comprises: an antibody heavy chain variable (VH) domain comprising a CDR-H1 sequence comprising the amino acid sequence of GFTFTKAW (SEQ ID NO:55), a CDR-H2 sequence comprising the amino acid sequence of IKDKSNSYAT (SEQ ID NO:56), and a CDR-H3 sequence comprising the amino acid sequence of RGVYYALSPFDY (SEQ ID NO:57); and/or an antibody light chain variable (VL) domain comprising a CDR-L1 sequence comprising the amino acid sequence of QSLVHENLFTY (SEQ ID NO:61), a CDR-L2 sequence comprising the amino acid sequence of KVS (SEQ ID NO:64), and a CDR-L3 sequence comprising the amino acid sequence of GQGTQYPFT (SEQ ID NO:65). In some embodiments, a binding site that binds CD3 comprises: an antibody heavy chain variable (VH) domain comprising a CDR-H1 sequence comprising the amino acid sequence of GFTFTKAW (SEQ ID NO:55), a CDR-H2 sequence comprising the amino acid sequence of IKDKSNSYAT (SEQ ID NO:56), and a CDR-H3 sequence comprising the amino acid sequence of RGVYYALSPFDY (SEQ ID NO:57); and an antibody light chain variable (VL) domain comprising a CDR-L1 sequence comprising the amino acid sequence of QSLVHENLFTY (SEQ ID NO:61), a CDR-L2 sequence comprising the amino acid sequence of KVS (SEQ ID NO:64), and a CDR-L3 sequence comprising the amino acid sequence of GQGTQYPFT (SEQ ID NO:65).

[0379] In some embodiments, a binding site that binds CD3 comprises: an antibody heavy chain variable (VH) domain comprising a CDR-H1 sequence comprising the amino acid sequence of GFTFTKAW (SEQ ID NO:55), a CDR-H2 sequence comprising the amino acid sequence of IKDKSNSYAT (SEQ ID NO:56), and a CDR-H3 sequence comprising the amino acid sequence of RGVYYALSPFDY (SEQ ID NO:57); and/or an antibody light chain variable (VL) domain comprising a CDR-L1 sequence comprising the amino acid sequence of QSLVHENLRTY (SEQ ID NO:62), a CDR-L2 sequence comprising the amino acid sequence of KVS (SEQ ID NO:64), and a CDR-L3 sequence comprising the amino acid sequence of GQGTQYPFT (SEQ ID NO:65). In some embodiments, a binding site that binds CD3 comprises: an antibody heavy chain variable (VH) domain comprising a CDR-H1 sequence comprising the amino acid sequence of GFTFTKAW (SEQ ID NO:55), a CDR-H2 sequence comprising the amino acid sequence of IKDKSNSYAT (SEQ ID NO:56), and a CDR-H3 sequence comprising the amino acid sequence of RGVYYALSPFDY (SEQ ID NO:57); and an antibody light chain variable (VL) domain comprising a CDR-L1 sequence comprising the amino acid sequence of QSLVHENLRTY (SEQ ID NO:62), a CDR-L2 sequence comprising the amino acid sequence of KVS (SEQ ID NO:64), and a CDR-L3 sequence comprising the amino acid sequence of GQGTQYPFT (SEQ ID NO:65).

[0380] In some embodiments, a binding site that binds CD3 comprises: an antibody heavy chain variable (VH) domain comprising an amino acid sequence that is at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of

QVQLVESGGGVVQPGRSLRLSCAASGFTFTKAWMHWRQAPGKQLEWVAQIKDKS
NSYATYYADSVKGRFTISRDDSKNTLYLQMNSLRAEDTAVYYCRGVYYALSPFDY WGQGTTLVTVSS (SEQ ID NO:93), and/or an antibody light chain variable (VL) domain comprising an amino acid sequence that is at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to an amino acid sequence selected from the group consisting of DIVMTQTPLSLSVTPGQPASISCKSSQSLVHQNAQTYLSWYLQKPGQSPQSLIYKVS
NRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCGQGTQYPFTFGSGTKVEIK (SEQ ID NO:95),
DIVMTQTPLSLSVTPGQPASISCKSSQSLVHENLQTYLSWYLQKPGQSPQSLIYKVS
NRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCGQGTQYPFTFGSGTKVEIK (SEQ ID NO:96),
DIVMTQTPLSLSVTPGQPASISCKSSQSLVHENLFTYLSWYLQKPGQSPQSLIYKVS
NRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCGQGTQYPFTFGSGTKVEIK (SEQ ID NO:97), and
DIVMTQTPLSLSVTPGQPASISCKSSQSLVHENLRTYLSWYLQKPGQSPQSLIYKVS
NRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCGQGTQYPFTFGSGTKVEIK (SEQ ID NO:98). In some
embodiments, a binding site that binds CD3 comprises: an antibody heavy chain variable (VH) domain comprising the amino
acid sequence of SEQ ID NO:93, and/or an antibody light chain variable (VL) domain comprising an amino acid sequence
selected from the group consisting of SEQ ID NO:95, SEQ ID NO:96, SEQ ID NO:97, and SEQ ID NO:98. In some
embodiments, a binding site that binds CD3 comprises: an antibody heavy chain variable (VH) domain comprising the amino
acid sequence of SEQ ID NO:93, and an antibody light chain variable (VL) domain comprising an amino acid sequence
selected from the group consisting of SEQ ID NO:95, SEQ ID NO:96, SEQ ID NO:97, and SEQ ID NO:98.

[0381] In some embodiments, a binding site that binds CD3 comprises: an antibody heavy chain variable (VH) domain comprising an amino acid sequence that is at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of

QVQLVESGGGVVQPGRSLRLSCAASGFTFTKAWMHWRQAPGKQLEWVAQIKDKS
NSYATYYADSVKGRFTISRDDSKNTLYLQMNSLRAEDTAVYYCRGVYYALSPFDY WGQGTTLVTVSS (SEQ ID NO:93), and/or an antibody light chain variable (VL) domain comprising an amino acid sequence that is at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least

QVQLVESGGGVVQPGRSLRLSCAASGFTFTKAWMHWVRQAPGKQLEWVAQIKDKS
NSYATYYASSVKGRFTISRDDSKNTLYLQMNSLRAEDTAVYYCRGVYYALSPFDYW GQGLTVTVSS (SEQ ID
NO:595), and/or an antibody light chain variable (VL) domain comprising an amino acid sequence that is at least 85%, at

least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of DIVMTQTPLSLSVTPGQPASISCKSSQSLVHQNAQTYLSWYLQKPGQSPQSLIYKVS NRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCGQGTQYPFTFGSGTKVEIK (SEQ ID NO:95). In some embodiments, a binding site that binds CD3 comprises: an antibody heavy chain variable (VH) domain comprising the amino acid sequence of SEQ ID NO:595, and/or an antibody light chain variable (VL) domain comprising the amino acid sequence of SEQ ID NO:95. In some embodiments, a binding site that binds CD3 comprises: an antibody heavy chain variable (VH) domain comprising the amino acid sequence of SEQ ID NO:595, and an antibody light chain variable (VL) domain comprising the amino acid sequence of SEQ ID NO:95

[0386] In some embodiments of any of the above embodiments, the binding protein is a trispecific binding protein. In some embodiments, the trispecific binding protein comprising an antigen binding site that binds a tumor target protein (including, without limitation, CD38 or HER2), an antigen binding site that binds a CD28 polypeptide, and an antigen binding site that binds a CD3 polypeptide. In some embodiments, the binding protein is a trispecific binding protein comprising four polypeptides comprising three antigen binding sites, wherein the polypeptide of formula I and the polypeptide of formula II form a cross-over light chain-heavy chain pair (e.g., as described herein). In some embodiments, the VH and VL domains of any of the anti-CD3 antigen binding sites described above represent V.sub.H2 and V.sub.L2 and form a second antigen binding site that binds a CD3 polypeptide. In some embodiments, V.sub.H1 and V.sub.L1 form a first antigen binding site that binds a CD28 polypeptide, the VH and VL domains of any of the anti-CD3 antigen binding sites described above and/or in Table 5 represent V.sub.H2 and V.sub.L2 and form a second antigen binding site that binds a CD3 polypeptide, and V.sub.H3 and V.sub.L3 form a third antigen binding site that binds a tumor target protein (including, without limitation, CD38 or HER2).

[0387] Sequences of exemplary anti-CD3 antigen binding sites are provided in Table 5. In some embodiments, an anti-CD3 antigen binding site of the present disclosure comprises 1, 2, 3, 4, 5, or all 6 CDR sequences of an anti-CD3 antibody described in Table 5. In some embodiments, an anti-CD3 antigen binding site of the present disclosure comprises a VH domain sequence and/or VL domain sequence of an anti-CD3 antibody described in Table 5.

TABLE-US-00004 TABLE 5 Anti-CD3 binding protein sequences. Sequence SEQ ID Type Molecule Description
NO Sequence CDR Anti-CD3 CDR-H1 55 GFTFTKAW (mid) original CDR-H2 56 IKDKSNSYAT original CDR-H3 57
RGVYYALSPFDY original CDR-L1 58 QSLVHNNANTY original CDR-L1 59 QSLVHQNAQTY QQ CDR-L1 60
QSLVHENLQTY ENLQ CDR-L1 61 QSLVHENLFTY ENLF CDR-L1 62 QSLVHENLRTY ENLR CDR-L1 63
QSLVHDNAQTY DNAQ CDR-L2 64 KVS original CDR-L3 65 GQGTQYPFT Original CD3mid 180
QSLVHX.sub.1NX.sub.2X.sub.3TY, consensus wherein X.sub.1 is E or Q, X.sub.2 is A CDR-L1 or L,
and X.sub.3 is Q, R, or F Variable Anti-CD3 VH 93 QVQLVESGGGVVQPGRSLRLSCAASGFT Domain (mid)
FTKAWMHWVRQAPGKQLEWVAQIKDK SNSYATYYADSVKGRFTISRDDSKNTLY
LQMNSLRAEDTAVYYCRGVYYALSPFD YWGQGTTLTVSS VL 94 DIVMTQTPLSLSVTPGQPASISCKSSQSL
Original VHNNANTYLSWYLQKPGQSPQSLIYKVS NRFSGVPDRFSGSGSGTDFTLKISRVEAE
DVG VYYCGQGTQYPFTFGSGTKVEIK VL 95 DIVMTQTPLSLSVTPGQPASISCKSSQSL 32/35 QQ
VHQNAQTYLSWYLQKPGQSPQSLIYKVS NRFSGVPDRFSGSGSGTDFTLKISRVEAE
DVG VYYCGQGTQYPFTFGSGTKVEIK VL 96 DIVMTQTPLSLSVTPGQPASISCKSSQSL ENLQ
VHENLQTYLSWYLQKPGQSPQSLIYKVS NRFSGVPDRFSGSGSGTDFTLKISRVEAE
DVG VYYCGQGTQYPFTFGSGTKVEIK VL 97 DIVMTQTPLSLSVTPGQPASISCKSSQSL ENLF
VHENLFTYLSWYLQKPGQSPQSLIYKVS NRFSGVPDRFSGSGSGTDFTLKISRVEAE
DVG VYYCGQGTQYPFTFGSGTKVEIK VL 98 DIVMTQTPLSLSVTPGQPASISCKSSQSL ENLR
VHENLRTYLSWYLQKPGQSPQSLIYKVS NRFSGVPDRFSGSGSGTDFTLKISRVEAE
DVG VYYCGQGTQYPFTFGSGTKVEIK VL 99 DIVMTQTPLSLSVTPGQPASISCKSSQSL DNAQ
VHDNAQTYLSWYLQKPGQSPQSLIYKVS NRFSGVPDRFSGSGSGTDFTLKISRVEAE
DVG VYYCGQGTQYPFTFGSGTKVEIK VH 185S 595 QVQLVESGGGVVQPGRSLRLSCAASGFT
FTKAWMHWVRQAPGKQLEWVAQIKDK SNSYATYYASSVKGRFTISRDDSKNTLY
LQMNSLRAEDTAVYYCRGVYYALSPFD YWGQGTTLTVSS

Linkers

[0388] In some embodiments, the linkers L.sub.1, L.sub.2, L.sub.3, and L.sub.4 range from no amino acids (length=0) to about 100 amino acids long, or less than 100, 50, 40, 30, 20, or 15 amino acids or less. The linkers can also be 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acids long. L.sub.1, L.sub.2, L.sub.3, and L.sub.4 in one binding protein may all have the same amino acid sequence or may all have different amino acid sequences.

[0389] Examples of suitable linkers include, for example, GGGSGGGGS (SEQ ID NO:69), GGGSGGGSGGGGS (SEQ ID NO:70), S, RT, TKGPS (SEQ ID NO:68), GQPKAAP (SEQ ID NO:67), GSGSGSGG (SEQ ID NO:71), and DKHT (SEQ ID NO:66), as well as those disclosed in International Publication Nos. WO2017/074878 and WO2017/180913. The examples listed above are not intended to limit the scope of the disclosure in any way, and linkers comprising randomly selected amino acids selected from the group consisting of valine, leucine, isoleucine, serine, threonine, lysine, arginine, histidine, aspartate, glutamate, asparagine, glutamine, glycine, and proline have been shown to be suitable in the binding proteins.

[0390] The identity and sequence of amino acid residues in the linker may vary depending on the type of secondary structural element necessary to achieve in the linker. For example, glycine, serine, and alanine are best for linkers having maximum flexibility. Some combination of glycine, proline, threonine, and serine are useful if a more rigid and extended linker is

necessary. Any amino acid residue may be considered as a linker in combination with other amino acid residues to construct larger peptide linkers as necessary depending on the desired properties.

[0391] In some embodiments, the length of L.sub.1 is at least twice the length of L.sub.3. In some embodiments, the length of L.sub.2 is at least twice the length of L.sub.4. In some embodiments, the length of L.sub.1 is at least twice the length of L.sub.3, and the length of L.sub.2 is at least twice the length of L.sub.4. In some embodiments, L.sub.1 is 3 to 12 amino acid residues in length, L.sub.2 is 3 to 14 amino acid residues in length, L.sub.3 is 1 to 8 amino acid residues in length, and L.sub.4 is 1 to 3 amino acid residues in length. In some embodiments, L.sub.1 is 5 to 10 amino acid residues in length, L.sub.2 is 5 to 8 amino acid residues in length, L.sub.3 is 1 to 5 amino acid residues in length, and L.sub.4 is 1 to 2 amino acid residues in length. In some embodiments, L.sub.1 is 7 amino acid residues in length, L.sub.2 is 5 amino acid residues in length, L.sub.3 is 1 amino acid residue in length, and L.sub.4 is 2 amino acid residues in length.

[0392] In some embodiments, L.sub.1, L.sub.2, L.sub.3 and L.sub.4 each independently are zero amino acids in length or comprise a sequence selected from the group consisting of GGGSGGGGS (SEQ ID NO:69), GGGSGGGSGGGGS (SEQ ID NO:70), S, RT, TKGPS (SEQ ID NO:68), GQPKAAP (SEQ ID NO:67), and GSGSSGSGG (SEQ ID NO:71). In some embodiments, L.sub.1, L.sub.2, L.sub.3 and L.sub.4 each independently comprise a sequence selected from the group consisting of GGGSGGGGS (SEQ ID NO:69), GGGSGGGSGGGGS (SEQ ID NO:70), S, RT, TKGPS (SEQ ID NO:68), GQPKAAP (SEQ ID NO:67), and GSGSSGSGG (SEQ ID NO:71). In some embodiments, L.sub.1 comprises the sequence GQPKAAP (SEQ ID NO:67), L.sub.2 comprises the sequence TKGPS (SEQ ID NO:68), L.sub.3 comprises the sequence S, and L.sub.4 comprises the sequence RT.

[0393] In some embodiments, at least one of L.sub.1, L.sub.2, L.sub.3 or L.sub.4 comprises the sequence DKTHT (SEQ ID NO:66). In some embodiments, L.sub.1, L.sub.2, L.sub.3 and L.sub.4 comprise the sequence DKTHT (SEQ ID NO:66).

Fc Regions and Constant Domains

[0394] In some embodiments, a binding protein of the present disclosure comprises a second polypeptide chain further comprising an Fc region linked to C.sub.H1, the Fc region comprising an immunoglobulin hinge region and C.sub.H2 and C.sub.H3 immunoglobulin heavy chain constant domains. In some embodiments, a binding protein of the present disclosure comprises a third polypeptide chain further comprising an Fc region linked to C.sub.H1, the Fc region comprising an immunoglobulin hinge region and C.sub.H2 and C.sub.H3 immunoglobulin heavy chain constant domains. In some embodiments, a binding protein of the present disclosure comprises a second polypeptide chain further comprising an Fc region linked to C.sub.H1, the Fc region comprising an immunoglobulin hinge region and C.sub.H2 and C.sub.H3 immunoglobulin heavy chain constant domains, and a third polypeptide chain further comprising an Fc region linked to C.sub.H1, the Fc region comprising an immunoglobulin hinge region and C.sub.H2 and C.sub.H3 immunoglobulin heavy chain constant domains.

[0395] In some embodiments, a binding protein of the present disclosure comprises a full-length antibody heavy chain or a polypeptide chain comprising an Fc region. In some embodiments, the Fc region is a human Fc region, e.g., a human IgG1, IgG2, IgG3, or IgG4 Fc region. In some embodiments, the Fc region includes an antibody hinge, C.sub.H1, C.sub.H2, C.sub.H3, and optionally C.sub.H4 domains. In some embodiments, the Fc region is a human IgG1 Fc region. In some embodiments, the Fc region is a human IgG4 Fc region. In some embodiments, the Fc region includes one or more of the mutations described infra. In some embodiments, the Fc region is an Fc region of one of the heavy chain polypeptides (e.g., polypeptide 2 or 3) of a binding protein shown in Table 4. In some embodiments, the heavy chain constant region is a constant region of one of the heavy chain polypeptides (e.g., polypeptide 2 or 3) of a binding protein shown in Table 4. In some embodiments, the light chain constant region is a constant region of one of the light chain polypeptides (e.g., polypeptide 1 or 4) of a binding protein shown in Table 4.

[0396] In some embodiments, a binding protein of the present disclosure includes one or two Fc variants. The term “Fc variant” as used herein refers to a molecule or sequence that is modified from a native Fc but still comprises a binding site for the salvage receptor, FcRn (neonatal Fc receptor). Exemplary Fc variants, and their interaction with the salvage receptor, are known in the art. Thus, the term “Fc variant” can comprise a molecule or sequence that is humanized from a non-human native Fc. Furthermore, a native Fc comprises regions that can be removed because they provide structural features or biological activity that are not required for the antibody-like binding proteins of the invention. Thus, the term “Fc variant” comprises a molecule or sequence that lacks one or more native Fc sites or residues, or in which one or more Fc sites or residues has been modified, that affect or are involved in: (1) disulfide bond formation, (2) incompatibility with a selected host cell, (3) N-terminal heterogeneity upon expression in a selected host cell, (4) glycosylation, (5) interaction with complement, (6) binding to an Fc receptor other than a salvage receptor, or (7) antibody-dependent cellular cytotoxicity (ADCC).

[0397] In some embodiments, a binding protein of the present disclosure (e.g., a trispecific binding protein) comprises a “knob” mutation on the second polypeptide chain and a “hole” mutation on the third polypeptide chain. In some embodiments, a binding protein of the present disclosure comprises a “knob” mutation on the third polypeptide chain and a “hole” mutation on the second polypeptide chain. In some embodiments, the “knob” mutation comprises substitution(s) at positions corresponding to positions 354 and/or 366 of human IgG1 or IgG4 according to EU Index. In some embodiments, the amino acid substitutions are S354C, T366W, T366Y, S354C and T366W, or S354C and T366Y. In some embodiments, the “knob” mutation comprises substitutions at positions corresponding to positions 354 and 366 of human IgG1 or IgG4 according to EU Index. In some embodiments, the amino acid substitutions are S354C and T366W. In some embodiments, the “hole” mutation comprises substitution(s) at positions corresponding to positions 407 and, optionally, 349, 366, and/or 368 and of human IgG1 or IgG4 according to EU Index. In some embodiments, the amino acid substitutions are Y407V or Y407T and optionally Y349C, T366S, and/or L368A. In some embodiments, the “hole” mutation comprises substitutions at positions corresponding to positions 349, 366, 368, and 407 of human IgG1 or IgG4 according to EU Index. In some

first Fc region comprises amino acid substitutions at positions corresponding to positions 228, 349, 366, 368, 407, and 409 of human IgG4 according to EU Index, wherein the amino acid substitutions are S228P, Y349C, T366S, L368A, Y407V, and R409K; and wherein the third polypeptide chain further comprises a second Fc region linked to CH1, wherein the second Fc region is a human IgG4 Fc region comprising an immunoglobulin hinge region and CH2 and CH3 immunoglobulin heavy chain constant domains, wherein the second Fc region comprises amino acid substitutions at positions corresponding to positions 228, 354, 366, and 409 of human IgG4 according to EU Index, wherein the amino acid substitutions are S228P, S354C, T366W, and R409K.

[0404] In some embodiments, the second polypeptide chain further comprises a first Fc region linked to CH1, wherein the first Fc region is a human IgG4 Fc region comprising an immunoglobulin hinge region and CH2 and CH3 immunoglobulin heavy chain constant domains, wherein the first Fc region comprises amino acid substitutions at positions corresponding to positions 234, 235, 354, and 366 of human IgG4 according to EU Index, wherein the amino acid substitutions are F234A, L235A, S354C, and T366W; and wherein the third polypeptide chain further comprises a second Fc region linked to CH1, wherein the second Fc region is a human IgG4 Fc region comprising an immunoglobulin hinge region and CH2 and CH3 immunoglobulin heavy chain constant domains, wherein the second Fc region comprises amino acid substitutions at positions corresponding to positions 234, 235, 349, 366, 368, and 407 of human IgG4 according to EU Index, wherein the amino acid substitutions are F234A, L235A, Y349C, T366S, L368A, and Y407V. In some embodiments, the second polypeptide chain further comprises a first Fc region linked to CH1, wherein the first Fc region is a human IgG4 Fc region comprising an immunoglobulin hinge region and CH2 and CH3 immunoglobulin heavy chain constant domains, wherein the first Fc region comprises amino acid substitutions at positions corresponding to positions 234, 235, 349, 366, 368, and 407 of human IgG4 according to EU Index, wherein the amino acid substitutions are F234A, L235A, Y349C, T366S, L368A, and Y407V; and wherein the third polypeptide chain further comprises a second Fc region linked to CH1, wherein the second Fc region is a human IgG4 Fc region comprising an immunoglobulin hinge region and CH2 and CH3 immunoglobulin heavy chain constant domains, wherein the second Fc region comprises amino acid substitutions at positions corresponding to positions 234, 235, 354, and 366 of human IgG4 according to EU Index, wherein the amino acid substitutions are F234A, L235A, S354C, and T366W.

[0405] In some embodiments, a binding protein of the present disclosure comprises one or more mutations to reduce effector function, e.g., Fc receptor-mediated antibody-dependent cellular phagocytosis (ADCP), complement-dependent cytotoxicity (CDC), and/or antibody-dependent cellular cytotoxicity (ADCC). In some embodiments, the second polypeptide chain further comprises a first Fc region linked to C.sub.H1, the first Fc region comprising an immunoglobulin hinge region and C.sub.H2 and C.sub.H3 immunoglobulin heavy chain constant domains; wherein the third polypeptide chain further comprises a second Fc region linked to C.sub.H1, the second Fc region comprising an immunoglobulin hinge region and C.sub.H2 and C.sub.H3 immunoglobulin heavy chain constant domains; wherein the first and second Fc regions are human IgG1 Fc regions; and wherein the first and the second Fc regions each comprise amino acid substitutions at positions corresponding to positions 234 and 235 of human IgG1 according to EU Index, wherein the amino acid substitutions are L234A and L235A. In some embodiments, the Fc regions of the second and the third polypeptide chains are human IgG1 Fc regions, and wherein the Fc regions each comprise amino acid substitutions at positions corresponding to positions 234 and 235 of human IgG1 according to EU Index, wherein the amino acid substitutions are L234A and L235A. In some embodiments, the second polypeptide chain further comprises a first Fc region linked to C.sub.H1, the first Fc region comprising an immunoglobulin hinge region and C.sub.H2 and C.sub.H3 immunoglobulin heavy chain constant domains; wherein the third polypeptide chain further comprises a second Fc region linked to C.sub.H1, the second Fc region comprising an immunoglobulin hinge region and C.sub.H2 and C.sub.H3 immunoglobulin heavy chain constant domains; wherein the first and second Fc regions are human IgG1 Fc regions; and wherein the first and the second Fc regions each comprise amino acid substitutions at positions corresponding to positions 234, 235, and 329 of human IgG1 according to EU Index, wherein the amino acid substitutions are L234A, L235A, and P329A. In some embodiments, the Fc regions of the second and the third polypeptide chains are human IgG1 Fc regions, and wherein the Fc regions each comprise amino acid substitutions at positions corresponding to positions 234, 235, and 329 of human IgG1 according to EU Index, wherein the amino acid substitutions are L234A, L235A, and P329A. In some embodiments, the Fc regions of the second and the third polypeptide chains are human IgG4 Fc regions, and the Fc regions each comprise amino acid substitutions at positions corresponding to positions 234 and 235 of human IgG4 according to EU Index, wherein the amino acid substitutions are F234A and L235A. In some embodiments, the binding protein comprises a second polypeptide chain further comprising a first Fc region linked to C.sub.H1, the first Fc region comprising an immunoglobulin hinge region and C.sub.H2 and C.sub.H3 immunoglobulin heavy chain constant domains, and a third polypeptide chain further comprising a second Fc region linked to C.sub.H1, the second Fc region comprising an immunoglobulin hinge region and C.sub.H2 and C.sub.H3 immunoglobulin heavy chain constant domains; and wherein the first and the second Fc regions each comprise amino acid substitutions at positions corresponding to positions 234 and 235 of human IgG4 according to EU Index, wherein the amino acid substitutions are F234A and L235A.

[0406] In some embodiments, the second polypeptide chain further comprises a first Fc region linked to CH1, wherein the first Fc region is a human IgG4 Fc region comprising an immunoglobulin hinge region and CH2 and CH3 immunoglobulin heavy chain constant domains, wherein the first Fc region comprises amino acid substitutions at positions corresponding to positions 228, 234, 235, 354, 366, and 409 of human IgG4 according to EU Index, wherein the amino acid substitutions are S228P, F234A, L235A, S354C, T366W, and R409K; and wherein the third polypeptide chain further comprises a second Fc region linked to CH1, wherein the second Fc region is a human IgG4 Fc region comprising an immunoglobulin hinge region and CH2 and CH3 immunoglobulin heavy chain constant domains, wherein the second Fc region comprises amino acid

substitutions at positions corresponding to positions 228, 234, 235, 349, 366, 368, 407, and 409 of human IgG4 according to EU Index, wherein the amino acid substitutions are S228P, F234A, L235A, Y349C, T366S, L368A, Y407V, and R409K. In some embodiments, the second polypeptide chain further comprises a first Fc region linked to CH1, wherein the first Fc region is a human IgG4 Fc region comprising an immunoglobulin hinge region and CH2 and CH3 immunoglobulin heavy chain constant domains, wherein the first Fc region comprises amino acid substitutions at positions corresponding to positions 228, 234, 235, 349, 366, 368, 407, and 409 of human IgG4 according to EU Index, wherein the amino acid substitutions are S228P, F234A, L235A, Y349C, T366S, L368A, Y407V, and R409K; and wherein the third polypeptide chain further comprises a second Fc region linked to CH1, wherein the second Fc region is a human IgG4 Fc region comprising an immunoglobulin hinge region and CH2 and CH3 immunoglobulin heavy chain constant domains, wherein the second Fc region comprises amino acid substitutions at positions corresponding to positions 228, 234, 235, 354, 366, and 409 of human IgG4 according to EU Index, wherein the amino acid substitutions are S228P, F234A, L235A, S354C, T366W, and R409K.

[0407] In some embodiments, the Fc region is a human IgG4 Fc region comprising one or more mutations that reduce or eliminate FcγI and/or FcγII binding. In some embodiments, the Fc region is a human IgG4 Fc region comprising one or more mutations that reduce or eliminate FcγI and/or FcγII binding but do not affect FcRn binding. In some embodiments, the Fc region is a human IgG4 Fc region comprising amino acid substitutions at positions corresponding to positions 228 and/or 409 of human IgG4 according to EU Index. In some embodiments, the amino acid substitutions are S228P and/or R409K. In some embodiments, the Fc region is a human IgG4 Fc region comprising amino acid substitutions at positions corresponding to positions 234 and/or 235 of human IgG4 according to EU Index. In some embodiments, the amino acid substitutions are F234A and/or L235A. In some embodiments, the Fc region is a human IgG4 Fc region comprising amino acid substitutions at positions corresponding to positions 228, 234, 235, and/or 409 of human IgG4 according to EU Index. In some embodiments, the amino acid substitutions are S228P, F234A, L235A, and/or R409K. In some embodiments, the Fc region is a human IgG4 Fc region comprising amino acid substitutions at positions corresponding to positions 233-236 of human IgG4 according to EU Index. In some embodiments, the amino acid substitutions are E233P, F234V, L235A, and a deletion at 236. In some embodiments, the Fc region is a human IgG4 Fc region comprising amino acid mutations at substitutions corresponding to positions 228, 233-236, and/or 409 of human IgG4 according to EU Index. In some embodiments, the amino acid mutations are S228P; E233P, F234V, L235A, and a deletion at 236; and/or R409K.

[0408] In some embodiments, the Fc region comprises one or more mutations that reduce or eliminate Fc receptor binding and/or effector function of the Fc region (e.g., Fc receptor-mediated antibody-dependent cellular phagocytosis (ADCP), complement-dependent cytotoxicity (CDC), and/or antibody-dependent cellular cytotoxicity (ADCC)).

[0409] In some embodiments, the Fc region is a human IgG1 Fc region comprising one or more amino acid substitutions at positions corresponding to positions 234, 235, and/or 329 of human IgG1 according to EU Index. In some embodiments, the amino acid substitutions are L234A, L235A, and/or P329A. In some embodiments, the Fc region is a human IgG1 Fc region comprising amino acid substitutions at positions corresponding to positions 298, 299, and/or 300 of human IgG1 according to EU Index. In some embodiments, the amino acid substitutions are S298N, T299A, and/or Y300S.

[0410] In some embodiments, a binding protein of the present disclosure comprises one or more mutations to improve stability, e.g., of the hinge region and/or dimer interface of IgG4 (See e.g., Spiess, C. et al. (2013) J. Biol. Chem. 288:26583-26593). In some embodiments, the mutation comprises substitutions at positions corresponding to positions 228 and 409 of human IgG4 according to EU Index, wherein the amino acid substitutions are S228P and R409K. In some embodiments, the binding protein comprises a second polypeptide chain further comprising a first Fc region linked to C.sub.H1, the first Fc region comprising an immunoglobulin hinge region and C.sub.H2 and C.sub.H3 immunoglobulin heavy chain constant domains, and a third polypeptide chain further comprising a second Fc region linked to C.sub.H1, the second Fc region comprising an immunoglobulin hinge region and C.sub.H2 and C.sub.H3 immunoglobulin heavy chain constant domains; wherein the first and second Fc regions are human IgG4 Fc regions; and wherein the first and the second Fc regions each comprise amino acid substitutions at positions corresponding to positions 228 and 409 of human IgG4 according to EU Index, wherein the amino acid substitutions are S228P and R409K. In some embodiments, a binding protein of the present disclosure comprises knob and hole mutations and one or more mutations to improve stability. In some embodiments, the first and/or second Fc regions are human IgG4 Fc regions.

[0411] In some embodiments, the Fc region is a human IgG1 Fc region comprising one or more amino acid substitutions at positions corresponding to positions 234, 235, and/or 329 of human IgG1 according to EU Index. In some embodiments, the amino acid substitutions are L234A, L235A, and/or P329A. In some embodiments, the Fc region is a human IgG1 Fc region comprising amino acid substitutions at positions corresponding to positions 298, 299, and/or 300 of human IgG1 according to EU Index. In some embodiments, the amino acid substitutions are S298N, T299A, and/or Y300S.

Nucleic Acids

[0412] Other aspects of the present disclosure relate to isolated nucleic acid molecules comprising a nucleotide sequence encoding any of the binding proteins described herein. Exemplary and non-limiting nucleic acid sequences are provided in Table 5.

[0413] Other aspects of the present disclosure relate to kits of polynucleotides, e.g., that encode one or more polypeptides of a binding protein as described herein. In some embodiments, a kit of polynucleotides of the present disclosure comprises one, two, three, or four polynucleotides of a kit of polynucleotides comprising: (a) a first polynucleotide comprising the polynucleotide sequence of SEQ ID NO:189, a second polynucleotide comprising the polynucleotide sequence of SEQ ID NO:190, a third polynucleotide comprising the polynucleotide sequence of SEQ ID NO:191, and a fourth polynucleotide comprising the polynucleotide sequence of SEQ ID NO:192; (b) a first polynucleotide comprising the polynucleotide

second polypeptide chain of the binding protein, a third vector encoding the third polypeptide chain of the binding protein, and a fourth vector encoding the fourth polypeptide chain of the binding protein, e.g., as shown in the polynucleotides of Table 6. In some embodiments, the vector system comprises a first vector encoding the first and second polypeptide chains of the binding protein, and a second vector encoding the third and fourth polypeptide chains of the binding protein. In some embodiments, the vector system comprises a first vector encoding the first and third polypeptide chains of the binding protein, and a second vector encoding the second and fourth polypeptide chains of the binding protein. In some embodiments, the vector system comprises a first vector encoding the first and fourth polypeptide chains of the binding protein, and a second vector encoding the second and third polypeptide chains of the binding protein. In some embodiments, the vector system comprises a first vector encoding the first, second, third, and fourth polypeptide chains of the binding protein. The one or more vectors of the vector system may be any of the vectors described herein. In some embodiments, the one or more vectors are expression vectors. In some embodiments, the first, second, third, and fourth polynucleotides are present on one or more expression vectors, e.g., one, two, three, or four expression vectors.

[0415] Standard recombinant DNA methodologies are used to construct the polynucleotides that encode the polypeptides which form the binding proteins, incorporate these polynucleotides into recombinant expression vectors, and introduce such vectors into host cells. See e.g., Sambrook et al., 2001, MOLECULAR CLONING: A LABORATORY MANUAL (Cold Spring Harbor Laboratory Press, 3rd ed.). Enzymatic reactions and purification techniques may be performed according to manufacturer's specifications, as commonly accomplished in the art, or as described herein. Unless specific definitions are provided, the nomenclature utilized in connection with, and the laboratory procedures and techniques of, analytical chemistry, synthetic organic chemistry, and medicinal and pharmaceutical chemistry described herein are those well-known and commonly used in the art. Similarly, conventional techniques may be used for chemical syntheses, chemical analyses, pharmaceutical preparation, formulation, delivery, and treatment of patients.

[0416] In some embodiments, the isolated nucleic acid is operably linked to a heterologous promoter to direct transcription of the binding protein-coding nucleic acid sequence. A promoter may refer to nucleic acid control sequences which direct transcription of a nucleic acid. A first nucleic acid sequence is operably linked to a second nucleic acid sequence when the first nucleic acid sequence is placed in a functional relationship with the second nucleic acid sequence. For instance, a promoter is operably linked to a coding sequence of a binding protein if the promoter affects the transcription or expression of the coding sequence. Examples of promoters may include, but are not limited to, promoters obtained from the genomes of viruses (such as polyoma virus, fowlpox virus, adenovirus (such as Adenovirus 2), bovine papilloma virus, avian sarcoma virus, cytomegalovirus, a retrovirus, hepatitis-B virus, Simian Virus 40 (SV40), and the like), from heterologous eukaryotic promoters (such as the actin promoter, an immunoglobulin promoter, from heat-shock promoters, and the like), the CAG-promoter (Niwa et al., Gene 108(2):193-9, 1991), the phosphoglycerate kinase (PGK)-promoter, a tetracycline-inducible promoter (Masui et al., Nucleic Acids Res. 33:e43, 2005), the lac system, the trp system, the tac system, the trc system, major operator and promoter regions of phage lambda, the promoter for 3-phosphoglycerate kinase, the promoters of yeast acid phosphatase, and the promoter of the yeast alpha-mating factors. Polynucleotides encoding binding proteins of the present disclosure may be under the control of a constitutive promoter, an inducible promoter, or any other suitable promoter described herein or other suitable promoter that will be readily recognized by one skilled in the art.

[0417] In some embodiments, the isolated nucleic acid is incorporated into a vector. In some embodiments, the vector is an expression vector. Expression vectors may include one or more regulatory sequences operatively linked to the polynucleotide to be expressed. The term "regulatory sequence" includes promoters, enhancers and other expression control elements (e.g., polyadenylation signals). Examples of suitable enhancers may include, but are not limited to, enhancer sequences from mammalian genes (such as globin, elastase, albumin, α -fetoprotein, insulin and the like), and enhancer sequences from a eukaryotic cell virus (such as SV40 enhancer on the late side of the replication origin (bp 100-270), the cytomegalovirus early promoter enhancer, the polyoma enhancer on the late side of the replication origin, adenovirus enhancers, and the like). Examples of suitable vectors may include, for example, plasmids, cosmids, episomes, transposons, and viral vectors (e.g., adenoviral, vaccinia viral, Sindbis-viral, measles, herpes viral, lentiviral, retroviral, adeno-associated viral vectors, etc.). Expression vectors can be used to transfect host cells, such as, for example, bacterial cells, yeast cells, insect cells, and mammalian cells. Biologically functional viral and plasmid DNA vectors capable of expression and replication in a host are known in the art, and can be used to transfect any cell of interest.

Host Cells

[0418] Other aspects of the present disclosure relate to a host cell (e.g., an isolated host cell) comprising one or more isolated polynucleotides, vectors, and/or vector systems described herein. In some embodiments, an isolated host cell of the present disclosure is cultured in vitro. In some embodiments, the host cell is a bacterial cell (e.g., an *E. coli* cell). In some embodiments, the host cell is a yeast cell (e.g., an *S. cerevisiae* cell). In some embodiments, the host cell is an insect cell. Examples of insect host cells may include, for example, *Drosophila* cells (e.g., S2 cells), *Trichoplusia ni* cells (e.g., High Five™ cells), and *Spodoptera frugiperda* cells (e.g., Sf21 or Sf9 cells). In some embodiments, the host cell is a mammalian cell. Examples of mammalian host cells may include, for example, human embryonic kidney cells (e.g., 293 or 293 cells subcloned for growth in suspension culture), Expi293™ cells, CHO cells, baby hamster kidney cells (e.g., BHK, ATCC CCL 10), mouse sertoli cells (e.g., TM4 cells), monkey kidney cells (e.g., CV1 ATCC CCL 70), African green monkey kidney cells (e.g., VERO-76, ATCC CRL-1587), human cervical carcinoma cells (e.g., HELA, ATCC CCL 2), canine kidney cells (e.g., MDCK, ATCC CCL 34), buffalo rat liver cells (e.g., BRL 3A, ATCC CRL 1442), human lung cells (e.g., W138, ATCC CCL 75), human liver cells (e.g., Hep G2, HB 8065), mouse mammary tumor cells (e.g., MMT 060562, ATCC CCL51), TRI cells, MRC 5 cells, FS4 cells, a human hepatoma line (e.g., Hep G2), and myeloma cells (e.g., NS0 and Sp2/0 cells).

[0419] Other aspects of the present disclosure relate to a method of producing any of the binding proteins described herein.

In some embodiments, the method includes a) culturing a host cell (e.g., any of the host cells described herein) comprising an isolated nucleic acid, vector, and/or vector system (e.g., any of the isolated nucleic acids, vectors, and/or vector systems described herein) under conditions such that the host cell expresses the binding protein; and b) isolating the binding protein from the host cell. Methods of culturing host cells under conditions to express a protein are well known to one of ordinary skill in the art. Methods of isolating proteins from cultured host cells are well known to one of ordinary skill in the art, including, for example, by affinity chromatography (e.g., two step affinity chromatography comprising protein A affinity chromatography followed by size exclusion chromatography).

Pharmaceutical Compositions for Treating and/or Preventing Cancer

[0420] Therapeutic or pharmaceutical compositions comprising binding proteins are within the scope of the disclosure. Such therapeutic or pharmaceutical compositions can comprise a therapeutically effective amount of a binding protein, or binding protein-drug conjugate, in admixture with a pharmaceutically or physiologically acceptable formulation agent selected for suitability with the mode of administration.

[0421] Acceptable formulation materials are nontoxic to recipients at the dosages and concentrations employed.

[0422] The pharmaceutical composition can contain formulation materials for modifying, maintaining, or preserving, for example, the pH, osmolarity, viscosity, clarity, color, isotonicity, odor, sterility, stability, rate of dissolution or release, adsorption, or penetration of the composition. Suitable formulation materials include, but are not limited to, amino acids (such as glycine, glutamine, asparagine, arginine, or lysine), antimicrobials, antioxidants (such as ascorbic acid, sodium sulfite, or sodium hydrogen-sulfite), buffers (such as borate, bicarbonate, Tris-HCl, citrates, phosphates, or other organic acids), bulking agents (such as mannitol or glycine), chelating agents (such as ethylenediamine tetraacetic acid (EDTA)), complexing agents (such as caffeine, polyvinylpyrrolidone, beta-cyclodextrin, or hydroxypropyl-beta-cyclodextrin), fillers, monosaccharides, disaccharides, and other carbohydrates (such as glucose, mannose, or dextrans), proteins (such as serum albumin, gelatin, or immunoglobulins), coloring, flavoring and diluting agents, emulsifying agents, hydrophilic polymers (such as polyvinylpyrrolidone), low molecular weight polypeptides, salt-forming counterions (such as sodium), preservatives (such as benzalkonium chloride, benzoic acid, salicylic acid, thimerosal, phenethyl alcohol, methylparaben, propylparaben, chlorhexidine, sorbic acid, or hydrogen peroxide), solvents (such as glycerin, propylene glycol, or polyethylene glycol), sugar alcohols (such as mannitol or sorbitol), suspending agents, surfactants or wetting agents (such as pluronics; PEG; sorbitan esters; polysorbates such as polysorbate 20 or polysorbate 80; triton; tromethamine; lecithin; cholesterol or tyloxapal), stability enhancing agents (such as sucrose or sorbitol), tonicity enhancing agents (such as alkali metal halides—e.g., sodium or potassium chloride—or mannitol sorbitol), delivery vehicles, diluents, excipients and/or pharmaceutical adjuvants (see, e.g., REMINGTON'S PHARMACEUTICAL SCIENCES (18th Ed., A. R. Gennaro, ed., Mack Publishing Company 1990), and subsequent editions of the same, incorporated herein by reference for any purpose).

[0423] The optimal pharmaceutical composition will be determined by a skilled artisan depending upon, for example, the intended route of administration, delivery format, and desired dosage. Such compositions can influence the physical state, stability, rate of in vivo release, and rate of in vivo clearance of the binding protein.

[0424] The primary vehicle or carrier in a pharmaceutical composition can be either aqueous or non-aqueous in nature. For example, a suitable vehicle or carrier for injection can be water, physiological saline solution, or artificial cerebrospinal fluid, possibly supplemented with other materials common in compositions for parenteral administration. Neutral buffered saline or saline mixed with serum albumin are further exemplary vehicles. Other exemplary pharmaceutical compositions comprise Tris buffer of about pH 7.0-8.5, or acetate buffer of about pH 4.0-5.5, which can further include sorbitol or a suitable substitute. In one embodiment of the disclosure, binding protein compositions can be prepared for storage by mixing the selected composition having the desired degree of purity with optional formulation agents in the form of a lyophilized cake or an aqueous solution. Further, the binding protein can be formulated as a lyophilizate using appropriate excipients such as sucrose.

[0425] The pharmaceutical compositions of the disclosure can be selected for parenteral delivery or subcutaneous.

Alternatively, the compositions can be selected for inhalation or for delivery through the digestive tract, such as orally. The preparation of such pharmaceutically acceptable compositions is within the skill of the art.

[0426] The formulation components are present in concentrations that are acceptable to the site of administration. For example, buffers are used to maintain the composition at physiological pH or at a slightly lower pH, typically within a pH range of from about 5 to about 8.

[0427] When parenteral administration is contemplated, the therapeutic compositions for use can be in the form of a pyrogen-free, parenterally acceptable, aqueous solution comprising the desired binding protein in a pharmaceutically acceptable vehicle. A particularly suitable vehicle for parenteral injection is sterile distilled water in which a binding protein is formulated as a sterile, isotonic solution, properly preserved. Yet another preparation can involve the formulation of the desired molecule with an agent, such as injectable microspheres, bio-erodible particles, polymeric compounds (such as polylactic acid or polyglycolic acid), beads, or liposomes, that provides for the controlled or sustained release of the product which can then be delivered via a depot injection. Hyaluronic acid can also be used, and this can have the effect of promoting sustained duration in the circulation. Other suitable means for the introduction of the desired molecule include implantable drug delivery devices.

[0428] In one embodiment, a pharmaceutical composition can be formulated for inhalation. For example, a binding protein can be formulated as a dry powder for inhalation. Binding protein inhalation solutions can also be formulated with a propellant for aerosol delivery. In yet another embodiment, solutions can be nebulized.

[0429] It is also contemplated that certain formulations can be administered orally. In one embodiment of the disclosure, binding proteins that are administered in this fashion can be formulated with or without those carriers customarily used in the

comprising of solid dosage forms such as tablets and capsules. For example, a capsule can be designed to release the active portion of the formulation at the point in the gastrointestinal tract where bioavailability is maximized and pre-systemic degradation is minimized. Additional agents can be included to facilitate absorption of the binding protein. Diluents, flavorings, low melting point waxes, vegetable oils, lubricants, suspending agents, tablet disintegrating agents, and binders can also be employed.

[0430] Another pharmaceutical composition can involve an effective quantity of binding proteins in a mixture with non-toxic excipients that are suitable for the manufacture of tablets. By dissolving the tablets in sterile water, or another appropriate vehicle, solutions can be prepared in unit-dose form. Suitable excipients include, but are not limited to, inert diluents, such as calcium carbonate, sodium carbonate or bicarbonate, lactose, or calcium phosphate; or binding agents, such as starch, gelatin, or acacia; or lubricating agents such as magnesium stearate, stearic acid, or talc.

[0431] Additional pharmaceutical compositions of the disclosure will be evident to those skilled in the art, including formulations involving binding proteins in sustained- or controlled-delivery formulations. Techniques for formulating a variety of other sustained- or controlled-delivery means, such as liposome carriers, bio-erodible microparticles or porous beads and depot injections, are also known to those skilled in the art. Additional examples of sustained-release preparations include semipermeable polymer matrices in the form of shaped articles, e.g. films, or microcapsules. Sustained release matrices can include polyesters, hydrogels, polylactides, copolymers of L-glutamic acid and gamma ethyl-L-glutamate, poly(2-hydroxyethyl-methacrylate), ethylene vinyl acetate, or poly-D(-)-3-hydroxybutyric acid. Sustained-release compositions can also include liposomes, which can be prepared by any of several methods known in the art.

[0432] Pharmaceutical compositions to be used for in vivo administration typically must be sterile. This can be accomplished by filtration through sterile filtration membranes. Where the composition is lyophilized, sterilization using this method can be conducted either prior to, or following, lyophilization and reconstitution. The composition for parenteral administration can be stored in lyophilized form or in a solution. In addition, parenteral compositions generally are placed into a container having a sterile access port, for example, an intravenous solution bag or vial having a stopper pierceable by a hypodermic injection needle.

[0433] Once the pharmaceutical composition has been formulated, it can be stored in sterile vials as a solution, suspension, gel, emulsion, solid, or as a dehydrated or lyophilized powder. Such formulations can be stored either in a ready-to-use form or in a form (e.g., lyophilized) requiring reconstitution prior to administration.

[0434] The disclosure also encompasses kits for producing a single-dose administration unit. The kits can each contain both a first container having a dried protein and a second container having an aqueous formulation. Also included within the scope of this disclosure are kits containing single and multi-chambered pre-filled syringes (e.g., liquid syringes and lyosyringes).

[0435] The effective amount of a binding protein pharmaceutical composition to be employed therapeutically will depend, for example, upon the therapeutic context and objectives. One skilled in the art will appreciate that the appropriate dosage levels for treatment will thus vary depending, in part, upon the molecule delivered, the indication for which the binding protein is being used, the route of administration, and the size (body weight, body surface, or organ size) and condition (the age and general health) of the patient. Accordingly, the clinician can titer the dosage and modify the route of administration to obtain the optimal therapeutic effect.

[0436] Dosing frequency will depend upon the pharmacokinetic parameters of the binding protein in the formulation being used. Typically, a clinician will administer the composition until a dosage is reached that achieves the desired effect. The composition can therefore be administered as a single dose, as two or more doses (which may or may not contain the same amount of the desired molecule) over time, or as a continuous infusion via an implantation device or catheter. Further refinement of the appropriate dosage is routinely made by those of ordinary skill in the art and is within the ambit of tasks routinely performed by them. Appropriate dosages can be ascertained through use of appropriate dose-response data.

[0437] The route of administration of the pharmaceutical composition is in accord with known methods, e.g., orally; through injection by intravenous, intraperitoneal, intracerebral (intraparenchymal), intracerebroventricular, intramuscular, intraocular, intraarterial, intraportal, or intralesional routes; by sustained release systems; or by implantation devices. Where desired, the compositions can be administered by bolus injection or continuously by infusion, or by implantation device.

[0438] The composition can also be administered locally via implantation of a membrane, sponge, or other appropriate material onto which the desired molecule has been absorbed or encapsulated. Where an implantation device is used, the device can be implanted into any suitable tissue or organ, and delivery of the desired molecule can be via diffusion, timed-release bolus, or continuous administration.

[0439] The pharmaceutical compositions can be used to prevent and/or treat HIV infection. The pharmaceutical compositions can be used as a standalone therapy or in combination with standard anti-retroviral therapy.

[0440] The disclosure also relates to a kit comprising a binding protein and other reagents useful for detecting target antigen levels in biological samples. Such reagents can include a detectable label, blocking serum, positive and negative control samples, and detection reagents. In some embodiments, the kit comprises a composition comprising any binding protein, polynucleotide, vector, vector system, and/or host cell described herein. In some embodiments, the kit comprises a container and a label or package insert on or associated with the container. Suitable containers include, for example, bottles, vials, syringes, IV solution bags, etc. The containers may be formed from a variety of materials such as glass or plastic. The container holds a composition which is by itself or combined with another composition effective for treating, preventing and/or diagnosing a condition (e.g., HIV infection) and may have a sterile access port (for example the container may be an intravenous solution bag or a vial having a stopper pierceable by a hypodermic injection needle). In some embodiments, the label or package insert indicates that the composition is used for preventing, diagnosing, and/or treating the condition of choice. Alternatively, or additionally, the article of manufacture or kit may further comprise a second (or third) container

comprising a pharmaceutically-acceptable buffer, such as bacteriostatic water for injection (BWFI), phosphate-buffered saline, Ringer's solution and dextrose solution. It may further include other materials desirable from a commercial and user standpoint, including other buffers, diluents, filters, needles, and syringes.

Methods and Uses for Binding Proteins

Virus

[0441] Certain aspects of the present disclosure relate to methods for expanding virus-specific memory T cells. In some embodiments, the methods comprise contacting a virus-specific memory T cell with a binding protein of the present disclosure, e.g., a trispecific binding protein that comprises a first antigen binding site that binds a CD28 polypeptide, a second antigen binding site that binds a CD3 polypeptide, and a third antigen binding site that binds a CD38 polypeptide.

[0442] In some embodiments, the virus-specific memory T cell is contacted with the binding protein in vitro or ex vivo.

[0443] In some embodiments, contacting the virus-specific memory T cell with the binding protein causes activation and/or proliferation of virus-specific memory T cells.

[0444] Other aspects of the present disclosure relate to methods for expanding T cells. In some embodiments, the methods comprise contacting a T cell with a binding protein of the present disclosure, e.g., a trispecific binding protein that comprises a first antigen binding site that binds a CD28 polypeptide, a second antigen binding site that binds a CD3 polypeptide, and a third antigen binding site that binds a CD38 polypeptide.

[0445] In some embodiments, the T cell is a memory T cell or an effector T cell.

[0446] In some embodiments, the T cell expresses a chimeric antigen receptor (CAR) on its cell surface or comprises a polynucleotide encoding a CAR.

[0447] Other aspects of the present disclosure relate to methods for treating chronic viral infection, e.g., in an individual in need thereof. In some embodiments, the methods comprise administering to an individual in need thereof an effective amount of a binding protein of the present disclosure, e.g., a trispecific binding protein that comprises a first antigen binding site that binds a CD28 polypeptide, a second antigen binding site that binds a CD3 polypeptide, and a third antigen binding site that binds a CD38 polypeptide.

[0448] In some embodiments, the individual is a human.

[0449] In some embodiments, the binding protein is administered to the individual in pharmaceutical formulation comprising the binding protein and a pharmaceutically acceptable carrier.

[0450] In some embodiments, administration of the binding protein results in activation and/or proliferation of virus-specific memory T cells in the individual.

[0451] In any of the above methods, memory T cells can be CD8⁺ or CD4⁺ memory T cells. In any of the above methods, memory T cells can be central memory T cells (T.sub.CM) or effector memory T cells (T.sub.EM).

Cancer

[0452] Certain aspects of the present disclosure relate to methods for preventing and/or treating cancer in a patient. In some embodiments, the methods comprise administering to the patient a therapeutically effective amount of a binding protein or pharmaceutical composition of the present disclosure.

[0453] In some embodiments, a binding protein of the present disclosure is administered to a patient in need thereof for the treatment or prevention of cancer. In some embodiments, the present disclosure relates to a method of preventing and/or treating a proliferative disease or disorder (e.g., cancer). In some embodiments, the method comprises administering to a patient a therapeutically effective amount of at least one of the binding proteins, or pharmaceutical compositions related thereto, described herein. In some embodiments, the present disclosure relates to uses of at least one of the binding proteins, or pharmaceutical compositions related thereto, described herein for preventing and/or treating a proliferative disease or disorder (e.g., cancer) in a patient in need thereof. In some embodiments, the present disclosure relates to at least one of the binding proteins, or pharmaceutical compositions related thereto, described herein for use in the manufacture of a medicament for preventing and/or treating a proliferative disease or disorder (e.g., cancer) in a patient in need thereof. In some embodiments, the patient is a human.

[0454] In some embodiments, the at least one binding protein is administered (or is to be administered) in combination with one or more anti-cancer therapies (e.g., any anti-cancer therapy known in the art, such as a chemotherapeutic agent or therapy). In some embodiments, the at least one binding protein is administered (or is to be administered) before the one or more anti-cancer therapies. In some embodiments, the at least one binding protein is administered (or is to be administered) concurrently with the one or more anti-cancer therapies. In some embodiments, the at least one binding protein is administered (or is to be administered) after the one or more anti-cancer therapies.

[0455] In some embodiments, the binding protein comprises one or two antigen binding site(s) that binds a T-cell surface protein and another antigen binding site that binds the extracellular domain of a human HER2 polypeptide. In some embodiments, the binding protein comprises an antigen binding site that binds the extracellular domain of a human HER2 polypeptide, an antigen binding site that binds a human CD28 polypeptide, and an antigen binding site that binds a human CD3 polypeptide.

[0456] In some embodiments, cancer cells from the individual express HER2. In some embodiments, the patient is selected for treatment on the basis that the cells of the cancer express a human HER2 polypeptide. Assays known in the art suitable for detecting HER2 expression by cancer cells include, without limitation, immunohistochemical (IHC) and fluorescence in situ hybridization (FISH) assays.

[0457] In some embodiments, the cancer (e.g., HER2-positive cancer) is breast cancer, colorectal cancer, gastric cancer, or non-small cell lung cancer (NSCLC).

[0458] In some embodiments, the binding protein comprises one or two antigen binding site(s) that binds a T-cell surface

protein and another antigen binding site that binds the extracellular domain of a human CD38 polypeptide. In some embodiments, the binding protein comprises an antigen binding site that binds the extracellular domain of a human CD38 polypeptide, an antigen binding site that binds a human CD28 polypeptide, and an antigen binding site that binds a human CD3 polypeptide.

[0459] In some embodiments, cancer cells from the individual express CD38. In some embodiments, cells of the cancer express a human CD38 isoform A polypeptide on their cell surface. In some embodiments, cells of the cancer express a human CD38 isoform E polypeptide on their cell surface. In some embodiments, the patient is selected for treatment on the basis that the cells of the cancer express a human CD38 isoform E polypeptide on their cell surface. In some embodiments, the cancer cells express CD38 and CD28. In some embodiments, the cancer cells express CD38 and do not express CD28.

[0460] In some embodiments, the cancer (e.g., CD38-positive cancer) is multiple myeloma, acute lymphoblastic leukemia, chronic lymphocytic leukemia, acute myeloid leukemia, lymphoma, breast cancer such as Her2+ breast cancer, prostate cancer, germinal center B-cell lymphoma or B-cell acute lymphoblastic leukemia. In certain embodiments, the cancer is multiple myeloma. In certain embodiments, the cancer is acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), or a B cell lymphoma.

[0461] In certain embodiments, the cancer is multiple myeloma. Anti-CD38 antibodies have been tested for the treatment of multiple myeloma, such as daratumumab. However, while multiple myeloma is considered treatable, relapse is inevitable in almost all patients, leading to the development of treatment-refractory disease. In some embodiments, the cancer is relapsed or refractory multiple myeloma. In some embodiments, the patient has been treated with a prior multiple myeloma treatment. In some embodiments, a binding protein of the present disclosure is administered to the patient as a 1.sup.st, 2.sup.nd or 3.sup.rd line treatment for multiple myeloma. Without wishing to be bound to theory, it is thought that an anti-CD38xanti-CD28xanti-CD3 binding protein of the present disclosure may be useful in treating multiple myeloma, e.g., by recruiting T cells to tumor cells via anti-CD38 (or anti-CD28/anti-CD38), activation of engaged T cells via anti-CD3/anti-CD28, and/or killing of tumor cells through perforin/granzyme-based mechanisms. CD28 has been reported as a novel cancer marker for multiple myeloma. See Nair, J. R. et al. (2011) *J. Immunol.* 187:1243-1253.

[0462] Any of the binding proteins described herein may find use in the methods of the present disclosure.

[0463] In some embodiments of any of the methods of the present disclosure, prior to administration of the binding protein, the patient has been treated with daratumumab. As described herein, the present disclosure provides anti-CD38 binding proteins and sites that do not compete for binding CD38 with daratumumab. Without wishing to be bound to theory, it is thought that this is advantageous because a patient previously treated with daratumumab can be treated with a binding protein of the present disclosure, e.g., without a wash-out period prior to treatment.

[0464] The binding proteins can be employed in any known assay method, such as competitive binding assays, direct and indirect sandwich assays, and immunoprecipitation assays for the detection and quantitation of one or more target antigens. The binding proteins will bind the one or more target antigens with an affinity that is appropriate for the assay method being employed.

[0465] For diagnostic applications, in certain embodiments, binding proteins can be labeled with a detectable moiety. The detectable moiety can be any one that is capable of producing, either directly or indirectly, a detectable signal. For example, the detectable moiety can be a radioisotope, such as .sup.3H, .sup.14C, .sup.32P, .sup.35S, .sup.125I, .sup.99Tc, .sup.111In, or .sup.67Ga; a fluorescent or chemiluminescent compound, such as fluorescein isothiocyanate, rhodamine, or luciferin; or an enzyme, such as alkaline phosphatase, β -galactosidase, or horseradish peroxidase.

[0466] The binding proteins are also useful for in vivo imaging. A binding protein labeled with a detectable moiety can be administered to an animal, preferably into the bloodstream, and the presence and location of the labeled antibody in the host assayed. The binding protein can be labeled with any moiety that is detectable in an animal, whether by nuclear magnetic resonance, radiology, or other detection means known in the art.

[0467] For clinical or research applications, in certain embodiments, binding proteins can be conjugated to a cytotoxic agent. A variety of antibodies coupled to cytotoxic agents (i.e., antibody-drug conjugates) have been used to target cytotoxic payloads to specific tumor cells. Cytotoxic agents and linkers that conjugate the agents to an antibody are known in the art; see, e.g., Parslow, A. C. et al. (2016) *Biomedicines* 4:14 and Kalim, M. et al. (2017) *Drug Des. Devel. Ther.* 11:2265-2276. Binding Protein Therapeutic Compositions and Administration Thereof for Treating and/or Preventing Cancer

[0468] Therapeutic or pharmaceutical compositions comprising binding proteins are within the scope of the disclosure. Such therapeutic or pharmaceutical compositions can comprise a therapeutically effective amount of a binding protein, or binding protein-drug conjugate, in admixture with a pharmaceutically or physiologically acceptable formulation agent selected for suitability with the mode of administration. These pharmaceutical compositions may find use in any of the methods and uses described herein (e.g., ex vivo, in vitro, and/or in vivo).

[0469] Acceptable formulation materials preferably are nontoxic to recipients at the dosages and concentrations employed.

[0470] The pharmaceutical composition can contain formulation materials for modifying, maintaining, or preserving, for example, the pH, osmolarity, viscosity, clarity, color, isotonicity, odor, sterility, stability, rate of dissolution or release, adsorption, or penetration of the composition. Suitable formulation materials include, but are not limited to, amino acids (such as glycine, glutamine, asparagine, arginine, or lysine), antimicrobials, antioxidants (such as ascorbic acid, sodium sulfite, or sodium hydrogen-sulfite), buffers (such as borate, bicarbonate, Tris-HCl, citrates, phosphates, or other organic acids), bulking agents (such as mannitol or glycine), chelating agents (such as ethylenediamine tetraacetic acid (EDTA)), complexing agents (such as caffeine, polyvinylpyrrolidone, beta-cyclodextrin, or hydroxypropyl-beta-cyclodextrin), fillers, monosaccharides, disaccharides, and other carbohydrates (such as glucose, mannose, or dextrans), proteins (such as serum albumin, gelatin, or immunoglobulins), coloring, flavoring and diluting agents, emulsifying agents, hydrophilic polymers

(such as polyvinylpyrrolidone), low molecular weight polypeptides, salt-forming counterions (such as sodium), preservatives (such as benzalkonium chloride, benzoic acid, salicylic acid, thimerosal, phenethyl alcohol, methylparaben, propylparaben, chlorhexidine, sorbic acid, or hydrogen peroxide), solvents (such as glycerin, propylene glycol, or polyethylene glycol), sugar alcohols (such as mannitol or sorbitol), suspending agents, surfactants or wetting agents (such as pluronics; PEG; sorbitan esters; polysorbates such as polysorbate 20 or polysorbate 80; triton; tromethamine; lecithin; cholesterol or tyloxapal), stability enhancing agents (such as sucrose or sorbitol), tonicity enhancing agents (such as alkali metal halides—preferably sodium or potassium chloride—or mannitol sorbitol), delivery vehicles, diluents, excipients and/or pharmaceutical adjuvants (see, e.g., REMINGTON'S PHARMACEUTICAL SCIENCES (18th Ed., A. R. Gennaro, ed., Mack Publishing Company 1990), and subsequent editions of the same, incorporated herein by reference for any purpose).

[0471] The optimal pharmaceutical composition will be determined by a skilled artisan depending upon, for example, the intended route of administration, delivery format, and desired dosage. Such compositions can influence the physical state, stability, rate of in vivo release, and rate of in vivo clearance of the binding protein.

[0472] The primary vehicle or carrier in a pharmaceutical composition can be either aqueous or non-aqueous in nature. For example, a suitable vehicle or carrier for injection can be water, physiological saline solution, or artificial cerebrospinal fluid, possibly supplemented with other materials common in compositions for parenteral administration. Neutral buffered saline or saline mixed with serum albumin are further exemplary vehicles. Other exemplary pharmaceutical compositions comprise Tris buffer of about pH 7.0-8.5, or acetate buffer of about pH 4.0-5.5, which can further include sorbitol or a suitable substitute. In one embodiment of the disclosure, binding protein compositions can be prepared for storage by mixing the selected composition having the desired degree of purity with optional formulation agents in the form of a lyophilized cake or an aqueous solution. Further, the binding protein can be formulated as a lyophilizate using appropriate excipients such as sucrose.

[0473] The pharmaceutical compositions of the disclosure can be selected for parenteral delivery or subcutaneous.

Alternatively, the compositions can be selected for inhalation or for delivery through the digestive tract, such as orally. The preparation of such pharmaceutically acceptable compositions is within the skill of the art.

[0474] The formulation components are present in concentrations that are acceptable to the site of administration. For example, buffers are used to maintain the composition at physiological pH or at a slightly lower pH, typically within a pH range of from about 5 to about 8.

[0475] When parenteral administration is contemplated, the therapeutic compositions for use can be in the form of a pyrogen-free, parenterally acceptable, aqueous solution comprising the desired binding protein in a pharmaceutically acceptable vehicle. A particularly suitable vehicle for parenteral injection is sterile distilled water in which a binding protein is formulated as a sterile, isotonic solution, properly preserved. Yet another preparation can involve the formulation of the desired molecule with an agent, such as injectable microspheres, bio-erodible particles, polymeric compounds (such as polylactic acid or polyglycolic acid), beads, or liposomes, that provides for the controlled or sustained release of the product which can then be delivered via a depot injection. Hyaluronic acid can also be used, and this can have the effect of promoting sustained duration in the circulation. Other suitable means for the introduction of the desired molecule include implantable drug delivery devices.

[0476] In one embodiment, a pharmaceutical composition can be formulated for inhalation. For example, a binding protein can be formulated as a dry powder for inhalation. Binding protein inhalation solutions can also be formulated with a propellant for aerosol delivery. In yet another embodiment, solutions can be nebulized.

[0477] It is also contemplated that certain formulations can be administered orally. In one embodiment of the disclosure, binding proteins that are administered in this fashion can be formulated with or without those carriers customarily used in the compounding of solid dosage forms such as tablets and capsules. For example, a capsule can be designed to release the active portion of the formulation at the point in the gastrointestinal tract when bioavailability is maximized and pre-systemic degradation is minimized. Additional agents can be included to facilitate absorption of the binding protein. Diluents, flavorings, low melting point waxes, vegetable oils, lubricants, suspending agents, tablet disintegrating agents, and binders can also be employed.

[0478] Another pharmaceutical composition can involve an effective quantity of binding proteins in a mixture with non-toxic excipients that are suitable for the manufacture of tablets. By dissolving the tablets in sterile water, or another appropriate vehicle, solutions can be prepared in unit-dose form. Suitable excipients include, but are not limited to, inert diluents, such as calcium carbonate, sodium carbonate or bicarbonate, lactose, or calcium phosphate; or binding agents, such as starch, gelatin, or acacia; or lubricating agents such as magnesium stearate, stearic acid, or talc.

[0479] Additional pharmaceutical compositions of the disclosure will be evident to those skilled in the art, including formulations involving binding proteins in sustained- or controlled-delivery formulations. Techniques for formulating a variety of other sustained- or controlled-delivery means, such as liposome carriers, bio-erodible microparticles or porous beads and depot injections, are also known to those skilled in the art. Additional examples of sustained-release preparations include semipermeable polymer matrices in the form of shaped articles, e.g. films, or microcapsules. Sustained release matrices can include polyesters, hydrogels, polylactides, copolymers of L-glutamic acid and gamma ethyl-L-glutamate, poly(2-hydroxyethyl-methacrylate), ethylene vinyl acetate, or poly-D(-)-3-hydroxybutyric acid. Sustained-release compositions can also include liposomes, which can be prepared by any of several methods known in the art.

[0480] Pharmaceutical compositions to be used for in vivo administration typically must be sterile. This can be accomplished by filtration through sterile filtration membranes. Where the composition is lyophilized, sterilization using this method can be conducted either prior to, or following, lyophilization and reconstitution. The composition for parenteral administration can be stored in lyophilized form or in a solution. In addition, parenteral compositions generally are placed into a container

having a sterile access port, for example, an intravenous solution bag or vial having a stopper pierceable by a hypodermic injection needle.

[0481] Once the pharmaceutical composition has been formulated, it can be stored in sterile vials as a solution, suspension, gel, emulsion, solid, or as a dehydrated or lyophilized powder. Such formulations can be stored either in a ready-to-use form or in a form (e.g., lyophilized) requiring reconstitution prior to administration.

[0482] The disclosure also relates to a kit comprising a binding protein and other reagents useful for detecting target antigen levels in biological samples. Such reagents can include a detectable label, blocking serum, positive and negative control samples, and detection reagents. In some embodiments, the kit comprises a composition comprising any binding protein, polynucleotide, vector, vector system, and/or host cell described herein. In some embodiments, the kit comprises a container and a label or package insert on or associated with the container. Suitable containers include, for example, bottles, vials, syringes, IV solution bags, etc. The containers may be formed from a variety of materials such as glass or plastic. The container holds a composition which is by itself or combined with another composition effective for treating, preventing and/or diagnosing a condition and may have a sterile access port (for example the container may be an intravenous solution bag or a vial having a stopper pierceable by a hypodermic injection needle). In some embodiments, the label or package insert indicates that the composition is used for preventing, diagnosing, and/or treating the condition of choice. Alternatively, or additionally, the article of manufacture or kit may further comprise a second (or third) container comprising a pharmaceutically-acceptable buffer, such as bacteriostatic water for injection (BWI), phosphate-buffered saline, Ringer's solution and dextrose solution. It may further include other materials desirable from a commercial and user standpoint, including other buffers, diluents, filters, needles, and syringes.

[0483] The disclosure also encompasses kits for producing a single-dose administration unit. The kits can each contain both a first container having a dried protein and a second container having an aqueous formulation. Also included within the scope of this disclosure are kits containing single and multi-chambered pre-filled syringes (e.g., liquid syringes and lysyringes).

[0484] The effective amount of a binding protein pharmaceutical composition to be employed therapeutically will depend, for example, upon the therapeutic context and objectives. One skilled in the art will appreciate that the appropriate dosage levels for treatment will thus vary depending, in part, upon the molecule delivered, the indication for which the binding protein is being used, the route of administration, and the size (body weight, body surface, or organ size) and condition (the age and general health) of the patient. Accordingly, the clinician can titer the dosage and modify the route of administration to obtain the optimal therapeutic effect.

[0485] Dosing frequency will depend upon the pharmacokinetic parameters of the binding protein in the formulation being used. Typically, a clinician will administer the composition until a dosage is reached that achieves the desired effect. The composition can therefore be administered as a single dose, as two or more doses (which may or may not contain the same amount of the desired molecule) over time, or as a continuous infusion via an implantation device or catheter. Further refinement of the appropriate dosage is routinely made by those of ordinary skill in the art and is within the ambit of tasks routinely performed by them. Appropriate dosages can be ascertained through use of appropriate dose-response data.

[0486] The route of administration of the pharmaceutical composition is in accord with known methods, e.g., orally; through injection by intravenous, intraperitoneal, intracerebral (intraparenchymal), intracerebroventricular, intramuscular, intraocular, intraarterial, intraportal, or intralesional routes; by sustained release systems; or by implantation devices. Where desired, the compositions can be administered by bolus injection or continuously by infusion, or by implantation device.

[0487] The composition can also be administered locally via implantation of a membrane, sponge, or other appropriate material onto which the desired molecule has been absorbed or encapsulated. Where an implantation device is used, the device can be implanted into any suitable tissue or organ, and delivery of the desired molecule can be via diffusion, timed-release bolus, or continuous administration.

TABLE-US-00005 TABLE 1 Trispecific binding protein polypeptide sequences Poly- peptide Number SEQ (acc. to ID Molecule formula) NO Sequence HER2 (WT- 1 100

DIVMTQTPLSLSVTPGQPASISCKSSQSLVHQNAQTYLSWYLQKPGQSPQSLIYKVSNRFSGVPDRFSGSGSG
trastuzumab)/

TDFTLKISRVEAEDVGVYYCGQGTQYPFTFGSGTKVEIKDKTHTDIQMTQSPSSLSASVGDRTITCQASQNI
CD28supxCD3mid

YVWLNWYQQKPGKAPKLLIYKASNLHTGVPSRFSGSGSGTDFTLTISLQPEDATYYCQQGQTYPTFGQG
(32/35 QQ

TKLEIKDKTHTRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDS (LC);
DKTHT KDSTYLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC linkers on 2 101

QVQLVQSGAEVVKPGASVKVSCKASGYTFTSYIHVWRQAPGGLEWIGSIYPGNVNTNYAQKFQGRATL
HC/LC) IgG4

TVDTISISTAYMELSRRLSDDTAVYYCTRSHYGLDWNFDVWGKGTITVTVSSDKTHTQVQLVESGGGVVQPG FALA
RSLRLSCAASGFTFTKAWMHWRQAPGKQLEWVAQIKDKSNSYATYYADSVKGRFTISRDDSKNTLYLQM BP
1 NSLRAEDTAVYYCRGVYYALSPFDYWGQGLTVTVSSDKTHTASTKGPSVFPLAPCSRSTSESTAALGCLVK
DYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVTVPSSSLGKTKYTCNVDPKPSNTKVDKRVESKY
GPPCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVDVVSQEDPEVQFNWYVDGVEVHNAKTKPREE
QFNSTYRVVSVLTVHLQDNLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVCTLPPSQEEMTKNQVSL
CAVKGFPYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLVSKLTVDKSRWQEGNVFSCSVMHEALHNHYT
QKSLSLSLG 3 102

EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTIS

ADTSKNTAYLQMNSLRAEDTAVYYCSRWGGEFGFYAMDYWGQGLTVTVSSASTKGPSVFPLAPCSRSTSES
TAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGKTKYTCNVDHKPSNTK
VDKRVESKYGPPCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVDVVSQEDPEVQFNWYVDGVEV
HNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPCQE
EMTKNQVSLWCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQEGNVFSCSV
MHEALHNHYTQKSLSLGLG 4 103

DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSRSGTDFTL
TISSLQPEDFATYYCQGHYTTPTFTGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREA
KVQWKVDNALQSGNSQESVTEQDSKDYSLSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC HER2 1
104 DIVMTQTPLSLSVTPGQPASISCKSSQSLVHQNAQTYLSWYQLKPGQSPQSLIYKVSNRFSGVDPDRFSGSGSG
(30R/55Q/102E +
TDFTLKISRVEAEDVGVYYCGQGTQYPFTFGSGTKVEIKDKTHTDIQMTQSPSSLSASVGDRVTITCQASQNI LC-
WT- YVWLNWYQQKPGKAPKLLIYKASNLHTGVPSRFSGSGSGTDFTLTISLQPEDATYYCQQGQTYPTYTFGQG
trastuzumab)/
TKLEIKDKTHTRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDS
CD28supxCD3mid KDSTYSLSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (32/35 QQ 2 105
QVQLVQSGAEVVKPGASVKVSKKASGYTFTSYIHVWRQAPGQGLEWIGSIYPGNVNTNYAQKFQGRATL (LC);
DKTHT TVDTSISTAYMELSRLSDDTAVYYCTRSHYGLDWNFDVWGKGTTVTVSSDKTHTQVQLVESGGGVVQPG
linkers on
RSLRLSCAASGFTFTKAWMHVWRQAPGKQLEWVAQIKDKSNSYATYYADSVKGRFTISRDDSKNTLYLQM
HC/LC) IgG4
NSLRAEDTAVYYCRGVYYALSPFDYWGQGLTVTVSSDKTHTASTKGPSVFPLAPCSRSTSESTAALGCLVK FALA
DYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGKTKYTCNVDHKPSNTKVDKRVESKY BP
2 GPPCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVDVVSQEDPEVQFNWYVDGVEVHNAKTKPREE
QFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVCTLPSSQEEMTKNQVSL
CAVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQEGNVFSCSV MHEALHNHYT
QKSLSLGLG 3 106

EVQLVESGGGLVQPGGSLRLSCAASGFNIRDYIHVWRQAPGKGLEWVARIYPTQGYTRYADSVKGRFTIS
ADTSKNTAYLQMNSLRAEDTAVYYCSRWGGEFGFYAMDYWGQGLTVTVSSASTKGPSVFPLAPCSRSTSES
TAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGKTKYTCNVDHKPSNTK
VDKRVESKYGPPCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVDVVSQEDPEVQFNWYVDGVEV
HNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPCQE
EMTKNQVSLWCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQEGNVFSCSV
MHEALHNHYTQKSLSLGLG 4 107

DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSRSGTDFTL
TISSLQPEDFATYYCQGHYTTPTFTGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAK
VQWKVDNALQSGNSQESVTEQDSKDYSLSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC HER2 1
108 DIVMTQTPLSLSVTPGQPASISCKSSQSLVHDNAQTYLSWYQLKPGQSPQSLIYKVSNRFSGVDPDRFSGSGSG
(30R/55Q/102E +
TDFTLKISRVEAEDVGVYYCGQGTQYPFTFGSGTKVEIKDKTHTDIQMTQSPSSLSASVGDRVTITCQASQNI LC-
WT- YVWLNWYQQKPGKAPKLLIYKASNLHTGVPSRFSGSGSGTDFTLTISLQPEDATYYCQQGQTYPTYTFGQG
trastuzumab)/
TKLEIKDKTHTRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDS
CD28.sub.supxCD3.sub.mid KDSTYSLSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (DNAQ (LC); 2
109 QVQLVQSGAEVVKPGASVKVSKKASGYTFTSYIHVWRQAPGQGLEWIGSIYPGNVNTNYAQKFQGRATL
DKTHT linkers
TVDTSISTAYMELSRLSDDTAVYYCTRSHYGLDWNFDVWGKGTTVTVSSDKTHTQVQLVESGGGVVQPG on
HC/LC) IgG4
RSLRLSCAASGFTFTKAWMHVWRQAPGKQLEWVAQIKDKSNSYATYYADSVKGRFTISRDDSKNTLYLQM FALA
NSLRAEDTAVYYCRGVYYALSPFDYWGQGLTVTVSSDKTHTASTKGPSVFPLAPCSRSTSESTAALGCLVK BP #
8 DYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGKTKYTCNVDHKPSNTKVDKRVESKY
GPPCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVDVVSQEDPEVQFNWYVDGVEVHNAKTKPREE
QFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVCTLPSSQEEMTKNQVSL
CAVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQEGNVFSCSV MHEALHNHYT
QKSLSLGLG 3 110

EVQLVESGGGLVQPGGSLRLSCAASGFNIRDYIHVWRQAPGKGLEWVARIYPTQGYTRYADSVKGRFTIS
ADTSKNTAYLQMNSLRAEDTAVYYCSRWGGEFGFYAMDYWGQGLTVTVSSASTKGPSVFPLAPCSRSTSES
TAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGKTKYTCNVDHKPSNTK
VDKRVESKYGPPCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVDVVSQEDPEVQFNWYVDGVEV
HNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPCQE
EMTKNQVSLWCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQEGNVFSCSV
MHEALHNHYTQKSLSLGLG 4 111

DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSRSGTDFTL

TISSLQPEDFATYYCQHYTTPPTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREA
KVQWKVDNALQSGNSQESVTEQDSKDYSLSTLTLKADYEEKHKVYACEVTHQGLSSPVTKSFNRGEC HER2 1
286 DIVMTQTPLSLSVTPGQPASISCKSSQSLVHQAQTYLSWYWLQKPGQSPQSLIYKVSNRFSGVPDRFSGSGSG
(30R/56A/
TDFTLKISRVEAEDVGVYYCGQGTQYPFTFGSGTKVEIKDKTHTDIQMTQSPSSLSASVGDRVTITCQASQNI 102S
+ LC-WT-
YVWLNWYQQKPGKAPKLLIYKASNLHTGVPSRFSGSGSGTDFTLTISLQPEDATYYCQQGQTYPTYTFGQG
trastuzumab)/
TKLEIKDKTHTTRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDS
CD28supxCD3mid KDSTYSLSTLTLKADYEEKHKVYACEVTHQGLSSPVTKSFNRGEC (32/35QQ185E) 2 287
QVQLVQSGAEVVKPGASVKVSCKASGYTFTSYIHVWRQAPGQGLEWIGSIYPGNVNTNYAQKFQGRATL IgG4
FALA TVDTSISTAYMELSRLRSDDTAVYYCTRSHYGLDWNFDVWGKGTITVTVSSDKTHTQVQLVESGGGVVQPG
BP # 3
RSLRLSCAASGFTFTKAWMHVWRQAPGKQLEWVAQIKDKSNTSYATYYADSVKGRFTISRDDSKNTLYLQM
NSLRAEDTAVYYCRGVYYALSPFDYWGQGLTVTVSSDKTHTASTKGPSVFPLAPCSRSTSESTAALGCLVK
DYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVTVPSSSLGKTYTCNVDPHKPSNTKVDKRVESKY
GPPCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVDVDSQEDPEVQFNWYVDGVEVHNAKTKPREE
QFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVCTLPPSQEEMTKNQVSL
CAVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLVSKLTVDKSRWQEGNVFSCSVMEALHNHYT
QKSLSLSLG 3 288
EVQLVESGGGLVQPGGSLRLSCAASGFTNIRDTYIHWVRQAPGKGLEWVARTYPTNAYTRYADSVKGRFTIS
ADTSKNTAYLQMNSLRAEDTAVYYCSRWGGSGFYAMDYWGQGLTVTVSSASTKGPSVFPLAPCSRSTSES
TAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVTVPSSSLGKTYTCNVDPHKPSNTK
VDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVDVDSQEDPEVQFNWYVDGVEVH
NAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPCQEE
MTKNQVSLWCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLVSKLTVDKSRWQEGNVFSCSV
MEALHNHYTQKSLSLSLG 4 289
DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSRSGTDFTL
TISSLQPEDFATYYCQHYTTPPTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREA
KVQWKVDNALQSGNSQESVTEQDSKDYSLSTLTLKADYEEKHKVYACEVTHQGLSSPVTKSFNRGEC HER2 1
290 DIVMTQTPLSLSVTPGQPASISCKSSQSLVHQAQTYLSWYWLQKPGQSPQSLIYKVSNRFSGVPDRFSGSGSG
(30R/55Q/102E +
TDFTLKISRVEAEDVGVYYCGQGTQYPFTFGSGTKVEIKGQPKAAPDIQMTQSPSSLSASVGDRVTITCQASQ LC-
WT- NIYVWLNWYQQKPGKAPKWKYKASNLHTGVPSRFSGSGSGTDFTLTISLQPEDATYYCQQGQTYPTYTFG
trastuzumab)/
QGTKLEIKTKGPSRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQ
CD28supxCD3mid DSKDYSLSTLTLKADYEEKHKVYACEVTHQGLSSPVTKSFNRGEC (32/35QQ185E) 2 291
QVQLVQSGAEVVKPGASVKVSCKASGYTFTSYIHVWRQAPGQGLEWIGSIYPGNVNTNYAQKFQGRATL IgG4
FALA TVDTSISTAYMELSRLRSDDTAVYYCTRSHYGLDWNFDVWGKGTITVTVSSDKTHTQVQLVESGGGVVQPG
BP # 4
RSLRLSCAASGFTFTKAWMHVWRQAPGKQLEWVAQIKDKSNTSYATYYAESVKGRFTISRDDSKNTLYLQM
NSLRAEDTAVYYCRGVYYALSPFDYWGQGLTVTVSSDKTHTASTKGPSVFPLAPCSRSTSESTAALGCLVK
DYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVTVPSSSLGKTYTCNVDPHKPSNTKVDKRVESKY
GPPCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVDVDSQEDPEVQFNWYVDGVEVHNAKTKPREE
QFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVCTLPPSQEEMTKNQVSL
CAVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLVSKLTVDKSRWQEGNVFSCSVMEALHNHYT
QKSLSLSLG 3 292
EVQLVESGGGLVQPGGSLRLSCAASGFTNIRDTYIHWVRQAPGKGLEWVARIYPTQGYTRYADSVKGRFTIS
ADTSKNTAYLQMNSLRAEDTAVYYCSRWGGEGFYAMDYWGQGLTVTVSSASTKGPSVFPLAPCSRSTSES
TAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVTVPSSSLGKTYTCNVDPHKPSNTK
VDKRVESKYGPPCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVDVDSQEDPEVQFNWYVDGVEV
HNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPCQE
EMTKNQVSLWCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLVSKLTVDKSRWQEGNVFSCSV
MEALHNHYTQKSLSLSLG 4 293
DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSRSGTDFTL
TISSLQPEDFATYYCQHYTTPPTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAK
VQWKVDNALQSGNSQESVTEQDSKDYSLSTLTLKADYEEKHKVYACEVTHQGLSSPVTKSFNRGEC HER2 1
294 DIVMTQTPLSLSVTPGQPASISCKSSQSLVHQAQTYLSWYWLQKPGQSPQSLIYKVSNRFSGVPDRFSGSGSG
(30R/55Q/102E +
TDFTLKISRVEAEDVGVYYCGQGTQYPFTFGSGTKVEIKGQPKAAPDIQMTQSPSSLSASVGDRVTITCQASQ LC-
WT- NIYVWLNWYQQKPGKAPKLLIYKASNLHTGVPSRFSGSGSGTDFTLTISLQPEDATYYCQQGQTYPTYTFG
trastuzumab)/
QGTKLEIKTKGPSRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQ

CD28supxCD3mid DSKDSTYLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (32/35QQ185S) 2 295
QVQLVQSGAEVVKPGASVKVSKASGYTFTSYIHWVRQAPGQGLEWIGSIYPGNVNTNYAQKFQGRATL IgG4
FALA TVDTSISTAYMELSRLRSDDTAVYYCTRSHYGLDWNFDVWGKGTTVTVSSSQVQLVESGGGVVQPGRSLR
BP # 5

LSCAASGFTFTKAWMHWRQAPGKQLEWVAQIKDKSNSYATYYASSVKGRFTISRDDSKNTLYLQMNSLR
AEDTAVYYCRGVYYALSPFDYWGQGTLLTVSSRTASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVT
VSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCP
APEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYR
VVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVCTLPSSQEEMTKNQVSLSCAVKGF
YPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFLVSKLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSL SLG 3
296 EVQLVESGGGLVQPGGSLRLSCAASGFNIRDYIHWVRQAPGKGLEWVARIYPTQGYTRYADSVKGRFTIS
ADTSKNTAYLQMNSLRAEDTAVYYCSRWGGEFGFYAMDYWGQGTLLTVSSASTKGPSVFPLAPCSRSTSES
TAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGKTYTCNVDHKPSNTK
VDKRVESKYGPPCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEV
HNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPCQE
EMTKNQVSLWCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFLVSKLTVDKSRWQEGNVFSCSV
MHEALHNHYTQKSLSLSLG 4 297

DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSRSGTDFTL
TISSLQPEDFATYYCQGHYTTTPPTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAK
VQWKVDNALQSGNSQESVTEQDSKSTYLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC HER2 1
298 DIVMTQTPLSLSVTPGQPASISCKSSQSLVHQAQTYLSWYLLQKPGQSPQSLIYKVSNRFSGVPRDFSGSGS
(30R/55Q/102E +

GTDFTLKISRVEAEDVGYYCGQGTQYPFTFGSGTKVEIKGQPKAAPDIQMTQSPSSLSASVGDRVTITCQAS LC-
WT- QNIYVWLNWYQQKPGKAPKLLIYKASNLHTGVPSRFSGSGSGTDFTLTISLQPEDATYYCQGGQTYPYTF
trastuzumab)/

GQGTKLEIKTKGPSRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTE
CD28supxCD3mid QDSKSTYLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (32/33/35QSQ 2 299
QVQLVQSGAEVVKPGASVKVSKASGYTFTSYIHWVRQAPGQGLEWIGSIYPGNVNTNYAQKFQGRATL 185S)
IgG4 TVDTSISTAYMELSRLRSDDTAVYYCTRSHYGLDWNFDVWGKGTTVTVSSSQVQLVESGGGVVQPGRSLR
FALA LSCAASGFTFTKAWMHWRQAPGKQLEWVAQIKDKSNSYATYYASSVKGRFTISRDDSKNTLYLQMNSLR
BP # 6

AEDTAVYYCRGVYYALSPFDYWGQGTLLTVSSRTASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVT
VSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCP
APEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYR
VVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVCTLPSSQEEMTKNQVSLSCAVKGF
YPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFLVSKLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSL SLG 3
300 EVQLVESGGGLVQPGGSLRLSCAASGFNIRDYIHWVRQAPGKGLEWVARIYPTQGYTRYADSVKGRFTIS
ADTSKNTAYLQMNSLRAEDTAVYYCSRWGGEFGFYAMDYWGQGTLLTVSSASTKGPSVFPLAPCSRSTSES
TAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLOSSGLYSLSSVVTVPSSSLGKTYTCNVDHKPSNTK
VDKRVESKYGPPCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEV
HNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPCQE
EMTKNQVSLWCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFLVSKLTVDKSRWQEGNVFSCSV
MHEALHNHYTQKSLSLSLG 4 301

DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSRSGTDFTL
TISSLQPEDFATYYCQGHYTTTPPTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAK
VQWKVDNALQSGNSQESVTEQDSKSTYLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC HER2 1
112 DIVMTQTPLSLSVTPGQPASISCKSSQSLVHQAQTYLSWYLLQKPGQSPQSLIYKVSNRFSGVPRDFSGSGSG
(30R/55Q/102E +

TDFTLKISRVEAEDVGYYCGQGTQYPFTFGSGTKVEIKGQPKAAPDIQMTQSPSSLSASVGDRVTITCQASQ LC-
WT- NIYVWLNWYQQKPGKAPKLLIYKASNLHTGVPSRFSGSGSGTDFTLTISLQPEDATYYCQGGQTYPYTFG
trastuzumab)/

QGTKLEIKTKGPSRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQ
CD28.sub.supxCD3.sub.mid DSKDSTYLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (32/35QQ
(LC); 2 113

QVQLVQSGAEVVKPGASVKVSKASGYTFTSYIHWVRQAPGQGLEWIGSIYPGNVNTNYAQKFQGRATL L1
linker) IgG4

TVDTSISTAYMELSRLRSDDTAVYYCTRSHYGLDWNFDVWGKGTTVTVSSSQVQLVESGGGVVQPGRSLR FALA
LSCAASGFTFTKAWMHWRQAPGKQLEWVAQIKDKSNSYATYYADSVKGRFTISRDDSKNTLYLQMNSLR BP
9 AEDTAVYYCRGVYYALSPFDYWGQGTLLTVSSRTASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVT
VSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCP
APEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYR
VVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVCTLPSSQEEMTKNQVSLSCAVKGF
YPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFLVSKLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSL SLG 3

114 EVQLVESGGGLVQPGGSLRLSCAASGFNIRDYIHVVRQAPGKGLEWVARIYPTQGYTRYADSVKGRFTIS
ADTSKNTAYLQMNSLRAEDTAVYYCSRWGGEGFYAMDYWGQGTTLTVSSASTKGPSVFPLAPCSRSTSES
TAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGKTYTCNVDHKPSNTK
VDKRVESKYGPPCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEV
HNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPCQE
EMTKNQVSLWCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFLYSKLTVDKSRWQEGNVFSCSV
MHEALHNHYTQKSLSLGLG 4 115
DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGRSGTDFTL
TISSLQPEDFATYYCQGHYTPPTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAK
VQWKVDNALQSGNSQESVTEQDSKDYSLSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC HER2-
30R/ 1 116
DIVMTQTPLSLSVTPGQPASISCKSSQSLVHNNANTYLSWYLQKPGQSPQSLIYKVSNRFSGVDPDRFSGSGSG
55Q/102S +
TDFTLKISRVEAEDVGVYYCGQGTQYPFTFGSGTKVEIKGQPKAAPDIQMTQSPSSLSASVGDRVTITCQASQ LC-
WT- NIYVWLNWYQQKPGKAPKLLIYKASNLHTGVPSRFSGSGSGTDFTLTISLQPEDFATYYCQQGQTYPYTFG
trastuzumab/
QGTKLEIKTKGPSRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQ
CD28supxCD3mid DSKDSTYSLSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC L1 linker 2 117
QVQLVQSGAEVVKPGASVKVSKKASGYTFTSYIHVVRQAPGQGLEWIGSIYPGNVNTNYAQKFQGRATL IgG4
FALA TVDTSISTAYMELSRLRSDDTAVYYCTRSHYGLDWNFDVWGKGTITVTVSSSQVQLVESGGGVVQPGRLR
BP # 10
LSCAASGFTFTKAWMHVVRQAPGKQLEWVAQIKDKSNSYATYYADSVKGRFTISRDDSKNTLYLQMNSLR
AEDTAVYYCRGVYYALSPFDYWGQGTTLTVSSRTASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVT
VSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCP
APEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYR
VSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVCTLPSSQEEMTKNQVSLSCAVKGF
YPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFLVSKLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSL SLG 3
118 EVQLVESGGGLVQPGGSLRLSCAASGFNIRDYIHVVRQAPGKGLEWVARTYPTQGYTRYADSVKGRFTIS
ADTSKNTAYLQMNSLRAEDTAVYYCSRWGGSGFYAMDYWGQGTTLTVSSASTKGPSVFPLAPCSRSTSES
TAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGKTYTCNVDHKPSNTK
VDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVH
NAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPCQEE
MTKNQVSLWCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFLYSKLTVDKSRWQEGNVFSCSV
MHEALHNHYTQKSLSLGLG 4 119
DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGRSGTDFTL
TISSLQPEDFATYYCQGHYTPPTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAK
VQWKVDNALQSGNSQESVTEQDSKDYSLSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC HER2-
30R/ 1 120
DIVMTQTPLSLSVTPGQPASISCKSSQSLVHNNANTYLSWYLQKPGQSPQSLIYKVSNRFSGVDPDRFSGSGSG
56A/102S +
TDFTLKISRVEAEDVGVYYCGQGTQYPFTFGSGTKVEIKGQPKAAPDIQMTQSPSSLSASVGDRVTITCQASQ LC-
WT- NIYVWLNWYQQKPGKAPKLLIYKASNLHTGVPSRFSGSGSGTDFTLTISLQPEDFATYYCQQGQTYPYTFG
trastuzumab/
QGTKLEIKTKGPSRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQ
CD28supxCD3mid DSKDSTYSLSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC L1 linker 2 121
QVQLVQSGAEVVKPGASVKVSKKASGYTFTSYIHVVRQAPGQGLEWIGSIYPGNVNTNYAQKFQGRATL IgG4
FALA TVDTSISTAYMELSRLRSDDTAVYYCTRSHYGLDWNFDVWGKGTITVTVSSSQVQLVESGGGVVQPGRLR
BP # 11
LSCAASGFTFTKAWMHVVRQAPGKQLEWVAQIKDKSNSYATYYADSVKGRFTISRDDSKNTLYLQMNSLR
AEDTAVYYCRGVYYALSPFDYWGQGTTLTVSSRTASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVT
VSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCP
APEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYR
VSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVCTLPSSQEEMTKNQVSLSCAVKGF
YPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFLVSKLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSL SLG 3
122 EVQLVESGGGLVQPGGSLRLSCAASGFNIRDYIHVVRQAPGKGLEWVARIYPTNAYTRYADSVKGRFTIS
ADTSKNTAYLQMNSLRAEDTAVYYCSRWGGSGFYAMDYWGQGTTLTVSSASTKGPSVFPLAPCSRSTSES
TAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGKTYTCNVDHKPSNTK
VDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVH
NAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPCQEE
MTKNQVSLWCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFLYSKLTVDKSRWQEGNVFSCSV
MHEALHNHYTQKSLSLGLG 4 123
DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGRSGTDFTL
TISSLQPEDFATYYCQGHYTPPTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAK

VQWKVDNALQSGNSQESVTEQDSKDYSLSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC HER2-30R/ 1 124
DIVMTQTPLSLSVTPGQPASISCKSSQSLVHNNANTYLSWYWLQKPGQSPQSLIYKVS NRFS GVPDRFSGSGSG
56A/102E/
TDFTLKISRVEAEDVGVYYCGQGTQYPFTFGSGTKVEIKGQPKAAPDIQMTQSPSSLSASVGDRVTITCQASQ
CD28supxCD3mid
NIYVWLNWYQQKPGKAPKWKYKASNLHTGVPSRFSGSGSGTDFTLTISLQPEDATYYCQQGQTYPTYTFG L1
linker QGTKLEIKTKGPSRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQ
IgG4 FALA DSKDYSLSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC BP # 12 2 125
QVQLVQSGAEVVKPGASVKVSKKASGYTFTSYIHVWRQAPGQGLEWIGSIYPGNVNTNYAQKFQGRATL
TVDTSTISAYMELSRLLRSDDTAVYYCTRSHYGLDWNFDVWGKGTITVTVSSSQVQLVESGGGVVQPGSRSLR
LSCAASGFTFTKAWMHWRQAPGKQLEWVAQIKDKSNSYATYYADSVKGRFTISRDDSKNTLYLQMNSLR
AEDTAVYYCRGVYYALSPFDYWGQGTLVTVSSRTASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVT
VSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTCTYTCNVDPHKPSNTKVDKRVESKYGPPCPPCP
APEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSDQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYR
VVSVELTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVCTLPSSQEEEMTKNQVSLSCAVKGF
YPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFLVSKLTVDKSRWQEGNVFSCSV MHEALHNHYTQKSLSL SLG 3
126 EVQLVESGGGLVQPGGSLRLSCAASGFNI RDTYIHVWRQAPGKGLEWVARTYPTNAYTRYADSVKGRFTIS
ADTSKNTAYLQMNSLRAEDTAVYYCSRWGGEFGFYAMDYWGQGTLVTVSSASTKGPSVFPLAPCSRSTSES
TAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTCTYTCNVDPHKPSNTK
VDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSDQEDPEVQFNWYVDGVEVH
NAKTKPREEQFNSTYRVVSVELTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPCQEE
MTKNQVSLWCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFLYSKLTVDKSRWQEGNVFSCSV
MHEALHNHYTQKSLSLSLG 4 127
DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSRSGTDFTL
TISLQPEDFATYYCQHYTTPPTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAK
VQWKVDNALQSGNSQESVTEQDSKDYSLSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC HER2- 1
128 DIVMTQTPLSLSVTPGQPASISCKSSQSLVHQNAQTYLSWYWLQKPGQSPQSLIYKVS NRFS GVPDRFSGSGSG
WT +
TDFTLKISRVEAEDVGVYYCGQGTQYPFTFGSGTKVEIKGQPKAAPDIQMTQSPSSLSASVGDRVTITCQASQ
trastuzumab/
NIYVWLNWYQQKPGKAPKWKYKASNLHTGVPSRFSGSGSGTDFTLTISLQPEDATYYCQQGQTYPTYTFG
CD28supxCD3mid
QGTKLEIKTKGPSRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQ
(32/35QQ) DSKDYSLSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC L1 linker IgG4 2 129
QVQLVQSGAEVVKPGASVKVSKKASGYTFTSYIHVWRQAPGQGLEWIGSIYPGNVNTNYAQKFQGRATL FALA
TVDTSTISAYMELSRLLRSDDTAVYYCTRSHYGLDWNFDVWGKGTITVTVSSSQVQLVESGGGVVQPGSRSLR BP
15 LSCAASGFTFTKAWMHWRQAPGKQLEWVAQIKDKSNSYATYYADSVKGRFTISRDDSKNTLYLQMNSLR
AEDTAVYYCRGVYYALSPFDYWGQGTLVTVSSRTASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVT
VSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTCTYTCNVDPHKPSNTKVDKRVESKYGPPCPPCP
APEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSDQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYR
VVSVELTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVCTLPSSQEEEMTKNQVSLSCAVKGF
YPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFLVSKLTVDKSRWQEGNVFSCSV MHEALHNHYTQKSLSL SLG 3
130 EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHVWRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTIS
ADTSKNTAYLQMNSLRAEDTAVYYCSRWGGEFGFYAMDYWGQGTLVTVSSASTKGPSVFPLAPCSRSTSES
TAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTCTYTCNVDPHKPSNTK
VDKRVESKYGPPCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSDQEDPEVQFNWYVDGVEV
HNAKTKPREEQFNSTYRVVSVELTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPCQE
EMTKNQVSLWCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFLYSKLTVDKSRWQEGNVFSCSV
MHEALHNHYTQKSLSLSLG 4 131
DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSRSGTDFTL
TISLQPEDFATYYCQHYTTPPTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAK
VQWKVDNALQSGNSQESVTEQDSKDYSLSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC HER2/ 1
132 DIVMTQTPLSLSVTPGQPASISCKSSQSLVHNNANTYLSWYWLQKPGQSPQSLIYKVS NRFS GVPDRFSGSGSG
CD28.sub.supxCD3.sub.mid
TDFTLKISRVEAEDVGVYYCGQGTQYPFTFGSGTKVEIKDKTHTDIQMTQSPSSLSASVGDRVTITCQASQNI
DKTHT linkers
YVWLNWYQQKPGKAPKWKYKASNLHTGVPSRFSGSGSGTDFTLTISLQPEDATYYCQQGQTYPTYTFGQG on
HC/LC) IgG4
TKLEIKDKTHTRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDS FALA
KDYSLSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC BP # 25 2 133
QVQLVQSGAEVVKPGASVKVSKKASGYTFTSYIHVWRQAPGQGLEWIGSIYPGNVNTNYAQKFQGRATL
TVDTSTISAYMELSRLLRSDDTAVYYCTRSHYGLDWNFDVWGKGTITVTVSSDKTHTQVQLVESGGGVVQPG

RSLRLSCAASGFTFTKAWMHWVRQAPGKQLEWVAQIKDKSNSYATYYADSVKGRFTISRDDS KNTLYLQM
NSLRAEDTAVYYCRGVYYALSPFDYWGGQTLTVSSDKTHTASTKGPSVFPLAPCSRSTSESTAALGCLVK
DYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVTVPSSSLGKTYTCNV DHKPSNTKVKDKRVE
SKY GPPCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVDVVSQEDPEVQFNWYVDGVEVHNA
KTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVCTLP
PSQEEMTKNQVSLVCAVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQ
EGNVFSCSV MHEALHNHYTQKSLSLSLG 3 134
EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGR
FTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQTLTVSSASTKGPSVFPLAPCS
RSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVTVPSSSLGKTYTC
NV DHKPSNTKVKDKRVE SKY GPPCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVDV
VSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLP
SSIEKTISKAKGQPREPQVYTLPPCQEMTKNQVSLWCLVKGFYPSDIAVEWESNGQPENNYKTTP
PVLDSDGSFFLVSKLTVDKSRWQEGNVFSCSV MHEALHNHYTQKSLSLSLG 4 135
DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFS
GSRSGDTFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGT
ASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSSTLTLSKADYEKHKVYACEVTHQ
GLSSPVTKSFNRGEC HER2/ 1 136
DIVMTQTPLSLSVTPGQPASISCKSSQSLVHENLRITYLSWYLQKPGQSPQSLIYKVSNRFS
GVPDRFSGSGCD28.sub.supxCD3.sub.mid
SGTDFTLKISRVEAEDVGVYYCGQGTQYPFTFGSGTKVEIKDKTHTDIQMTQSPSSLSASVG
DRVTITCQA (32/33/3435
SQNIYVWLNWYQQKPGKAPKWKYKASNLHTGVPSRFSGSGSGTDFTLTISSLQPEDATYYCQ
QGQTYPYTFGQENLR (LC);
GTKLEIKDKTHTTRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSG
NSQESVTEQD DKTHT linkers SKDSTYLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKS
FNRGEC on HC/LC) IgG4 2 137
QVQLVQSGAEVVKPGASVKVSCKASGYTFTSYIHWVRQAPGQGLEWIGSIYPGNVNTNYAQK
FQGRATL FALA TVDTSISTAYMELSRLSDDTAVYYCTRSHYGLDWNFDVWGKGTTVTVSSDKT
HTQVQLVESGGGVVQPG BP # 26
RSLRLSCAASGFTFTKAWMHWVRQAPGKQLEWVAQIKDKSNSYATYYADSVKGRFTISRDDS
KNTLYLQMNSLRAEDTAVYYCRGVYYALSPFDYWGGQTLTVSSDKTHTASTKGPSVFPLAPCS
RSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVTVPSSSLGKTY
TCNV DHKPSNTKVKDKRVE SKY GPPCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTC
VVDVVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKV
SNKGLPSSIEKTISKAKGQPREPQVCTLPSPQEEMTKNQVSLVCAVKGFYPSDIAVEWESNGQ
PENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQEGNVFSCSV MHEALHNHYTQKSLSLSLG 3
138
EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGR
FTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQTLTVSSASTKGPSVFPLAPCS
RSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVTVPSSSLGKTYTC
NV DHKPSNTKVKDKRVE SKY GPPCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVDV
VSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLP
SSIEKTISKAKGQPREPQVYTLPPCQEMTKNQVSLWCLVKGFYPSDIAVEWESNGQPENNYKTTP
PVLDSDGSFFLVSKLTVDKSRWQEGNVFSCSV MHEALHNHYTQKSLSLSLG 4 139
DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFS
GSRSGDTFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGT
ASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSSTLTLSKADYEKHKVYACEVTHQ
GLSSPVTKSFNRGEC HER2/ 1 140
DIVMTQTPLSLSVTPGQPASISCKSSQSLVHENLQTYLSWYLQKPGQSPQSLIYKVSNRFS
GVPDRFSGSGCD28.sub.supxCD3.sub.mid
SGTDFTLKISRVEAEDVGVYYCGQGTQYPFTFGSGTKVEIKDKTHTDIQMTQSPSSLSASVG
DRVTITCQA (32/33/3435
SQNIYVWLNWYQQKPGKAPKLLIYKASNLHTGVPSRFSGSGSGTDFTLTISSLQPEDATYYCQ
QGQTYPYENLQ (LC); TFGQGTKLEIKDKTHTTRTVAAPSVFIFPPSDEQLKSGTASVVCLL
NNFYPREAKVQWKVDNALQSGNSQESDKTHT linkers VTEQDSKDSSTLTLSKADYEKHKVY
ACEVTHQGLSSPVTKSFNRGEC on HC/LC) IgG4 2 141
QVQLVQSGAEVVKPGASVKVSCKASGYTFTSYIHWVRQAPGQGLEWIGSIYPGNVNTNYAQK
FQGRATL FALA TVDTSISTAYMELSRLSDDTAVYYCTRSHYGLDWNFDVWGKGTTVTVSSDKT
HTQVQLVESGGGVVQPG BP # 27
RSLRLSCAASGFTFTKAWMHWVRQAPGKQLEWVAQIKDKSNSYATYYADSVKGRFTISRDDS
KNTLYLQMNSLRAEDTAVYYCRGVYYALSPFDYWGGQTLTVSSDKTHTASTKGPSVFPLAPCS
RSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVTVPSSSLGKTYTC
NV DHKPSNTKVKDKRVE SKY GPPCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVDV
VSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLP
SSIEKTISKAKGQPREPQVCTLPSPQEEMTKNQVSLVCAVKGFYPSDIAVEWESNGQPENNYKTTP
PVLDSDGSFFLVSKLTVDKSRWQEGNVFSCSV MHEALHNHYTQKSLSLSLG 3 142
EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGR
FTIS

ADTSKNTAYLQMNLSRAEDTAVYYCSRWGGDGFYAMDYWGQGLTVTVSSASTKGPSVFPLAPCSRSTSES
TAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGKTKYTCNVDHKPSNTK
VDKRVESKYGPPCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVDVDSQEDPEVQFNWYVDGVEV
HNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPCQE
EMTKNQVSLWCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFLYSKLTVDKSRWQEGNVFSCSV
MHEALHNHYTQKSLSLGLG 4 143

DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGRSGTDFTL
TISSLQPEDFATYYCQGHYTTPTFTGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREA
KVQWKVDNALQSGNSQESVTEQDSKDYSLSTLTLSKADYEEKHKVYACEVTHQGLSSPVTKSFNRGEC HER2/ 1
144 DIVMTQTPLSLSVTPGQPASISCKSSQSLVHENLFTYLSWYLQKPGQSPQSLIYKVSNRFSGVDPDRFSGSG
CD28.sub.supxCD3.sub.mid

SGTDFTLKISRVEAEDVGVYYCGQGTQYPFTFGSGTKVEIKDKTHTDIQMTQSPSSLSASVGDRVTITCQA
(32/33/3435

SQNIYVWLNWYQQKPGKAPKLLIYKASNLHTGVPSRFSGSGSGTDFTLTISSLQPEDATYYCQGGQTYPY ENLF
(LC); TFGQGTKLEIKDKTHTRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQES
DKTHT linkers VTEQDSKDYSLSTLTLSKADYEEKHKVYACEVTHQGLSSPVTKSFNRGEC on HC/LC) IgG4
2 145 QVQLVQSGAEVVKPGASVKVSCKASGYTFTSYIHVWRQAPGQGLEWIGSIYPGNVNTNYAQKFQGRATL
FALA TVDTSISTAYMELSRLRSDDTAVYYCTRSHYGLDWNFDVWGKGTITVTVSSDKTHTQVQLVESGGGVVQPG
BP # 28

RSLRLSCAASGFTFTKAWMHVVRQAPGKQLEWVAQIKDKSNSYATYYADSVKGRFTISRDDSKNTLYLQM
NSLRAEDTAVYYCRGVYYALSPFDYWGQGLTVTVSSDKTHTASTKGPSVFPLAPCSRSTSESTAALGCLVK
DYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGKTKYTCNVDHKPSNTKVDKRVESKY
GPPCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVDVDSQEDPEVQFNWYVDGVEVHNAKTKPREE
QFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVCTLPSSQEEMTKNQVSL
CAVKGFPYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFLVSKLTVDKSRWQEGNVFSCSVMHEALHNHYT
QKSLSLGLG 3 146

EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTIS
ADTSKNTAYLQMNLSRAEDTAVYYCSRWGGDGFYAMDYWGQGLTVTVSSASTKGPSVFPLAPCSRSTSES
TAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGKTKYTCNVDHKPSNTK
VDKRVESKYGPPCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVDVDSQEDPEVQFNWYVDGVEV
HNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPCQE
EMTKNQVSLWCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFLYSKLTVDKSRWQEGNVFSCSV
MHEALHNHYTQKSLSLGLG 4 147

DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGRSGTDFTL
TISSLQPEDFATYYCQGHYTTPTFTGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFY
PREAKVQWKVDNALQSGNSQESVTEQDSKDYSLSTLTLSKADYEEKHKVYACEVTHQGLSSPVTKS FNRGEC
anti- 1 148

DIVMTQTPLSLSVTPGQPASISCKSSQSLVHNNANTYLSWYLQKPGQSPQSLIYKVSNRFSGVDPDRFSGSGSG
Her2/CD3/3CD28

TDFTLKISRVEAEDVGVYYCGQGTQYPFTFGSGTKVEIKGQPKAAPDIQMTQSPSSLSASVGDRVTITCQASQ
IgG4 FALA

NIYVWLNWYQQKPGKAPKLLIYKASNLHTGVPSRFSGSGSGTDFTLTISSLQPEDATYYCQGGQTYPYTFG BP
#29 QGTKLEIKTKGPSRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQ
DSKDYSLSTLTLSKADYEEKHKVYACEVTHQGLSSPVTKSFNRGEC 2 149

QVQLVQSGAEVVKPGASVKVSCKASGYTFTSYIHVWRQAPGQGLEWIGSIYPGNVNTNYAQKFQGRATL
TVDTSISTAYMELSRLRSDDTAVYYCTRSHYGLDWNFDVWGKGTITVTVSSSQVQLVESGGGVVQPGRLR
LSCAASGFTFTKAWMHVVRQAPGKQLEWVAQIKDKSNSYATYYADSVKGRFTISRDDSKNTLYLQMNLSR
AEDTAVYYCRGVYYALSPFDYWGQGLTVTVSSRTASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVT
VSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGKTKYTCNVDHKPSNTKVDKRVESKYGPPCPPCP
APEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVDVDSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYR
VSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVCTLPSSQEEMTKNQVSLSCAVKGF
YPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFLVSKLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSL SLG 3
150 EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTIS
ADTSKNTAYLQMNLSRAEDTAVYYCSRWGGDGFYAMDYWGQGLTVTVSSASTKGPSVFPLAPCSRSTSES
TAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGKTKYTCNVDHKPSNTK
VDKRVESKYGPPCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVDVDSQEDPEVQFNWYVDGVEV
HNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPCQE
EMTKNQVSLWCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFLYSKLTVDKSRWQEGNVFSCSV
MHEALHNHYTQKSLSLGLG 4 151

DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGRSGTDFTL
TISSLQPEDFATYYCQGHYTTPTFTGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPRE
AKVQWKVDNALQSGNSQESVTEQDSKDYSLSTLTLSKADYEEKHKVYACEVTHQGLSSPVTKSFNRGEC
HER230R/55Q/ 1 152

DIVMTQTPLSL SVTPGQPASISCKSSQSLVHENLRTYLSWYLQKPGQSPQSLIYKVS NRFS GVPDRFSGSGS 102E/
GTDFTLKISRVEAEDVG VYYCGQGTQYPFTFGSGTKVEIKDKTHTDI QMTQSPSSLSASV GDRVTITCQASQ
CD28.sub.supxCD3.sub.mid
NIYVWLNWYQQKPGKAPKWKYKASNLHTGVPSRFS GSGSGTDFTLTIS SLQPEDIATYYCQQGQTYPYTFGQ
(32/33/3435
GTKLEIKDKTHTRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQ ENLR
(LC); DSKDSTYLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC DKHTH linkers 2 153
QVQLVQSGAEVVKPGASVKVSCKASGYTFTSYIHWVRQAPGQGLEWIGSIYPGNVNTNYAQKFQGRATL on
HC/LC) IgG4
TVDTSISTAYMELSR LRSDDTAVYYCTRSHYGLDWNFDVWGKGTTVTVSSDKTHTQVQLVESGGGVVQPG FALA
RSLRLSCAASGFTFTKAWMHVVRQAPGKQLEWVAQIKDKSNSYATYYADSVKGRFTISRDDSKNTLYLQM BP
31 NSLRAEDTAVYYCRGVYYALSPFDYWGGQTLTVTVSSDKTHTASTKGPSVFPLAPCSRSTSESTAALGCLVK
DYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVTVVPSSSLGKTKYTCNV DHKPSNTKVDKRVESKY
GPPCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVDVVSQEDPEVQFNWYVDGVEVHNAKTKPREE
QFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVCTLPSSQEEMTKNQVSL
CAVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLVSKLTVDKSRWQEGNVFSCSV MHEALHNHYT
QKSLSLSLG 3 154
EVQLVESGGGLVQPGGSLRLSCAASGFNIRDYIHWVRQAPGKGLEWVARIYPTQGYTRYADSVKGRFTIS
ADTSKNTAYLQMNSLRAEDTAVYYCSRWGGEGFYAMDYWGQGT LTVTVSSASTKGPSVFPLAPCSRSTSES
TAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVTVVPSSSLGKTKYTCNV DHKPSNTK
VDKRVESKYGPPCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVDVVSQEDPEVQFNWYVDGVEV
HNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPCQE
EMTKNQVSLWCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLVSKLTVDKSRWQEGNVFSCSV
MHEALHNHYTQKSLSLSLG 4 155
DIQMTQSPSSLSASV GDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFS GSRSGTDFTL
TISSSLQPEDFATYYCQHYYTTPPTFGGQTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYP
REAKVQWKVDNALQSGNSQESVTEQDSKDSTYLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
CD38VH1/ 1 156
DIVMTQTPLSL SVTPGQPASISCKSSQSLVHENLQTYLSWYLQKPGQSPQSLIYKVS NRFS GVPDRFSGSG CD28supx
SGTDFTLKISRVEAEDVG VYYCGQGTQYPFTFGSGTKVEIKDKTHTDI QMTQSPSSLSASV GDRVTITCQA
CD3mid_ENLQ
SQNIYVWLNWYQQKPGKAPKLLIYKASNLHTGVPSRFS GSGSGTDFTLTIS SLQPEDIATYYCQQGQTYPY DKHTH
TFGQGGTKLEIKDKTHTRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQES IgG4
FALA VTEQDSKDSTYLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC BP # 1 2 157
QVQLVQSGAEVVKPGASVKVSCKASGYTFTSYIHWVRQAPGQGLEWIGSIYPGNVNTNYAQKFQGRATL
TVDTSISTAYMELSR LRSDDTAVYYCTRSHYGLDWNFDVWGKGTTVTVSSDKTHTQVQLVESGGGVVQPG
RSLRLSCAASGFTFTKAWMHVVRQAPGKQLEWVAQIKDKSNSYATYYADSVKGRFTISRDDSKNTLYLQM
NSLRAEDTAVYYCRGVYYALSPFDYWGGQTLTVTVSSDKTHTASTKGPSVFPLAPCSRSTSESTAALGCLVK
DYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVTVVPSSSLGKTKYTCNV DHKPSNTKVDKRVESKY
GPPCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVDVVSQEDPEVQFNWYVDGVEVHNAKTKPREE
QFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVCTLPSSQEEMTKNQVSL
CAVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLVSKLTVDKSRWQEGNVFSCSV MHEALHNHYT
QKSLSLSLG 3 158
QVQLVQSGAEVVKPGASVKVSCKASGYTFTSYAMHWVKEAPGQRLEWIGYIYPGQGGTNYNQKFQGRAT
LTADTSASTAYMELSSLRSEDTAVYFCARTGGLRRAYFTYWGQGT LTVTVSSASTKGPSVFPLAPCSRSTSES
TAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVTVVPSSSLGKTKYTCNV DHKPSNTK
VDKRVESKYGPPCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVDVVSQEDPEVQFNWYVDGVEV
HNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPCQE
EMTKNQVSLWCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLVSKLTVDKSRWQEGNVFSCSV
MHEALHNHYTQKSLSLSLG 4 159
DIVLTQSPATLSLSPGERATISCRASQSVSSYGQGMHWYQQKPGQPRLLIYGASSRATGIPARFSGS
GSGTDFTLTISPLEDFAVYYCQQNKEDPWTFGGGKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVC
LLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYLSSTLTLSKADYEKHKVYACEVTHQGLSS
PVTKSFNRGEC CD38hhy992/ 1 160
DIVMTQTPLSL SVTPGQPASISCKSSQSLVHENLQTYLSWYLQKPGQSPQSLIYKVS NRFS GVPDRFSGSGS CD28supx
GTDFTLKISRVEAEDVG VYYCGQGTQYPFTFGSGTKVEIKDKTHTDI QMTQSPSSLSASV GDRVTITCQASQ
CD3mid_ENLQ
NIYVWLNWYQQKPGKAPKWKYKASNLHTGVPSRFS GSGSGTDFTLTIS SLQPEDIATYYCQQGQTYPYTFGQG
DKHTH
TKLEIKDKTHTRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDS IgG4
FALA KDSTYLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC BP # 5' 2 161
QVQLVQSGAEVVKPGASVKVSCKASGYTFTSYIHWVRQAPGQGLEWIGSIYPGNVNTNYAQKFQGRATL
TVDTSISTAYMELSR LRSDDTAVYYCTRSHYGLDWNFDVWGKGTTVTVSSDKTHTQVQLVESGGGVVQPG

RSLRLSCAASGFTFTKAWMHVVRQAPGKQLEWVAQIKDKSNSYATYYADSVKGRFTISRDDS KNTLYLQM
NSLRAEDTAVYYCRGVYYALSPFDYWGGQTLTVTVSSDKTHTASTKGPSVFPLAPCSRSTSESTAALGCLVK
DYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVTVTPSSSLGKTYTCNV DHKPSNTKVDKRVESKY
GPPCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVDVVSQEDPEVQFNWYVDGVEVHNAKTKPREE
QFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVCTLPSSQEEMTKNQVSL
CAVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQEGNVFSCSVMHEALHNHYT
QKSLSLSLG 3 162
QVQLVQSGAEVKKPGASVKVSCKVSGYTLTEFSIHVVRQAPGQGLEWMGGFDPEDGETIYAQKFQGRVIM
TEDTSTD TAYMEMNSLRSEDTAIYYCTTG RFFDWFWGQTLTVTVSSASTKGPSVFPLAPCSRSTSESTAALG
CLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVTVTPSSSLGKTYTCNV DHKPSNTKVDKRV
ESKYGPPCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVDVVSQEDPEVQFNWYVDGVEVHNAKTK
PREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPCQEEMTKNQ
VSLWCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQEGNVFSCSVMHEALH
NHYTQKSLSLSLG 4 163
EIILTQSPAILSLSPGERATLSCRASQSVISRFLSWYQVKPGLAPRLLIYGA STRATGIPVRFSGSGSGT
DFSLTISSLQPEDCAVYYCQQDSNLPITFGGQTRLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNF
YPREAKVQWKVDNALQSGNSQESVTEQDSK DSTYLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSF NRGEC
CD38hyb5739/ 1 164 DIVMTQTPLSLSVTPGQPASISCKSSQSLVHENLQTYLSWYLQKPGQSPQSLIYKVS NRFS GVP
CD28supx DRFSGSGSGTDFTLKISRVEAEDVGVYYCGGQTQYPFTFGSGTKVE CD3mid_ENLQ
IKDKTHTDIQMTQSPSSLSASVGDRVTITCQASQNIYVWLNWYQQKPGKAPKWKYKASNLHTGVP DKHTHT
SRFSGSGSGTDFTLTISLQPEDATYYCQQGQTYPTFTFGGQTKLEIKDKHTHTRTV IgG4 FALA
AAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSK BP # 6'
DSTYLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC 2 165
QVQLVQSGAEVVKPGASVKVSCKASGYTFTSYIHWVRQAPGQGLEWIGSIYPGNVNTNYA QKFQGRATL
TVDTSTIS TAYMELSRLRSDDTAVYYCTRSHYGLDWNFDVWGKGTTVTVSSDKTHTOVOLVESGGGVVOPG
RSLRLSCAASGFTFTKAWMHVVRQAPGKQLEWVAQIKDKSNSYATYYADSVKGRFTISRDDS KNTLYLQM
NSLRAEDTAVYYCRGVYYALSPFDYWGGQTLTVTVSSDKTHTASTKGPSVFPLAPCSRSTSESTAALGCLVK
DYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVTVTPSSSLGKTYTCNV DHKPSNTKVDKRVESKY
GPPCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVDVVSQEDPEVQFNWYVDGVEVHNAKTKPREE
QFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVCTLPSSQEEMTKNQVSL
CAVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQEGNVFSCSVMHEALHNHYT
QKSLSLSLG 3 166
QVQLQQSGPELV RPGTSVKVSCKASGYAFTTYLVEWIKQRPGQGLEWIGVINPGSGSTNYNEKFKGKATLT
VDRSSTTAYMHL SGLTSDDSAVYFCARYAYGYWGQTTLT TVSSASTKGPSVFPLAPCSRSTSESTAALGCLV
KDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVTVTPSSSLGKTYTCNV DHKPSNTKVDKRVE SK
YGPCCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVDVVSQEDPEVQFNWYVDGVEVHNAKTKPRE
EQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPCQEEMTKNQVS
LWCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQEGNVFSCSVMHEALHN
HYTQKSLSLSLG 4 167
DIVMTQSQKFMSASVGDRVSITCKASQNVGTAVAWYQQQPGHSPKQLIYSASNRYTGVPDRFTGSGAGTDF
TLTISNIQSEDLADYFCQQYSTYPFTFGSGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFY
PREAKVQWKVDNALQSGNSQESVTEQDSK DSTYLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKS FNRGEC
CD38hyb6284/ 1 168
DIVMTQTPLSLSVTPGQPASISCKSSQSLVHENLQTYLSWYLQKPGQSPQSLIYKVS NRFS GVPDRFSGS CD28supx
GSGTDFTLKISRVEAEDVGVYYCGGQTQYPFTFGSGTKVEIKDKTHTDIQMTQSPSSLSASVGDRVTITC
CD3mid_ENLQ
QASQNIYVWLNWYQQKPGKAPKWKYKASNLHTGVPSRFSGSGSGTDFTLTISLQPEDATYYCQQGQTYP DKHTHT
YTFGGQTKLEIKDKHTHTRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQ IgG4
FALA ESVTEQDSK DSTYLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC BP # 7 2 169
QVQLVQSGAEVVKPGASVKVSCKASGYTFTSYIHWVRQAPGQGLEWIGSIYPGNVNTNYA QKFQGRATL
TVDTSTIS TAYMELSRLRSDDTAVYYCTRSHYGLDWNFDVWGKGTTVTVSSDKTHTQVQLVESGGGVVQPG
RSLRLSCAASGFTFTKAWMHVVRQAPGKQLEWVAQIKDKSNSYATYYADSVKGRFTISRDDS KNTLYLQM
NSLRAEDTAVYYCRGVYYALSPFDYWGGQTLTVTVSSDKTHTASTKGPSVFPLAPCSRSTSESTAALGCLVK
DYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVTVTPSSSLGKTYTCNV DHKPSNTKVDKRVESKY
GPPCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVDVVSQEDPEVQFNWYVDGVEVHNAKTKPREE
QFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVCTLPSSQEEMTKNQVSL
CAVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQEGNVFSCSVMHEALHNHYT
QKSLSLSLG 3 170
QVQLLQSGAELVRPGVSVKISCTGSGYSFTNYAVHWVKQSHVKSLEWIGVISPYYGDTTYNQKFTGKATMT
VDKSSSTAYMELARLTSEDSAIYFCARRFEGFYYSMDYWGQGSTVTVSSASTKGPSVFPLAPCSRSTSESTA
ALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVTVTPSSSLGKTYTCNV DHKPSNTKVD
KRVESKYGPPCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVDVVSQEDPEVQFNWYVDGVEVHN
AKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPCQEEM

TKNQVSLWCLVKGFPYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQEGNVFSCSVMH
EALHNHYTQKSLSLSLG 4 171
DIVMTQTPLSLSVTPGQPASISCKSSQSLVHENLQTYLSWYLQKPGQSPQSLIYKVSNRFSGVPDRFSGSGS
TDFTLKISRVEAEDLGVYLCSQSTHVLPTFGSGTQLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNN
FYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKS
FNRGEC CD38hhy1195/ 1 172
DIVMTQTPLSLSVTPGQPASISCKSSQSLVHENLQTYLSWYLQKPGQSPQSLIYKVSNRFSGVPDRFSGSGS CD28supx
GTDFTLKISRVEAEDVGVIYCGQGTQYPFTFGSGTKVEIKDKTHTDIQMTQSPSSLSASVGDRVTITCQASQ
CD3mid_ENLQ
NIYVWLNWYQQKPGKAPKWKYKASNLHTGVPSRFSGSGSGTDFTLTISLQPEDATYYCQQGQTYPYTFGQ DKTHT
GTKLEIKDKTHTTRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQ IgG4
FALA DSKDSTYLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC BP # 8 2 173
QVQLVQSGAEVVKPGASVKVSCKASGYTFTSYIHVWRQAPGQGLEWIGSIYPGNVNTNYAQKFQGRATL
TVDTISISTAYMELSRRLRSDDTAVYYCTRSHYGLDWNFDVWGKGTITVTVSSDKTHTQVQLVESGGGVVQPG
RSLRLSCAASGFTFTKAWMHVWRQAPGKQLEWVAQIKDKSNSYATYYADSVKGRFTISRDDSKNTLYLQM
NSLRAEDTAVYYCRGVYYALSPFDYWGQGTITVTVSSDKTHTASTKGPSVFPLAPCSRSTSESTAALGCLVK
DYFPEPVTISWNSGALTSGVHTFPAVLQSSGLYSLSSVTVPSSSLGKTKYTCNVDPHKPSNTKVDKRVESKY
GPPCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSDQEDPEVQFNWYVDGVEVHNAAKTKPREE
QFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVCTLPPSQEEMTKNQVSL
CAVKGFPYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQEGNVFSCSVMHEALHNHYT
QKSLSLSLG 3 174
QVQLVESGGGVVQPGRSLRLSCAASGFTFSYGYMYWVRQAPGKGLEWVAVIWIYDGSNKYYADSVKGRFTI
SRDNSKNTLYLQMNSLRAEDTAVYHCARDPGLRYFDGGMVWGQGTITVTVSSASTKGPSVFPLAPCSRST
SESTAALGCLVKDYFPEPVTISWNSGALTSGVHTFPAVLQSSGLYSLSSVTVPSSSLGKTKYTCNVDPHKPS
NTKVDKRVESKYGPPCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSDQEDPEVQFNWYVDG
VEVHNAAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPP
CQEEMTKNQVSLWCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQEGNVF
CSVMHEALHNHYTQKSLSLSLG 4 175
DIQLTQSPSFLSASVGDRVTITCRASQGISSYLAWYQQKPGKAPKLLIFAASTLHSGVPSRFSGSGSGTEF
TLTISLQPEDFATYYCQQLNSFPYTFGQGTGLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPR
EAKVQWKVDNALQSGNSQESVTEQDSKDSTYLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
CD38hhy1370/ 1 176
DIVMTQTPLSLSVTPGQPASISCKSSQSLVHENLQTYLSWYLQKPGQSPQSLIYKVSNRFSGVPDRFSG CD28supx
SGSGTDFTLKISRVEAEDVGVIYCGQGTQYPFTFGSGTKVEIKDKTHTDIQMTQSPSSLSASVGDRVTI
CD3mid_ENLQ
TCQASQNIYVWLNWYQQKPGKAPKLLIYKASNLHTGVPSRFSGSGSGTDFTLTISLQPEDATYYCQQ DKTHT
GQTYPYTFGQGTGLEIKDKTHTTRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNAL IgG4
FALA QSGNSQESVTEQDSKDSTYLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC BP # 9 2 177
QVQLVQSGAEVVKPGASVKVSCKASGYTFTSYIHVWRQAPGQGLEWIGSIYPGNVNTNYAQKFQGRATL
TVDTISISTAYMELSRRLRSDDTAVYYCTRSHYGLDWNFDVWGKGTITVTVSSDKTHTQVQLVESGGGVVQPG
RSLRLSCAASGFTFTKAWMHVWRQAPGKQLEWVAQIKDKSNSYATYYADSVKGRFTISRDDSKNTLYLQM
NSLRAEDTAVYYCRGVYYALSPFDYWGQGTITVTVSSDKTHTASTKGPSVFPLAPCSRSTSESTAALGCLVK
DYFPEPVTISWNSGALTSGVHTFPAVLQSSGLYSLSSVTVPSSSLGKTKYTCNVDPHKPSNTKVDKRVESKY
GPPCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSDQEDPEVQFNWYVDGVEVHNAAKTKPREE
QFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVCTLPPSQEEMTKNQVSL
CAVKGFPYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQEGNVFSCSVMHEALHNHYT
QKSLSLSLG 3 178
QVQLVESGGGVVQPGRSLRLSCAASGFTFSYGMHWVRQAPGKGLEWVAVIWIYDGSNKYYADSVKGRFTI
SGDNSKNTLYLQMNSLRAEDTAVYYCARMFRGAFDYWGQGTITVTVSSASTKGPSVFPLAPCSRSTSESTA
LGCLVKDYFPEPVTISWNSGALTSGVHTFPAVLQSSGLYSLSSVTVPSSSLGKTKYTCNVDPHKPSNTKVDK
RVESKYGPPCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSDQEDPEVQFNWYVDGVEVHNA
KTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPCQEEMT
KNQVSLWCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQEGNVFSCSVMHE
ALHNHYTQKSLSLSLG 4 179
AIQMTQSPSSLSASVGDRVTITCRASQGIRNDLGWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTL
TISGLQPEDSATYYCLQDYIYYPTFGQGTGLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKV
QWKVDNALQSGNSQESVTEQDSKDSTYLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
CD38hu5739/ 1 181
DIVMTQTPLSLSVTPGQPASISCKSSQSLVHENLQTYLSWYLQKPGQSPQSLIYKVSNRFSGVPDRF CD28supx
SGSGSGTDFTLKISRVEAEDVGVIYCGQGTQYPFTFGSGTKVEIKDKTHTDIQMTQSPSSLSASVG
CD3mid_ENLQ
RVTITCQASQNIYVWLNWYQQKPGKAPKLLIYKASNLHTGVPSRFSGSGSGTDFTLTISLQPEDIA DKTHT
TYYCQQGQTYPYTFGQGTGLEIKDKTHTTRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKV IgG4 FALA

QWKVDNALQSGNSQESVTEQDSKDYSLSSSTLTLSKADYEKHKV YACEVTHQGLSSPVTKSFNRGEC 2 182
QVQLVQSGAEVVKPGASVKVSKASGYTFTSYIHVWRQAPGQGLEWIGSIYPGNVNTNYAQKFQGRATL
TVDTISISTAYMELSRRLSDDTAVYYCTRSHYGLDWNFDVWGKGTITVTVSSDKTHTQVQLVESGGGVVQPG
RSLRLSCAASGFTFTKAWMHVWRQAPGKQLEWVAQIKDKSNSYATYYADSVKGRFTISRDDSKNTLYLQM
NSLRAEDTAVYYCRGVYYALSPFDYWGQGLTVTVSSDKTHTASTKGPSVFPLAPCSRSTSESTAALGCLVK
DYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVTVPSSSLGKTKYTCNVDPHKPSNTKVDKRVESKY
GPPCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVDVVSQEDPEVQFNWYVDGVEVHNAKTKPREE
QFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVCTLPPSQEEMTKNQVSL
CAVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQEGNVFSCSVMHEALHNHYT
QKSLSLSLG 3 183

QVQLVQSGAEVVKPGASVKVSKASGYAFTTYLVWIRQRPGQGLEWMGVINPGSGSTNYAQKFQGRVT
MTVDRSSTTAYMELSRRLSDDTAVYYCARYAYGYWGQGLTVTVSSASTKGPSVFPLAPCSRSTSESTAALG
CLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVTVPSSSLGKTKYTCNVDPHKPSNTKVDKRV
ESKYGPPCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVDVVSQEDPEVQFNWYVDGVEVHNAKTK
PREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPCQEEMTKNQ
VSLWCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQEGNVFSCSVMHEALH
NHYTQKSLSLSLG 4 184

DIQMTQSPSSLSASVGDRVTITCRASQNVGTAVAWYQQKPGKSPKQLIYSASNRYTGVPSTRFSGSGSGTDFT
LTISSLQPEDLATYYCQQYSTYPTFTFGQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPRE
AKVQWKVDNALQSGNSQESVTEQDSKDYSLSSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
CD3hu6284/ 1 185

DIVMTQTPLSLSVTPGQPASISCKSSQSLVHENLQTYLSWYLQKPGQSPQSLIYKVSNNRFSGVPDRFSGS CD28supx
GSGTDFTLKISRVEAEDVGVYYCGGTQYPTFTFGSGTKVEIKDKTHTDIQMTQSPSSLSASVGDRVTITC
CD3mid_ENLQ

QASQNIYVWLNWYQQKPGKAPKLLIYKASNLHTGVPSRFSGSGSGTDFTLTISSLQPEDLATYYCQQGQT DKTHT
YPYTFGQGTKLEIKDKTHTRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGN IgG4
FALA SQESVTEQDSKDYSLSSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC 2 186

QVQLVQSGAEVVKPGASVKVSKASGYTFTSYIHVWRQAPGQGLEWIGSIYPGNVNTNYAQKFQGRATL
TVDTISISTAYMELSRRLSDDTAVYYCTRSHYGLDWNFDVWGKGTITVTVSSDKTHTQVQLVESGGGVVQPG
RSLRLSCAASGFTFTKAWMHVWRQAPGKQLEWVAQIKDKSNSYATYYADSVKGRFTISRDDSKNTLYLQM
NSLRAEDTAVYYCRGVYYALSPFDYWGQGLTVTVSSDKTHTASTKGPSVFPLAPCSRSTSESTAALGCLVK
DYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVTVPSSSLGKTKYTCNVDPHKPSNTKVDKRVESKY
GPPCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVDVVSQEDPEVQFNWYVDGVEVHNAKTKPREE
QFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVCTLPPSQEEMTKNQVSL
CAVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQEGNVFSCSVMHEALHNHYT
QKSLSLSLG 3 187

QVQLVQSGAEVVKPGASVKVSKASGYSFTNYAVHWVRQAPGQGLEWMGVISPYYGDTTYAQKFQGRVT
MTVDKSSSTAYMELSRRLSDDTAVYYCARRFEGFYYSMDYWGQGLTVTVSSASTKGPSVFPLAPCSRSTSE
STAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVTVPSSSLGKTKYTCNVDPHKPSNT
KVDKRVESKYGPPCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVDVVSQEDPEVQFNWYVDGVE
VHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPC
QEEMTKNQVSLWCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQEGNVFSC
SVMHEALHNHYTQKSLSLSLG 4 188

DVVMTQSPLSLPVTLGQPASISCRPSQSLVHSNGNTYLNWYQQRPGQSPKLLIYKVSKRFSGVPDRFSGSGSG
TDFTLKISRVEAEDVGVYYCSQSTHVPLTFGGGTGKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFY
REAKVQWKVDNALQSGNSQESVTEQDSKDYSLSSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRG EC
TABLE-US-00006 TABLE 6 Trispecific binding protein polynucleotide sequences Polypeptide Number SEQ
(acc. to ID Molecule formula) NO Sequence HER2 (WT- 1 189

GACATCGTGATGACCCAGACCCCCCTGAGCCTGAGCGTGACACCTGGACAGCCTGCCAGCATCAGCTGCAAGAGC
trastuzumab)/
AGCCAGAGCCTGGTGCACCAGAACGCCAGACCTACCTGAGCTGGTATCTGCAGAAGCCCGGCCAGAGCCCCCAG
CD28sup × CD3mid
TCCCTGATCTACAAGGTGTCCAACAGATTCAGCGGCGTGCCCGACAGATTCTCCGGCAGCGGCTCTGGCACCGACT
(32/35 QQ
TCACCCTGAAGATCAGCCGGGTGGAAGCCGAGGACGTGGGCGTGACTATTGTGGCCAGGGCACCCAGTACCCCT
(LC); DKTHT
TCACCTTTGGCAGCGGCACCAAGGTGGAATCAAGGACAAAACCCATACCGACATCCAGATGACCCAGAGCCCCA
linkers on
GCAGCCTGTCTGCCAGCGTGGGCGACAGAGTGACCATCACCTGTCAGGCCAGCCAGAACATCTACGTGTGGCTGA
HC/LC) IgG4
ACTGGTATCAGCAGAAGCCCGGCAAGGCCCCCAAGCTGCTGATCTACAAGGCCAGCAACCTGCACACCGGCGTGC
FALA
CCAGCAGATTTTCTGGCAGCGGCTCCGGCACCGACTTCACCCTGACAATCAGCTCCCTGCAGCCCGAGGACATTGC

CACCTACTACTGCCAGCAGGGCCAGACCTACCCCTACACCTTTGGCCAGGGCACCAAGCTGGAATCAAGGATAA
GACCCACACCCGTACGGTGGCCGCTCCAGCGTGTTCATCTTCCCACCTAGCGACGAGCAGCTGAAGTCCGGCACA
GCCTCTGTCTGTGCTGCTGAACAACTTCTACCCCCGCGAGGCCAAAGTGCAGTGGAAGGTGGACAACGCCCTGC
AGAGCGGCAACAGCCAGGAAAGCGTGACCGAGCAGGACAGCAAGGACTCCACCTACAGCCTGAGCAGCACCTTG
ACACTGAGCAAGGCCGACTACGAGAAGCACAAGGTGTACGCCTGCGAAGTGACCCACCAGGGCCTGTCTAGCCCC
GTGACCAAGAGCTTCAACCGGGGCGAGTGT 2 190

CAGGTGCAGCTGGTGCAGTCTGGCGCCGAGGTGCTGAAACCTGGCGCCTCTGTGAAGGTGTCCTGCAAGGCCAGC
GGCTACACCTTTACCAGCTACTACATCCACTGGGTGCGCCAGGCCCTGGACAGGGACTGGAATGGATCGGCAGC
ATCTACCCCCGCAACGTGAACACCAACTACGCCCAGAAGTTCCAGGGCAGAGCCACCCTGACCGTGGACACCAGC
ATCAGCACCGCCTACATGGAAGTGAAGCGGCTGAGAAGCGACGACACCGCCGTGTACTACTGCACCCGGTCCCAC
TACGGCCTGGATTGGAAGTTCGACGTGTGGGGCAAGGGCACCACCGTGACAGTGTCTAGCGACAAAACCCATACC
CAGGTGCAGCTGGTGGAACTCTGGCGGCGGAGTGGTGCAGCCTGGCAGAAGCCTGAGACTGAGCTGTGCCGCCAGC
GGCTTCACCTTCACCAAGGCCTGGATGCACTGGGTGCGCCAGGCCCTGGAAAGCAGCTGGAATGGGTGGCCAG
ATCAAGGACAAGAGCAACAGCTACGCCACCTACTACGCCGACAGCGTGAAGGGCCGGTTACCATCAGCCGGGAC
GACAGCAAGAACACCCTGTACCTGCAGATGAACAGCCTGCGGGCCGAGGACACCGCCGTGTACTACTGTGCGGGC
GTGTACTATGCCCTGAGCCCCCTTCGATTACTGGGGCCAGGGAACCCCTCGTGACCGTGTCTAGTGATAAGACCCACA
CCGCCAGCACAAAGGGCCCATCGGTGTTCCCTCTGGCCCCCTTGACAGCAGAAGCACCAGCGAATCTACAGCCGCCCT
GGGCTGCCTCGTGAAGGACTACTTTCCCAGACCCGTGACCGTGTCTCTGGAAGTCTGGCGCTCTGACAAGCGGCGTG
CACACCTTTCCAGCCGTGCTCCAGAGCAGCGGCCTGTACTCTCTGAGCAGCGTCTGTGACAGTGCCAGCAGCAGCC
TGGGCACCAAGACCTACACCTGTAACGTGGACCACAAGCCCAGCAACACCAAGGTGGACAAGCGGGTGGAACTTA
AGTACGGCCCTCCCTGCCCTCCTTGCCAGCCCCCTGAAGCTGCCGGCGGACCCTCCGTGTTCCCTGTTCCCCCAAAG
CCCAAGGACACCCTGATGATCAGCCGGACCCCCGAAGTGACCTGCGTGGTGGTGGATGTGTCCCAGGAAGATCCC
GAGGTGCAGTTCAATTGGTACGTGGACGGCGTGGAAGTGCACAACGCCAAGACCAAGCCCAGAGAGGAACAGTTC
AACAGCACCTACCGGGTGGTGTCCGTGCTGACCGTGTCTGCACCAGGACTGGCTGAACGGCAAAGAGTACAAGTGC
AAGGTGTCCAACAAGGGCCTGCCAGCTCCATCGAGAAAACCATCAGCAAGGCCAAGGGCCAGCCCCGCGAGCCT
CAAGTGTGTACCCTGCCCCCTAGCCAGGAAGAGATGACCAAGAACCAGGTGTCCCTGAGCTGTGCCGTGAAAGGC
TTCTACCCCAGCGACATTGCCGTGGAATGGGAGAGCAACGGCCAGCCCGAGAACAATAACAAGACCACCCCCCT
GTGCTGGACAGCGACGGCTCATTCTTCCCTGGTGTCCAAGCTGACCGTGGACAAGAGCCGGTGGCAGGAAGGCAAC
GTGTTACAGCTGCTCCGTGATGCACGAGGCCCTGCACAACCACTACACCCAGAAGTCCCTGTCTCTGTCCCTGGGC

3 191

GAAGTGCAGCTGGTGGAACTCTGGCGGCGGACTGGTGCAGCCTGGCGGATCTCTGAGACTGAGCTGTGCCGCCAGC
GGCTTCAACATCAAGGACACCTACATCCACTGGGTGCGCCAGGCCCTGGCAAGGGACTGGAATGGGTGGCCAGA
ATCTACCCCACCAACGGCTACACCAGATACGCCGACAGCGTGAAGGGCCGGTTACCATCAGCGCCGACACCAGC
AAGAACACCGCCTACCTGCAGATGAACAGCCTGCGGGCCGAGGACACCGCCGTGTACTACTGTAGTAGATGGGGA
GGCGACGGCTTCTACGCCATGGACTATTGGGGCCAGGGCACCCCTCGTGACCGTGTCTAGTGCGTCGACCAAGGGCC
CATCGGTGTTCCCTCTGGCCCCCTTGACAGCAGAAGCACCAGCGAATCTACAGCCGCCCTGGGCTGCCTCGTGAAGGA
CTACTTTCCCGAGCCCGTGACCGTGTCTGGAAGTCTGGCGCTCTGACAAGCGGCGTGACACCTTTCCAGCCGTG
CTCCAGAGCAGCGGCCTGTACTCTCTGAGCAGCGTCTGTGACAGTGCCAGCAGCAGCCTGGGCACCAAGACCTAC
ACCTGTAACGTGGACCACAAGCCCAGCAACACCAAGGTGGACAAGCGGGTGGAACTTAAGTACGGCCCTCCCTGC
CCTCCTTGCCCAGCCCCCTGAAGCTGCCGGCGGACCCCTCCGTGTTCCCTGTTCCCCCAAAGCCCAAGGACACCCTGA
TGATCAGCCGGACCCCCGAAGTGACCTGCGTGGTGGTGGATGTGTCCCAGGAAGATCCCGAGGTGCAGTTCAATT
GGTACGTGGACGGCGTGGAAGTGCACAACGCCAAGACCAAGCCCAGAGAGGAACAGTTCAACAGCACCTACCGG
GTGGTGTCCGTGCTGACCGTGTCTGCACCAGGACTGGCTGAACGGCAAAGAGTACAAGTGAAGGTGTCCAACAAG
GGCCTGCCAGCTCCATCGAGAAAACCATCAGCAAGGCCAAGGGCCAGCCCCGCGAGCCTCAAGTGTATACCCTG
CCCCCTTGCCAGGAAGAGATGACCAAGAACCAGGTGTCCCTGTGGTGTCTCGTGAAAGGCTTCTACCCCAGCGACA
TTGCCGTGGAATGGGAGAGCAACGGCCAGCCCGAGAACAATAACAAGACCACCCCCCTGTGCTGGACAGCGACG
GCTCATTCTTCCCTGTACTCCAAGCTGACCGTGGACAAGAGCCGGTGGCAGGAAGGCAACGTGTTACAGCTGCTCCGT
GATGCACGAGGCCCTGCACAACCACTACACCCAGAAGTCCCTGTCTCTGTCCCTGGGC 4 192

GACATCCAGATGACCCAGAGCCCCAGCAGCCTGTCTGCCAGCGTGGGCGACAGAGTGACCATCACCTGTAGAGCC
AGCCAGGACGTGAACACCGCCGTGGCCTGGTATCAGCAGAAGCCTGGCAAGGGCCCCCAAGCTGCTGATCTACAGC
GCCAGCTTCCCTGTACAGCGGCGTGCCCAGCAGATTCAGCGGAAGCAGAAGCGGCACCGACTTCACCCTGACCATC
AGCTCCCTGCAGCCCAGGACTTCGCCACCTACTACTGCCAGCAGCACTACACCACCCCCCCCCACATTTGGCCAGG
GCACCAAGGTGGAAATCAAGCGTACGGTGGCCGCTCCCAGCGTGTTCATCTTCCCACCTAGCGACGAGCAGCTGA
AGTCCGGCACAGCCTCTGTCTGTGCTGCTGAACAACTTCTACCCCCGCGAGGGCCAAAGTGCAGTGGAAGGTGG
ACAACGCCCTGCAGAGCGGCAACAGCCAGGAAAGCGTGACCGAGCAGGACAGCAAGGACTCCACCTACAGCCTG
AGCAGCACCCCTGACACTGAGCAAGGCCGACTACGAGAAGCACAAGGTGTACGCCTGCGAAGTGACCCACCAGGG
CCTGTCTAGCCCCGTGACCAAGAGCTTCAACCGGGGCGAGTGT HER2 1 193

GACATCGTGATGACCCAGACCCCCCTGAGCCTGAGCGTGACACCTGGACAGCCTGCCAGCATCAGCTGCAAGAGC
(30R/55Q/102E +

AGCCAGAGCCTGGTGCACCAGAACGCCACGACCTACCTGAGCTGGTATCTGCAGAAGCCCGGCCAGAGCCCCCAG
LC-WT-

TCCCTGATCTACAAGGTGTCCAACAGATTCAGCGGCGTGCCCGACAGATTCTCCGGCAGCGGCTCTGGCACCGACT

trastuzumab)/

TCACCCTGAAGATCAGCCGGGTGGAAGCCGAGGACGTGGGCGTGTA TATTGTGGCCAGGGCACCCAGTACCCCT
CD28sup × CD3mid

TCACCTTTGGCAGCGGCACCAAGGTGGAATCAAGGACAAAACCCATACCGACATCCAGATGACCCAGAGCCCCA
(32/35 QQ (LC);

GCAGCCTGTCTGCCAGCGTGGGCGACAGAGTGACCATCACCTGTCAGGCCAGCCAGAACATCTACGTGTGGCTGA
DKTHT linkers on

ACTGGTATCAGCAGAAGCCCCGGCAAGGCCCCCAAGCTGCTGATCTACAAGGCCAGCAACCTGCACACCGGCGTGC
HC /LC) IgG4

CCAGCAGATTTCTGGCAGCGGCTCCGGCACCGACTTCACCCTGACAATCAGCTCCCTGCAGCCCGAGGACATTGC
FALA

CACCTACTACTGCCAGCAGGGCCAGACCTACCCCTACACCTTTGGCCAGGGCACCAAGCTGGAATCAAGGATAA
BP # 2

GACCCACACCCGTACGGTGGCCGCTCCCAGCGTGTTTCATCTTCCCACCTAGCGACGAGCAGCTGAAGTCCGGCACA
GCCTCTGTCTGTGCTGCTGAACAACTTCTACCCCCGCGAGGCCAAAGTGCAGTGGAAGGTGGACAACGCCCTGC
AGAGCGGCAACAGCCAGGAAAGCGTGACCGAGCAGGACAGCAAGGACTCCACCTACAGCCTGAGCAGCACCTTG
ACACTGAGCAAGGCCGACTACGAGAAGCACAAGGTGTACGCCTGCGAAGTGACCCACCAGGGCCTGTCTAGCCCC
GTGACCAAGAGCTTCAACCGGGGCGAGTGT 2 194

CAGGTGCAGCTGGTGCAGTCTGGCGCCGAGGTCGTGAAACCTGGCGCCTCTGTGAAGGTGTCCTGCAAGGCCAGC
GGCTACACCTTTACCAGCTACTACATCCACTGGGTGCGCCAGGCCCTGGACAGGGACTGGAATGGATCGGCAGC
ATCTACCCCCGCAACGTGAACACCAACTACGCCCAGAAGTTCAGGGCAGAGCCACCCTGACCGTGGACACCAGC
ATCAGCACCGCCTACATGGAAGTGAAGCGGCTGAGAAGCGACGACACCGCCGTGTACTACTGCACCCGGTCCCAC
TACGGCCTGGATTGGAAGTTCGACGTGTGGGGCAAGGGCACACCGTGACAGTGTCTAGCGACAAAACCCATACC
CAGGTGCAGCTGGTGGAACTCTGGCGGCGGAGTGGTGCAGCCTGGCAGAAGCCTGAGACTGAGCTGTGCCGCCAGC
GGCTTCACCTTCACCAAGGCCTGGATGCACTGGGTGCGCCAGGCCCTGGAAAGCAGCTGGAATGGGTGGCCAG
ATCAAGGACAAGAGCAACAGCTACGCCACCTACTACGCCGACAGCGTGAAGGGCCGGTTCACCATCAGCCGGGAC
GACAGCAAGAACACCCTGTACCTGCAGATGAACAGCCTGCGGGCCGAGGACACCGCCGTGTACTACTGTGCGGGC
GTGTACTATGCCCTGAGCCCCCTTCGATTACTGGGGCCAGGGAACCCTCGTGACCGTGTCTAGTGATAAGACCCACA
CCGCCAGCACAAAGGGCCCATCGGTGTTCCCTCTGGCCCCCTTGACAGCAGAAGCACCAGCGAATCTACAGCCGCCCT
GGGCTGCCTCGTGAAGGACTACTTTCCCGAGCCCGTGACCGTGTCTGGAAGTCTGGCGCTCTGACAAGCGGCGTG
CACACCTTTCCAGCCGTGCTCCAGAGCAGCGGCCTGTACTCTCTGAGCAGCGTCGTGACAGTGCCAGCAGCAGCC
TGGGCACCAAGACCTACACCTGTAACGTGGACCACAAGGCCAGCAACACCAAGGTGGACAAGCGGGTGGAACTCTA
AGTACGGCCCTCCCTGCCCTCCTTGCCAGCCCCCTGAAGCTGCCGGCGGACCCTCCGTGTTCTGTTCCCCCAAAG
CCCAAGGACACCCTGATGATCAGCCGGACCCCCGAAGTGACCTGCGTGGTGGTGGATGTGTCCCAGGAAGATCCC
GAGGTGCAGTTCAATTGGTACGTGGACGGCGTGGAAGTGACACAACGCCAAGACCAAGCCCAGAGAGGAACAGTTC
AACAGCACCTACCGGGTGGTGTCCGTGCTGACCGTGTCTGCACCAGGACTGGCTGAACGGCAAAGAGTACAAGTGC
AAGGTGTCCAACAAGGGCCTGCCAGCTCCATCGAGAAAACCATCAGCAAGGCCAAGGGCCAGCCCCGCGAGCCT
CAAGTGTGTACCCTGCCCCCTAGCCAGGAAGAGATGACCAAGAACCAGGTGTCCCTGAGCTGTGCCGTGAAAGGC
TTCTACCCCAGCGACATTGCCGTGGAATGGGAGAGCAACGGCCAGCCCGAGAACAATAAGACCACCCCCCT
GTGCTGGACAGCGACGGCTCATTCTTCTTGGTGTCCAAGCTGACCGTGGACAAGAGCCGGTGGCAGGAAGGCAAC
GTGTTACAGCTGCTCCGTGATGCACGAGGCCCTGCACAACCACTACACCCAGAAGTCCCTGTCTCTGTCCCTGGGC
3 195

GAAGTGCAGCTGGTGGAACTCTGGCGGCGGACTGGTGCAGCCTGGCGGATCTCTGAGACTGAGCTGTGCCGCCAGC
GGCTTCAACATCCGGGACACCTACATCCACTGGGTGCGCCAGGCCCTGGCAAGGGACTGGAATGGGTGGCCAGA
ATCTACCCCACCCAGGGCTACACCAGATACGCCGACAGCGTGAAGGGCCGGTTCACCATCAGCGCCGACACCAGC
AAGAACACCGCCTACCTGCAGATGAACAGCCTGCGGGCCGAGGACACCGCCGTGTACTACTGTAGTAGATGGGGA
GGCGAAGGCTTCTACGCCATGGACTATTGGGGCCAGGGCACCCCTCGTGACCGTGTCTAGTGCGTCGACCAAGGGC
CCATCGGTGTTCCCTCTGGCCCCCTTGACAGCAGAAGCACCAGCGAATCTACAGCCGCCCTGGGCTGCCTCGTGAAGG
ACTACTTTCCCGAGCCCCTGACCGTGTCTGGAAGTCTGGCGCTCTGACAAGCGGCGTGCACACCTTTCCAGCCGT
GCTCCAGAGCAGCGGCCTGTACTCTCTGAGCAGCGTCGTGACAGTGCCCAGCAGCAGCCTGGGCACCAAGACCTA
CACCTGTAACGTGGACCACAAGGCCAGCAACACCAAGGTGGACAAGCGGGTGGAACTCTAAGTACGGCCCTCCCTG
CCCTCCTTGCCCAGCCCCCTGAAGCTGCCGGCGGACCCTCCGTGTTCCCTGTTCCCCCAAAGCCCAAGGACACCCTG
ATGATCAGCCGGACCCCCGAAGTGACCTGCGTGGTGGTGGATGTGTCCCAGGAAGATCCCGAGGTGCAGTTCAAT
TGGTACGTGGACGGCGTGGAAGTGACACAACGCCAAGACCAAGGCCAGAGAGGAACAGTTCACACAGCACCTACCG
GGTGGTGTCCGTGCTGACCGTGTCTGCACCAGGACTGGCTGAACGGCAAAGAGTACAAGTGCAAGGTGTCCAACAA
GGGCCTGCCAGCTCCATCGAGAAAACCATCAGCAAGGCCAAGGGCCAGCCCCGCGAGCCTCAAGTGTATACCCT
GCCCCCTTGCCAGGAAGAGATGACCAAGAACCAGGTGTCCCTGTGGTGTCTCGTGAAAGGCTTCTACCCCAGCGAC
ATTGCCGTGGAATGGGAGAGCAACGGCCAGCCCGAGAACAACTACAAGACCACCCCCCTGTGCTGGACAGCGAC
GGCTCATTCTTCTGTACTCCAAGCTGACCGTGGACAAGAGCCGGTGGCAGGAAGGCAACGTGTTACAGCTGCTCCG
TGATGCACGAGGCCCTGCACAACCACTACACCCAGAAGTCCCTGTCTGTCCCTGGGC 4 196

CAGGTGCAGCTGGTGCAGTCTGGCGCCGAGGTCGTGAAACCTGGCGCCTCTGTGAAGGTGTCCTGCAAGGCCAGC
GGCTACACCTTTACCAGCTACTACATCCACTGGGTGCGCCAGGCCCTGGACAGGGACTGGAATGGATCGGCAGC
ATCTACCCCCGCAACGTGAACACCAACTACGCCCAGAAGTTCAGGGCAGAGCCACCCTGACCGTGGACACCAGC

ATCAGACCGCCTACATGGAACCTGAGCCGGCTGAGAAGCGACGACACCGCCGTGTACTACTGACCCGGTCCCAC
TACGGCCTGGATTGGAACCTTCGACGTGTGGGGCAAGGGCACCACCGTGACAGTGTCTAGCGACAAAACCCATACC
CAGGTGCAGCTGGTGGAACTCTGGCGGCGGAGTGGTGCAGCCTGGCAGAAGCCTGAGACTGAGCTGTGCCGCCAGC
GGCTTCACCTTCACCAAGGCCTGGATGCACTGGGTGCGCCAGGCCCTGGAAAGCAGCTGGAATGGGTGGCCCAG
ATCAAGGACAAGAGCAACAGCTACGCCACCTACTACGCCGACAGCGTGAAGGGCCGGTTTACCATCAGCCGGGAC
GACAGCAAGAACACCCTGTACCTGCAGATGAACAGCCTGCGGGCCGAGGACACCGCCGTGTACTACTGTGCGGGC
GTGTACTATGCCCTGAGCCCCCTTCGATTACTGGGGCCAGGGAACCCTCGTGACCGTGTCTAGTGATAAGACCCACA
CCGCCAGCACAAAGGGCCCATCGGTGTTCCCTCTGGCCCCCTTGACAGCAGAAGCACCAGCGAATCTACAGCCGCCCT
GGGTGCCTCGTGAAGGACTACTTTCCCGAGCCCCGTGACCGTGTCTTGAAGTCTGGCGCTCTGACAAGCGGCGTG
CACACCTTTCCAGCCGTGCTCCAGAGCAGCGGCCTGTACTCTCTGAGCAGCGTCGTGACAGTGCCCAGCAGCAGCC
TGGGCACCAAGACCTACACCTGTAACGTGGACCACAAGCCCAGCAACACCAAGGTGGACAAGCGGGTGGAATCTA
AGTACGGCCCTCCCTGCCCTCCTTGCCCAGCCCCCTGAAGCTGCGGCGGACCCCTCCGTGTTCTCTGTTCCCCCAAAG
CCCAAGGACACCCTGATGATCAGCCGGACCCCCGAAGTGACCTGCGTGGTGGTGGATGTGTCCCAGGAAGATCCC
GAGGTGCAGTTCAATTGGTACGTGGACGGCGTGGAAGTGCACAACGCCAAGACCAAGCCCAGAGAGGAACAGTTC
AACAGCACCTACCGGGTGGTGTCCGTGCTGACCGTGTCTGCACCAGGACTGGCTGAACGGCAAAGAGTACAAGTGC
AAGGTGTCCAACAAGGGCCTGCCCAGCTCCATCGAGAAAACCATCAGCAAGGCCAAGGGCCAGCCCCGCGAGCCT
CAAGTGTGTACCCTGCCCCCTAGCCAGGAAGAGATGACCAAGAACCAGGTGTCCCTGAGCTGTGCCGTGAAAGGC
TTCTACCCCAGCGACATTGCCGTGGAATGGGAGAGCAACGGCCAGCCCGAGAACAATAAGACCACCCCCCT
GTGCTGGACAGCGACGGCTCATTCTTCCCTGGTGTCCAAGCTGACCGTGGACAAGAGCCGGTGGCAGGAAGGCAAC
GTGTTTACAGCTGCTCCGTGATGCACGAGGCCCTGCACAACCACTACACCCAGAAGTCCCTGTCTCTGTCCCTGGGC
HER2 1 197
GACATCGTGATGACCCAGACCCCCCTGAGCCTGAGCGTGACACCTGGACAGCCTGCCAGCATCAGCTGCAAGAGC
(30R/55Q/102E +
AGCCAGAGCCTGGTGCACGACAACGCCCCAGACCTACCTGAGCTGGTATCTGCAGAAGCCCCGGCCAGAGCCCCCAG
LC-WT-
TCCCTGATCTACAAGGTGTCCAACAGATTCAGCGGCGTGCCCGACAGATTCTCCGGCAGCGGCTCTGGCACCGACT
trastuzumab)/
TCACCCTGAAGATCAGCCGGGTGGAAGCCGAGGACGTGGGCGTGACTATTGTGGCCAGGGCACCCAGTACCCCT
CD28.sub.sup × CD3.sub.mid
TCACCTTTGGCAGCGGCACCAAGGTGGAAATCAAGGACAAAACCCATACCGACATCCAGATGACCCAGAGCCCCA
(DNAQ (LC);
GCAGCCTGTCTGCCAGCGTGGGCGACAGAGTGACCATCACCTGTCAGGCCAGCCAGAACATCTACGTGTGGCTGA
DKTHT linkers
ACTGGTATCAGCAGAAGCCCCGGCAAGGCCCCCAAGCTGCTGATCTACAAGGCCAGCAACCTGCACACCGGCGTGC
on HC/LC) IgG4
CCAGCAGATTTCTGGCAGCGGCTCCGGCACCGACTTCACCCTGACAATCAGCTCCCTGCAGCCCGAGGACATTGC
FALA
CACCTACTACTGCCAGCAGGGCCAGACCTACCCCTACACCTTTGGCCAGGGCACCAAGCTGGAAATCAAGGATAA
BP # 8
GACCCACACCCGTACGGTGGCCGCTCCCAGCGTGTTCATCTTCCCACCTAGCGACGAGCAGCTGAAGTCCGGCACA
GCCTCTGTGCTGTGCCTGCTGAACAACTTCTACCCCCGCGAGGCCAAAGTGCAGTGGAAGGTGGACAACGCCCTGC
AGAGCGGCAACAGCCAGGAAAGCGTGACCGAGCAGGACAGCAAGGACTCCACCTACAGCCTGAGCAGCACCCCTG
ACACTGAGCAAGGCCGACTACGAGAAGCACAAGGTGTACGCCTGCGAAGTGACCCACCAGGGCCTGTCTAGCCCC
GTGACCAAGAGCTTCAACCGGGGCGAGTGT 2 198
CAGGTGCAGCTGGTGCAGTCTGGCGCCGAGGTCTGTGAAACCTGGCGCCTCTGTGAAGGTGTCCTGCAAGGCCAGC
GGCTACACCTTTACCAGCTACTACATCCACTGGGTGCGCCAGGCCCTGGACAGGGACTGGAATGGATCGGCAGC
ATCTACCCCGGCAACGTGAACACCAACTACGCCCAGAAGTTCCAGGGCAGAGCCACCCTGACCGTGGACACCAGC
ATCAGCACCGCCTACATGGAAGTGAAGCGGCTGAGAAGCGACGACACCGCCGTGTACTACTGCACCCGGTCCCAC
TACGGCCTGGATTGGAACCTTCGACGTGTGGGGCAAGGGCACCACCGTGACAGTGTCTAGCGACAAAACCCATACC
CAGGTGCAGCTGGTGGAACTCTGGCGGCGGAGTGGTGCAGCCTGGCAGAAGCCTGAGACTGAGCTGTGCCGCCAGC
GGCTTCACCTTCACCAAGGCCTGGATGCACTGGGTGCGCCAGGCCCTGGAAAGCAGCTGGAATGGGTGGCCCAG
ATCAAGGACAAGAGCAACAGCTACGCCACCTACTACGCCGACAGCGTGAAGGGCCGGTTTACCATCAGCCGGGAC
GACAGCAAGAACACCCTGTACCTGCAGATGAACAGCCTGCGGGCCGAGGACACCGCCGTGTACTACTGTGCGGGC
GTGTACTATGCCCTGAGCCCCCTTCGATTACTGGGGCCAGGGAACCCTCGTGACCGTGTCTAGTGATAAGACCCACA
CCGCCAGCACAAAGGGCCCATCGGTGTTCCCTCTGGCCCCCTTGACAGCAGAAGCACCAGCGAATCTACAGCCGCCCT
GGGTGCCTCGTGAAGGACTACTTTCCCGAGCCCCGTGACCGTGTCTTGAAGTCTGGCGCTCTGACAAGCGGCGTG
CACACCTTTCCAGCCGTGCTCCAGAGCAGCGGCCTGTACTCTCTGAGCAGCGTCGTGACAGTGCCCAGCAGCAGCC
TGGGCACCAAGACCTACACCTGTAACGTGGACCACAAGCCCAGCAACACCAAGGTGGACAAGCGGGTGGAATCTA
AGTACGGCCCTCCCTGCCCTCCTTGCCCAGCCCCCTGAAGCTGCGGCGGACCCCTCCGTGTTCTCTGTTCCCCCAAAG
CCCAAGGACACCCTGATGATCAGCCGGACCCCCGAAGTGACCTGCGTGGTGGTGGATGTGTCCCAGGAAGATCCC
GAGGTGCAGTTCAATTGGTACGTGGACGGCGTGGAAGTGCACAACGCCAAGACCAAGCCCAGAGAGGAACAGTTC
AACAGCACCTACCGGGTGGTGTCCGTGCTGACCGTGTCTGCACCAGGACTGGCTGAACGGCAAAGAGTACAAGTGC
AAGGTGTCCAACAAGGGCCTGCCCAGCTCCATCGAGAAAACCATCAGCAAGGCCAAGGGCCAGCCCCGCGAGCCT

CAAGTGTGTCACCTGCCCCCTAGCCAGGAAGATGACCAAGAACCAGGTGTCCCTGAGCTGTGCCGTGAAAGGC
TTCTACCCCAGCGACATTGCCGTGGAATGGGAGAGCAACGGCCAGCCCCGAGAACAACCTACAAGACCACCCCCCT
GTGCTGGACAGCGACGGCTCATTCTTCCTGGTGTCCAAGCTGACCGTGGACAAGAGCCGGTGGCAGGAAGGCAAC
GTGTTTCAGCTGCTCCGTGATGCACGAGGCCCTGCACAACCACTACACCCAGAAGTCCCTGTCTCTGTCCCTGGGC

3 199

GAAGTGCAGCTGGTGGAAATCTGGCGGCGGACTGGTGCAGCCTGGCGGATCTCTGAGACTGAGCTGTGCCGCCAGC
GGCTTCAACATCCGGGACACCTACATCCACTGGGTGCGCCAGGCCCTGGCAAGGGACTGGAATGGGTGGCCAGA
ATCTACCCCACCCAGGGCTACACCAGATACGCCGACAGCGTGAAGGGCCGGTTACCATCAGCGCCGACACCAGC
AAGAACACCGCCTACCTGCAGATGAACAGCCTGCGGGCCGAGGACACCGCCGTGTACTACTGTAGTAGATGGGGA
GGCGAAGGCTTCTACGCCATGGACTATTGGGGCCAGGGCACCCCTCGTGACCGTGTCTAGTGCGTCGACCAAGGGC
CCATCGGTGTTCCCTCTGGCCCCCTTGACGACAGAAGCACCCAGCGAATCTACAGCCGCCCTGGGCTGCCTCGTGAAGG
ACTACTTTCCCGAGCCCGTGACCGTGTCTGGAACCTCTGGCGCTCTGACAAGCGGCGTGACACACCTTTCCAGCCGT
GCTCCAGAGCAGCGGCCCTGTACTCTCTGAGCAGCGTCGTGACAGTGCCCAGCAGCAGCCTGGGCACCAAGACCTA
CACCTGTAACTGGACCACAAGCCCAGCAACACCAAGGTGGACAAGCGGGTGGAATCTAAGTACGGGCCCTCCCTG
CCCTCCTTGCCAGCCCCCTGAAGCTGCCGGCGGACCCTCCGTGTTCCCTGTTCCCCCAAAGCCCAAGGACACCCTG
ATGATCAGCCGGACCCCCGAAGTGACCTGCGTGGTGGTGGATGTGTCCAGGAAGATCCCGAGGTGCAGTTCAAT
TGGTACGTGGACGGCGTGGAAGTGCACAACGCCAAGACCAAGCCCAGAGAGGAACAGTTCAACAGCACCTACCG
GGTGGTGTCCGTGCTGACCGTGCTGCACCAGGACTGGCTGAACGGCAAAGAGTACAAGTGCAAGGTGTCCAACAA
GGGCCTGCCAGCTCCATCGAGAAAACCATCAGCAAGGCCAAGGGCCAGCCCCGCGAGCCTCAAGTGTATACCCT
GCCCCCTTGCCAGGAAGAGATGACCAAGAACCAGGTGTCCCTGTGGTGTCTCGTGAAAGGCTTCTACCCCAGCGAC
ATTGCCGTGGAATGGGAGAGCAACGGCCAGCCCCGAGAACAACCTACAAGACCACCCCCCTGTGCTGGACAGCGAC
GGCTCATTCTTCCTGTACTCCAAGCTGACCGTGGACAAGAGCCGGTGGCAGGAAGGCAACGTGTTTCAGCTGCTCCG
TGATGCACGAGGCCCTGCACAACCACTACACCCAGAAGTCCCTGTCTCTGTCCCTGGGC

4 200

CAGGTGCAGCTGGTGCAGTCTGGCGCCGAGGTCTGTGAAACCTGGCGCCTCTGTGAAGGTGTCCTGCAAGGCCAGC
GGCTACACCTTTACCAGCTACTACATCCACTGGGTGCGCCAGGCCCTGGACAGGGACTGGAATGGATCGGCAGC
ATCTACCCCGGCAACGTGAACACCAACTACGCCCAGAAGTTCCAGGGCAGAGCCACCCTGACCGTGGACACCAGC
ATCAGCACCGCCTACATGGAAGTGAAGCCGGCTGAGAAGCGACGACACCGCCGTGTACTACTGCACCCGGTCCCAC
TACGGCCTGGATTGGAACCTTCGACGTGTGGGGCAAGGGCACACCCTGACAGTGTCTAGCGACAAAACCCATACC
CAGGTGCAGCTGGTGGAAATCTGGCGGCGGAGTGGTGCAGCCTGGCAGAAGCCTGAGACTGAGCTGTGCCGCCAGC
GGCTTACCTTCACCAAGGCCTGGATGCACTGGGTGCGCCAGGCCCTGGAAAGCAGCTGGAATGGGTGGCCAG
ATCAAGGACAAGAGCAACAGCTACGCCACCTACTACGCCGACAGCGTGAAGGGCCGGTTACCATCAGCCGGGAC
GACAGCAAGAACACCCTGTACCTGCAGATGAACAGCCTGCGGGCCGAGGACACCGCCGTGTACTACTGTCCGGGC
GTGTACTATGCCCTGAGCCCCCTTCGATTACTGGGGCCAGGGAACCCTCGTGACCGTGTCTAGTGATAAGACCCACA
CCGCCAGCACAAAGGGCCCATCGGTGTTCCCTCTGGCCCCCTTGACGACAGAAGCACCCAGCGAATCTACAGCCGCCCT
GGGCTGCCTCGTGAAGGACTACTTTCCCGAGCCCGTGACCGTGTCTGGAACCTCTGGCGCTCTGACAAGCGGCGTG
CACACCTTTCCAGCCGTGCTCCAGAGCAGCGGCCCTGTACTCTCTGAGCAGCGTCGTGACAGTGCCCAGCAGCAGCC
TGGGCACCAAGACCTACACCTGTAACTGGACCACAAGCCCAGCAACACCAAGGTGGACAAGCGGGTGGAATCTA
AGTACGGGCCCTCCCTGCCCTCCTTGCCAGCCCCCTGAAGCTGCCGGCGGACCCTCCGTGTTCCCTGTTCCCCCAAAG
CCCAAGGACACCCTGATGATCAGCCGGACCCCCGAAGTGACCTGCGTGGTGGTGGATGTGTCCCAGGAAGATCCC
GAGGTGCAGTTCAATTGGTACGTGGACGGCGTGGAAGTGCACAACGCCAAGACCAAGCCCAGAGAGGAACAGTTC
AACAGCACCTACCGGGTGGTGTCCGTGCTGACCGTGCTGCACCAGGACTGGCTGAACGGCAAAGAGTACAAGTGC
AAGGTGTCCAACAAGGGCCTGCCAGCTCCATCGAGAAAACCATCAGCAAGGCCAAGGGCCAGCCCCGCGAGCCT
CAAGTGTGTACCCTGCCCCCTAGCCAGGAAGAGATGACCAAGAACCAGGTGTCCCTGAGCTGTGCCGTGAAAGGC
TTCTACCCCAGCGACATTGCCGTGGAATGGGAGAGCAACGGCCAGCCCCGAGAACAACCTACAAGACCACCCCCCT
GTGCTGGACAGCGACGGCTCATTCTTCCTGGTGTCCAAGCTGACCGTGGACAAGAGCCGGTGGCAGGAAGGCAAC
GTGTTTCAGCTGCTCCGTGATGCACGAGGCCCTGCACAACCACTACACCCAGAAGTCCCTGTCTCTGTCCCTGGGC

HER2 1 201

GACATCGTGATGACCCAGACCCCCCTGAGCCTGAGCGTGACACCTGGACAGCCTGCCAGCATCAGCTGCAAGAGC
(30R/55Q/102E +
AGCCAGAGCCTGGTGCACCAGAACGCCAGACCTACCTGAGCTGGTATCTGCAGAAGCCCGGCCAGAGCCCCCAG
LC-WT-
TCCCTGATCTACAAGGTGTCCAACAGATTCAGCGGCGTGCCCGACAGATTCTCCGGCAGCGGCTCTGGCACCGACT
trastuzumab)/
TCACCTGAAGATCAGCCGGGTGGAAGCCGAGGACGTGGGCGTGACTATTGTGGCCAGGGCACCCAGTACCCCT
CD28.sub.sup × CD3.sub.mid
TCACCTTTGGCAGCGGCACCAAGGTGGAATCAAGGGCCAGCCCAAGGCCGCCCGGACATCCAGATGACCCAGA
(32/35QQ (LC);
GCCCCAGCAGCCTGTCTGCCAGCGTGGGCGACAGAGTGACCATCACCTGTCAGGCCAGCCAGAACATCTACGTGT
FALA) IgG4
GGCTGAACTGGTATCAGCAGAAGCCCCGGCAAGGGCCCCCAAGCTGCTGATCTACAAGGCCAGCAACCTGCACACCG
L1 linker
GCGTGCCCAGCAGATTTTCTGGCAGCGGCTCCGGCACCGACTTCACCCTGACAATCAGCTCCCTGCAGCCCCGAGGA
BP #9

GAGGTTCAGTTGATTGGTACCTGGAGAGTGCACAAACGCCAAGACCAAGCCCAGAGAGGAACAGTTC
AACAGCACCTACCGGGTGGTGTCCGTGCTGACCGTGCTGCACCAGGACTGGCTGAACGGCAAAGAGTACAAGTGC
AAGGTGTCCAACAAGGGCCTGCCAGCTCCATCGAGAAAACCATCAGCAAGGCCAAGGGCCAGCCCCGCGAGCCT
CAAGTGTGTACCCTGCCCCCTAGCCAGGAAGAGATGACCAAGAACCAGGTGTCCCTGAGCTGTGCCGTGAAAGGC
TTCTACCCCAGCGACATTGCCGTGGAATGGGAGAGCAACGGCCAGCCCGAGAACAATAAGACCACCCCCCT
GTGCTGGACAGCGACGGCTCATTCTTCTGCTGGTGTCCAAGCTGACCGTGGACAAGAGCCGGTGGCAGGAAGGCAAC
GTGTTGAGCTGCTCCGTGATGCACGAGGCCCTGCACAACCACTACACCCAGAAGTCCCTGTCTCTGTCCCTGGGC
HER2-30R/ 1 205
GACATCGTGATGACCCAGACCCCCCTGAGCCTGAGCGTGACACCTGGACAGCCTGCCAGCATCAGCTGCAAGAGC
55Q/102S + LC-
AGCCAGAGCCTGGTGCACAACAACGCCAACACCTACCTGAGCTGGTATCTGCAGAAGCCCCGGCCAGAGCCCCCAG
WT-
TCCCTGATCTACAAGGTGTCCAACAGATTCAGCGGCGTGCCCGACAGATTCTCCGGCAGCGGCTCTGGCACCGACT
trastuzumab/
TCACCCTGAAGATCAGCCGGGTGGAAGCCGAGGACGTGGGCGTGTAATTATTGTGGCCAGGGCACCCAGTACCCCT
CD28sup × CD3mid
TCACCTTTGGCAGCGGCACCAAGGTGGAATCAAGGGCCAGCCCAAGGCCGCCCCCGACATCCAGATGACCCAGA
L1 linker
GCCCCAGCAGCCTGTCTGCCAGCGTGCGCGACAGAGTGACCATCACCTGTCAGGCCAGCCAGAACATCTACGTGT
IgG4 FALA
GGCTGAACTGGTATCAGCAGAAGCCCCGGCAAGGCCCCCAAGCTGCTGATCTACAAGGCCAGCAACCTGCACACCG
BP # 10
GCGTGCCAGCAGATTTTCTGGCAGCGGCTCCGGCACCGACTTCACCCTGACAATCAGCTCCCTGCAGCCCGAGGA
CATTGCCACCTACTACTGCCAGCAGGGCCAGACCTACCCCTACACCTTTGGCCAGGGCACCAAGCTGGAAATCAAG
ACCAAGGGCCCCAGCCGTACGGTGGCCGCTCCCAGCGTGTTTCATCTTCCCACCTAGCGACGAGCAGCTGAAGTCCG
GCACAGCCTCTGTCTGTGCCTGCTGAACAACCTTCTACCCCCGCGAGGCCAAAGTGCAGTGGAAGGTGGACAACG
CCCTGCAGAGCGGCAACAGCCAGGAAAGCGTGACCGAGCAGGACAGCAAGGACTCCACCTACAGCCTGAGCAGC
ACCCTGACACTGAGCAAGGCCGACTACGAGAAGCACAAGGTGTACGCCTGCGAAGTGACCCACCAGGGCCTGTCT
AGCCCCGTGACCAAGAGCTTCAACCGGGGCGAGTGT 2 206
CAGGTGCAGCTGGTGCAGTCTGGCGCCGAGGTCGTGAAACCTGGCGCCTCTGTGAAGGTGTCCTGCAAGGCCAGC
GGCTACACCTTTACCAGCTACTACATCCACTGGGTGCGCCAGGCCCTGGACAGGGACTGGAATGGATCGGCAGC
ATCTACCCCCGGCAACGTGAACACCAACTACGCCCAGAAGTTCCAGGGCAGAGCCACCCTGACCGTGGACACCAGC
ATCAGCACCGCCTACATGGAAGTGAAGCCGGCTGAGAAGCGACGACACCGCCGTGTACTACTGCACCCGGTCCCAC
TACGGCCTGGATTGGAAGTTCGACGTGTGGGGCAAGGGCACCAACCGTGACAGTGTCTAGCAGCCAGGTGCAGCTG
GTGGAATCTGGCGGCGGAGTGGTGCAGCCTGGCAGAAGCCTGAGACTGAGCTGTGCCGCCAGCGGCTTCACCTTC
ACCAAGGCCTGGATGCACTGGGTGCGCCAGGCCCTGGAAAGCAGCTGGAATGGGTGGCCAGATCAAGGACAA
GAGCAACAGCTACGCCACCTACTACGCCGACAGCGTGAAGGGCCGGTTTACCATCAGCCGGGACGACAGCAAGAA
CACCTGTACCTGCAGATGAACAGCCTGCGGGCCGAGGACACCGCCGTGTACTACTGTCCGGGGCGTGTACTATGCC
CTGAGCCCCCTTCGATTACTGGGGCCAGGGAACCTCGTGACCGTGTCTAGTCGGACCGCCAGCACAAAGGGCCCAT
CGGTGTTCCCTCTGGCCCCCTTGCAGCAGAAGCACCAAGCGAATCTACAGCCGCCCTGGGCTGCCTCGTGAAGGACTA
CTTTCCTCGAGCCCGTGACCGTGTCTGGAACCTCTGGCGCTCTGACAAGCGGCGTGCACACCTTTCCAGCCGTGCTC
CAGAGCAGCGGCCTGTACTCTCTGAGCAGCGTCTGTGACAGTGGCCAGCAGCAGCCTGGGCACCAAGACCTACACC
TGTAACGTGGACCACAAGCCCAGCAACACCAAGGTGGACAAGCGGGTGGAAATCTAAGTACGGCCCTCCCTGCCCT
CCTTGCCCAGCCCCCTGAAGCTGCCGGCGGACCCTCCGTGTTCTGTTCCTGTTCCCCCCAAAGCCCAAGGACACCCTGATGA
TCAGCCGGACCCCCGAAGTGACCTGCGTGGTGGTGGATGTGTCCCAGGAAGATCCCGAGGTGCAGTTCAATTGGT
ACGTGGACGGCGTGGAAAGTGACAACGCCAAGACCAAGCCCAGAGAGGAACAGTTCAACAGCACCTACCGGGTG
GTGTCCGTGCTGACCGTGTGTCACCAGGACTGGCTGAACGGCAAAGAGTACAAGTGAAGGTGTCCAACAAGGGC
CTGCCAGCTCCATCGAGAAAACCATCAGCAAGGCCAAGGGCCAGCCCCGCGAGCCTCAAGTGTGTACCCTGCCC
CCTAGCCAGGAAGAGATGACCAAGAACCAGGTGTCCCTGAGCTGTGCCGTGAAAGGCTTCTACCCCAGCGACATT
GCCGTGGAATGGGAGAGCAACGGCCAGCCCGAGAACAATAAGACCACCCCCCTGTGCTGGACAGCGACGG
CTCATTCTTCTGCTGTTCCAAGCTGACCGTGGACAAGAGCCGGTGGCAGGAAGGCAACGTGTTGAGCTGCTCCGTG
ATGCACGAGGCCCTGCACAACCACTACACCCAGAAGTCCCTGTCTCTGTCCCTGGGC 3 207
GAAGTGCAGCTGGTGGAAATCTGGCGGCGGACTGGTGCAGCCTGGCGGATCTCTGAGACTGAGCTGTGCCGCCAGC
GGCTTCAACATCCGGGACACCTACATCCACTGGGTGCGCCAGGCCCTGGCAAGGGACTGGAATGGGTGGCCAGA
ATCTACCCCACCCAGGGCTACACCAGATACGCCGACAGCGTGAAGGGCCGGTTTACCATCAGCGCCGACACCAGC
AAGAACACCGCCTACCTGCAGATGAACAGCCTGCGGGCCGAGGACACCGCCGTGTACTACTGTAGTAGATGGGGA
GGCTCCGGCTTCTACGCCATGGACTATTGGGGCCAGGGCACCCCTCGTGACCGTGTCTAGTGGTTCGACCAAGGGCC
CATCGGTGTTCCCTCTGGCCCCCTTGCAGCAGAAGCACCAAGCGAATCTACAGCCGCCCTGGGCTGCCTCGTGAAGGA
CTACTTTCCCGAGCCCGTGACCGTGTCTGGAACCTCTGGCGCTCTGACAAGCGGCGTGCACACCTTTCCAGCCGTG
CTCCAGAGCAGCGGCCTGTACTCTCTGAGCAGCGTCTGTGACAGTGGCCAGCAGCAGCCTGGGCACCAAGACCTAC
ACCTGTAACGTGGACCACAAGCCCAGCAACACCAAGGTGGACAAGCGGGTGGAAATCTAAGTACGGCCCTCCCTGC
CCTCCTTGCCCAGCCCCCTGAATTTCTGGGGCGGACCCTCCGTGTTCTGTTCCCCCCAAAGCCCAAGGACACCCTGAT
GATCAGCCGGACCCCCGAAGTGACCTGCGTGGTGGTGGATGTGTCCCAGGAAGATCCCGAGGTGCAGTTCAATTG

GTACCTGGACGGCGTGGAAAGTGCACAACGGCCAAAGACCAAGCCCCAGAGAGGAACAGTTCAACAGCACCTACCGGG
TGGTGTCCGTGCTGACCGTGCTGCACCAGGACTGGCTGAACGGCAAAGAGTACAAGTGCAAGGTGTCCAACAAGG
GCCTGCCCAGCTCCATCGAGAAAACCATCAGCAAGGCCAAGGGCCAGCCCCGCGAGCCTCAAGTGTATACCTGCTGC
CCCCTTGCCAGGAAGAGATGACCAAGAACCAGGTGTCCCTGTGGTGTCTCGTGAAAAGGCTTCTACCCCAGCGACAT
TGCCGTGGAATGGGAGAGCAACGGCCAGCCCCGAGAACAACCTACAAGACCACCCCCCTGTGCTGGACAGCGACGG
CTCATTCTTCCTGTACTCCAAGCTGACCGTGGACAAGAGCCGGTGGCAGGAAGGCAACGTGTTTCAGCTGCTCCGTG
ATGCACGAGGCCCTGCACAACCACTACACCCAGAAGTCCCTGTCTCTGTCCCTGGGC 4 208

CAGGTGCAGCTGGTGCAGTCTGGCGCCGAGGTCTGTGAAACCTGGCGCCTCTGTGAAGGTGTCCTGCAAGGCCAGC
GGCTACACCTTTACCAGCTACTACATCCACTGGGTGCGCCAGGCCCTGGACAGGGACTGGAATGGATCGGCAGC
ATCTACCCCGGCAACGTGAACACCAACTACGCCCAGAAGTTCCAGGGCAGAGCCACCCTGACCGTGGACACCAGC
ATCAGCACCGCCTACATGGAAGTGAAGCCGGCTGAGAAGCGACGACACCGCCGTGTACTACTGCACCCGGTCCCAC
TACGGCCTGGATTGGAAGTTCGACGTGTGGGGCAAGGGCACCACCGTGACAGTGTCTAGCGACAAAACCCATACC
CAGGTGCAGCTGGTGGAAATCTGGCGGCGGAGTGGTGCAGCCTGGCAGAAGCCTGAGACTGAGCTGTGCCGCCAGC
GGCTTCACCTTCACCAAGGCCTGGATGCACTGGGTGCGCCAGGCCCTGGAAAGCAGCTGGAATGGGTGGCCCAG
ATCAAGGACAAGAGCAACAGCTACGCCACCTACTACGCCGACAGCGTGAAGGGCCGGTTACCATCAGCCGGGAC
GACAGCAAGAACACCCTGTACCTGCAGATGAACAGCCTGCGGGCCGAGGACACCGCCGTGTACTACTGTGCGGGC
GTGTACTATGCCCTGAGCCCCCTTCGATTACTGGGGCCAGGGAACCCTCGTGACCGTGTCTAGTGATAAGACCCACA
CCGCCAGCACAAAGGGCCCATCGGTGTTCCCTCTGGCCCCCTTGACAGCAGAAGCACCAGCGAATCTACAGCCGCCCT
GGGCTGCCTCGTGAAGGACTACTTTCCCGAGCCCGTGACCGTGTCTGGAAGTCTGGCGCTCTGACAAGCGGCGTG
CACACCTTTCCAGCCGTGCTCCAGAGCAGCGGCCTGTACTCTCTGAGCAGCGTCTGTGACAGTGCCAGCAGCAGCC
TGGGCACCAAGACCTACACCTGTAACGTGGACCACAAGCCCAGCAACACCAAGGTGGACAAGCGGGTGGAAATCTA
AGTACGGCCCTCCCTGCCCTCCTTGCCAGCCCCCTGAAGCTGCCGGCGGACCCTCCGTGTTCCCTGTTCCCCCAAAG
CCCAAGGACACCCTGATGATCAGCCGGACCCCCGAAGTGACCTGCGTGGTGGTGGATGTGTCCCAGGAAGATCCC
GAGGTGCAGTTCAATTGGTACGTGGACGGCGTGGAAGTGCACAACGCCAAGACCAAGCCCAGAGAGGAACAGTTC
AACAGCACCTACCGGGTGGTGTCCGTGCTGACCGTGTCTGCACCAGGACTGGCTGAACGGCAAAGAGTACAAGTGC
AAGGTGTCCAACAAGGGCCTGCCAGCTCCATCGAGAAAACCATCAGCAAGGCCAAGGGCCAGCCCCGCGAGCCT
CAAGTGTGTACCCTGCCCCCTAGCCAGGAAGAGATGACCAAGAACCAGGTGTCCCTGAGCTGTGCCGTGAAAAGGC
TTCTACCCCAGCGACATTGCCGTGGAATGGGAGAGCAACGGCCAGCCCCGAGAACAACCTACAAGACCACCCCCCT
GTGCTGGACAGCGACGGCTCATTCTTCCTGGTGTCCAAGCTGACCGTGGACAAGAGCCGGTGGCAGGAAGGCAAC
GTGTTTCAGCTGCTCCGTGATGCACGAGGCCCTGCACAACCACTACACCCAGAAGTCCCTGTCTCTGTCCCTGGGC

HER2-30R/ 1 209

GACATCGTGATGACCCAGACCCCCCTGAGCCTGAGCGTGACACCTGGACAGCCTGCCAGCATCAGCTGCAAGAGC
56A/102S + LC-
AGCCAGAGCCTGGTGCACAACAACGCCAACACCTACCTGAGCTGGTATCTGCAGAAGCCCGGCCAGAGCCCCCAG
WT-

TCCCTGATCTACAAGGTGTCCAACAGATTCAGCGGCGTGCCCGACAGATTCTCCGGCAGCGGCTCTGGCACCGACT
trastuzumab/

TCACCCTGAAGATCAGCCGGGTGGAAGCCGAGGACGTGGGCGTGTACTATTGTGGCCAGGGCACCCAGTACCCCT
CD28sup × CD3mid

TCACCTTTGGCAGCGGCACCAAGGTGGAAATCAAGGGCCAGCCCCAAGGCCGCCCCCGACATCCAGATGACCCAGA
L1 linker IgG4

GCCCCAGCAGCCTGTCTGCCAGCGTGGGCGACAGAGTGACCATCACCTGTCAGGCCAGCCAGAACATCTACGTGT
FALA

GGCTGAACTGGTATCAGCAGAAGCCCGGCAAGGCCCCCAAGCTGCTGATCTACAAGGCCAGCAACCTGCACACCG
BP # 11

GCGTGGCCAGCAGATTTTCTGGCAGCGGCTCCGGCACCGACTTCACCCTGACAATCAGCTCCCTGCAGCCCCGAGGA
CATTGCCACCTACTACTGCCAGCAGGGCCAGACCTACCCCTACACCTTTGGCCAGGGCACCAAGCTGGAAATCAAG
ACCAAGGGCCCCAGCCGTACGGTGGCCGCTCCCAGCGTGTTTCATCTTCCCACCTAGCGACGAGCAGCTGAAGTCCG
GCACAGCCTCTGTCTGTGCCTGCTGAACAACCTTCTACCCCCGCGAGGGCCAAAGTGCAAGTGGAAAGGTGGACAACG
CCCTGCAGAGCGGCAACAGCCAGGAAAGCGTGACCGAGCAGGACAGCAAGGACTCCACCTACAGCCTGAGCAGC
ACCCTGACACTGAGCAAGGCCGACTACGAGAAGCACAAGGTGTACGCCTGCGAAGTGACCCACCAGGGCCTGTCT
AGCCCCGTGACCAAGAGCTTCAACCGGGGCGAGTGT 2 210

CAGGTGCAGCTGGTGCAGTCTGGCGCCGAGGTCTGTGAAACCTGGCGCCTCTGTGAAGGTGTCCTGCAAGGCCAGC
GGCTACACCTTTACCAGCTACTACATCCACTGGGTGCGCCAGGCCCTGGACAGGGACTGGAATGGATCGGCAGC
ATCTACCCCGGCAACGTGAACACCAACTACGCCCAGAAGTTCCAGGGCAGAGCCACCCTGACCGTGGACACCAGC
ATCAGCACCGCCTACATGGAAGTGAAGCCGGCTGAGAAGCGACGACACCGCCGTGTACTACTGCACCCGGTCCCAC
TACGGCCTGGATTGGAAGTTCGACGTGTGGGGCAAGGGCACCACCGTGACAGTGTCTAGCAGCCAGGTGCAGCTG
GTGGAATCTGGCGGCGGAGTGGTGCAGCCTGGCAGAAGCCTGAGACTGAGCTGTGCCGCCAGCGGCTTCACCTTC
ACCAAGGCCTGGATGCACTGGGTGCGCCAGGCCCTGGAAAGCAGCTGGAATGGGTGGCCCAGATCAAGGACAA
GAGCAACAGCTACGCCACCTACTACGCCGACAGCGTGAAGGGCCGGTTACCATCAGCCGGGACGACAGCAAGAA
CACCTGTACCTGCAGATGAACAGCCTGCGGGCCGAGGACACCGCCGTGTACTACTGTGCGGGCGTGTACTATGCC
CTGAGCCCCCTTCGATTACTGGGGCCAGGGAACCCTCGTGACCGTGTCTAGTCGGACCGCCAGCACAAAGGGCCCAT
CGGTGTTCCCTCTGGCCCCCTTGACAGCAGAAGCACCAGCGAATCTACAGCCGCCCTGGGCTGCCTCGTGAAGGACTA

CTTTCCGAGACCCCTGACCTGCTGCTGGAACCTGCGCTCTGACAAAGCGGCTGCACACCTTTCCAGCCGTGCTC
CAGAGCAGCGGCCTGTACTCTCTGAGCAGCGTCGTGACAGTGGCCAGCAGCAGCCTGGGCACCAAGACCTACACC
TGTAACGTGGACCACAAGCCCAGCAACACCAAGGTGGACAAGCGGGTGAATCTAAGTACGGCCCTCCCTGCCCT
CCTTGCCCAGCCCCTGAAGCTGCCGGCGGACCCTCCGTGTTCTCTGTTCCCCCAAGCCCAAGGACACCCTGATGA
TCAGCCGGACCCCCGAAGTGACCTGCGTGGTGGTGGATGTGTCCCAGGAAGATCCCGAGGTGCAGTTCAATTGGT
ACGTGGACGGCGTGGAAGTGACACAACGCCAAGACCAAGCCCAGAGAGGAACAGTTCAACAGCACCTACCGGGTG
GTGTCCGTGCTGACCGTGCTGCACCAGGACTGGCTGAACGGCAAAGAGTACAAGTGCAAGGTGTCCAACAAGGGC
CTGCCCAGCTCCATCGAGAAAACCATCAGCAAGGCCAAGGGCCAGCCCCGCGAGCCTCAAGTGTGTACCCTGCCC
CCTAGCCAGGAAGAGATGACCAAGAACCAGGTGTCCCTGAGCTGTGCCGTGAAAGGCTTCTACCCCAGCGACATT
GCCGTGGAATGGGAGAGCAACGGCCAGCCCGAGAACAATAACAAGACCACCCCCCTGTGCTGGACAGCGACGG
CTCATTCTTCCTGGTGTCCAAGCTGACCGTGGACAAGAGCCGGTGGCAGGAAGGCAACGTGTTTCAGCTGCTCCGTG
ATGCACGAGGCCCTGCACAACCACTACACCCAGAAGTCCCTGTCTCTGTCCCTGGGC 3 211
GAAGTGCAGCTGGTGGAAATCTGGCGGCGGACTGGTGCAGCCTGGCGGATCTCTGAGACTGAGCTGTGCCGCCAGC
GGCTTCAACATCCGGGACACCTACATCCACTGGGTGCGCCAGGCCCTGGCAAGGGACTGGAATGGGTGGCCAGA
ATCTACCCCACCAACGCCTACACCAGATACGCCGACAGCGTGAAGGGCCGGTTACCATCAGCGCCGACACCAGC
AAGAACACCGCCTACCTGCAGATGAACAGCCTGCGGGCCGAGGACACCGCCGTGTACTACTGTAGTAGATGGGGA
GGCTCCGGCTTCTACGCCATGGACTATTGGGGCCAGGGCACCCCTCGTGACCGTGTCTAGTGCGTCGACCAAGGGCC
CATCGGTGTTCCCTCTGGCCCCCTTGACAGCAGAAGCACCAGCGAATCTACAGCCGCCCTGGGCTGCCTCGTGAAGGA
CTACTTTCCCGAGCCCGTGACCGTGTCTGGAACCTCTGGCGCTCTGACAAGCGGCGTGCACACCTTTCCAGCCGTG
CTCCAGAGCAGCGGCCTGTACTCTCTGAGCAGCGTCGTGACAGTGGCCAGCAGCAGCCTGGGCACCAAGACCTAC
ACCTGTAACGTGGACCACAAGCCCAGCAACACCAAGGTGGACAAGCGGGTGAATCTAAGTACGGCCCTCCCTGC
CCTCCTTGCCCAGCCCCTGAATTTCTGGGCGGACCCTCCGTGTTCTCTGTTCCCCCAAGCCCAAGGACACCCTGAT
GATCAGCCGGACCCCCGAAGTGACCTGCGTGGTGGTGGATGTGTCCCAGGAAGATCCCGAGGTGCAGTTCAATTG
GTACGTGGACGGCGTGGAAGTGACACAACGCCAAGACCAAGCCCAGAGAGGAACAGTTCAACAGCACCTACCGGG
TGGTGTCCGTGCTGACCGTGCTGCACCAGGACTGGCTGAACGGCAAAGAGTACAAGTGCAAGGTGTCCAACAAGG
GCCTGCCCAGCTCCATCGAGAAAACCATCAGCAAGGCCAAGGGCCAGCCCCGCGAGCCTCAAGTGTATACCCTGC
CCCCTTGCCAGGAAGAGATGACCAAGAACCAGGTGTCCCTGTGGTGTCTCGTGAAAGGCTTCTACCCCAGCGACAT
TGCCGTGGAATGGGAGAGCAACGGCCAGCCCGAGAACAATAACAAGACCACCCCCCTGTGCTGGACAGCGACGG
CTCATTCTTCCTGTACTCCAAGCTGACCGTGGACAAGAGCCGGTGGCAGGAAGGCAACGTGTTTCAGCTGCTCCGTG
ATGCACGAGGCCCTGCACAACCACTACACCCAGAAGTCCCTGTCTCTGTCCCTGGGC 4 212
CAGGTGCAGCTGGTGCAGTCTGGCGCCGAGGTCTGTGAACCTGGCGCCTCTGTGAAGGTGTCTTGCAAGGCCAGC
GGCTACACCTTTACCAGCTACTACATCCACTGGGTGCGCCAGGCCCTGGACAGGGACTGGAATGGATCGGCAGC
ATCTACCCCGGCAACGTGAACACCAACTACGCCCAGAAGTTCCAGGGCAGAGCCACCCTGACCGTGGACACCAGC
ATCAGCACCGCCTACATGGAAGTGAAGCCGGCTGAGAAGCGACGACACCGCCGTGTACTACTGCACCCGGTCCCAC
TACGGCCTGGATTGGAAGTTCGACGTGTGGGGCAAGGGCACCAACCGTGACAGTGTCTAGCGACAAAACCCATACC
CAGGTGCAGCTGGTGGAAATCTGGCGGCGGAGTGGTGCAGCCTGGCAGAAGCCTGAGACTGAGCTGTGCCGCCAGC
GGCTTACCTTACCAAGGCCTGGATGCACTGGGTGCGCCAGGCCCTGGAAAGCAGCTGGAATGGGTGGCCAG
ATCAAGGACAAGAGCAACAGCTACGCCACCTACTACGCCGACAGCGTGAAGGGCCGGTTACCATCAGCCGGGAC
GACAGCAAGAACACCCTGTACCTGCAGATGAACAGCCTGCGGGCCGAGGACACCGCCGTGTACTACTGTCCGGGC
GTGTACTATGCCCTGAGCCCCCTTCGATTACTGGGGCCAGGGAACCCTCGTGACCGTGTCTAGTGATAAGACCCACA
CCGCCAGCACAAAGGGCCCATCGGTGTTCCCTCTGGCCCCCTTGACAGCAGAAGCACCAGCGAATCTACAGCCGCCCT
GGGCTGCCTCGTGAAGGACTACTTTCCCGAGCCCGTGACCGTGTCTTGGAACCTCTGGCGCTCTGACAAGCGGCGTG
CACACCTTTCCAGCCGTGCTCCAGAGCAGCGGCCTGTACTCTCTGAGCAGCGTCGTGACAGTGGCCAGCAGCAGCC
TGGGCACCAAGACCTACACCTGTAACGTGGACCACAAGCCCAGCAACACCAAGGTGGACAAGCGGGTGAATCTA
AGTACGGCCCTCCCTGCCCTCCTTGCCCAGCCCCCTGAAGCTGCCGGCGGACCCTCCGTGTTCTCTGTTCCCCCAAG
CCCAAGGACACCCTGATGATCAGCCGGACCCCCGAAGTGACCTGCGTGGTGGTGGATGTGTCCCAGGAAGATCCC
GAGGTGCAGTTCAATTGGTACGTGGACGGCGTGGAAGTGACACAACGCCAAGACCAAGCCCAGAGAGGAACAGTTC
AACAGCACCTACCGGGTGGTGTCCGTGCTGACCGTGTCTGCACCAGGACTGGCTGAACGGCAAAGAGTACAAGTGC
AAGGTGTCCAACAAGGGCCTGCCAGCTCCATCGAGAAAACCATCAGCAAGGCCAAGGGCCAGCCCCGCGAGCCT
CAAGTGTGTACCCTGCCCCCTAGCCAGGAAGAGATGACCAAGAACCAGGTGTCCCTGAGCTGTGCCGTGAAAGGC
TTCTACCCCAGCGACATTGCCGTGGAATGGGAGAGCAACGGCCAGCCCGAGAACAATAACAAGACCACCCCCCT
GTGCTGGACAGCGACGGCTCATTCTTCCTGGTGTCCAAGCTGACCGTGGACAAGAGCCGGTGGCAGGAAGGCAAC
GTGTTTCAGCTGCTCCGTGATGCACGAGGCCCTGCACAACCACTACACCCAGAAGTCCCTGTCTCTGTCCCTGGGC
HER2-30R/ 1 213
GACATCGTGATGACCCAGACCCCCCTGAGCCTGAGCGTGACACCTGGACAGCCTGCCAGCATCAGCTGCAAGAGC
56A/102E/
AGCCAGAGCCTGGTGCACAACAACGCCAACACCTACCTGAGCTGGTATCTGCAGAAGCCCCGGCCAGAGCCCCCAG
CD28sup × CD3mid
TCCCTGATCTACAAGGTGTCCAACAGATTCAGCGGCGTGCCCGACAGATTCTCCGGCAGCGGCTCTGGCACCGACT
L1 linker IgG4
TCACCCTGAAGATCAGCCGGGTGGAAGCCGAGGACGTGGGCGTGTACTATTGTGGCCAGGGCACCCAGTACCCCT
FALA
TCACCTTTGGCAGCGGCACCAAGGTGGAATCAAGGGCCAGCCCAAGGCCGCCCCCGACATCCAGATGACCCAGA

GCCCCAGCAGCCTGTCTGCCAGCGTGGGCGACAGAGTGACCATCACCTGTCAGGCCAGCCAGAACATCTACGTGT
GGCTGAACTGGTATCAGCAGAAGCCCGGCAAGGCCCCCAAGCTGCTGATCTACAAGGCCAGCAACCTGCACACCG
GCGTGCCAGCAGATTTTCTGGCAGCGGCTCCGGCACCGACTTCACCCTGACAATCAGCTCCCTGCAGCCCCGAGGA
CATTGCCACCTACTACTGCCAGCAGGGCCAGACCTACCCCTACACCTTTGGCCAGGGCACCAAGCTGGAAATCAAG
ACCAAGGGCCCCAGCCGTACGGTGGCCGCTCCCAGCGTGTTTCATCTTCCCACCTAGCGACGAGCAGCTGAAGTCCG
GCACAGCCTCTGTCTGTGCCTGCTGAACAACCTTACCCCCGCGAGGCCAAAGTGCAGTGGAAGGTGGACAACG
CCCTGCAGAGCGGCAACAGCCAGGAAAGCGTGACCGAGCAGGACAGCAAGGACTCCACCTACAGCCTGAGCAGC
ACCCTGACACTGAGCAAGGCCGACTACGAGAAGCACAAGGTGTACGCCTGCGAAGTGACCCACCAGGGCCTGTCT
AGCCCCGTGACCAAGAGCTTCAACCGGGGCGAGTGT 2 214

CAGGTGCAGCTGGTGCAGTCTGGCGCCGAGGTCGTGAAACCTGGCGCCTCTGTGAAGGTGTCCTGCAAGGCCAGC
GGCTACACCTTTACCAGCTACTACATCCACTGGGTGCGCCAGGCCCTGGACAGGGACTGGAATGGATCGGCAGC
ATCTACCCCGGCAACGTGAACACCAACTACGCCCAGAAGTTCCAGGGCAGAGCCACCCTGACCGTGGACACCAGC
ATCAGCACCGCCTACATGGAAGTGAAGCCGGCTGAGAAGCGACGACACCGCCGTGTACTACTGCACCCGGTCCCAC
TACGGCCTGGATTGGAACCTTCGACGTGTGGGGCAAGGGCACACCGTGACAGTGTCTAGCAGCCAGGTGCAGCTG
GTGGAATCTGGCGGCGGAGTGGTGCAGCCTGGCAGAAGCCTGAGACTGAGCTGTGCCGCCAGCGGCTTCACCTTC
ACCAAGGCCTGGATGCACTGGGTGCGCCAGGCCCTGGAAAGCAGCTGGAATGGGTGGCCAGATCAAGGACAA
GAGCAACAGCTACGCCACCTACTACGCCGACAGCGTGAAGGGCCGGTTCACCATCAGCCGGGACGACAGCAAGAA
CACCTGTACCTGCAGATGAACAGCCTGCGGGCCGAGGACACCGCCGTGTACTACTGTCCGGGGCGTGTACTATGCC
CTGAGCCCCCTTCGATTACTGGGGCCAGGGAACCCTCGTGACCGTGTCTAGTCCGACCGCCAGCACAAAGGGCCCAT
CGGTGTTCCCTCTGGCCCCCTTGACGAGAAGCACCAGCGAATCTACAGCCGCCCTGGGCTGCCTCGTGAAGGACTA
CTTTCCTCGAGCCCGTGACCGTGTCTGGAACCTCTGGCGCTCTGACAAGCGGCGTGCACACCTTTCCAGCCGTGCTC
CAGAGCAGCGGCCTGTACTCTCTGAGCAGCGTCTGTGACAGTGGCCAGCAGCAGCCTGGGCACCAAGACCTACACC
TGTAACGTGGACCACAAGCCCAGCAACACCAAGGTGGACAAGCGGGTGAATCTAAGTACGGCCCTCCCTGCCCT
CCTTGCCCAGCCCCCTGAAGCTGCCGGCGGACCCTCCGTGTTCTCTGTTCCCCCAAAGCCCAAGGACACCCTGATGA
TCAGCCGGACCCCCGAAGTGACCTGCGTGGTGGTGGATGTGTCCCAGGAAGATCCCGAGGTGCAGTTCAATTGGT
ACGTGGACGGCGTGGAAGTGCACAACGCCAAGACCAAGCCCAGAGAGGAACAGTTCAACAGCACCTACCGGGTG
GTGTCCGTGCTGACCGTGTCTGCACCAGGACTGGCTGAACGGCAAAGAGTACAAGTGAAGGTGTCCAACAAGGGC
CTGCCCAGCTCCATCGAGAAAACCATCAGCAAGGCCAAGGGCCAGCCCCGCGAGCCTCAAGTGTGTACCCTGCCC
CCTAGCCAGGAAGAGATGACCAAGAACCAGGTGTCCCTGAGCTGTGCCGTGAAAGGCTTCTACCCAGCGACATT
GCCGTGGAATGGGAGAGCAACGGCCAGCCCGAGAACAACCTACAAGACCACCCCCCTGTGCTGGACAGCGACGG
CTCATTCTTCCTGGTGTCCAAGCTGACCGTGGACAAGAGCCGGTGGCAGGAAGGCAACGTGTTACGCTGCTCCGTG
ATGCACGAGGCCCTGCACAACCACTACACCCAGAAGTCCCTGTCTCTGTCCCTGGGC 3 215

GAAGTGCAGCTGGTGGAAATCTGGCGGCGGACTGGTGCAGCCTGGCGGATCTCTGAGACTGAGCTGTGCCGCCAGC
GGCTTCAACATCCGGGACACCTACATCCACTGGGTGCGCCAGGCCCTGGCAAGGGACTGGAATGGGTGGCCAGA
ATCTACCCCAACCAACGCCTACACCAGATACGCCGACAGCGTGAAGGGCCGGTTCACCATCAGCGCCGACACCAGC
AAGAACACCGCCTACCTGCAGATGAACAGCCTGCGGGCCGAGGACACCGCCGTGTACTACTGTAGTAGATGGGGA
GGCGAAGGCTTCTACGCCATGGACTATTGGGGCCAGGGCACCCCTCGTGACCGTGTCTAGTGCCTCGACCAAGGGC
CCATCGGTGTTCCCTCTGGCCCCCTTGACGAGAGAAGCACCAGCGAATCTACAGCCGCCCTGGGCTGCCTCGTGAAGG
ACTACTTTCCCGAGCCCGTGACCGTGTCTGGAACCTCTGGCGCTCTGACAAGCGGCGTGCACACCTTTCCAGCCGT
GCTCCAGAGCAGCGGCCTGTACTCTCTGAGCAGCGTCTGTGACAGTGGCCAGCAGCAGCCTGGGCACCAAGACCTA
CACCTGTAACGTGGACCACAAGCCCAGCAACACCAAGGTGGACAAGCGGGTGAATCTAAGTACGGCCCTCCCTG
CCCTCCTTGCCCAGCCCCCTGAATTTCTGGGCGGACCCTCCGTGTTCTCTGTTCCCCCAAAGCCCAAGGACACCCTGA
TGATCAGCCGGACCCCCGAAGTGACCTGCGTGGTGGTGGATGTGTCCCAGGAAGATCCCGAGGTGCAGTTCAATT
GGTACGTGGACGGCGTGGAAGTGCACAACGCCAAGACCAAGCCCAGAGAGGAACAGTTCAACAGCACCTACCGG
GTGGTGTCCGTGCTGACCGTGTCTGCACCAGGACTGGCTGAACGGCAAAGAGTACAAGTGAAGGTGTCCAACAAG
GGCCTGCCAGCTCCATCGAGAAAACCATCAGCAAGGCCAAGGGCCAGCCCCGCGAGCCTCAAGTGTATACCCTG
CCCCCTTGCCAGGAAGAGATGACCAAGAACCAGGTGTCCCTGTGGTGTCTCGTGAAAGGCTTCTACCCAGCGACA
TTGCCGTGGAATGGGAGAGCAACGGCCAGCCCGAGAACAACCTACAAGACCACCCCCCTGTGCTGGACAGCGACG
GCTCATTCTTCCTGTACTCCAAGCTGACCGTGGACAAGAGCCGGTGGCAGGAAGGCAACGTGTTACGCTGCTCCGT
GATGCACGAGGCCCTGCACAACCACTACACCCAGAAGTCCCTGTCTCTGTCCCTGGGC 4 216

CAGGTGCAGCTGGTGCAGTCTGGCGCCGAGGTCGTGAAACCTGGCGCCTCTGTGAAGGTGTCCTGCAAGGCCAGC
GGCTACACCTTTACCAGCTACTACATCCACTGGGTGCGCCAGGCCCTGGACAGGGACTGGAATGGATCGGCAGC
ATCTACCCCGGCAACGTGAACACCAACTACGCCCAGAAGTTCCAGGGCAGAGCCACCCTGACCGTGGACACCAGC
ATCAGCACCGCCTACATGGAAGTGAAGCCGGCTGAGAAGCGACGACACCGCCGTGTACTACTGCACCCGGTCCCAC
TACGGCCTGGATTGGAACCTTCGACGTGTGGGGCAAGGGCACACCGTGACAGTGTCTAGCGACAAAACCCATACC
CAGGTGCAGCTGGTGGAAATCTGGCGGCGGAGTGGTGCAGCCTGGCAGAAGCCTGAGACTGAGCTGTGCCGCCAGC
GGCTTACCTTACCAAGGCCTGGATGCACTGGGTGCGCCAGGCCCTGGAAAGCAGCTGGAATGGGTGGCCAG
ATCAAGGACAAGAGCAACAGCTACGCCACCTACTACGCCGACAGCGTGAAGGGCCGGTTCACCATCAGCCGGGAC
GACAGCAAGAACACCCTGTACCTGCAGATGAACAGCCTGCGGGCCGAGGACACCGCCGTGTACTACTGTCCGGGC
GTGTACTATGCCCTGAGCCCCCTTCGATTACTGGGGCCAGGGAACCCTCGTGACCGTGTCTAGTGATAAGACCCACA
CCGCCAGCACAAAGGGCCCATCGGTGTTCCCTCTGGCCCCCTTGACGAGAGAAGCACCAGCGAATCTACAGCCGCCCT
GGGCTGCCTCGTGAAGGACTACTTTCCCGAGCCCGTGACCGTGTCTGGAACCTCTGGCGCTCTGACAAGCGGCGTG

CACACATTTCAGCTGCCAGAGCAGCCGCTGTACTCTCTGAGCAGCGTCGTGACAGTGCCGAGCAGCAGCC
TGGGCACCAAGACCTACACCTGTAACGTGGACCACAAGCCCAGCAACACCAAGGTGGACAAGCGGGTGGAATCTA
AGTACGGCCCTCCCTGCCCTCCTTGCCAGCCCTGAAGCTGCCGGCGGACCCCTCCGTGTTCTCTGTTCCCCCAAAG
CCCAAGGACACCCTGATGATCAGCCGGACCCCCGAAGTGACCTGCGTGGTGGTGGATGTGTCCCAGGAAGATCCC
GAGGTGCAGTTCAATTGGTACGTGGACGGCGTGGAAGTGCACAACGCCAAGACCAAGCCCAGAGAGGAACAGTTC
AACAGCACCTACCGGGTGGTGTCCGTGCTGACCGTGCTGCACCAGGACTGGCTGAACGGCAAAGAGTACAAGTGC
AAGGTGTCCAACAAGGGCCTGCCAGCTCCATCGAGAAAACCATCAGCAAGGCCAAGGGCCAGCCCCGCGAGCCT
CAAGTGTGTACCCTGCCCCCTAGCCAGGAAGAGATGACCAAGAACCAGGTGTCCCTGAGCTGTGCCGTGAAAGGC
TTCTACCCAGCGACATTGCCGTGGAATGGGAGAGCAACGGCCAGCCCGAGAACAATAAGACCACCCCCCT
GTGCTGGACAGCGACGGCTCATTCTTCTTGGTGTCCAAGCTGACCGTGGACAAGAGCCGGTGGCAGGAAGGCAAC
GTGTTAGCTGCTCCGTGATGCACGAGGCCCTGCACAACCACTACACCCAGAAGTCCCTGTCTCTGTCCCTGGGC
HER2-WT + 1 217
GACATCGTGATGACCCAGACCCCCCTGAGCCTGAGCGTGACACCTGGACAGCCTGCCAGCATCAGCTGCAAGAGC
trastuzumab/
AGCCAGAGCCTGGTGCACCAGAACGCCAGACCTACCTGAGCTGGTATCTGCAGAAGCCCGGCCAGAGCCCCAG
CD28sup × CD3mid
TCCCTGATCTACAAGGTGTCCAACAGATTCAGCGGCGTGCCCGACAGATTCTCCGGCAGCGGCTCTGGCACCGACT
(32/35QQ) L1
TCACCTGAAGATCAGCCGGGTGGAAGCCGAGGACGTGGGCGTGTAATTGTGGCCAGGGCACCCAGTACCCCT
linker IgG4
TCACCTTTGGCAGCGGCACCAAGGTGGAAATCAAGGGCCAGCCCAAGGCCGCCCCCGACATCCAGATGACCCAGA
FALA BP # 15
GCCCCAGCAGCCTGTCTGCCAGCGTGGGCGACAGAGTGACCATCACCTGTCAGGCCAGCCAGAACATCTACGTGT
GGCTGAACTGGTATCAGCAGAAGCCCGGCAAGGCCCCCAAGCTGCTGATCTACAAGGCCAGCAACCTGCACACCG
GCGTGCCAGCAGATTTTCTGGCAGCGGCTCCGGCACCGACTTCACCTGACAATCAGCTCCCTGCAGCCCGAGGA
CATTGCCACCTACTACTGCCAGCAGGGCCAGACCTACCCCTACACCTTTGGCCAGGGCACCAAGCTGGAAATCAAG
ACCAAGGGCCCCAGCCGTACGGTGGCCGCTCCCAGCGTGTTTATCTTCCCACCTAGCGACGAGCAGCTGAAGTCCG
GCACAGCCTCTGTCTGTGCCTGCTGAACAATTCTACCCCCGCGAGGCCAAAGTGCAGTGGAAGGTGGACAACG
CCCTGCAGAGCGGCAACAGCCAGGAAAGCGTGACCGAGCAGGACAGCAAGGACTCCACCTACAGCCTGAGCAGC
ACCCTGACACTGAGCAAGGCCGACTACGAGAAGCACAAGGTGTACGCCTGCGAAGTGACCCACCAGGGCCTGTCT
AGCCCCGTGACCAAGAGCTTCAACCGGGGCGAGTGT 2 218
CAGGTGCAGCTGGTGCAGTCTGGCGCCGAGGTGCTGAAACCTGGCGCCTCTGTGAAGGTGTCCTGCAAGGCCAGC
GGCTACACCTTTACCAGCTACTACATCCACTGGGTGCGCCAGGCCCTGGACAGGGACTGGAATGGATCGGCAGC
ATCTACCCCGGCAACGTGAACACCAACTACGCCCAGAAGTTCCAGGGCAGAGCCACCCTGACCGTGGACACCAGC
ATCAGCACCGCCTACATGGAAGTGAAGCCGGCTGAGAAGCGACGACACCGCCGTGTACTACTGCACCCGGTCCCAC
TACGGCCTGGATTGGAAGTTCGACGTGTGGGGCAAGGGCACCAACCGTGACAGTGTCTAGCAGCCAGGTGCAGCTG
GTGGAATCTGGCGGCGGAGTGGTGCAGCCTGGCAGAAGCCTGAGACTGAGCTGTGCCGCCAGCGGCTTCACCTTC
ACCAAGGCCTGGATGCACTGGGTGCGCCAGGCCCTGGAAAGCAGCTGGAATGGGTGGCCAGATCAAGGACAA
GAGCAACAGCTACGCCACCTACTACGCCGACAGCGTGAAGGGCCGGTTACCATCAGCCGGGACGACAGCAAGAA
CACCTGTACCTGCAGATGAACAGCCTGCGGGCCGAGGACACCGCCGTGTACTACTGTCCGGGGCGTGTACTATGCC
CTGAGCCCCCTTCGATTACTGGGGCCAGGGAACCCTCGTGACCGTGTCTAGTCGGACCGCCAGCACAAAGGGCCCAT
CGGTGTTCCCTCTGGCCCCCTTGACAGCAGAAGCACCAAGCGAATCTACAGCCGCCCTGGGCTGCCTCGTGAAGGACTA
CTTCCCCGAGCCCGTGACCGTGTCTGGAAGTCTGGCGCTCTGACAAGCGGCGTGCACACCTTTCCAGCCGTGCTC
CAGAGCAGCGGCCTGTACTCTCTGAGCAGCGTCTGTGACAGTGGCCAGCAGCAGCCTGGGCACCAAGACCTACACC
TGTAACGTGGACCACAAGCCCAGCAACACCAAGGTGGACAAGCGGGTGAATCTAAGTACGGCCCTCCCTGCCCT
CCTTGCCAGCCCTGAAGCTGCCGGCGGACCCCTCCGTGTTCTCTGTTCCCCCAAAGCCCAAGGACACCCTGATGA
TCAGCCGGACCCCCGAAGTGACCTGCGTGGTGGTGGATGTGTCCCAGGAAGATCCCGAGGTGCAGTTCAATTGGT
ACGTGGACGGCGTGGAAGTGCACAACGCCAAGACCAAGCCCAGAGAGGAACAGTTCAACAGCACCTACCGGGTG
GTGTCCGTGCTGACCGTGTGTCACCAGGACTGGCTGAACGGCAAAGAGTACAAGTGAAGGTGTCCAACAAGGGC
CTGCCAGCTCCATCGAGAAAACCATCAGCAAGGCCAAGGGCCAGCCCCGCGAGCCTCAAGTGTGTACCCTGCCC
CCTAGCCAGGAAGAGATGACCAAGAACCAGGTGTCCCTGAGCTGTGCCGTGAAAGGCTTCTACCCAGCGACATT
GCCGTGGAATGGGAGAGCAACGGCCAGCCCGAGAACAATAAGACCACCCCCCTGTGCTGGACAGCGACGG
CTCATTCTTCTTGGTGTCCAAGCTGACCGTGGACAAGAGCCGGTGGCAGGAAGGCAACGTGTTAGCTGCTCCGTG
ATGCACGAGGCCCTGCACAACCACTACACCCAGAAGTCCCTGTCTCTGTCCCTGGGC 3 219
GAAGTGCAGCTGGTGGAAATCTGGCGGCGGACTGGTGCAGCCTGGCGGATCTCTGAGACTGAGCTGTGCCGCCAGC
GGCTTCAACATCAAGGACACCTACATCCACTGGGTGCGCCAGGCCCTGGCAAGGGACTGGAATGGGTGGCCAGA
ATCTACCCACCAACGGCTACACCAGATACGCCGACAGCGTGAAGGGCCGGTTACCATCAGCGCCGACACCAGC
AAGAACACCGCCTACCTGCAGATGAACAGCCTGCGGGCCGAGGACACCGCCGTGTACTACTGTAGTAGATGGGGA
GGCGACGGCTTCTACGCCATGGACTATTGGGGCCAGGGCACCCCTCGTGACCGTGTCTAGTGCCTCGACCAAGGGCC
CATCGGTGTTCCCTCTGGCCCCCTTGACAGCAGAAGCACCAAGCGAATCTACAGCCGCCCTGGGCTGCCTCGTGAAGGA
CTACTTTCCCGAGCCCGTGACCGTGTCTTGGAACTCTGGCGCTCTGACAAGCGGCGTGCACACCTTTCCAGCCGTG
CTCCAGAGCAGCGGCCTGTACTCTCTGAGCAGCGTCTGTGACAGTGGCCAGCAGCAGCCTGGGCACCAAGACCTAC
ACCTGTAACGTGGACCACAAGCCCAGCAACACCAAGGTGGACAAGCGGGTGAATCTAAGTACGGCCCTCCCTGC

CTCTTCGCGAGCCCTGAAGCTGCCGGCGACCTCCGTGTTCTCTTCCCCCAAGGCCAAGGACACCTGA
TGATCAGCCGGACCCCCGAAGTGACCTGCGTGGTGGTGGATGTGTCCCAGGAAGATCCCGAGGTGCAGTTCAATT
GGTACGTGGACGGCGTGGAAGTGCACAACGCCAAGACCAAGCCCAGAGAGGAACAGTTCAACAGCACCTACCGG
GTGGTGTCCGTGCTGACCGTGCTGCACCAGGACTGGCTGAACGGCAAAGAGTACAAGTGCAAGGTGTCCAACAAG
GGCCTGCCAGCTCCATCGAGAAAACCATCAGCAAGGCCAAGGGCCAGCCCCGCGAGCCTCAAGTGTATACCCTG
CCCCCTTGCCAGGAAGAGATGACCAAGAACCAGGTGTCCCTGTGGTGTCTCGTGAAAGGCTTCTACCCCAGCGACA
TTGCCGTGGAATGGGAGAGCAACGGCCAGCCCGAGAACAACACTACAAGACCACCCCCCTGTGCTGGACAGCGACG
GCTCATTCTTCCTGTACTCCAAGCTGACCGTGAGACAAGAGCCGGTGGCAGGAAGGCAACGTGTTTACGCTGCTCCGT
GATGCACGAGGCCCTGCACAACCACTACACCCAGAAGTCCCTGTCTCTGTCCCTGGGC 4 220
GACATCCAGATGACCCAGAGCCCCAGCAGCCTGTCTGCCAGCGTGGGCGACAGAGTGACCATCACCTGTAGAGCC
AGCCAGGACGTGAACACCGCCGTGGCCTGGTATCAGCAGAAGCCTGGCAAGGCCCCCAAGCTGCTGATCTACAGC
GCCAGCTTCCTGTACAGCGGCGTGCCAGCAGATTCAGCGGAAGCAGAAGCGGCACCGACTTCACCCTGACCATC
AGCTCCCTGCAGCCCGAGGACTTCGCCACCTACTACTGCCAGCAGCACTACACCACCCCCCCCCACATTTGGCCAGG
GCACCAAGGTGGAAATCAAGCGTACGGTGGCCGCTCCCAGCGTGTTCATCTTCCACCTAGCGACGAGCAGCTGA
AGTCCGGCACAGCCTCTGTCTGTGCTGCTGAACAACCTTCTACCCCCGCGAGGCCAAAGTGCAAGTGGAAAGGTGG
ACAACGCCCTGCAGAGCGGCAACAGCCAGGAAAGCGTGACCGAGCAGGACAGCAAGGACTCCACCTACAGCCTG
AGCAGCACCCCTGACACTGAGCAAGGCCGACTACGAGAAGCACAAGGTGTACGCCTGCGAAGTGACCCACCAGGG
CCTGTCTAGCCCCGTGACCAAGAGCTTCAACCGGGGCGAGTGT HER2/ 1 221
GACATCGTGATGACCCAGACCCCCCTGAGCCTGAGCGTGACACCTGGACAGCCTGCCAGCATCAGCTGCAAGAGC
CD28.sub.sup × CD3.sub.mid
AGCCAGAGCCTGGTGCACAACAACGCCAACACCTACCTGAGCTGGTATCTGCAGAAGCCCGGCCAGAGCCCCCAG
DKTHT linkers
TCCCTGATCTACAAGGTGTCCAACAGATTCAGCGGCGTGCCCGACAGATTCTCCGGCAGCGGCTCTGGCACCGACT
on HC/LC) IgG4
TCACCCTGAAGATCAGCCGGGTGGAAGCCGAGGACGTGGGCGTGTAATTGTGGCCAGGGCACCCAGTACCCCT
FALA
TCACCTTTGGCAGCGGCACCAAGGTGGAAATCAAGGACAAAACCCATACCGACATCCAGATGACCCAGAGCCCCA
BP # 25
GCAGCCTGTCTGCCAGCGTGGGCGACAGAGTGACCATCACCTGTGAGGCCAGCCAGAACATCTACGTGTGGCTGA
ACTGGTATCAGCAGAAGCCCGGCAAGGCCCCCAAGCTGCTGATCTACAAGGCCAGCAACCTGCACACCGGCGTGC
CCAGCAGATTTTCTGGCAGCGGCTCCGGCACCGACTTCACCCTGACAATCAGCTCCCTGCAGCCCGAGGACATTGC
CACCTACTACTGCCAGCAGGGCCAGACCTACCCCTACACCTTTGGCCAGGGCACCAAGCTGGAAATCAAGGATAA
GACCCACACCCGTACGGTGGCCGCTCCCAGCGTGTTCATCTTCCACCTAGCGACGAGCAGCTGAAGTCCGGCACA
GCCTCTGTCTGTGCTGCTGAACAACCTTCTACCCCCGCGAGGCCAAAGTGCAAGTGGAAAGGTGGACAACGCCCTGC
AGAGCGGCAACAGCCAGGAAAGCGTGACCGAGCAGGACAGCAAGGACTCCACCTACAGCCTGAGCAGCACCCCTG
ACACTGAGCAAGGCCGACTACGAGAAGCACAAGGTGTACGCCTGCGAAGTGACCCACCAGGGCCTGTCTAGCCCC
GTGACCAAGAGCTTCAACCGGGGCGAGTGT 2 222
CAGGTGCAGCTGGTGCAGTCTGGCGCCGAGGTGCTGAAACCTGGCGCCTCTGTGAAGGTGTCCTGCAAGGCCAGC
GGCTACACCTTTACCAGCTACTACATCCACTGGGTGCGCCAGGCCCTGGACAGGGACTGGAATGGATCGGCAGC
ATCTACCCCGGCAACGTGAACACCAACTACGCCCAGAAGTTCAGGGCAGAGCCACCCTGACCGTGGACACCAGC
ATCAGCACCGCCTACATGGAAGTGAAGCCGGCTGAGAAGCGACGACACCGCCGTGTACTACTGCACCCGGTCCCAC
TACGGCCTGGATTGGAAGTTCGACGTGTGGGGCAAGGGCACACCGTGCAGTGTCTAGCGACAAAACCCATACC
CAGGTGCAGCTGGTGGAAATCTGGCGGCGGAGTGGTGCAGCCTGGCAGAAGCCTGAGACTGAGCTGTGCCGCCAGC
GGCTTACCTTCACCAAGGCCTGGATGCACTGGGTGCGCCAGGCCCTGGAAAGCAGCTGGAATGGGTGGCCAG
ATCAAGGACAAGAGCAACAGCTACGCCACCTACTACGCCGACAGCGTGAAGGGCCGGTTACCATCAGCCGGGAC
GACAGCAAGAACACCCTGTACCTGCAGATGAACAGCCTGCGGGCCGAGGACACCGCCGTGTACTACTGTGCGGGC
GTGTACTATGCCCTGAGCCCCCTTCGATTACTGGGGCCAGGGAACCCCTCGTGACCGTGTCTAGTGATAAGACCCACA
CCGCCAGCACAAAGGGCCCATCGGTGTTCCCTCTGGCCCCCTTGACAGCAGAAGCACCCAGCGAATCTACAGCCGCCCT
GGGCTGCCTCGTGAAGGACTACTTTCCCGAGCCCGTGACCGTGTCTGGAACCTCTGGCGCTCTGACAAGCGGCGTG
CACACCTTTCCAGCCGTGCTCCAGAGCAGCGGCCTGTACTCTCTGAGCAGCGTCTGTACAGTGCCCAGCAGCAGCC
TGGGCACCAAGACCTACACCTGTAACGTGGACCACAAGCCCAGCAACACCAAGGTGGACAAGCGGGTGGAAATCTA
AGTACGGCCCTCCCTGCCCTCCTTGCCAGCCCCCTGAAGCTGCCGGCGGACCCCTCCGTGTTCCCTGTTCCCCCAAAG
CCCAAGGACACCCTGATGATCAGCCGGACCCCCGAAGTGACCTGCGTGGTGGTGGATGTGTCCCAGGAAGATCCC
GAGGTGCAGTTCAATTGGTACGTGGACGGCGTGGAAGTGACAACGCCAAGACCAAGCCCAGAGAGGAACAGTTC
AACAGCACCTACCGGGTGGTGTCCGTGCTGACCGTGTCTGCACCAGGACTGGCTGAACGGCAAAGAGTACAAGTGC
AAGGTGTCCAACAAGGGCCTGCCAGCTCCATCGAGAAAACCATCAGCAAGGCCAAGGGCCAGCCCCGCGAGCCT
CAAGTGTGTACCCTGCCCCCTAGCCAGGAAGAGATGACCAAGAACCAGGTGTCCCTGAGCTGTGCCGTGAAAGGC
TTCTACCCCAGCGACATTGCCGTGGAATGGGAGAGCAACGGCCAGCCCGAGAACAACACTACAAGACCACCCCCCT
GTGCTGGACAGCGACGGCTCATTCTTCCTGGTGTCCAAGCTGACCGTGGACAAGAGCCGGTGGCAGGAAGGCAAC
GTGTTTACGCTGCTCCGTGATGCACGAGGCCCTGCACAACCACTACACCCAGAAGTCCCTGTCTCTGTCCCTGGGC
3 223
GAAGTGCAGCTGGTGGAAATCTGGCGGCGGACTGGTGCAGCCTGGCGGATCTCTGAGACTGAGCTGTGCCGCCAGC
GGCTTCAACATCAAGGACACCTACATCCACTGGGTGCGCCAGGCCCTGGCAAGGGACTGGAATGGGTGGCCAGA

ATCTACCCACCAACGGCTACACCCAGATACAGCGTGAAGGGCCGGTTCCACCATCAGCGCCGACACCAGC
AAGAACACCCGCTACCTGCAGATGAACAGCCTGCGGGCCGAGGACACCGCCGTGTACTACTGTAGTAGATGGGGA
GGCGACGGCTTCTACGCCATGGACTATTGGGGCCAGGGCACCCCTCGTGACCGTGTCTAGTGCCTCGACCAAGGGCC
CATCGGTGTTCCCTCTGGCCCCCTTGACAGCAGAAGCACCAAGCAATCTACAGCCGCCCTGGGCTGCCTCGTGAAGGA
CTACTTTCCCGAGCCCGTGACCGTGTCTTGGAACTCTGGCGCTCTGACAAGCGGCGTGACACCTTTCCAGCCGTG
CTCCAGAGCAGCGGCCTGTACTCTCTGAGCAGCGTCGTGACAGTGCCCAGCAGCAGCCTGGGCACCAAGACCTAC
ACCTGTAACGTGGACCACAAGCCCAGCAACACCAAGGTGGACAAGCGGGTGAATCTAAGTACGGCCCTCCCTGC
CCTCCTTGCCCAGCCCCCTGAAGCTGCCGGCGGACCCCTCCGTGTTTCTGTTCCCCCAAGCCCAAGGACACCCTGA
TGATCAGCCGGACCCCCGAAGTGACCTGCGTGGTGGTGGATGTGTCCCAGGAAGATCCCGAGGTGCAGTTCAATT
GGTACGTGGACGGCGTGGAAGTGCACAACGCCAAGACCAAGCCCAGAGAGGAACAGTTCAACAGCACCTACCGG
GTGGTGTCCGTGCTGACCGTGCTGCACCAGGACTGGCTGAACGGCAAAGAGTACAAGTGCAAGGTGTCCAACAAG
GGCCTGCCCAGCTCCATCGAGAAAACCATCAGCAAGGCCAAGGGCCAGCCCCGCGAGCCTCAAGTGTATACCCTG
CCCCCTTGCCAGGAAGAGATGACCAAGAACCAGGTGTCCCTGTGGTGTCTCGTGAAAGGCTTCTACCCCAGCGACA
TTGCCGTGGAATGGGAGAGCAACGGCCAGCCCGAGAACAACCTACAAGACCACCCCCCTGTGCTGGACAGCGACG
GCTCATTCTTCTGTACTCCAAGCTGACCGTGGACAAGAGCCGGTGGCAGGAAGGCAACGTGTTACGCTGCTCCGT
GATGCACGAGGCCCTGCACAACCACTACACCCAGAAGTCCCTGTCTCTGTCCCTGGGC 4 224
GACATCCAGATGACCCAGAGCCCCAGCAGCCTGTCTGCCAGCGTGGGCGACAGAGTGACCATCACCTGTAGAGCC
AGCCAGGACGTGAACACCGCCGTGGCCTGGTATCAGCAGAAGCCTGGCAAGGCCCCCAAGCTGCTGATCTACAGC
GCCAGCTTCCCTGTACAGCGGCGTGCCCAGCAGATTCAGCGGAAGCAGAAGCGGCACCGACTTCACCCTGACCATC
AGCTCCCTGCAGCCCAGGACTTCGCCACCTACTACTGCCAGCAGCACTACACCACCCCCCCCCACATTTGGCCAGG
GCACCAAGGTGGAAATCAAGCGTACGGTGGCCGCTCCCAGCGTGTTCATCTTCCCACCTAGCGACGAGCAGCTGA
AGTCCGGCACAGCCTCTGTCTGTGCTGCTGAACAACCTTCTACCCCCGCGAGGCCAAAGTGCAAGTGAAGGTGG
ACAACGCCCTGCAGAGCGGCAACAGCCAGGAAAGCGTGACCGAGCAGGACAGCAAGGACTCCACCTACAGCCTG
AGCAGCACCCCTGACACTGAGCAAGGCCGACTACGAGAAGCACAAGGTGTACGCCTGCGAAGTGACCCACCAGGG
CCTGTCTAGCCCCGTGACCAAGAGCTTCAACCGGGGCGAGTGT HER2/ 1 225
GACATCGTGATGACCCAGACCCCCCTGAGCCTGAGCGTGACACCTGGACAGCCTGCCAGCATCAGCTGCAAGAGC
CD28.sub.sup × CD3.sub.mid
AGCCAGAGCCTGGTGCACGAGAACCTGCGTACCTACCTGAGCTGGTATCTGCAGAAGCCCGGCCAGAGCCCCCAG
(32/33/3435
TCCCTGATCTACAAGGTGTCCAACAGATTCAGCGGCGTGCCCGACAGATTCTCCGGCAGCGGCTCTGGCACCGACT
ENLR (LC);
TCACCCTGAAGATCAGCCGGGTGGAAGCCGAGGACGTGGGCGTGTACTATTGTGGCCAGGGCACCCAGTACCCCT
DKTHT linkers
TCACCTTTGGCAGCGGCACCAAGGTGGAATCAAGGACAAAACCCATACCGACATCCAGATGACCCAGAGCCCCA
on HC/LC)
GCAGCCTGTCTGCCAGCGTGGGCGACAGAGTGACCATCACCTGTCAGGCCAGCCAGAACATCTACGTGTGGCTGA
IgG4 FALA
ACTGGTATCAGCAGAAGCCCGGCAAGGGCCCCCAAGCTGCTGATCTACAAGGCCAGCAACCTGCACACCGGCGTGC
BP # 26
CCAGCAGATTTTCTGGCAGCGGCTCCGGCACCGACTTCACCCTGACAATCAGCTCCCTGCAGCCCGAGGACATTGC
CACCTACTACTGCCAGCAGGGCCAGACCTACCCCTACACCTTTGGCCAGGGCACCAAGCTGGAATCAAGGATAA
GACCCACACCCGTACGGTGGCCGCTCCCAGCGTGTTCATCTTCCCACCTAGCGACGAGCAGCTGAAGTCCGGCACA
GCCTCTGTCTGTGCTGCTGAACAACCTTCTACCCCCGCGAGGCCAAAGTGCAAGTGAAGGTGGACAACGCCCTGC
AGAGCGGCAACAGCCAGGAAAGCGTGACCGAGCAGGACAGCAAGGACTCCACCTACAGCCTGAGCAGCACCCCTG
ACACTGAGCAAGGCCGACTACGAGAAGCACAAGGTGTACGCCTGCGAAGTGACCCACCAGGGCCTGTCTAGCCCC
GTGACCAAGAGCTTCAACCGGGGCGAGTGT 2 226
CAGGTGCAGCTGGTGCAGTCTGGCGCCGAGGTCTGTGAACCTGGCGCCTCTGTGAAGGTGTCCTGCAAGGCCAGC
GGCTACACCTTTACCAGCTACTACATCCACTGGGTGCGCCAGGCCCTTGACAGGGACTGGAATGGATCGGCAGC
ATCTACCCCGGCAACGTGAACACCAACTACGCCCAGAAGTTCCAGGGCAGAGCCACCCTGACCGTGGACACCAGC
ATCAGCACCGCCTACATGGAAGTGAAGCCGGCTGAGAAGCGACGACACCGCCGTGTACTACTGCACCCGGTCCCAC
TACGGCCTGGATTGGAACCTTCGACGTGTGGGGCAAGGGCACACCGTGACAGTGTCTAGCGACAAAACCCATACC
CAGGTGCAGCTGGTGGAACTCTGGCGGCGGAGTGGTGCAGCCTGGCAGAAGCCTGAGACTGAGCTGTGCCGCCAGC
GGCTTACCTTACCAAGGCCTGGATGCACTGGGTGCGCCAGGCCCTTGAAAGCAGCTGGAATGGGTGGCCAG
ATCAAGGACAAGAGCAACAGCTACGCCACCTACTACGCCGACAGCGTGAAGGGCCGGTTTACCATCAGCCGGGAC
GACAGCAAGAACACCCTGTACCTGCAGATGAACAGCCTGCGGGCCGAGGACACCGCCGTGTACTACTGTCCGGGC
GTGTACTATGCCCTGAGCCCCCTTCGATTACTGGGGCCAGGGAACCCCTCGTGACCGTGTCTAGTGATAAGACCCACA
CCGCCAGCACAAAGGGCCCATCGGTGTTCCCTCTGGCCCCCTTGACAGCAGAAGCACCAAGCAATCTACAGCCGCCCT
GGGCTGCCTCGTGAAGGACTACTTTCCCGAGCCCGTGACCGTGTCTGGAACCTCTGGCGCTCTGACAAGCGGCGTG
CACACCTTTCCAGCCGTGCTCCAGAGCAGCGGCCTGTACTCTCTGAGCAGCGTCGTGACAGTGCCCAGCAGCAGCC
TGGGCACCAAGACCTACACCTGTAACGTGGACCACAAGCCCAGCAACACCAAGGTGGACAAGCGGGTGGAACTTA
AGTACGGCCCTCCCTGCCCTCCTTGCCCAGCCCCCTGAAGCTGCCGGCGGACCCCTCCGTGTTTCTGTTCCCCCAAG
CCCAAGGACACCCTGATGATCAGCCGGACCCCCGAAGTGACCTGCGTGGTGGTGGATGTGTCCCAGGAAGATCCC
GAGGTGCAGTTCAATTGGTACGTGGACGGCGTGGAAGTGCACAACGCCAAGACCAAGCCCAGAGAGGAACAGTTC

AAACGACCTACCGGGTGGTGTCCGTGCTGACCGTGCTGCACACAGGACTGGCTGAACGGCAAAGAGTACAAGTGC
AAGGTGTCCAACAAGGGCCTGCCAGCTCCATCGAGAAAACCATCAGCAAGGCCAAGGGCCAGCCCCGCGAGCCT
CAAGTGTGTACCCTGCCCCCTAGCCAGGAAGAGATGACCAAGAACCAGGTGTCCCTGAGCTGTGCCGTGAAAGGC
TTCTACCCCAGCGACATTGCCGTGGAATGGGAGAGCAACGGCCAGCCCCGAGAACAATAACAAGACCACCCCCCT
GTGCTGGACAGCGACGGCTCATTTCTTCTTGGTGTCCAAGCTGACCGTGGACAAGAGCCGGTGGCAGGAAGGCAAC
GTGTTTCAGCTGCTCCGTGATGCACGAGGCCCTGCACAACCACTACACCCAGAAGTCCCTGTCTGTCCCTGGGC
3 227
GAAGTGCAGCTGGTGGAAATCTGGCGGCGGACTGGTGCAGCCTGGCGGATCTCTGAGACTGAGCTGTGCCGCCAGC
GGCTTCAACATCAAGGACACCTACATCCACTGGGTGCGCCAGGCCCTGGCAAGGGACTGGAATGGGTGGCCAGA
ATCTACCCCACCAACGGCTACACCAGATACGCCGACAGCGTGAAGGGCCGGTTCACCATCAGCGCCGACACCAGC
AAGAACACCGCCTACCTGCAGATGAACAGCCTGCGGGCCGAGGACACCGCCGTGTACTACTGTAGTAGATGGGGA
GGCGACGGCTTCTACGCCATGGACTATTGGGGCCAGGGCACCCCTCGTGACCGTGTCTAGTGCCTCGACCAAGGGCC
CATCGGTGTTCCCTCTGGCCCCCTTGCAGCAGAAGCACCAAGCGAATCTACAGCCGCCCTGGGCTGCCTCGTGAAGGA
CTACTTTCCCGAGCCCGTGACCGTGTCTTGGAACTCTGGCGCTCTGACAAGCGGCGTGACACCTTTCCAGCCGTG
CTCCAGAGCAGCGGCCTGTACTCTCTGAGCAGCGTCGTGACAGTGCCCAGCAGCAGCCTGGGCACCAAGACCTAC
ACCTGTAACGTGGACCACAAGCCCAGCAACACCAAGGTGGACAAGCGGGTGGAAATCTAAGTACGGCCCTCCCTGC
CCTCCTTGCCCAGCCCCCTGAAGCTGCCGGCGGACCCCTCCGTGTTCCCTGTTCCCCCAAGGCCAAGGACACCCTGA
TGATCAGCCGGACCCCCGAAGTGACCTGCGTGGTGGTGGATGTGTCCCAGGAAGATCCCGAGGTGCAGTTCAATT
GGTACGTGGACGGCGTGGAAGTGCACAACGCCAAGACCAAGCCCAGAGAGGAACAGTTCAACAGCACCTACCGG
GTGGTGTCCGTGCTGACCGTGTCTGCACCAGGACTGGCTGAACGGCAAAGAGTACAAGTGAAGGTGTCCAACAAG
GGCCTGCCAGCTCCATCGAGAAAACCATCAGCAAGGCCAAGGGCCAGCCCCGCGAGCCTCAAGTGTATACCCTG
CCCCCTTGCCAGGAAGAGATGACCAAGAACCAGGTGTCCCTGTGGTGTCTCGTGAAAGGCTTCTACCCCAGCGACA
TTGCCGTGGAATGGGAGAGCAACGGCCAGCCCCGAGAACAATAACAAGACCACCCCCCTGTGCTGGACAGCGACG
GCTCATTCTTCTGTACTCCAAGCTGACCGTGGACAAGAGCCGGTGGCAGGAAGGCAACGTGTTTCAGCTGCTCCGT
GATGCACGAGGCCCTGCACAACCACTACACCCAGAAGTCCCTGTCTGTCTGTCCCTGGGC 4 228
GACATCCAGATGACCCAGAGCCCCAGCAGCCTGTCTGCCAGCGTGGGCGACAGAGTGACCATCACCTGTAGAGCC
AGCCAGGACGTGAACACCGCCGTGGCCTGGTATCAGCAGAAGCCTGGCAAGGCCCCCAAGCTGCTGATCTACAGC
GCCAGCTTCCCTGTACAGCGGCGTGCCCAGCAGATTCAGCGGAAGCAGAAGCGGCACCGACTTCACCCTGACCATC
AGCTCCCTGCAGCCCAGGACTTCGCCACCTACTACTGCCAGCAGCACTACACCACCCCCCCCCACATTTGGCCAGG
GCACCAAGGTGGAAATCAAGCGTACGGTGGCCGCTCCCAGCGTGTTTCATCTTCCACCTAGCGACGAGCAGCTGA
AGTCCGGCACAGCCTCTGTCTGTGCTGTGAACAACCTTCTACCCCCGCGAGGCCAAAGTGCAGTGGAAGGTGG
ACAACGCCCTGCAGAGCGGCAACAGCCAGGAAAGCGTGACCGAGCAGGACAGCAAGGACTCCACCTACAGCCTG
AGCAGCACCTGACACTGAGCAAGGCCGACTACGAGAAGCACAAGGTGTACGCCTGCGAAGTGACCCACCAGGG
CCTGTCTAGCCCCGTGACCAAGAGCTTCAACCGGGGCGAGTGT HER2/ 1 229
GACATCGTGATGACCCAGACCCCCCTGAGCCTGAGCGTGACACCTGGACAGCCTGCCAGCATCAGCTGCAAGAGC
CD28.sub.sup × CD3.sub.mid
AGCCAGAGCCTGGTGCACGAGAACCTGCAGACCTACCTGAGCTGGTATCTGCAGAAGCCCGGCCAGAGCCCCCAG
(32/33/3435
TCCCTGATCTACAAGGTGTCCAACAGATTCAGCGGCGTGCCCGACAGATTCTCCGGCAGCGGCTCTGGCACCGACT
ENLQ (LC);
TCACCCTGAAGATCAGCCGGGTGGAAGCCGAGGACGTGGGCGTGTACTATTGTGGCCAGGGCACCCAGTACCCCT
DKTHT linkers
TCACCTTTGGCAGCGGCACCAAGGTGGAATCAAGGACAAAACCCATACCGACATCCAGATGACCCAGAGCCCCA
on HC/LC) IgG4
GCAGCCTGTCTGCCAGCGTGGGCGACAGAGTGACCATCACCTGTCAGGCCAGCCAGAACATCTACGTGTGGCTGA
FALA
ACTGGTATCAGCAGAAGCCCGGCAAGGCCCCCAAGCTGCTGATCTACAAGGCCAGCAACCTGCACACCGGCGTGC
BP # 27
CCAGCAGATTTTCTGGCAGCGGCTCCGGCACCGACTTCACCCTGACAATCAGCTCCCTGCAGCCCGAGGACATTGC
CACCTACTACTGCCAGCAGGGCCAGACCTACCCCTACACCTTTGGCCAGGGCACCAAGCTGGAAATCAAGGATAA
GACCCACACCCGTACGGTGGCCGCTCCCAGCGTGTTTCATCTTCCACCTAGCGACGAGCAGCTGAAGTCCGGCACA
GCCTCTGTCTGTGCTGTGAACAACCTTCTACCCCCGCGAGGCCAAAGTGCAGTGGAAGGTGGACAACGCCCTGC
AGAGCGGCAACAGCCAGGAAAGCGTGACCGAGCAGGACAGCAAGGACTCCACCTACAGCCTGAGCAGCACCTG
ACACTGAGCAAGGCCGACTACGAGAAGCACAAGGTGTACGCCTGCGAAGTGACCCACCAGGGCCTGTCTAGCCCC
GTGACCAAGAGCTTCAACCGGGGCGAGTGT 2 230
CAGGTGCAGCTGGTGCAGTCTGGCGCCGAGGTGCTGAAACCTGGCGCCTCTGTGAAGGTGTCCTGCAAGGCCAGC
GGCTACACCTTTACCAGCTACTACATCCACTGGGTGCGCCAGGCCCTGGACAGGGACTGGAATGGATCGGCAGC
ATCTACCCCGGCAACGTGAACACCAACTACGCCCAGAAGTTCCAGGGCAGAGCCACCCTGACCGTGGACACCAGC
ATCAGCACCGCCTACATGGAAGTGAAGCGGCTGAGAAGCGACGACACCGCCGTGTACTACTGCACCCGGTCCCAC
TACGGCCTGGATTGGAACCTTCGACGTGTGGGGCAAGGGCACCCGTGACAGTGTCTAGCGACAAAACCCATACC
CAGGTGCAGCTGGTGGAAATCTGGCGGCGGAGTGGTGCAGCCTGGCAGAAGCCTGAGACTGAGCTGTGCCGCCAGC
GGCTTACCTTACCAAGGCCTGGATGCACTGGGTGCGCCAGGCCCTGGAAAGCAGCTGGAATGGGTGGCCAG
ATCAAGGACAAGAGCAACAGCTACGCCACCTACTACGCCGACAGCGTGAAGGGCCGGTTCACCATCAGCCGGGAC

GACAGCAAGAACACCTGTACCTGCAGATGAACAGCCTGCGGGCCGAGGACACCGCCGTGTACTACTGTGCGGGG
GTGTACTATGCCCTGAGCCCCCTTCGATTACTGGGGCCAGGGAACCCCTCGTGACCGTGTCTAGTGATAAGACCCACA
CCGCCAGCACAAAGGGCCCATCGGTGTTCCCTCTGGCCCCCTTGACAGCAGAAGCACCAGCGAATCTACAGCCGCCCT
GGGCTGCCTCGTGAAGGACTACTTTCCCGAGCCCCGTGACCGTGTCTGGAAGTCTGGCGCTCTGACAAGCGGCGTG
CACACCTTTCCAGCCGTGCTCCAGAGCAGCGGCCTGTACTCTCTGAGCAGCGTCGTGACAGTGCCCAGCAGCAGCC
TGGGCACCAAGACCTACACCTGTAACGTGGACCACAAGCCCAGCAACACCAAGGTGGACAAGCGGGTGAATCTA
AGTACGGCCCTCCCTGCCCTCCTTGCCAGCCCCCTGAAGCTGCCGGCGGACCCCTCCGTGTTCCCTGTTCCCCCAAAG
CCCAAGGACACCCTGATGATCAGCCGGACCCCCGAAGTGACCTGCGTGGTGGTGGATGTGTCCCAGGAAGATCCC
GAGGTGCAGTTCAATTGGTACGTGGACGGCGTGGAAGTGCACAACGCCAAGACCAAGCCCAGAGAGGAACAGTTC
AACAGCACCTACCGGGTGGTGTCCGTGCTGACCGTGCTGCACCAGGACTGGCTGAACGGCAAAGAGTACAAGTGC
AAGGTGTCCAACAAGGGCCTGCCAGCTCCATCGAGAAAACCATCAGCAAGGCCAAGGGCCAGCCCCGCGAGCCT
CAAGTGTGTACCCTGCCCCCTAGCCAGGAAGAGATGACCAAGAACCAGGTGTCCCTGAGCTGTGCCGTGAAAGGC
TTCTACCCCAGCGACATTGCCGTGGAATGGGAGAGCAACGGCCAGCCCCGAGAACAATAACAAGACCACCCCCCT
GTGCTGGACAGCGACGGCTCATTCTTCCTGGTGTCCAAGCTGACCGTGGACAAGAGCCGGTGGCAGGAAGGCAAC
GTGTTACAGCTGCTCCGTGATGCACGAGGCCCTGCACAACCACTACACCCAGAAGTCCCTGTCTCTGTCCCTGGGC

3 231

GAAGTGCAGCTGGTGGAAATCTGGCGGCGGACTGGTGCAGCCTGGCGGATCTCTGAGACTGAGCTGTGCCGCCAGC
GGCTTCAACATCAAGGACACCTACATCCACTGGGTGCGCCAGGCCCTGGCAAGGGACTGGAATGGGTGGCCAGA
ATCTACCCCACCAACGGCTACACCAGATACGCCGACAGCGTGAAGGGCCGGTTCACCATCAGCGCCGACACCAGC
AAGAACACCGCCTACCTGCAGATGAACAGCCTGCGGGCCGAGGACACCGCCGTGTACTACTGTAGTAGATGGGGA
GGCGACGGCTTCTACGCCATGGACTATTGGGGCCAGGGCACCCCTCGTGACCGTGTCTAGTGCGTCGACCAAGGGCC
CATCGGTGTTCCCTCTGGCCCCCTTGACAGCAGAAGCACCAGCGAATCTACAGCCGCCCTGGGCTGCCTCGTGAAGGA
CTACTTTCCCGAGCCCCGTGACCGTGTCTGGAAGTCTGGCGCTCTGACAAGCGGCGTGCACACCTTTCCAGCCGTG
CTCCAGAGCAGCGGCCTGTACTCTCTGAGCAGCGTCGTGACAGTGCCCAGCAGCAGCCTGGGCACCAAGACCTAC
ACCTGTAACGTGGACCACAAGCCCAGCAACACCAAGGTGGACAAGCGGGTGAATCTAAGTACGGCCCTCCCTGC
CCTCCTTGCCCAGCCCCCTGAAGCTGCCGGCGGACCCCTCCGTGTTCCCTGTTCCCCCAAAGCCCAAGGACACCCTGA
TGATCAGCCGGACCCCCGAAGTGACCTGCGTGGTGGTGGATGTGTCCCAGGAAGATCCCGAGGTGCAGTTCAATT
GGTACGTGGACGGCGTGGAAGTGCACAACGCCAAGACCAAGCCCAGAGAGGAACAGTTCAACAGCACCTACCGG
GTGGTGTCCGTGCTGACCGTGCTGCACCAGGACTGGCTGAACGGCAAAGAGTACAAGTGCAAGGTGTCCAACAAG
GGCCTGCCAGCTCCATCGAGAAAACCATCAGCAAGGCCAAGGGCCAGCCCCGCGAGCCTCAAGTGTATACCCTG
CCCCCTTGCCAGGAAGAGATGACCAAGAACCAGGTGTCCCTGTGGTGTCTCGTGAAAGGCTTCTACCCCAGCGACA
TTGCCGTGGAATGGGAGAGCAACGGCCAGCCCGAGAACAATAACAAGACCACCCCCCTGTGCTGGACAGCGACG
GCTCATTCTTCCTGTACTCCAAGCTGACCGTGGACAAGAGCCGGTGGCAGGAAGGCAACGTGTTACAGCTGCTCCGT
GATGCACGAGGCCCTGCACAACCACTACACCCAGAAGTCCCTGTCTCTGTCCCTGGGC

4 232

GACATCCAGATGACCCAGAGCCCCAGCAGCCTGTCTGCCAGCGTGGGCGACAGAGTGACCATCACCTGTAGAGCC
AGCCAGGACGTGAACACCGCCGTGGCCTGGTATCAGCAGAAGCCTGGCAAGGCCCCCAAGCTGCTGATCTACAGC
GCCAGCTTCCTGTACAGCGGCGTGCCCAGCAGATTCAGCGGAAGCAGAAGCGGCACCGACTTCACCCTGACCATC
AGCTCCCTGCAGCCCGAGGACTTCGCCACCTACTACTGCCAGCAGCACTACACCACCCCCCCCCACATTTGGCCAGG
GCACCAAGGTGGAAATCAAGCGTACGGTGGCCGCTCCCAGCGTGTTTCATCTTCCCACCTAGCGACGAGCAGCTGA
AGTCCGGCACAGCCTCTGTCTGTGCTGCTGAACAACCTTCTACCCCCGCGAGGCCAAAGTGCAGTGGAAGGTGG
ACAACGCCCTGCAGAGCGGCAACAGCCAGGAAAGCGTGACCGAGCAGGACAGCAAGGACTCCACCTACAGCCTG
AGCAGCACCCCTGACACTGAGCAAGGCCGACTACGAGAAGCACAAAGGTGTACGCCTGCGAAGTGACCCACCAGGG
CCTGTCTAGCCCCGTGACCAAGAGCTTCAACCGGGGCGAGTGT

HER2/

1

233

GACATCGTGATGACCCAGACCCCCCTGAGCCTGAGCGTGACACCTGGACAGCCTGCCAGCATCAGCTGCAAGAGC
CD28.sub.sup × CD3.sub.mid
AGCCAGAGCCTGGTGCACGAGAACCTGTTACCTACCTGAGCTGGTATCTGCAGAAGCCCGGCCAGAGCCCCCAG
(32/33/3435

TCCCTGATCTACAAGGTGTCCAACAGATTCAGCGGCGTGCCCGACAGATTCTCCGGCAGCGGCTCTGGCACCGACT
ENLF (LC);
TCACCCTGAAGATCAGCCGGGTGGAAGCCGAGGACGTGGGCGTGACTATTGTGGCCAGGGCACCCAGTACCCCT
DKTHT linkers

TCACCTTTGGCAGCGGCACCAAGGTGGAAATCAAGGACAAAACCCATACCGACATCCAGATGACCCAGAGCCCCA
on HC/LC)
GCAGCCTGTCTGCCAGCGTGGGCGACAGAGTGACCATCACCTGTCAGGCCAGCCAGAACATCTACGTGTGGCTGA
IgG4 FALA

ACTGGTATCAGCAGAAGCCCGGCAAGGCCCCCAAGCTGCTGATCTACAAGGCCAGCAACCTGCACACCGGCGTG
BP # 28

CCAGCAGATTTTCTGGCAGCGGCTCCGGCACCGACTTCACCCTGACAATCAGCTCCCTGCAGCCCGAGGACATTGC
CACCTACTACTGCCAGCAGGGCCAGACCTACCCCTACACCTTTGGCCAGGGCACCAAGCTGGAAATCAAGGATAA
GACCCACACCCGTACGGTGGCCGCTCCCAGCGTGTTTCATCTTCCCACCTAGCGACGAGCAGCTGAAGTCCGGCACA
GCCTCTGTCTGTGCTGCTGAACAACCTTCTACCCCCGCGAGGCCAAAGTGCAGTGGAAGGTGGACAACGCCCTGC
AGAGCGGCAACAGCCAGGAAAGCGTGACCGAGCAGGACAGCAAGGACTCCACCTACAGCCTGAGCAGCACCCCTG
ACACTGAGCAAGGCCGACTACGAGAAGCACAAAGGTGTACGCCTGCGAAGTGACCCACCAGGGCCTGTCTAGCCCC

GTGACCAAGAGCTTCAACCGGGGCGAGTGT 2 234

CAGGTGCAGCTGGTGCAGTCTGGCGCCGAGGTCTGTGAAACCTGGCGCCTCTGTGAAGGTGTCCTGCAAGGCCAGC
GGCTACACCTTTACCAGCTACTACATCCACTGGGTGCGCCAGGCCCTGGACAGGGACTGGAATGGATCGGCAGC
ATCTACCCCGGCAACGTGAACACCAACTACGCCCAGAAGTTCCAGGGCAGAGCCACCCTGACCGTGGACACCAGC
ATCAGCACCGCCTACATGGAAGTGAAGCCGGCTGAGAAGCGACGACACCGCCGTGTACTACTGCACCCGGTCCCAC
TACGGCCTGGATTGGAACCTTCGACGTGTGGGGCAAGGGCACCACCGTGACAGTGTCTAGCGACAAAACCCATACC
CAGGTGCAGCTGGTGGAACTCTGGCGGCGGAGTGGTGCAGCCTGGCAGAAGCCTGAGACTGAGCTGTGCCGCCAGC
GGCTTCACCTTCACCAAGGCCTGGATGCACTGGGTGCGCCAGGCCCTGGAAAGCAGCTGGAATGGGTGGCCAG
ATCAAGGACAAGAGCAACAGCTACGCCACCTACTACGCCGACAGCGTGAAGGGCCGGTTACCATCAGCCGGGAC
GACAGCAAGAACACCCTGTACCTGCAGATGAACAGCCTGCGGGCCGAGGACACCGCCGTGTACTACTGTCCGGGC
GTGTACTATGCCCTGAGCCCCCTTCGATTACTGGGGCCAGGGAACCTCGTGACCGTGTCTAGTGATAAGACCCACA
CCGCCAGCACAAAGGGCCCATCGGTGTTCCCTCTGGCCCCCTTGACAGCAGAAGCACCAGCGAATCTACAGCCGCCCT
GGGCTGCCTCGTGAAGGACTACTTTCCCGAGCCCCGTGACCGTGTCTGGAACCTCTGGCGCTCTGACAAGCGGCGTG
CACACCTTTCCAGCCGTGCTCCAGAGCAGCGGCCTGTACTCTCTGAGCAGCGTCGTGACAGTGCCCAGCAGCAGCC
TGGGCACCAAGACCTACACCTGTAACGTGGACCACAAGCCCAGCAACACCAAGGTGGACAAGCGGGTGGAATCTA
AGTACGGCCCTCCCTGCCCTCCTTGCCCAGCCCCCTGAAGCTGCCGGCGGACCCCTCCGTGTTCCCTGTTCCCCCAAAG
CCCAAGGACACCCTGATGATCAGCCGGACCCCCGAAGTGACCTGCGTGGTGGTGGATGTGTCCCAGGAAGATCCC
GAGGTGCAGTTCAATTGGTACGTGGACGGCGTGGAAGTGACAACGCCAAGACCAAGCCCAGAGAGGAACAGTTC
AACAGCACCTACCGGGTGGTGTCCGTGCTGACCGTGTGTCACCAGGACTGGCTGAACGGCAAAGAGTACAAGTGC
AAGGTGTCCAACAAGGGCCTGCCAGCTCCATCGAGAAAACCATCAGCAAGGCCAAGGGCCAGCCCCGCGAGCCT
CAAGTGTGTACCCTGCCCCCTAGCCAGGAAGAGATGACCAAGAACCAGGTGTCCCTGAGCTGTGCCGTGAAAGGC
TTCTACCCAGCGACATTGCCGTGGAATGGGAGAGCAACGGCCAGCCCGAGAACAATAACAAGACCACCCCCCT
GTGCTGGACAGCGACGGCTCATTCTTCCCTGGTGTCCAAGCTGACCGTGGACAAGAGCCGGTGGCAGGAAGGCAAC
GTGTTACAGCTGCTCCGTGATGCACGAGGCCCTGCACAACCACTACACCCAGAAGTCCCTGTCTCTGTCCCTGGGC

3 235

GAAGTGCAGCTGGTGGAACTCTGGCGGCGGACTGGTGCAGCCTGGCGGATCTCTGAGACTGAGCTGTGCCGCCAGC
GGCTTCAACATCAAGGACACCTACATCCACTGGGTGCGCCAGGCCCTGGCAAGGGACTGGAATGGGTGGCCAGA
ATCTACCCACCAACGGCTACACCAGATACGCCGACAGCGTGAAGGGCCGGTTACCATCAGCGCCGACACCAGC
AAGAACACCGCCTACCTGCAGATGAACAGCCTGCGGGCCGAGGACACCGCCGTGTACTACTGTAGTAGATGGGGA
GGCGACGGCTTCTACGCCATGGACTATTGGGGCCAGGGCACCCTCGTGACCGTGTCTAGTGCGTCGACCAAGGGCC
CATCGGTGTTCCCTCTGGCCCCCTTGACAGCAGAAGCACCAGCGAATCTACAGCCGCCCTGGGCTGCCTCGTGAAGGA
CTACTTTCCCGAGCCCCGTGACCGTGTCTGGAACCTCTGGCGCTCTGACAAGCGGCGTGACACCTTTCCAGCCGTG
CTCCAGAGCAGCGGCCTGTACTCTCTGAGCAGCGTCGTGACAGTGCCCAGCAGCAGCCTGGGCACCAAGACCTAC
ACCTGTAACGTGGACCACAAGCCCAGCAACACCAAGGTGGACAAGCGGGTGGAATCTAAGTACGGCCCTCCCTGC
CCTCCTTGCCCAGCCCCCTGAAGCTGCCGGCGGACCCCTCCGTGTTCCCTGTTCCCCCAAAGCCCAAGGACACCCTGA
TGATCAGCCGGACCCCCGAAGTGACCTGCGTGGTGGTGGATGTGTCCCAGGAAGATCCCGAGGTGCAGTTCAATT
GGTACGTGGACGGCGTGGAAGTGACAACGCCAAGACCAAGCCCAGAGAGGAACAGTTCAACAGCACCTACCGG
GTGGTGTCCGTGCTGACCGTGTGTCACCAGGACTGGCTGAACGGCAAAGAGTACAAGTGCAAGGTGTCCAACAAG
GGCCTGCCAGCTCCATCGAGAAAACCATCAGCAAGGCCAAGGGCCAGCCCCGCGAGCCTCAAGTGTATACCCTG
CCCCCTTGCCAGGAAGAGATGACCAAGAACCAGGTGTCCCTGTGGTGTCTCGTGAAAGGCTTCTACCCCAGCGACA
TTGCCGTGGAATGGGAGAGCAACGGCCAGCCCGAGAACAATAACAAGACCACCCCCCTGTGCTGGACAGCGACG
GCTCATTCTTCCCTGTACTCCAAGCTGACCGTGGACAAGAGCCGGTGGCAGGAAGGCAACGTGTTACAGCTGCTCCGT
GATGCACGAGGCCCTGCACAACCACTACACCCAGAAGTCCCTGTCTCTGTCCCTGGGC 4 236

GACATCCAGATGACCCAGAGCCCCAGCAGCCTGTCTGCCAGCGTGGGCGACAGAGTGACCATCACCTGTAGAGCC
AGCCAGGACGTGAACACCGCCGTGGCCTGGTATCAGCAGAAGCCTGGCAAGGCCCCCAAGCTGCTGATCTACAGC
GCCAGCTTCCCTGTACAGCGGCGTGCCCAGCAGATTCAGCGGAAGCAGAAGCGGCACCGACTTCACCCTGACCATC
AGCTCCCTGCAGCCCAGGACTTCGCCACCTACTACTGCCAGCAGCACTACACCACCCCCCCCCACATTTGGCCAGG
GCACCAAGGTGGAAATCAAGCGTACGGTGGCCGCTCCCAGCGTGTTCATCTTCCCACCTAGCGACGAGCAGCTGA
AGTCCGGCACAGCCTCTGTCTGTGCTGCTGAACAACCTTCTACCCCCGCGAGGCCAAAGTGCAAGTGGAAAGTGG
ACAACGCCCTGCAGAGCGGCAACAGCCAGGAAAGCGTGACCGAGCAGGACAGCAAGGACTCCACCTACAGCCTG
AGCAGCACCCCTGACACTGAGCAAGGCCGACTACGAGAAGCACAAGGTGTACGCCTGCGAAGTGACCCACCAGGG
CCTGTCTAGCCCCGTGACCAAGAGCTTCAACCGGGGCGAGTGT anti- 1 237

GACATCGTGATGACCCAGACCCCCCTGAGCCTGAGCGTGACACCTGGACAGCCTGCCAGCATCAGCTGCAAGAGC
Her2/CD3/3CD28

AGCCAGAGCCTGGTGCACAACAACGCCAACACCTACCTGAGCTGGTATCTGCAGAAGCCCGGCCAGAGCCCCCAG
IgG4 FALA

TCCCTGATCTACAAGGTGTCCAACAGATTACAGCGGCGTGCCCCAGAGATTCTCCGGCAGCGGCTCTGGCACCGACT
BP # 29

TCACCCTGAAGATCAGCCGGGTGGAAGCCGAGGACGTGGGCGTGTACTATTGTGGCCAGGGCACCCAGTACCCCT
TCACCTTTGGCAGCGGCACCAAGGTGGAAATCAAGGGCCAGCCCAAGGCCGCCCCCGACATCCAGATGACCCAGA
GCCCCAGCAGCCTGTCTGCCAGCGTGGGCGACAGAGTGACCATCACCTGTCAGGCCAGCCAGAACATCTACGTGT
GGCTGAACTGGTATCAGCAGAAGCCCGGCAAGGCCCCCAAGCTGCTGATCTACAAGGCCAGCAACCTGCACACCG
CGGTGCCAGCAGATTTTCTGGCAGCGGCTCCGGCACCGACTTCACCCTGACAATCAGCTCCCTGCAGCCCCAGGA

CATTGCCACTACTGCTACGAGCCAGGGCCAGACCTACACCTTTGGCCACGGCACCAGCTGGAAATCAAG
ACCAAGGGCCCCAGCCGTACGGTGGCCGCTCCCAGCGTGTTTCATCTTCCCACCTAGCGACGAGCAGCTGAAGTCCG
GCACAGCCTCTGTCTGTGCTGTGAACAACTTCTACCCCCGCGAGGCCAAAGTGCAGTGGAAGGTGGACAACG
CCCTGCAGAGCGGCAACAGCCAGGAAAGCGTGACCGAGCAGGACAGCAAGGACTCCACCTACAGCCTGAGCAGC
ACCCTGACACTGAGCAAGGCCGACTACGAGAAGCACAAGGTGTACGCCTGCGAAGTGACCCACCAGGGCCTGTCT
AGCCCCGTGACCAAGAGCTTCAACCGGGGCGAGTGT 2 238
CAGGTGCAGCTGGTGCAGTCTGGCGCCGAGGTCGTGAAACCTGGCGCCTCTGTGAAGGTGTCCTGCAAGGCCAGC
GGCTACACCTTTACCAGCTACTACATCCACTGGGTGCGCCAGGCCCTGGACAGGGACTGGAATGGATCGGCAGC
ATCTACCCCCGCAACGTGAACACCAACTACGCCCAGAAGTTCCAGGGCAGAGCCACCCTGACCGTGACACCAGC
ATCAGCACCGCCTACATGGAAGTGAAGCGGCTGAGAAGCGACGACACCGCCGTGTACTACTGCACCCGGTCCCAC
TACGGCCTGGATTGGAAGTTCGACGTGTGGGGCAAGGGCACCACCGTGACAGTGTCTAGCAGCCAGGTGCAGCTG
GTGGAATCTGGCGGCGGAGTGGTGCAGCCTGGCAGAAGCCTGAGACTGAGCTGTGCCGCCAGCGGCTTCACCTTC
ACCAAGGCCTGGATGCACTGGGTGCGCCAGGCCCTGGAAAGCAGCTGGAATGGGTGGCCAGATCAAGGACAA
GAGCAACAGCTACGCCACCTACTACGCCGACAGCGTGAAGGGCCGGTTTACCATCAGCCGGGACGACAGCAAGAA
CACCTGTACCTGCAGATGAACAGCCTGCGGGCCGAGGACACCGCCGTGTACTACTGTGCGGGCGTGTACTATGCC
CTGAGCCCCCTTCGATTACTGGGGCCAGGGAACCTCGTGACCGTGTCTAGTCGGACCGCCAGCACAAAGGGCCCAT
CGGTGTTCCCTCTGGCCCCCTTGACAGCAGAAGCACCAGCGAATCTACAGCCGCCCTGGGCTGCCTCGTGAAGGACTA
CTTCCCGAGCCCCGTGACCGTGTCTGGAAGTCTGGCGCTCTGACAAGCGGCGTGCACACCTTTCCAGCCGTGCTC
CAGAGCAGCGGCCTGTACTCTCTGAGCAGCGTTCGTGACAGTGGCCAGCAGCAGCCTGGGCACCAAGACCTACACC
TGTAACGTGGACCACAAGCCCAGCAACACCAAGGTGGACAAGCGGGTGGAAATCTAAGTACGGCCCTCCCTGCCCT
CCTTGCCCAGCCCCCTGAAGCTGCCGGCGGACCCCTCCGTGTTCTGTTCCCCCCAAAGCCCAAGGACACCCTGATGA
TCAGCCGGACCCCCGAAGTGACCTGCGTGGTGGTGGATGTGTCCCAGGAAGATCCCGAGGTGCAGTTCAATTGGT
ACGTGGACGGCGTGGAAGTGACAACGCCAAGACCAAGCCCAGAGAGGAACAGTTCAACAGCACCTACCGGGTG
GTGTCCGTGCTGACCGTGTGTCACCAGGACTGGCTGAACGGCAAAGAGTACAAGTGCAAGGTGTCCAACAAGGGC
CTGCCCAGCTCCATCGAGAAAACCATCAGCAAGGCCAAGGGCCAGCCCCGCGAGCCTCAAGTGTGTACCCTGCCC
CCTAGCCAGGAAGAGATGACCAAGAACCAGGTGTCCCTGAGCTGTGCCGTGAAAGGCTTCTACCCCAGCGACATT
GCCGTGGAATGGGAGAGCAACGGCCAGCCCGAGAACAATAAGACCACCCCCCTGTGCTGGACAGCGACGG
CTCATTCTTCTGTGTCCAAGCTGACCGTGGACAAGAGCCGGTGGCAGGAAGGCAACGTGTTTCAGCTGCTCCGTG
ATGCACGAGGCCCTGCACAACCACTACACCCAGAAGTCCCTGTCTCTGTCCCTGGGC 3 239
GAAGTGCAGCTGGTGGAAATCTGGCGGCGGACTGGTGCAGCCTGGCGGATCTCTGAGACTGAGCTGTGCCGCCAGC
GGCTTCAACATCAAGGACACCTACATCCACTGGGTGCGCCAGGCCCTGGCAAGGGACTGGAATGGGTGGCCAGA
ATCTACCCCACCAACGGCTACACCAGATACGCCGACAGCGTGAAGGGCCGGTTTACCATCAGCGCCGACACCAGC
AAGAACACCGCCTACCTGCAGATGAACAGCCTGCGGGCCGAGGACACCGCCGTGTACTACTGTAGTAGATGGGGA
GGCGACGGCTTCTACGCCATGGACTATTGGGGCCAGGGCACCCCTCGTGACCGTGTCTAGTGCCTCGACCAAGGGCC
CATCGGTGTTCCCTCTGGCCCCCTTGACAGCAGAAGCACCAGCGAATCTACAGCCGCCCTGGGCTGCCTCGTGAAGGA
CTACTTTCCCGAGCCCGTGACCGTGTCTCTGGAAGTCTGGCGCTCTGACAAGCGGCGTGCACACCTTTCCAGCCGTG
CTCCAGAGCAGCGGCCTGTACTCTCTGAGCAGCGTTCGTGACAGTGGCCAGCAGCAGCCTGGGCACCAAGACCTAC
ACCTGTAACGTGGACCACAAGCCCAGCAACACCAAGGTGGACAAGCGGGTGGAAATCTAAGTACGGCCCTCCCTGC
CCTCCTTGCCCAGCCCCCTGAAGCTGCCGGCGGACCCCTCCGTGTTCTGTTCCCCCCAAAGCCCAAGGACACCCTGA
TGATCAGCCGGACCCCCGAAGTGACCTGCGTGGTGGTGGATGTGTCCCAGGAAGATCCCGAGGTGCAGTTCAATT
GGTACGTGGACGGCGTGGAAGTGACAACGCCAAGACCAAGCCCAGAGAGGAACAGTTCAACAGCACCTACCGG
GTGGTGTCCGTGCTGACCGTGTGTCACCAGGACTGGCTGAACGGCAAAGAGTACAAGTGCAAGGTGTCCAACAAG
GGCCTGCCCAGCTCCATCGAGAAAACCATCAGCAAGGCCAAGGGCCAGCCCCGCGAGCCTCAAGTGTATACCCTG
CCCCCTTGCCAGGAAGAGATGACCAAGAACCAGGTGTCCCTGTGGTGTCTCGTGAAAGGCTTCTACCCCAGCGACA
TTGCCGTGGAATGGGAGAGCAACGGCCAGCCCGAGAACAATAAGACCACCCCCCTGTGCTGGACAGCGACG
GCTCATTCTTCTGTACTCCAAGCTGACCGTGGACAAGAGCCGGTGGCAGGAAGGCAACGTGTTTCAGCTGCTCCGT
GATGCACGAGGCCCTGCACAACCACTACACCCAGAAGTCCCTGTCTCTGTCCCTGGGC 4 240
GACATCCAGATGACCCAGAGCCCCAGCAGCCTGTCTGCCAGCGTGGGCGACAGAGTGACCATCACCTGTAGAGCC
AGCCAGGACGTGAACACCGCCGTGGCCTGGTATCAGCAGAAGCCTGGCAAGGGCCCCCAAGCTGCTGATCTACAGC
GCCAGCTTCCCTGTACAGCGGCGTGCCCAGCAGATTCAGCGGAAGCAGAAGCGGCACCGACTTCACCCTGACCATC
AGCTCCCTGCAGCCCAGGACTTCGCCACCTACTACTGCCAGCAGCACTACACCACCCCCCCCCACATTTGGCCAGG
GCACCAAGGTGGAAATCAAGCGTACGGTGGCCGCTCCCAGCGTGTTTCATCTTCCCACCTAGCGACGAGCAGCTGA
AGTCCGGCACAGCCTCTGTCTGTGCTGTGAACAACTTCTACCCCCGCGAGGCCAAAGTGCAGTGGAAGGTGG
ACAACGCCCTGCAGAGCGGCAACAGCCAGGAAAGCGTGACCGAGCAGGACAGCAAGGACTCCACCTACAGCCTG
AGCAGCACCCCTGACACTGAGCAAGGCCGACTACGAGAAGCACAAGGTGTACGCCTGCGAAGTGACCCACCAGGG
CCTGTCTAGCCCCGTGACCAAGAGCTTCAACCGGGGCGAGTGT HER230R/55Q/ 1 241
GACATCGTGATGACCCAGACCCCCCTGAGCCTGAGCGTGACACCTGGACAGCCTGCCAGCATCAGCTGCAAGAGC
102E/
AGCCAGAGCCTGGTGCACGAGAACCTGCGTACCTACCTGAGCTGGTATCTGCAGAAGCCCGGCCAGAGCCCCCAG
CD28.sub.sup × CD3.sub.mid
TCCCTGATCTACAAGGTGTCCAACAGATTCAGCGGCGTGCCCCAGACAGATTCTCCGGCAGCGGCTCTGGCACCGACT
(32/33/3435
TCACCCTGAAGATCAGCCGGGTGGAAGCCGAGGACGTGGGCGTGTACTATTGTGGCCAGGGCACCCAGTACCCCT

ENLR (LC);

TCACCTTTGGCAGCGGCACCAAGGTGGAAATCAAGGACAAAACCCATACCGACATCCAGATGACCCAGAGCCCCA
DKTHT linkers

GCAGCCTGTCTGCCAGCGTGGGCGACAGAGTGACCATCACCTGTGAGGCCAGCCAGAACATCTACGTGTGGCTGA
on HC/LC)

ACTGGTATCAGCAGAAGCCCCGGCAAGGCCCCCAAGCTGCTGATCTACAAGGCCAGCAACCTGCACACCGGCGTGC
IgG4 FALA

CCAGCAGATTTTCTGGCAGCGGCTCCGGCACCGACTTCACCCTGACAATCAGCTCCCTGCAGCCCGAGGACATTGC
BP # 31

CACCTACTACTGCCAGCAGGGCCAGACCTACCCCTACACCTTTGGCCAGGGCACCAAGCTGGAAATCAAGGATAA
GACCCACACCCGTACGGTGGCCGCTCCCAGCGTGTTTCATCTTCCCACCTAGCGACGAGCAGCTGAAGTCCGGCACA
GCCTCTGTCTGTGCTGCTGAACAACTTCTACCCCCGCGAGGCCAAAGTGCAGTGGAAGGTGGACAACGCCCTGC
AGAGCGGCAACAGCCAGGAAAGCGTGACCGAGCAGGACAGCAAGGACTCCACCTACAGCCTGAGCAGCACCCCTG
ACACTGAGCAAGGCCGACTACGAGAAGCACAAGGTGTACGCCTGCGAAGTGACCCACCAGGGCCTGTCTAGCCCC
GTGACCAAGAGCTTCAACCGGGGCGAGTGT 2 242

CAGGTGCAGCTGGTGCAGTCTGGCGCCGAGGTGCTGAAACCTGGCGCCTCTGTGAAGGTGTCCTGCAAGGCCAGC
GGCTACACCTTTACCAGCTACTACATCCACTGGGTGCGCCAGGCCCTGGACAGGGACTGGAATGGATCGGCAGC
ATCTACCCCGGCAACGTGAACACCAACTACGCCCAGAAGTTCCAGGGCAGAGCCACCCTGACCGTGGACACCAGC
ATCAGCACCGCCTACATGGAAGTGAAGCGGCTGAGAAGCGACGACACCGCCGTGTACTACTGCACCCGGTCCCAC
TACGGCCTGGATTGGAAGTTCGACGTGTGGGGCAAGGGCACACCGTGACAGTGTCTAGCGACAAAACCCATACC
CAGGTGCAGCTGGTGGAAATCTGGCGGCGGAGTGGTGCAGCCTGGCAGAAGCCTGAGACTGAGCTGTGCCGCCAGC
GGCTTCACCTTCACCAAGGCCTGGATGCACTGGGTGCGCCAGGCCCTGGAAAGCAGCTGGAATGGGTGGCCCGAG
ATCAAGGACAAGAGCAACAGCTACGCCACCTACTACGCCGACAGCGTGAAGGGCCGGTTTACCATCAGCCGGGAC
GACAGCAAGAACACCCTGTACCTGCAGATGAACAGCCTGCGGGCCGAGGACACCGCCGTGTACTACTGTGCGGGC
GTGTACTATGCCCTGAGCCCCCTTCGATTACTGGGGCCAGGGAACCCCTCGTGACCGTGTCTAGTGATAAGACCCACA
CCGCCAGCACAAAGGGCCCATCGGTGTTCCCTCTGGCCCCCTTGACAGCAGAAGCACCCAGCGAATCTACAGCCGCCCT
GGGCTGCCTCGTGAAGGACTACTTTCCCGAGCCCGTGACCGTGTCTGGAAGTCTGGCGCTCTGACAAGCGGCGTG
CACACCTTTCCAGCCGTGCTCCAGAGCAGCGGCCTGTACTCTCTGAGCAGCGTCTGTGACAGTGCCCAGCAGCAGCC
TGGGCACCAAGACCTACACCTGTAACGTGGACCACAAGCCCAGCAACACCAAGGTGGACAAGCGGGTGAATCTA
AGTACGGCCCTCCCTGCCCTCCTTGCCAGCCCCCTGAAGCTGCCGGCGGACCCCTCCGTGTTCCCTGTTCCCCCAAAG
CCCAAGGACACCCTGATGATCAGCCGGACCCCCGAAGTGACCTGCGTGGTGGTGGATGTGTCCCAGGAAGATCCC
GAGGTGCAGTTCAATTGGTACGTGGACGGCGTGGAAGTGACACAACGCCAAGACCAAGCCCAGAGAGGAACAGTTC
AACAGCACCTACCGGGTGGTGTCCGTGCTGACCGTGTCTGCACCAGGACTGGCTGAACGGCAAAGAGTACAAGTGC
AAGGTGTCCAACAAGGGCCTGCCAGCTCCATCGAGAAAACCATCAGCAAGGCCAAGGGCCAGCCCCGCGAGCCT
CAAGTGTGTACCCTGCCCCCTAGCCAGGAAGAGATGACCAAGAACCAGGTGTCCCTGAGCTGTGCCGTGAAAGGC
TTCTACCCAGCGACATTGCCGTGGAATGGGAGAGCAACGGCCAGCCCGAGAACAACTACAAGACCACCCCCCT
GTGCTGGACAGCGACGGCTCATTCTTCCCTGGTGTCCAAGCTGACCGTGGACAAGAGCCGGTGGCAGGAAGGCAAC
GTGTTTACAGCTGCTCCGTGATGCACGAGGCCCTGCACAACCACTACACCCAGAAGTCCCTGTCTCTGTCCCTGGGC
3 243

GAAGTGCAGCTGGTGGAAATCTGGCGGCGGACTGGTGCAGCCTGGCGGATCTCTGAGACTGAGCTGTGCCGCCAGC
GGCTTCAACATCCGGGACACCTACATCCACTGGGTGCGCCAGGCCCTGGCAAGGGACTGGAATGGGTGGCCAGA
ATCTACCCACCCAGGGCTACACCAGATACGCCGACAGCGTGAAGGGCCGGTTTACCATCAGCGCCGACACCAGC
AAGAACACCGCCTACCTGCAGATGAACAGCCTGCGGGCCGAGGACACCGCCGTGTACTACTGTAGTAGATGGGGA
GGCGAAGGCTTCTACGCCATGGACTATTGGGGCCAGGGCACCCCTCGTGACCGTGTCTAGTGCGTCGACCAAGGGC
CCATCGGTGTTCCCTCTGGCCCCCTTGACAGCAGAAGCACCCAGCGAATCTACAGCCGCCCTGGGCTGCCTCGTGAAGG
ACTACTTTCCCGAGCCCGTGACCGTGTCTGGAAGTCTGGCGCTCTGACAAGCGGCGTGCACACCTTTCCAGCCGT
GCTCCAGAGCAGCGGCCTGTACTCTCTGAGCAGCGTCTGTGACAGTGCCCAGCAGCAGCCTGGGCACCAAGACCTA
CACCTGTAACGTGGACCACAAGCCCAGCAACACCAAGGTGGACAAGCGGGTGAATCTAAGTACGGCCCTCCCTG
CCCTCCTTGCCCAGCCCCCTGAAGCTGCCGGCGGACCCCTCCGTGTTCCCTGTTCCCCCAAAGCCCAAGGACACCCCTG
ATGATCAGCCGGACCCCCGAAGTGACCTGCGTGGTGGTGGATGTGTCCCAGGAAGATCCCGAGGTGCAGTTCAAT
TGGTACGTGGACGGCGTGGAAGTGACACAACGCCAAGACCAAGCCCAGAGAGGAACAGTTCAACAGCACCTACCG
GGTGGTGTCCGTGCTGACCGTGTCTGCACCAGGACTGGCTGAACGGCAAAGAGTACAAGTGCAAGGTGTCCAACAA
GGGCCTGCCAGCTCCATCGAGAAAACCATCAGCAAGGCCAAGGGCCAGCCCCGCGAGCCTCAAGTGTATACCCT
GCCCCCTTGCCAGGAAGAGATGACCAAGAACCAGGTGTCCCTGTGGTGTCTCGTGAAAGGCTTCTACCCAGCGAC
ATTGCCGTGGAATGGGAGAGCAACGGCCAGCCCGAGAACAACTACAAGACCACCCCCCTGTGCTGGACAGCGAC
GGCTCATTCTTCCCTGTACTCCAAGCTGACCGTGGACAAGAGCCGGTGGCAGGAAGGCAACGTGTTTACAGCTGCTCCG
TGATGCACGAGGCCCTGCACAACCACTACACCCAGAAGTCCCTGTCTGTCCCTGGGC 4 244

GACATCCAGATGACCCAGAGCCCCAGCAGCCTGTCTGCCAGCGTGGGCGACAGAGTGACCATCACCTGTAGAGCC
AGCCAGGACGTGAACACCGCCGTGGCCTGGTATCAGCAGAAGCCTGGCAAGGCCCCCAAGCTGCTGATCTACAGC
GCCAGCTTCCCTGTACAGCGGCGTGCCCAGCAGATTCAGCGGAAGCAGAAGCGGCACCGACTTCACCCTGACCATC
AGCTCCCTGCAGCCCGAGGACTTCGCCACCTACTACTGCCAGCAGCACTACACCACCCCCCCCCACATTTGGCCAGG
GCACCAAGGTGGAAATCAAGCGTACGGTGGCCGCTCCCAGCGTGTTTCATCTTCCCACCTAGCGACGAGCAGCTGA
AGTCCGGCACAGCCTCTGTCTGTGCTGCTGAACAACTTCTACCCCCGCGAGGCCAAAGTGCAGTGGAAGGTGG

ACCAACCTGTCAGAGCGGCAACAGCCAGGAAAGCGTGACCGAGCAGGACAGCAAGGACTCCACCTACAGCCTG
AGCAGCACCTGACACTGAGCAAGGCCGACTACGAGAAGCACAAGGTGTACGCCTGCGAAGTGACCCACCAGGG
CCTGTCTAGCCCCGTGACCAAGAGCTTCAACCGGGGCGAGTGT CD38VH1/ 1 245
GACATCGTGATGACCCAGACCCCCCTGAGCCTGAGCGTGACACCTGGACAGCCTGCCAGCATCAGCTGCAAGAGC
CD28sup ×
AGCCAGAGCCTGGTGCACGAGAACCTGTTCACCTACCTGAGCTGGTATCTGCAGAAGCCCGGCCAGAGCCCCCAG
CD3mid_ENLQ
TCCCTGATCTACAAGGTGTCCAACAGATTCAGCGGCGTGCCCGACAGATTCTCCGGCAGCGGCTCTGGCACCGACT
DKTHT IgG4
TCACCCTGAAGATCAGCCGGGTGGAAGCCGAGGACGTGGGCGTGTACTATTGTGGCCAGGGCACCCAGTACCCCT
FALA
TCACCTTTGGCAGCGGCACCAAGGTGGAATCAAGGACAAAACCCATACCGACATCCAGATGACCCAGAGCCCCA
BP # 1
GCAGCCTGTCTGCCAGCGTGGGCGACAGAGTGACCATCACCTGTCAGGCCAGCCAGAACATCTACGTGTGGCTGA
ACTGGTATCAGCAGAAGCCCGGCAAGGCCCCCAAGCTGCTGATCTACAAGGCCAGCAACCTGCACACCGGCGTGC
CCAGCAGATTTTCTGGCAGCGGCTCCGGCACCGACTTCACCCTGACAATCAGCTCCCTGCAGCCCGAGGACATTGC
CACCTACTACTGCCAGCAGGGCCAGACCTACCCCTACACCTTTGGCCAGGGCACCAAGCTGGAATCAAGGATAA
GACCCACACCCGTACGGTGGCCGCTCCCAGCGTGTTCATCTTCCCACCTAGCGACGAGCAGCTGAAGTCCGGCACA
GCCTCTGTCTGTGCTGCTGAACAACTTCTACCCCCGCGAGGCCAAAGTGCAGTGGAAGGTGGACAACGCCCTGC
AGAGCGGCAACAGCCAGGAAAGCGTGACCGAGCAGGACAGCAAGGACTCCACCTACAGCCTGAGCAGCACCCCTG
ACACTGAGCAAGGCCGACTACGAGAAGCACAAGGTGTACGCCTGCGAAGTGACCCACCAGGGCCTGTCTAGCCCC
GTGACCAAGAGCTTCAACCGGGGCGAGTGT 2 246
CAGGTGCAGCTGGTGCAGTCTGGCGCCGAGGTCGTGAAACCTGGCGCCTCTGTGAAGGTGTCCTGCAAGGCCAGC
GGCTACACCTTTACCAGCTACTACATCCACTGGGTGCGCCAGGCCCTGGACAGGGACTGGAATGGATCGGCAGC
ATCTACCCCGGCAACGTGAACACCAACTACGCCCAGAAGTTCCAGGGCAGAGCCACCCTGACCGTGGACACCAGC
ATCAGCACCGCCTACATGGAAGTGAAGCGGCTGAGAAGCGACGACACCGCCGTGTACTACTGCACCCGGTCCCAC
TACGGCCTGGATTGGAAGTTCGACGTGTGGGGCAAGGGCACACCGTGACAGTGTCTAGCGACAAAACCCATACC
CAGGTGCAGCTGGTGGAACTCTGGCGGCGGAGTGGTGCAGCCTGGCAGAAGCCTGAGACTGAGCTGTGCCGCCAGC
GGCTTCACCTTCACCAAGGCCTGGATGCACTGGGTGCGCCAGGCCCTGGAAAGCAGCTGGAATGGGTGGCCAG
ATCAAGGACAAGAGCAACAGCTACGCCACCTACTACGCCGACAGCGTGAAGGGCCGGTTACCATCAGCCGGGAC
GACAGCAAGAACACCCTGTACCTGCAGATGAACAGCCTGCGGGCCGAGGACACCGCCGTGTACTACTGTCCGGGC
GTGTACTATGCCCTGAGCCCCCTTCGATTACTGGGGCCAGGGAACCCCTCGTGACCGTGTCTAGTGATAAGACCCACA
CCGCCAGCACAAAGGGCCCATCGGTGTTCCCTCTGGCCCCCTTGACAGCAGAAGCACCAGCGAATCTACAGCCGCCCT
GGGCTGCCTCGTGAAGGACTACTTTCCCGAGCCCGTGACCGTGTCTGGAAGTCTGGCGCTCTGACAAGCGGCGTG
CACACCTTTCCAGCCGTGCTCCAGAGCAGCGGCCTGTACTCTCTGAGCAGCGTCTGTGACAGTGCCCAGCAGCAGCC
TGGGCACCAAGACCTACACCTGTAACGTGGACCACAAGCCCAGCAACACCAAGGTGGACAAGCGGGTGGAATCTA
AGTACGGCCCTCCCTGCCCTCCTTGCCCAGCCCCCTGAAGCTGCCGGCGGACCCCTCCGTGTTCTGTTCCCCCAAAG
CCCAAGGACACCCTGATGATCAGCCGGACCCCCGAAGTGACCTGCGTGGTGGTGGATGTGTCCCAGGAAGATCCC
GAGGTGCAGTTCAATTGGTACGTGGACGGCGTGGAAGTGACACAACGCCAAGACCAAGCCCAGAGAGGAACAGTTC
AACAGCACCTACCGGGTGGTGTCCGTGCTGACCGTGTCTGCACCAGGACTGGCTGAACGGCAAAGAGTACAAGTGC
AAGGTGTCCAACAAGGGCCTGCCAGCTCCATCGAGAAAACCATCAGCAAGGCCAAGGGCCAGCCCCGCGAGCCT
CAAGTGTGTACCCTGCCCCCTAGCCAGGAAGAGATGACCAAGAACCAGGTGTCCCTGAGCTGTGCCGTGAAAGGC
TTCTACCCCAGCGACATTGCCGTGGAATGGGAGAGCAACGGCCAGCCCCGAGAACAACCTACAAGACCACCCCCCT
GTGCTGGACAGCGACGGCTCATTTCTTCTGGTGTCCAAGCTGACCGTGGACAAGAGCCGGTGGCAGGAAGGCAAC
GTGTTACAGCTGCTCCGTGATGCACGAGGCCCTGCACAACCACTACACCCAGAAGTCCCTGTCTCTGTCCCTGGGC
3 247
CAGGTGCAGCTGGTGCAGTCTGGCGCCGAAGTCGTGAAACCTGGCGCCTCCGTGAAGGTGTCCTGCAAGGCCAGC
GGCTACACCTTTACCAGCTACGCCATGCACTGGGTCAAAGAGGCCCTGGCCAGAGACTGGAATGGATCGGCTAC
ATCTACCCCGGCCAGGGCGGCACCAACTACAACCAGAAGTTCCAGGGCAGAGCCACCCTGACCGCCGATACAAGC
GCCAGCACCGCCTACATGGAAGTGAAGCGCCTGCGGAGCGAGGATACCGCCGTGTACTTCTGTGCCAGAACAGGC
GGCCTGAGGCGGGCCTACTTTACCTATTGGGGCCAGGGCACCCCTCGTGACCGTGTCTAGCGCTAGCACAAAGGGCC
CATCGGTGTTCCCTCTGGCCCCCTTGACAGCAGAAGCACCAGCGAATCTACAGCCGCCCTGGGCTGCCTCGTGAAGGA
CTACTTTCCCGAGCCCGTGACCGTGTCTGGAAGTCTGGCGCTCTGACAAGCGGCGTGACACCTTTCCAGCCGTG
CTCCAGAGCAGCGGCCTGTACTCTCTGAGCAGCGTCTGTGACAGTGCCCAGCAGCAGCCTGGGCACCAAGACCTAC
ACCTGTAACGTGGACCACAAGCCCAGCAACACCAAGGTGGACAAGCGGGTGGAATCTAAGTACGGCCCTCCCTGC
CCTCCTTGCCCAGCCCCCTGAAGCTGCCGGCGGACCCCTCCGTGTTCTGTTCCCCCAAAGCCCAAGGACACCCTGA
TGATCAGCCGGACCCCCGAAGTGACCTGCGTGGTGGTGGATGTGTCCCAGGAAGATCCCGAGGTGCAGTTCAATT
GGTACGTGGACGGCGTGGAAGTGACACAACGCCAAGACCAAGCCCAGAGAGGAACAGTTCAACAGCACCTACCGG
GTGGTGTCCGTGCTGACCGTGTCTGCACCAGGACTGGCTGAACGGCAAAGAGTACAAGTGCAAGGTGTCCAACAAG
GGCCTGCCAGCTCCATCGAGAAAACCATCAGCAAGGCCAAGGGCCAGCCCCGCGAGCCTCAAGTGTATACCCTG
CCCCCTTGCCAGGAAGAGATGACCAAGAACCAGGTGTCCCTGTGGTGTCTCGTGAAAGGCTTCTACCCCAGCGACA
TTGCCGTGGAATGGGAGAGCAACGGCCAGCCCCGAGAACAACCTACAAGACCACCCCCCTGTGCTGGACAGCGACG
GCTCATTCTTCTGTACTCCAAGCTGACCGTGGACAAGAGCCGGTGGCAGGAAGGCAACGTGTTACAGCTGCTCCGT

GATGCGACGAGCCCTGCACAACCACTACACCAAGAAGTCCCTGTCTCTGTCCCTGGGC 4 248
GACATCGTGTGCTGACACAGAGCCCTGCCACCCTGTCTCTGAGCCCTGGCGAGAGAGCCACCATCAGCTGTAGAGCC
AGCCAGAGCGTGTCCAGCTACGGCCAGGGCTTCATGCACTGGTATCAGCAGAAGCCCGGCCAGCCCCCAGACTG
CTGATCTATGGCGCCAGCAGCAGAGCCACAGGCATCCCCGCCAGATTTTCTGGCTCTGGCAGCGGCACCGACTTCA
CCCTGACAATCAGCCCCCTGGAACCCGAGGACTTCGCCGTGTACTACTGCCAGCAGAACAAAGAGGACCCCTGGA
CCTTCGGCGGAGGCACCAAGCTGGAATCAAGCGTACGGTGGCCGCTCCAGCGTGTTTCATCTTCCCACCTAGCGA
CGAGCAGCTGAAGTCCGGCACAGCCTCTGTCTGTGCTGCTGAACAACTTCTACCCCCGCGAGGCCAAGGTGCAG
TGGAAGGTGGACAATGCCCTGCAGAGCGGCAACAGCCAGGAAAGCGTGACCGAGCAGGACAGCAAGGACTCCAC
CTACAGCCTGAGCAGCACCCTGACCCTGTCCAAGGCCGATTACGAGAAGCACAAGGTGTACGCCTGCGAAGTGAC
CCACCAGGGCCTGTCTAGCCCCGTGACCAAGAGCTTCAACCGGGGCGAGTGC CD38hhy992/ 1 249
GACATCGTGATGACCCAGACCCCCCTGAGCCTGAGCGTGACACCTGGACAGCCTGCCAGCATCAGCTGCAAGAGC
CD28sup ×
AGCCAGAGCCTGGTGCACGAGAACCTGCAGACCTACCTGAGCTGGTATCTGCAGAAGCCCGGCCAGAGCCCCCAG
CD3mid_ENLQ
TCCCTGATCTACAAGGTGTCCAACAGATTCAGCGGCGTGCCCGACAGATTCTCCGGCAGCGGCTCTGGCACCGACT
DKTHT IgG4
TCACCCTGAAGATCAGCCGGGTGGAAGCCGAGGACGTGGGCGTGACTATTGTGGCCAGGGCACCCAGTACCCCT
FALA
TCACCTTTGGCAGCGGCACCAAGGTGGAATCAAGGACAAAACCCATACCGACATCCAGATGACCCAGAGCCCCA
BP # 5
GCAGCCTGTCTGCCAGCGTGGGCGACAGAGTGACCATCACCTGTGAGGCCAGCCAGAACATCTACGTGTGGCTGA
ACTGGTATCAGCAGAAGCCCGGCAAGGCCCCCAAGCTGCTGATCTACAAGGCCAGCAACCTGCACACCGGCGTGC
CCAGCAGATTTTCTGGCAGCGGCTCCGGCACCGACTTCACCCTGACAATCAGCTCCCTGCAGCCCGAGGACATTGC
CACCTACTACTGCCAGCAGGGCCAGACCTACCCCTACACCTTTGGCCAGGGCACCAAGCTGGAATCAAGGATAA
GACCCACACCCGTACGGTGGCCGCTCCAGCGTGTTTCATCTTCCCACCTAGCGACGAGCAGCTGAAGTCCGGCACA
GCCTCTGTCTGTGCTGCTGCTGAACAACTTCTACCCCCGCGAGGCCAAAGTGCAGTGGAAGGTGGACAACGCCCTGC
AGAGCGGCAACAGCCAGGAAAGCGTGACCGAGCAGGACAGCAAGGACTCCACCTACAGCCTGAGCAGCACCCTG
ACACTGAGCAAGGCCGACTACGAGAAGCACAAGGTGTACGCCTGCGAAGTGACCCACCAGGGCCTGTCTAGCCCC
GTGACCAAGAGCTTCAACCGGGGCGAGTGT 2 250
CAGGTGCAGCTGGTGCAGTCTGGCGCCGAGGTCGTGAAACCTGGCGCCTCTGTGAAGGTGTCCTGCAAGGCCAGC
GGCTACACCTTTACCAGCTACTACATCCACTGGGTGCGCCAGGCCCTGGACAGGGACTGGAATGGATCGGCAGC
ATCTACCCCGGCAACGTGAACACCAACTACGCCCAGAAGTTCCAGGGCAGAGCCACCCTGACCGTGACACCCAGC
ATCAGCACCGCCTACATGGAAGTGAAGCCGGCTGAGAAGCGACGACACCGCCGTGTACTACTGCACCCGGTCCCAC
TACGGCCTGGATTGGAAGTTCGACGTGTGGGGCAAGGGCACCAACCGTGACAGTGTCTAGCGACAAAACCCATACC
CAGGTGCAGCTGGTGGAACTCTGGCGGCGGAGTGGTGCAGCCTGGCAGAAGCCTGAGACTGAGCTGTGCCGCCAGC
GGCTTCACCTTCACCAAGGCCTGGATGCACTGGGTGCGCCAGGCCCTGGAAAGCAGCTGGAATGGGTGGCCCGAG
ATCAAGGACAAGAGCAACAGCTACGCCACCTACTACGCCGACAGCGTGAAGGGCCGGTTACCATCAGCCGGGAC
GACAGCAAGAACACCCTGTACCTGCAGATGAACAGCCTGCGGGCCGAGGACACCGCCGTGTACTACTGTCCGGGC
GTGTACTATGCCCTGAGCCCCCTTCGATTACTGGGGCCAGGGAACCCCTCGTGACCGTGTCTAGTGATAAGACCCACA
CCGCCAGCACAAAGGGCCCATCGGTGTTCCCTCTGGCCCCCTTGACAGCAGAAGCACCCAGCGAATCTACAGCCGCCCT
GGGCTGCCTCGTGAAGGACTACTTTCCCGAGCCCGTGACCGTGTCTGGAACCTCTGGCGCTCTGACAAGCGGCGTG
CACACCTTTCCAGCCGTGCTCCAGAGCAGCGGCCTGTACTCTCTGAGCAGCGTCTGTGACAGTGCCAGCAGCAGCC
TGGGCACCAAGACCTACACCTGTAACGTGGACCACAAGCCCAGCAACACCAAGGTGGACAAGCGGGTGGAATCTA
AGTACGGCCCTCCCTGCCCTCCTTGCCAGCCCCCTGAAGCTGCCGGCGGACCCTCCGTGTTCCCTGTTCCCCCAAAG
CCCAAGGACACCCTGATGATCAGCCGGACCCCCGAAGTGACCTGCGTGGTGGTGGATGTGTCCCAGGAAGATCCC
GAGGTGCAGTTCAATTGGTACGTGGACGGCGTGGAAGTGCACAACGCCAAGACCAAGCCCAGAGAGGAACAGTTC
AACAGCACCTACCGGGTGGTGTCCGTGCTGACCGTGTGTCACCAGGACTGGCTGAACGGCAAAGAGTACAAGTGC
AAGGTGTCCAACAAGGGCCTGCCAGCTCCATCGAGAAAACCATCAGCAAGGCCAAGGGCCAGCCCCGCGAGCCT
CAAGTGTGTACCCTGCCCCCTAGCCAGGAAGAGATGACCAAGAACCAGGTGTCCCTGAGCTGTGCCGTGAAAGGC
TTCTACCCCAGCGACATTGCCGTGGAATGGGAGAGCAACGGCCAGCCCGAGAACAATAAGACCACCCCCCT
GTGCTGGACAGCGACGGCTCATTCTTCCCTGGTGTCCAAGCTGACCGTGGACAAGAGCCGGTGGCAGGAAGGCAAC
GTGTTACAGCTGCTCCGTGATGCACGAGGCCCTGCACAACCACTACACCCAGAAGTCCCTGTCTCTGTCCCTGGGC
3 251
CAGGTTACAGCTGGTTCAGTCTGGCGCCGAAGTGAAGAAACCTGGCGCCTCTGTGAAGGTGTCCTGCAAGGTGTCCG
GCTACACCCTGACCGAGTTCAGCATCCACTGGGTCCGACAGGCTCCAGGACAAGGCTTGGAATGGATGGGCGGCT
TCGATCCCGAGGACGGCGAAACAATCTACGCCCAGAAATTCCAGGGCCGCGTGATCATGACCGAGGACACCTCTA
CCGACACCGCCTACATGGAATGAACAGCCTGCGGAGCGAGGATACCGCCATCTACTACTGTACCACCGGCAGAT
TCTTCGACTGGTTCTGGGGCCAGGGCACCCCTGGTTACAGTCTCTTCTGCGTCGACCAAGGGCCCATCGGTGTTCCCT
CTGGCCCCCTTGACAGCAGAAGCACCCAGCGAATCTACAGCCGCCCTGGGCTGCCTCGTGAAGGACTACTTTCCCGAGC
CCGTGACCGTGTCTGGAACCTCTGGCGCTCTGACAAGCGGCGTGACACCTTTCCAGCCGTGCTCCAGAGCAGCGG
CCTGTACTCTCTGAGCAGCGTCTGTGACAGTGCCCGAGCAGCAGCCTGGGCACCAAGACCTACACCTGTAACGTGGAC
CACAAGCCCAGCAACACCAAGGTGGACAAGCGGGTGGAATCTAAGTACGGCCCTCCCTGCCCTCCTTGCCAGCC
CCTGAAGCTGCCGGCGGACCCTCCGTGTTCCCTGTTCCCCCAAAGCCCAAGGACACCCTGATGATCAGCCGGACCC

CCGAAGTGACCTGCGTGGTGGTGGATGTGTCGCCAGGAAGATCCCCGAGGTGCAGTTCAATTGGTACGTGGACGGCG
TGGAAGTGCACAACGCCAAGACCAAGCCCAGAGAGGAACAGTTCAACAGCACCTACCGGGTGGTGTCCGTGCTGA
CCGTGCTGCACCAGGACTGGCTGAACGGCAAAGAGTACAAGTGAAGGTGTCCAACAAGGGCCTGCCCAGCTCCA
TCGAGAAAACCATCAGCAAGGCCAAGGGCCAGCCCCGCGAGCCTCAAGTGTATACCCTGCCCCCTTGCCAGGAAG
AGATGACCAAGAACCAGGTGTCCCTGTGGTGTCTCGTGAAAGGCTTCTACCCCAGCGACATTGCCGTGGAATGGG
AGAGCAACGGCCAGCCCGAGAACAATAACAAGACCACCCCCCTGTGCTGGACAGCGACGGCTCATTCTTCCTGT
ACTCCAAGCTGACCGTGGACAAGAGCCGGTGGCAGGAAGGCAACGTGTTTCAGCTGCTCCGTGATGCACGAGGCC
TGCACAACCACTACACCCAGAAGTCCCTGTCTCTGTCCCTGGGC 4 252
GAGATCATCCTGACACAGAGCCCCGCCATCCTGTCACTGTCTCCAGGCGAAAGAGCCACACTGAGCTGTAGAGCC
AGCCAGAGCGTGATCAGCAGATTCTGTAGCTGGTATCAAGTGAAGCCCGGACTGGCCCCCTCGGCTGTTGATATATG
GCGCCTCTACACGCGCCACAGGCATCCCTGTTAGATTTTCTGGCAGCGGCTCCGGCACCGACTTCAGCCTGACAAT
TAGCAGCCTGCAGCCTGAGGACTGCGCCGTGTACTACTGTACGAGGACAGCAACCTGCCTATCACCTTCGGCCAG
GGCACCAGACTGGAATCAAGCGTACGGTGGCCGCTCCCAGCGTGTTTCATCTTCCCACCTAGCGACGAGCAGCTG
AAGTCCGGCACAGCCTCTGTCTGTGCCTGCTGAACAACCTTCTACCCCCGCGAGGCCAAAGTGCAGTGGAAAGGTG
GACAACGCCCTGCAGAGCGGCAACAGCCAGGAAAGCGTGACCGAGCAGGACAGCAAGGACTCCACCTACAGCCT
GAGCAGCACCTGACACTGAGCAAGGCCGACTACGAGAAGCACAAGGTGTACGCTGCGAAGTGACCCACCAGG
GCCTGTCTAGCCCCGTGACCAAGAGCTTCAACCGGGGCGAGTGT CD38^{hyb5739/} 1 253
GACATCGTGATGACCCAGACCCCCCTGAGCCTGAGCGTGACACCTGGACAGCCTGCCAGCATCAGCTGCAAGAGC
CD28^{sup} ×
AGCCAGAGCCTGGTGCACGAGAACCTGCAGACCTACCTGAGCTGGTATCTGCAGAAGCCCCGGCCAGAGCCCCCAG
CD3^{mid}_ENLQ
TCCCTGATCTACAAGGTGTCCAACAGATTCAGCGGCGTGCCCGACAGATTCTCCGGCAGCGGCTCTGGCACCGACT
DKTHT IgG4
TCACCCTGAAGATCAGCCGGGTGGAAGCCGAGGACGTGGGCGTGTAATTGTGGCCAGGGCACCCAGTACCCCT
FALA
TCACCTTTGGCAGCGGCACCAAGGTGGAATCAAGGACAAAACCCATACCGACATCCAGATGACCCAGAGCCCCA
BP # 6
GCAGCCTGTCTGCCAGCGTGGGCGACAGAGTGACCATCACCTGTCAAGGCCAGCCAGAACATCTACGTGTGGCTGA
ACTGGTATCAGCAGAAGCCCCGGCAAGGCCCCCAAGCTGCTGATCTACAAGGCCAGCAACCTGCACACCGGCGTGC
CCAGCAGATTTTCTGGCAGCGGCTCCGGCACCGACTTCACCCTGACAATCAGCTCCCTGCAGCCCGAGGACATTGC
CACCTACTACTGCCAGCAGGGCCAGACCTACCCCTACACCTTTGGCCAGGGCACCAAGCTGGAATCAAGGATAA
GACCCACACCCGTACGGTGGCCGCTCCCAGCGTGTTTCATCTTCCCACCTAGCGACGAGCAGCTGAAGTCCGGCACA
GCCTCTGTCTGTGCCTGCTGAACAACCTTCTACCCCCGCGAGGCCAAAGTGCAGTGGAAAGGTGGACAACGCCCTGC
AGAGCGGCAACAGCCAGGAAAGCGTGACCGAGCAGGACAGCAAGGACTCCACCTACAGCCTGAGCAGCACCCCTG
ACACTGAGCAAGGCCGACTACGAGAAGCACAAGGTGTACGCTGCGAAGTGACCCACCAGGGCCTGTCTAGCCCC
GTGACCAAGAGCTTCAACCGGGGCGAGTGT 2 254
CAGGTGCAGCTGGTGCAGTCTGGCGCCGAGGTGCTGAAACCTGGCGCCTCTGTGAAGGTGTCCTGCAAGGCCAGC
GGCTACACCTTTACCAGCTACTACATCCACTGGGTGCGCCAGGCCCTGGACAGGGACTGGAATGGATCGGCAGC
ATCTACCCCGGCAACGTGAACACCAACTACGCCCAGAAGTTCCAGGGCAGAGCCACCCTGACCGTGGACACCAGC
ATCAGCACCGCCTACATGGAAGTGAAGCGGCTGAGAAGCGACGACACCGCCGTGTACTACTGCACCCCGTCCCAC
TACGGCCTGGATTGGAACCTTCGACGTGTGGGGCAAGGGCACCACCGTGACAGTGTCTAGCGACAAAACCCATACC
CAGGTGCAGCTGGTGGAAATCTGGCGGCGGAGTGGTGCAGCCTGGCAGAAGCCTGAGACTGAGCTGTGCCGCCAGC
GGCTTACCTTCACCAAGGCCTGGATGCACTGGGTGCGCCAGGCCCTGGAAAGCAGCTGGAATGGGTGGCCCGAG
ATCAAGGACAAGAGCAACAGCTACGCCACCTACTACGCCGACAGCGTGAAGGGCCGGTTACCATCAGCCGGGAC
GACAGCAAGAACACCCTGTACCTGCAGATGAACAGCCTGCGGGCCGAGGACACCGCCGTGTACTACTGTGCGGGC
GTGTACTATGCCCTGAGCCCCCTTCGATTACTGGGGCCAGGGAACCTCGTGACCGTGTCTAGTGATAAGACCCACA
CCGCCAGCACAAAGGGCCCATCGGTGTTCCCTCTGGCCCCCTTGACAGCAGAAGCACCAGCGAATCTACAGCCGCCCT
GGGCTGCCTCGTGAAGGACTACTTTCCCGAGCCCGTGACCGTGTCTGGAACCTCTGGCGCTCTGACAAGCGGCGTG
CACACCTTTCCAGCCGTGCTCCAGAGCAGCGGCCTGTACTCTCTGAGCAGCGTCTGTACAGTGCCCAGCAGCAGCC
TGGGCACCAAGACCTACACCTGTAACGTGGACCACAAGCCCAGCAACACCAAGGTGGACAAGCGGGTGGAATCTA
AGTACGGCCCTCCCTGCCCTCCTTGCCCAGCCCCGTAAGCTGCCGGCGGACCCCTCCGTGTTCCCTGTTCCCCCAAAG
CCCAAGGACACCCTGATGATCAGCCGGACCCCCGAAGTGACCTGCGTGGTGGTGGATGTGTCCCAGGAAGATCCC
GAGGTGCAGTTCAATTGGTACGTGGACGGCGTGGAAGTGACAACGCCAAGACCAAGCCCAGAGAGGAACAGTTC
AACAGCACCTACCGGGTGGTGTCCGTGCTGACCGTGTCTGCACCAGGACTGGCTGAACGGCAAAGAGTACAAGTGC
AAGGTGTCCAACAAGGGCCTGCCAGCTCCATCGAGAAAACCATCAGCAAGGCCAAGGGCCAGCCCCGCGAGCCT
CAAGTGTGTACCCTGCCCCCTAGCCAGGAAGAGATGACCAAGAACCAGGTGTCCCTGAGCTGTGCCGTGAAAGGC
TTCTACCCAGCGACATTGCCGTGGAATGGGAGAGCAACGGCCAGCCCGAGAACAATAACAAGACCACCCCCCT
GTGCTGGACAGCGACGGCTCATTCTTCCTGGTGTCCAAGCTGACCGTGGACAAGAGCCGGTGGCAGGAAGGCAAC
GTGTTTCAGCTGCTCCGTGATGCACGAGGCCCTGCACAACCACTACACCCAGAAGTCCCTGTCTCTGTCCCTGGGC
3 255
CAGGTTTCAGCTGCAGCAGTCTGGCCCCGAACCTCGTTAGACCTGGCACCTCTGTGAAGGTGTCCTGCAAGGCCAGCG
GCTACGCCTTTACCACCTACCTGGTGGAAATGGATCAAGCAGAGGCCTGGACAGGGCCTCGAGTGGATCGGAGTGA
TCAATCCTGGCAGCGGCAGCACCAACTACAACGAGAAGTTCAAGGGCAAAGGCCACACTGACCGTGGACAGAAGC

AGCACAGCCTACATGCACCTGAGCGCGCTGACCTCTGATGACAGCGCCGTGTACTTCTGCGCCAGATACGCCT
ATGGCTATTGGGGCCAGGGCACAAACCTGACCGTTAGCTCTGCGTCGACCAAGGGCCCATCGGTGTTCCCTCTGGC
CCTTGCAGCAGAAGCACCAGCGAATCTACAGCCGCCCTGGGCTGCCTCGTGAAGGACTACTTTCCCGAGCCCGTG
ACCGTGTCTGGAACCTCTGGCGCTCTGACAAGCGGCGTGCACACCTTTCCAGCCGTGCTCCAGAGCAGCGGCCTGT
ACTCTCTGAGCAGCGTCGTGACAGTGGCCAGCAGCAGCCTGGGCACCAAGACCTACACCTGTAACGTGGACCACA
AGCCCAGCAACACCAAGGTGGACAAGCGGGTGGAAATCTAAGTACGGCCCTCCCTGCCCTCCTTGCCCAGCCCCTG
AAGCTGCCGGCGGACCCTCCGTGTTCCCTGTTCCCCCAAAGCCCAAGGACACCCTGATGATCAGCCGGACCCCCGA
AGTGACCTGCGTGTTGGTGGATGTGTCCCAGGAAGATCCCGAGGTGCAGTTCAATTGGTACGTGGACGGCGTGGA
AGTGCACAACGCCAAGACCAAGCCCAGAGAGGAACAGTTCAACAGCACCTACCGGGTGGTGTCCGTGCTGACCGT
GCTGCACCAGGACTGGCTGAACGGCAAAGAGTACAAGTGCAAGGTGTCCAACAAGGGCCTGCCAGCTCCATCGA
GAAAACCATCAGCAAGGCCAAGGGCCAGCCCCGCGAGCCTCAAGTGTATACCCTGCCCCCTTGCCAGGAAGAGAT
GACCAAGAACCAGGTGTCCCTGTGGTGTCTCGTGAAAGGCTTCTACCCAGCGACATTGCCGTGGAATGGGAGAG
CAACGGCCAGCCCGAGAACAATAAGACCACCCCCCTGTGCTGGACAGCGACGGCTCATTCTTCTGTACTCC
AAGCTGACCGTGGACAAGAGCCGGTGGCAGGAAGGCAACGTGTTACAGCTGCTCCGTGATGCACGAGGCCCTGCAC
AACCACTACACCCAGAAGTCCCTGTCTCTGTCCCTGGGC 4 256

GACATCGTGATGACCCAGAGCCAGAAATTCATGAGCGCCAGCGTGGGCGACAGAGTGTCCATCACATGTAAAGCC
AGCCAGAACGTGGGCACAGCCGTGGCTTGGTATCAGCAGCAGCCTGGCCACTCTCCTAAGCAGCTGATCTACAGC
GCCAGCAACAGATACACCGGCGTGCCCGATAGATTCACAGGATCTGGCGCCGGAACCGACTTCACCCTGACCATC
AGCAACATCCAGAGCGAGGACCTGGCCGACTACTTCTGCCAGCAGTACAGCACATACCCCTTCACCTTTGGCAGCG
GCACCAAGCTGGAAATCAAGCGTACGGTGGCCGCTCCCAGCGTGTTCATCTTCCACCTAGCGACGAGCAGCTGA
AGTCCGGGCACAGCCTCTGTCTGTGCTGCTGAACAATTCTACCCCCGCGAGGCCAAAGTGCAGTGGAAGGTGG
ACAACGCCCTGCAGAGCGGCAACAGCCAGGAAAGCGTGACCGAGCAGGACAGCAAGGACTCCACCTACAGCCTG
AGCAGCACCCCTGACACTGAGCAAGGCCGACTACGAGAAGCACAAGGTGTACGCCTGCGAAGTGACCCACCAGGG
CCTGTCTAGCCCCGTGACCAAGAGCTTCAACCGGGGCGAGTGT CD38hyb6284/ 1 257

GACATCGTGATGACCCAGACCCCCCTGAGCCTGAGCGTGACACCTGGACAGCCTGCCAGCATCAGCTGCAAGAGC
CD28sup ×
AGCCAGAGCCTGGTGCACGAGAACCTGCAGACCTACCTGAGCTGGTATCTGCAGAAGCCCGGCCAGAGCCCCCAG
CD3mid_ENLQ

TCCCTGATCTACAAGGTGTCCAACAGATTCAGCGGCGTGCCCGACAGATTCTCCGGCAGCGGCTCTGGCACCGACT
DKTHT IgG4
TCACCCTGAAGATCAGCCGGGTGGAAGCCGAGGACGTGGGCGTGTACTATTGTGGCCAGGGCACCCAGTACCCCT
FALA

TCACCTTTGGCAGCGGCACCAAGGTGGAATCAAGGACAAAACCCATACCGACATCCAGATGACCCAGAGCCCCA
BP # 7

GCAGCCTGTCTGCCAGCGTGGGCGACAGAGTGACCATCACCTGTCAGGCCAGCCAGAACATCTACGTGTGGCTGA
ACTGGTATCAGCAGAAGCCCGGCAAGGCCCCCAAGCTGCTGATCTACAAGGCCAGCAACCTGCACACCGGCGTGC
CCAGCAGATTTTCTGGCAGCGGCTCCGGCACCGACTTCACCCTGACAATCAGCTCCCTGCAGCCCGAGGACATTGC
CACCTACTACTGCCAGCAGGGCCAGACCTACCCCTACACCTTTGGCCAGGGCACCAAGCTGGAATCAAGGATAA
GACCCACACCCGTACGGTGGCCGCTCCCAGCGTGTTCATCTTCCACCTAGCGACGAGCAGCTGAAGTCCGGGCACA
GCCTCTGTCTGTGCTGCTGAACAATTCTACCCCCGCGAGGCCAAAGTGCAGTGGAAGGTGGACAACGCCCTGC
AGAGCGGCAACAGCCAGGAAAGCGTGACCGAGCAGGACAGCAAGGACTCCACCTACAGCCTGAGCAGCACCCCTG
ACACTGAGCAAGGCCGACTACGAGAAGCACAAGGTGTACGCCTGCGAAGTGACCCACCAGGGCCTGTCTAGCCCC
GTGACCAAGAGCTTCAACCGGGGCGAGTGT 2 258

CAGGTGCAGCTGGTGCAGTCTGGCGCCGAGGTCTGTGAAACCTGGCGCCTCTGTGAAGGTGTCCTGCAAGGCCAGC
GGCTACACCTTTACCAGCTACTACATCCACTGGGTGCGCCAGGCCCTGGACAGGGACTGGAATGGATCGGCAGC
ATCTACCCCGGCAACGTGAACACCAACTACGCCCAGAAGTTCCAGGGCAGAGCCACCCTGACCGTGGACACCAGC
ATCAGCACCGCCTACATGGAAGTGAAGCGGCTGAGAAGCGACGACACCGCCGTGTACTACTGCACCCGGTCCCAC
TACGGCCTGGATTGGAACCTTCGACGTGTGGGGCAAGGGCACCACCGTGACAGTGTCTAGCGACAAAACCCATAAC
CAGGTGCAGCTGGTGGAAATCTGGCGGCGGAGTGGTGCAGCCTGGCAGAAGCCTGAGACTGAGCTGTGCCGCCAGC
GGCTTCACCTTCACCAAGGCCTGGATGCACTGGGTGCGCCAGGCCCTGGAAAGCAGCTGGAATGGGTGGCCAG
ATCAAGGACAAGAGCAACAGCTACGCCACCTACTACGCCGACAGCGTGAAGGGCCGGTTACCATCAGCCGGGAC
GACAGCAAGAACACCCTGTACCTGCAGATGAACAGCCTGCGGGCCGAGGACACCGCCGTGTACTACTGTCCGGGC
GTGTACTATGCCCTGAGCCCCCTTCGATTACTGGGGCCAGGGAACCCTCGTGACCGTGTCTAGTGATAAGACCCACA
CCGCCAGCACAAAGGGCCCATCGGTGTTCCCTCTGGCCCCCTTGACAGCAGAAGCACCAGCGAATCTACAGCCGCCCT
GGGCTGCCTCGTGAAGGACTACTTTCCCGAGCCCGTGACCGTGTCTGGAACCTCTGGCGCTCTGACAAGCGGCGTG
CACACCTTTCCAGCCGTGCTCCAGAGCAGCGGCCTGTACTCTCTGAGCAGCGTCGTGACAGTGGCCAGCAGCAGCC
TGGGCACCAAGACCTACACCTGTAACGTGGACCACAAGCCCAGCAACACCAAGGTGGACAAGCGGGTGGAATCTA
AGTACGGCCCTCCCTGCCCTCCTTGCCCAGCCCCCTGAAGCTGCCGGCGGACCCTCCGTGTTCCCTGTTCCCCCAAAG
CCCAAGGACACCCTGATGATCAGCCGGACCCCCGAAGTGACCTGCGTGGTGGTGGATGTGTCCCAGGAAGATCCC
GAGGTGCAGTTCAATTGGTACGTGGACGGCGTGGAAGTGACACAACGCCAAGACCAAGCCCAGAGAGGAACAGTTC
AACAGCACCTACCGGGTGGTGTCCGTGCTGACCGTGTGTCACCAGGACTGGCTGAACGGCAAAGAGTACAAGTGC
AAGGTGTCCAACAAGGGCCTGCCAGCTCCATCGAGAAAACCATCAGCAAGGCCAAGGGCCAGCCCCGCGAGCCT
CAAGTGTGTACCCTGCCCCCTAGCCAGGAAGAGATGACCAAGAACCAGGTGTCCCTGAGCTGTGCCGTGAAAGGC

TTCTACCCGACGCGACGCGGCTGGAATCGGAGAGCAACGGCCAGCCCGAGCCCAAGCAATACAAAGACACCCCCCT
GTGCTGGACAGCGACGGCTCATTCTTCTGCTGGTGTCCAAGCTGACCGTGGACAAGAGCCGGTGGCAGGAAGGCAAC
GTGTTACAGCTGCTCCGTGATGCACGAGGCCCTGCACAACCACTACACCCAGAAGTCCCTGTCTCTGTCCCTGGGC

3 259

CAGGTTACAGCTGCTGCAGTCTGGCGCCGAACCTTGTACAGACCTGGCGTGTCCGTGAAGATCAGCTGTACAGGCAGCG
GCTACAGCTTACCAACTACGCCGTGCACTGGGTCAAGCAGAGCCACGTGAAGTCCCTGGAATGGATCGGCGTGA
TCAGCCCCTACTACGGCGACACCACCTACAACCAGAAGTTCACCGGCAAGGCCACCATGACCGTGGACAAGTCTA
GCAGCACCGCCTACATGGAAGTGGCCAGACTGACCAGCGAGGACAGCGCCATCTACTTTTGGCCGAGAAGATTCTG
AGGGCTTCTACTACAGCATGGAAGTGGGGCCAGGGCACCAGCGTGACAGTTTCTTCTGCGTCGACCAAGGGCCC
ATCGGTGTTCCCTCTGGCCCCCTGACAGCAGAAGCACCAGCGAATCTACAGCCGCCCTGGGCTGCCTCGTGAAGGAC
TACTTTCCCGAGCCCGTGACCGTGTCTGGAAGTCTGGCGCTCTGACAAGCGGCGTGACACACCTTCCAGCCGTGC
TCCAGAGCAGCGGCCTGTACTCTCTGAGCAGCGTCGTGACAGTGGCCAGCAGCAGCCTGGGCACCAAGACCTACA
CCTGTAACGTGGACCACAAGCCCAGCAACACCAAGGTGGACAAGCGGGTGGAAATCTAAGTACGGCCCTCCCTGCC
CTCCTTGGCCAGCCCTGAAGCTGCCGGCGGACCCTCCGTGTTCTCTGTTCCCCCAAAGCCCAAGGACACCCTGAT
GATCAGCCGGACCCCGAAGTGACCTGCGTGGTGGTGGATGTGTCCAGGAAGATCCCGAGGTGCAGTTCAATTG
GTACGTGGACGGCGTGGAAGTGCACAACGCCAAGACCAAGCCCAGAGAGGAACAGTTCAACAGCACCTACCGGG
TGGTGTCCGTGCTGACCGTGCTGCACCAGGACTGGCTGAACGGCAAAGAGTACAAGTGCAAGGTGTCCAACAAGG
GCCTGCCCAGCTCCATCGAGAAAACCATCAGCAAGGCCAAGGGCCAGCCCCGCGAGCCTCAAGTGTATACCCCTGC
CCCCTTGGCAGGAAGAGATGACCAAGAACCAGGTGTCCCTGTGGTGTCTCGTGAAAGGCTTCTACCCAGCGACAT
TGCCGTGGAATGGGAGAGCAACGGCCAGCCCGAGAACAACCTACAAGACCACCCCCCTGTGCTGGACAGCGACGG
CTCATTCTTCTGTACTCCAAGCTGACCGTGGACAAGAGCCGGTGGCAGGAAGGCAACGTGTTACAGCTGCTCCGTG
ATGCACGAGGCCCTGCACAACCACTACACCCAGAAGTCCCTGTCTCTGTCCCTGGGC 4 260

GACGTGGTCATGATCCAGACACCTCTGAGCCTGCCTGTGTCTCTGGGAGATCAGGCCAGCATCAGCTGCAGACCTA
GCCAGTCTCTGGTGCACAGCAACGGCAACACCTACCTGAACTGGTATCTGCAGAGGCCCGGACAGAGCCCCAAGC
TGCTGATCTACAAGGTGTCCAAGCGGTTACAGCGGCGTGCCCGATAGATTTTCTGGCAGCGGCTCTGGCACCGACTT
CACCTGAAGATTAGCAGAGTGGAAGCCGAGGACCTGGGCGTGTACCTGTGTTCTCAGAGCACACACGTGCCCT
GACCTTTGGCAGCGGAACCCAGCTGGAAATCAAGCGTACGGTGGCCGCTCCCAGCGTGTTTCATCTTCCCACCTAGC
GACGAGCAGCTGAAGTCCGGCACAGCCTCTGTCTGTGCCTGCTGAACAACCTTCTACCCCCGCGAGGCCAAAGTGC
AGTGGAAGGTGGACAACGCCCTGCAGAGCGGCAACAGCCAGGAAAGCGTGACCGAGCAGGACAGCAAGGACTCC
ACCTACAGCCTGAGCAGCACCTTGACACTGAGCAAGGCCGACTACGAGAAGCACAAGGTGTACGCCTGCGAAGTG
ACCCACCAGGGCCTGTCTAGCCCCGTGACCAAGAGCTTCAACCGGGGCGAGTGT CD38hhy1195/ 1 261

GACATCGTGATGACCCAGACCCCCCTGAGCCTGAGCGTGACACCTGGACAGCCTGCCAGCATCAGCTGCAAGAGC
CD28sup ×
AGCCAGAGCCTGGTGCACGAGAACCTGCAGACCTACCTGAGCTGGTATCTGCAGAAGCCCGGCCAGAGCCCCCAG
CD3mid_ENLQ

TCCCTGATCTACAAGGTGTCCAACAGATTCAGCGGCGTGCCCGACAGATTCTCCGGCAGCGGCTCTGGCACCGACT
DKTHT IgG4
TCACCCTGAAGATCAGCCGGGTGGAAGCCGAGGACGTGGGCGTGACTATTGTGGCCAGGGCACCCAGTACCCCT
FALA

TCACCTTTGGCAGCGGCACCAAGGTGGAAATCAAGGACAAAACCCATACCGACATCCAGATGACCCAGAGCCCCA
BP # 8

GCAGCCTGTCTGCCAGCGTGGGCGACAGAGTGACCATCACCTGTACAGGCCAGCCAGAACATCTACGTGTGGCTGA
ACTGGTATCAGCAGAAGCCCGGCAAGGCCCCCAAGCTGCTGATCTACAAGGCCAGCAACCTGCACACCGGCGTGC
CCAGCAGATTTTCTGGCAGCGGCTCCGGCACCGACTTCACCCTGACAATCAGCTCCCTGCAGCCCGAGGACATTGC
CACCTACTACTGCCAGCAGGGCCAGACCTACCCCTACACCTTTGGCCAGGGCACCAAGCTGGAAATCAAGGATAA
GACCCACACCCGTACGGTGGCCGCTCCCAGCGTGTTTCATCTTCCCACCTAGCGACGAGCAGCTGAAGTCCGGCACA
GCCTCTGTCTGTGCCTGCTGAACAACCTTCTACCCCCGCGAGGCCAAAGTGCAAGTGGAAAGGTGGACAACGCCCTGC
AGAGCGGCAACAGCCAGGAAAGCGTGACCGAGCAGGACAGCAAGGACTCCACCTACAGCCTGAGCAGCACCCCTG
ACACTGAGCAAGGCCGACTACGAGAAGCACAAGGTGTACGCCTGCGAAGTGACCCACCAGGGCCTGTCTAGCCCC
GTGACCAAGAGCTTCAACCGGGGCGAGTGT 2 262

CAGGTGCAGCTGGTGCAGTCTGGCGCCGAGGTCGTGAAACCTGGCGCCTCTGTGAAGGTGTCTGCAAGGCCAGC
GGCTACACCTTTACCAGCTACTACATCCACTGGGTGCGCCAGGCCCTGGACAGGGACTGGAATGGATCGGCAGC
ATCTACCCCGGCAACGTGAACACCAACTACGCCCAGAAGTTCAGGGCAGAGCCACCCTGACCGTGGACACCAGC
ATCAGCACCGCCTACATGGAAGTGGCCGCTGAGAAGCGACGACACCGCCGTGTACTACTGCACCCGGTCCCAC
TACGGCCTGGATTGGAAGTTCGACGTGTGGGGCAAGGGCACACCGTGCAGTGTCTAGCGACAAAACCCATACC
CAGGTGCAGCTGGTGGAAATCTGGCGGCGGAGTGGTGCAGCCTGGCAGAAGCCTGAGACTGAGCTGTGCCGCCAGC
GGCTTACCTTACCAAGGCCTGGATGCACTGGGTGCGCCAGGCCCTGGAAAGCAGCTGGAATGGGTGGCCCAG
ATCAAGGACAAGAGCAACAGCTACGCCACCTACTACGCCGACAGCGTGAAGGGCCGGTTACCATCAGCCGGGAC
GACAGCAAGAACACCCTGTACCTGCAGATGAACAGCCTGCGGGCCGAGGACACCGCCGTGTACTACTGTCCGGGC
GTGTACTATGCCCTGAGCCCCCTTCGATTACTGGGGCCAGGGAACCCTCGTGACCGTGTCTAGTGATAAGACCCACA
CCGCCAGCACAAAGGGCCCATCGGTGTTCCCTCTGGCCCCCTTGCAGCAGAAGCACCAGCGAATCTACAGCCGCCCT
GGGCTGCCTCGTGAAGGACTACTTTCCCGAGCCCGTGACCGTGTCTGGAAGTCTGGCGCTCTGACAAGCGGCGTG
CACACCTTTCAGCCGTGCTCCAGAGCAGCGGCCTGTACTCTCTGAGCAGCGTCGTGACAGTGGCCAGCAGCAGCC

TGGCCACAAGACCTACACCTGTAACGTGGACCCACAAGCCCCAGCAACACCAAGGTGGACAAAGCGGGTGGAATCTA
AGTACGGCCCTCCCTGCCCTCCTTGCCCAGCCCCCTGAAGCTGCCGGCGGACCCCTCCGTGTTCTGTTCCTCCCAAG
CCCAAGGACACCCTGATGATCAGCCGGACCCCCGAAGTGACCTGCGTGGTGGTGGATGTGTCCCAGGAAGATCCC
GAGGTGCAGTTCAATTGGTACGTGGACGGCGTGGAAGTGACACAACGCCAAGACCAAGCCCAGAGAGGAACAGTTC
AACAGCACCTACCGGGTGGTGTCCGTGCTGACCGTGCTGCACCAGGACTGGCTGAACGGCAAAGAGTACAAGTGC
AAGGTGTCCAACAAGGGCCTGCCAGCTCCATCGAGAAAACCATCAGCAAGGCCAAGGGCCAGCCCCGCGAGCCT
CAAGTGTGTACCCTGCCCCCTAGCCAGGAAGAGATGACCAAGAACCAGGTGTCCCTGAGCTGTGCCGTGAAAGGC
TTCTACCCCAGCGACATTGCCGTGGAATGGGAGAGCAACGGCCAGCCCCGAGAACAATAAGACCACCCCCCT
GTGCTGGACAGCGACGGCTCATTCTTCCTGGTGTCCAAGCTGACCGTGGACAAGAGCCGGTGGCAGGAAGGCAAC
GTGTTGAGCTGCTCCGTGATGCACGAGGCCCTGCACAACCACTACACCCAGAAGTCCCTGTCTCTGTCCCTGGGC
3 263

CAGGTGCAGCTGGTGGAAATCTGGCGGCGGAGTGGTGCAGCCTGGCAGAAGCCTGAGACTGAGCTGTGCCGCCAGC
GGCTTACCTTCAGCAGCTACGGCATGTACTGGGTGCGCCAGGCCCTGGCAAAGGCCTGGAATGGGTGGCCGTG
ATTTGGTACGACGGCAGCAACAAGTACTACGCCGACAGCGTGAAGGGCCGGTTACCATCTCCCGGGACAACAGC
AAGAACACCCTGTACCTGCAGATGAACAGCCTGCGGGCCGAGGACACAGCCGTGTATCACTGCGCCAGAGATCCC
GGCCTGCGGTACTTTGACGGCGGCATGGATGTGTGGGGCCAGGGCACAACCGTGACCGTGTATCTGCGTCGACC
AAGGGCCCATCGGTGTTCCCTCTGGCCCCCTTGACGACAGAAGCACCCAGCGAATCTACAGCCGCCCTGGGCTGCCTCG
TGAAGGACTACTTTCCCGAGCCCGTGACCGTGTCTGGAACCTCTGGCGCTCTGACAAGCGGCGTGACACCTTTCC
AGCCGTGCTCCAGAGCAGCGGCCTGTACTCTCTGAGCAGCGTCGTGACAGTGCCAGCAGCAGCCTGGGCACCAA
GACCTACACCTGTAACGTGGACCACAAGCCCAGCAACACCAAGGTGGACAAGCGGGTGGAAATCTAAGTACGGCCC
TCCCTGCCCTCCTTGCCCAGCCCCCTGAAGCTGCCGGCGGACCCCTCCGTGTTCTGTTCCTGTTCCCCCAAGCCCAAGGAC
ACCCTGATGATCAGCCGGACCCCCGAAGTGACCTGCGTGGTGGTGGATGTGTCCCAGGAAGATCCCGAGGTGCAG
TTCAATTGGTACGTGGACGGCGTGGAAGTGACACAACGCCAAGACCAAGCCCAGAGAGGAACAGTTCAACAGCACC
TACCGGGTGGTGTCCGTGCTGACCGTGCTGCACCAGGACTGGCTGAACGGCAAAGAGTACAAGTGCAAGGTGTCC
AACAAGGGCCTGCCAGCTCCATCGAGAAAACCATCAGCAAGGCCAAGGGCCAGCCCCGCGAGCCTCAAGTGTAT
ACCCTGCCCCCTTGCCAGGAAGAGATGACCAAGAACCAGGTGTCCCTGTGGTGTCTCGTGAAAGGCTTCTACCCCA
GCGACATTGCCGTGGAATGGGAGAGCAACGGCCAGCCCCGAGAACAATAAGACCACCCCCCTGTGCTGGACA
GCGACGGCTCATTCTTCCTGTACTCCAAGCTGACCGTGGACAAGAGCCGGTGGCAGGAAGGCAACGTGTTGAGCT
GCTCCGTGATGCACGAGGCCCTGCACAACCACTACACCCAGAAGTCCCTGTCTCTGTCCCTGGGC 4 264

GACATCCAGCTGACCCAGAGCCCCAGCTTTCTGAGCGCCAGCGTGGGCGACAGAGTGACCATCACCTGTAGAGCC
AGCCAGGGCATCAGCAGCTACCTGGCCTGGTATCAGCAGAAGCCCCGGCAAGGCCCCCAACTGCTGATCTTTGCC
GCCAGCACACTGCACAGCGGCGTGCCAGCAGATTTTCTGGCAGCGGCTCCGGCACCGAGTTCACCCTGACAATCA
GCAGCCTGCAGCCCGAGGACTTCGCCACCTACTACTGCCAGCAGCTGAACAGCTTCCCCTACACCTTCGGCCAGGG
CACCAAGCTGGAAATCAAGCGTACGGTGGCCGCTCCAGCGTGTTTCATCTTCCCACCTAGCGACGAGCAGCTGAA
GTCCGGCACAGCCTCTGTCTGTGCTGTGAACAACCTTCTACCCCCGCGAGGCCAAAGTGCAAGTGGAAAGGTGGAC
AACGCCCTGCAGAGCGGCAACAGCCAGGAAAGCGTGACCGAGCAGGACAGCAAGGACTCCACCTACAGCCTGAG
CAGCACCTGACACTGAGCAAGGCCGACTACGAGAAGCACAAGGTGTACGCCTGCGAAGTGACCCACCAGGGCCT
GTCTAGCCCCGTGACCAAGAGCTTCAACCGGGGCGAGTGT CD38hy1370/ 1 265

GACATCGTGATGACCCAGACCCCCCTGAGCCTGAGCGTGACACCTGGACAGCCTGCCAGCATCAGCTGCAAGAGC
CD28sup ×
AGCCAGAGCCTGGTGCACGAGAACCTGCAGACCTACCTGAGCTGGTATCTGCAGAAGCCCCGGCCAGAGCCCCCAG
CD3mid_ENLQ
TCCCTGATCTACAAGGTGTCCAACAGATTCAGCGGCGTGCCCGACAGATTCTCCGGCAGCGGCTCTGGCACCGACT
DKTHT IgG4
TCACCCTGAAGATCAGCCGGGTGGAAGCCGAGGACGTGGGCGTGACTATTGTGGCCAGGGCACCCAGTACCCCT
FALA

TCACCTTTGGCAGCGGCACCAAGGTGGAATCAAGGACAAAACCCATACCGACATCCAGATGACCCAGAGCCCCA
BP # 9

GCAGCCTGTCTGCCAGCGTGGGCGACAGAGTGACCATCACCTGTGAGGCCAGCCAGAACATCTACGTGTGGCTGA
ACTGGTATCAGCAGAAGCCCGGCAAGGCCCCCAAGCTGCTGATCTACAAGGCCAGCAACCTGCACACCGGCGTGC
CCAGCAGATTTTCTGGCAGCGGCTCCGGCACCGACTTCACCCTGACAATCAGCTCCCTGCAGCCCGAGGACATTGC
CACCTACTACTGCCAGCAGGGCCAGACCTACCCCTACACCTTTGGCCAGGGCACCAAGCTGGAATCAAGGATAA
GACCCACACCCGTACGGTGGCCGCTCCAGCGTGTTTCATCTTCCCACCTAGCGACGAGCAGCTGAAGTCCGGCACA
GCCTCTGTCTGTGCTGTGAACAACCTTCTACCCCCGCGAGGCCAAAGTGCAAGTGGAAAGGTGGACAACGCCCTGC
AGAGCGGCAACAGCCAGGAAAGCGTGACCGAGCAGGACAGCAAGGACTCCACCTACAGCCTGAGCAGCACCCCTG
ACACTGAGCAAGGCCGACTACGAGAAGCACAAGGTGTACGCCTGCGAAGTGACCCACCAGGGCCTGTCTAGCCCC
GTGACCAAGAGCTTCAACCGGGGCGAGTGT 2 266

CAGGTGCAGCTGGTGCAGTCTGGCGCCGAGGTGCTGAAACCTGGCGCCTCTGTGAAGGTGTCCTGCAAGGCCAGC
GGCTACACCTTTACCAGCTACTACATCCACTGGGTGCGCCAGGCCCTGGACAGGGACTGGAATGGATCGGCAGC
ATCTACCCCGGCAACGTGAACACCAACTACGCCCAGAAGTTCCAGGGCAGAGCCACCCTGACCGTGGACACCAGC
ATCAGCACCGCCTACATGGAAGTGAAGCGGCTGAGAAGCGACGACACCGCCGTGTACTACTGCACCCGGTCCCAC
TACGGCCTGGATTGGAACCTTCGACGTGTGGGGCAAGGGCACCCGTGACAGTGTCTAGCGACAAAACCCATACC
CAGGTGCAGCTGGTGGAAATCTGGCGGCGGAGTGGTGCAGCCTGGCAGAAGCCTGAGACTGAGCTGTGCCGCCAGC

GGTTTCACCTTACCAAGGCCCTGGATGCGGCTGCGCCAGGCCCTGGAAAGCAGCTGGAATGGGTGGCCCCAG
ATCAAGGACAAGAGCAACAGCTACGCCACCTACTACGCCGACAGCGTGAAGGGCCGGTTTACCATCAGCCGGGAC
GACAGCAAGAACACCCTGTACCTGCAGATGAACAGCCTGCGGGCCGAGGACACCGCCGTGTACTACTGTCGGGGC
GTGTACTATGCCCTGAGCCCCCTTCGATTACTGGGGCCAGGGAACCCTCGTGACCGTGTCTAGTGATAAGACCCACA
CCGCCAGCACAAAGGGCCCCATCGGTGTTCCCTCTGGCCCCCTTGACAGCAGAAGCACCAGCGAATCTACAGCCGCCCT
GGGCTGCCTCGTGAAGGACTACTTTCCCGAGCCCGTGACCGTGTCTGGAACCTCTGGCGCTCTGACAAGCGGCGTG
CACACCTTTCCAGCCGTGCTCCAGAGCAGCGGCCTGTACTCTCTGAGCAGCGTCTGTACAGTGCCCAGCAGCAGCC
TGGGCACCAAGACCTACACCTGTAACGTGGACCACAAGCCCAGCAACACCAAGGTGGACAAGCGGGTGGAAATCTA
AGTACGGGCCCTCCCTGCCCTCCTTGCCAGCCCCCTGAAGCTGCCGGCGGACCCTCCGTGTTCCCTGTTCCCCCAAAG
CCCAAGGACACCCTGATGATCAGCCGGACCCCCGAAGTGACCTGCGTGGTGGTGGATGTGTCCCAGGAAGATCCC
GAGGTGCAGTTCAATTGGTACGTGGACGGCGTGGAAGTGCACAACGCCAAGACCAAGCCCAGAGAGGAACAGTTC
AACAGCACCTACCGGGTGGTGTCCGTGCTGACCGTGTCTGCACCAGGACTGGCTGAACGGCAAAGAGTACAAGTGC
AAGGTGTCCAACAAGGGCCTGCCAGCTCCATCGAGAAAACCATCAGCAAGGCCAAGGGCCAGCCCCGCGAGCCT
CAAGTGTGTACCCTGCCCCCTAGCCAGGAAGAGATGACCAAGAACCAGGTGTCCCTGAGCTGTGCCGTGAAAGGC
TTCTACCCCAGCGACATTGCCGTGGAATGGGAGAGCAACGGCCAGCCCCGAGAACAATAACAAGACCACCCCCCT
GTGCTGGACAGCGACGGCTCATTCTTCCCTGGTGTCCAAGCTGACCGTGGACAAGAGCCGGTGGCAGGAAGGCAAC
GTGTTACAGCTGCTCCGTGATGCACGAGGCCCTGCACAACCACTACACCCAGAAGTCCCTGTCTCTGTCCCTGGGC

3 267

CAGGTGCAGCTGGTGGAAAGCGGCGGAGGCGTGGTGCAGCCTGGCAGGTCTCTGAGACTGAGCTGTGCCGCCAGC
GGCTTCACCTTCAGCAGCTACGGAATGCACTGGGTGCGCCAGGCCCTGGCAAAGGACTGGAATGGGTGGCCGTG
ATTTGGTACGACGGCAGCAACAAGTACTACGCCGACAGCGTGAAGGGCCGGTTTACCATCAGCGGCGACAACAGC
AAGAACACCCTGTACCTGCAGATGAACAGCCTGCGGGCCGAGGACACCGCCGTGTACTACTGCGCCAGAATGTTT
AGAGGCGCCTTCGACTACTGGGGCCAGGGCACACTCGTGACCGTGTCTAGTGCGTCGACCAAGGGCCCATCGGTG
TTCCCTCTGGCCCCCTTGACAGCAGAAGCACCAGCGAATCTACAGCCGCCCTGGGCTGCCTCGTGAAGGACTACTTTC
CCGAGCCCGTGACCGTGTCTGGAACCTCTGGCGCTCTGACAAGCGGCGTGCACACCTTTCCAGCCGTGCTCCAGAG
CAGCGGCCTGTACTCTCTGAGCAGCGTCTGTGACAGTGCCCAGCAGCAGCCTGGGCACCAAGACCTACACCTGTAA
CGTGGACCACAAGCCCAGCAACACCAAGGTGGACAAGCGGGTGGAAATCTAAGTACGGCCCTCCCTGCCCTCCTTG
CCCAGCCCCCTGAAGCTGCCGGCGGACCCTCCGTGTTCCCTGTTCCCCCAAAGGCCAAGGACACCCTGATGATCAGC
CGGACCCCCGAAGTGACCTGCGTGGTGGTGGATGTGTCCCAGGAAGATCCCGAGGTGCAGTTCAATTGGTACGTG
GACGGCGTGAAGTGCACAACGCCAAGACCAAGCCCAGAGAGGAACAGTTCAACAGCACCTACCGGGTGGTGTCT
CGTGCTGACCGTGTCTGCACCAGGACTGGCTGAACGGCAAAGAGTACAAGTGAAGGTGTCCAACAAGGGCCTGCC
CAGCTCCATCGAGAAAACCATCAGCAAGGCCAAGGGCCAGCCCCGCGAGCCTCAAGTGTATACCCTGCCCCCTTG
CCAGGAAGAGATGACCAAGAACCAGGTGTCCCTGTGGTGTCTCGTGAAAGGCTTCTACCCCAGCGACATTGCCGT
GGAATGGGAGAGCAACGGCCAGCCCCGAGAACAATAACAAGACCACCCCCCTGTGCTGGACAGCGACGGCTCATT
CTTCCCTGTACTCCAAGCTGACCGTGGACAAGAGCCGGTGGCAGGAAGGCAACGTGTTACAGCTGCTCCGTGATGCAC
GAGGCCCTGCACAACCACTACACCCAGAAGTCCCTGTCTCTGTCCCTGGGC

4 268

GCCATCCAGATGACCCAGAGCCCCAGCAGCCTGTCTGCCAGCGTGGGCGACAGAGTGACCATCACCTGTAGAGCC
AGCCAGGGCATCCGGAACGACCTGGGCTGGTATCAGCAGAAGCCTGGCAAGGCCCCCAAGCTGCTGATCTACGCC
GCTAGCTCTCTGCAGTCCGGCGTGCCCAGCAGATTTTCTGGCAGCGGCTCCGGCACCGACTTCACCCTGACAATCT
CTGGCCTGCAGCCCCAGGACAGCGCCACCTACTACTGTCTGCAAGACTACATCTACTACCCACCTTCGGCCAGGG
CACCAAGGTGGAAATCAAGCGTACGGTGGCCGCTCCAGCGTGTTTCATCTTCCCACCTAGCGACGAGCAGCTGAA
GTCCGGCACAGCCTCTGTCTGTGCCTGCTGAACAATTCTACCCCCGCGAGGCCAAAGTGCAAGTGGAAAGGTGGAC
AACGCCCTGCAGAGCGGCAACAGCCAGGAAAGCGTGACCGAGCAGGACAGCAAGGACTCCACCTACAGCCTGAG
CAGCACCTGACACTGAGCAAGGCCGACTACGAGAAGCACAAGGTGTACGCCTGCGAAGTGACCCACCAGGGCCT
GTCTAGCCCCGTGACCAAGAGCTTCAACCGGGGCGAGTGT

CD38hu5739/ 1 269

GACATCGTGATGACCCAGACCCCCCTGAGCCTGAGCGTGACACCTGGACAGCCTGCCAGCATCAGCTGCAAGAGC
CD28sup ×

AGCCAGAGCCTGGTGCACGAGAACCCTGCAGACCTACCTGAGCTGGTATCTGCAGAAGCCCGGCCAGAGCCCCCAG
CD3mid_ENLQ

TCCCTGATCTACAAGGTGTCCAACAGATTCAGCGGCGTGCCCGACAGATTCTCCGGCAGCGGCTCTGGCACCGACT
DKTHT IgG4

TCACCCTGAAGATCAGCCGGGTGGAAAGCCGAGGACGTGGGCGTGTACTATTGTGGCCAGGGCACCCAGTACCCCT
FALA

TCACCTTTGGCAGCGGCACCAAGGTGGAAATCAAGGACAAAACCCATACCGACATCCAGATGACCCAGAGCCCCA
GCAGCCTGTCTGCCAGCGTGGGCGACAGAGTGACCATCACCTGTGAGGCCAGCCAGAACATCTACGTGTGGCTGA
ACTGGTATCAGCAGAAGCCCGGCAAGGCCCCCAAGCTGCTGATCTACAAGGCCAGCAACCTGCACACCGGCGTGC
CCAGCAGATTTTCTGGCAGCGGCTCCGGCACCGACTTCACCCTGACAATCAGCTCCCTGCAGCCCCGAGGACATTGC
CACCTACTACTGCCAGCAGGGCCAGACCTACCCCTACACCTTTGGCCAGGGCACCAAGCTGGAAATCAAGGATAA
GACCCACACCCGTACGGTGGCCGCTCCAGCGTGTTTCATCTTCCCACCTAGCGACGAGCAGCTGAAGTCCGGCACA
GCCTCTGTCTGTGCTGTGCTGCTGAACAATTCTACCCCCGCGAGGCCAAAGTGCAAGTGGAAAGGTGGACAACGCCCTGC
AGAGCGGCAACAGCCAGGAAAGCGTGACCGAGCAGGACAGCAAGGACTCCACCTACAGCCTGAGCAGCACCCCTG
ACACTGAGCAAGGCCGACTACGAGAAGCACAAGGTGTACGCCTGCGAAGTGACCCACCAGGGCCTGTCTAGCCCC
GTGACCAAGAGCTTCAACCGGGGCGAGTGT

2 270

3 271

AACCACTACACCCAGAAGTCCCTGTCTCTGTCCCTGGGC 4 272

GTCTAGCCCCGTGACCAAGAGCTTCAACCGGGGCGAGTGT CD38hu6284/ 1 273

CD28sup ×

CD3mid_ENLQ

DKTHT IgG4

FALA

TCACCTTTGGCAGCGGCACCAAGGTGGAAATCAAGGACAAAACCCATACCGACATCCAGATGACCCAGAGCCCCA

GCAGCCTGTCTGCCAGCGTGGGCGACAGAGTGACCATCACCTGTCAGGCCAGCCAGAACATCTACGGTGTGGCTGA

GGAGCCCTGTGTGCGAGCGTGGGCGACAGAGGTGTGACCAATGACCTGTCTAGGCGCAGCCAGATACATCTACCTGTGTGGCTGTGA
ACTCGTATCAGCAGAAAGCCCCGCAAGGCCGCCCAAGCTGCTGATCTACAAGGCCAGCAACCTGCACACCGGGCGCTCG

ACTGGTATCAGGCAGAAAGCCCGGCAAGGCCCCCAAGCTGCTGATCTACAAAGGCCAGCAACCCTGCACACCAGGCTGCG
GGAGGAGATTCTCTGGGAGGGGGCTGGGGGAGGGGAGTTGAGGGCTGAGAAATCAGGCTGGGCTGGAGGGGGAGGAGATTG

CCAGCAGATTTCCTGGCAGCGGCTCCGGCACCGACTTCACCCTGACAATCAGCTCCCTGCAGCCCGAGGACAATGC

CACTTACCTGACCTAGCCAGGCGACCTACCCCTTGGCCAGGACCAAGCTGGAATCAAGGATAA
GACCCACACCCGTACGGTGGCCGCTCCCAGCGTGTTCATCTTCCCACCTAGCGACGAGCAGCTGAAGTCCGGCACA
GCCTCTGTCTGTGCTGCTGAACAACTTCTACCCCCGCGAGGCCAAAGTGCAGTGGAAGGTGGACAACGCCCTGC
AGAGCGGCAACAGCCAGGAAAGCGTGACCGAGCAGGACAGCAAGGACTCCACCTACAGCCTGAGCAGCACCTGT
ACACTGAGCAAGGCCGACTACGAGAAGCACAAGGTGTACGCCTGCGAAGTGACCCACCAGGGCCTGTCTAGCCCC
GTGACCAAGAGCTTCAACCGGGGCGAGTGT 2 274

CAGGTGCAGCTGGTGCAGTCTGGCGCCGAGGTCGTGAAACCTGGCGCCTCTGTGAAGGTGTCCTGCAAGGCCAGC
GGCTACACCTTTACCAGCTACTACATCCACTGGGTGCGCCAGGCCCTGGACAGGGACTGGAATGGATCGGCAGC
ATCTACCCCCGCAACGTGAACACCAACTACGCCCAGAAGTTCCAGGGCAGAGCCACCCTGACCGTGACACCAGC
ATCAGCACCGCCTACATGGAAGTGAAGCGGCTGAGAAGCGACGACACCGCCGTGTACTACTGCACCCGGTCCCAC
TACGGCCTGGATTGGAAGTTCGACGTGTGGGGCAAGGGCACCACCGTGACAGTGTCTAGCGACAAAACCCATAACC
CAGGTGCAGCTGGTGGAACTCTGGCGGCGGAGTGGTGCAGCCTGGCAGAAGCCTGAGACTGAGCTGTGCCGCCAGC
GGCTTCACCTTCACCAAGGCCTGGATGCACTGGGTGCGCCAGGCCCTGGAAAGCAGCTGGAATGGGTGGCCAG
ATCAAGGACAAGAGCAACAGCTACGCCACCTACTACGCCGACAGCGTGAAGGGCCGGTTACCATCAGCCGGGAC
GACAGCAAGAACACCCTGTACCTGCAGATGAACAGCCTGCGGGCCGAGGACACCGCCGTGTACTACTGTCCGGGC
GTGTACTATGCCCTGAGCCCCCTTCGATTACTGGGGCCAGGGAACCCTCGTGACCGTGTCTAGTGATAAGACCCACA
CCGCCAGCACAAAGGGCCCATCGGTGTTCCCTCTGGCCCCCTTGACAGCAGAAGCACCAGCGAATCTACAGCCGCCCT
GGGCTGCCTCGTGAAGGACTACTTTCCCGAGCCCCGTGACCGTGTCTGGAAGTCTGGCGCTCTGACAAGCGGCGTG
CACACCTTTCCAGCCGTGCTCCAGAGCAGCGGCCTGTACTCTCTGAGCAGCGTCTGTGACAGTGCCCAGCAGCAGCC
TGGGCACCAAGACCTACACCTGTAACGTGGACCACAAGCCCAGCAACACCAAGGTGGACAAGCGGGTGGAACTCTA
AGTACGGCCCTCCCTGCCCTCCTTGCCAGCCCCCTGAAGCTGCCGGCGGACCCTCCGTGTTCCCTGTTCCCCCAAAG
CCCAAGGACACCCTGATGATCAGCCGGACCCCCGAAGTGACCTGCGTGGTGGTGGATGTGTCCCAGGAAGATCCC
GAGGTGCAGTTCAATTGGTACGTGGACGGCGTGGAAGTGCACAACGCCAAGACCAAGCCCAGAGAGGAACAGTTC
AACAGCACCTACCGGGTGGTGTCCGTGCTGACCGTGTCTGCACCAGGACTGGCTGAACGGCAAAGAGTACAAGTGC
AAGGTGTCCAACAAGGGCCTGCCAGCTCCATCGAGAAAACCATCAGCAAGGCCAAGGGCCAGCCCCGCGAGCCT
CAAGTGTGTACCCTGCCCCCTAGCCAGGAAGAGATGACCAAGAACCAGGTGTCCCTGAGCTGTGCCGTGAAAGGC
TTCTACCCCAGCGACATTGCCGTGGAATGGGAGAGCAACGGCCAGCCCGAGAACAATAAGACCACCCCCCT
GTGCTGGACAGCGACGGCTCATTCTTCCCTGGTGTCCAAGCTGACCGTGGACAAGAGCCGGTGGCAGGAAGGCAAC
GTGTTACAGCTGCTCCGTGATGCACGAGGCCCTGCACAACCACTACACCCAGAAGTCCCTGTCTCTGTCCCTGGGC
3 275

CAGGTTACAGCTGGTTCAGTCTGGCGCCGAAGTGAAGAAACCTGGCGCCTCTGTGAAGGTGTCCTGCAAGGCCAGC
GGCTACAGCTTCACCAATTACGCCGTGCACTGGGTCCGACAGGCTCCAGGACAAGGACTGGAATGGATGGGCGTG
ATCAGCCCCTACTACGGCGATACCACATACGCCCAGAAATTCCAGGGCAGAGTGACCATGACCGTGGACAAGAGC
AGCAGCACCGCCTACATGGAAGTGAAGCAGACTGAGAAGCGACGACACCGCCGTGTACTACTGCGCCAGAAGATTC
GAGGGCTTCTACTACAGCATGGACTACTGGGGCCAGGGCACCCTGGTTACAGTCTCTTCTGCGTCGACCAAGGGCC
CATCGGTGTTCCCTCTGGCCCCCTTGACAGCAGAAGCACCAGCGAATCTACAGCCGCCCTGGGCTGCCTCGTGAAGGA
CTACTTTCCCGAGCCCGTGACCGTGTCTCTGGAAGTCTGGCGCTCTGACAAGCGGCGTGACACCTTTCCAGCCGTG
CTCCAGAGCAGCGGCCTGTACTCTCTGAGCAGCGTCTGTGACAGTGCCCAGCAGCAGCCTGGGCACCAAGACCTAC
ACCTGTAACGTGGACCACAAGCCCAGCAACACCAAGGTGGACAAGCGGGTGGAACTTAAGTACGGCCCTCCCTGC
CCTCCTTGCCCAGCCCCCTGAAGCTGCCGGCGGACCCTCCGTGTTCCCTGTTCCCCCAAAGCCCAAGGACACCCTGA
TGATCAGCCGGACCCCCGAAGTGACCTGCGTGGTGGTGGATGTGTCCCAGGAAGATCCCGAGGTGCAGTTCAATT
GGTACGTGGACGGCGTGGAAGTGCACAACGCCAAGACCAAGCCCAGAGAGGAACAGTTCAACAGCACCTACCGG
GTGGTGTCCGTGCTGACCGTGTCTGCACCAGGACTGGCTGAACGGCAAAGAGTACAAGTGAAGGTGTCCAACAAG
GGCCTGCCAGCTCCATCGAGAAAACCATCAGCAAGGCCAAGGGCCAGCCCCGCGAGCCTCAAGTGTATACCCTG
CCCCCTTGCCAGGAAGAGATGACCAAGAACCAGGTGTCCCTGTGGTGTCTCGTGAAAGGCTTCTACCCCAGCGACA
TTGCCGTGGAATGGGAGAGCAACGGCCAGCCCGAGAACAATAAGACCACCCCCCTGTGCTGGACAGCGACG
GCTCATTCTTCTGTACTCCAAGCTGACCGTGGACAAGAGCCGGTGGCAGGAAGGCAACGTGTTACAGCTGCTCCGT
GATGCACGAGGCCCTGCACAACCACTACACCCAGAAGTCCCTGTCTCTGTCCCTGGGC 4 276

GACGTGGTCATGACACAGAGCCCTCTGAGCCTGCCTGTGACACTGGGACAGCCTGCCAGCATCAGCTGTAGACCTA
GCCAGAGCCTGGTGCACAGCAACGGCAACACCTACCTGAAGTGGTATCAGCAGAGGGCCCGGACAGAGCCCCAAGC
TGCTGATCTACAAGGTGTCCAAGCGGTTACAGCGGCGTGCCCGATAGATTTTCTGGCAGCGGCTCTGGCACCGACTT
CACCTGAAGATTAGCAGAGTGGAAGCCGAGGACGTGGGCGTGTACTACTGTAGCCAGTCTACCCACGTGCCACT
GACCTTTGGCGGCGGAACAAAGGTGGAAATCAAGCGTACGGTGGCCGCTCCCAGCGTGTTTCATCTTCCCACCTAGC
GACGAGCAGCTGAAGTCCGGCACAGCCTCTGTCTGTGCTGTGAACAACCTTCTACCCCCGCGAGGCCAAAGTGC
AGTGGAAAGGTGGACAACGCCCTGCAGAGCGGCAACAGCCAGGAAAGCGTGACCGAGCAGGACAGCAAGGACTCC
ACCTACAGCCTGAGCAGCACCCCTGACACTGAGCAAGGCCGACTACGAGAAGCACAAGGTGTACGCCTGCGAAGTG
ACCCACCAGGGCCTGTCTAGCCCCGTGACCAAGAGCTTCAACCGGGGCGAGTGT

III. Trispecific and/or Trivalent Binding Proteins for Treating and/or Preventing HIV/AIDS

[0488] Certain aspects of the present disclosure relate to trispecific and/or trivalent binding proteins. Any of the CDRs or variable domains of any of the antigen binding proteins described herein may find use in a trispecific binding protein of the present disclosure. Trispecific binding proteins of various formats are contemplated. In some embodiments, the binding protein of the disclosure is a trispecific and/or trivalent binding protein comprising four polypeptide chains that form three antigen binding sites that specifically bind one or more HIV target proteins, wherein a first polypeptide chain comprises a

structure represented by the formula:

V.sub.L2-L.sub.1-V.sub.L1-L.sub.2-C.sub.L [I]

and a second polypeptide chain comprises a structure represented by the formula:

V.sub.H1-L.sub.3-V.sub.H2-L.sub.4-C.sub.H1-hinge-C.sub.H2-C.sub.H3 [II]

and a third polypeptide chain comprises a structure represented by the formula:

V.sub.H3-C.sub.H1-hinge-C.sub.H2-C.sub.H3 [III]

and a fourth polypeptide chain comprises a structure represented by the formula:

V.sub.L3-C.sub.L [IV] [0489] wherein: [0490] V.sub.L1 is a first immunoglobulin light chain variable domain; [0491] V.sub.L2 is a second immunoglobulin light chain variable domain; [0492] V.sub.L3 is a third immunoglobulin light chain variable domain; [0493] V.sub.H1 is a first immunoglobulin heavy chain variable domain; [0494] V.sub.H2 is a second immunoglobulin heavy chain variable domain; [0495] V.sub.H3 is a third immunoglobulin heavy chain variable domain; [0496] C.sub.L is an immunoglobulin light chain constant domain; [0497] C.sub.H1 is an immunoglobulin C.sub.H1 heavy chain constant domain; [0498] C.sub.H2 is an immunoglobulin C.sub.H2 heavy chain constant domain; [0499] C.sub.H3 is an immunoglobulin C.sub.H3 heavy chain constant domain; [0500] hinge is an immunoglobulin hinge region connecting the C.sub.H1 and C.sub.H2 domains; and [0501] L.sub.1, L.sub.2, L.sub.3 and L.sub.4 are amino acid linkers; [0502] and wherein the polypeptide of formula I and the polypeptide of formula II form a cross-over light chain-heavy chain pair. [0503] In some embodiments, the first polypeptide chain and the second polypeptide chain have a cross-over orientation that forms two distinct antigen binding sites. In some embodiments, the V.sub.H1 and V.sub.L1 form a binding pair and form the first antigen binding site. In some embodiments, the V.sub.H2 and V.sub.L2 form a binding pair and form the second antigen binding site. In some embodiments, the third polypeptide and the fourth polypeptide form a third antigen binding site. In some embodiments, the V.sub.H3 and V.sub.L3 form a binding pair and form the third antigen binding site. [0504] In some embodiments, the term “HIV” as used herein means Human Immunodeficiency Virus. As used herein, the term “HIV infection” generally encompasses infection of a host, particularly a human host, by the human immunodeficiency virus (HIV) family of retroviruses including, but not limited to, HIV I, HIV II, HIV III (also known as HTLV-II, LAV-1, LAV-2). HIV can be used herein to refer to any strains, forms, subtypes, clades and variations in the HIV family. Thus, treating HIV infection will encompass the treatment of a person who is a carrier of any of the HIV family of retroviruses or a person who is diagnosed with active AIDS, as well as the treatment or prophylaxis of the AIDS-related conditions in such persons. [0505] In some embodiments, the term “AIDS” as used herein means Acquired Immunodeficiency Syndrome. AIDS is caused by HIV. [0506] In some embodiments, the terms “CD4bs” or “CD4 binding site” refer to the binding site for CD4 (cluster of differentiation 4), which is a glycoprotein found on the surface of immune cells such as T helper cells, monocytes, macrophages, and dendritic cells. [0507] In some embodiments, the term “glycoprotein 160” or “gp160 protein” refers to the envelope glycoprotein complex of HIV and which is a homotrimer that is cleaved into gp120 and gp41 subunits. [0508] In some embodiments, the term “MPER” refers to the membrane-proximal external region of glycoprotein 41 (gp41), which is a subunit of the envelope protein complex of retroviruses, including HIV. [0509] In some embodiments, the term “glycan” refers to the carbohydrate portion of a glycoconjugate, such as a glycoprotein, glycolipid, or a proteoglycan. In the disclosed binding proteins, glycan refers to the HIV-1 envelope glycoprotein gp120. [0510] In some embodiments, e.g., as used in reference to a binding protein for treating and/or preventing HIV/AIDS, the term “T-cell engager” refers to binding proteins directed to a host's immune system, more specifically the T cells' cytotoxic activity as well as directed to a HIV target protein. [0511] In some embodiments, the term “trimer apex” refers to apex of HIV-1 envelope glycoprotein gp120. [0512] In some embodiments, a “neutralizing” binding protein as used herein refers to a molecule that is able to block or substantially reduce an effector function of a target antigen to which it binds. As used herein, “substantially reduce” means at least about 60%, preferably at least about 70%, more preferably at least about 75%, even more preferably at least about 80%, still more preferably at least about 85%, most preferably at least about 90% reduction of an effector function of the target antigen. [0513] In some embodiments, e.g., as used in reference to a binding protein for treating and/or preventing HIV/AIDS, the terms “treatment” or “treat” as used herein refer to both therapeutic treatment and prophylactic or preventative measures. Those in need of treatment include those having the disorder as well as those prone to have a disorder or those in which the disorder is to be prevented. In particular embodiments, binding proteins can be used to treat humans infected with HIV, or humans susceptible to HIV infection, or ameliorate HIV infection in a human subject infected with HIV. The binding proteins can also be used to prevent HIV in a human patient. [0514] It should be understood as that treating humans infected with HIV include those subjects who are at any one of the several stages of HIV infection progression, which, for example, include acute primary infection syndrome (which can be asymptomatic or associated with an influenza-like illness with fevers, malaise, diarrhea and neurologic symptoms such as headache), asymptomatic infection (which is the long latent period with a gradual decline in the number of circulating

CD4.sup.+ T cells) and AIDS (which is defined by more serious AIDS-defining illnesses and/or a decline in the circulating CD4 cell count to below a level that is compatible with effective immune function). In addition, treating or preventing HIV infection will also encompass treating suspected infection by HIV after suspected past exposure to HIV by e.g., contact with HIV-contaminated blood, blood transfusion, exchange of body fluids, “unsafe” sex with an infected person, accidental needle stick, receiving a tattoo or acupuncture with contaminated instruments, or transmission of the virus from a mother to a baby during pregnancy, delivery or shortly thereafter.

[0515] In some embodiments, one or more of the antigen binding sites binds an HIV target protein. In some embodiments, V.sub.H3 and V.sub.L3 form a third antigen binding site that binds an HIV target protein. In some embodiments, V.sub.H1 and V.sub.L1 form a first antigen binding site that binds a T cell target protein, V.sub.H2 and V.sub.L2 form a second antigen binding site that binds a T cell target protein, and V.sub.H3 and V.sub.L3 form a third antigen binding site that binds an HIV target protein. In some embodiments, V.sub.H1 and V.sub.L1 form a first antigen binding site that binds a T cell target protein, V.sub.H2 and V.sub.L2 form a second antigen binding site that binds a CD3 polypeptide, and V.sub.H3 and V.sub.L3 form a third antigen binding site that binds an HIV target protein. In some embodiments, V.sub.H1 and V.sub.L1 form a first antigen binding site that binds a CD28 polypeptide, V.sub.H2 and V.sub.L2 form a second antigen binding site that binds a CD3 polypeptide, and V.sub.H3 and V.sub.L3 form a third antigen binding site that binds an HIV target protein.

[0516] In some embodiments, the binding proteins specifically bind to one or more HIV target proteins (e.g., as described infra) and one or more target proteins on a T-cell including T cell receptor complex. These T-cell engager binding proteins are capable of recruiting T cells transiently to target cells and, at the same time, activating the cytolytic activity of the T cells. The T-cell engager trispecific antibodies can be used to activate HIV-1 reservoirs and redirect/activate T cells to lyse latently infected HIV-1.sup.+ T cells. Examples of target proteins on T cells include but are not limited to CD3 and CD28, among others. In some embodiments, the trispecific binding proteins may be generated by combining the antigen binding domains of two or more monospecific antibodies (parent antibodies) into one antibody. See International Publication Nos. WO 2011/038290 A2, WO 2013/086533 A1, WO 2013/070776 A1, WO 2012/154312 A1, and WO 2013/163427 A1. The binding proteins of the disclosure may be prepared using domains or sequences obtained or derived from any human or non-human antibody, including, for example, human, murine, or humanized antibodies.

[0517] In some embodiments of the disclosure, the trivalent binding protein is capable of binding three different antigen targets. In one embodiment, the binding protein is trispecific and one light chain-heavy chain pair is capable of binding two different antigen targets or epitopes and one light chain-heavy chain pair is capable of binding one antigen target or epitope.

[0518] In some embodiments, a binding protein of the present disclosure binds one or more HIV target proteins and one or more T cell target proteins. In some embodiments, the binding protein is capable of specifically binding one HIV target protein and two different epitopes on a single T cell target protein. In some embodiments, the binding protein is capable of specifically binding one HIV target protein and two different T cell target proteins (e.g., CD28 and CD3). In some embodiments, the first and second polypeptide chains of the binding protein form two antigen binding sites that specifically target two T cell target proteins, and the third and fourth polypeptide chains of the binding protein form an antigen binding site that specifically binds an HIV target protein. In some embodiments, the one or more HIV target proteins are one or more of glycoprotein 120, glycoprotein 41, and glycoprotein 160. In some embodiments, the one or more T cell target proteins are one or more of CD3 and CD28.

[0519] In some embodiments, a binding protein of the present disclosure comprises four polypeptide chains that form three antigen binding sites that specifically bind one or more HIV target proteins, wherein the first polypeptide chain comprises the amino acid sequence of SEQ ID NO:362 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:362; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO:363 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:363; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO:364 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:364; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO:365 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:365.

[0520] In some embodiments, a binding protein of the present disclosure comprises four polypeptide chains that form three antigen binding sites that specifically bind one or more HIV target proteins, wherein the first polypeptide chain comprises the amino acid sequence of SEQ ID NO:366 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:366; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO:367 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:367; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO:368 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:368; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO:369 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:369.

[0521] In some embodiments, a binding protein of the present disclosure comprises four polypeptide chains that form three antigen binding sites that specifically bind one or more HIV target proteins, wherein the first polypeptide chain comprises the amino acid sequence of SEQ ID NO:370 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:370; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO:371 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:371; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO:372 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:372; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO:373 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:373.

[0522] In some embodiments, a binding protein of the present disclosure comprises four polypeptide chains that form three antigen binding sites that specifically bind one or more HIV target proteins, wherein the first polypeptide chain comprises the

amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:473.

[0546] In some embodiments, a binding protein of the present disclosure comprises four polypeptide chains that form three antigen binding sites that specifically bind one or more HIV target proteins, wherein the first polypeptide chain comprises the amino acid sequence of SEQ ID NO:474 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:474; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO:475 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:475; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO:476 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:476; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO:477 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:477.

[0547] Exemplary and non-limiting polypeptides that may find use in any of the trispecific binding proteins described herein are provided in Table 4A.

Anti-HIV Binding Sites

[0548] Certain aspects of the present disclosure relate to binding proteins that comprise an antigen binding site that binds an HIV target protein or polypeptide.

[0549] In some embodiments, the HIV target protein is glycoprotein 120, glycoprotein 41, or glycoprotein 160. In some embodiments, a binding protein binds one or more of: glycoprotein 120, glycoprotein 41, and glycoprotein 160. Exemplary HIV target proteins include, without limitation, MPER of the HIV-1 gp41 protein, a CD4 binding site of the HIV-1 gp120 protein, a glycan in the V3 loop of the HIV-1 gp120 protein, or a trimer apex of the HIV-1 gp120 protein or gp160. For example, in some embodiments, a binding protein of the present disclosure comprises an antigen binding site that binds a CD4 binding site of the HIV-1 gp120 protein. Exemplary antigen binding sites that bind HIV target proteins contemplated for use herein include, without limitation, those described in International Publication No. WO2017/074878, such as those from antibodies CD4BS “a”, CD4BS “b”, MPER, MPER_100W, V1/V2 “a”, V1/V2 “b”, or V3.

[0550] In some embodiments, a binding protein comprising an antigen binding site that binds an HIV target protein is monospecific and/or monovalent, bispecific and/or bivalent, trispecific and/or trivalent, or multispecific and/or multivalent. In some embodiments, a binding protein that comprises an antigen binding site that binds an HIV target protein is a trispecific binding protein comprising four polypeptides that form three antigen binding sites.

[0551] In some embodiments, a binding protein of the present disclosure comprises an antigen binding site comprising: an antibody heavy chain variable (VH) domain comprising a CDR-H1 sequence comprising the amino acid sequence of NCPIN (SEQ ID NO:302) a CDR-H2 sequence comprising the amino acid sequence of WMKPRHGAVSYARQLQG (SEQ ID NO:303), and a CDR-H3 sequence comprising the amino acid sequence of GKYCTARDYYNWDFEH (SEQ ID NO:304); and/or an antibody light chain variable (VL) domain comprising a CDR-L1 sequence comprising the amino acid sequence of RTSQYGSLA (SEQ ID NO:305), a CDR-L2 sequence comprising the amino acid sequence of SGSTRAA (SEQ ID NO:306), and a CDR-L3 sequence comprising the amino acid sequence of QQYEF (SEQ ID NO:307). In some embodiments, a binding protein of the present disclosure comprises an antigen binding site comprising: an antibody heavy chain variable (VH) domain comprising a CDR-H1 sequence comprising the amino acid sequence of NCPIN (SEQ ID NO:302) a CDR-H2 sequence comprising the amino acid sequence of WMKPRHGAVSYARQLQG (SEQ ID NO:303), and a CDR-H3 sequence comprising the amino acid sequence of GKYCTARDYYNWDFEH (SEQ ID NO:304); and an antibody light chain variable (VL) domain comprising a CDR-L1 sequence comprising the amino acid sequence of RTSQYGSLA (SEQ ID NO:305), a CDR-L2 sequence comprising the amino acid sequence of SGSTRAA (SEQ ID NO:306), and a CDR-L3 sequence comprising the amino acid sequence of QQYEF (SEQ ID NO:307).

[0552] In some embodiments, a binding protein of the present disclosure comprises an antigen binding site comprising: an antibody heavy chain variable (VH) domain comprising a CDR-H1 sequence comprising the amino acid sequence of GYTFTAHI (SEQ ID NO:308) a CDR-H2 sequence comprising the amino acid sequence of IKPQYGAV (SEQ ID NO:309) or IKPQYGAT (SEQ ID NO:310); and/or an antibody light chain variable (VL) domain comprising a CDR-L1 sequence comprising the amino acid sequence of QGVGSD (SEQ ID NO:312), a CDR-L2 sequence comprising the amino acid sequence of HTS (SEQ ID NO:313), and a CDR-L3 sequence comprising the amino acid sequence of CQVLQF (SEQ ID NO:314). In some embodiments, a binding protein of the present disclosure comprises an antigen binding site comprising: an antibody heavy chain variable (VH) domain comprising a CDR-H1 sequence comprising the amino acid sequence of GYTFTAHI (SEQ ID NO:308) a CDR-H2 sequence comprising the amino acid sequence of IKPQYGAV (SEQ ID NO:309) or IKPQYGAT (SEQ ID NO:310); and an antibody light chain variable (VL) domain comprising a CDR-L1 sequence comprising the amino acid sequence of QGVGSD (SEQ ID NO:312), a CDR-L2 sequence comprising the amino acid sequence of HTS (SEQ ID NO:313), and a CDR-L3 sequence comprising the amino acid sequence of CQVLQF (SEQ ID NO:314). In some embodiments, a binding protein of the present disclosure comprises an antigen binding site comprising: an antibody heavy chain variable (VH) domain comprising a CDR-H1 sequence comprising the amino acid sequence of GYTFTAHI (SEQ ID NO:308) a CDR-H2 sequence comprising the amino acid sequence of IKPQYGAV (SEQ ID NO:309); and an antibody light chain variable (VL) domain comprising a CDR-L1 sequence comprising the amino acid sequence of QGVGSD (SEQ ID NO:312), a CDR-L2 sequence comprising the amino acid sequence of HTS (SEQ ID NO:313), and a CDR-L3 sequence comprising the amino acid sequence of CQVLQF (SEQ ID NO:314). In some embodiments, a binding protein of the present disclosure comprises an antigen binding site comprising: an antibody heavy chain variable (VH) domain comprising a CDR-H1 sequence comprising the amino acid sequence of GYTFTAHI (SEQ ID NO:308) a CDR-H2 sequence comprising the amino acid sequence of IKPQYGAV (SEQ ID NO:309); and an antibody light chain variable (VL) domain comprising a CDR-L1 sequence comprising the amino acid sequence of QGVGSD (SEQ ID NO:312), a CDR-L2 sequence comprising the amino acid sequence of HTS (SEQ ID NO:313), and a CDR-L3 sequence comprising the amino acid sequence of CQVLQF (SEQ ID NO:314).

acid sequence of CQVLQF (SEQ ID NO:314). In some embodiments, a binding protein of the present disclosure comprises an antigen binding site comprising: an antibody heavy chain variable (VH) domain comprising a CDR-H1 sequence comprising the amino acid sequence of GYTFTAHI (SEQ ID NO:308) a CDR-H2 sequence comprising the amino acid sequence of IKPQYGAT (SEQ ID NO:310); and/or an antibody light chain variable (VL) domain comprising a CDR-L1 sequence comprising the amino acid sequence of QGVGSD (SEQ ID NO:312), a CDR-L2 sequence comprising the amino acid sequence of HTS (SEQ ID NO:313), and a CDR-L3 sequence comprising the amino acid sequence of CQVLQF (SEQ ID NO:314). In some embodiments, a binding protein of the present disclosure comprises an antigen binding site comprising: an antibody heavy chain variable (VH) domain comprising a CDR-H1 sequence comprising the amino acid sequence of GYTFTAHI (SEQ ID NO:308) a CDR-H2 sequence comprising the amino acid sequence of IKPQYGAT (SEQ ID NO:310); and an antibody light chain variable (VL) domain comprising a CDR-L1 sequence comprising the amino acid sequence of QGVGSD (SEQ ID NO:312), a CDR-L2 sequence comprising the amino acid sequence of HTS (SEQ ID NO:313), and a CDR-L3 sequence comprising the amino acid sequence of CQVLQF (SEQ ID NO:314).

[0553] In some embodiments, a binding protein of the present disclosure comprises an antigen binding site comprising: an antibody heavy chain variable (VH) domain comprising a CDR-H1 sequence comprising the amino acid sequence of DCTLN (SEQ ID NO:315) a CDR-H2 sequence comprising the amino acid sequence of WLKPRWGAVNYARPLQG (SEQ ID NO:316), and a CDR-H3 sequence comprising the amino acid sequence of GKNCDYNWDFEH (SEQ ID NO:317); and/or an antibody light chain variable (VL) domain comprising a CDR-L1 sequence comprising the amino acid sequence of RTSQYGLA (SEQ ID NO:318), a CDR-L2 sequence comprising the amino acid sequence of SGSTRAA (SEQ ID NO:319), and a CDR-L3 sequence comprising the amino acid sequence of QQYEF (SEQ ID NO:320). In some embodiments, a binding protein of the present disclosure comprises an antigen binding site comprising: an antibody heavy chain variable (VH) domain comprising a CDR-H1 sequence comprising the amino acid sequence of DCTLN (SEQ ID NO:315) a CDR-H2 sequence comprising the amino acid sequence of WLKPRWGAVNYARPLQG (SEQ ID NO:316), and a CDR-H3 sequence comprising the amino acid sequence of GKNCDYNWDFEH (SEQ ID NO:317); and an antibody light chain variable (VL) domain comprising a CDR-L1 sequence comprising the amino acid sequence of RTSQYGLA (SEQ ID NO:318), a CDR-L2 sequence comprising the amino acid sequence of SGSTRAA (SEQ ID NO:319), and a CDR-L3 sequence comprising the amino acid sequence of QQYEF (SEQ ID NO:320).

[0554] In some embodiments, a binding protein of the present disclosure comprises an antigen binding site with a VH domain comprising an extended heavy chain FR3 loop of antibody VRC03, e.g., as described in Liu, Q. et al. (2019) Nat. Commun. 10:721.

[0555] In some embodiments, a binding protein of the present disclosure comprises an antigen binding site comprising: an antibody heavy chain variable (VH) domain comprising an amino acid sequence that is at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of QVRLSQSGGQMKKPGDSMRISCRASGYEFINCPINWIRLAPGKRPEWMGWMKPRHG AVSYARQLQGRVTMTRDMYSETAFLELRSLTSDDTAVYFCTRGKYCTARDYYNWD FEHWGQGTPVTVSS (SEQ ID NO:344), and/or an antibody light chain variable (VL) domain comprising an amino acid sequence that is at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SLTQSPGTLSLSPGETAIISCRTSQYGLAWYQQRPGQAPRLVIYSGSTRAAGIPDRFS GSRWGPDPYNTISNLESGDFGVYYCQQYEFFGQGTKVQVDIK (SEQ ID NO:346). In some embodiments, a binding protein of the present disclosure comprises an antigen binding site comprising: an antibody heavy chain variable (VH) domain comprising the amino acid sequence of SEQ ID NO:344, and/or an antibody light chain variable (VL) domain comprising the amino acid sequence of SEQ ID NO:346. In some embodiments, a binding protein of the present disclosure comprises an antigen binding site comprising: an antibody heavy chain variable (VH) domain comprising the amino acid sequence of SEQ ID NO:344, and an antibody light chain variable (VL) domain comprising the amino acid sequence of SEQ ID NO:346.

[0556] In some embodiments, a binding protein of the present disclosure comprises an antigen binding site comprising: an antibody heavy chain variable (VH) domain comprising an amino acid sequence that is at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of QVRLSQSGGQMKKPGDSMRISCRASGYEFINCPINWIRLAPGKRPEWMGWMKPRHG AVSYARQLQGRVTMTRQLSQDPDDPDWGTAFLERSLTSDDTAVYFCTRGKYCTA RDYYNWD FEHWGQGTPVTVSS (SEQ ID NO:345), and/or an antibody light chain variable (VL) domain comprising an amino acid sequence that is at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of SLTQSPGTLSLSPGETAIISCRTSQYGLAWYQQRPGQAPRLVIYSGSTRAAGIPDRFS GSRWGPDPYNTISNLESGDFGVYYCQQYEFFGQGTKVQVDIK (SEQ ID NO:346). In some embodiments, a binding protein of the present disclosure comprises an antigen binding site comprising: an antibody heavy chain variable (VH) domain comprising the amino acid sequence of SEQ ID NO:345, and/or an antibody light chain variable (VL) domain comprising the amino acid sequence of SEQ ID NO:346. In some embodiments, a binding protein of the present disclosure comprises an antigen binding site comprising: an antibody heavy chain variable (VH) domain comprising the amino acid sequence of SEQ ID NO:345, and an antibody light chain variable (VL) domain comprising the amino acid sequence of SEQ ID NO:346.

[0557] In some embodiments, a binding protein of the present disclosure comprises an antigen binding site comprising: an antibody heavy chain variable (VH) domain comprising an amino acid sequence that is at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of RAHLVQSGTAMKKPGASVRVSCQTSGYTFTAHLFWFRQAPGRGLEWVGWIKPQY GAVNFGGGFRDRVTLTRDVYREIAYMDIRGLKPDDTAVYYCARDRSYGDSSWALD AWGQGTTVVVSA (SEQ ID NO:347), and/or an antibody light chain variable (VL) domain comprising an amino acid sequence that is at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of YIHVTQSPSSLSVSIQDRVTINCQTSQGVGSDLHWYQHKPGRAPKLLIHHTSSVEDGV PSRFSGSGFHSTFNLITISDLQADDIATYYCQVLQFFGRGSRLHIK (SEQ ID NO:350). In some embodiments, a binding protein of the present disclosure comprises an antigen binding site comprising: an antibody heavy chain variable (VH) domain comprising the amino acid sequence of SEQ ID NO:347, and/or an antibody light chain variable (VL) domain comprising the amino acid sequence of SEQ ID NO:350. In some embodiments, a binding protein of the present disclosure comprises an antigen binding site comprising: an antibody heavy chain variable (VH) domain comprising the amino acid sequence of SEQ ID NO:347, and an antibody light chain variable (VL) domain comprising the amino acid sequence of SEQ ID NO:350.

[0558] In some embodiments, a binding protein of the present disclosure comprises an antigen binding site comprising: an antibody heavy chain variable (VH) domain comprising an amino acid sequence that is at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of RAHLVQSGTAMKKPGASVRVSCQTSGYTFTAHLFWFRQAPGRGLEWVGWIKPQY GATNFGGGFRDRVTLTRDVYREIAYMDIRGLKPDDTAVYYCARDRSYGDSSWALD AWGQGTTVVVSA (SEQ ID NO:348), and/or an antibody light chain variable (VL) domain comprising an amino acid sequence that is at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of YIHVTQSPSSLSVSIQDRVTINCQTSQGVGSDLHWYQHKPGRAPKLLIHHTSSVEDGV PSRFSGSGFHSTFNLITISDLQADDIATYYCQVLQFFGRGSRLHIK (SEQ ID NO:350). In some embodiments, a binding protein of the present disclosure comprises an antigen binding site comprising: an antibody heavy chain variable (VH) domain comprising the amino acid sequence of SEQ ID NO:348, and/or an antibody light chain variable (VL) domain comprising the amino acid sequence of SEQ ID NO:350. In some embodiments, a binding protein of the present disclosure comprises an antigen binding site comprising: an antibody heavy chain variable (VH) domain comprising the amino acid sequence of SEQ ID NO:348, and an antibody light chain variable (VL) domain comprising the amino acid sequence of SEQ ID NO:350.

[0559] In some embodiments, a binding protein of the present disclosure comprises an antigen binding site comprising: an antibody heavy chain variable (VH) domain comprising an amino acid sequence that is at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of RAHLVQSGTAMKKPGASVRVSCQTSGYTFTAHLFWFRQAPGRGLEWVGWIKPQY GAVNFGGGFRDRVTLTRQLSQDPDDPDWGIAYMDIRGLKPDDTAVYYCARDRSYG DSSWALDAWGQGTTVVVSA (SEQ ID NO:349), and/or an antibody light chain variable (VL) domain comprising an amino acid sequence that is at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of YIHVTQSPSSLSVSIQDRVTINCQTSQGVGSDLHWYQHKPGRAPKLLIHHTSSVEDGV PSRFSGSGFHSTFNLITISDLQADDIATYYCQVLQFFGRGSRLHIK (SEQ ID NO:350). In some embodiments, a binding protein of the present disclosure comprises an antigen binding site comprising: an antibody heavy chain variable (VH) domain comprising the amino acid sequence of SEQ ID NO:349, and/or an antibody light chain variable (VL) domain comprising the amino acid sequence of SEQ ID NO:350. In some embodiments, a binding protein of the present disclosure comprises an antigen binding site comprising: an antibody heavy chain variable (VH) domain comprising the amino acid sequence of SEQ ID NO:349, and an antibody light chain variable (VL) domain comprising the amino acid sequence of SEQ ID NO:350.

[0560] In some embodiments, a binding protein of the present disclosure comprises an antigen binding site comprising: an antibody heavy chain variable (VH) domain comprising an amino acid sequence that is at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of QVQLVQSGGQMKKPGESMRISCRASGYEFIDCTLNWIRLAPGKRPEWMGWLKPRW GAVNYARPLQGRVTMTRQLSQDPDDPDWGTAFLRLSLTVDDTAVYFCTRGNCD YNWDFEHWGRGTPVIVSS (SEQ ID NO:351), and/or an antibody light chain variable (VL) domain comprising an amino acid sequence that is at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of LTQSPGTLSPGETAIISCRTSQYGSALAWYQQRPGQAPRLVIYSGSTRAAGIPDRFSG SRWGPDPYNLTISNLESGDFGVYYCQQYEFFGQGTVQVDIK (SEQ ID NO:352). In some embodiments, a binding protein of the present disclosure comprises an antigen binding site comprising: an antibody heavy chain variable (VH)

domain comprising the amino acid sequence of SEQ ID NO:351, and/or an antibody light chain variable (VL) domain comprising the amino acid sequence of SEQ ID NO:352. In some embodiments, a binding protein of the present disclosure comprises an antigen binding site comprising: an antibody heavy chain variable (VH) domain comprising the amino acid sequence of SEQ ID NO:351, and an antibody light chain variable (VL) domain comprising the amino acid sequence of SEQ ID NO:352.

[0561] In some embodiments of any of the above embodiments, the binding protein is a trispecific binding protein. In some embodiments, the trispecific binding protein comprising an antigen binding site that binds an HIV target protein, an antigen binding site that binds a CD28 polypeptide, and an antigen binding site that binds a CD3 polypeptide. In some embodiments, the binding protein is a trispecific binding protein comprising four polypeptides comprising three antigen binding sites, wherein the polypeptide of formula I and the polypeptide of formula II form a cross-over light chain-heavy chain pair (e.g., as described herein). In some embodiments, the VH and VL domains of any of the anti-CD38 antigen binding sites described above represent V.sub.H3 and V.sub.L3 and form a third antigen binding site that binds an HIV target protein. In some embodiments, V.sub.H1 and V.sub.L1 form a first antigen binding site that binds a CD28 polypeptide, V.sub.H2 and V.sub.L2 form a second antigen binding site that binds a CD3 polypeptide, and the VH and VL domains of any of the anti-HIV antigen binding sites described above and/or in Table 1A represent V.sub.H3 and V.sub.L3 and form a third antigen binding site that binds an HIV target protein.

[0562] Sequences of exemplary anti-HIV antigen binding sites are provided in Table 1A. In some embodiments, a binding protein comprising an anti-HIV antigen binding site of the present disclosure comprises 1, 2, 3, 4, 5, or all 6 CDR sequences of an anti-HIV antibody described in Table 1A. In some embodiments, a binding protein comprising an anti-HIV antigen binding site of the present disclosure comprises a VH domain sequence and/or VL domain sequence of an anti-HIV antibody described in Table 1A.

TABLE-US-00007 TABLE 1A Anti-HIV binding protein sequences. Sequence SEQ Type Molecule Description ID NO Sequence CDR VRC07_523 CDR-H1 302 NCPIN (anti-Env CDR-H2 303 WMKPRHGAVSYARQLQG gp120 CDR-H3 304 GKYCTARDYYNWDFEH CD4bs) CDR-L1 305 RTSQYGSLA CDR-L2 306 SGSTRAA CDR-L3 307 QQYEF N6 CDR-H1 308 GYTFTAHI (anti-Env CDR-H2 309 IKPQYGAV gp120 Original CD4bs) CDR-H2 rw52 310 IKPQYGAT CDR-H3 311 DRSYGDSSWALDA CDR-L1 312 QGVGSD CDR-L2 313 HTS CDR-L3 314 CQVLQF VRC01.23 CDR-H1 315 DCTLN CDR-H2 316 WLKPRWGAVNYARPLQG CDR-H3 317 GKNCDYNWDFEH CDR-L1 318 RTSQYGSLA CDR-L2 319 SGSTRAA CDR-L3 320 QQYEF Variable VRC07_523 VH 344 QVRLSQSGGQMKKPGDSMRISCRASG domain YEFINCPINWIRLAPGKRPEWMGWM KPRHGAVSYARQLQGRVTMTRDMYS ETAFLELRSLTSDDTAVYFCTRGKYC TARDYYNWDFEHWGQGTPTVTVSS FR3-03 VH 345 QVRLSQSGGQMKKPGDSMRISCRASG YEFINCPINWIRLAPGKRPEWMGWM KPRHGAVSYARQLQGRVTMTRQLSQ DPDDPDWGTAFLELRSLTSDDTAVYF CTRGKYCTARDYYNWDFEHWGQGT PTVTVSS VL 346 SLTQSPGTLSPGETAIISCRTSQYGS LAWYQQRPGQAPRLVIYSGSTRAAGI PDRFSGSRWGPDYNTISNLESGDFG VYYCQQYEFFGQGTKVQVDIK N6 VH 347 RAHLVQSGTAMKKPGASVRVSCQTS GYTFTAHLFWFRQAPGRGLEWVGWI KPQYGAVNFGGGFRDRVTLTRDVYR EIAYMDIRGLKPDDTAVYYCARDRSY GDSSWALDAWGQGTTVVSA rw52 VH 348 RAHLVQSGTAMKKPGASVRVSCQTS GYTFTAHLFWFRQAPGRGLEWVGWI KPQYGATNFGGGFRDRVTLTRDVYR EIAYMDIRGLKPDDTAVYYCARDRSY GDSSWALDAWGQGTTVVSA FR3-03 VH 349 RAHLVQSGTAMKKPGASVRVSCQTS GYTFTAHLFWFRQAPGRGLEWVGWI KPQYGAVNFGGGFRDRVTLTRQLSQ DPDDPDWGTIAYMDIRGLKPDDTAVY YCARDRSYGDSSWALDAWGQGTTV VVSA VL 350 YIHVTQSPSSLSVSIGDRVTINCQTSQG VGSDLHWYQHKKPGRAPKLLIHTSSV EDGVPSRFSGSGFHTSFNLTISDLQAD DIATYYCQVLQFFGRGSRHLHIK VRC01.23 VH 351 QVQLVQSGGQMKKPGESMRISCRAS GYEFIDCTLNWIRLAPGKRPEWMGW LKPRWGAVNYARPLQGRVTMTRQLS QDPDDPDWGTAFLELRSLTVDDTAV YFCTRGKNCYNWDFEHWGRGTPVI VSS VL 352 LTQSPGTLSPGETAIISCRTSQYGS L AWYQQRPGQAPRLVIYSGSTRAAGIP DRFSGSRWGPDYNTISNLESGDFGV YYCQQYEFFGQGTKVQVDIK

Anti-CD28 Binding Sites

[0563] Certain aspects of the present disclosure relate to binding proteins that comprise an antigen binding site that binds a CD28 polypeptide. In some embodiments, the CD28 polypeptide is a human CD28 polypeptide, also known as Tp44. Human CD28 polypeptides are known in the art and include, without limitation, the polypeptides represented by NCBI Accession Numbers XP_011510499.1, XP_011510497.1, XP_011510496.1, NP_001230007.1, NP_001230006.1, or NP_006130.1, or a polypeptide produced from NCBI Gene ID Number 940. In some embodiments, a binding protein comprising an antigen binding site that binds a CD28 polypeptide is monospecific and/or monovalent, bispecific and/or bivalent, trispecific and/or trivalent, or multispecific and/or multivalent. In some embodiments, a binding protein that comprises an antigen binding site that binds a CD28 polypeptide is a trispecific binding protein comprising four polypeptides that form three antigen binding sites. In some embodiments, a binding protein that comprises an antigen binding site that binds a CD28 polypeptide is a trispecific binding protein comprising four polypeptides that form three antigen binding sites, one of which binds a CD28 polypeptide, and one of which binds a CD3 polypeptide. In some embodiments, a binding protein that comprises an antigen binding site that binds a CD28 polypeptide is a trispecific binding protein comprising four polypeptides that form three antigen binding sites, one of which binds a CD28 polypeptide, one of which binds a CD3 polypeptide, and one of which binds an HIV target protein.

[0564] In some embodiments, a binding protein of the present disclosure comprises an antigen binding site comprising: an antibody heavy chain variable (VH) domain comprising a CDR-H1 sequence comprising the amino acid sequence of

GYTFTSYYY (SEQ ID NO:332), a CDR-H2 sequence comprising the amino acid sequence of IYPGNVNT (SEQ ID NO:333), and a CDR-H3 sequence comprising the amino acid sequence of TRSHYGLDWNFDV (SEQ ID NO:334); and/or an antibody light chain variable (VL) domain comprising a CDR-L1 sequence comprising the amino acid sequence of QNIYVW (SEQ ID NO:335), a CDR-L2 sequence comprising the amino acid sequence of KAS (SEQ ID NO:336), and a CDR-L3 sequence comprising the amino acid sequence of QQGQTPYPY (SEQ ID NO:337). In some embodiments, a binding protein of the present disclosure comprises an antigen binding site comprising: an antibody heavy chain variable (VH) domain comprising a CDR-H1 sequence comprising the amino acid sequence of GYTFTSYYY (SEQ ID NO:332), a CDR-H2 sequence comprising the amino acid sequence of IYPGNVNT (SEQ ID NO:333), and a CDR-H3 sequence comprising the amino acid sequence of TRSHYGLDWNFDV (SEQ ID NO:334); and an antibody light chain variable (VL) domain comprising a CDR-L1 sequence comprising the amino acid sequence of QNIYVW (SEQ ID NO:335), a CDR-L2 sequence comprising the amino acid sequence of KAS (SEQ ID NO:336), and a CDR-L3 sequence comprising the amino acid sequence of QQGQTPYPY (SEQ ID NO:337).

[0565] In some embodiments, a binding protein of the present disclosure comprises an antigen binding site comprising: an antibody heavy chain variable (VH) domain comprising an amino acid sequence that is at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of QVQLVQSGAEVVKPGASVKVCKASGYTFTSYIHWVRQAPGQGLEWIGSIYPGNVNTNYAQKFQGRATLTVDTISITAYMELSRLSDDTAVYYCTRSHYGLDWNFDVWG KGTTVTVSS (SEQ ID NO:360), and/or an antibody light chain variable (VL) domain comprising an amino acid sequence that is at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of DIQMTQSPSSLSASVGDRTITCQASQNIYVWLNWYQKPGKAPKLLIYKASNLHTGVPSRFGSGSGTDFLTITSLQPEDATYYCQQGQTPYPTFGQGQTKLEIK (SEQ ID NO:361). In some embodiments, a binding protein of the present disclosure comprises an antigen binding site comprising: an antibody heavy chain variable (VH) domain comprising the amino acid sequence of SEQ ID NO:360, and/or an antibody light chain variable (VL) domain comprising the amino acid sequence of SEQ ID NO:361. In some embodiments, a binding protein of the present disclosure comprises an antigen binding site comprising: an antibody heavy chain variable (VH) domain comprising the amino acid sequence of SEQ ID NO:360, and an antibody light chain variable (VL) domain comprising the amino acid sequence of SEQ ID NO:361.

[0566] In some embodiments of any of the above embodiments, the binding protein is a trispecific binding protein. In some embodiments, the trispecific binding protein comprising an antigen binding site that binds an HIV target protein, an antigen binding site that binds a CD28 polypeptide, and an antigen binding site that binds a CD3 polypeptide. In some embodiments, the binding protein is a trispecific binding protein comprising four polypeptides comprising three antigen binding sites, wherein the polypeptide of formula I and the polypeptide of formula II form a cross-over light chain-heavy chain pair (e.g., as described herein). In some embodiments, the VH and VL domains of any of the anti-CD28 antigen binding sites described above represent V.sub.H1 and V.sub.L1 and form a first antigen binding site that binds a CD28 polypeptide. In some embodiments, the VH and VL domains of any of the anti-CD28 antigen binding sites described above represent V.sub.H1 and V.sub.L1 and form a first antigen binding site that binds a CD28 polypeptide, V.sub.H2 and V.sub.L2 form a second antigen binding site that binds a CD3 polypeptide, and V.sub.H3 and V.sub.L3 and form a third antigen binding site that binds an HIV target protein.

[0567] Sequences of exemplary anti-CD28 antigen binding sites are provided in Table 2. In some embodiments, a binding protein comprising an anti-CD28 antigen binding site of the present disclosure comprises 1, 2, 3, 4, 5, or all 6 CDR sequences of an anti-CD28 antibody described in Table 2A. In some embodiments, a binding protein comprising an anti-CD28 antigen binding site of the present disclosure comprises a VH domain sequence and/or VL domain sequence of an anti-CD28 antibody described in Table 2A.

TABLE-US-00008 TABLE 2A Anti-CD28 binding protein sequences. Sequence SEQ Type Molecule Description
ID NO Sequence CDR Anti-CD28 CDR-H1 332 GYTFTSYYY (sup) CDR-H2 333 IYPGNVNT CDR-H3 334
TRSHYGLDWNFDV CDR-L1 335 QNIYVW CDR-L2 336 KAS CDR-L3 337 QQGQTPYPY Variable Anti-CD28 VH 360
QVQLVQSGAEVVKPGASVKVCKAS Domain (sup) GYTFTSYIHWVRQAPGQGLEWIGSI
YPGNVNTNYAQKFQGRATLTVDTISITAYMELSRLSDDTAVYYCTRSHYG LDWNFDVWGKGTTVTVSS VL 361
DIQMTQSPSSLSASVGDRTITCQASQ NIYVWLNWYQKPGKAPKLLIYKAS
NLHTGVPSRFGSGSGTDFLTITSLQPEDATYYCQQGQTPYPTFGQGQTKLEI K
Anti-CD3 Binding Sites

[0568] Certain aspects of the present disclosure relate to binding proteins that comprise an antigen binding site that binds a CD3 polypeptide. In some embodiments, the CD3 polypeptide is a human CD3 polypeptide, including CD3-delta (also known as T3D, IMD19, and CD3-DELTA), CD3-epsilon (also known as T3E, IMD18, and TCRE), and CD3-gamma (also known as T3G, IMD17, and CD3-GAMMA). Human CD3 polypeptides are known in the art and include, without limitation, the polypeptides represented by NCBI Accession Numbers XP_006510029.1 or NP_031674.1, or a polypeptide produced from NCBI Gene ID Numbers 915, 916, or 917. In some embodiments, a binding protein comprising an antigen binding site that binds a CD3 polypeptide is monospecific and/or monovalent, bispecific and/or bivalent, trispecific and/or trivalent, or multispecific and/or multivalent. In some embodiments, a binding protein that comprises an antigen binding site that binds a CD3 polypeptide is a trispecific binding protein comprising four polypeptides that form three antigen binding sites. In some embodiments, a binding protein that comprises an antigen binding site that binds a CD3 polypeptide is a trispecific binding

and a CDR-L3 sequence comprising the amino acid sequence of GQGTQYPFT (SEQ ID NO:331). In some embodiments, a binding protein of the present disclosure comprises an antigen binding site comprising: an antibody heavy chain variable (VH) domain comprising a CDR-H1 sequence comprising the amino acid sequence of GFTFTKAW (SEQ ID NO:321), a CDR-H2 sequence comprising the amino acid sequence of IKDKSNSYAT (SEQ ID NO:322), and a CDR-H3 sequence comprising the amino acid sequence of RGVYYALSPFDY (SEQ ID NO:323); and an antibody light chain variable (VL) domain comprising a CDR-L1 sequence comprising the amino acid sequence of QSLVHENLRTY (SEQ ID NO:328), a CDR-L2 sequence comprising the amino acid sequence of KVS (SEQ ID NO:330), and a CDR-L3 sequence comprising the amino acid sequence of GQGTQYPFT (SEQ ID NO:331).

[0574] In some embodiments, a binding protein of the present disclosure comprises an antigen binding site comprising: an antibody heavy chain variable (VH) domain comprising an amino acid sequence that is at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of QVQLVESGGGVVQPGRSLRLSCAASGFTFTKAWMHWVRQAPGKQLEWVAQIKDKSNSYATYYADSVKGRFTISRDDSKNTLYLQMNSLRAEDTAVYYCRGVYYALSPFDY WGQGTLVTVSS (SEQ ID NO:353), and/or an antibody light chain variable (VL) domain comprising an amino acid sequence that is at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to an amino acid sequence selected from the group consisting of DIVMTQTPLSLSVTPGQPASISCKSSQSLVHQNAQTYLSWYLQKPGQSPQSLIYKVSNRFSGVLPDRFSGSGSGTDFTLKISRVEAEDVGVYYCGQGTQYPFTFGSGTKVEIK (SEQ ID NO:355), DIVMTQTPLSLSVTPGQPASISCKSSQSLVHENLQTYLSWYLQKPGQSPQSLIYKVSNRFSGVLPDRFSGSGSGTDFTLKISRVEAEDVGVYYCGQGTQYPFTFGSGTKVEIK (SEQ ID NO:356), DIVMTQTPLSLSVTPGQPASISCKSSQSLVHENLFTYLSWYLQKPGQSPQSLIYKVSNRFSGVLPDRFSGSGSGTDFTLKISRVEAEDVGVYYCGQGTQYPFTFGSGTKVEIK (SEQ ID NO:357), and DIVMTQTPLSLSVTPGQPASISCKSSQSLVHENLRTYLSWYLQKPGQSPQSLIYKVSNRFSGVLPDRFSGSGSGTDFTLKISRVEAEDVGVYYCGQGTQYPFTFGSGTKVEIK (SEQ ID NO:358). In some embodiments, a binding protein of the present disclosure comprises an antigen binding site comprising: an antibody heavy chain variable (VH) domain comprising the amino acid sequence of SEQ ID NO:353, and/or an antibody light chain variable (VL) domain comprising an amino acid sequence selected from the group consisting of SEQ ID NO:355, SEQ ID NO:356, SEQ ID NO:357, and SEQ ID NO:358. In some embodiments, a binding protein of the present disclosure comprises an antigen binding site comprising: an antibody heavy chain variable (VH) domain comprising the amino acid sequence of SEQ ID NO:353, and an antibody light chain variable (VL) domain comprising an amino acid sequence selected from the group consisting of SEQ ID NO:355, SEQ ID NO:356, SEQ ID NO:357, and SEQ ID NO:358.

[0575] In some embodiments, a binding protein of the present disclosure comprises an antigen binding site comprising: an antibody heavy chain variable (VH) domain comprising an amino acid sequence that is at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of QVQLVESGGGVVQPGRSLRLSCAASGFTFTKAWMHWVRQAPGKQLEWVAQIKDKSNSYATYYADSVKGRFTISRDDSKNTLYLQMNSLRAEDTAVYYCRGVYYALSPFDY WGQGTLVTVSS (SEQ ID NO:353), and/or an antibody light chain variable (VL) domain comprising an amino acid sequence that is at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of DIVMTQTPLSLSVTPGQPASISCKSSQSLVHQNAQTYLSWYLQKPGQSPQSLIYKVSNRFSGVLPDRFSGSGSGTDFTLKISRVEAEDVGVYYCGQGTQYPFTFGSGTKVEIK (SEQ ID NO:355). In some embodiments, a binding protein of the present disclosure comprises an antigen binding site comprising: an antibody heavy chain variable (VH) domain comprising the amino acid sequence of SEQ ID NO:353, and/or an antibody light chain variable (VL) domain comprising the amino acid sequence of SEQ ID NO:355. In some embodiments, a binding protein of the present disclosure comprises an antigen binding site comprising: an antibody heavy chain variable (VH) domain comprising the amino acid sequence of SEQ ID NO:353, and an antibody light chain variable (VL) domain comprising the amino acid sequence of SEQ ID NO:355.

[0576] In some embodiments, a binding protein of the present disclosure comprises an antigen binding site comprising: an antibody heavy chain variable (VH) domain comprising an amino acid sequence that is at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of QVQLVESGGGVVQPGRSLRLSCAASGFTFTKAWMHWVRQAPGKQLEWVAQIKDKSNSYATYYADSVKGRFTISRDDSKNTLYLQMNSLRAEDTAVYYCRGVYYALSPFDY WGQGTLVTVSS (SEQ ID NO:353), and/or an antibody light chain variable (VL) domain comprising an amino acid sequence that is at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of DIVMTQTPLSLSVTPGQPASISCKSSQSLVHENLQTYLSWYLQKPGQSPQSLIYKVSNRFSGVLPDRFSGSGSGTDFTLKISRVEAEDVGVYYCGQGTQYPFTFGSGTKVEIK (SEQ ID NO:356). In some embodiments, a binding protein of the present disclosure comprises an antigen binding site comprising: an antibody heavy chain variable (VH) domain comprising the amino acid sequence of SEQ ID NO:353, and/or an antibody light chain variable (VL) domain comprising the amino acid sequence of SEQ ID NO:356. In some embodiments, a binding protein of the

present disclosure comprises an antigen binding site comprising: an antibody heavy chain variable (VH) domain comprising the amino acid sequence of SEQ ID NO:353, and an antibody light chain variable (VL) domain comprising the amino acid sequence of SEQ ID NO:356.

[0577] In some embodiments, a binding protein of the present disclosure comprises an antigen binding site comprising: an antibody heavy chain variable (VH) domain comprising an amino acid sequence that is at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of QVQLVESGGGVVQPGRSLRLSCAASGFTFTKAWMHWRQAPGKQLEWVAQIKDKS NSYATYYADSVKGRFTISRDDSKNTLYLQMNSLRAEDTAVYYCRGVYYALSPFDY WGQGTLLTVSS (SEQ ID NO:353), and/or an antibody light chain variable (VL) domain comprising an amino acid sequence that is at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of DIVMTQTPLSLSVTPGQPASISCKSSQSLVHENLFTYLSWYLRKPGQSPQSLIYKVS NR FSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCGQGTQYPFTFGSGTKVEIK (SEQ ID NO:357). In some embodiments, a binding protein of the present disclosure comprises an antigen binding site comprising: an antibody heavy chain variable (VH) domain comprising the amino acid sequence of SEQ ID NO:353, and/or an antibody light chain variable (VL) domain comprising the amino acid sequence of SEQ ID NO:357. In some embodiments, a binding protein of the present disclosure comprises an antigen binding site comprising: an antibody heavy chain variable (VH) domain comprising the amino acid sequence of SEQ ID NO:353, and an antibody light chain variable (VL) domain comprising the amino acid sequence of SEQ ID NO:357.

[0578] In some embodiments, a binding protein of the present disclosure comprises an antigen binding site comprising: an antibody heavy chain variable (VH) domain comprising an amino acid sequence that is at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of QVQLVESGGGVVQPGRSLRLSCAASGFTFTKAWMHWRQAPGKQLEWVAQIKDKS NSYATYYADSVKGRFTISRDDSKNTLYLQMNSLRAEDTAVYYCRGVYYALSPFDY WGQGTLLTVSS (SEQ ID NO:353), and/or an antibody light chain variable (VL) domain comprising an amino acid sequence that is at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of DIVMTQTPLSLSVTPGQPASISCKSSQSLVHENLRTYLSWYLRKPGQSPQSLIYKVS NR FSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCGQGTQYPFTFGSGTKVEIK (SEQ ID NO:358). In some embodiments, a binding protein of the present disclosure comprises an antigen binding site comprising: an antibody heavy chain variable (VH) domain comprising the amino acid sequence of SEQ ID NO:353, and/or an antibody light chain variable (VL) domain comprising the amino acid sequence of SEQ ID NO:358. In some embodiments, a binding protein of the present disclosure comprises an antigen binding site comprising: an antibody heavy chain variable (VH) domain comprising the amino acid sequence of SEQ ID NO:353, and an antibody light chain variable (VL) domain comprising the amino acid sequence of SEQ ID NO:358.

[0579] Advantageously, anti-CD3 binding sites are described herein with high affinity binding to human CD3 polypeptides and potential manufacturing liabilities (e.g., deamidation sites) removed.

[0580] In some embodiments of any of the above embodiments, the binding protein is a trispecific binding protein. In some embodiments, the trispecific binding protein comprising an antigen binding site that binds an HIV target protein, an antigen binding site that binds a CD28 polypeptide, and an antigen binding site that binds a CD3 polypeptide. In some embodiments, the binding protein is a trispecific binding protein comprising four polypeptides comprising three antigen binding sites, wherein the polypeptide of formula I and the polypeptide of formula II form a cross-over light chain-heavy chain pair (e.g., as described herein). In some embodiments, the VH and VL domains of any of the anti-CD3 antigen binding sites described above represent V.sub.H2 and V.sub.L2 and form a second antigen binding site that binds a CD3 polypeptide. In some embodiments, V.sub.H1 and V.sub.L1 form a first antigen binding site that binds a CD28 polypeptide, the VH and VL domains of any of the anti-CD3 antigen binding sites described above and/or in Table 3 represent V.sub.H2 and V.sub.L2 and form a second antigen binding site that binds a CD3 polypeptide, and V.sub.H3 and V.sub.L3 form a third antigen binding site that binds an HIV target protein.

[0581] Sequences of exemplary anti-CD3 antigen binding sites are provided in Table 3. In some embodiments, a binding protein comprising an anti-CD3 antigen binding site of the present disclosure comprises 1, 2, 3, 4, 5, or all 6 CDR sequences of an anti-CD3 antibody described in Table 3A. In some embodiments, a binding protein comprising an anti-CD3 antigen binding site of the present disclosure comprises a VH domain sequence and/or VL domain sequence of an anti-CD3 antibody described in Table 3A.

TABLE-US-00009 TABLE 3A Anti-CD3 binding protein sequences. Sequence SEQ Type Molecule Description ID NO Sequence CDR Anti-CD3 CDR-H1 321 GFTFTKAW (mid) original CDR-H2 322 IKDKSNSYAT original CDR-H3 323 RGVYYALSPFDY original CDR-L1 324 QSLVHNNANTY original CDR-L1 QQ 325 QSLVHQNAQTY CDR-L1 ENLQ 326 QSLVHENLQTY CDR-L1 ENLF 327 QSLVHENLFTY CDR-L1 ENLR 328 QSLVHENLRTY CDR-L1 329 QSLVHDNAQTY DNAQ CDR-L2 330 KVS original CDR-L3 331 GQGTQYPFT Original consensus 594 QSLVHX.sub.1NX.sub.2X.sub.3TY, CDR-L1 wherein X.sub.1 is E or Q, X.sub.2 is A or L, and X.sub.3 is Q, R, or F Variable Anti-CD3 VH 353 QVQLVESGGGVVQPGRSLRLSCAASG domain (mid) FTFTKAWMHWRQAPGKQLEWVAQ IKDKSNSYATYYADSVKGRFTISRDDS

KNTLYLQMNLSRAEDYVY YALSPFDYWGQGLVTVSS VL 354
 DIVMTQTPLSLSVTPGQPASISCKSSQS Original LVHNNANTYLSWYLQKPGQSPQSLIY
 KVSNRFSGVDPDRFSGSGSGTDFTLKIS RVEAEDVG VYYCGQGTQYPFTFGSG TKVEIK VL 355
 DIVMTQTPLSLSVTPGQPASISCKSSQS 32/35 QQ LVHQNAQTYLSWYLQKPGQSPQSLIY
 KVSNRFSGVDPDRFSGSGSGTDFTLKIS RVEAEDVG VYYCGQGTQYPFTFGSG TKVEIK VL 356
 DIVMTQTPLSLSVTPGQPASISCKSSQS ENLQ LVHENLQTYLSWYLQKPGQSPQSLIY
 KVSNRFSGVDPDRFSGSGSGTDFTLKIS RVEAEDVG VYYCGQGTQYPFTFGSG TKVEIK VL 357
 DIVMTQTPLSLSVTPGQPASISCKSSQS ENLF LVHENLFTYLSWYLQKPGQSPQSLIY
 KVSNRFSGVDPDRFSGSGSGTDFTLKIS RVEAEDVG VYYCGQGTQYPFTFGSG TKVEIK VL 358
 DIVMTQTPLSLSVTPGQPASISCKSSQS ENLR LVHENLRTYLSWYLQKPGQSPQSLIY
 KVSNRFSGVDPDRFSGSGSGTDFTLKIS RVEAEDVG VYYCGQGTQYPFTFGSG TKVEIK VL 359
 DIVMTQTPLSLSVTPGQPASISCKSSQS DNAQ LVHDNAQTYLSWYLQKPGQSPQSLIY
 KVSNRFSGVDPDRFSGSGSGTDFTLKIS RVEAEDVG VYYCGQGTQYPFTFGSG TKVEIK

Linkers

[0582] In some embodiments, the linkers L.sub.1, L.sub.2, L.sub.3, and L.sub.4 range from no amino acids (length=0) to about 100 amino acids long, or less than 100, 50, 40, 30, 20, or 15 amino acids or less. The linkers can also be 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acids long. L.sub.1, L.sub.2, L.sub.3, and L.sub.4 in one binding protein may all have the same amino acid sequence or may all have different amino acid sequences.

[0583] Examples of suitable linkers include, for example, GGGGSGGGGS (SEQ ID NO:341), GGGGSGGGGS (SEQ ID NO:342), S, RT, TKGPS (SEQ ID NO:340), GQPKAAP (SEQ ID NO:339), GSGSSGSGG (SEQ ID NO:343), and DKHTT (SEQ ID NO:338), as well as those disclosed in International Publication Nos. WO2017/074878 and WO2017/180913. The examples listed above are not intended to limit the scope of the disclosure in any way, and linkers comprising randomly selected amino acids selected from the group consisting of valine, leucine, isoleucine, serine, threonine, lysine, arginine, histidine, aspartate, glutamate, asparagine, glutamine, glycine, and proline have been shown to be suitable in the binding proteins.

[0584] The identity and sequence of amino acid residues in the linker may vary depending on the type of secondary structural element necessary to achieve in the linker. For example, glycine, serine, and alanine are best for linkers having maximum flexibility. Some combination of glycine, proline, threonine, and serine are useful if a more rigid and extended linker is necessary. Any amino acid residue may be considered as a linker in combination with other amino acid residues to construct larger peptide linkers as necessary depending on the desired properties.

[0585] In some embodiments, the length of L.sub.1 is at least twice the length of L.sub.3. In some embodiments, the length of L.sub.2 is at least twice the length of L.sub.4. In some embodiments, the length of L.sub.1 is at least twice the length of L.sub.3, and the length of L.sub.2 is at least twice the length of L.sub.4. In some embodiments, L.sub.1 is 3 to 12 amino acid residues in length, L.sub.2 is 3 to 14 amino acid residues in length, L.sub.3 is 1 to 8 amino acid residues in length, and L.sub.4 is 1 to 3 amino acid residues in length. In some embodiments, L.sub.1 is 5 to 10 amino acid residues in length, L.sub.2 is 5 to 8 amino acid residues in length, L.sub.3 is 1 to 5 amino acid residues in length, and L.sub.4 is 1 to 2 amino acid residues in length. In some embodiments, L.sub.1 is 7 amino acid residues in length, L.sub.2 is 5 amino acid residues in length, L.sub.3 is 1 amino acid residue in length, and L.sub.4 is 2 amino acid residues in length.

[0586] In some embodiments, L.sub.1, L.sub.2, L.sub.3 and L.sub.4 each independently are zero amino acids in length or comprise a sequence selected from the group consisting of GGGGSGGGGS (SEQ ID NO:341), GGGGSGGGGS (SEQ ID NO:342), S, RT, TKGPS (SEQ ID NO:340), GQPKAAP (SEQ ID NO:339), and GSGSSGSGG (SEQ ID NO:42). In some embodiments, L.sub.1, L.sub.2, L.sub.3 and L.sub.4 each independently comprise a sequence selected from the group consisting of GGGGSGGGGS (SEQ ID NO:341), GGGGSGGGGS (SEQ ID NO:342), S, RT, TKGPS (SEQ ID NO:340), GQPKAAP (SEQ ID NO:339), and GSGSSGSGG (SEQ ID NO:343). In some embodiments, L.sub.1 comprises the sequence GQPKAAP (SEQ ID NO:339), L.sub.2 comprises the sequence TKGPS (SEQ ID NO:340), L.sub.3 comprises the sequence S, and L.sub.4 comprises the sequence RT.

[0587] In some embodiments, at least one of L.sub.1, L.sub.2, L.sub.3 or L.sub.4 comprises the sequence DKHTT (SEQ ID NO:338). In some embodiments, L.sub.1, L.sub.2, L.sub.3 and L.sub.4 comprise the sequence DKHTT (SEQ ID NO:338).

Fc Regions and Constant Domains

[0588] In some embodiments, a binding protein of the present disclosure comprises a second polypeptide chain further comprising an Fc region linked to C.sub.H1, the Fc region comprising an immunoglobulin hinge region and C.sub.H2 and C.sub.H3 immunoglobulin heavy chain constant domains. In some embodiments, a binding protein of the present disclosure comprises a third polypeptide chain further comprising an Fc region linked to C.sub.H1, the Fc region comprising an immunoglobulin hinge region and C.sub.H2 and C.sub.H3 immunoglobulin heavy chain constant domains. In some embodiments, a binding protein of the present disclosure comprises a second polypeptide chain further comprising an Fc region linked to C.sub.H1, the Fc region comprising an immunoglobulin hinge region and C.sub.H2 and C.sub.H3 immunoglobulin heavy chain constant domains, and a third polypeptide chain further comprising an Fc region linked to C.sub.H1, the Fc region comprising an immunoglobulin hinge region and C.sub.H2 and C.sub.H3 immunoglobulin heavy chain constant domains.

[0589] In some embodiments, a binding protein of the present disclosure comprises a full-length antibody heavy chain or a polypeptide chain comprising an Fc region. In some embodiments, the Fc region is a human Fc region, e.g., a human IgG1, IgG2, IgG3, or IgG4 Fc region. In some embodiments, the Fc region includes an antibody hinge, C.sub.H1, C.sub.H2, C.sub.H3, and optionally C.sub.H4 domains. In some embodiments, the Fc region is a human IgG1 Fc region. In some

embodiments, the Fc region is a human IgG4 Fc region. In some embodiments, the Fc region includes one or more of the mutations described infra. In some embodiments, the Fc region is an Fc region of one of the heavy chain polypeptides (e.g. polypeptide 2 or 3) of a binding protein shown in Table 4. In some embodiments, the heavy chain constant region is a constant region of one of the heavy chain polypeptides (e.g., polypeptide 2 or 3) of a binding protein shown in Table 4. In some embodiments, the light chain constant region is a constant region of one of the light chain polypeptides (e.g. polypeptide 1 or 4) of a binding protein shown in Table 4A.

[0590] In some embodiments, a binding protein of the present disclosure includes one or two Fc variants. The term “Fc variant” as used herein refers to a molecule or sequence that is modified from a native Fc but still comprises a binding site for the salvage receptor, FcRn (neonatal Fc receptor). Exemplary Fc variants, and their interaction with the salvage receptor, are known in the art. Thus, the term “Fc variant” can comprise a molecule or sequence that is humanized from a non-human native Fc. Furthermore, a native Fc comprises regions that can be removed because they provide structural features or biological activity that are not required for the antibody-like binding proteins of the invention. Thus, the term “Fc variant” comprises a molecule or sequence that lacks one or more native Fc sites or residues, or in which one or more Fc sites or residues has been modified, that affect or are involved in: (1) disulfide bond formation, (2) incompatibility with a selected host cell, (3) N-terminal heterogeneity upon expression in a selected host cell, (4) glycosylation, (5) interaction with complement, (6) binding to an Fc receptor other than a salvage receptor, or (7) antibody-dependent cellular cytotoxicity (ADCC).

[0591] In some embodiments, a binding protein of the present disclosure (e.g., a trispecific binding protein) comprises a “knob” mutation on the second polypeptide chain and a “hole” mutation on the third polypeptide chain. In some embodiments, a binding protein of the present disclosure comprises a “knob” mutation on the third polypeptide chain and a “hole” mutation on the second polypeptide chain. In some embodiments, the “knob” mutation comprises substitution(s) at positions corresponding to positions 354 and/or 366 of human IgG1 or IgG4 according to EU Index. In some embodiments, the amino acid substitutions are S354C, T366W, T366Y, S354C and T366W, or S354C and T366Y. In some embodiments, the “knob” mutation comprises substitutions at positions corresponding to positions 354 and 366 of human IgG1 or IgG4 according to EU Index. In some embodiments, the amino acid substitutions are S354C and T366W. In some embodiments, the “hole” mutation comprises substitution(s) at positions corresponding to positions 407 and, optionally, 349, 366, and/or 368 and of human IgG1 or IgG4 according to EU Index. In some embodiments, the amino acid substitutions are Y407V or Y407T and optionally Y349C, T366S, and/or L368A. In some embodiments, the “hole” mutation comprises substitutions at positions corresponding to positions 349, 366, 368, and 407 of human IgG1 or IgG4 according to EU Index. In some embodiments, the amino acid substitutions are Y349C, T366S, L368A, and Y407V.

[0592] In some embodiments, the second polypeptide chain further comprises a first Fc region linked to CH1, the first Fc region comprising an immunoglobulin hinge region and CH2 and CH3 immunoglobulin heavy chain constant domains, wherein the first Fc region comprises amino acid substitution(s) at positions corresponding to positions 366 and optionally 354 of human IgG1 or IgG4 according to EU Index, wherein the amino acid substitutions are T366W or T366Y and optionally S354C; and wherein the third polypeptide chain further comprises a second Fc region linked to CH1, the second Fc region comprising an immunoglobulin hinge region and CH2 and CH3 immunoglobulin heavy chain constant domains, wherein the second Fc region comprises amino acid substitution(s) at positions corresponding to positions 407 and optionally 349, 366, and/or 368 and of human IgG1 or IgG4 according to EU Index, wherein the amino acid substitutions are Y407V or Y407T and optionally Y349C, T366S, and/or L368A.

[0593] In some embodiments, the second polypeptide chain further comprises a first Fc region linked to CH1, the first Fc region comprising an immunoglobulin hinge region and CH2 and CH3 immunoglobulin heavy chain constant domains, wherein the first Fc region comprises amino acid substitution(s) at positions corresponding to positions 407 and optionally 349, 366, and/or 368 and of human IgG1 or IgG4 according to EU Index, wherein the amino acid substitutions are Y407V or Y407T and optionally Y349C, T366S, and/or L368A; and wherein the third polypeptide chain further comprises a second Fc region linked to CH1, the second Fc region comprising an immunoglobulin hinge region and CH2 and CH3 immunoglobulin heavy chain constant domains, wherein the second Fc region comprises amino acid substitution(s) at positions corresponding to positions 366 and optionally 354 of human IgG1 or IgG4 according to EU Index, wherein the amino acid substitutions are T366W or T366Y and optionally S354C.

[0594] In some embodiments, the second polypeptide chain further comprises a first Fc region linked to CH1, the first Fc region comprising an immunoglobulin hinge region and CH2 and CH3 immunoglobulin heavy chain constant domains, wherein the first Fc region comprises amino acid substitution at position corresponding to position 366 of human IgG1 or IgG4 according to EU Index, wherein the amino acid substitution is T366W; and wherein the third polypeptide chain further comprises a second Fc region linked to CH1, the second Fc region comprising an immunoglobulin hinge region and CH2 and CH3 immunoglobulin heavy chain constant domains, wherein the second Fc region comprises amino acid substitution(s) at positions corresponding to positions 366, 368, and/or 407 and of human IgG1 or IgG4 according to EU Index, wherein the amino acid substitutions are T366S, L368A, and/or Y407V.

[0595] In some embodiments, the second polypeptide chain further comprises a first Fc region linked to CH1, the first Fc region comprising an immunoglobulin hinge region and CH2 and CH3 immunoglobulin heavy chain constant domains, wherein the first Fc region comprises amino acid substitution(s) at positions corresponding to positions 366, 368, and/or 407 and of human IgG1 or IgG4 according to EU Index, wherein the amino acid substitutions are T366S, L368A, and/or Y407V; and wherein the third polypeptide chain further comprises a second Fc region linked to CH1, the second Fc region comprising an immunoglobulin hinge region and CH2 and CH3 immunoglobulin heavy chain constant domains, wherein the second Fc region comprises amino acid substitution at position corresponding to position 366 of human IgG1 or IgG4 according to EU Index, wherein the amino acid substitution is T366W.

[0596] In some embodiments, the second polypeptide chain further comprises a first Fc region linked to CH1, the first Fc region comprising an immunoglobulin hinge region and CH2 and CH3 immunoglobulin heavy chain constant domains, wherein the first Fc region comprises amino acid substitutions at positions corresponding to positions 354 and 366 of human IgG1 or IgG4 according to EU Index, wherein the amino acid substitutions are S354C and T366W; and wherein the third polypeptide chain further comprises a second Fc region linked to CH1, the second Fc region comprising an immunoglobulin hinge region and CH2 and CH3 immunoglobulin heavy chain constant domains, wherein the second Fc region comprises amino acid substitutions at positions corresponding to positions 349, 366, 368, and 407 of human IgG1 or IgG4 according to EU Index, wherein the amino acid substitutions are Y349C, T366S, L368A, and Y407V. In some embodiments, the second polypeptide chain further comprises a first Fc region linked to CH1, the first Fc region comprising an immunoglobulin hinge region and CH2 and CH3 immunoglobulin heavy chain constant domains, wherein the first Fc region comprises amino acid substitutions at positions corresponding to positions 349, 366, 368, and 407 of human IgG1 or IgG4 according to EU Index, wherein the amino acid substitutions are Y349C, T366S, L368A, and Y407V; and wherein the third polypeptide chain further comprises a second Fc region linked to CH1, the second Fc region comprising an immunoglobulin hinge region and CH2 and CH3 immunoglobulin heavy chain constant domains, wherein the second Fc region comprises amino acid substitutions at positions corresponding to positions 354 and 366 of human IgG1 or IgG4 according to EU Index, wherein the amino acid substitutions are S354C and T366W. In some embodiments, the first and/or second Fc regions are human IgG1 Fc regions. In some embodiments, the first and/or second Fc regions are human IgG4 Fc regions.

[0597] In some embodiments, the second polypeptide chain further comprises a first Fc region linked to CH1, wherein the first Fc region is a human IgG4 Fc region comprising an immunoglobulin hinge region and CH2 and CH3 immunoglobulin heavy chain constant domains, wherein the first Fc region comprises amino acid substitutions at positions corresponding to positions 228, 354, 366, and 409 of human IgG4 according to EU Index, wherein the amino acid substitutions are S228P, S354C, T366W, and R409K; and wherein the third polypeptide chain further comprises a second Fc region linked to CH1, wherein the second Fc region is a human IgG4 Fc region comprising an immunoglobulin hinge region and CH2 and CH3 immunoglobulin heavy chain constant domains, wherein the second Fc region comprises amino acid substitutions at positions corresponding to positions 228, 349, 366, 368, 407, and 409 of human IgG4 according to EU Index, wherein the amino acid substitutions are S228P, Y349C, T366S, L368A, Y407V, and R409K. In some embodiments, the second polypeptide chain further comprises a first Fc region linked to CH1, wherein the first Fc region is a human IgG4 Fc region comprising an immunoglobulin hinge region and CH2 and CH3 immunoglobulin heavy chain constant domains, wherein the first Fc region comprises amino acid substitutions at positions corresponding to positions 228, 349, 366, 368, 407, and 409 of human IgG4 according to EU Index, wherein the amino acid substitutions are S228P, Y349C, T366S, L368A, Y407V, and R409K; and wherein the third polypeptide chain further comprises a second Fc region linked to CH1, wherein the second Fc region is a human IgG4 Fc region comprising an immunoglobulin hinge region and CH2 and CH3 immunoglobulin heavy chain constant domains, wherein the second Fc region comprises amino acid substitutions at positions corresponding to positions 228, 354, 366, and 409 of human IgG4 according to EU Index, wherein the amino acid substitutions are S228P, S354C, T366W, and R409K.

[0598] In some embodiments, the second polypeptide chain further comprises a first Fc region linked to CH1, wherein the first Fc region is a human IgG4 Fc region comprising an immunoglobulin hinge region and CH2 and CH3 immunoglobulin heavy chain constant domains, wherein the first Fc region comprises amino acid substitutions at positions corresponding to positions 234, 235, 354, and 366 of human IgG4 according to EU Index, wherein the amino acid substitutions are F234A, L235A, S354C, and T366W; and wherein the third polypeptide chain further comprises a second Fc region linked to CH1, wherein the second Fc region is a human IgG4 Fc region comprising an immunoglobulin hinge region and CH2 and CH3 immunoglobulin heavy chain constant domains, wherein the second Fc region comprises amino acid substitutions at positions corresponding to positions 234, 235, 349, 366, 368, and 407 of human IgG4 according to EU Index, wherein the amino acid substitutions are F234A, L235A, Y349C, T366S, L368A, and Y407V. In some embodiments, the second polypeptide chain further comprises a first Fc region linked to CH1, wherein the first Fc region is a human IgG4 Fc region comprising an immunoglobulin hinge region and CH2 and CH3 immunoglobulin heavy chain constant domains, wherein the first Fc region comprises amino acid substitutions at positions corresponding to positions 234, 235, 349, 366, 368, and 407 of human IgG4 according to EU Index, wherein the amino acid substitutions are F234A, L235A, Y349C, T366S, L368A, and Y407V; and wherein the third polypeptide chain further comprises a second Fc region linked to CH1, wherein the second Fc region is a human IgG4 Fc region comprising an immunoglobulin hinge region and CH2 and CH3 immunoglobulin heavy chain constant domains, wherein the second Fc region comprises amino acid substitutions at positions corresponding to positions 234, 235, 354, and 366 of human IgG4 according to EU Index, wherein the amino acid substitutions are F234A, L235A, S354C, and T366W.

[0599] In some embodiments, a binding protein of the present disclosure comprises one or more mutations to reduce effector function, e.g., Fc receptor-mediated antibody-dependent cellular phagocytosis (ADCP), complement-dependent cytotoxicity (CDC), and/or antibody-dependent cellular cytotoxicity (ADCC). In some embodiments, the second polypeptide chain further comprises a first Fc region linked to C.sub.H1, the first Fc region comprising an immunoglobulin hinge region and C.sub.H2 and C.sub.H3 immunoglobulin heavy chain constant domains; wherein the third polypeptide chain further comprises a second Fc region linked to C.sub.H1, the second Fc region comprising an immunoglobulin hinge region and C.sub.H2 and C.sub.H3 immunoglobulin heavy chain constant domains; wherein the first and second Fc regions are human IgG1 Fc regions; and wherein the first and the second Fc regions each comprise amino acid substitutions at positions corresponding to positions 234 and 235 of human IgG1 according to EU Index, wherein the amino acid substitutions are L234A and L235A. In some embodiments, the Fc regions of the second and the third polypeptide chains are human IgG1 Fc

regions, and wherein the Fc regions each comprise amino acid substitutions at positions corresponding to positions 234 and 235 of human IgG1 according to EU Index, wherein the amino acid substitutions are L234A and L235A. In some embodiments, the second polypeptide chain further comprises a first Fc region linked to C.sub.H1, the first Fc region comprising an immunoglobulin hinge region and C.sub.H2 and C.sub.H3 immunoglobulin heavy chain constant domains; wherein the third polypeptide chain further comprises a second Fc region linked to C.sub.H1, the second Fc region comprising an immunoglobulin hinge region and C.sub.H2 and C.sub.H3 immunoglobulin heavy chain constant domains; wherein the first and second Fc regions are human IgG1 Fc regions; and wherein the first and the second Fc regions each comprise amino acid substitutions at positions corresponding to positions 234, 235, and 329 of human IgG1 according to EU Index, wherein the amino acid substitutions are L234A, L235A, and P329A. In some embodiments, the Fc regions of the second and the third polypeptide chains are human IgG1 Fc regions, and wherein the Fc regions each comprise amino acid substitutions at positions corresponding to positions 234, 235, and 329 of human IgG1 according to EU Index, wherein the amino acid substitutions are L234A, L235A, and P329A. In some embodiments, the Fc regions of the second and the third polypeptide chains are human IgG4 Fc regions, and the Fc regions each comprise amino acid substitutions at positions corresponding to positions 234 and 235 of human IgG4 according to EU Index, wherein the amino acid substitutions are F234A and L235A. In some embodiments, the binding protein comprises a second polypeptide chain further comprising a first Fc region linked to C.sub.H1, the first Fc region comprising an immunoglobulin hinge region and C.sub.H2 and C.sub.H3 immunoglobulin heavy chain constant domains, and a third polypeptide chain further comprising a second Fc region linked to C.sub.H1, the second Fc region comprising an immunoglobulin hinge region and C.sub.H2 and C.sub.H3 immunoglobulin heavy chain constant domains; and wherein the first and the second Fc regions each comprise amino acid substitutions at positions corresponding to positions 234 and 235 of human IgG4 according to EU Index, wherein the amino acid substitutions are F234A and L235A.

[0600] In some embodiments, the second polypeptide chain further comprises a first Fc region linked to CH1, wherein the first Fc region is a human IgG4 Fc region comprising an immunoglobulin hinge region and CH2 and CH3 immunoglobulin heavy chain constant domains, wherein the first Fc region comprises amino acid substitutions at positions corresponding to positions 228, 234, 235, 354, 366, and 409 of human IgG4 according to EU Index, wherein the amino acid substitutions are S228P, F234A, L235A, S354C, T366W, and R409K; and wherein the third polypeptide chain further comprises a second Fc region linked to CH1, wherein the second Fc region is a human IgG4 Fc region comprising an immunoglobulin hinge region and CH2 and CH3 immunoglobulin heavy chain constant domains, wherein the second Fc region comprises amino acid substitutions at positions corresponding to positions 228, 234, 235, 349, 366, 368, 407, and 409 of human IgG4 according to EU Index, wherein the amino acid substitutions are S228P, F234A, L235A, Y349C, T366S, L368A, Y407V, and R409K. In some embodiments, the second polypeptide chain further comprises a first Fc region linked to CH1, wherein the first Fc region is a human IgG4 Fc region comprising an immunoglobulin hinge region and CH2 and CH3 immunoglobulin heavy chain constant domains, wherein the first Fc region comprises amino acid substitutions at positions corresponding to positions 228, 234, 235, 349, 366, 368, 407, and 409 of human IgG4 according to EU Index, wherein the amino acid substitutions are S228P, F234A, L235A, Y349C, T366S, L368A, Y407V, and R409K; and wherein the third polypeptide chain further comprises a second Fc region linked to CH1, wherein the second Fc region is a human IgG4 Fc region comprising an immunoglobulin hinge region and CH2 and CH3 immunoglobulin heavy chain constant domains, wherein the second Fc region comprises amino acid substitutions at positions corresponding to positions 228, 234, 235, 354, 366, and 409 of human IgG4 according to EU Index, wherein the amino acid substitutions are S228P, F234A, L235A, S354C, T366W, and R409K.

[0601] In some embodiments, the Fc region is a human IgG4 Fc region comprising one or more mutations that reduce or eliminate FcγI and/or FcγII binding. In some embodiments, the Fc region is a human IgG4 Fc region comprising one or more mutations that reduce or eliminate FcγI and/or FcγII binding but do not affect FcRn binding. In some embodiments, the Fc region is a human IgG4 Fc region comprising amino acid substitutions at positions corresponding to positions 228 and/or 409 of human IgG4 according to EU Index. In some embodiments, the amino acid substitutions are S228P and/or R409K. In some embodiments, the Fc region is a human IgG4 Fc region comprising amino acid substitutions at positions corresponding to positions 234 and/or 235 of human IgG4 according to EU Index. In some embodiments, the amino acid substitutions are F234A and/or L235A. In some embodiments, the Fc region is a human IgG4 Fc region comprising amino acid substitutions at positions corresponding to positions 228, 234, 235, and/or 409 of human IgG4 according to EU Index. In some embodiments, the amino acid substitutions are S228P, F234A, L235A, and/or R409K. In some embodiments, the Fc region is a human IgG4 Fc region comprising amino acid substitutions at positions corresponding to positions 233-236 of human IgG4 according to EU Index. In some embodiments, the amino acid substitutions are E233P, F234V, L235A, and a deletion at 236. In some embodiments, the Fc region is a human IgG4 Fc region comprising amino acid mutations at substitutions corresponding to positions 228, 233-236, and/or 409 of human IgG4 according to EU Index. In some embodiments, the amino acid mutations are S228P; E233P, F234V, L235A, and a deletion at 236; and/or R409K.

[0602] In some embodiments, the Fc region comprises one or more mutations that reduce or eliminate Fc receptor binding and/or effector function of the Fc region (e.g., Fc receptor-mediated antibody-dependent cellular phagocytosis (ADCP), complement-dependent cytotoxicity (CDC), and/or antibody-dependent cellular cytotoxicity (ADCC)).

[0603] In some embodiments, the Fc region is a human IgG1 Fc region comprising one or more amino acid substitutions at positions corresponding to positions 234, 235, and/or 329 of human IgG1 according to EU Index. In some embodiments, the amino acid substitutions are L234A, L235A, and/or P329A. In some embodiments, the Fc region is a human IgG1 Fc region comprising amino acid substitutions at positions corresponding to positions 298, 299, and/or 300 of human IgG1 according to EU Index. In some embodiments, the amino acid substitutions are S298N, T299A, and/or Y300S.

[0604] In some embodiments, a binding protein of the present disclosure comprises one or more mutations to improve stability, e.g., of the hinge region and/or dimer interface of IgG4 (See e.g., Spiess, C. et al. (2013) *J. Biol. Chem.* 288:26583-26593). In some embodiments, the mutation comprises substitutions at positions corresponding to positions 228 and 409 of human IgG4 according to EU Index, wherein the amino acid substitutions are S228P and R409K. In some embodiments, the binding protein comprises a second polypeptide chain further comprising a first Fc region linked to C.sub.H1, the first Fc region comprising an immunoglobulin hinge region and C.sub.H2 and C.sub.H3 immunoglobulin heavy chain constant domains, and a third polypeptide chain further comprising a second Fc region linked to C.sub.H1, the second Fc region comprising an immunoglobulin hinge region and C.sub.H2 and C.sub.H3 immunoglobulin heavy chain constant domains; wherein the first and second Fc regions are human IgG4 Fc regions; and wherein the first and the second Fc regions each comprise amino acid substitutions at positions corresponding to positions 228 and 409 of human IgG4 according to EU Index, wherein the amino acid substitutions are S228P and R409K. In some embodiments, a binding protein of the present disclosure comprises knob and hole mutations and one or more mutations to improve stability. In some embodiments, the first and/or second Fc regions are human IgG4 Fc regions.

[0605] In some embodiments, the Fc region is a human IgG1 Fc region comprising one or more amino acid substitutions at positions corresponding to positions 234, 235, and/or 329 of human IgG1 according to EU Index. In some embodiments, the amino acid substitutions are L234A, L235A, and/or P329A. In some embodiments, the Fc region is a human IgG1 Fc region comprising amino acid substitutions at positions corresponding to positions 298, 299, and/or 300 of human IgG1 according to EU Index. In some embodiments, the amino acid substitutions are S298N, T299A, and/or Y300S.

Nucleic Acids

[0606] Other aspects of the present disclosure relate to isolated nucleic acid molecules comprising a nucleotide sequence encoding any of the binding proteins described herein. Exemplary and non-limiting nucleic acid sequences are provided in Table 5A.

[0607] Other aspects of the present disclosure relate to kits of polynucleotides, e.g., that encode one or more polypeptides of a binding protein as described herein. In some embodiments, a kit of polynucleotides of the present disclosure comprises one, two, three, or four polynucleotides of a kit of polynucleotides comprising: (a) a first polynucleotide comprising the polynucleotide sequence of SEQ ID NO:478, a second polynucleotide comprising the polynucleotide sequence of SEQ ID NO:479, a third polynucleotide comprising the polynucleotide sequence of SEQ ID NO:480, and a fourth polynucleotide comprising the polynucleotide sequence of SEQ ID NO:481; (b) a first polynucleotide comprising the polynucleotide sequence of SEQ ID NO:482, a second polynucleotide comprising the polynucleotide sequence of SEQ ID NO:483, a third polynucleotide comprising the polynucleotide sequence of SEQ ID NO:484, and a fourth polynucleotide comprising the polynucleotide sequence of SEQ ID NO:485; (c) a first polynucleotide comprising the polynucleotide sequence of SEQ ID NO:486, a second polynucleotide comprising the polynucleotide sequence of SEQ ID NO:487, a third polynucleotide comprising the polynucleotide sequence of SEQ ID NO:488, and a fourth polynucleotide comprising the polynucleotide sequence of SEQ ID NO:489; (d) a first polynucleotide comprising the polynucleotide sequence of SEQ ID NO:490, a second polynucleotide comprising the polynucleotide sequence of SEQ ID NO:491, a third polynucleotide comprising the polynucleotide sequence of SEQ ID NO:492, and a fourth polynucleotide comprising the polynucleotide sequence of SEQ ID NO:493; (e) a first polynucleotide comprising the polynucleotide sequence of SEQ ID NO:494, a second polynucleotide comprising the polynucleotide sequence of SEQ ID NO:495, a third polynucleotide comprising the polynucleotide sequence of SEQ ID NO:496, and a fourth polynucleotide comprising the polynucleotide sequence of SEQ ID NO:497; (f) a first polynucleotide comprising the polynucleotide sequence of SEQ ID NO:498, a second polynucleotide comprising the polynucleotide sequence of SEQ ID NO:499, a third polynucleotide comprising the polynucleotide sequence of SEQ ID NO:500, and a fourth polynucleotide comprising the polynucleotide sequence of SEQ ID NO:501; (g) a first polynucleotide comprising the polynucleotide sequence of SEQ ID NO:502, a second polynucleotide comprising the polynucleotide sequence of SEQ ID NO:503, a third polynucleotide comprising the polynucleotide sequence of SEQ ID NO:504, and a fourth polynucleotide comprising the polynucleotide sequence of SEQ ID NO:505; (h) a first polynucleotide comprising the polynucleotide sequence of SEQ ID NO:506, a second polynucleotide comprising the polynucleotide sequence of SEQ ID NO:507, a third polynucleotide comprising the polynucleotide sequence of SEQ ID NO:508, and a fourth polynucleotide comprising the polynucleotide sequence of SEQ ID NO:509; (i) a first polynucleotide comprising the polynucleotide sequence of SEQ ID NO:510, a second polynucleotide comprising the polynucleotide sequence of SEQ ID NO:511, a third polynucleotide comprising the polynucleotide sequence of SEQ ID NO:512, and a fourth polynucleotide comprising the polynucleotide sequence of SEQ ID NO:513; (j) a first polynucleotide comprising the polynucleotide sequence of SEQ ID NO:514, a second polynucleotide comprising the polynucleotide sequence of SEQ ID NO:515, a third polynucleotide comprising the polynucleotide sequence of SEQ ID NO:516, and a fourth polynucleotide comprising the polynucleotide sequence of SEQ ID NO:517; (k) a first polynucleotide comprising the polynucleotide sequence of SEQ ID NO:518, a second polynucleotide comprising the polynucleotide sequence of SEQ ID NO:519, a third polynucleotide comprising the polynucleotide sequence of SEQ ID NO:520, and a fourth polynucleotide comprising the polynucleotide sequence of SEQ ID NO:521; (l) a first polynucleotide comprising the polynucleotide sequence of SEQ ID NO:522, a second polynucleotide comprising the polynucleotide sequence of SEQ ID NO:523, a third polynucleotide comprising the polynucleotide sequence of SEQ ID NO:524, and a fourth polynucleotide comprising the polynucleotide sequence of SEQ ID NO:525; (m) a first polynucleotide comprising the polynucleotide sequence of SEQ ID NO:526, a second polynucleotide comprising the polynucleotide sequence of SEQ ID NO:527, a third polynucleotide comprising the polynucleotide sequence of SEQ ID NO:528, and a fourth polynucleotide comprising the polynucleotide sequence of SEQ ID NO:529; (n) a first polynucleotide comprising the polynucleotide sequence of SEQ ID NO:530, a second polynucleotide comprising the polynucleotide

sequence of SEQ ID NO:531, a third polynucleotide comprising the polynucleotide sequence of SEQ ID NO:532, and a fourth polynucleotide comprising the polynucleotide sequence of SEQ ID NO:533; (o) a first polynucleotide comprising the polynucleotide sequence of SEQ ID NO:534, a second polynucleotide comprising the polynucleotide sequence of SEQ ID NO:535, a third polynucleotide comprising the polynucleotide sequence of SEQ ID NO:536, and a fourth polynucleotide comprising the polynucleotide sequence of SEQ ID NO:537; (p) a first polynucleotide comprising the polynucleotide sequence of SEQ ID NO:538, a second polynucleotide comprising the polynucleotide sequence of SEQ ID NO:539, a third polynucleotide comprising the polynucleotide sequence of SEQ ID NO:540, and a fourth polynucleotide comprising the polynucleotide sequence of SEQ ID NO:541; (q) a first polynucleotide comprising the polynucleotide sequence of SEQ ID NO:542, a second polynucleotide comprising the polynucleotide sequence of SEQ ID NO:543, a third polynucleotide comprising the polynucleotide sequence of SEQ ID NO:544, and a fourth polynucleotide comprising the polynucleotide sequence of SEQ ID NO:545; (r) a first polynucleotide comprising the polynucleotide sequence of SEQ ID NO:546, a second polynucleotide comprising the polynucleotide sequence of SEQ ID NO:547, a third polynucleotide comprising the polynucleotide sequence of SEQ ID NO:548, and a fourth polynucleotide comprising the polynucleotide sequence of SEQ ID NO:549; (s) a first polynucleotide comprising the polynucleotide sequence of SEQ ID NO:550, a second polynucleotide comprising the polynucleotide sequence of SEQ ID NO:551, a third polynucleotide comprising the polynucleotide sequence of SEQ ID NO:552, and a fourth polynucleotide comprising the polynucleotide sequence of SEQ ID NO:553; (t) a first polynucleotide comprising the polynucleotide sequence of SEQ ID NO:554, a second polynucleotide comprising the polynucleotide sequence of SEQ ID NO:555, a third polynucleotide comprising the polynucleotide sequence of SEQ ID NO:556, and a fourth polynucleotide comprising the polynucleotide sequence of SEQ ID NO:557; (u) a first polynucleotide comprising the polynucleotide sequence of SEQ ID NO:558, a second polynucleotide comprising the polynucleotide sequence of SEQ ID NO:559, a third polynucleotide comprising the polynucleotide sequence of SEQ ID NO:560, and a fourth polynucleotide comprising the polynucleotide sequence of SEQ ID NO:561; (v) a first polynucleotide comprising the polynucleotide sequence of SEQ ID NO:562, a second polynucleotide comprising the polynucleotide sequence of SEQ ID NO:563, a third polynucleotide comprising the polynucleotide sequence of SEQ ID NO:564, and a fourth polynucleotide comprising the polynucleotide sequence of SEQ ID NO:565; (w) a first polynucleotide comprising the polynucleotide sequence of SEQ ID NO:566, a second polynucleotide comprising the polynucleotide sequence of SEQ ID NO:567, a third polynucleotide comprising the polynucleotide sequence of SEQ ID NO:568, and a fourth polynucleotide comprising the polynucleotide sequence of SEQ ID NO:569; (x) a first polynucleotide comprising the polynucleotide sequence of SEQ ID NO:570, a second polynucleotide comprising the polynucleotide sequence of SEQ ID NO:571, a third polynucleotide comprising the polynucleotide sequence of SEQ ID NO:572, and a fourth polynucleotide comprising the polynucleotide sequence of SEQ ID NO:573; (y) a first polynucleotide comprising the polynucleotide sequence of SEQ ID NO:574, a second polynucleotide comprising the polynucleotide sequence of SEQ ID NO:575, a third polynucleotide comprising the polynucleotide sequence of SEQ ID NO:576, and a fourth polynucleotide comprising the polynucleotide sequence of SEQ ID NO:577; (z) a first polynucleotide comprising the polynucleotide sequence of SEQ ID NO:578, a second polynucleotide comprising the polynucleotide sequence of SEQ ID NO:579, a third polynucleotide comprising the polynucleotide sequence of SEQ ID NO:580, and a fourth polynucleotide comprising the polynucleotide sequence of SEQ ID NO:581; (aa) a first polynucleotide comprising the polynucleotide sequence of SEQ ID NO:582, a second polynucleotide comprising the polynucleotide sequence of SEQ ID NO:583, a third polynucleotide comprising the polynucleotide sequence of SEQ ID NO:584, and a fourth polynucleotide comprising the polynucleotide sequence of SEQ ID NO:585; (bb) a first polynucleotide comprising the polynucleotide sequence of SEQ ID NO:586, a second polynucleotide comprising the polynucleotide sequence of SEQ ID NO:587, a third polynucleotide comprising the polynucleotide sequence of SEQ ID NO:588, and a fourth polynucleotide comprising the polynucleotide sequence of SEQ ID NO:589; or (cc) a first polynucleotide comprising the polynucleotide sequence of SEQ ID NO:590, a second polynucleotide comprising the polynucleotide sequence of SEQ ID NO:591, a third polynucleotide comprising the polynucleotide sequence of SEQ ID NO:592, and a fourth polynucleotide comprising the polynucleotide sequence of SEQ ID NO:593.

[0608] Other aspects of the present disclosure relate to a vector system comprising one or more vectors encoding a first, second, third, and fourth polypeptide chain of any of the binding proteins described herein. In some embodiments, the vector system comprises a first vector encoding the first polypeptide chain of the binding protein, a second vector encoding the second polypeptide chain of the binding protein, a third vector encoding the third polypeptide chain of the binding protein, and a fourth vector encoding the fourth polypeptide chain of the binding protein, e.g., as shown in the polynucleotides of Table 5. In some embodiments, the vector system comprises a first vector encoding the first and second polypeptide chains of the binding protein, and a second vector encoding the third and fourth polypeptide chains of the binding protein. In some embodiments, the vector system comprises a first vector encoding the first and third polypeptide chains of the binding protein, and a second vector encoding the second and fourth polypeptide chains of the binding protein. In some embodiments, the vector system comprises a first vector encoding the first and fourth polypeptide chains of the binding protein, and a second vector encoding the second and third polypeptide chains of the binding protein. In some embodiments, the vector system comprises a first vector encoding the first, second, third, and fourth polypeptide chains of the binding protein. The one or more vectors of the vector system may be any of the vectors described herein. In some embodiments, the one or more vectors are expression vectors. In some embodiments, the first, second, third, and fourth polynucleotides are present on one or more expression vectors, e.g., one, two, three, or four expression vectors.

[0609] Standard recombinant DNA methodologies are used to construct the polynucleotides that encode the polypeptides which form the binding proteins, incorporate these polynucleotides into recombinant expression vectors, and introduce such vectors into host cells. See e.g., Sambrook et al., 2001, MOLECULAR CLONING: A LABORATORY MANUAL (Cold

Spring Harbor Laboratory Press, 3rd ed.). Enzymatic reactions and purification techniques may be performed according to manufacturer's specifications, as commonly accomplished in the art, or as described herein. Unless specific definitions are provided, the nomenclature utilized in connection with, and the laboratory procedures and techniques of, analytical chemistry, synthetic organic chemistry, and medicinal and pharmaceutical chemistry described herein are those well-known and commonly used in the art. Similarly, conventional techniques may be used for chemical syntheses, chemical analyses, pharmaceutical preparation, formulation, delivery, and treatment of patients.

[0610] In some embodiments, the isolated nucleic acid is operably linked to a heterologous promoter to direct transcription of the binding protein-coding nucleic acid sequence. A promoter may refer to nucleic acid control sequences which direct transcription of a nucleic acid. A first nucleic acid sequence is operably linked to a second nucleic acid sequence when the first nucleic acid sequence is placed in a functional relationship with the second nucleic acid sequence. For instance, a promoter is operably linked to a coding sequence of a binding protein if the promoter affects the transcription or expression of the coding sequence. Examples of promoters may include, but are not limited to, promoters obtained from the genomes of viruses (such as polyoma virus, fowlpox virus, adenovirus (such as Adenovirus 2), bovine papilloma virus, avian sarcoma virus, cytomegalovirus, a retrovirus, hepatitis-B virus, Simian Virus 40 (SV40), and the like), from heterologous eukaryotic promoters (such as the actin promoter, an immunoglobulin promoter, from heat-shock promoters, and the like), the CAG-promoter (Niwa et al., *Gene* 108(2):193-9, 1991), the phosphoglycerate kinase (PGK)-promoter, a tetracycline-inducible promoter (Masui et al., *Nucleic Acids Res.* 33:e43, 2005), the lac system, the trp system, the tac system, the trc system, major operator and promoter regions of phage lambda, the promoter for 3-phosphoglycerate kinase, the promoters of yeast acid phosphatase, and the promoter of the yeast alpha-mating factors. Polynucleotides encoding binding proteins of the present disclosure may be under the control of a constitutive promoter, an inducible promoter, or any other suitable promoter described herein or other suitable promoter that will be readily recognized by one skilled in the art.

[0611] In some embodiments, the isolated nucleic acid is incorporated into a vector. In some embodiments, the vector is an expression vector. Expression vectors may include one or more regulatory sequences operatively linked to the polynucleotide to be expressed. The term "regulatory sequence" includes promoters, enhancers and other expression control elements (e.g., polyadenylation signals). Examples of suitable enhancers may include, but are not limited to, enhancer sequences from mammalian genes (such as globin, elastase, albumin, α -fetoprotein, insulin and the like), and enhancer sequences from a eukaryotic cell virus (such as SV40 enhancer on the late side of the replication origin (bp 100-270), the cytomegalovirus early promoter enhancer, the polyoma enhancer on the late side of the replication origin, adenovirus enhancers, and the like). Examples of suitable vectors may include, for example, plasmids, cosmids, episomes, transposons, and viral vectors (e.g., adenoviral, vaccinia viral, Sindbis-viral, measles, herpes viral, lentiviral, retroviral, adeno-associated viral vectors, etc.). Expression vectors can be used to transfect host cells, such as, for example, bacterial cells, yeast cells, insect cells, and mammalian cells. Biologically functional viral and plasmid DNA vectors capable of expression and replication in a host are known in the art, and can be used to transfect any cell of interest.

Host Cells

[0612] Other aspects of the present disclosure relate to a host cell (e.g., an isolated host cell) comprising one or more isolated polynucleotides, vectors, and/or vector systems described herein. In some embodiments, an isolated host cell of the present disclosure is cultured in vitro. In some embodiments, the host cell is a bacterial cell (e.g., an *E. coli* cell). In some embodiments, the host cell is a yeast cell (e.g., an *S. cerevisiae* cell). In some embodiments, the host cell is an insect cell. Examples of insect host cells may include, for example, *Drosophila* cells (e.g., S2 cells), *Trichoplusia ni* cells (e.g., High Five™ cells), and *Spodoptera frugiperda* cells (e.g., Sf21 or Sf9 cells). In some embodiments, the host cell is a mammalian cell. Examples of mammalian host cells may include, for example, human embryonic kidney cells (e.g., 293 or 293 cells subcloned for growth in suspension culture), Expi293™ cells, CHO cells, baby hamster kidney cells (e.g., BHK, ATCC CCL 10), mouse sertoli cells (e.g., TM4 cells), monkey kidney cells (e.g., CV1 ATCC CCL 70), African green monkey kidney cells (e.g., VERO-76, ATCC CRL-1587), human cervical carcinoma cells (e.g., HELA, ATCC CCL 2), canine kidney cells (e.g., MDCK, ATCC CCL 34), buffalo rat liver cells (e.g., BRL 3A, ATCC CRL 1442), human lung cells (e.g., W138, ATCC CCL 75), human liver cells (e.g., Hep G2, HB 8065), mouse mammary tumor cells (e.g., MMT 060562, ATCC CCL51), TRI cells, MRC 5 cells, FS4 cells, a human hepatoma line (e.g., Hep G2), and myeloma cells (e.g., NS0 and Sp2/0 cells).

[0613] Other aspects of the present disclosure relate to a method of producing any of the binding proteins described herein. In some embodiments, the method includes a) culturing a host cell (e.g., any of the host cells described herein) comprising an isolated nucleic acid, vector, and/or vector system (e.g., any of the isolated nucleic acids, vectors, and/or vector systems described herein) under conditions such that the host cell expresses the binding protein; and b) isolating the binding protein from the host cell. Methods of culturing host cells under conditions to express a protein are well known to one of ordinary skill in the art. Methods of isolating proteins from cultured host cells are well known to one of ordinary skill in the art, including, for example, by affinity chromatography (e.g., two step affinity chromatography comprising protein A affinity chromatography followed by size exclusion chromatography).

Pharmaceutical Compositions for Treating and/or Preventing HIV/AIDS

[0614] Therapeutic or pharmaceutical compositions comprising binding proteins are within the scope of the disclosure. Such therapeutic or pharmaceutical compositions can comprise a therapeutically effective amount of a binding protein, or binding protein-drug conjugate, in admixture with a pharmaceutically or physiologically acceptable formulation agent selected for suitability with the mode of administration.

[0615] Acceptable formulation materials are nontoxic to recipients at the dosages and concentrations employed.

[0616] The pharmaceutical composition can contain formulation materials for modifying, maintaining, or preserving, for example, the pH, osmolarity, viscosity, clarity, color, isotonicity, odor, sterility, stability, rate of dissolution or release,

adsorption, or penetration of the composition. Suitable formulation materials include, but are not limited to, amino acids (such as glycine, glutamine, asparagine, arginine, or lysine), antimicrobials, antioxidants (such as ascorbic acid, sodium sulfite, or sodium hydrogen-sulfite), buffers (such as borate, bicarbonate, Tris-HCl, citrates, phosphates, or other organic acids), bulking agents (such as mannitol or glycine), chelating agents (such as ethylenediamine tetraacetic acid (EDTA)), complexing agents (such as caffeine, polyvinylpyrrolidone, beta-cyclodextrin, or hydroxypropyl-beta-cyclodextrin), fillers, monosaccharides, disaccharides, and other carbohydrates (such as glucose, mannose, or dextrans), proteins (such as serum albumin, gelatin, or immunoglobulins), coloring, flavoring and diluting agents, emulsifying agents, hydrophilic polymers (such as polyvinylpyrrolidone), low molecular weight polypeptides, salt-forming counterions (such as sodium), preservatives (such as benzalkonium chloride, benzoic acid, salicylic acid, thimerosal, phenethyl alcohol, methylparaben, propylparaben, chlorhexidine, sorbic acid, or hydrogen peroxide), solvents (such as glycerin, propylene glycol, or polyethylene glycol), sugar alcohols (such as mannitol or sorbitol), suspending agents, surfactants or wetting agents (such as pluronics; PEG; sorbitan esters; polysorbates such as polysorbate 20 or polysorbate 80; triton; tromethamine; lecithin; cholesterol or tyloxapal), stability enhancing agents (such as sucrose or sorbitol), tonicity enhancing agents (such as alkali metal halides—e.g., sodium or potassium chloride—or mannitol sorbitol), delivery vehicles, diluents, excipients and/or pharmaceutical adjuvants (see, e.g., REMINGTON'S PHARMACEUTICAL SCIENCES (18th Ed., A. R. Gennaro, ed., Mack Publishing Company 1990), and subsequent editions of the same, incorporated herein by reference for any purpose).

[0617] The optimal pharmaceutical composition will be determined by a skilled artisan depending upon, for example, the intended route of administration, delivery format, and desired dosage. Such compositions can influence the physical state, stability, rate of in vivo release, and rate of in vivo clearance of the binding protein.

[0618] The primary vehicle or carrier in a pharmaceutical composition can be either aqueous or non-aqueous in nature. For example, a suitable vehicle or carrier for injection can be water, physiological saline solution, or artificial cerebrospinal fluid, possibly supplemented with other materials common in compositions for parenteral administration. Neutral buffered saline or saline mixed with serum albumin are further exemplary vehicles. Other exemplary pharmaceutical compositions comprise Tris buffer of about pH 7.0-8.5, or acetate buffer of about pH 4.0-5.5, which can further include sorbitol or a suitable substitute. In one embodiment of the disclosure, binding protein compositions can be prepared for storage by mixing the selected composition having the desired degree of purity with optional formulation agents in the form of a lyophilized cake or an aqueous solution. Further, the binding protein can be formulated as a lyophilizate using appropriate excipients such as sucrose.

[0619] The pharmaceutical compositions of the disclosure can be selected for parenteral delivery or subcutaneous. Alternatively, the compositions can be selected for inhalation or for delivery through the digestive tract, such as orally. The preparation of such pharmaceutically acceptable compositions is within the skill of the art.

[0620] The formulation components are present in concentrations that are acceptable to the site of administration. For example, buffers are used to maintain the composition at physiological pH or at a slightly lower pH, typically within a pH range of from about 5 to about 8.

[0621] When parenteral administration is contemplated, the therapeutic compositions for use can be in the form of a pyrogen-free, parenterally acceptable, aqueous solution comprising the desired binding protein in a pharmaceutically acceptable vehicle. A particularly suitable vehicle for parenteral injection is sterile distilled water in which a binding protein is formulated as a sterile, isotonic solution, properly preserved. Yet another preparation can involve the formulation of the desired molecule with an agent, such as injectable microspheres, bio-erodible particles, polymeric compounds (such as polylactic acid or polyglycolic acid), beads, or liposomes, that provides for the controlled or sustained release of the product which can then be delivered via a depot injection. Hyaluronic acid can also be used, and this can have the effect of promoting sustained duration in the circulation. Other suitable means for the introduction of the desired molecule include implantable drug delivery devices.

[0622] In one embodiment, a pharmaceutical composition can be formulated for inhalation. For example, a binding protein can be formulated as a dry powder for inhalation. Binding protein inhalation solutions can also be formulated with a propellant for aerosol delivery. In yet another embodiment, solutions can be nebulized.

[0623] It is also contemplated that certain formulations can be administered orally. In one embodiment of the disclosure, binding proteins that are administered in this fashion can be formulated with or without those carriers customarily used in the compounding of solid dosage forms such as tablets and capsules. For example, a capsule can be designed to release the active portion of the formulation at the point in the gastrointestinal tract where bioavailability is maximized and pre-systemic degradation is minimized. Additional agents can be included to facilitate absorption of the binding protein. Diluents, flavorings, low melting point waxes, vegetable oils, lubricants, suspending agents, tablet disintegrating agents, and binders can also be employed.

[0624] Another pharmaceutical composition can involve an effective quantity of binding proteins in a mixture with non-toxic excipients that are suitable for the manufacture of tablets. By dissolving the tablets in sterile water, or another appropriate vehicle, solutions can be prepared in unit-dose form. Suitable excipients include, but are not limited to, inert diluents, such as calcium carbonate, sodium carbonate or bicarbonate, lactose, or calcium phosphate; or binding agents, such as starch, gelatin, or acacia; or lubricating agents such as magnesium stearate, stearic acid, or talc.

[0625] Additional pharmaceutical compositions of the disclosure will be evident to those skilled in the art, including formulations involving binding proteins in sustained- or controlled-delivery formulations. Techniques for formulating a variety of other sustained- or controlled-delivery means, such as liposome carriers, bio-erodible microparticles or porous beads and depot injections, are also known to those skilled in the art. Additional examples of sustained-release preparations include semipermeable polymer matrices in the form of shaped articles, e.g. films, or microcapsules. Sustained release

matrices can include polyesters, polyols, poly(lactides, copolymers of L-glutamic acid and gamma ethyl-L-glutamate, poly(2-hydroxyethyl-methacrylate), ethylene vinyl acetate, or poly-D(-)-3-hydroxybutyric acid. Sustained-release compositions can also include liposomes, which can be prepared by any of several methods known in the art.

[0626] Pharmaceutical compositions to be used for in vivo administration typically must be sterile. This can be accomplished by filtration through sterile filtration membranes. Where the composition is lyophilized, sterilization using this method can be conducted either prior to, or following, lyophilization and reconstitution. The composition for parenteral administration can be stored in lyophilized form or in a solution. In addition, parenteral compositions generally are placed into a container having a sterile access port, for example, an intravenous solution bag or vial having a stopper pierceable by a hypodermic injection needle.

[0627] Once the pharmaceutical composition has been formulated, it can be stored in sterile vials as a solution, suspension, gel, emulsion, solid, or as a dehydrated or lyophilized powder. Such formulations can be stored either in a ready-to-use form or in a form (e.g., lyophilized) requiring reconstitution prior to administration.

[0628] The disclosure also encompasses kits for producing a single-dose administration unit. The kits can each contain both a first container having a dried protein and a second container having an aqueous formulation. Also included within the scope of this disclosure are kits containing single and multi-chambered pre-filled syringes (e.g., liquid syringes and lysyringes).

[0629] The effective amount of a binding protein pharmaceutical composition to be employed therapeutically will depend, for example, upon the therapeutic context and objectives. One skilled in the art will appreciate that the appropriate dosage levels for treatment will thus vary depending, in part, upon the molecule delivered, the indication for which the binding protein is being used, the route of administration, and the size (body weight, body surface, or organ size) and condition (the age and general health) of the patient. Accordingly, the clinician can titer the dosage and modify the route of administration to obtain the optimal therapeutic effect.

[0630] Dosing frequency will depend upon the pharmacokinetic parameters of the binding protein in the formulation being used. Typically, a clinician will administer the composition until a dosage is reached that achieves the desired effect. The composition can therefore be administered as a single dose, as two or more doses (which may or may not contain the same amount of the desired molecule) over time, or as a continuous infusion via an implantation device or catheter. Further refinement of the appropriate dosage is routinely made by those of ordinary skill in the art and is within the ambit of tasks routinely performed by them. Appropriate dosages can be ascertained through use of appropriate dose-response data.

[0631] The route of administration of the pharmaceutical composition is in accord with known methods, e.g., orally; through injection by intravenous, intraperitoneal, intracerebral (intraparenchymal), intracerebroventricular, intramuscular, intraocular, intraarterial, intraportal, or intralesional routes; by sustained release systems; or by implantation devices. Where desired, the compositions can be administered by bolus injection or continuously by infusion, or by implantation device.

[0632] The composition can also be administered locally via implantation of a membrane, sponge, or other appropriate material onto which the desired molecule has been absorbed or encapsulated. Where an implantation device is used, the device can be implanted into any suitable tissue or organ, and delivery of the desired molecule can be via diffusion, timed-release bolus, or continuous administration.

[0633] The pharmaceutical compositions can be used to prevent and/or treat HIV infection. The pharmaceutical compositions can be used as a standalone therapy or in combination with standard anti-retroviral therapy.

[0634] The disclosure also relates to a kit comprising a binding protein and other reagents useful for detecting target antigen levels in biological samples. Such reagents can include a detectable label, blocking serum, positive and negative control samples, and detection reagents. In some embodiments, the kit comprises a composition comprising any binding protein, polynucleotide, vector, vector system, and/or host cell described herein. In some embodiments, the kit comprises a container and a label or package insert on or associated with the container. Suitable containers include, for example, bottles, vials, syringes, IV solution bags, etc. The containers may be formed from a variety of materials such as glass or plastic. The container holds a composition which is by itself or combined with another composition effective for treating, preventing and/or diagnosing a condition (e.g., HIV infection) and may have a sterile access port (for example the container may be an intravenous solution bag or a vial having a stopper pierceable by a hypodermic injection needle). In some embodiments, the label or package insert indicates that the composition is used for preventing, diagnosing, and/or treating the condition of choice. Alternatively, or additionally, the article of manufacture or kit may further comprise a second (or third) container comprising a pharmaceutically-acceptable buffer, such as bacteriostatic water for injection (BWFI), phosphate-buffered saline, Ringer's solution and dextrose solution. It may further include other materials desirable from a commercial and user standpoint, including other buffers, diluents, filters, needles, and syringes.

Methods and Uses for Binding Proteins in Treating and/or Preventing HIV/AIDS

[0635] Certain aspects of the present disclosure relate to methods of preventing HIV infection in a patient, treating HIV infection in a patient, preventing AIDS in a patient, and treating AIDS in a patient, using any of the binding proteins or pharmaceutical compositions disclosed herein. Any of the binding proteins or pharmaceutical compositions disclosed herein may find use in a method of the present disclosure, e.g., methods for preventing HIV infection in a patient, treating HIV infection in a patient, preventing AIDS in a patient, and treating AIDS in a patient.

[0636] FIG. 19 illustrates an exemplary and non-limiting format for a trispecific binding protein that may be employed in the methods and uses described herein. As shown in FIG. 20, a proposed mechanism by which the binding protein shown in FIG. 19 may result in elimination of the HIV reservoir cells in a patient involves: (1) activation of latently infected CD4⁺ T cells via the anti-CD28 and anti-CD3 arms of the trispecific binding protein; (2) recruitment of CD8⁺ T cells to activated, latently infected CD4⁺ T cells via anti-Env and anti-CD3 arms; (3) activation of engaged CD8⁺ T cells via the anti-CD28 and anti-CD3 arms; and (4) killing of latently infected CD4⁺ T cells through a Perforin/Granzyme mechanism. Advantageously, this

mechanism was thought to activate and subsequently kill HIV-1 reservoir cells, providing a novel strategy for attacking the HIV-1 reservoir in a patient.

[0637] In some embodiments, the methods of the present disclosure comprise administering to the patient a therapeutically effective amount of at least one of the binding proteins or pharmaceutical compositions described herein.

[0638] In some embodiments, the at least one binding protein is administered in combination with an anti-retroviral therapy (e.g., an anti-HIV therapy). In some embodiments, the at least one binding protein is administered before the anti-retroviral therapy. In some embodiments, the at least one binding protein is administered concurrently with the anti-retroviral therapy. In some embodiments, the at least one binding protein is administered after the anti-retroviral therapy. In some embodiments, the at least one binding protein is co-administered with any standard anti-retroviral therapy known in the art.

[0639] In some embodiments, administration of the at least one binding protein or pharmaceutical composition results in elimination of one or more latently and/or chronically HIV-infected cells in the patient. In some embodiments, administration of the at least one binding protein results in neutralization of one or more HIV virions and results in elimination of one or more latently and/or chronically HIV-infected cells in the patient. In some embodiments, the patient is a human.

TABLE-US-00010 TABLE 4A Trispecific binding protein polypeptide sequences. Polypeptide Number SEQ (acc. to ID Molecule formula) NO Sequence Trispecific 1 1 362

DIVMTQTPLSLSVTPGQPASISCKSSQSLVHNNANTYLSWYLQKPGQSPQSLIYKVSNRFSGVDPDRFSGSGSGTDFTLKISR VRC07_523/

VEAEDVGVYYCGQGTQYPFTFGSGTKVEIKGQPKAAPDIQMTQSPSSLSASVGDRVITITCQASQNIYVWLNWYQQKPGK CD28sup ×

APKLLIYKASNLHTGVPSRFSGSGSGTDFTLTISLQPEDATYYCQQGQTYPYTFGQGTKLEIKTKGPSRTVAAPSVFIFPPS CD3mid IgG1

DEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDYSLSSLTLSKADYEKHKVYACEVTHQG LALA/P329A LSSPVTKSFNRGEC 2 363

QVQLVQSGAEVVKPGASVKVSCKASGYTFTSYIHWRQAPGQGLEWIGSIYPGNVNTNYAQKFQGRATLTVDTSISTA YMELSRRLSDDTAVYYCTRSHYGLDWNFDVWGKGTITVTVSSSQVQLVESGGGVVQPGRSLRLSCAASGFTFTKAWMH WVRQAPGKQLEWVAQIKDKSNSYATYYADSVKGRFTISRDDSKNTLYLQMNSLRAEDTAVYYCRGVYALSPFDYWG QGTLVTVSSRTASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVT VPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSH EDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALAAPIEKTISKAKGQPREP QVCTLPPSRDELTKNQVSLSCAVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQQGNVFSCS VMHEALHNHYTQKSLSLSPG 3 364

QVRLSQSGGQMKKPGDSMRISCRASGYEFINCPINWIRLAPGKRPEWMGWMKPRHGAVSYARQLQGRVTMTTRDMYSET AFLELRSLTSDDTAVYFCTRGKYCTARDYYNWDEERWGQGTPTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYF PEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVTVTPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPA PEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLH QDWLNGKEYKCKVSNKALAAPIEKTISKAKGQPREPVYTLPPCRDELTKNQVSLWCLVKGFYPSDIAVEWESNGQPEN NYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG 4 365

SLTQSPGTLTSLSPGETAIISCRTSQYGSRLAWYQQRPGQAPRLVIYSGSTRAAGIPDRFSGSRWGPDPYNTISNLESGDFGVYY CQYQEFFGQGTQVQVDIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSK DSTYSLSSLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC Trispecific 2 1 366

DIVMTQTPLSLSVTPGQPASISCKSSQSLVHNNANTYLSWYLQKPGQSPQSLIYKVSNRFSGVDPDRFSGSGSGTDFTLKISR VRC07_523/

VEAEDVGVYYCGQGTQYPFTFGSGTKVEIKGQPKAAPDIQMTQSPSSLSASVGDRVITITCQASQNIYVWLNWYQQKPGK CD28sup ×

APKLLIYKASNLHTGVPSRFSGSGSGTDFTLTISLQPEDATYYCQQGQTYPYTFGQGTKLEIKTKGPSRTVAAPSVFIFPPS CD3mid IgG1

DEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDYSLSSLTLSKADYEKHKVYACEVTHQG NNAS LSSPVTKSFNRGEC 2 367

QVQLVQSGAEVVKPGASVKVSCKASGYTFTSYIHWRQAPGQGLEWIGSIYPGNVNTNYAQKFQGRATLTVDTSISTA YMELSRRLSDDTAVYYCTRSHYGLDWNFDVWGKGTITVTVSSSQVQLVESGGGVVQPGRSLRLSCAASGFTFTKAWMH WVRQAPGKQLEWVAQIKDKSNSYATYYADSVKGRFTISRDDSKNTLYLQMNSLRAEDTAVYYCRGVYALSPFDYWG QGTLVTVSSRTASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVT VPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSH EDPEVKFNWYVDGVEVHNAKTKPREEQYNNASRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQ VCTLPPSRDELTKNQVSLSCAVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQQGNVFSCS VMHEALHNHYTQKSLSLSPG 3 368

QVRLSQSGGQMKKPGDSMRISCRASGYEFINCPINWIRLAPGKRPEWMGWMKPRHGAVSYARQLQGRVTMTTRDMYSET AFLELRSLTSDDTAVYFCTRGKYCTARDYYNWDEERWGQGTPTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYF PEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVTVTPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPA PELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNNASRVVSVLTVLHQ DWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPVYTLPPCRDELTKNQVSLWCLVKGFYPSDIAVEWESNGQPENNY KTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG 4 369

SLTQSPGTLTSLSPGETAIISCRTSQYGSRLAWYQQRPGQAPRLVIYSGSTRAAGIPDRFSGSRWGPDPYNTISNLESGDFGVYY

CQQYEFFGQGTQVVDIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSK
DSTYLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC Trispecific 3 1 370
DIVMTQTPLSLSVTPGQPASISCKSSQSLVHNNANTYLSWYQLQKPGQSPQSLIYKVSNRFSGVPDRFSGSGSGTDFTLKISR
VRC07_523/
VEAEDVGYYYCGQGTQYPFTFGSGTKVEIKGQPKAAPDIQMTQSPSSLSASVGDRVTTITCQASQNIYVWLNWYQQKPGK
CD28sup ×
APKLLIYKASNLHTGVPSRFSGSGSGTDFTLTISLQPEDATYYCQQGQTYPYTFGQGTKLEIKTKGPSRTVAAPSVFIFPPS
CD3mid IgG4
DEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYLSSTLTLSKADYEKHKVYACEVTHQG
FALA/409K LSSPVTKSFNRGEC 2 371
QVQLVQSGAEVVKPGASVKVSCKASGYTFTSYIHVVWRQAPGGGLEWIGSIYPGNVNTNYAQKFQGRATLTVDTSISTA
YMELSRRLSDDTAVYYCTRSHYGLDWNFDVWGKGTITVTVSSSQVQLVESGGGVVQPGSRSLRLSCAASGFTFTKAWMH
WVRQAPGKQLEWVAQIKDKSNSYATYYADSVKGRFTISRDDSKNTLYLQMNSLRAEDTAVYYCRGVYYALSPFDYWG
QGTLTVTSSRTASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVTV
PSSSLGKTKYTCNVDPKPSNTKVDKRVESKYGPPCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSDQEDPE
VQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVCTL
PPSQEEMTKNQVSLTSCAVKGFPYSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQEGNVFSCSVMHEA
LHNHYTQKSLSLGL 3 372
QVRLSQSGGQMKKPGDSMRISCRASGYEFINCPINWIRLAPGKRPEWMGWMKPRHGAVSYARQLQGRVTMTRDMYSET
AFLELRSLTSDDTAVYFCTRGKYCTARDYYNWDFEHWGQGTPTVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYF
PEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVTVPSLGLTKYTCNVDPKPSNTKVDKRVESKYGPPCPPCPAPEA
AGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSDQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDW
LNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPCQEEMTKNQVSLWCLVKGFYPSDIAVEWESNGQPENNYKT
TPPVLDSDGSFFLVSKLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLGL 4 373
SLTQSPGTLSLSPGETAIISCRTSQYGSRLAWYQQRPGQAPRLVIYSGSTRAAGIPDRFSGSRWGPDPYNTISNLESGDFGVY
CQQYEFFGQGTQVVDIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSK
DSTYLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC Trispecific 4 1 374
DIVMTQTPLSLSVTPGQPASISCKSSQSLVHNAQTYLSWYQLQKPGQSPQSLIYKVSNRFSGVPDRFSGSGSGTDFTLKISR
VRC07_523/
VEAEDVGYYYCGQGTQYPFTFGSGTKVEIKGQPKAAPDIQMTQSPSSLSASVGDRVTTITCQASQNIYVWLNWYQQKPGK
CD28sup ×
APKLLIYKASNLHTGVPSRFSGSGSGTDFTLTISLQPEDATYYCQQGQTYPYTFGQGTKLEIKTKGPSRTVAAPSVFIFPPS
CD3mid_QQ
DEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYLSSTLTLSKADYEKHKVYACEVTHQG
IgG4 LSSPVTKSFNRGEC FALA/409K 2 375
QVQLVQSGAEVVKPGASVKVSCKASGYTFTSYIHVVWRQAPGGGLEWIGSIYPGNVNTNYAQKFQGRATLTVDTSISTA
YMELSRRLSDDTAVYYCTRSHYGLDWNFDVWGKGTITVTVSSSQVQLVESGGGVVQPGSRSLRLSCAASGFTFTKAWMH
WVRQAPGKQLEWVAQIKDKSNSYATYYADSVKGRFTISRDDSKNTLYLQMNSLRAEDTAVYYCRGVYYALSPFDYWG
QGTLTVTSSRTASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVTV
PSSSLGKTKYTCNVDPKPSNTKVDKRVESKYGPPCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSDQEDPE
VQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVCTL
PPSQEEMTKNQVSLTSCAVKGFPYSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQEGNVFSCSVMHEA
LHNHYTQKSLSLGL 3 376
QVRLSQSGGQMKKPGDSMRISCRASGYEFINCPINWIRLAPGKRPEWMGWMKPRHGAVSYARQLQGRVTMTRDMYSET
AFLELRSLTSDDTAVYFCTRGKYCTARDYYNWDFEHWGQGTPTVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYF
PEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVTVPSLGLTKYTCNVDPKPSNTKVDKRVESKYGPPCPPCPAPEA
AGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSDQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDW
LNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPCQEEMTKNQVSLWCLVKGFYPSDIAVEWESNGQPENNYKT
TPPVLDSDGSFFLVSKLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLGL 4 377
SLTQSPGTLSLSPGETAIISCRTSQYGSRLAWYQQRPGQAPRLVIYSGSTRAAGIPDRFSGSRWGPDPYNTISNLESGDFGVY
CQQYEFFGQGTQVVDIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSK
DSTYLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC Trispecific 6 1 378
DIVMTQTPLSLSVTPGQPASISCKSSQSLVHNAQTYLSWYQLQKPGQSPQSLIYKVSNRFSGVPDRFSGSGSGTDFTLKISR
VRC07_523/
VEAEDVGYYYCGQGTQYPFTFGSGTKVEIKDKTHTDIQTQSPSSLSASVGDRVTTITCQASQNIYVWLNWYQQKPGKAP
CD28sup ×
KLLIYKASNLHTGVPSRFSGSGSGTDFTLTISLQPEDATYYCQQGQTYPYTFGQGTKLEIKDKTHTRTVAAPSVFIFPPSD
CD3mid_QQ
EQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYLSSTLTLSKADYEKHKVYACEVTHQGL
IgG4 SSPVTKSFNRGEC FALA/409K_ DKHT linker 2 379
QVQLVQSGAEVVKPGASVKVSCKASGYTFTSYIHVVWRQAPGGGLEWIGSIYPGNVNTNYAQKFQGRATLTVDTSISTA
YMELSRRLSDDTAVYYCTRSHYGLDWNFDVWGKGTITVTVSSSQVQLVESGGGVVQPGSRSLRLSCAASGFTFTKAWMH
WVRQAPGKQLEWVAQIKDKSNSYATYYADSVKGRFTISRDDSKNTLYLQMNSLRAEDTAVYYCRGVYYALSPFDYWG

QGTTLVTSSRTASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVTV
PSSSLGTKTYTCNVDPHKSNTKVDKRVESKYGPPCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVDVDSQEDPE
VQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVCTL
PPSQEEMTKNQVSLSCAVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQEGNVFSCSVMHEA
LHNHYTQKSLSLGLG 3 380

QVRLSQSGGQMKKPGDSMRISCRASGYEFINCPINWIRLAPGKRPEWMGWMKPRHGAVSYARQLQGRVTMTRDMYSET
AFLELRSLTSDDTAVYFCTRGRKYCTARDYYNWDFEHWGQGTPTVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYF
PEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVTVPSSSLGTKTYTCNVDPHKSNTKVDKRVESKYGPPCPPCPAPEA
AGGPSVFLFPPKPKDTLMISRTPEVTCVVDVDSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDW
LNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPCQEEMTKNQVSLWCLVKGFYPSDIAVEWESNGQPENNYKT
TPPVLDSDGSFFLVSKLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLGLG 4 381

SLTQSPGTLTSLSPGETAIISCRTSQYGSRAWYQQRPGQAPRLVIYSGSTRAAGIPDRFSGSRWGPDYNTISNLESGDFGVY
CQYQEFFGQGTQVQVDIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSK
DSTYLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC Trispecific 8 1 382

DIVMTQTPLSLSVTPGQPASISCKSSQSLVHQNAQTYLSWYLQKPGQSPQSLIYKVSNRFSGVDPDRFSGSGSGTDFTLKISR
VRC07_523/
VEAEDVGYYCGQGTQYPFTFGSGTKVEIKDKTHTDIQMTQSPSSLSASVGDRVTITCQASQNIYVWLNWYQQKPGKAP
CD28sup ×

KLLIYKASNLHTGVPSRFSGSGSGTDFTLTISLQPEDATYYCQQGQTYPTYTFGQGTKEIKDKTHTTRTVAAPSVFIFPPSD
CD3mid_QQ

EQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYLSSTLTLSKADYEKHKVYACEVTHQGL
IgG1_NNAS/ SSPVTKSFNRGEC 409K_DKTHT linker 2 383

QVQLVQSGAEVVKPGASVKVSCKASGYTFTSYIHVWRQAPGQGLEWIGSIYPGNVNTNYAQKFQGRATLTVDTSISTA
YMELSRRLSDDTAVYYCTRSHYGLDWNFDVWGKGTITVTVSSDKTHTQVQLVESGGGVVQPGSRSLRLSCAASGFTTKA
WMHWVRQAPGKQLEWVAQIKDKSNSYATYYADSVKGRFTISRDDSKNTLYLQMNSLRAEDTAVYYCRGVYALSPFD
YWGQGTTLTVSSDKTHTASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLY
SLSSVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCV
VVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNNASRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAK
GQPREPQVCTLPSPRDELTKNQVSLSCAVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQQG
NVFSCSVMHEALHNHYTQKSLSLSPG 3 384

QVRLSQSGGQMKKPGDSMRISCRASGYEFINCPINWIRLAPGKRPEWMGWMKPRHGAVSYARQLQGRVTMTRDMYSET
AFLELRSLTSDDTAVYFCTRGRKYCTARDYYNWDFERWGGQGTPTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYF
PEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPA
PELLGGPSVFLFPPKPKDTLMISRTPEVTCVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNNASRVVSVLTVLHQ
DWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPCRDELTKNQVSLWCLVKGFYPSDIAVEWESNGQPENNY
KTTPPVLDSDGSFFLVSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG 4 385

SLTQSPGTLTSLSPGETAIISCRTSQYGSRAWYQQRPGQAPRLVIYSGSTRAAGIPDRFSGSRWGPDYNTISNLESGDFGVY
CQYQEFFGQGTQVQVDIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSK
DSTYLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC Trispecific 9 1 386

DIVMTQTPLSLSVTPGQPASISCKSSQSLVHENLQTYLSWYLQKPGQSPQSLIYKVSNRFSGVDPDRFSGSGSGTDFTLKISR
VRC07_523_
EAEDVGYYCGQGTQYPFTFGSGTKVEIKDKTHTDIQMTQSPSSLSASVGDRVTITCQASQNIYVWLNWYQQKPGKAPK
FR3-03/
LLIYKASNLHTGVPSRFSGSGSGTDFTLTISLQPEDATYYCQQGQTYPTYTFGQGTKEIKDKTHTTRTVAAPSVFIFPPSDE
CD28sup ×

QLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYLSSTLTLSKADYEKHKVYACEVTHQGLS
CD3mid_ SPVTKSFNRGEC ENLQ IgG4 FALA/409K_DKTHT linker 2 387

QVQLVQSGAEVVKPGASVKVSCKASGYTFTSYIHVWRQAPGQGLEWIGSIYPGNVNTNYAQKFQGRATLTVDTSISTA
YMELSRRLSDDTAVYYCTRSHYGLDWNFDVWGKGTITVTVSSQVQLVESGGGVVQPGSRSLRLSCAASGFTTKAWMH
WVRQAPGKQLEWVAQIKDKSNSYATYYADSVKGRFTISRDDSKNTLYLQMNSLRAEDTAVYYCRGVYALSPFDYWG
QGTTLVTSSRTASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVTV
PSSSLGTKTYTCNVDPHKSNTKVDKRVESKYGPPCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVDVDSQEDPE
VQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVCTL
PPSQEEMTKNQVSLSCAVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQEGNVFSCSVMHEA
LHNHYTQKSLSLGLG 3 388

QVRLSQSGGQMKKPGDSMRISCRASGYEFINCPINWIRLAPGKRPEWMGWMKPRHGAVSYARQLQGRVTMTRQLSQDP
DDPDWGTAFLELRSLTSDDTAVYFCTRGRKYCTARDYYNWDEEHWGQGTPTVTVSSASTKGPSVFPLAPCSRSTSESTAALG
CLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVTVPSSSLGTKTYTCNVDPHKSNTKVDKRVESKYGPPCP
CPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVDVDSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLT
VLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPCQEEMTKNQVSLWCLVKGFYPSDIAVEWESNGQ
PENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLGLG 4 389

SLTQSPGTLTSLSPGETAIISCRTSQYGSRAWYQQRPGQAPRLVIYSGSTRAAGIPDRFSGSRWGPDYNTISNLESGDFGVY
CQYQEFFGQGTQVQVDIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSK

DSTYLSSTLTLSKADYEHKHKVYACEVTHQGLSSPVTKSFNRGEC Trispecific 10 1 390
DIVMTQTPLSLSVTPGQPASISCKSSQSLVHENLFTYLSWY LQKPGQSPQSLIYKVS NRFSGVPDRFSGSGSGTDFTLKISRV
VRC07_523_
EAEDVG VYYCGQGTQYPFTFGSGTKVEIKDKTHTDIQMTQSPSSLSASVGDRV TITCQASQNIYVWLNWYQKPGKAPK
FR3-03/
LLIYKASN LHTGVPSRFSGSGSGTDFTLTISLQPED IATYYCQQGQTYPTYTFGQGTKLEIKDKTHTTRTVAAPSVFIFPPSDE
CD28sup ×
QLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSK DSTYLSSTLTLSKADYEHKHKVYACEVTHQGLS
CD3mid_ SPVTKSFNRGEC ENLF IgG4 FALA/409K_ DKTHT linker 2 391
QVQLVQSGAEVVKPGASVKV SCKASGYTFTSYIHWVRQAPGQGLEWIGSIYPGNVNTNYAQKFQGRATLTVDTSISTA
YME LSRLRSDDTAVYYCTRSHYGLDWNFDVWGKGTTVTVSSSQVLVESGGGVVQPRSLRLSCAASGFTFTKAWMH
WVRQAPGKQLEWVAQIKDKSNSYATYYADSVKGRFTISRDDSKNTLYLQMNSLRAEDTAVYYCRGVYYALSPFDYWG
QGT LVTVSSRTASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVT
PSSSLGTKTYTCNV DHKPSNTKVDKRVESKYGPPCPPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVDSQEDPE
VQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVCT
LPPSQEEMTKNQVSLSCAVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFLVSKLTVDKSRWQEGNVFSCSVMHEA
LHNHYTQKSLSLSPG 3 392
QVRLSQSGGQMKKPGDSMRISCRASGYEFINCPINWIRLAPGKRPEWMGWMKPRHGAVSYARQLQGRVTMTRQLSQDP
DDPDWGTAFL ELRLSTDDTAVYFCTR GKYCTARDYYNWDEEHWGQGPVTVSSASTKGPSVFPLAPCSRSTSESTAALG
CLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNV DHKPSNTKVDKRVESKYGPPCP
PCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVDSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLT
VVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPCQEEMTKNQVSLWCLVKGFYPSDIAVEWESNGQ
PENNYKTTTPVLDSDGSFFLYSKLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSPG 4 393
SLTQSPGTL SLSPGETAIISCRTSQYGS LAWYQQRPGQAPRLVIYSGSTRAAGIPDRFSGSRWGP DYNL TISNLESGDFGVYY
CQQYEFFGQGT KVQVDIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSK
DSTYLSSTLTLSKADYEHKHKVYACEVTHQGLSSPVTKSFNRGEC Trispecific 11 1 394
DIVMTQTPLSLSVTPGQPASISCKSSQSLVHENLQTYLSWY LQKPGQSPQSLIYKVS NRFSGVPDRFSGSGSGTDFTLKISRV
VRC07_523_
EAEDVG VYYCGQGTQYPFTFGSGTKVEIKDKTHTDIQMTQSPSSLSASVGDRV TITCQASQNIYVWLNWYQKPGKAPK
FR3-03/
LLIYKASN LHTGVPSRFSGSGSGTDFTLTISLQPED IATYYCQQGQTYPTYTFGQGTKLEIKDKTHTTRTVAAPSVFIFPPSDE
CD28sup ×
QLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSK DSTYLSSTLTLSKADYEHKHKVYACEVTHQGLS
CD3mid_ SPVTKSFNRGEC ENLQ IgG1_ NNAS_ DKTHT linker 2 395
QVQLVQSGAEVVKPGASVKV SCKASGYTFTSYIHWVRQAPGQGLEWIGSIYPGNVNTNYAQKFQGRATLTVDTSISTA
YME LSRLRSDDTAVYYCTRSHYGLDWNFDVWGKGTTVTVSSDKTHTQVQLVESGGGVVQPRSLRLSCAASGFTFTKA
WMHWVRQAPGKQLEWVAQIKDKSNSYATYYADSVKGRFTISRDDSKNTLYLQMNSLRAEDTAVYYCRGVYYALSPFD
YWGGQGT LVTVSSDKTHTASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLY
SLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCV
VVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNNASRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAK
GQPREPQVCTLPSSRDELTKNQVSLSCAVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFLVSKLTVDKSRWQQG
NVFSCSVMHEALHNHYTQKSLSLSPG 3 396
QVRLSQSGGQMKKPGDSMRISCRASGYEFINCPINWIRLAPGKRPEWMGWMKPRHGAVSYARQLQGRVTMTRQLSQDP
DDPDWGTAFL ELRLSTDDTAVYFCTR GKYCTARDYYNWDEEHWGQGPVTVSSASTKGPSVFPLAPSSKSTSGGTAAL
GCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKT
HTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNNASRVV
SVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPCRDELTKNQVSLWCLVKGFYPSDIAVEWES
NGQPENNYKTTTPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG 4 397
SLTQSPGTL SLSPGETAIISCRTSQYGS LAWYQQRPGQAPRLVIYSGSTRAAGIPDRFSGSRWGP DYNL TISNLESGDFGVYY
CQQYEFFGQGT KVQVDIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSK
DSTYLSSTLTLSKADYEHKHKVYACEVTHQGLSSPVTKSFNRGEC Trispecific 12 1 398
DIVMTQTPLSLSVTPGQPASISCKSSQSLVHENLFTYLSWY LQKPGQSPQSLIYKVS NRFSGVPDRFSGSGSGTDFTLKISRV
VRC07_523_
EAEDVG VYYCGQGTQYPFTFGSGTKVEIKDKTHTDIQMTQSPSSLSASVGDRV TITCQASQNIYVWLNWYQKPGKAPK
FR3-03/
LLIYKASN LHTGVPSRFSGSGSGTDFTLTISLQPED IATYYCQQGQTYPTYTFGQGTKLEIKDKTHTTRTVAAPSVFIFPPSDE
CD28sup ×
QLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSK DSTYLSSTLTLSKADYEHKHKVYACEVTHQGLS
CD3mid_ SPVTKSFNRGEC ENLF IgG1_ NNAS_ DKTHT linker 2 399
QVQLVQSGAEVVKPGASVKV SCKASGYTFTSYIHWVRQAPGQGLEWIGSIYPGNVNTNYAQKFQGRATLTVDTSISTA
YME LSRLRSDDTAVYYCTRSHYGLDWNFDVWGKGTTVTVSSDKTHTQVQLVESGGGVVQPRSLRLSCAASGFTFTKA
WMHWVRQAPGKQLEWVAQIKDKSNSYATYYADSVKGRFTISRDDSKNTLYLQMNSLRAEDTAVYYCRGVYYALSPFD
YWGGQGT LVTVSSDKTHTASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLY

SLSSVTVPSSSLGTQTYICNVNHNKPSNTKVDDKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCV
VVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNNASRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAK
GQPREPQVCTLPSPRDELTKNQVSLSCAVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQQG
NVFSCSVMHEALHNHYTQKSLSLSPG 3 400

QVRLSQSGGQMKKPGDSMRISCRASGYEFINCPINWIRLAPGKRPEWMGWMKPRHGAVSYARQLQGRVTMTRQLSQDP
DDPDWGTAFLELRSLTSDDTAVYFCTRKGKYCTARDYYNWDEEHWGQGPVTVSSASTKGPSVFPLAPSSKSTSGGTAAL
GCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVTVVPSSSLGTQTYICNVNHNKPSNTKVDDKVEPKSCDKT
HTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNNASRVV
SVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPCRDELTKNQVSLWCLVKGFYPSDIAVEWES
NGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG 4 401

SLTQSPGTLSLSPGETAIISCRTSQYGSRAWYQQRPGQAPRLVIYSGSTRAAGIPDRFSGSRWGPDYNLNISLESDFGVYY
CQQYEFFGQGTQVQVDIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSK
DSTYLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC Trispecific 13 1 402

DIVMTQTPLSLSVTPGQPASISCKSSQSLVHNNANTYLSWYLQKPGQSPQSLIYKVSNNRFSGVPPDRFSGSGSGTDFTLKISR
N6/CD28sup ×

VEAEDVGYYCGQGTQYPFTFGSGTKVEIKGQPKAAPDIQMTQSPSSLSASVGDRVTITCQASQNIYVWLNWYQQKPGK
CD3mid

APKLLIYKASNLHTGVPSRFSGSGSGTDFTLTISLQPEDATYYCQQGQTYPYTFGQGTKEIKTKGPSRTVAAPSVFIFPPS
IgG4

DEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKSTYLSSTLTLSKADYEKHKVYACEVTHQG
LSSPVTKSFNRGEC 2 403

QVQLVQSGAEVVKPGASVKVSCKASGYTFTSYIHVWRQAPGQGLEWIGSIYPGNVNTNYAQKFQGRATLTVDTSISTA
YMELSRRLSDDTAVYYCTRSHYGLDWNFDVWGKGTITVTVSSSQVQLVESGGGVVQPGRSLRLSCAASGFTFTKAWMH
WVRQAPGKQLEWVAQIKDKSNSYATYYADSVKGRFTISRDDSKNTLYLQMNSLRAEDTAVYYCRGVYALSPFDYWG
QGTLTVTSSRTASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVTV
PSSSLGTKTYTCNVDPHKPSNTKVDKRVESKYGPPCPPCPAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVVDVVSQEDPEV
QFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVCTLP
PSQEEMTKNQVSLSCAVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQEGNVFSCSVMHEAL
HNHYTQKSLSLSPG 3 404

RAHLVQSGTAMKKPGASVRVSCQTSQGYTFTAHLFWFRQAPGRGLEWVGWIKPQYGAVNFGGGFRDRVTLTRDVYREIA
YMDIRGLKPDDTAVYYCARDRSYGDSSWALDAWGQGTITVTVSSAASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEP
VTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVTVVPSSSLGTKTYTCNVDPHKPSNTKVDKRVESKYGPPCPPCPAPPVAGP
SVFLFPPKPKDTLMISRTPEVTCVVDVVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGK
EYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPCQEEMTKNQVSLWCLVKGFYPSDIAVEWESNGQPENNYKTTPPV
DSDGSFFLYSKLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSPG 4 405

YIHVTQSPSSLSVSGDRVTINCQTSQGVGSDLHWYQHKKPGRAPKLLIHHTSSVEDGVPSRFSGSGFHTSFNLTISDLQADDI
ATYYCQVLQFFGRGSRLLHIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD
SKDSTYLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC Trispecific 14 1 406

DIVMTQTPLSLSVTPGQPASISCKSSQSLVHNNANTYLSWYLQKPGQSPQSLIYKVSNNRFSGVPPDRFSGSGSGTDFTLKISR
N6/CD28sup ×

VEAEDVGYYCGQGTQYPFTFGSGTKVEIKGQPKAAPDIQMTQSPSSLSASVGDRVTITCQASQNIYVWLNWYQQKPGK
CD3mid

APKLLIYKASNLHTGVPSRFSGSGSGTDFTLTISLQPEDATYYCQQGQTYPYTFGQGTKEIKTKGPSRTVAAPSVFIFPPS
IgG4

DEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKSTYLSSTLTLSKADYEKHKVYACEVTHQG
LSSPVTKSFNRGEC 2 407

QVQLVQSGAEVVKPGASVKVSCKASGYTFTSYIHVWRQAPGQGLEWIGSIYPGNVNTNYAQKFQGRATLTVDTSISTA
YMELSRRLSDDTAVYYCTRSHYGLDWNFDVWGKGTITVTVSSSQVQLVESGGGVVQPGRSLRLSCAASGFTFTKAWMH
WVRQAPGKQLEWVAQIKDKSNSYATYYADSVKGRFTISRDDSKNTLYLQMNSLRAEDTAVYYCRGVYALSPFDYWG
QGTLTVTSSRTASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVTV
PSSSLGTKTYTCNVDPHKPSNTKVDKRVESKYGPPCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVDVVSQEDPE
VQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVCTLP
PPSQEEMTKNQVSLSCAVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQEGNVFSCSVMHEA
LHNHYTQKSLSLSPG 3 408

RAHLVQSGTAMKKPGASVRVSCQTSQGYTFTAHLFWFRQAPGRGLEWVGWIKPQYGAVNFGGGFRDRVTLTRDVYREIA
YMDIRGLKPDDTAVYYCARDRSYGDSSWALDAWGQGTITVTVSSAASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEP
VTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVTVVPSSSLGTKTYTCNVDPHKPSNTKVDKRVESKYGPPCPPCPAPEAAG
GPSVFLFPPKPKDTLMISRTPEVTCVVDVVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLN
GKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPCQEEMTKNQVSLWCLVKGFYPSDIAVEWESNGQPENNYKTTP
PVLDSDGSFFLYSKLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSPG 4 409

YIHVTQSPSSLSVSGDRVTINCQTSQGVGSDLHWYQHKKPGRAPKLLIHHTSSVEDGVPSRFSGSGFHTSFNLTISDLQADDI
ATYYCQVLQFFGRGSRLLHIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD
SKDSTYLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC Trispecific 15 1 410

DIVMTQTPLSLSVTPGQPASISCKSSQSLVHQNAQTYLSWYLQKPGQSPQSLIYKVS NRFSGV PDRFSGSGSGTDFTLKISR
N6/CD28sup ×
VEAEDVG VYYCGQGTQYPFTFGSGTKVEIKGQPKAAPDIQMTQSPSSLSASVGDRVTITCQASQNIYVWLNWYQQKPGK
CD3mid_QQ
APKLLIYKASNLHTGVPSRFSGSGSGTDFTLTISLQPEDATYYCQQGQTYPYTFGQGTKLEIKTKGPSRTVAAPSVFIFPPS
IgG4
DEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDYSLSTLTLSKADYEKHKVYACEVTHQG
FALA/409K LSPVTKSFNRGEC 2 411
QVQLVQSGAEVVKPGASVKVSCKASGYTFTSYIHVWRQAPGQGLEWIGSIYPGNVNTNYAQKFQGRATLTVDTSISTA
YMELSRRLSDDTAVYYCTRSHYGLDNFVWGKGTITVTVSSSQVLVESGGGVVQPGRLRLSCAASGFTFTKAWMH
WVRQAPGKQLEWVAQIKDKSNSYATYYADSVKGRFTISRDDSKNTLYLQMNSLRAEDTAVYYCRGVYYALSPFDYWG
QGTLTVTSSRTASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVTV
PSSSLGTKTYTCNV DHKPSNTKVDKRVESKYGPPCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVDSQEDPE
VQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVCTL
PPSQEEMTKNQVSLSCAVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFLVSKLTVDKSRWQEGNVFSCSVMHEA
LHNHYTQKSLSLGLG 3 412
RAHLVQSGTAMKKPGASVRVSCQTSGYTFTAHLFWFRQAPGRGLEWVGWIKPQYGAVNFGGGFRDRVTLTTRDVYREIA
YMDIRGLKPDDTAVYYCARDRSYGDSSWALDAWGQGTITVTVSSAASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEP
VTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVTVPSSSLGTKTYTCNV DHKPSNTKVDKRVESKYGPPCPPCPAPEAAG
GPSVFLFPPKPKDTLMISRTPEVTCVVVDVDSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLN
GKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPCQEEMTKNQVSLWCLVKGFYPSDIAVEWESNGQPENNYKTTTP
PVLDSDGSFFLVSKLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLGLG 4 413
YIHVTQSPSSLSVSIQDRVTINCQTSQGVGSDLHWYQHHPGRAPKLLIHHTSSVEDGVPSRFSGSGFHTSFNLTISDLQADDI
ATYYCQVLQFFGRGSRLLHIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD
SKDYSLSTLTLSKADYEKHKVYACEVTHQGLSPVTKSFNRGEC Trispecific 16 1 414
DIVMTQTPLSLSVTPGQPASISCKSSQSLVHQNAQTYLSWYLQKPGQSPQSLIYKVS NRFSGV PDRFSGSGSGTDFTLKISR
N6/CD28sup ×
VEAEDVG VYYCGQGTQYPFTFGSGTKVEIKDKTHTDIQTQSPSSLSASVGDRVTITCQASQNIYVWLNWYQQKPGKAP
CD3mid_QQ
KLLIYKASNLHTGVPSRFSGSGSGTDFTLTISLQPEDATYYCQQGQTYPYTFGQGTKLEIKDKTHTRTVAAPSVFIFPPSD
IgG4
EQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDYSLSTLTLSKADYEKHKVYACEVTHQGL
FALA/409K_ SSPVTKSFNRGEC DKTHT linker 2 415
QVQLVQSGAEVVKPGASVKVSCKASGYTFTSYIHVWRQAPGQGLEWIGSIYPGNVNTNYAQKFQGRATLTVDTSISTA
YMELSRRLSDDTAVYYCTRSHYGLDNFVWGKGTITVTVSSDKTHTQVQLVESGGGVVQPGRLRLSCAASGFTFTKA
WMHWVRQAPGKQLEWVAQIKDKSNSYATYYADSVKGRFTISRDDSKNTLYLQMNSLRAEDTAVYYCRGVYYALSPFD
YWGQGTLTVTSSDKTHTASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYS
LSSVTVPSSSLGTKTYTCNV DHKPSNTKVDKRVESKYGPPCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVD
VDSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPR
EPQVCTLPPSQEEMTKNQVSLSCAVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFLVSKLTVDKSRWQEGNVFS
CSVMHEALHNHYTQKSLSLGLG 3 416
RAHLVQSGTAMKKPGASVRVSCQTSGYTFTAHLFWFRQAPGRGLEWVGWIKPQYGAVNFGGGFRDRVTLTTRDVYREIA
YMDIRGLKPDDTAVYYCARDRSYGDSSWALDAWGQGTITVTVSSAASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEP
VTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVTVPSSSLGTKTYTCNV DHKPSNTKVDKRVESKYGPPCPPCPAPEAAG
GPSVFLFPPKPKDTLMISRTPEVTCVVVDVDSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLN
GKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPCQEEMTKNQVSLWCLVKGFYPSDIAVEWESNGQPENNYKTTTP
PVLDSDGSFFLVSKLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLGLG 4 417
YIHVTQSPSSLSVSIQDRVTINCQTSQGVGSDLHWYQHHPGRAPKLLIHHTSSVEDGVPSRFSGSGFHTSFNLTISDLQADDI
ATYYCQVLQFFGRGSRLLHIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD
SKDYSLSTLTLSKADYEKHKVYACEVTHQGLSPVTKSFNRGEC Trispecific 17 1 418
DIVMTQTPLSLSVTPGQPASISCKSSQSLVHNNANTYLSWYLQKPGQSPQSLIYKVS NRFSGV PDRFSGSGSGTDFTLKISR
N6/CD28sup ×
VEAEDVG VYYCGQGTQYPFTFGSGTKVEIKDKTHTDIQTQSPSSLSASVGDRVTITCQASQNIYVWLNWYQQKPGKAP
CD3mid
KLLIYKASNLHTGVPSRFSGSGSGTDFTLTISLQPEDATYYCQQGQTYPYTFGQGTKLEIKDKTHTRTVAAPSVFIFPPSD
IgG4
EQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDYSLSTLTLSKADYEKHKVYACEVTHQGL
FALA/409K_ SSPVTKSFNRGEC DKTHT linker 2 419
QVQLVQSGAEVVKPGASVKVSCKASGYTFTSYIHVWRQAPGQGLEWIGSIYPGNVNTNYAQKFQGRATLTVDTSISTA
YMELSRRLSDDTAVYYCTRSHYGLDNFVWGKGTITVTVSSDKTHTQVQLVESGGGVVQPGRLRLSCAASGFTFTKA
WMHWVRQAPGKQLEWVAQIKDKSNSYATYYADSVKGRFTISRDDSKNTLYLQMNSLRAEDTAVYYCRGVYYALSPFD
YWGQGTLTVTSSDKTHTASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYS
LSSVTVPSSSLGTKTYTCNV DHKPSNTKVDKRVESKYGPPCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVD

VSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVCTLPSPSQEEMTKNQVSLSCAVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLGLG 3 420

RAHLVQSGTAMKKPGASVRVSCQTSGYTFTAHLFWFRQAPGRGLEWVGWIKPQYGAVNFGGGFRDRVTLTRDVYREIAYMDIRGLKPDDTAVYYCARDRSYGDSSWALDAWGQGTTVVSAASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVTVPSSSLGTQTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVDVVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPCQEEMTKNQVSLWCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLGLG 4 421

YIHVTQSPSSLSVSGDRVTINCQTSQGVGSDLHWYQHKKPGRAPKLLIHHTSSVEDGVPSRFSGSGFHTSFNLTISDLQADDIATYYCQVLQFFGRGSRLHIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC Trispecific 19 1 422

DIVMTQTPLSLSVTPGQPASISCKSSQSLVHQAQTYLSWYLQKPGQSPQSLIYKVSNRFSGVPDRFSGSGSGTDFTLKISR N6/CD28sup ×

VEAEDVGYYCGQGTQYPFTFGSGTKVEIKDKTHTDIQMTQSPSSLSASVGDRVTITCQASQNIYVWLNWYQQKPGKAPCD3mid_QQ

KLLIYKASNLHTGVPSRFSGSGSGTDFTLTISSLQPEDIATYYCQQGQTYPTYTFGQGTKLEIKDKTHTTRTVAAPSVFIFPPSDIgG1_NNAS_

EQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYLSSTLTLSKADYEKHKVYACEVTHQGLDKTHT linker SSPVTKSFNRGEC 2 423

QVQLVQSGAEVVKPGASVKVSCKASGYTFTSYIHWVRQAPGQGLEWIGSIYPGNVNTNYAQKFQGRATLTVDTTSISTAYMELSRRLSDDTAVYYCTRSHYGLDWNFDVWGKGTITVTVSSDKTHTQVQLVESGGGVVQPGRSLRLSCAASGFTFKAWMHWVRQAPGKQLEWVAQIKDKSNSYATYYADSVKGRFTISRDDSKNTLYLQMNSLRAEDTAVYYCRGVYYALSPFDYWGQGTITVTVSSDKTHTASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNNASRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVCTLPSPRDELTKNQVSLSCAVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG 3 424

RAHLVQSGTAMKKPGASVRVSCQTSGYTFTAHLFWFRQAPGRGLEWVGWIKPQYGAVNFGGGFRDRVTLTRDVYREIAYMDIRGLKPDDTAVYYCARDRSYGDSSWALDAWGQGTTVVSAASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNNASRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVCTLPSPRDELTKNQVSLSCAVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG 4 425

YIHVTQSPSSLSVSGDRVTINCQTSQGVGSDLHWYQHKKPGRAPKLLIHHTSSVEDGVPSRFSGSGFHTSFNLTISDLQADDIATYYCQVLQFFGRGSRLHIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC Trispecific 21 1 426

DIVMTQTPLSLSVTPGQPASISCKSSQSLVHDNAQTYLSWYLQKPGQSPQSLIYKVSNRFSGVPDRFSGSGSGTDFTLKISR N6/CD28sup ×

VEAEDVGYYCGQGTQYPFTFGSGTKVEIKDKTHTDIQMTQSPSSLSASVGDRVTITCQASQNIYVWLNWYQQKPGKAPCD3mid_

KLLIYKASNLHTGVPSRFSGSGSGTDFTLTISSLQPEDIATYYCQQGQTYPTYTFGQGTKLEIKDKTHTTRTVAAPSVFIFPPSDDNAQ_IgG4

EQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYLSSTLTLSKADYEKHKVYACEVTHQGLFALA/409K_ SSPVTKSFNRGEC DKTHT linker 2 427

QVQLVQSGAEVVKPGASVKVSCKASGYTFTSYIHWVRQAPGQGLEWIGSIYPGNVNTNYAQKFQGRATLTVDTTSISTAYMELSRRLSDDTAVYYCTRSHYGLDWNFDVWGKGTITVTVSSDKTHTQVQLVESGGGVVQPGRSLRLSCAASGFTFKAWMHWVRQAPGKQLEWVAQIKDKSNSYATYYADSVKGRFTISRDDSKNTLYLQMNSLRAEDTAVYYCRGVYYALSPFDYWGQGTITVTVSSDKTHTASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSVTVPSSSLGTQTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVDVVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVCTLPSPSQEEMTKNQVSLSCAVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLGLG 3 428

RAHLVQSGTAMKKPGASVRVSCQTSGYTFTAHLFWFRQAPGRGLEWVGWIKPQYGAVNFGGGFRDRVTLTRDVYREIAYMDIRGLKPDDTAVYYCARDRSYGDSSWALDAWGQGTTVVSAASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVTVPSSSLGTQTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVDVVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPCQEEMTKNQVSLWCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLGLG 4 429

YIHVTQSPSSLSVSGDRVTINCQTSQGVGSDLHWYQHKKPGRAPKLLIHHTSSVEDGVPSRFSGSGFHTSFNLTISDLQADDIATYYCQVLQFFGRGSRLHIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC Trispecific 22 1 430

DIVMTQTPLSLSVTPGQPASISCKSSQSLVHENLQTYLSWYLQKPGQSPQSLIYKVSNRFSGVPDRFSGSGSGTDFTLKISR

N6/CD28sup ×
EAEDVG VYYCGQGTQYPFTFGSGTKVEIKDKTHTDIQMTQSPSSLSASVGDRVITITCQASQNIYVWLNWYQQKPGKAPK
CD3mid_
LLIYKASNLHTGVPSRFGSGSGTDFTLTISSLQPEDIATYYCQQGQTYPTYTFGQGTKLEIKDKTHTRTVAAPSVFIFPPSDE
ENLQ IgG4
QLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYLSSTLTLSKADYEKHKVYACEVTHQGLS
FALA/409K_ SPVTKSFNRGEC DKHTH linker 2 431
QVQLVQSGAEVVKPGASVKVSCKASGYTFTSYIHVWRQAPGQGLEWIGSIYPGNVNTNYAQKFQGRATLTVDTSISTA
YMELSRRLSDDTAVYYCTRSHYGLDWNFDVWGKGTITVTVSSDKTHTQVQLVESGGGVVQPGRLRLSCAASGFTFKA
WMHWVRQAPGKQLEWVAQIKDKSNSYATYYADSVKGRFTISRDDSKNTLYLQMNSLRAEDTAVYYCRGVYYALSPFD
YWGQGTITVTVSSDKTHTASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPTVSWNSGALTSGVHTFPAVLQSSGLYS
LSSVTVTPSSSLGKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVD
VSQEDPEVQFNWYVDGVEVHNATKPREEQFNSTYRVVSVLTVHLHQQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPR
EPQVCTLPPSQEEMTKNQVSLSCAVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQEGNVFS
CSVMHEALHNHYTQKSLSLGLG 3 432
RAHLVQSGTAMKKPGASVRVSCQTSGYTFTAHLFWFRQAPGRGLEWVGWIKPQYGAVNFGGGFRDRVTLTRDVYREIA
YMDIRGLKPDDTAVYYCARDRSYGDSSWALDAWGQGTITVTVSSAASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEP
TVTVSWNSGALTSGVHTFPAVLQSSGLYSLSVTVTPSSSLGKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEAAG
GPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNATKPREEQFNSTYRVVSVLTVHLHQQDWLN
GKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPCQEEMTKNQVSLWCLVKGFYPSDIAVEWESNGQPENNYKTTP
PVLDSDGSFFLVSKLTVDKSRWQEGNVFSCSVMEALHNHYTQKSLSLGLG 4 433
YIHVTQSPSSLSVIGDRVITINCQTSQGVGSDLHWYQHKPGRAPKLLIHHTSSVEDGVPSRFGSGGFHTSFNLTISDLQADDI
ATYYCQVLQFFGRGSRLLHIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD
SKDSTYLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC Trispecific 23 1 434
DIVMTQTPLSLSVTPGQPASISCKSSQSLVHENLRTYLSWYLRKPGQSPQSLIYKVSNRFGVDPDRFGSGSGTDFTLKISRV
N6/CD28sup ×
EAEDVG VYYCGQGTQYPFTFGSGTKVEIKDKTHTDIQMTQSPSSLSASVGDRVITITCQASQNIYVWLNWYQQKPGKAPK
CD3mid_
LLIYKASNLHTGVPSRFGSGSGTDFTLTISSLQPEDIATYYCQQGQTYPTYTFGQGTKLEIKDKTHTRTVAAPSVFIFPPSDE
ENLR IgG4
QLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYLSSTLTLSKADYEKHKVYACEVTHQGLS
FALA/409K_ SPVTKSFNRGEC DKHTH linker 2 435
QVQLVQSGAEVVKPGASVKVSCKASGYTFTSYIHVWRQAPGQGLEWIGSIYPGNVNTNYAQKFQGRATLTVDTSISTA
YMELSRRLSDDTAVYYCTRSHYGLDWNFDVWGKGTITVTVSSDKTHTQVQLVESGGGVVQPGRLRLSCAASGFTFKA
WMHWVRQAPGKQLEWVAQIKDKSNSYATYYADSVKGRFTISRDDSKNTLYLQMNSLRAEDTAVYYCRGVYYALSPFD
YWGQGTITVTVSSDKTHTASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPTVSWNSGALTSGVHTFPAVLQSSGLYS
LSSVTVTPSSSLGKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVD
VSQEDPEVQFNWYVDGVEVHNATKPREEQFNSTYRVVSVLTVHLHQQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPR
EPQVCTLPPSQEEMTKNQVSLSCAVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQEGNVFS
CSVMHEALHNHYTQKSLSLGLG 3 436
RAHLVQSGTAMKKPGASVRVSCQTSGYTFTAHLFWFRQAPGRGLEWVGWIKPQYGAVNFGGGFRDRVTLTRDVYREIA
YMDIRGLKPDDTAVYYCARDRSYGDSSWALDAWGQGTITVTVSSAASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEP
TVTVSWNSGALTSGVHTFPAVLQSSGLYSLSVTVTPSSSLGKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEAAG
GPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNATKPREEQFNSTYRVVSVLTVHLHQQDWLN
GKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPCQEEMTKNQVSLWCLVKGFYPSDIAVEWESNGQPENNYKTTP
PVLDSDGSFFLVSKLTVDKSRWQEGNVFSCSVMEALHNHYTQKSLSLGLG 4 437
YIHVTQSPSSLSVIGDRVITINCQTSQGVGSDLHWYQHKPGRAPKLLIHHTSSVEDGVPSRFGSGGFHTSFNLTISDLQADDI
ATYYCQVLQFFGRGSRLLHIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD
SKDSTYLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC Trispecific 24 1 438
DIVMTQTPLSLSVTPGQPASISCKSSQSLVHENLFTYLSWYLRKPGQSPQSLIYKVSNRFGVDPDRFGSGSGTDFTLKISRV
N6/CD28sup ×
EAEDVG VYYCGQGTQYPFTFGSGTKVEIKDKTHTDIQMTQSPSSLSASVGDRVITITCQASQNIYVWLNWYQQKPGKAPK
CD3mid_
LLIYKASNLHTGVPSRFGSGSGTDFTLTISSLQPEDIATYYCQQGQTYPTYTFGQGTKLEIKDKTHTRTVAAPSVFIFPPSDE
ENLF IgG4
QLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYLSSTLTLSKADYEKHKVYACEVTHQGLS
FALA/409K_ SPVTKSFNRGEC DKHTH linker 2 439
QVQLVQSGAEVVKPGASVKVSCKASGYTFTSYIHVWRQAPGQGLEWIGSIYPGNVNTNYAQKFQGRATLTVDTSISTA
YMELSRRLSDDTAVYYCTRSHYGLDWNFDVWGKGTITVTVSSDKTHTQVQLVESGGGVVQPGRLRLSCAASGFTFKA
WMHWVRQAPGKQLEWVAQIKDKSNSYATYYADSVKGRFTISRDDSKNTLYLQMNSLRAEDTAVYYCRGVYYALSPFD
YWGQGTITVTVSSDKTHTASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPTVSWNSGALTSGVHTFPAVLQSSGLYS
LSSVTVTPSSSLGKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVD
VSQEDPEVQFNWYVDGVEVHNATKPREEQFNSTYRVVSVLTVHLHQQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPR

EPQVCTLPSPQEEMTKNQVSLSCAVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLVSKLTVDKSRWQEGNVFS
CSVMHEALHNHYTQKSLSLSLG 3 440
RAHLVQSGTAMKKPGASVRVSCQTSGYTFTAHLFWFRQAPGRGLEWVGWIKPQYGAVNFGGGFRDRVTLTRDVYREIA
YMDIRGLKPDDTAVYYCARDRSYGDSSWALDAWGQGTTVVVSAASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEP
VTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEAAG
GPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLN
GKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPCQEEMTKNQVSLWCLVKGFYPSDIAVEWESNGQPENNYKTP
PVLDSDGSFFLYSKLTVDKSRWQEGNVFSCSMHEALHNHYTQKSLSLSLG 4 441
YIHVTQSPSSLSVIGDRVTINCQTSQGVGSDLHWYQHHPGRAPKLLIHHTSSVEDGVPSRFSGSGFHTSFNLTISDLQADDI
ATYYCQVLQFFGRGSRLLHIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD
SKDSTYLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC Trispecific 25 1 442
DIVMTQTPLSLSVTPGQPASISCKSSQSLVHENLQTYLSWYLQKPGQSPQSLIYKVSNRFSGVPDRFSGSGSGTDFTLKISR
V N6_rw52/
EAEDVG VYYCGQGTQYPFTFGSGTKVEIKDKTHTDIQMTQSPSSLSASVGDRVTITCQASQNIYVWLNWYQQKPGKAPK
CD28sup ×
LLIYKASNLHTGVPSRFSGSGSGTDFTLTISLQPEDATYYCQGGQTYPTYTFGQGTKLEIKDKTHTRTVAAPSVFIFPPSDE
CD3mid_
QLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYLSSTLTLSKADYEKHKVYACEVTHQGLS
ENLQ IgG4 SPVTKSFNRGEC FALA/409K_ DKHT linker 2 443
QVQLVQSGAEVVKPGASVKVSCKASGYTFTSYIHVWRQAPGQGLEWIGSIYPGNVNTNYAQKFQGRATLTVDTSISTA
YMELSRRLSDDTAVYYCTRSHYGLDWNFDVWGKGTTVTVSSDKTHTQVQLVESGGGVVQPGRLRLSCAASGFTFKA
WMHWVRQAPGKQLEWVAQIKDKSNSYATYYADSVKGRFTISRDDSKNTLYLQMNSLRAEDTAVYYCRGVYYALSPFD
YWGQGTLVTVSSDKTHTASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYS
LSSVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVD
VSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPR
EPQVCTLPSPQEEMTKNQVSLSCAVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLVSKLTVDKSRWQEGNVFS
CSVMHEALHNHYTQKSLSLSLG 3 444
RAHLVQSGTAMKKPGASVRVSCQTSGYTFTAHLFWFRQAPGRGLEWVGWIKPQYGATNFGGGFRDRVTLTRDVYREIA
YMDIRGLKPDDTAVYYCARDRSYGDSSWALDAWGQGTTVVVSAASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEP
VTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEAAG
GPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLN
GKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPCQEEMTKNQVSLWCLVKGFYPSDIAVEWESNGQPENNYKTP
PVLDSDGSFFLYSKLTVDKSRWQEGNVFSCSMHEALHNHYTQKSLSLSLG 4 445
YIHVTQSPSSLSVIGDRVTINCQTSQGVGSDLHWYQHHPGRAPKLLIHHTSSSEEGVPSRFSGSGFHTSFNLTISDLQADDI
ATYYCQVLQFFGRGSRLLHIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD
SKDSTYLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC Trispecific 26 1 446
DIVMTQTPLSLSVTPGQPASISCKSSQSLVHENLFTYLSWYLQKPGQSPQSLIYKVSNRFSGVPDRFSGSGSGTDFTLKISR
V N6_rw52/
EAEDVG VYYCGQGTQYPFTFGSGTKVEIKDKTHTDIQMTQSPSSLSASVGDRVTITCQASQNIYVWLNWYQQKPGKAPK
CD28sup ×
LLIYKASNLHTGVPSRFSGSGSGTDFTLTISLQPEDATYYCQGGQTYPTYTFGQGTKLEIKDKTHTRTVAAPSVFIFPPSDE
CD3mid_
QLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYLSSTLTLSKADYEKHKVYACEVTHQGLS
ENLF IgG4 SPVTKSFNRGEC FALA/409K_ DKHT linker 2 447
QVQLVQSGAEVVKPGASVKVSCKASGYTFTSYIHVWRQAPGQGLEWIGSIYPGNVNTNYAQKFQGRATLTVDTSISTA
YMELSRRLSDDTAVYYCTRSHYGLDWNFDVWGKGTTVTVSSDKTHTQVQLVESGGGVVQPGRLRLSCAASGFTFKA
WMHWVRQAPGKQLEWVAQIKDKSNSYATYYADSVKGRFTISRDDSKNTLYLQMNSLRAEDTAVYYCRGVYYALSPFD
YWGQGTLVTVSSDKTHTASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYS
LSSVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVD
VSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPR
EPQVCTLPSPQEEMTKNQVSLSCAVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLVSKLTVDKSRWQEGNVFS
CSVMHEALHNHYTQKSLSLSLG 3 448
RAHLVQSGTAMKKPGASVRVSCQTSGYTFTAHLFWFRQAPGRGLEWVGWIKPQYGATNFGGGFRDRVTLTRDVYREIA
YMDIRGLKPDDTAVYYCARDRSYGDSSWALDAWGQGTTVVVSAASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEP
VTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEAAG
GPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLN
GKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPCQEEMTKNQVSLWCLVKGFYPSDIAVEWESNGQPENNYKTP
PVLDSDGSFFLYSKLTVDKSRWQEGNVFSCSMHEALHNHYTQKSLSLSLG 4 449
YIHVTQSPSSLSVIGDRVTINCQTSQGVGSDLHWYQHHPGRAPKLLIHHTSSSEEGVPSRFSGSGFHTSFNLTISDLQADDI
ATYYCQVLQFFGRGSRLLHIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD
SKDSTYLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC Trispecific 27 1 450
DIVMTQTPLSLSVTPGQPASISCKSSQSLVHENLFTYLSWYLQKPGQSPQSLIYKVSNRFSGVPDRFSGSGSGTDFTLKISR
V N6_rw52/

EAEDVGYYCGQGTQYPFTFGSGTKVEIKDKTHTDIQMTQSPSSLSASVGDRVITITCQASQNIYVWLNWYQQKPGKAPK
CD28sup ×
LLIYKASNLHTGVPSRFSGSGSGTDFTLTISSLQPEDIATYYCQQGQTYPTYTFGQGTKLEIKDKTHTTRTVAAPS VFIFPPSDE
CD3mid_
QLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYLSSTLTLSKADYEKHKVYACEVTHQGLS
ENLF SPVTKSFNRGEC IgG1_NNAS_ DKTHT linker 2 451
QVQLVQSGAEVVKPGASVKVSKASGYTFTSYIHWVRQAPGQGLEWIGSIYPGNVNTNYAQKFQGRATLTVDT SISTA
YMELSRRLSDDTAVYYCTRSHYGLDWNFDVWGKGT TVTVSSDKTHTQVQLVESGGGVVQPRSLRLSCAASGFTFKA
WMHWVRQAPGKQLEWVAQIKDKSNSYATYYADSVKGRFTISRDDSKNTLYLQMNSLRAEDTAVYYCRGVYYALSPFD
YWGQGT LVTVSSDKTHTASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVT VSWNSGALTSGVHTFPAVLQSSGLY
SLSSV VTPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEL LGGPSVFLFPPKPKDTLMISRTPEVTCV
VVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNNASRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAK
GQPREPQVCTLPSPRDELTKNQVSLSCAVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQQG
NVFSCSVMHEALHNHYTQKSLSLSPG 3 452
RAHLVQSGTAMKKPGASVRVSCQTSGYTFTAHLFWFRQAPGRGLEWVGWIKPQYGATNFGGGFRDRVTLTRDVYREIA
YMDIRGLKPDDTAVYYCARDRSYGDSSWALDAWGQGT TVVVSAASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEP
VT VSWNSGALTSGVHTFPAVLQSSGLYSLSSV VTPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEL
LGGPSVFLFPPKPKDTLMISRTPEVTCV VVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNNASRVVSVLTVLHQDW
LNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPCRDELTKNQVSLWCLVKGFYPSDIAVEWESNGQPENNYKT
TPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG 4 453
YIHVTQSPSSLSV SIGDRV TINCQTSQGVGSDLHWYQHKPGRAPKLLIHHTSSSEEGVPSRFSGSGFHTSFNLTISDLQADDI
ATYYCQVLQFFGRGSR LHIKRTVAAPS VFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD
SKDSTYLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC Trispecific 28 1 454
DIVMTQTPLSLSVTPGQPASISCKSSQSLVHENLQTYLSWYLQKPGQSPQSLIYKVS NRFSGVPDRFSGSGSGTDFTLKISRV
N6_FR3-03/

EAEDVGYYCGQGTQYPFTFGSGTKVEIKDKTHTDIQMTQSPSSLSASVGDRVITITCQASQNIYVWLNWYQQKPGKAPK
CD28sup ×
LLIYKASNLHTGVPSRFSGSGSGTDFTLTISSLQPEDIATYYCQQGQTYPTYTFGQGTKLEIKDKTHTTRTVAAPS VFIFPPSDE
CD3mid_
QLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYLSSTLTLSKADYEKHKVYACEVTHQGLS
ENLQ IgG4 SPVTKSFNRGEC FALA/409K_ DKTHT linker 2 455
QVQLVQSGAEVVKPGASVKVSKASGYTFTSYIHWVRQAPGQGLEWIGSIYPGNVNTNYAQKFQGRATLTVDT SISTA
YMELSRRLSDDTAVYYCTRSHYGLDWNFDVWGKGT TVTVSSDKTHTQVQLVESGGGVVQPRSLRLSCAASGFTFKA
WMHWVRQAPGKQLEWVAQIKDKSNSYATYYADSVKGRFTISRDDSKNTLYLQMNSLRAEDTAVYYCRGVYYALSPFD
YWGQGT LVTVSSDKTHTASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVT VSWNSGALTSGVHTFPAVLQSSGLYS
LSSV VTPSSSLGKTYTCNV DHKPSNTKVDKRVESKYGPPCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCV VVD
VSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPR
EPQVCTLPQSQEEMTKNQVSLSCAVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQEGNVFS
CSVMHEALHNHYTQKSLSLSLG 3 456
RAHLVQSGTAMKKPGASVRVSCQTSGYTFTAHLFWFRQAPGRGLEWVGWIKPQYGAVNFGGGFRDRVTLTRQLSQDP
DDPDWGIAYMDIRGLKPDDTAVYYCARDRSYGDSSWALDAWGQGT TVVVSAASTKGPSVFPLAPCSRSTSESTAALGCL
VKDYFPEPVT VSWNSGALTSGVHTFPAVLQSSGLYSLSSV VTPSSSLGKTYTCNV DHKPSNTKVDKRVESKYGPPCPPC
PAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCV VVDVVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVL
HQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPCQEEMTKNQVSLWCLVKGFYPSDIAVEWESNGQPE
NNYKTTPPVLDSDGSFFLYSKLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLG 4 457
YIHVTQSPSSLSV SIGDRV TINCQTSQGVGSDLHWYQHKPGRAPKLLIHHTSSVEDGVPSRFSGSGFHTSFNLTISDLQADDI
ATYYCQVLQFFGRGSR LHIKRTVAAPS VFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD
SKDSTYLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC Trispecific 29 1 458
DIVMTQTPLSLSVTPGQPASISCKSSQSLVHENLFTYLSWYLQKPGQSPQSLIYKVS NRFSGVPDRFSGSGSGTDFTLKISRV
N6_FR3-03/

EAEDVGYYCGQGTQYPFTFGSGTKVEIKDKTHTDIQMTQSPSSLSASVGDRVITITCQASQNIYVWLNWYQQKPGKAPK
CD28sup ×
LLIYKASNLHTGVPSRFSGSGSGTDFTLTISSLQPEDIATYYCQQGQTYPTYTFGQGTKLEIKDKTHTTRTVAAPS VFIFPPSDE
CD3mid_
QLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYLSSTLTLSKADYEKHKVYACEVTHQGLS
ENLF IgG4 SPVTKSFNRGEC FALA/409K_ DKTHT linker 2 459
QVQLVQSGAEVVKPGASVKVSKASGYTFTSYIHWVRQAPGQGLEWIGSIYPGNVNTNYAQKFQGRATLTVDT SISTA
YMELSRRLSDDTAVYYCTRSHYGLDWNFDVWGKGT TVTVSSDKTHTQVQLVESGGGVVQPRSLRLSCAASGFTFKA
WMHWVRQAPGKQLEWVAQIKDKSNSYATYYADSVKGRFTISRDDSKNTLYLQMNSLRAEDTAVYYCRGVYYALSPFD
YWGQGT LVTVSSDKTHTASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVT VSWNSGALTSGVHTFPAVLQSSGLYS
LSSV VTPSSSLGKTYTCNV DHKPSNTKVDKRVESKYGPPCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCV VVD
VSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPR
EPQVCTLPQSQEEMTKNQVSLSCAVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQEGNVFS

CSVMHEALHNHYTQKSLSLSLG 3 460

RAHLVQSGTAMKKPGASVRVSCQTSGYTFTAHLFWFRQAPGRGLEWVGWIKPQYGAVNFGGGFRDRVTLTRQLSQDP
DDPDWGIAYMDIRGLKPDDTAVYYCARDRSYGDSSWALDAWGQGTTVVSAASTKGPSVFPLAPCSRSTSESTAALGCL
VKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYTCNVDHKPSNTKVDKRVESKYGPPCPPC
PAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSDQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVL
HQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPCQEEMTKNQVSLWCLVKGFYPSDIAVEWESNGQPE
NNYKTTTPVLDSDGSFFLYSKLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSPG 4 461

YIHVTQSPSSLSVSIQDRVTINCQTSQGVGSDLHWYQHHPGRAPKLLIHHTSSVEDGVPSRFSGSGFHTSFNLTISDLQADDI
ATYYCQVLQFFGRGSRHLHIKRTVAAPSVFIFPPSDEQLKSGTASVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD
SKDSTYLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC Trispecific 30 1 462

DIVMTQTPLSLSVTPGQPASISCKSSQSLVHENLQTYLSWYLQKPGQSPQSLIYKVSNRFSGVPDRFSGSGSGTDFTLKISR
V N6_FR3-03/

EAEDVGYYYCGQGTQYPFTFGSGTKVEIKDKTHTDIQMTQSPSSLSASVGDRVITITCQASQNIYVWLNWYQQKPGKAPK
CD28sup ×

LLIYKASNLHTGVPSRFSGSGSGTDFTLTISLQPEDATYYCQGGQTYPTYTFGQGTKLEIKDKTHTRTVAAPSVFIFPPSDE
CD3mid_

QLKSGTASVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYLSSTLTLSKADYEKHKVYACEVTHQGLS
ENLQIgG1_ SPVTKSFNRGEC NNAS_DKTHT linker 2 463

QVQLVQSGAEVVKPGASVKVSCKASGYTFTSYIHVWRQAPGQGLEWIGSIYPGNVNTNYAQKFQGRATLTVDTISTA
YMELSRRLSDDTAVYYCTRSHYGLDWNFDVWGKGTITVTVSSDKTHTQVQLVESGGGVVQPGRLRLSCAASGFTFKA
WMHWVRQAPGKQLEWVAQIKDKNSYATYYADSVKGRFTISRDDSKNTLYLQMNSLRAEDTAVYYCRGVYYALSPFD
YWGQGTITVTVSSDKTHTASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLY
SLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCV
VVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNNASRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAK
GQPREPQVCTLPSPRDELTKNQVSLSCAVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFLVSKLTVDKSRWQQG
NVFSCSVMHEALHNHYTQKSLSLSPG 3 464

RAHLVQSGTAMKKPGASVRVSCQTSGYTFTAHLFWFRQAPGRGLEWVGWIKPQYGAVNFGGGFRDRVTLTRQLSQDP
DDPDWGIAYMDIRGLKPDDTAVYYCARDRSYGDSSWALDAWGQGTTVVSAASTKGPSVFPLAPSSKSTSGGTAALGC
LVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHT
CPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNNASRVVSV
LTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPCRDELTKNQVSLWCLVKGFYPSDIAVEWESNG
QPENNYKTTTPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG 4 465

YIHVTQSPSSLSVSIQDRVTINCQTSQGVGSDLHWYQHHPGRAPKLLIHHTSSVEDGVPSRFSGSGFHTSFNLTISDLQADDI
ATYYCQVLQFFGRGSRHLHIKRTVAAPSVFIFPPSDEQLKSGTASVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD
SKDSTYLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC Trispecific 31 1 466

DIVMTQTPLSLSVTPGQPASISCKSSQSLVHENLFTYLSWYLQKPGQSPQSLIYKVSNRFSGVPDRFSGSGSGTDFTLKISR
V N6_FR3-03/

EAEDVGYYYCGQGTQYPFTFGSGTKVEIKDKTHTDIQMTQSPSSLSASVGDRVITITCQASQNIYVWLNWYQQKPGKAPK
CD28sup ×

LLIYKASNLHTGVPSRFSGSGSGTDFTLTISLQPEDATYYCQGGQTYPTYTFGQGTKLEIKDKTHTRTVAAPSVFIFPPSDE
CD3mid_

QLKSGTASVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYLSSTLTLSKADYEKHKVYACEVTHQGLS
ENLF SPVTKSFNRGEC IgG1_NNAS_DKTHT linker 2 467

QVQLVQSGAEVVKPGASVKVSCKASGYTFTSYIHVWRQAPGQGLEWIGSIYPGNVNTNYAQKFQGRATLTVDTISTA
YMELSRRLSDDTAVYYCTRSHYGLDWNFDVWGKGTITVTVSSDKTHTQVQLVESGGGVVQPGRLRLSCAASGFTFKA
WMHWVRQAPGKQLEWVAQIKDKNSYATYYADSVKGRFTISRDDSKNTLYLQMNSLRAEDTAVYYCRGVYYALSPFD
YWGQGTITVTVSSDKTHTASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLY
SLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCV
VVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNNASRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAK
GQPREPQVCTLPSPRDELTKNQVSLSCAVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFLVSKLTVDKSRWQQG
NVFSCSVMHEALHNHYTQKSLSLSPG 3 468

RAHLVQSGTAMKKPGASVRVSCQTSGYTFTAHLFWFRQAPGRGLEWVGWIKPQYGAVNFGGGFRDRVTLTRQLSQDP
DDPDWGIAYMDIRGLKPDDTAVYYCARDRSYGDSSWALDAWGQGTTVVSAASTKGPSVFPLAPSSKSTSGGTAALGC
LVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHT
CPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNNASRVVSV
LTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPCRDELTKNQVSLWCLVKGFYPSDIAVEWESNG
QPENNYKTTTPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG 4 469

YIHVTQSPSSLSVSIQDRVTINCQTSQGVGSDLHWYQHHPGRAPKLLIHHTSSVEDGVPSRFSGSGFHTSFNLTISDLQADDI
ATYYCQVLQFFGRGSRHLHIKRTVAAPSVFIFPPSDEQLKSGTASVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD
SKDSTYLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC Trispecific 34 1 470

DIVMTQTPLSLSVTPGQPASISCKSSQSLVHENLQTYLSWYLQKPGQSPQSLIYKVSNRFSGVPDRFSGSGSGTDFTLKISR
V VRC01.23/

EAEDVGYYYCGQGTQYPFTFGSGTKVEIKDKTHTDIQMTQSPSSLSASVGDRVITITCQASQNIYVWLNWYQQKPGKAPK

CD28sup ×
LLIYKASNLHTGVPSRFSGSGSGTDFTLTISLQPEDATYYCQQGQTYPTYTFGQGTKLEIKDKTHTRTVAAPS VFIFPPSDE
CD3mid_
QLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYLSSTLTLSKADYEKHKVYACEVTHQGLS
ENLQ IgG4 SPVTKSFNRGEC FALA/409K_ DKHTH linker 2 471
QVQLVQSGAEVVKPGASVKVSKASGYTFTSYIHVWRQAPGQGLEWIGSIYPGNVNTNYAQKFQGRATLTVDT SISTA
YMELSRRLSDDTAVYYCTRSHYGLDWNFDVWGKGT TTVTVSSDKTHTQVQLVESGGGVVQPRSLRLSCAASGFTFKA
WMHWVRQAPGKQLEWVAQIKDKSNSYATYYADSVKGRFTISRDDSKNTLYLQMNSLRAEDTAVYYCRGVYYALSPFD
YWGQGT LTVTVSSDKTHTASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVT VSWNSGALTSGVHTFPAVLQSSGLYS
LSSVTVTPSSSLGTKTYTCNV DHKPSNTKVDKRVESKYGPPCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVD
VSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPR
EPQVCTLPQSQEEMTKNQVSLSCAVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLVSKLTVDKSRWQEGNVFS
CSVMHEALHNHYTQKSLSLGLG 3 472
QVQLVQSGGQMKKPGESMRISCRASGYEFIDCTLNWIRLAPGKRPEWMGWLKPRWGAVNYARPLQGRVTMTRQLSQDP
DDPDWGTAFLELRSLTVDDTAVYFCTRGKNC DYNWDEERWGRGTPVIVSSASTKGPSVFPLAPCSRSTSESTAALGCLVK
DYFPEPVT VSWNSGALTSGVHTFPAVLQSSGLYSLSSVTVTPSSSLGTKTYTCNV DHKPSNTKVDKRVESKYGPPCPPCPA
PEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQ
DWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPCQEEMTKNQVSLWCLVKGFYPSDIAVEWESNGQPEN
YKTPPVLDSDGSFFLYSKLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLGLG 4 473
LTQSPGTLSPGETAII SCRTS QYGSLAWYQQRPGQAPRLVIYSGSTRAAGIPDRFSGSRWGP DYNLTISNLESGDFGVYY
CQQYEFFGQGTKVQVDIKRTVAAPS VFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSK
DSTYLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC Trispecific 35 1 474
DIVMTQTPLSLSVTPGQPASISCKSSQSLVHENLFTYLSWY LQKPGQSPQSLIYKVS NRFSGVPDRFSGSGSGTDFTLKISR
VRC01.23/
EAEDVG VYYCGQGTQYPFTFGSGTKVEIKDKTHTDI QMTQSPSSLSASVGDRVITTCQASQNIYVWLNWYQQKPGKAPK
CD28sup ×
LLIYKASNLHTGVPSRFSGSGSGTDFTLTISLQPEDATYYCQQGQTYPTYTFGQGTKLEIKDKTHTRTVAAPS VFIFPPSDE
CD3mid_
QLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYLSSTLTLSKADYEKHKVYACEVTHQGLS
ENLF IgG4 SPVTKSFNRGEC FALA/409K_ DKHTH linker 2 475
QVQLVQSGAEVVKPGASVKVSKASGYTFTSYIHVWRQAPGQGLEWIGSIYPGNVNTNYAQKFQGRATLTVDT SISTA
YMELSRRLSDDTAVYYCTRSHYGLDWNFDVWGKGT TTVTVSSDKTHTQVQLVESGGGVVQPRSLRLSCAASGFTFKA
WMHWVRQAPGKQLEWVAQIKDKSNSYATYYADSVKGRFTISRDDSKNTLYLQMNSLRAEDTAVYYCRGVYYALSPFD
YWGQGT LTVTVSSDKTHTASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVT VSWNSGALTSGVHTFPAVLQSSGLYS
LSSVTVTPSSSLGTKTYTCNV DHKPSNTKVDKRVESKYGPPCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVD
VSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPR
EPQVCTLPQSQEEMTKNQVSLSCAVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLVSKLTVDKSRWQEGNVFS
CSVMHEALHNHYTQKSLSLGLG 3 476
QVQLVQSGGQMKKPGESMRISCRASGYEFIDCTLNWIRLAPGKRPEWMGWLKPRWGAVNYARPLQGRVTMTRQLSQDP
DDPDWGTAFLELRSLTVDDTAVYFCTRGKNC DYNWDEERWGRGTPVIVSSASTKGPSVFPLAPCSRSTSESTAALGCLVK
DYFPEPVT VSWNSGALTSGVHTFPAVLQSSGLYSLSSVTVTPSSSLGTKTYTCNV DHKPSNTKVDKRVESKYGPPCPPCPA
PEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQ
DWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPCQEEMTKNQVSLWCLVKGFYPSDIAVEWESNGQPEN
YKTPPVLDSDGSFFLYSKLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLGLG 4 477
LTQSPGTLSPGETAII SCRTS QYGSLAWYQQRPGQAPRLVIYSGSTRAAGIPDRFSGSRWGP DYNLTISNLESGDFGVYY
CQQYEFFGQGTKVQVDIKRTVAAPS VFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSK
DSTYLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
TABLE-US-00011 TABLE 5 Trispecific binding protein polynucleotide sequences Poly- peptide Number (acc. to
SEQ for- ID Molecule mula) NO Sequence Trispecific 1 1 478
GACATCGTGATGACCCAGACCCCCCTGAGCCTGAGCGTGACACCTGGACAGCCTGCCAGCATCAGCTGCAAGAGCA
VRC07_523/
GCCAGAGCCTGGTGCACAACAACGCCAACACCTACCTGAGCTGGTATCTGCAGAAGCCCGGCCAGAGCCCCCAGTC
CD28sup ×
CCTGATCTACAAGGTGTCCAACAGATTCAGCGGCGTGCCCGACAGATTCTCCGGCAGCGGCTCTGGCACCGACTTCA
CD3mid IgG1
CCCTGAAGATCAGCCGGGTGGAAGCCGAGGACGTGGGCGTGTACTATTGTGGCCAGGGCACCCAGTACCCCTTCACC
LALA/P329A
TTTGGCAGCGGCACCAAGGTGGAATCAAGGGCCAGCCCAAGGCCGCCCCCGACATCCAGATGACCCAGAGCCCCA
GCAGCCTGTCTGCCAGCGTGGGCGACAGAGTGACCATCACCTGTCAGGCCAGCCAGAACATCTACGTGTGGCTGAAC
TGGTATCAGCAGAAGCCCGGCAAGGCCCCCAAGCTGCTGATCTACAAGGCCAGCAACCTGCACACCGGCGTGCCCA
GCAGATTTTCTGGCAGCGGCTCCGGCACCGACTTCACCCTGACAATCAGCTCCCTGCAGCCCGAGGACATTGCCACC
TACTACTGCCAGCAGGGCCAGACCTACCCCTACACCTTTGGCCAGGGCACCAAGCTGGAAATCAAGACCAAGGGCC
CCAGCCGTACGGTGGCCGCTCCAGCGTGTTTCATCTTCCCACCTAGCGACGAGCAGCTGAAGTCCGGCACAGCCTCT

GTCTGTCCTGCTGAACAACCTTCTACCCCGCAGGCCAAAGTGCAGTGGAAAGGTGGACAACGCCCTGCAGAGCG
GCAACAGCCAGGAAAGCGTGACCGAGCAGGACAGCAAGGACTCCACCTACAGCCTGAGCAGCACCCTGACACTGAG
CAAGGCCGACTACGAGAAGCACAAAGGTGTACGCCTGCGAAGTGACCCACCAGGGCCTGTCTAGCCCCGTGACCAAG
AGCTTCAACCGGGGCGAGTGT 2 479
CAGGTGCAGCTGGTGCAGTCTGGCGCCGAGGTCTGTGAAACCTGGCGCCTCTGTGAAGGTGTCCTGCAAGGCCAGCGG
CTACACCTTTACCAGCTACTACATCCACTGGGTGCGCCAGGCCCTGGACAGGGACTGGAATGGATCGGCAGCATCT
ACCCCGGCAACGTGAACACCAACTACGCCCAGAAGTTCCAGGGCAGAGCCACCCTGACCGTGGACACCAGCATCAG
CACCGCCTACATGGAAGTGAAGCCGGCTGAGAAGCGACGACACCGCCGTGTACTACTGCACCCGGTCCCACTACGGCC
TGGATTGGAACCTTCGACGTGTGGGGCAAGGGCACCACCGTGACAGTGTCTAGCAGCCAGGTGCAGCTGGTGGAAATCT
GGCGGCGGAGTGGTGCAGCCTGGCAGAAGCCTGAGACTGAGCTGTGCCGCCAGCGGCTTCACCTTCACCAAGGCCT
GGATGCACTGGGTGCGCCAGGCCCTGGAAAGCAGCTGGAATGGGTGGCCAGATCAAGGACAAGAGCAACAGCTA
CGCCACCTACTACGCCGACAGCGTGAAGGGCCGGTTCACCATCAGCCGGGACGACAGCAAGAACACCCTGTACCTG
CAGATGAACAGCCTGCGGGCCGAGGACACCGCCGTGTACTACTGTGCGGGCGTGTACTATGCCCTGAGCCCCCTTCGA
TTACTGGGGCCAGGGAACCCTCGTGACCGTGTCTAGTCGGACCGCCAGCACAAAGGGCCCCAGCGTGTTCCCTCTGG
CCCCTAGCAGCAAGAGCACATCTGGCGGAACAGCCGCCCTGGGCTGCCTCGTGAAGGACTACTTTCCCGAGCCCCGTG
ACCGTGTCTCTGGAATTCTGGCGCCCTGACCAGCGGCGTGCACACCTTTCCAGCTGTGCTGCAGTCCAGCGGCCTGTA
CAGCCTGAGCAGCGTCGTGACAGTGCCCAGCAGCTCTCTGGGCACCCAGACCTACATCTGCAACGTGAACCACAAGC
CCAGCAACACCAAGGTGGACAAGAAGGTGGAACCCAAGAGCTGCGACAAGACCCACACCTGTCCCCCTTGTCTGCGC
CCCGAAGCCGCGGAGGCCCTTCCGTGTTCCCTGTTCCCCCAAGGCCAAGGACACCCTGATGATCAGCCGGACCCC
CGAAGTGACCTGCGTGGTGGTGGATGTGTCCCACGAGGACCCTGAAGTGAAGTTCAATTGGTACGTGGACGGCGTGG
AAGTGCACAACGCCAAGACCAAGCCAAGAGAGGAACAGTACAACAGCACCTACCGGGTGGTGTCCGTGCTGACCGT
GCTGCACCAGGACTGGCTGAACGGCAAAGAGTACAAGTGCAAGGTGTCCAACAAGGCCCTGGCCGCCCCCATCGAG
AAAACCATCAGCAAGGCCAAGGGCCAGCCCCGCGAACCCAGGTGTGCACACTGCCCCCAAGCAGGGACGAGCTGA
CCAAGAACCAGGTGTCCCTGAGCTGTGCCGTGAAAGGCTTCTACCCCTCCGATATCGCCGTGGAATGGGAGAGCAAC
GGCCAGCCCGAGAACAATAAGACCACCCCCCTGTGCTGGACAGCGACGGCTCATTCTTCTGGTGTCCAAGCT
GACAGTGGACAAGTCCCGGTGGCAGCAGGGCAACGTGTTAGCTGCTCCGTGATGCACGAGGCCCTGCACAACCAC
TACACCAGAAGTCCCTGAGCCTGAGCCCCGGCTAGTGA 3 480
CAAGTGCGGCTGTCTCAGTCTGGCGGCCAGATGAAGAAACCCGGCGACAGCATGCGGATCAGCTGCAGAGCCAGCG
GCTACGAGTTCATCAACTGCCCCATCAACTGGATCAGACTGGCCCCTGGCAAGCGGCCTGAGTGGATGGATGGATG
AAGCCCAGACACGGGGCCGTGTCTACGCCAGACAGCTGCAGGGCAGAGTGACCATGACCCGGGACATGTACAGCG
AGACAGCCTTCTCTGGAAGTGCAGGAGCCTGACCAGCGACGATACCGCCGTGTACTTCTGCACCCGGGGCAAGTACTGC
ACCGCCAGAGACTACTACAAGTGGGACTTCGAGCACTGGGGCCAGGGCACACCTGTGACAGTGTCTAGCGCTTCGAC
CAAGGGCCCCAGCGTGTTCCTCTGGCCCCTAGCAGCAAGAGCACATCTGGCGGAACAGCCGCCCTGGGCTGCCTCG
TGAAGGACTACTTTCCCGAGCCCCGTGACCGTGTCTCTGGAATTCTGGCGCCCTGACCAGCGGCGTGCACACCTTTCCA
GCTGTGCTGCAGTCCAGCGGCCTGTACAGCCTGAGCAGCGTCGTGACAGTGCCCAGCAGCTCTCTGGGCACCCAGAC
CTACATCTGCAACGTGAACCACAAGCCCAGCAACACCAAGGTGGACAAGAAGGTGGAACCCAAGAGCTGCGACAAG
ACCCACACCTGTCCCCCTTGTCTGCCCCGAAGCCGCCGGAGGCCCTTCCGTGTTCTCTGTTCCCCCAAGGCCAA
GGACACCCTGATGATCAGCCGGACCCCCGAAGTGACCTGCGTGGTGGTGGATGTGTCCCACGAGGACCCTGAAGTGA
AGTTCAATTGGTACGTGGACGGCGTGGAAAGTGACAACGCCAAGACCAAGCCAAGAGAGGAACAGTACAACAGCAC
CTACCGGGTGGTGTCCGTGCTGACCGTGTCTGCACCAGGACTGGCTGAACGGCAAAGAGTACAAGTGCAAGGTGTCC
AACAAGGCCCTGGCCGCCCCCATCGAGAAAACCATCAGCAAGGCCAAGGGCCAGCCCCGCGAACCCAGGTGTACA
CACTGCCCCCATGCAGGGACGAGCTGACCAAGAACCAGGTGTCCCTGTGGTGTCTGGTGAAAGGCTTCTACCCCTCC
GATATCGCCGTGGAATGGGAGAGCAACGGCCAGCCCCGAGAACAATAAGACCACCCCCCTGTGCTGGACAGCG
ACGGCTCATTCTTCTGTACTCCAAGCTGACAGTGGACAAGTCCCGGTGGCAGCAGGGCAACGTGTTAGCTGCTCC
GTGATGCACGAGGCCCTGCACAACCACTACACCCAGAAGTCCCTGAGCCTGAGCCCCGGC 4 481
AGCCTGACACAGAGCCCTGGCACCCCTGTCACTGAGCCCAGGCGAGACAGCCATCATCAGCTGCCGGACAAGCCAGT
ACGGCAGCCTGGCCTGGTATCAGCAGAGGCCTGGACAGGCCCCAGACTCGTGATCTACAGCGGCAGCACAAAGAGC
CGCCGGAATCCCCGATAGATTACGCGGCTCCAGATGGGGACCCGACTACAACCTGACCATCAGCAACCTGGAAAGC
GGCGACTTCGGCGTGTACTACTGCCAGCAGTACGAGTTCTTCGGCCAGGGCACCAAGGTGCAGGTGGACATCAAGCG
TACGGTGGCCGCTCCCAGCGTGTTCATCTTCCCACCTAGCGACGAGCAGCTGAAGTCCGGCACAGCCTCTGTCTGT
GCCTGTGAACAACCTTCTACCCCCGCGAGGCCAAAGTGCAGTGGAAAGGTGGACAACGCCCTGCAGAGCGGCAACAG
CCAGGAAAGCGTGACCGAGCAGGACAGCAAGGACTCCACCTACAGCCTGAGCAGCACCCCTGACACTGAGCAAGGCC
GACTACGAGAAGCACAAAGGTGTACGCCTGCGAAGTGACCCACCAGGGCCTGTCTAGCCCCGTGACCAAGAGCTTCA
ACCGGGGCGAGTGT Trispecific 2 1 482
GACATCGTGATGACCCAGACCCCCCTGAGCCTGAGCGTGACACCTGGACAGCCTGCCAGCATCAGCTGCAAGAGCA
VRC07_523/
GCCAGAGCCTGGTGCACAACAACGCCAACACCTACCTGAGCTGGTATCTGCAGAAGCCCCGGCCAGAGCCCCCAGTC
CD28sup ×
CCTGATCTACAAGGTGTCCAACAGATTACGCGGCGTGCCCGACAGATTCTCCGGCAGCGGCTCTGGCACCGACTTCA
CD3mid IgG1
CCCTGAAGATCAGCCGGGTGGAAGCCGAGGACGTGGGCGTGTACTATTGTGGCCAGGGCACCCAGTACCCCTTACC
NNAS
TTTGGCAGCGGCACCAAGGTGGAATCAAGGGCCAGCCCAAGGCCGCCCGACATCCAGATGACCCAGAGCCCCA

CGAGCTGTGCTGCCAGCGTGGCGACAGAGTACCATCACCTGTTCAGGGCCAGCCAGAACATCTACGTGTGGCTGAAC
TGGTATCAGCAGAAGCCCCGGCAAGGCCCCCAAGCTGCTGATCTACAAGGCCAGCAACCTGCACACCGGCGTGCCCA
GCAGATTTTCTGGCAGCGGCTCCGGCACCGACTTCACCCTGACAATCAGCTCCCTGCAGCCCGAGGACATTGCCACC
TACTACTGCCAGCAGGGCCAGACCTACCCCTACACCTTTGGCCAGGGCACCAAGCTGGAAATCAAGACCAAGGGCC
CCAGCCGTACGGTGGCCGCTCCCAGCGTGTTTCATCTTCCCACCTAGCGACGAGCAGCTGAAGTCCGGCACAGCCTCT
GTCGTGTGCCTGCTGAACAACCTTCTACCCCCGCGAGGGCCAAAGTGCAGTGGAAGGTGGACAACGCCCTGCAGAGCG
GCAACAGCCAGGAAAGCGTGACCGAGCAGGACAGCAAGGACTCCACCTACAGCCTGAGCAGCACCCCTGACACTGAG
CAAGGCCGACTACGAGAAGCACAAAGGTGTACGCCTGCGAAGTGACCCACCAGGGCCTGTCTAGCCCCGTGACCAAG
AGCTTCAACCGGGGCGAGTGT 2 483

CAGGTGCAGCTGGTGCAGTCTGGCGCCGAGGTCTGTGAAACCTGGCGCCTCTGTGAAGGTGTCCTGCAAGGCCAGCGG
CTACACCTTTACCAGCTACTACATCCACTGGGTGCGCCAGGCCCTTGACAGGGACTGGAATGGATCGGCAGCATCT
ACCCCGGCAACGTGAACACCAACTACGCCCAGAAGTTCAGGGCAGAGCCACCCTGACCGTGGACACCAGCATCAG
CACCGCCTACATGGAAGTGAAGCCGGCTGAGAAGCGACGACACCGCCGTGTACTACTGCACCCGGTCCCCTACGGCC
TGGATTGGAACCTTCGACGTGTGGGGCAAGGGCACCAACCGTGACAGTGTCTAGCAGCCAGGTGCAGCTGGTGGAAATCT
GGCGGCGGAGTGGTGCAGCCTGGCAGAAGCCTGAGACTGAGCTGTGCCGCCAGCGGCTTCACCTTCACCAAGGCCT
GGATGCACTGGGTGCGCCAGGCCCTTGAAAGCAGCTGGAATGGGTGGCCCGAGATCAAGGACAAGAGCAACAGCTA
CGCCACCTACTACGCCGACAGCGTGAAGGGCCGGTTCACCATCAGCCGGGACGACAGCAAGAACACCCTGTACCTG
CAGATGAACAGCCTGCGGGCCGAGGACACCGCCGTGTACTACTGTGCGGGCGTGTACTATGCCCTGAGCCCCCTTCGA
TTACTGGGGCCAGGGAACCCTCGTGACCGTGTCTAGTCCGACCGCCAGCACAAAGGGCCCCAGCGTGTTCCCTCTGG
CCCCTAGCAGCAAGAGCACATCTGGCGGAACAGCCGCCCTGGGCTGCCTCGTGAAGGACTACTTTCCCGAGCCCCGTG
ACCGTGTCTCTGGAATTCTGGCGCCCTGACCAGCGGCGTGCACACCTTTCCAGCTGTGCTGCAGTCCAGCGGCCTGTA
CAGCCTGAGCAGCGTCGTGACAGTGCCCAGCAGCTCTCTGGGCACCCAGACCTACATCTGCAACGTGAACCACAAGC
CCAGCAACACCAAGGTGGACAAGAAGGTGGAACCCAAGAGCTGCGACAAGACCCACACCTGTCCCCCTTGTCTCTGCC
CCCGAACTGCTGGGAGGCCCTTCCGTGTTCTCTGTTCCCCCCTAAAGCCCAAGGACACCCTGATGATCAGCCGGACCCC
CGAAGTGACCTGCGTGGTGGTGGATGTGTCCCACGAGGACCCTGAAGTGAAGTTCAATTGGTACGTGGACGGCGTGG
AAGTGCACAACGCCAAGACCAAGCCAAGAGAGGAACAGTACAACAATGCCTCCCGGGTGGTGTCCGTGCTGACCGT
GCTGCACCAGGACTGGCTGAACGGCAAAAGAGTACAAGTGCAAGGTGTCCAACAAGGCCCTGCCTGCCCCCATCGAG
AAAACCATCAGCAAGGCCAAGGGCCAGCCCCGCGAACCCCAAGGTGTGCACACTGCCCCCAAGCAGGGACGAGCTGA
CCAAGAACCAGGTGTCCCTGAGCTGTGCCGTGAAAGGCTTCTACCCCTCCGATATCGCCGTGGAATGGGAGAGCAAC
GGCCAGCCCGAGAACAATAACAAGACCACCCCCCTGTGCTGGACAGCGACGGCTCATTCTTCTCTGGTGTCCAAGCT
GACAGTGGACAAGTCCCGGTGGCAGCAGGGCAACGTGTTACAGCTGCTCCGTGATGCACGAGGCCCTGCACAACCAC
TACACCAGAAGTCCCTGAGCCTGAGCCCCGGC 3 484

CAAGTGCGGCTGTCTCAGTCTGGCGGCCAGATGAAGAAACCCGGCGACAGCATGCGGATCAGCTGCAGAGCCAGCG
GCTACGAGTTCATCAACTGCCCCATCAACTGGATCAGACTGGCCCTTGCAAGCGGCCTGAGTGGATGGGATGGATG
AAGCCCAGACACGGGGCCGTGTCTACGCCAGACAGCTGCAGGGCAGAGTGACCATGACCCGGGACATGTACAGCG
AGACAGCCTTCTTGGAAGTGCAGGAGCCTGACCAGCGACGATACCGCCGTGTACTTCTGCACCCGGGGCAAGTACTGC
ACCGCCAGAGACTACTACAAGTGGGACTTCGAGCACTGGGGCCAGGGCACACCTGTGACAGTGTCTAGCGCTTCGAC
CAAGGGCCCATCGGTCTTCCCCCTGGCACCCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGCCTGG
TCAAGGACTACTTCCCCGAACCGGTGACGGTGTCTGGAAGTCAAGGCGCCCTGACCAGCGGCGTGCACACCTTCCCG
GCTGTCTTACAGTCTCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTTGGGACCCAGAC
CTACATCTGCAACGTGAATCACAAGCCCAGCAACACCAAGGTGGACAAGAAAGTTGAGCCCAAATCTTGTGACAAA
ACTCACACATGCCACCGTGCCAGCACCTGAACTCCTGGGGGGACCGTCAGTCTTCTCTTCCCCCAAACCCAA
GGACACCCTCATGATCTCCCGGACCCCTGAGGTACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCA
AGTTCAACTGGTATGTTGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACAATGC
CTCCCGTGTGGTCAGCGTCTCTACCGTCTCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAGTGAAGGTCTCCA
ACAAAGCCCTCCAGCCCCCATCGAGAAAACCATCTCCAAGGCCAAAGGGCAGCCCCGAGAACCACAGGTGTACAC
CCTGCCCCCATGCCGGGATGAGCTGACCAAGAATCAAGTCAGCCTGTGGTGCCTGGTAAAGGCTTCTATCCAGCG
ACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAATAACAAGACCACGCCTCCCGTGTGGACTCCGAC
GGCTCCTTCTTCTCTATTCAAAGTCAACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGT
GCTGCATGAGGCTCTGCACAGCCACTACACGCAGAAGAGCCTCTCCCTGTCTCCGGGT 4 485

AGCCTGACACAGAGCCCTGGCACCCCTGTCACTGAGCCCAGGCGAGACAGCCATCATCAGCTGCCGGACAAGCCAGT
ACGGCAGCCTGGCCTGGTATCAGCAGAGGCCTGGACAGGCCCCAGACTCGTGATCTACAGCGGCAGCACAAAGAGC
CGCCGGAATCCCCGATAGATTACGCGGCTCCAGATGGGGACCCGACTACAACCTGACCATCAGCAACCTGGAAAGC
GGCGACTTCGGCGTGTACTACTGCCAGCAGTACGAGTTCTTCGGCCAGGGCACCAAGGTGCAGGTGGACATCAAGCG
TACGGTGGCCGCTCCCAGCGTGTTTCATCTTCCCACCTAGCGACGAGCAGCTGAAGTCCGGCACAGCCTCTGTCTGT
GCCTGCTGAACAACCTTCTACCCCCGCGAGGGCCAAAGTGCAGTGGAAGGTGGACAACGCCCTGCAGAGCGGCAACAG
CCAGGAAAGCGTGACCGAGCAGGACAGCAAGGACTCCACCTACAGCCTGAGCAGCACCCCTGACACTGAGCAAGGCC
GACTACGAGAAGCACAAAGGTGTACGCCTGCGAAGTGACCCACCAGGGCCTGTCTAGCCCCGTGACCAAGAGCTTCA
ACCGGGGCGAGTGT Trispecific 3 1 486

GACATCGTGATGACCCAGACCCCCCTGAGCCTGAGCGTGACACCTGGACAGCCTGCCAGCATCAGCTGCAAGAGCA
VRC07_523/
GCCAGAGCCTGGTGCACAACAACGCCAACACCTACCTGAGCTGGTATCTGCAGAAGCCCGGCCAGAGCCCCCAGTC
CD28sup ×

CTGATCTACAAGGTGTCCAACAGATTTCAGCGCGGTGCCGACAGATTCTCCGGCAGCGGCTCTGGCACCGACTTCA
CD3mid IgG4
CCCTGAAGATCAGCCGGGTGGAAGCCGAGGACGTGGGCGTGTACTATTGTGGCCAGGGCACCCAGTACCCCTTCACC
FALA/409K
TTTGGCAGCGGCACCAAGGTGGAATCAAGGGCCAGCCCAAGGCCGCCCCGACATCCAGATGACCCAGAGCCCCA
GCAGCCTGTCTGCCAGCGTGGGCGACAGAGTGACCATCACCTGTCAGGCCAGCCAGAACATCTACGTGTGGCTGAAC
TGGTATCAGCAGAAGCCCGGCAAGGCCCCCAAGCTGCTGATCTACAAGGCCAGCAACCTGCACACCGGCGTGCCCA
GCAGATTTTCTGGCAGCGGCTCCGGCACCGACTTCACCCTGACAATCAGCTCCCTGCAGCCCGAGGACATTGCCACC
TACTACTGCCAGCAGGGCCAGACCTACCCCTACACCTTTGGCCAGGGCACCAAGCTGGAAATCAAGACCAAGGGCC
CCAGCCGTACGGTGGCCGCTCCCAGCGTGTTCATCTTCCCACCTAGCGACGAGCAGCTGAAGTCCGGCACAGCCTCT
GTCGTGTGCCTGCTGAACAACTTCTACCCCCGCGAGGCCAAAGTGCAGTGGAAGGTGGACAACGCCCTGCAGAGCG
GCAACAGCCAGGAAAGCGTGACCGAGCAGGACAGCAAGGACTCCACCTACAGCCTGAGCAGCACCCCTGACACTGAG
CAAGGCCGACTACGAGAAGCACAAAGGTGTACGCCTGCGAAGTGACCCACCAGGGCCTGTCTAGCCCCGTGACCAAG
AGCTTCAACCGGGGCGAGTGT 2 487
CAGGTGCAGCTGGTGCAGTCTGGCGCCGAGGTCTGTGAAACCTGGCGCCTCTGTGAAGGTGTCCTGCAAGGCCAGCGG
CTACACCTTTACCAGCTACTACATCCACTGGGTGCGCCAGGCCCTGGACAGGGACTGGAATGGATCGGCAGCATCT
ACCCCGGCAACGTGAACACCAACTACGCCCAGAAGTTCCAGGGCAGAGCCACCCTGACCGTGGACACCAGCATCAG
CACCGCCTACATGGAAGTGAAGCCGGCTGAGAAGCGACGACACCGCCGTGTACTACTGCACCCGGTCCCACTACGGCC
TGGATTGGAAGTTCGACGTGTGGGGCAAGGGCACCAACCGTGACAGTGTCTAGCAGCCAGGTGCAGCTGGTGGAAATCT
GGCGGCGGAGTGGTGCAGCCTGGCAGAAGCCTGAGACTGAGCTGTGCCGCCAGCGGCTTCACCTTCACCAAGGCCT
GGATGCACTGGGTGCGCCAGGCCCTGGAAAGCAGCTGGAATGGGTGGCCAGATCAAGGACAAGAGCAACAGCTA
CGCCACCTACTACGCCGACAGCGTGAAGGGCCGGTTCACCATCAGCCGGGACGACAGCAAGAACACCCTGTACCTG
CAGATGAACAGCCTGCGGGCCGAGGACACCGCCGTGTACTACTGTGCGGGCGTGTACTATGCCCTGAGCCCCCTTCGA
TTACTGGGGCCAGGGAACCCTCGTGACCGTGTCTAGTCGGACCGCCAGCACAAAGGGCCCATCGGTGTTCCCTCTGG
CCCCTTGACGACAGAAGCACCAAGCGAATCTACAGCCGCCCTGGGCTGCCTCGTGAAGGACTACTTTCCCGAGCCCGTG
ACCGTGTCTCTGGAAGTCTGGCGCTCTGACAAGCGGCGTGACACCTTTCCAGCCGTGCTCCAGAGCAGCGGCCTGTA
CTCTCTGAGCAGCGTCGTGACAGTGCCCAGCAGCAGCCTGGGCACCAAGACCTACACCTGTAACGTGGACCACAAGC
CCAGCAACACCAAGGTGGACAAGCGGGTGGAAATCTAAGTACGGCCCTCCCTGCCCTCCTTGCCCAGCCCCCTGAAGCT
GCCGGCGGACCCTCCGTGTTCTGTTCCTGTTCCTGTTCCTGTTCCTGTTCCTGTTCCTGTTCCTGTTCCTGTTCCTGT
CTGCGTGGTGGTGGATGTGTCCAGGAAGATCCCGAGGTGCAGTTCAATTGGTACGTGGACGGCGTGGAAGTGCACA
ACGCCAAGACCAAGCCCAGAGAGGAACAGTTCAACAGCACCTACCGGGTGGTGTCCGTGCTGACCGTGCTGCACCA
GACTGGCTGAACGGCAAAGAGTACAAGTGCAAGGTGTCCAACAAGGGCCTGCCAGCTCCATCGAGAAAACCATC
AGCAAGGCCAAGGGCCAGCCCCGCGAGCCTCAAGTGTGTACCCTGCCCCCTAGCCAGGAAGAGATGACCAAGAACC
AGGTGTCCCTGAGCTGTGCCGTGAAAGGCTTCTACCCCAGCGACATTGCCGTGGAATGGGAGAGCAACGGCCAGCCC
GAGAACAACCTACAAGACCACCCCCCTGTGCTGGACAGCGACGGCTCATTCTTCCTGGTGTCCAAGCTGACCGTGGA
CAAGAGCCGGTGGCAGGAAGGCAACGTGTTTCAGCTGCTCCGTGATGCACGAGGCCCTGCACAACCACTACACCCAG
AAGTCCCTGTCTCTGTCCCTGGGC 3 488
CAAGTGCGGCTGTCTCAGTCTGGCGGCCAGATGAAGAAACCCGGCGACAGCATGCGGATCAGCTGCAGAGCCAGCG
GCTACGAGTTCATCAACTGCCCCATCAACTGGATCAGACTGGCCCCCTGGCAAGCGGCCTGAGTGGATGGGATGGATG
AAGCCCAGACACGGGGCCGTGTCTACGCCAGACAGCTGCAGGGCAGAGTGACCATGACCCGGGACATGTACAGCG
AGACAGCCTTCCTGGAAGTGCAGGAGCCTGACCAGCGACGATACCGCCGTGTACTTCTGCACCCGGGGCAAGTACTGC
ACCGCCAGAGACTACTACAAGTGGGACTTCGAGCACTGGGGCCAGGGCACACCTGTGACAGTGTCTAGCGCTTCGAC
CAAGGGCCCATCGGTGTTCCCTCTGGCCCCCTTGACGACAGAAGCACCAAGCTGACAGCCGCCCTGGGCTGCCTCG
TGAAGGACTACTTTCCCGAGCCCGTGACCGTGTCTGGAAGTCTGGCGCTCTGACAAGCGGCGTGACACACCTTTCCA
GCCGTGCTCCAGAGCAGCGGCCTGTACTCTCTGAGCAGCGTCGTGACAGTGCCAGCAGCAGCCTGGGCACCAAGAC
CTACACCTGTAACGTGGACCACAAGCCCAGCAACACCAAGGTGGACAAGCGGGTGGAAATCTAAGTACGGCCCTCCCT
GCCCTCCTTGCCCAGCCCCCTGAAGCTGCCGGCGGACCCTCCGTGTTCTGTTCCTGTTCCTGTTCCTGTTCCTGTTCCT
ATGATCAGCCGGACCCCCGAAGTGACCTGCGTGGTGGTGGATGTGTCCAGGAAGATCCCGAGGTGCAGTTCAATTG
GTACGTGGACGGCGTGGAAGTGACACAACGCCAAGACCAAGCCCAGAGAGGAACAGTTCAACAGCACCTACCGGGTG
GTGTCCGTGCTGACCGTGTGACCAAGGACTGGCTGAACGGCAAAGAGTACAAGTGCAAGGTGTCCAACAAGGGCC
TGCCAGCTCCATCGAGAAAACCATCAGCAAGGCCAAGGGCCAGCCCCGCGAGCCTCAAGTGTATACCCTGCCCCCT
TGCCAGGAAGAGATGACCAAGAACCAGGTGTCCCTGTGGTGTCTCGTGAAAGGCTTCTACCCCAGCGACATTGCCGT
GGAATGGGAGAGCAACGGCCAGCCCCGAGAACAACCTACAAGACCACCCCCCTGTGCTGGACAGCGACGGCTCATTC
TTCCTGTACTCCAAGCTGACCGTGGACAAGAGCCGGTGGCAGGAAGGCAACGTGTTTCAGCTGCTCCGTGATGCACGA
GGCCCTGCACAACCACTACACCCAGAAGTCCCTGTCTCTGTCCCTGGGC 4 489
AGCCTGACACAGAGCCCTGGCACCCCTGTCACTGAGCCCAGGCGAGACAGCCATCATCAGCTGCCGGACAAGCCAGT
ACGGCAGCCTGGCCTGGTATCAGCAGAGGCCTGGACAGGCCCCAGACTCGTGATCTACAGCGGCAGCACAAAGAGC
CGCCGGAATCCCCGATAGATTCAGCGGCTCCAGATGGGGACCCGACTACAACCTGACCATCAGCAACCTGGAAAGC
GGCGACTTCGGCGTGTACTACTGCCAGCAGTACGAGTTCTTCGGCCAGGGCACCAAGGTGCAGGTGGACATCAAGCG
TACGGTGGCCGCTCCCAGCGTGTTCATCTTCCCACCTAGCGACGAGCAGCTGAAGTCCGGCACAGCCTCTGTCTGT
GCCTGTGAACAACCTTCTACCCCCGCGAGGCCAAAGTGCAGTGGAAGGTGGACAACGCCCTGCAGAGCGGCAACAG
CCAGGAAAGCGTGACCGAGCAGGACAGCAAGGACTCCACCTACAGCCTGAGCAGCACCCCTGACACTGAGCAAGGCC
GACTACGAGAAGCACAAAGGTGTACGCCTGCGAAGTGACCCACCAGGGCCTGTCTAGCCCCGTGACCAAGAGCTTCA

GACATCGTGATGACCCAGACCCCCCTGAGCCTGAGCGTGACACCTGGACAGCCTGCCAGCATCAGCTGCAAGAGCA
VRC07_523/

GCCAGAGCCTGGTGCACCAGAACGCCCAGACCTACCTGAGCTGGTATCTGCAGAAGCCCGGCCAGAGCCCCCAGTC
CD28sup ×

CCTGATCTACAAGGTGTCCAACAGATTCAGCGGCGTGCCCGACAGATTCTCCGGCAGCGGCTCTGGCACCGACTTCA
CD3mid_QQ

CCCTGAAGATCAGCCGGGTGGAAGCCGAGGACGTGGGCGTGTACTATTGTGGCCAGGGCACCCAGTACCCCTTCACC
IgG4

TTTGGCAGCGGCACCAAGGTGGAATCAAGGGCCAGCCCAAGGCCGCCCCCGACATCCAGATGACCCAGAGCCCCA
FALA/409K

GCAGCCTGTCTGCCAGCGTGGGCGACAGAGTGACCATCACCTGTCAGGCCAGCCAGAACATCTACGTGTGGCTGAAC
TGGTATCAGCAGAAGCCCGGCAAGGCCCCCAAGCTGCTGATCTACAAGGCCAGCAACCTGCACACCGGCGTGCCCA
GCAGATTTTCTGGCAGCGGCTCCGGCACCGACTTCACCCTGACAATCAGCTCCCTGCAGCCCGAGGACATTGCCACC
TACTACTGCCAGCAGGGCCAGACCTACCCCTACACCTTTGGCCAGGGCACCAAGCTGGAAATCAAGACCAAGGGCC
CCAGCCGTACGGTGGCCGCTCCAGCGTGTTCATCTTCCCACCTAGCGACGAGCAGCTGAAGTCCGGCACAGCCTCT
GTCGTGTGCCTGCTGAACAACCTTACCCCCGCGAGGCCAAAGTGCAGTGGAAGGTGGACAACGCCCTGCAGAGCG
GCAACAGCCAGGAAAGCGTGACCGAGCAGGACAGCAAGGACTCCACCTACAGCCTGAGCAGCACCCCTGACACTGAG
CAAGGCCGACTACGAGAAGCACAAAGGTGTACGCCTGCGAAGTGACCCACCAGGGCCTGTCTAGCCCCGTGACCAAG
AGCTTCAACCGGGGCGAGTGT 2 491

CAGGTGCAGCTGGTGCAGTCTGGCGCCGAGGTCTGTGAAACCTGGCGCCTCTGTGAAGGTGTCCTGCAAGGCCAGCGG
CTACACCTTTACCAGCTACTACATCCACTGGGTGCGCCAGGCCCCTGGACAGGGACTGGAATGGATCGGCAGCATCT
ACCCCGGCAACGTGAACACCAACTACGCCCAGAAGTTCAGGGCAGAGCCACCCTGACCGTGGACACCAGCATCAG
CACCGCCTACATGGAAGTGAAGCGGCTGAGAAGCGACGACACCGCCGTGTACTACTGCACCCGGTCCCACTACGGCC
TGGATTGGAACCTTCGACGTGTGGGGCAAGGGCACCAACCGTGACAGTGTCTAGCAGCCAGGTGCAGCTGGTGGAAATCT
GGCGGCGGAGTGGTGCAGCCTGGCAGAAGCCTGAGACTGAGCTGTGCCGCCAGCGGCTTCACCTTCACCAAGGCCT
GGATGCACTGGGTGCGCCAGGCCCTTGAAAGCAGCTGGAATGGGTGGCCAGATCAAGGACAAGAGCAACAGCTA
CGCCACCTACTACGCCGACAGCGTGAAGGGCCGGTTACCATCAGCCGGGACGACAGCAAGAACACCCTGTACCTG
CAGATGAACAGCCTGCGGGCCGAGGACACCGCCGTGTACTACTGTGCGGGCGTGTACTATGCCCTGAGCCCCCTTCGA
TTACTGGGGCCAGGGAACCCTCGTGACCGTGTCTAGTCGGACCGCCAGCACAAAGGGCCCATCGGTGTTCCCTCTGG
CCCCTTGACGAGCAGAAGCACCAAGCGAATCTACAGCCGCCCTGGGCTGCCTCGTGAAGGACTACTTTCCTGAGCCCGTG
ACCGTGTCTCTGGAAGTCTGGCGCTCTGACAAGCGGCGTGACACCTTTCCAGCCGTGCTCCAGAGCAGCGGCCTGTA
CTCTCTGAGCAGCGTCGTGACAGTGCCAGCAGCAGCCTGGGCACCAAGACCTACACCTGTAACGTGGACCACAAGC
CCAGCAACACCAAGGTGGACAAGCGGGTGGAAATCTAAGTACGGCCCTCCCTGCCCTCCTTGCCAGCCCCCTGAAGCT
GCCGGCGGACCCTCCGTGTTCTGTTCCCCCCAAAGCCCAAGGACACCCTGATGATCAGCCGGACCCCCGAAGTGAC
CTGCGTGGTGGTGGATGTGTCCAGGAAGATCCCGAGGTGCAGTTCAATTGGTACGTGGACGGCGTGGAAGTGCACA
ACGCCAAGACCAAGCCCAGAGAGGAACAGTTCAACAGCACCTACCGGGTGGTGTCCGTGCTGACCGTGCTGCACCA
GGAAGTGGCTGAACGGCAAAGAGTACAAGTGCAAGGTGTCCAACAAGGGCCTGCCAGCTCCATCGAGAAAACCATC
AGCAAGGCCAAGGGCCAGCCCCGCGAGCCTCAAGTGTGTACCCTGCCCCCTAGCCAGGAAGAGATGACCAAGAACC
AGGTGTCCCTGAGCTGTGCCGTGAAAGGCTTCTACCCCAGCGACATTGCCGTGGAATGGGAGAGCAACGGCCAGCCC
GAGAACAACCTACAAGACCACCCCCCTGTGCTGGACAGCGACGGCTCATTCTTCCCTGGTGTCCAAGCTGACCGTGGA
CAAGAGCCGGTGGCAGGAAGGCAACGTGTTTCAGCTGCTCCGTGATGCACGAGGCCCTGCACAACCACTACACCCAG
AAGTCCCTGTCTCTGTCCCTGGGC 3 492

CAAGTGCGGCTGTCTCAGTCTGGCGGCCAGATGAAGAAACCCGGCGACAGCATGCGGATCAGCTGCAGAGCCAGCG
GCTACGAGTTCATCAACTGCCCCATCAACTGGATCAGACTGGCCCCTGGCAAGCGGCCTGAGTGGATGGGATGGATG
AAGCCCAGACACGGGGCCGTGTCTACGCCAGACAGCTGCAGGGCAGAGTGACCATGACCCGGGACATGTACAGCG
AGACAGCCTTCTGGAAGTGCAGGAGCCTGACCAGCGACGATACCGCCGTGTACTTCTGCACCCGGGGCAAGTACTGC
ACCGCCAGAGACTACTACAAGTGGGACTTCGAGCACTGGGGCCAGGGCACACCTGTGACAGTGTCTAGCGCTTCGAC
CAAGGGCCCATCGGTGTTCCCTCTGGCCCCCTTGACGAGCAGAAGCACCAAGCGAATCTACAGCCGCCCTGGGCTGCCTCG
TGAAGGACTACTTTCCCGAGCCCGTGACCGTGTCTGGAAGTCTGGCGCTCTGACAAGCGGCGTGACACACCTTTCCA
GCCGTGCTCCAGAGCAGCGGCCTGTACTCTCTGAGCAGCGTCGTGACAGTGCCCAGCAGCAGCCTGGGCACCAAGAC
CTACACCTGTAACGTGGACCACAAGCCCAGCAACACCAAGGTGGACAAGCGGGTGGAAATCTAAGTACGGCCCTCCCT
GCCCTCCTTGCCAGCCCCCTGAAGCTGCCGGCGGACCCTCCGTGTTCTGTTCCCCCCAAAGCCCAAGGACACCCTG
ATGATCAGCCGGACCCCCGAAGTGACCTGCGTGGTGGTGGATGTGTCCAGGAAGATCCCGAGGTGCAGTTCAATTG
GTACGTGGACGGCGTGGAAGTGCACAACGCCAAGACCAAGCCCAGAGAGGAACAGTTCAACAGCACCTACCGGGTG
GTGTCCGTGCTGACCGTGCTGCACCAGGACTGGCTGAACGGCAAAGAGTACAAGTGCAAGGTGTCCAACAAGGGCC
TGCCAGCTCCATCGAGAAAACCATCAGCAAGGCCAAGGGCCAGCCCCGCGAGCCTCAAGTGTATACCTTGCCCCCT
TGCCAGGAAGAGATGACCAAGAACCAGGTGTCCCTGTGGTGTCTCGTGAAAGGCTTCTACCCCAGCGACATTGCCGT
GGAATGGGAGAGCAACGGCCAGCCCCGAGAACAACCTACAAGACCACCCCCCTGTGCTGGACAGCGACGGCTCATTC
TTCCTGTACTCCAAGCTGACCGTGGACAAGAGCCGGTGGCAGGAAGGCAACGTGTTTCAGCTGCTCCGTGATGCACGA
GGCCCTGCACAACCACTACACCCAGAAGTCCCTGTCTCTGTCCCTGGGC 4 493

AGCCTGACACAGAGCCCTGGCACCCCTGTCACTGAGCCCAGGCGAGACAGCCATCATCAGCTGCCGGACAAGCCAGT
ACGGCAGCCTGGCCTGGTATCAGCAGAGGCCTGGACAGGCCCCAGACTCGTGATCTACAGCGGCAGCACAAAGAGC

CGCCGGAATCCCGCATAGGATTTAGGCGGCTCCAGGATGGGACCTGACTACAACCTGACCATCAGCAACCTGGAAAGC
GGCGACTTCGGCGTGTACTACTGCCAGCAGTACGAGTTCTTCGGCCAGGGCACCAAGGTGCAGGTGGACATCAAGCG
TACGGTGGCCGCTCCCAGCGTGTTCATCTTCCCACCTAGCGACGAGCAGCTGAAGTCCGGCACAGCCTCTGTCTGT
GCCTGCTGAACAACTTCTACCCCCGCGAGGCCAAAGTGCAGTGGAAGGTGGACAACGCCCTGCAGAGCGGCAACAG
CCAGGAAAGCGTGACCGAGCAGGACAGCAAGGACTCCACCTACAGCCTGAGCAGCACCCCTGACACTGAGCAAGGCC
GACTACGAGAAGCACAAAGGTGTACGCCTGCGAAGTGACCCACCAGGGCCTGTCTAGCCCCGTGACCAAGAGCTTCA
ACCGGGGCGAGTGT Trispecific 6 1 494
GACATCGTGATGACCCAGACCCCCCTGAGCCTGAGCGTGACACCTGGACAGCCTGCCAGCATCAGCTGCAAGAGCA
VRC07_523/
GCCAGAGCCTGGTGCACCAGAACGCCCAGACCTACCTGAGCTGGTATCTGCAGAAGCCCGGCCAGAGCCCCCAGTC
CD28sup ×
CCTGATCTACAAGGTGTCCAACAGATTACGCGGCGTGCCCGACAGATTCTCCGGCAGCGGCTCTGGCACCGACTTCA
CD3mid_QQ
CCCTGAAGATCAGCCGGGTGGAAGCCGAGGACGTGGGCGTGTACTATTGTGGCCAGGGCACCCAGTACCCCTTCACC
IgG4
TTTGGCAGCGGCACCAAGGTGGAATCAAGGACAAAACCCATACCGACATCCAGATGACCCAGAGCCCCAGCAGCC
FALA/409K_
TGTCTGCCAGCGTGGGCGACAGAGTGACCATCACCTGTCAGGCCAGCCAGAACATCTACGTGTGGCTGAACTGGTAT
DKTHT linker
CAGCAGAAGCCCGGCAAGGCCCCCAAGCTGCTGATCTACAAGGCCAGCAACCTGCACACCGGCGTGCCCAGCAGAT
TTTCTGGCAGCGGCTCCGGCACCGACTTCACCCTGACAATCAGCTCCCTGCAGCCCGAGGACATTGCCACCTACTAC
TGCCAGCAGGGCCAGACCTACCCCTACACCTTTGGCCAGGGCACCAAGCTGGAATCAAGGATAAGACCCACACCCG
TACGGTGGCCGCTCCCAGCGTGTTCATCTTCCCACCTAGCGACGAGCAGCTGAAGTCCGGCACAGCCTCTGTCTGT
GCCTGCTGAACAACTTCTACCCCCGCGAGGCCAAAGTGCAGTGGAAGGTGGACAACGCCCTGCAGAGCGGCAACAG
CCAGGAAAGCGTGACCGAGCAGGACAGCAAGGACTCCACCTACAGCCTGAGCAGCACCCCTGACACTGAGCAAGGCC
GACTACGAGAAGCACAAAGGTGTACGCCTGCGAAGTGACCCACCAGGGCCTGTCTAGCCCCGTGACCAAGAGCTTCA
ACCGGGGCGAGTGT 2 495
CAGGTGCAGCTGGTGCAGTCTGGCGCCGAGGTTCGTGAAACCTGGCGCCTCTGTGAAGGTGTCCTGCAAGGCCAGCGG
CTACACCTTTACCAGCTACTACATCCACTGGGTGCGCCAGGCCCTGGACAGGGACTGGAATGGATCGGCAGCATCT
ACCCCGGCAACGTGAACACCAACTACGCCCAGAAGTTCCAGGGCAGAGCCACCCTGACCGTGGACACCAGCATCAG
CACCGCCTACATGGAAGTGCAGCGGCTGAGAAGCGACGACACCGCCGTGTACTACTGCACCCGGTCCCACTACGGCC
TGGATTGGAATCTCGACGTGTGGGGCAAGGGCACCAACCGTGACAGTGTCTAGCGACAAAACCCATACCCAGGTGCA
GCTGGTGGAACTCTGGCGGCGGAGTGGTGCAGCCTGGCAGAAGCCTGAGACTGAGCTGTGCCGCCAGCGGCTTCACCT
TCACCAAGGCCTGGATGCACTGGGTGCGCCAGGCCCTGGAAAGCAGCTGGAATGGGTGGCCAGATCAAGGACAA
GAGCAACAGCTACGCCACCTACTACGCCGACAGCGTGAAGGGCCGTTACCATCAGCCGGGACGACAGCAAGAAC
ACCCTGTACCTGCAGATGAACAGCCTGCGGGCCGAGGACACCGCCGTGTACTACTGTCGGGGCGTGTACTATGCCCT
GAGCCCCTTCGATTACTGGGGCCAGGGAACCCCTCGTGACCGTGTCTAGTGATAAGACCCACACCGCCAGCACAAAGG
GCCATCGGTGTTCCCTCTGGCCCCTTGACGACAGAAGCACCAGCGAATCTACAGCCGCCCTGGGCTGCCTCGTGAAG
GACTACTTTCCCGAGCCCGTGACCGTGTCTGGAACCTCTGGCGCTCTGACAAGCGGCGTGCACACCTTTCCAGCCGT
GCTCCAGAGCAGCGGCTGTACTCTCTGAGCAGCGTCGTGACAGTGCCCAGCAGCAGCCTGGGCACCAAGACCTACA
CCTGTAACGTGGACCACAAGCCCAGCAACACCAAGGTGGACAAGCGGGTGGAAATCTAAGTACGGCCCTCCCTGCCCT
CCTTGCCCAGCCCCCTGAAGCTGCCGGCGGACCCTCCGTGTTCCCTGTTCCCCCAAAGCCCAAGGACACCCTGATGAT
CAGCCGGACCCCCGAAGTGACCTGCGTGGTGGTGGATGTGTCCCAGGAAGATCCCAGAGGTGCAGTTCAATTGGTACG
TGGACGGCGTGGAAAGTGACAACGCCAAGACCAAGCCCAGAGAGGAACAGTTCAACAGCACCTACCGGGTGGTGTCC
GTGCTGACCGTGTCTGCACCAGGACTGGCTGAACGGCAAAGAGTACAAGTGCAAGGTGTCCAACAAGGGCCTGCCCA
GCTCCATCGAGAAAACCATCAGCAAGGCCAAGGGCCAGCCCCGCGAGCCTCAAGTGTGTACCCTGCCCCCTAGCCA
GGAAGAGATGACCAAGAACCAGGTGTCCCTGAGCTGTGCCGTGAAAGGCTTCTACCCAGCGACATTGCCGTGGAA
TGGGAGAGCAACGGCCAGCCCAGAACTACAAGACCACCCCCCTGTGCTGGACAGCGACGGCTCATTCTTCCT
GGTGTCCAAGCTGACCGTGGACAAGAGCCGGTGGCAGGAAGGCAACGTGTTACAGTGTCTCCGTGATGCACGAGGCC
CTGCACAACCACTACACCCAGAAGTCCCTGTCTCTGTCCCTGGGC 3 496
CAAGTGCGGCTGTCTCAGTCTGGCGGCCAGATGAAGAAACCCGGCGACAGCATGCGGATCAGCTGCAGAGCCAGCG
GCTACGAGTTCATCAACTGCCCCATCAACTGGATCAGACTGGCCCCTGGCAAGCGGCCTGAGTGGATGGATGGATG
AAGCCCAGACACGGGGCCGTGTCCTACGCCAGACAGCTGCAGGGCAGAGTGACCATGACCCGGGACATGTACAGCG
AGACAGCCTTCCTGGAAGTGCAGGAGCCTGACCAGCGACGATACCGCCGTGTACTTCTGCACCCGGGGCAAGTACTGC
ACCGCCAGAGACTACTACAAGTGGGACTTCGAGCACTGGGGCCAGGGCACACCTGTGACAGTGTCTAGCGCTTCGAC
CAAGGGCCCATCGGTGTTCCCTCTGGCCCCCTTGACGACAGAAGCACCAGCGAATCTACAGCCGCCCTGGGCTGCCTCG
TGAAGGACTACTTTCCCGAGCCCGTGACCGTGTCTGGAACCTCTGGCGCTCTGACAAGCGGCGTGCACACCTTTCCA
GCCGTGCTCCAGAGCAGCGGCCTGTACTCTCTGAGCAGCGTCGTGACAGTGCCCAGCAGCAGCCTGGGCACCAAGAC
CTACACCTGTAACGTGGACCACAAGCCCAGCAACACCAAGGTGGACAAGCGGGTGGAAATCTAAGTACGGCCCTCCCT
GCCCTCCTTGCCCAGCCCCCTGAAGCTGCCGGCGGACCCTCCGTGTTCCCTGTTCCCCCAAAGCCCAAGGACACCCTG
ATGATCAGCCGGACCCCCGAAGTGACCTGCGTGGTGGTGGATGTGTCCCAGGAAGATCCCAGAGGTGCAGTTCAATTG
GTACGTGGACGGCGTGGAAAGTGACAACGCCAAGACCAAGCCCAGAGAGGAACAGTTCAACAGCACCTACCGGGTG
GTGTCCGTGCTGACCGTGTCTGCACCAGGACTGGCTGAACGGCAAAGAGTACAAGTGCAAGGTGTCCAACAAGGGCC

TGCCAGCTCCATCGAGAAAACCATCAGCAAGGCCAAGGGCCAGCCCCGCGAGCCTCAAGTGTATACCCTGCCCCCT
TGCCAGGAAGAGATGACCAAGAACCAGGTGTCCCTGTGGTGTCTCGTGAAAGGCTTCTACCCAGCGACATTGCCGT
GGAATGGGAGAGCAACGGCCAGCCCGAGAACAACCTACAAGACCACCCCCCTGTGCTGGACAGCGACGGCTCATTC
TTCCTGTACTCCAAGCTGACCGTGGACAAGAGCCGGTGGCAGGAAGGCAACGTGTTTCAGCTGCTCCGTGATGCACGA
GGCCCTGCACAACCACTACACCCAGAAGTCCCTGTCTCTGTCCCTGGGC 4 497
AGCCTGACACAGAGCCCTGGCACCTGTCACTGAGCCCAGGCGAGACAGCCATCATCAGCTGCCGGACAAGCCAGT
ACGGCAGCCTGGCCTGGTATCAGCAGAGGCCTGGACAGGCCCCAGACTCGTGATCTACAGCGGCAGCACAAAGAGC
CGCCGAATCCCCGATAGATTACGCGGCTCCAGATGGGGACCCGACTACAACCTGACCATCAGCAACCTGGAAAGC
GGCGACTTCGGCGTGTACTACTGCCAGCAGTACGAGTTCTTCGGCCAGGGCACCAAGGTGCAGGTGGACATCAAGCG
TACGGTGGCCGCTCCCAGCGTGTTTCATCTTCCCACCTAGCGACGAGCAGCTGAAGTCCGGCACAGCCTCTGTCTGT
GCCTGCTGAACAACTTCTACCCCCGCGAGGCCAAAGTGCAGTGGAAGGTGGACAACGCCCTGCAGAGCGGCAACAG
CCAGGAAAGCGTGACCGAGCAGGACAGCAAGGACTCCACCTACAGCCTGAGCAGCACCCCTGACACTGAGCAAGGCC
GACTACGAGAAGCACAAAGGTGTACGCCTGCGAAGTGACCCACCAGGGCCTGTCTAGCCCCGTGACCAAGAGCTTCA
ACCGGGGCGAGTGT Trispecific 8 1 498
GACATCGTGATGACCCAGACCCCCCTGAGCCTGAGCGTGACACCTGGACAGCCTGCCAGCATCAGCTGCAAGAGCA
VRC07_523/
GCCAGAGCCTGGTGCACCAGAACGCCAGACCTACCTGAGCTGGTATCTGCAGAAGCCCGGCCAGAGCCCCCAGTC
CD28sup ×
CCTGATCTACAAGGTGTCCAACAGATTCAGCGGCGTGCCCGACAGATTCTCCGGCAGCGGCTCTGGCACCGACTTCA
CD3mid_QQ
CCCTGAAGATCAGCCGGGTGGAAGCCGAGGACGTGGGCGTGTACTATTGTGGCCAGGGCACCCAGTACCCCTTCACC
IgG1_NNAS/
TTTGGCAGCGGCACCAAGGTGGAATCAAGGACAAAACCCATACCGACATCCAGATGACCCAGAGCCCCAGCAGCC
409K_DKTHT
TGTCTGCCAGCGTGGGCGACAGAGTGACCATCACCTGTCAGGCCAGCCAGAACATCTACGTGTGGCTGAACTGGTAT
linker
CAGCAGAAGCCCGGCAAGGCCCCCAAGCTGCTGATCTACAAGGCCAGCAACCTGCACACCGGCGTGCCCAGCAGAT
TTTCTGGCAGCGGCTCCGGCACCGACTTCACCCTGACAATCAGCTCCCTGCAGCCCGAGGACATTGCCACCTACTAC
TGCCAGCAGGGCCAGACCTACCCCTACACCTTTGGCCAGGGCACCAAGCTGGAAATCAAGGATAAGACCCACACCCG
TACGGTGGCCGCTCCCAGCGTGTTTCATCTTCCCACCTAGCGACGAGCAGCTGAAGTCCGGCACAGCCTCTGTCTGT
GCCTGCTGAACAACTTCTACCCCCGCGAGGCCAAAGTGCAGTGGAAGGTGGACAACGCCCTGCAGAGCGGCAACAG
CCAGGAAAGCGTGACCGAGCAGGACAGCAAGGACTCCACCTACAGCCTGAGCAGCACCCCTGACACTGAGCAAGGCC
GACTACGAGAAGCACAAAGGTGTACGCCTGCGAAGTGACCCACCAGGGCCTGTCTAGCCCCGTGACCAAGAGCTTCA
ACCGGGGCGAGTGT 2 499
CAGGTGCAGCTGGTGCAGTCTGGCGCCGAGGTCTGTGAAACCTGGCGCCTCTGTGAAGGTGTCCTGCAAGGCCAGCGG
CTACACCTTTACCAGCTACTACATCCACTGGGTGCGCCAGGCCCTGGACAGGGACTGGAATGGATCGGCAGCATCT
ACCCCGGCAACGTGAACACCAACTACGCCCAGAAGTTCAGGGCAGAGCCACCCTGACCGTGGACACCAGCATCAG
CACCGCCTACATGGAAGTGTGAGCCGGCTGAGAAGCGACGACACCGCCGTGTACTACTGCACCCGGTCCCCTACGGCC
TGGATTGGAAGTTCGACGTGTGGGGCAAGGGCACCAACCGTGACAGTGTCTAGCGACAAAACCCATACCCAGGTGCA
GCTGGTGGAAATCTGGCGGCGGAGTGGTGCAGCCTGGCAGAAGCCTGAGACTGAGCTGTGCCGCCAGCGGCTTCACCT
TCACCAAGGCCTGGATGCACTGGGTGCGCCAGGCCCTGGAAAGCAGCTGGAATGGGTGGCCCAGATCAAGGACAA
GAGCAACAGCTACGCCACCTACTACGCCGACAGCGTGAAGGGCCGGTTCACCATCAGCCGGGACGACAGCAAGAAC
ACCCTGTACCTGCAGATGAACAGCCTGCGGGCCGAGGACACCGCCGTGTACTACTGTGCGGGCGTGTACTATGCCCT
GAGCCCCCTTCGATTACTGGGGCCAGGGAACCCTCGTGACCGTGTCTAGTGATAAGACCCACACCGCCAGCACAAAGG
GCCCCAGCGTGTTCCCTCTGGCCCCCTAGCAGCAAGAGCACATCTGGCGGAACAGCCGCCCTGGGCTGCCTCGTGAAG
GACTACTTTCCCGAGCCCGTGACCGTGTCTGGAATTCTGGCGCCCTGACCAGCGGCGTGCACACCTTTCCAGCTGT
GCTGCAGTCCAGCGGCTGTACAGCCTGAGCAGCGTCTGTGACAGTGCCCAGCAGCTCTCTGGGCACCCAGACCTACA
TCTGCAACGTGAACCACAAGCCCAGCAACACCAAGGTGGACAAGAAGGTGGAACCCAAGAGCTGCGACAAGACCCA
ACCTGTCCCCCTTGTCTGCCCCCGAAGTGTCTGGGAGGCCCTTCCGTGTTCTGTTCCCCCACAAGCCCAAGGACAC
CCTGATGATCAGCCGACCCCCGAAGTGACCTGCGTGGTGGTGGATGTGTCCCACGAGGACCCTGAAGTGAAGTTCA
ATTGGTACGTGGACGGCGTGGAAGTGCACAACGCCAAGACCAAGCCAAGAGAGGAACAGTACAACAATGCCTCCCG
GGTGGTGTCCGTGCTGACCGTGTGCAACCAGGACTGGCTGAACGGCAAAGAGTACAAGTGCAAGGTGTCCAACAAG
GCCCTGCCTGCCCCATCGAGAAAACCATCAGCAAGGCCAAGGGCCAGCCCCGCGAACCCAGGTGTGCACACTGC
CCCCAAGCAGGGACGAGCTGACCAAGAACCAGGTGTCCCTGAGCTGTGCCGTGAAAGGCTTCTACCCCTCCGATATC
GCCGTGGAATGGGAGAGCAACGGCCAGCCCGAGAACAACCTACAAGACCACCCCCCTGTGCTGGACAGCGACGGCT
CATTCTTCCTGGTGTCCAAGCTGACAGTGGACAAGTCCCGGTGGCAGCAGGGCAACGTGTTTCAGCTGCTCCGTGATG
CACGAGGCCCTGCACAACCACTACACCCAGAAGTCCCTGAGCCTGAGCCCCGGC 3 500
CAAGTGC GGCTGTCTCAGTCTGGCGGCCAGATGAAGAAACCCGGCGACAGCATGCGGATCAGCTGCAGAGCCAGCG
GCTACGAGTTCATCAACTGCCCCATCAACTGGATCAGACTGGCCCTGGCAAGCGGCCTGAGTGGATGGGATGGATG
AAGCCCAGACACGGGGCCGTGTCTACGCCAGACAGCTGCAGGGCAGAGTGACCATGACCCGGGACATGTACAGCG
AGACAGCCTTCCTGGAAGTGC GGAGCCTGACCAGCGACGATACCGCCGTGTACTTCTGCACCCGGGGCAAGTACTGC
ACCGCCAGAGACTACTACAACCTGGGACTTCGAGCACTGGGGCCAGGGCACACCTGTGACAGTGTCTAGCGCTTCGAC
CAAGGGCCCATCGGTCTTCCCCCTGGCACCCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGCCTGG

CTAAGGACTACTTCCCCGAACCGGTGACGGTGTCTGTTGGAATCAGGCGCCCTGACCCAGCGGGCGTGCACACCTTCCCG
GCTGTCTACAGTCTCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTTGGGCACCCAGAC
CTACATCTGCAACGTGAATCACAAGCCCAGCAACACCAAGGTGGACAAGAAAGTTGAGCCCAAATCTTGTGACAAA
ACTCACACATGCCACCGTGCCAGCACCTGAACTCCTGGGGGGACCGTCAGTCTTCTCTTCCCCCAAACCCAA
GGACACCCTCATGATCTCCCGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCA
AGTTCAACTGGTATGTTGACGGCGTGGAGGTGCATAATGCCAAGACAAAAGCCGCGGGGAGGAGCAGTACAACAATGC
CTCCCGTGTGGTCAGCGTCTCTACCGTCTCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCCA
ACAAAGCCCTCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAACCACAGGTGTACAC
CCTGCCCCCATGCCGGGATGAGCTGACCAAGAATCAAGTCAGCCTGTGGTGCCTGGTAAAGGCTTCTATCCAGCG
ACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACCTACAAGACCACGCCTCCCGTGTGGACTCCGA
CGGCTCCTTCTTCTCTATTCAAACTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCG
TGCTGCATGAGGCTCTGCACAGCCACTACACGCAGAAGAGCCTCTCCCTGTCTCCGGGT 4 501
AGCCTGACACAGAGCCCTGGCACCCCTGTCACTGAGCCCAGGCGAGACAGCCATCATCAGCTGCCGGACAAGCCAGT
ACGGCAGCCTGGCCTGGTATCAGCAGAGGCCTGGACAGGCCCCCAGACTCGTGATCTACAGCGGCAGCACAAAGAGC
CGCCGGAATCCCCGATAGATTCAGCGGCTCCAGATGGGGACCCGACTACAACCTGACCATCAGCAACCTGGAAAGC
GGCGACTTCGGCGTGTACTACTGCCAGCAGTACGAGTTCTTCGGCCAGGGCACCAAGGTGCAGGTGGACATCAAGCG
TACGGTGGCCGCTCCCAGCGTGTTCATCTTCCCACCTAGCGACGAGCAGCTGAAGTCCGGCACAGCCTCTGTCTGT
GCCTGCTGAACAACTTCTACCCCCGCGAGGCCAAAGTGCAGTGGAAGGTGGACAACGCCCTGCAGAGCGGCAACAG
CCAGGAAAGCGTGACCGAGCAGGACAGCAAGGACTCCACCTACAGCCTGAGCAGCACCCCTGACACTGAGCAAGGCC
GACTACGAGAAGCACAAAGGTGTACGCCTGCGAAGTGACCCACCAGGGCCTGTCTAGCCCCGTGACCAAGAGCTTCA
ACCGGGGCGAGTGT Trispecific 9 1 502
GACATCGTGATGACCCAGACCCCCCTGAGCCTGAGCGTGACACCTGGACAGCCTGCCAGCATCAGCTGCAAGAGCA
VRC07_523_
GCCAGAGCCTGGTGCACGAGAACCTGCAGACCTACCTGAGCTGGTATCTGCAGAAGCCCGGCCAGAGCCCCAGTC
FR3-03/
CCTGATCTACAAGGTGTCCAACAGATTCAGCGGCGTGCCCGACAGATTCTCCGGCAGCGGCTCTGGCACCGACTTCA
CD28sup ×
CCCTGAAGATCAGCCGGGTGGAAGCCGAGGACGTGGGCGTGTACTATTGTGGCCAGGGCACCCAGTACCCCTTCACC
CD3mid_
TTTGGCAGCGGCACCAAGGTGGAATCAAGGACAAAACCCATACCGACATCCAGATGACCCAGAGCCCCAGCAGCC
ENLQ IgG4
TGTCTGCCAGCGTGGGCGACAGAGTGACCATCACCTGTCAGGCCAGCCAGAACATCTACGTGTGGCTGAACTGGTAT
FALA/409K_
CAGCAGAAGCCCGGCAAGGCCCCCAAGCTGCTGATCTACAAGGCCAGCAACCTGCACACCGGCGTGCCAGCAGAT
DKTHT linker
TTTCTGGCAGCGGCTCCGGCACCGACTTCACCCTGACAATCAGCTCCCTGCAGCCCGAGGACATTGCCACCTACTAC
TGCCAGCAGGGCCAGACCTACCCCTACACCTTTGGCCAGGGCACCAAGCTGGAATCAAGGATAAGACCCACACCCG
TACGGTGGCCGCTCCCAGCGTGTTCATCTTCCCACCTAGCGACGAGCAGCTGAAGTCCGGCACAGCCTCTGTCTGT
GCCTGCTGAACAACTTCTACCCCCGCGAGGCCAAAGTGCAGTGGAAGGTGGACAACGCCCTGCAGAGCGGCAACAG
CCAGGAAAGCGTGACCGAGCAGGACAGCAAGGACTCCACCTACAGCCTGAGCAGCACCCCTGACACTGAGCAAGGCC
GACTACGAGAAGCACAAAGGTGTACGCCTGCGAAGTGACCCACCAGGGCCTGTCTAGCCCCGTGACCAAGAGCTTCA
ACCGGGGCGAGTGT 2 503
CAGGTGCAGCTGGTGCAGTCTGGCGCCGAGGTCTGTGAAACCTGGCGCCTCTGTGAAGGTGTCCTGCAAGGCCAGCGG
CTACACCTTTACCAGCTACTACATCCACTGGGTGCGCCAGGCCCCCTGGACAGGGACTGGAATGGATCGGCAGCATCT
ACCCCGGCAACGTGAACACCAACTACGCCCAGAAGTTCCAGGGCAGAGCCACCCTGACCGTGGACACCAGCATCAG
CACCGCCTACATGGAAGTGAAGCCGGCTGAGAAGCGACGACACCGCCGTGTACTACTGCACCCGGTCCCCTACGGCC
TGGATTGGAAGTTCGACGTGTGGGGCAAGGGCACCAACCGTGACAGTGTCTAGCGACAAAACCCATAACCCAGGTGCA
GCTGGTGGAACTCTGGCGGCGGAGTGGTGCAGCCTGGCAGAAGCCTGAGACTGAGCTGTGCCGCCAGCGGCTTCACT
TCACCAAGGCCTGGATGCACTGGGTGCGCCAGGCCCCCTGGAAGCAGCTGGAATGGGTGGCCCAGATCAAGGACAA
GAGCAACAGCTACGCCACCTACTACGCCGACAGCGTGAAGGGCCGGTTTACCATCAGCCGGGACGACAGCAAGAAC
ACCCTGTACCTGCAGATGAACAGCCTGCGGGCCGAGGACACCGCCGTGTACTACTGTGCGGGCGTGTACTATGCCCT
GAGCCCCCTTCGATTACTGGGGCCAGGGAACCCCTCGTGACCGTGTCTAGTGATAAGACCCACACCGCCAGCACAAAGG
GCCATCGGTGTTCCCTCTGGCCCCCTTGACGACAGAAGCACCAAGCGAATCTACAGCCGCCCTGGGCTGCCTCGTGAAG
GACTACTTTCCCGAGCCCGTGACCGTGTCTGGAAGTCTGGCGCTCTGACAAGCGGCGTGCACACCTTTCCAGCCGT
GCTCCAGAGCAGCGGCCTGTACTCTCTGAGCAGCGTCTGTGACAGTGGCCAGCAGCAGCCTGGGCACCAAGACCTACA
CCTGTAACGTGGACCACAAGCCCAGCAACACCAAGGTGGACAAGCGGGTGAATCTAAGTACGGCCCTCCCTGCCCT
CCTTGCCCAGCCCCCTGAAGCTGCCGGCGGACCCTCCGTGTTCTCTGTTCCCCCAAAGCCCAAGGACACCCTGATGAT
CAGCCGGACCCCCGAAGTGACCTGCGTGGTGGTGGATGTGTCCAGGAAGATCCCAGAGTGCAGTTCAATTGGTACG
TGGACGGCGTGGAAGTGACAAACGCCAAGACCAAGCCCAGAGAGGAACAGTTCAACAGCACCTACCGGGTGGTGTCC
GTGCTGACCGTGTCTGCACCAGGACTGGCTGAACGGCAAAGAGTACAAGTGCAAGGTGTCCAACAAGGGCCTGCCCA
GCTCCATCGAGAAAACCATCAGCAAGGCCAAGGGCCAGCCCCGCGAGCCTCAAGTGTGTACCCTGCCCCCTAGCCA
GGAAGAGATGACCAAGAACCAGGTGTCCCTGAGCTGTGCCGTGAAAGGCTTCTACCCAGCGACATTGCCGTGGAA
TGGGAGAGCAACGGCCAGCCCCGAGAACAACCTACAAGACCACCCCCCTGTGCTGGACAGCGACGGCTCATTCTTCT

GGTGTCTCAAGCTGACCCTGGACAAGAGACCGGTGGCAGGAAGCAACGTGTTTCAGCTGCTCCGTGATGCACGAGGCC
CTGCACAACCACTACACCCAGAAGTCCCTGTCTCTGTCCCTGGGC 3 504
CAAGTGCGGCTGTCTCAGTCTGGCGGCCAGATGAAGAAACCCGGCGACAGCATGCGGATCAGCTGCAGAGCCAGCG
GCTACGAGTTCATCAACTGCCCCATCAACTGGATCAGACTGGCCCCTGGCAAGCGGCCTGAGTGGATGGGATGGATG
AAGCCCAGACACGGGGCCGTGTCCTACGCCAGACAGCTGCAGGGCAGAGTGACCATGACCCGGCAGCTGAGCCAGG
ACCCTGATGATCCGGATTGGGGCACAGCCTTCCTGGAAGTGCAGGAGCCTGACCAGCGACGATACCGCCGTGTACTTC
TGCACCCGGGGCAAGTACTGCACCGCCAGAGACTACTACAAGTGGGACTTCGAGCACTGGGGCCAGGGCACACCTG
TGACAGTGTCTAGCGCTTCGACCAAGGGCCCATCGGTGTTCCCTCTGGCCCCTTGACGACAGAAGCACCAGCGAATCT
ACAGCCGCCCTGGGCTGCCTCGTGAAGGACTACTTTCCTGAGCCCGTGACCGTGTCTGGAAGTCTGGCGCTCTGAC
AAGCGGCGTGCACACCTTTCAGCCGTGCTCCAGAGCAGCGGCCTGTACTCTCTGAGCAGCGTCGTGACAGTGCCCA
GCAGCAGCCTGGGCACCAAGACCTACACCTGTAACGTGGACCACAAGCCCAGCAACACCAAGGTGGACAAGCGGGT
GGAATCTAAGTACGGCCCTCCCTGCCCTCCTTGCCAGCCCTGAAGCTGCCGGCGGACCCTCCGTGTTCTCTGTTCC
CCCCAAAGCCCAAGGACACCTGATGATCAGCCGGACCCCCGAAGTGACCTGCGTGGTGGTGGATGTGTCCCAGGAA
GATCCCGAGGTGCAGTTCAATTGGTACGTGGACGGCGTGGAAGTGACACAACGCCAAGACCAAGCCCAGAGAGGAAC
AGTTCAACAGCACCTACCGGGTGGTGTCCGTGCTGACCGTGTGTCACCAGGACTGGCTGAACGGCAAAGAGTACAA
GTGCAAGGTGTCCAACAAGGGCCTGCCAGCTCCATCGAGAAAACCATCAGCAAGGCCAAGGGCCAGCCCCGCGAG
CCTCAAGTGTATACCCTGCCCCCTTGCCAGGAAGAGATGACCAAGAACCAGGTGTCCCTGTGGTGTCTCGTGAAGG
CTTCTACCCAGCGACATTGCCGTGGAATGGGAGAGCAACGGCCAGCCCGAGAACAAGTACAAGACACCCCCCT
GTGCTGGACAGCGACGGCTCATTCTTCCTGTACTCCAAGCTGACCGTGGACAAGAGCCGGTGGCAGGAAGGCAACGT
GTTACAGCTGCTCCGTGATGCACGAGGCCCTGCACAACCACTACACCCAGAAGTCCCTGTCTCTGTCCCTGGGC 4

505
AGCCTGACACAGAGCCCTGGCACCCCTGTCACTGAGCCCAGGCGAGACAGCCATCATCAGCTGCCGGACAAGCCAGT
ACGGCAGCCTGGCCTGGTATCAGCAGAGGCCTGGACAGGCCCCAGACTCGTGATCTACAGCGGCAGCACAAAGAGC
CGCCGGAATCCCGATAGATTCAGCGGCTCCAGATGGGGACCCGACTACAACCTGACCATCAGCAACCTGGAAAGC
GGCGACTTCGGCGTGTACTACTGCCAGCAGTACGAGTTCTTCGGCCAGGGCACCAAGGTGCAGGTGGACATCAAGCG
TACGGTGGCCGCTCCCAGCGTGTTCATCTTCCACCTAGCGACGAGCAGCTGAAGTCCGGCACAGCCTCTGTCTGT
GCCTGTGAACAAGTCTACCCCCGCGAGGCCAAAGTGCAGTGGAAGGTGGACAACGCCCTGCAGAGCGGCAACAG
CCAGGAAAGCGTGACCGAGCAGGACAGCAAGGACTCCACCTACAGCCTGAGCAGCACCCCTGACACTGAGCAAGGCC
GACTACGAGAAGCACAAAGGTGTACGCCTGCGAAGTGACCCACCAGGGCCTGTCTAGCCCCGTGACCAAGAGCTTCA
ACCGGGGCGAGTGT Trispecific 1 506

GACATCGTGATGACCCAGACCCCCCTGAGCCTGAGCGTGACACCTGGACAGCCTGCCAGCATCAGCTGCAAGAGCA
10 VRC07_
GCCAGAGCCTGGTGCACGAGAACCTGTTACCTACCTGAGCTGGTATCTGCAGAAGCCCGGCCAGAGCCCCAGTCC
523_FR3-03/
CTGATCTACAAGGTGTCCAACAGATTACGCGGCGTGCCCGACAGATTCTCCGGCAGCGGCTCTGGCACCGACTTCAC
CD28sup ×
CCTGAAGATCAGCCGGGTGGAAGCCGAGGACGTGGGCGTGTACTATTGTGGCCAGGGCACCCAGTACCCCTTCACCT
CD3mid_
TTGGCAGCGGCACCAAGGTGGAATCAAGGACAAAACCCATACCGACATCCAGATGACCCAGAGCCCCAGCAGCCT
ENLF IgG4
GTCTGCCAGCGTGGGCGACAGAGTGACCATCACCTGTCAGGCCAGCCAGAACATCTACGTGTGGCTGAACTGGTATC
FALA/409K_
AGCAGAAGCCCGGCAAGGCCCCCAAGCTGCTGATCTACAAGGCCAGCAACCTGCACACCGGCGTGCCCAGCAGATT
DKTHT linker

TTCTGGCAGCGGCTCCGGCACCGACTTCACCCTGACAATCAGCTCCCTGCAGCCCCGAGGACATTGCCACCTACTACT
GCCAGCAGGGCCAGACCTACCCCTACACCTTTGGCCAGGGCACCAAGCTGGAAATCAAGGATAAGACCCACACCCG
TACGGTGGCCGCTCCCAGCGTGTTCATCTTCCACCTAGCGACGAGCAGCTGAAGTCCGGCACAGCCTCTGTCTGT
GCCTGTGAACAAGTCTACCCCCGCGAGGCCAAAGTGCAGTGGAAGGTGGACAACGCCCTGCAGAGCGGCAACAG
CCAGGAAAGCGTGACCGAGCAGGACAGCAAGGACTCCACCTACAGCCTGAGCAGCACCCCTGACACTGAGCAAGGCC
GACTACGAGAAGCACAAAGGTGTACGCCTGCGAAGTGACCCACCAGGGCCTGTCTAGCCCCGTGACCAAGAGCTTCA
ACCGGGGCGAGTGT 2 507

CAGGTGCAGCTGGTGCAGTCTGGCGCCGAGGTCGTGAAACCTGGCGCCTCTGTGAAGGTGTCCTGCAAGGCCAGCGG
CTACACCTTTACCAGCTACTACATCCACTGGGTGCGCCAGGCCCTGGACAGGGACTGGAATGGATCGGCAGCATCT
ACCCCGGCAACGTGAACACCAACTACGCCAGAAAGTTCAGGGCAGAGCCACCCTGACCGTGGACACCAGCATCAG
CACCGCCTACATGGAAGTGAAGCCGGCTGAGAAGCGACGACACCGCCGTGTACTACTGCACCCGGTCCCACTACGGCC
TGGATTGGAAGTTCGACGTGTGGGGCAAGGGCACCAACCGTGACAGTGTCTAGCGACAAAACCCATACCCAGGTGCA
GCTGGTGGAAATCTGGCGGCGGAGTGGTGCAGCCTGGCAGAAGCCTGAGACTGAGCTGTGCCGCCAGCGGCTTCACCT
TCACCAAGGCCTGGATGCACTGGGTGCGCCAGGCCCTGGAAAGCAGCTGGAATGGGTGGCCAGATCAAGGACAA
GAGCAACAGCTACGCCACCTACTACGCCGACAGCGTGAAGGGCCGGTTCACCATCAGCCGGGACGACAGCAAGAAC
ACCCTGTACCTGCAGATGAACAGCCTGCGGGCCGAGGACACCGCCGTGTACTACTGTCGGGGCGTGTACTATGCCCT
GAGCCCCTTCGATTACTGGGGCCAGGGAACCCCTCGTGACCGTGTCTAGTGATAAGACCCACACCGCCAGCACAAAGG
GCCATCGGTGTTCCCTCTGGCCCCTTGACGACAGAAGCACCAGCGAATCTACAGCCGCCCTGGGCTGCCTCGTGAAG
GACTACTTTCCTGAGCCCGTGACCGTGTCTGGAAGTCTGGCGCTCTGACAAGCGGCGTGACACACCTTTCAGCCGT

GCTCCAGAGCAGCGGCTGTACTCTCTGAGCAGCGTCTGTGACAGTGCCTCCAGCAGCAGCCTGGGACACCAAGACCTACA
CCTGTAACGTGGACCACAAGCCCAGCAACACCAAGGTGGACAAGCGGGTGGAAATCTAAGTACGGCCCTCCCTGCCCT
CCTTGCCCAGCCCCTGAAGCTGCCGGCGGACCCTCCGTGTTCTCTGTTCCCCCAAAGCCCAAGGACACCCTGATGAT
CAGCCGGACCCCCGAAGTGACCTGCGTGGTGGTGGATGTGTCCCAGGAAGATCCCAGAGTGCAGTTCAATTGGTACG
TGGACGGCGTGGAAGTGCACAACGCCAAGACCAAGCCCAGAGAGGAACAGTTCAACAGCACCTACCGGGTGGTGTCC
GTGCTGACCGTGCTGCACCAGGACTGGCTGAACGGCAAAGAGTACAAGTGCAAGGTGTCCAACAAGGGCCTGCCCA
GCTCCATCGAGAAAACCATCAGCAAGGCCAAGGGCCAGCCCCGCGAGCCTCAAGTGTGTACCCTGCCCCCTAGCCA
GGAAGAGATGACCAAGAACCAGGTGTCCCTGAGCTGTGCCGTGAAAGGCTTCTACCCAGCGACATTGCCGTGGAA
TGGGAGAGCAACGGCCAGCCCCGAGAACAATAAGACCAACCCCCCTGTGCTGGACAGCGACGGCTCATTCTTCCT
GGTGTCCAAGCTGACCGTGGACAAGAGCCGGTGGCAGGAAGGCAACGTGTTTCAGCTGCTCCGTGATGCACGAGGCC
CTGCACAACCACTACACCCAGAAGTCCCTGTCTCTGTCCCTGGGC 3 508

CAAGTGCGGCTGTCTCAGTCTGGCGGCCAGATGAAGAAACCCGGCGACAGCATGCGGATCAGCTGCAGAGCCAGCG
GCTACGAGTTTCATCAACTGCCCCATCAACTGGATCAGACTGGCCCCTGGCAAGCGGCCTGAGTGGATGGGATGGATG
AAGCCCAGACACGGGGCCGTGTCTACGCCAGACAGCTGCAGGGCAGAGTGACCATGACCCGGCAGCTGAGCCAGG
ACCCTGATGATCCGGATTGGGGCACAGCCTTCTGGAAGTGCAGGAGCCTGACCAGCGACGATACCGCCGTGTACTTC
TGACCCCGGGGCAAGTACTGCACCGCCAGAGACTACTACAAGTGGGACTTCGAGCACTGGGGCCAGGGCACACCTG
TGACAGTGTCTAGCGCTTCGACCAAGGGCCCATCGGTGTTCCCTCTGGCCCCTTGACAGCAGAAGCACCAGCGAATCT
ACAGCCGCCCTGGGCTGCCTCGTGAAGGACTACTTCCCGAGCCCCGTGACCGTGTCTGGAAGTCTGGCGCTCTGAC
AAGCGGCGTGACACACCTTTCAGCCGTGCTCCAGAGCAGCGGCCTGTACTCTCTGAGCAGCGTCGTGACAGTGCCCA
GCAGCAGCCTGGGCACCAAGACCTACACCTGTAACGTGGACCACAAGCCCAGCAACACCAAGGTGGACAAGCGGGTCC
GAATCTAAGTACGGCCCTCCCTGCCCTCCTTGCCAGCCCCCTGAAGCTGCCGGCGGACCCTCCGTGTTCTCTGTTCCT
CCCAAAGCCCAAGGACACCCTGATGATCAGCCGGACCCCCGAAGTGACCTGCGTGGTGGTGGATGTGTCCCAGGAA
GATCCCGAGGTGCAGTTCAATTGGTACGTGGACGGCGTGGAAGTGCACAACGCCAAGACCAAGCCCAGAGAGGAAC
AGTTCAACAGCACCTACCGGGTGGTGTCCGTGCTGACCGTGTCTGCACCAGGACTGGCTGAACGGCAAAGAGTACAA
GTGCAAGGTGTCCAACAAGGGCCTGCCAGCTCCATCGAGAAAACCATCAGCAAGGCCAAGGGCCAGCCCCGCGAG
CCTCAAGTGTATACCCTGCCCCCTTGCCAGGAAGAGATGACCAAGAACCAGGTGTCCCTGTGGTGTCTCGTGAAAGG
CTTCTACCCAGCGACATTGCCGTGGAATGGGAGAGCAACGGCCAGCCCCGAGAACAATAAGACCAACCCCCCT
GTGCTGGACAGCGACGGCTCATTCTTCTGTACTCCAAGCTGACCGTGGACAAGAGCCGGTGGCAGGAAGGCAACGT
GTTTCAGCTGCTCCGTGATGCACGAGGCCCTGCACAACCACTACACCCAGAAGTCCCTGTCTCTGTCCCTGGGC 4
509

AGCCTGACACAGAGCCCTGGCACCCCTGTCACTGAGCCCAGGCGAGACAGCCATCATCAGCTGCCGGACAAGCCAGT
ACGGCAGCCTGGCCTGGTATCAGCAGAGGCCTGGACAGGCCCCAGACTCGTGATCTACAGCGGCAGCACAAAGAGC
CGCCGGAATCCCGATAGATTACGCGGCTCCAGATGGGGACCCGACTACAACCTGACCATCAGCAACCTGGAAAGC
GGCGACTTCGGCGTGTACTACTGCCAGCAGTACGAGTTCTTCGGCCAGGGCACCAAGGTGCAGGTGGACATCAAGCG
TACGGTGGCCGCTCCCAGCGTGTTCATCTTCCACCTAGCGACGAGCAGCTGAAGTCCGGCACAGCCTCTGTCTGT
GCCTGTGAACAACTTCTACCCCCGCGAGGCCAAAGTGCAGTGGAAGGTGGACAACGCCCTGCAGAGCGGCAACAG
CCAGGAAAGCGTGACCGAGCAGGACAGCAAGGACTCCACCTACAGCCTGAGCAGCACCCCTGACACTGAGCAAGGCC
GACTACGAGAAGCACAAAGGTGTACGCCTGCGAAGTGACCCACCAGGGCCTGTCTAGCCCCGTGACCAAGAGCTTCA
ACCGGGGCGAGTGT Trispecific 1 510

GACATCGTGATGACCCAGACCCCCCTGAGCCTGAGCGTGACACCTGGACAGCCTGCCAGCATCAGCTGCAAGAGCA
11 VRC07_
GCCAGAGCCTGGTGCACGAGAACCTGCAGACCTACCTGAGCTGGTATCTGCAGAAGCCCGGCCAGAGCCCCCAGTC
523_FR3-03/
CCTGATCTACAAGGTGTCCAACAGATTCAGCGGCGTGCCCGACAGATTCTCCGGCAGCGGCTCTGGCACCGACTTCA
CD28sup ×
CCCTGAAGATCAGCCGGGTGGAAGCCGAGGACGTGGGCGTGTACTATTGTGGCCAGGGCACCCAGTACCCCTTCACC
CD3mid_
TTTGGCAGCGGCACCAAGGTGGAATCAAGGACAAAACCCATACCGACATCCAGATGACCCAGAGCCCCAGCAGCC
ENLQ
TGTCTGCCAGCGTGGGCGACAGAGTGACCATCACCTGTCAGGCCAGCCAGAACATCTACGTGTGGCTGAACTGGTAT
IgG1_NNAS_
CAGCAGAAGCCCGGCAAGGCCCCCAAGCTGCTGATCTACAAGGCCAGCAACCTGCACACCGGCGTGCCCAGCAGAT
DKTHT linker
TTTCTGGCAGCGGCTCCGGCACCGACTTCACCCTGACAATCAGCTCCCTGCAGCCCGAGGACATTGCCACCTACTAC
TGCCAGCAGGGCCAGACCTACCCCTACACCTTTGGCCAGGGCACCAAGCTGGAAATCAAGGATAAGACCCACACCCG
TACGGTGGCCGCTCCCAGCGTGTTCATCTTCCACCTAGCGACGAGCAGCTGAAGTCCGGCACAGCCTCTGTCTGT
GCCTGTGAACAACTTCTACCCCCGCGAGGCCAAAGTGCAGTGGAAGGTGGACAACGCCCTGCAGAGCGGCAACAG
CCAGGAAAGCGTGACCGAGCAGGACAGCAAGGACTCCACCTACAGCCTGAGCAGCACCCCTGACACTGAGCAAGGCC
GACTACGAGAAGCACAAAGGTGTACGCCTGCGAAGTGACCCACCAGGGCCTGTCTAGCCCCGTGACCAAGAGCTTCA
ACCGGGGCGAGTGT 2 511

CAGGTGCAGCTGGTGCAGTCTGGCGCCGAGGTCTGTGAAACCTGGCGCCTCTGTGAAGGTGTCCTGCAAGGCCAGCGG
CTACACCTTTACCAGCTACTACATCCACTGGGTGCGCCAGGCCCTGGACAGGGACTGGAATGGATCGGCAGCATCT
ACCCCGGCAACGTGAACACCAACTACGCCCAGAAGTTCAGGGCAGAGCCACCCTGACCGTGGACACCAGCATCAG

ACCAGCTATGGAACCTGAGCCGGCTGAGAAAGCGACGACACCGCCGTGTACTACTGCACCCGGTCCCCTACCGGC
TGGATTGGAACCTTCGACGTGTGGGGCAAGGGCACCACTGACAGTGTCTAGCGACAAAACCCATACCCAGGTGCA
GCTGGTGGAAATCTGGCGGCGGAGTGGTGCAGCCTGGCAGAAGCCTGAGACTGAGCTGTGCCGCCAGCGGCTTCACCT
TCACCAAGGCCTGGATGCACTGGGTGCGCCAGGCCCTGGAAAAGCAGCTGGAATGGGTGGCCCAGATCAAGGACAA
GAGCAACAGCTACGCCACCTACTACGCCGACAGCGTGAAGGGCCGGTTACCATCAGCCGGGACGACAGCAAGAAC
ACCCTGTACCTGCAGATGAACAGCCTGCGGGCCGAGGACACCGCCGTGTACTACTGTCTGGGGCGTGTACTATGCCCT
GAGCCCCCTTCGATTACTGGGGCCAGGGAACCCTCGTGACCGTGTCTAGTGATAAGACCCACACCGCCAGCACAAAGG
GCCCCAGCGTGTTCCCTCTGGCCCCCTAGCAGCAAGAGCACATCTGGCGGAACAGCCGCCCTGGGCTGCCTCGTGAAG
GACTACTTTCCCGAGCCCCGTGACCGTGTCTTGGAAATTCTGGCGCCCTGACCAGCGGCGTGCACACCTTTCCAGCTGT
GCTGCAGTCCAGCGGCTGTACAGCCTGAGCAGCGTCTGTGACAGTGCCAGCAGCTCTCTGGGCACCCAGACCTACA
TCTGCAACGTGAACCACAAGCCCAGCAACACCAAGGTGGACAAGAAGGTGGAACCCAAGAGCTGCGACAAGACCCA
ACCTGTCCCCCTTGTCTGCCCCCGAACTGCTGGGAGGCCCTTCCGTGTTCTGTTCCCCCCAAAGCCCAAGGACAC
CCTGATGATCAGCCGGACCCCCGAAGTGACCTGCGTGGTGGTGGATGTGTCCCACGAGGACCCTGAAGTGAAGTTCA
ATTGGTACGTGGACGGCGTGGAAGTGCACAACGCCAAGACCAAGCCAAGAGAGGAACAGTACAACAATGCCTCCCG
GGTGGTGTCCGTGCTGACCGTGTGCAACCAGGACTGGCTGAACGGCAAAGAGTACAAGTGCAAGGTGTCCAACAAG
GCCCTGCCTGCCCCCATCGAGAAAACCATCAGCAAGGCCAAGGGCCAGCCCCGCGAACCCAGGTGTGCACACTGC
CCCCAAGCAGGGACGAGCTGACCAAGAACCAGGTGTCCCTGAGCTGTGCCGTGAAAGGCTTCTACCCCTCCGATATC
GCCGTGGAATGGGAGAGCAACGGCCAGCCCGAGAACAACCTACAAGACCACCCCCCTGTGCTGGACAGCGACGGCT
CATCTTCCCTGGTGTCCAAGCTGACAGTGGACAAGTCCCGGTGGCAGCAGGGCAACGTGTTACAGCTGCTCCGTGATG
CACGAGGCCCTGCACAACCACTACACCCAGAAGTCCCTGAGCCTGAGCCCCGGC 3 512

CAAGTGCGGCTGTCTCAGTCTGGCGGCCAGATGAAGAAACCCGGCGACAGCATGCGGATCAGCTGCAGAGCCAGCG
GCTACGAGTTCATCAACTGCCCCATCAACTGGATCAGACTGGCCCTGGCAAGCGGCCTGAGTGGATGGGATGGATG
AAGCCCAGACACGGGGCCGTGTCTACGCCAGACAGCTGCAGGGCAGAGTGACCATGACCCGGCAGCTGAGCCAGG
ACCCTGATGATCCGGATTGGGGCACAGCCTTCCCTGGAAGTGCAGGAGCCTGACCAGCGACGATACCGCCGTGTACTTC
TGCACCCGGGGCAAGTACTGCACCGCCAGAGACTACTACAAGTGGGACTTCGAGCACTGGGGCCAGGGCACACCTG
TGACAGTGTCTAGCGCTTCGACCAAGGGGCCATCGGTCTTCCCCCTGGCACCCCTCCTCCAAGAGCACCTCTGGGGGC
ACAGCGGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCTGTGGAAGTCAAGGCGCCCTGAC
CAGCGGCGTGCACACCTTCCCGGCTGTCTACAGTCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCT
CCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAACACCAAGGTGGACAAGAAAGTT
GAGCCCAAATCTTGTGACAAAACCTCACACATGCCACCGTGCCAGCACCTGAACTCCTGGGGGGACCGTCAGTCTT
CCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGA
GCCACGAAGACCCTGAGGTCAAGTTCAACTGGTATGTTGACGGCGTGAGGTGCATAATGCCAAGACAAAGCCCGC
GGAGGAGCAGTACAACAATGCCTCCCGTGTGGTCAGCGTCTCACCGTCTGACCCAGGACTGGCTGAATGGCAAGG
AGTACAAGTGCAAGGTCTCCAACAAAGCCCTCCAGCCCCCATCGAGAAAACCATCTCCAAGCCAAAGGGCAGCC
CCGAGAACCACAGGTGTACACCCTGCCCCCATGCCGGGATGAGCTGACCAAGAATCAAGTCAGCCTGTGGTGCCTGG
TAAAAGGCTTCTATCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACCAC
GCCTCCCGTGTGGAAGTCCGACGGCTCCTTCTTCTCTACTCAAACTCACCGTGGACAAGAGCAGGTGGCAGCAGG
GGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCG
GGT 4 513

AGCCTGACACAGAGCCCTGGCACCCCTGTCACTGAGCCCAGGCGAGACAGCCATCATCAGCTGCCGGACAAGCCAGT
ACGGCAGCCTGGCCTGGTATCAGCAGAGGCCTGGACAGGCCCCAGACTCGTGATCTACAGCGGCAGCACAAAGAGC
CGCCGGAATCCCCGATAGATTACGCGGCTCCAGATGGGGACCCGACTACAACCTGACCATCAGCAACCTGGAAAGC
GGCGACTTCGGCGTGTACTACTGCCAGCAGTACGAGTTCTTCGGCCAGGGCACCAAGGTGCAGGTGGACATCAAGCG
TACGGTGGCCGCTCCCAGCGTGTTCATCTTCCACCTAGCGACGAGCAGCTGAAGTCCGGCACAGCCTCTGTCTGTGT
GCCTGCTGAACAACTTCTACCCCCGCGAGGCCAAAGTGCAGTGGAAGGTGGACAACGCCCTGCAGAGCGGCAACAG
CCAGGAAAGCGTGACCGAGCAGGACAGCAAGGACTCCACCTACAGCCTGAGCAGCACCCCTGACACTGAGCAAGGCC
GACTACGAGAAGCACAAAGGTGTACGCCTGCGAAGTGACCCACCAGGGCCTGTCTAGCCCCGTGACCAAGAGCTTCA
ACCGGGGCGAGTGT Trispecific 1 514

GACATCGTGATGACCCAGACCCCCCTGAGCCTGAGCGTGACACCTGGACAGCCTGCCAGCATCAGCTGCAAGAGCA
12 VRC07_
GCCAGAGCCTGGTGCACGAGAACCTGTTACCTACCTGAGCTGGTATCTGCAGAAGCCCGGCCAGAGCCCCCAGTCC
523_FR3-03/
CTGATCTACAAGGTGTCCAACAGATTACGCGGCGTGCCCGACAGATTCTCCGGCAGCGGCTCTGGCACCGACTTCAC
CD28sup ×
CCTGAAGATCAGCCGGGTGGAAGCCGAGGACGTGGGCGTGTACTATTGTGGCCAGGGCACCCAGTACCCCTTCACCT
CD3mid_
TTGGCAGCGGCACCAAGGTGGAATCAAGGACAAAACCCATACCGACATCCAGATGACCCAGAGCCCCAGCAGCCT
ENLF
GTCTGCCAGCGTGGGCGACAGAGTGACCATCACCTGTCAGGCCAGCCAGAACATCTACGTGTGGCTGAACTGGTATC
IgG1_NNAS_
AGCAGAAGCCCGGCAAGGCCCCCAAGCTGCTGATCTACAAGGCCAGCAACCTGCACACCGGCGTGCCAGCAGATT
DKTHT linker
TTCTGGCAGCGGCTCCGGCACCGACTTCACCCTGACAATCAGCTCCCTGCAGCCCGAGGACATTGCCACCTACTACT

CCAGGAGGCCAGACTACCCCTACACCTTTGGCCAGGGCACCAAGCTGGAAATCAAGGATAAGACCCACACCCG
TACGGTGGCCGCTCCCAGCGTGTTCATCTTCCACCTAGCGACGAGCAGCTGAAGTCCGGCACAGCCTCTGTCTGT
GCCTGCTGAACAACTTCTACCCCCGCGAGGCCAAAGTGCAGTGGAAGGTGGACAACGCCCTGCAGAGCGGCAACAG
CCAGGAAAGCGTGACCGAGCAGGACAGCAAGGACTCCACCTACAGCCTGAGCAGCACCCCTGACACTGAGCAAGGCC
GACTACGAGAAGCACAAAGGTGTACGCCTGCGAAGTGACCCACCAGGGCCTGTCTAGCCCCGTGACCAAGAGCTTCA
ACCGGGGCGAGTGT 2 515
CAGGTGCAGCTGGTGCAGTCTGGCGCCGAGGTCGTGAAACCTGGCGCCTCTGTGAAGGTGTCCTGCAAGGCCAGCGG
CTACACCTTTACCAGCTACTACATCCACTGGGTGCGCCAGGCCCTGGACAGGGACTGGAATGGATCGGCAGCATCT
ACCCCGGCAACGTGAACACCAACTACGCCCAGAAGTTCAGGGCAGAGCCACCCTGACCGTGGACACCAGCATCAG
CACCGCCTACATGGAAGTGAAGCCGGCTGAGAAGCGACGACACCGCCGTGTACTACTGCACCCGGTCCCACTACGGCC
TGGATTGGAAGTTCGACGTGTGGGGCAAGGGCACCAACCGTGACAGTGTCTAGCGACAAAACCCATAACCCAGGTGCA
GCTGGTGGAAATCTGGCGGCGGAGTGGTGCAGCCTGGCAGAAGCCTGAGACTGAGCTGTGCCGCCAGCGGCTTACCT
TCACCAAGGCCTGGATGCACTGGGTGCGCCAGGCCCTGGAAAGCAGCTGGAATGGGTGGCCCAGATCAAGGACAA
GAGCAACAGCTACGCCACCTACTACGCCGACAGCGTGAAGGGCCGGTTCACCATCAGCCGGGACGACAGCAAGAAC
ACCCTGTACCTGCAGATGAACAGCCTGCGGGCCGAGGACACCGCCGTGTACTACTGTCGGGGCGTGTACTATGCCCT
GAGCCCCTTCGATTACTGGGGCCAGGGAACCCCTCGTGACCGTGTCTAGTGATAAGACCCACACCGCCAGCACAAAGG
GCCCCAGCGTGTCCCTCTGGCCCCCTAGCAGCAAGAGCACATCTGGCGGAACAGCCGCCCTGGGCTGCCTCGTGAAG
GACTACTTTCCCGAGCCCCGTGACCGTGTCTGGAATTCTGGCGCCCTGACCAGCGGCGTGCACACCTTTCCAGCTGT
GCTGCAGTCCAGCGGCTGTACAGCCTGAGCAGCGTCTGTGACAGTGCCCAGCAGCTCTCTGGGCACCCAGACCTACA
TCTGCAACGTGAACCACAAGCCCAGCAACACCAAGGTGGACAAGAAGGTGGAACCCAAGAGCTGCGACAAGACCCA
ACCTGTCCCCCTTGTCTGCCCCCGAAGTGTCTGGGAGGCCCTTCCGTGTTCTGTTCCCCCCAAGCCCAAGGACAC
CCTGATGATCAGCCGGACCCCCGAAGTGACCTGCGTGGTGGTGGATGTGTCCCACGAGGACCCTGAAGTGAAGTTCA
ATTGGTACGTGGACGGCGTGGAAGTGCACAACGCCAAGACCAAGCCAAGAGAGGAACAGTACAACAATGCCTCCCG
GGTGGTGTCCGTGCTGACCGTGTGTCACCAGGACTGGCTGAACGGCAAAGAGTACAAGTGCAAGGTGTCCAACAAG
GCCCTGCCTGCCCCCATCGAGAAAACCATCAGCAAGGCCAAGGGCCAGCCCCGCGAACCCAGGTGTGCACACTGC
CCCCAAGCAGGGACGAGCTGACCAAGAACCAGGTGTCCCTGAGCTGTGCCGTGAAAGGCTTCTACCCCTCCGATATC
GCCGTGGAATGGGAGAGCAACGGCCAGCCCGAGAACAACCTACAAGACCACCCCCCTGTGCTGGACAGCGACGGCT
CATCTTCTCTGGTGTCCAAGCTGACAGTGGACAAGTCCCGGTGGCAGCAGGGCAACGTGTTTCAGCTGCTCCGTGATG
CACGAGGCCCTGCACAACCACTACACCCAGAAGTCCCTGAGCCTGAGCCCCGGC 3 516
CAAGTGCGGCTGTCTCAGTCTGGCGGCCAGATGAAGAAACCCGGCGACAGCATGCGGATCAGCTGCAGAGCCAGCG
GCTACGAGTTCATCAACTGCCCCATCAACTGGATCAGACTGGCCCCTGGCAAGCGGCCTGAGTGGATGGATGGATG
AAGCCCAGACACGGGGCCGTGTCTACGCCAGACAGCTGCAGGGCAGAGTGACCATGACCCGGCAGCTGAGCCAGG
ACCCTGATGATCCGGATTGGGGCACAGCCTTCCCTGGAAGTGCAGGAGCCTGACCAGCGACGATAACCGCCGTGTACTTC
TGCACCCGGGGCAAGTACTGCACCGCCAGAGACTACTACAACCTGGGACTTCGAGCACTGGGGCCAGGGCACACCTG
TGACAGTGTCTAGCGCTTCGACCAAGGGCCCATCGGTCTTCCCCCTGGCACCCCTCCTCCAAGAGCACCTCTGGGGGC
ACAGCGGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCTGTGGAAGTCAAGCGCCCTGAC
CAGCGGCGTGCACACCTTCCCGGTGTCTTACAGTCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCT
CCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAACACCAAGGTGGACAAGAAAGTT
GAGCCCCAAATCTTGTGACAAAACCTCACACATGCCACCGTGCCAGCACCTGAACTCCTGGGGGGACCGTCAGTCTT
CCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGA
GCCACGAAGACCCTGAGGTCAAGTTCAACTGGTATGTTGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCCGG
GGAGGAGCAGTACAACAATGCCTCCCGTGTGGTCAGCGTCTCACCCTGTCACCAGGACTGGCTGAATGGCAAGG
AGTACAAGTGCAAGGTCTCCAACAAGGCCCTCCAGCCCCCATCGAGAAAACCATCTCCAAGCCAAAGGGCAGCC
CCGAGAACCACAGGTGTACACCCTGCCCCCATGCCGGGATGAGCTGACCAAGAATCAAGTCAGCCTGTGGTGCCTGG
TAAAAGGCTTCTATCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACCTACAAGACCAC
GCCTCCCGTGTCTGGACTCCGACGGCTCCTTCTTCTCTACTCAAACTCACCGTGGACAAGAGCAGGTGGCAGCAGG
GGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCG
GGT 4 517
AGCCTGACACAGAGCCCTGGCACCCCTGTCACTGAGCCCAGGCGAGACAGCCATCATCAGCTGCCGGACAAGCCAGT
ACGGCAGCCTGGCCTGGTATCAGCAGAGGCCTGGACAGGCCCCCAGACTCGTGATCTACAGCGGCAGCACAAAGAGC
CGCCGGAATCCCCGATAGATTACGCGGCTCCAGATGGGGACCCGACTACAACCTGACCATCAGCAACCTGGAAAGC
GGCGACTTCGGCGTGTACTACTGCCAGCAGTACGAGTTCTTCGGCCAGGGCACCAAGGTGCAGGTGGACATCAAGCG
TACGGTGGCCGCTCCCAGCGTGTTCATCTTCCACCTAGCGACGAGCAGCTGAAGTCCGGCACAGCCTCTGTCTGT
GCCTGCTGAACAACTTCTACCCCCGCGAGGCCAAAGTGCAGTGGAAGGTGGACAACGCCCTGCAGAGCGGCAACAG
CCAGGAAAGCGTGACCGAGCAGGACAGCAAGGACTCCACCTACAGCCTGAGCAGCACCCCTGACACTGAGCAAGGCC
GACTACGAGAAGCACAAAGGTGTACGCCTGCGAAGTGACCCACCAGGGCCTGTCTAGCCCCGTGACCAAGAGCTTCA
ACCGGGGCGAGTGT Trispecific 1 518
GACATCGTGATGACCCAGACCCCCCTGAGCCTGAGCGTGACACCTGGACAGCCTGCCAGCATCAGCTGCAAGAGCA
13 N6/
GCCAGAGCCTGGTGCACAACAACGCCAACACCTACCTGAGCTGGTATCTGCAGAAGCCCGGCCAGAGCCCCCAGTC
CD28sup ×
CCTGATCTACAAGGTGTCCAACAGATTCAGCGGCGTGCCCGACAGATTCTCCGGCAGCGGCTCTGGCACCGACTTCA
CD3mid

CCCTGAAGATCAGCCGGGTGGAAGCCGAGGACGTGGCGGTGTACTATTGTGGCCAGGGCACCCAGTACCCCTTCACC
IgG4
TTTGGCAGCGGCACCAAGGTGGAATCAAGGGCCAGCCCAAGGCCGCCCCGACATCCAGATGACCCAGAGCCCCA
GCAGCCTGTCTGCCAGCGTGGGCGACAGAGTGACCATCACCTGTCAAGGCCAGCCAGAACATCTACGTGTGGCTGAAC
TGGTATCAGCAGAAGCCCGGCAAGGCCCCCAAGCTGCTGATCTACAAGGCCAGCAACCTGCACACCGGCGTGCCCA
GCAGATTTTCTGGCAGCGGCTCCGGCACCGACTTCACCCTGACAATCAGCTCCCTGCAGCCCGAGGACATTGCCACC
TACTACTGCCAGCAGGGCCAGACCTACCCCTACACCTTTGGCCAGGGCACCAAGCTGGAATCAAGACCAAGGGCC
CCAGCCGTACGGTGGCCGCTCCAGCGTGTTCATCTTCCCACCTAGCGACGAGCAGCTGAAGTCCGGGCACAGCCTCT
GTCGTGTGCCTGCTGAACAACCTTCTACCCCCGCGAGGCCAAAGTGCAGTGGAAAGGTGGACAACGCCCTGCAGAGCG
GCAACAGCCAGGAAAGCGTGACCGAGCAGGACAGCAAGGACTCCACCTACAGCCTGAGCAGCACCCCTGACACTGAG
CAAGGCCGACTACGAGAAGCACAAAGGTGTACGCCTGCGAAGTGACCCACCAGGGCCTGTCTAGCCCCGTGACCAAG
AGCTTCAACCGGGGCGAGTGT 2 519
CAGGTGCAGCTGGTGCAGTCTGGCGCCGAGGTCTGTGAAACCTGGCGCCTCTGTGAAGGTGTCCTGCAAGGCCAGCGG
CTACACCTTTACCAGCTACTACATCCACTGGGTGCGCCAGGCCCTGGACAGGGACTGGAATGGATCGGCAGCATCT
ACCCCGGCAACGTGAACACCAACTACGCCCAGAAGTTCAGGGCAGAGCCACCCTGACCGTGGACACCAGCATCAG
CACCGCCTACATGGAAGTGAAGCCGGCTGAGAAGCGACGACACCGCCGTGTACTACTGCACCCGGTCCCACTACGGCC
TGGATTGGAACCTCGACGTGTGGGGCAAGGGCACCAACCGTGACAGTGTCTAGCAGCCAGGTGCAGCTGGTGGAAATCT
GGCGGCGGAGTGGTGCAGCCTGGCAGAAGCCTGAGACTGAGCTGTGCCGCCAGCGGCTTCACCTTCACCAAGGCCT
GGATGCACTGGGTGCGCCAGGCCCTGGAAAGCAGCTGGAATGGGTGGCCAGATCAAGGACAAGAGCAACAGCTA
CGCCACCTACTACGCCGACAGCGTGAAGGGCCGGTTCACCATCAGCCGGGACGACAGCAAGAACACCCTGTACCTG
CAGATGAACAGCCTGCGGGCCGAGGACACCGCCGTGTACTACTGTGCGGGCGTGTACTATGCCCTGAGCCCCCTTCGA
TTACTGGGGCCAGGGAACCCTCGTGACCGTGTCTAGTCGGACCGCCAGCACAAAGGGCCCATCGGTGTTCCCTCTGG
CCCCTTGACGAGCAAGCACCAGCGAATCTACAGCCGCCCTGGGCTGCCTCGTGAAGGACTACTTTCCCGAGCCCCGTG
ACCGTGTCTCTGGAACCTCTGGCGCTCTGACAAGCGGCGTGCACACCTTTCCAGCCGTGCTCCAGAGCAGCGGCCTGTA
CTCTCTGAGCAGCGTCGTGACAGTGCCCAGCAGCAGCCTGGGCACCAAGACCTACACCTGTAACGTGGACCACAAGC
CCAGCAACACCAAGGTGGACAAGCGGGTGGAAATCTAAGTACGGCCCTCCCTGCCCTCCTTGCCCAGCCCCCTCCTGTG
GCTGGACCCTCCGTGTTCCCTGTTCCCCCCAAAGCCCAAGGACACCCTGATGATCAGCCGGACCCCCGAAGTGACCTG
CGTGGTGGTGGATGTGTCCAGGAAGATCCCGAGGTGCAGTTCAATTGGTACGTGGACGGCGTGGAAGTGCACAAC
GCCAAGACCAAGCCCAGAGAGGAACAGTTCAACAGCACCTACCGGGTGGTGTCCGTGCTGACCGTGCTGCACCAGG
ACTGGCTGAACGGCAAAGAGTACAAGTGCAAGGTGTCCAACAAGGGCCTGCCAGCTCCATCGAGAAAACCATCAG
CAAGGCCAAGGGCCAGCCCCGCGAGCCTCAAGTGTGTACCCTGCCCCCTAGCCAGGAAGAGATGACCAAGAACCAG
GTGTCCCTGAGCTGTGCCGTGAAAGGCTTCTACCCAGCGACATTGCCGTGGAATGGGAGAGCAACGGCCAGCCCCGA
GAACAACCTACAAGACCACCCCCCTGTGCTGGACAGCGACGGCTCATTCTTCTGGTGTCCAAGCTGACCGTGGACA
AGAGCCGGTGGCAGGAAGGCAACGTGTTACAGCTGCTCCGTGATGCACGAGGCCCTGCACAACCACTACACCCAGAA
GTCCCTGTCTCTGTCCCTGGGC 3 520
AGAGCCCACCTGGTGCAGTCTGGCACCCGCCATGAAGAAACCAGGCGCCTCTGTGCGGGTGTCTGTGACACAAGCG
GCTACACCTTCACCGCCCACATCCTGTTCTGGTTCGCGCAGGCCCTGGCAGAGGACTGGAATGGGTGGGATGGATC
AAGCCCCAGTATGGCGCCGTGAACCTCGGCGGAGGCTTCCGGGATAGAGTGACCCTGACCCGGGACGTGTACCGCG
AGATCGCCTACATGGACATCCGGGGCCTGAAGCCCGATGACACCGCCGTGTACTACTGCGCCAGAGACAGAAGCTAC
GGCGACAGCAGCTGGGCTCTGGATGCTTGGGGCCAGGGCACAAACCGTGGTGGTGTCTGCCGCCTCTACAAAGGGCCC
ATCGGTGTTCCCTCTGGCCCCCTTGACGAGAGAAGCACCAGCGAATCTACAGCCGCCCTGGGCTGCCTCGTGAAGGACT
ACTTTCCCGAGCCCGTGACCGTGTCTCTGGAACCTCTGGCGCTCTGACAAGCGGCGTGACACCTTTCCAGCCGTGCTC
CAGAGCAGCGGCCTGTACTCTCTGAGCAGCGTCTGTGACAGTGCCAGCAGCAGCCTGGGCACCAAGACCTACACCTG
TAACGTGGACCACAAGCCCAGCAACACCAAGGTGGACAAGCGGGTGGAAATCTAAGTACGGCCCTCCCTGCCCTCCTT
GCCAGCCCCCTCCTGTGGCTGGACCCTCCGTGTTCCCTGTTCCCCCCAAAGCCCAAGGACACCCTGATGATCAGCCGG
ACCCCCGAAGTGACCTGCGTGGTGGTGGATGTGTCCCAGGAAGATCCCGAGGTGCAGTTCAATTGGTACGTGGACGG
CGTGGAAAGTGCACAACGCCAAGACCAAGCCCAGAGAGGAACAGTTCAACAGCACCTACCGGGTGGTGTCCGTGCTG
ACCGTGTGTCACCAGGACTGGCTGAACGGCAAAGAGTACAAGTGCAAGGTGTCCAACAAGGGCCTGCCAGCTCCA
TCGAGAAAACCATCAGCAAGGCCAAGGGCCAGCCCCGCGAGCCTCAAGTGTATACCCTGCCCCCTTGCCAGGAAGA
GATGACCAAGAACCAGGTGTCCCTGTGGTGTCTCGTGAAAGGCTTCTACCCAGCGACATTGCCGTGGAATGGGAGA
GCAACGGCCAGCCCGAGAACAACCTACAAGACCACCCCCCTGTGCTGGACAGCGACGGCTCATTCTTCTGTACTCC
AAGCTGACCGTGGACAAGAGCCGGTGGCAGGAAGGCAACGTGTTACAGCTGCTCCGTGATGCACGAGGCCCTGCACA
ACCACTACACCCAGAAGTCCCTGTCTCTGTCCCTGGGC 4 521
TACATCCACGTGACCCAGAGCCCCAGCAGCCTGTCCGTGTCCATCGGCGACAGAGTGACCATCAACTGCCAGACCTC
TCAGGGCGTGGGCAGCGACCTGCACTGGTATCAGCACAAGCCTGGCAGAGCCCCCAAGCTGCTGATCCACCACACA
AGCAGCGTGGAAGATGGCGTGCCAGCAGATTTTCCGGCAGCGGCTTCCACACCAGCTTCAACCTGACCATCAGCGA
TCTGCAGGCCGACGACATTGCCACCTACTATTGTCAGGTGCTGCAGTTCTTCCGGCAGAGGCAGCAGACTGCACATCA
AGCGTACGGTGGCCGCTCCAGCGTGTTCATCTTCCCACCTAGCGACGAGCAGCTGAAGTCCGGGCACAGCCTCTGTC
GTGTGCCTGCTGAACAACCTTCTACCCCCGCGAGGCCAAAGTGCAGTGGAAAGGTGGACAACGCCCTGCAGAGCGGCA
ACAGCCAGGAAAGCGTGACCGAGCAGGACAGCAAGGACTCCACCTACAGCCTGAGCAGCACCCCTGACACTGAGCAA
GGCCGACTACGAGAAGCACAAAGGTGTACGCCTGCGAAGTGACCCACCAGGGCCTGTCTAGCCCCGTGACCAAGAGC
TTCAACCGGGGCGAGTGT Trispecific 1 522
GACATCGTGATGACCCAGACCCCCCTGAGCCTGAGCGTGACACCTGGACAGCCTGCCAGCATCAGCTGCAAGAGCA

14 N6/

GCCAGAGCCTGGTGCACAACAACGCCAACACCTACCTGAGCTGGTATCTGCAGAAGCCCGGCCAGAGCCCCCAGTC
CD28sup ×

CCTGATCTACAAGGTGTCCAACAGATTCAGCGGCGTGCCCGACAGATTCTCCGGCAGCGGCTCTGGCACCGACTTCA
CD3mid

CCCTGAAGATCAGCCGGGTGGAAGCCGAGGACGTGGGCGTGTAATTGTGGCCAGGGCACCCAGTACCCCTTCACC
IgG4

TTTGGCAGCGGCACCAAGGTGGAATCAAGGGGCCAGCCCAAGGCCGCCCCGACATCCAGATGACCCAGAGCCCCA
GCAGCCTGTCTGCCAGCGTGCGCGACAGAGTGACCATCACCTGTGAGGCCAGCCAGAACATCTACGTGTGGCTGAAC
TGGTATCAGCAGAAGCCCGGCAAGGCCCCCAAGCTGCTGATCTACAAGGCCAGCAACCTGCACACCGGCGTGCCCA
GCAGATTTTCTGGCAGCGGCTCCGGCACCGACTTCACCTTGACAATCAGCTCCCTGCAGCCCGAGGACATTGCCACC
TACTACTGCCAGCAGGGCCAGACCTACCCCTACACCTTTGGCCAGGGCACCAAGCTGGAATCAAGACCAAGGGCC
CCAGCCGTACGGTGCGCGCTCCAGCGTGTTTCATCTTCCCACCTAGCGACGAGCAGCTGAAGTCCGGCACAGCCTCT
GTCGTGTGCTGTGAACAATTCTACCCCCGCGAGGCCAAAGTGCAGTGGAAGGTGGACAACGCCCTGCAGAGCG
GCAACAGCCAGGAAAGCGTGACCGAGCAGGACAGCAAGGACTCCACCTACAGCCTGAGCAGCACCTTGACACTGAG
CAAGGCCGACTACGAGAAGCACAAGGTGTACGCCTGCGAAGTGACCCACCAGGGCCTGTCTAGCCCCGTGACCAAG
AGCTTCAACCGGGGCGAGTGT 2 523

CAGGTGCAGCTGGTGCAGTCTGGCGCCGAGGTGCTGAAACCTGGCGCCTCTGTGAAGGTGTCCTGCAAGGCCAGCGG
CTACACCTTTACCAGCTACTACATCCACTGGGTGCGCCAGGCCCTGGACAGGGACTGGAATGGATCGGCAGCATCT
ACCCCGGCAACGTGAACACCAACTACGCCCAGAAGTTCAGGGCAGAGCCACCCTGACCGTGGACACCAGCATCAG
CACCGCCTACATGGAAGTGAAGCGGCTGAGAAGCGACGACACCGCCGTGTACTACTGCACCCGGTCCCACTACGGCC
TGGATTGGAATTCGACGTGTGGGGCAAGGGCACCAACCGTGACAGTGTCTAGCAGCCAGGTGCAGCTGGTGAATCT
GGCGGCGGAGTGGTGCAGCCTGGCAGAAGCCTGAGACTGAGCTGTGCCGCCAGCGGCTTCACCTTCACCAAGGCCT
GGATGCACTGGGTGCGCCAGGCCCTTGAAAGCAGCTGGAATGGGTGGCCAGATCAAGGACAAGAGCAACAGCTA
CGCCACCTACTACGCCGACAGCGTGAAGGGCCGGTTCACCATCAGCCGGGACGACAGCAAGAACACCCTGTACCTG
CAGATGAACAGCCTGCGGGCCGAGGACACCGCCGTGTACTACTGTGCGGGCGTGTACTATGCCCTGAGCCCCCTTCGA
TTACTGGGGCCAGGGAACCCTCGTGACCGTGTCTAGTCGGACCGCCAGCACAAAGGGCCCATCGGTGTTCCCTCTGG
CCCCTTGCAAGCAGCAGAAGCACCAGCGAATCTACAGCCGCCCTGGGCTGCCTCGTGAAGGACTACTTTCCCGAGCCCGTG
ACCGTGTCTGGAAGTCTGGCGCTCTGACAAGCGGCGTGACACCTTTCCAGCCGTGCTCCAGAGCAGCGGCCTGTA
CTCTCTGAGCAGCGTCGTGACAGTGCCAGCAGCAGCCTGGGCACCAAGACCTACACCTGTAACGTGGACCACAAGC
CCAGCAACACCAAGGTGGACAAGCGGGTGGAAATCTAAGTACGGCCCTCCCTGCCCTCCTTGCCCAGCCCCCTGAAGCT
GCCGGCGGACCCTCCGTGTTCTGTTCCTGTTCCCCCAGGACACCCCTGATGATCAGCCGGACCCCGAAGTGAC
CTGCGTGGTGGTGGATGTGTCCCAGGAAGATCCCGAGGTGCAGTTCAATTGGTACGTGGACGGCGTGGAAGTGCACA
ACGCCAAGACCAAGCCCAGAGAGGAACAGTTCAACAGCACCTACCGGGTGGTGTCCGTGCTGACCGTGCTGCACCA
GGACTGGCTGAACGGCAAAGAGTACAAGTGCAAGGTGTCCAACAAGGGCCTGCCAGCTCCATCGAGAAAACCATC
AGCAAGGCCAAGGGCCAGCCCCGCGAGCCTCAAGTGTGTACCCTGCCCCCTAGCCAGGAAGAGATGACCAAGAACC
AGGTGTCCCTGAGCTGTGCCGTGAAAGGCTTCTACCCCAGCGACATTGCCGTGGAATGGGAGAGCAACGGCCAGCCC
GAGAACAACCTACAAGACCACCCCCCTGTGCTGGACAGCGACGGCTCATTCTTCCTGGTGTCCAAGCTGACCGTGGA
CAAGAGCCGGTGGCAGGAAGGCAACGTGTTTCAGCTGCTCCGTGATGCACGAGGCCCTGCACAACCACTACACCCAG
AAGTCCCTGTCTCTGTCCCTGGGC 3 524

AGAGCCCACCTGGTGCAGTCTGGCACCGCCATGAAGAAACCAGGCGCCTCTGTGCGGGTGTCTGTGTCAGACAAGCG
GCTACACCTTCACCGCCACATCCTGTTCTGGTTCGGGCAGGCCCTGGCAGAGGACTGGAATGGGTGGGATGGATC
AAGCCCCAGTATGGCGCCGTGAACCTCGGCGGAGGCTTCCGGGATAGAGTGACCCTGACCCGGGACGTGTACCGCG
AGATCGCCTACATGGACATCCGGGGCCTGAAGCCCGATGACACCGCCGTGTACTACTGCGCCAGAGACAGAAGCTAC
GGCGACAGCAGCTGGGCTCTGGATGCTTGGGGCCAGGGCACAAACCGTGGTGGTGTCTGCCGCCTCTACAAAGGGCCC
ATCGGTGTTCCCTCTGGCCCCCTGCAGCAGAAGCACCAGCGAATCTACAGCCGCCNTGGGCTGCCTCGTGAAGGACT
ACTTTCCCGAGCCCGTGACCGTGTCTGGAAGTCTGGCGCTCTGACAAGCGGCGTGACACCTTTCCAGCCGTGCTC
CAGAGCAGCGGCTGTACTCTCTGAGCAGCGTCTGTGACAGTGCCAGCAGCAGCCTGGGCACCAAGACCTACACCTG
TAACGTGGACCACAAGCCCAGCAACACCAAGGTGGACAAGCGGGTGGAAATCTAAGTACGGCCCTCCCTGCCCTCCTT
GCCAGCCCCCTGAAGCTGCCGGCGGACCCTCCGTGTTCCCTGTTCCCCCAGGACACCCCTGATGATCAGC
CGGACCCCGAAGTGACCTGCGTGGTGGTGGATGTGTCCCAGGAAGATCCCGAGGTGCAGTTCAATTGGTACGTGGA
CGGCGTGGAAAGTGCACAACGCCAAGACCAAGCCCAGAGAGGAACAGTTCAACAGCACCTACCGGGTGGTGTCCGTG
CTGACCGTGCTGCACCAGGACTGGCTGAACGGCAAAGAGTACAAGTGCAAGGTGTCCAACAAGGGCCTGCCAGCT
CCATCGAGAAAACCATCAGCAAGGCCAAGGGCCAGCCCCGCGAGCCTCAAGTGTATACCCTGCCCCCTTGCCAGGA
AGAGATGACCAAGAACCAGGTGTCCCTGTGGTGTCTCGTGAAAGGCTTCTACCCCAGCGACATTGCCGTGGAATGGG
AGAGCAACGGCCAGCCCGAGAACAACTACAAGACCACCCCCCTGTGCTGGACAGCGACGGCTCATTCTTCCTGTAC
TCCAAGCTGACCGTGGAACAAGAGCCGGTGGCAGGAAGGCAACGTGTTTCAGCTGCTCCGTGATGCACGAGGCCCTGC
ACAACCACTACACCCAGAAGTCCCTGTCTCTGTCCCTGGGC 4 525

TACATCCACGTGACCCAGAGCCCCAGCAGCCTGTCCGTGTCCATCGGCGACAGAGTGACCATCAACTGCCAGACCTC
TCAGGGCGTGGGCAGCGACCTGCACTGGTATCAGCACAAGCCTGGCAGAGCCCCCAAGCTGCTGATCCACCACACA
AGCAGCGTGGAAGATGGCGTGCCAGCAGATTTCCGGCAGCGGCTTCCACACCAGCTTCAACCTGACCATCAGCGA
TCTGCAGGCCGACGACATTGCCACCTACTATTGTCAGGTGCTGCAGTTCTTCGGCAGAGGCAGCAGACTGCACATCA
AGCGTACGGTGGCGCTCCAGCGTGTTTCATCTTCCCACCTAGCGACGAGCAGCTGAAGTCCGGCACAGCCTCTGTC

GTGTGCTGTCTGAACAACTTCTTCTACCCCGAGGCCAAAGTGCAGTGGAAAGGTGGACAACGCCCTGCAGAGCGGCA
ACAGCCAGGAAAGCGTGACCGAGCAGGACAGCAAGGACTCCACCTACAGCCTGAGCAGCACCCTGACACTGAGCAA
GGCCGACTACGAGAAGCACAAGGTGTACGCCTGCGAAGTGACCCACCAGGGCCTGTCTAGCCCCGTGACCAAGAGC
TTCAACCGGGGCGAGTGT Trispecific 1 526
GACATCGTGATGACCCAGACCCCCCTGAGCCTGAGCGTGACACCTGGACAGCCTGCCAGCATCAGCTGCAAGAGCA
15 N6/
GCCAGAGCCTGGTGCACAACAACGCCAACACCTACCTGAGCTGGTATCTGCAGAAGCCCGGCCAGAGCCCCCAGTC
CD28sup ×
CCTGATCTACAAGGTGTCCAACAGATTACAGCGGCGTGCCCGACAGATTCTCCGGCAGCGGCTCTGGCACCGACTTCA
CD3mid_QQ
CCCTGAAGATCAGCCGGGTGGAAGCCGAGGACGTGGGCGTGTACTATTGTGGCCAGGGCACCCAGTACCCCTTCACC
IgG4
TTTGGCAGCGGCACCAAGGTGGAATCAAGGGCCAGCCCAAGGCCGCCCCCGACATCCAGATGACCCAGAGCCCCA
FALA/409K
GCAGCCTGTCTGCCAGCGTGGGCGACAGAGTGACCATCACCTGTCAGGCCAGCCAGAACATCTACGTGTGGCTGAAC
TGGTATCAGCAGAAGCCCGGCAAGGCCCCCAAGCTGCTGATCTACAAGGCCAGCAACCTGCACACCGGCGTGCCCA
GCAGATTTTCTGGCAGCGGCTCCGGCACCGACTTCACCCTGACAATCAGCTCCCTGCAGCCCGAGGACATTGCCACC
TACTACTGCCAGCAGGGCCAGACCTACCCCTACACCTTTGGCCAGGGCACCAAGCTGGAATCAAGACCAAGGGCC
CCAGCCGTACGGTGGCCGCTCCAGCGTGTTCATCTTCCCACCTAGCGACGAGCAGCTGAAGTCCGGCACAGCCTCT
GTCGTGTGCCTGCTGAACAACCTTCTACCCCCGCGAGGGCCAAAGTGCAGTGGAAAGGTGGACAACGCCCTGCAGAGCG
GCAACAGCCAGGAAAGCGTGACCGAGCAGGACAGCAAGGACTCCACCTACAGCCTGAGCAGCACCCTGACACTGAG
CAAGGCCGACTACGAGAAGCACAAGGTGTACGCCTGCGAAGTGACCCACCAGGGCCTGTCTAGCCCCGTGACCAAG
AGCTTCAACCGGGGCGAGTGT 2 527
CAGGTGCAGCTGGTGCAGTCTGGCGCCGAGGTCTGTGAAACCTGGCGCCTCTGTGAAGGTGTCCTGCAAGGCCAGCGG
CTACACCTTTACCAGCTACTACATCCACTGGGTGCGCCAGGCCCTTGACAGGGACTGGAATGGATCGGCAGCATCT
ACCCCGGCAACGTGAACACCAACTACGCCCAGAAGTTCAGGGCAGAGCCACCCTGACCGTGGACACCAGCATCAG
CACCGCCTACATGGAAGTGTGAGCCGGCTGAGAAGCGACGACACCGCCGTGTACTACTGCACCCGGTCCCACTACGGCC
TGGATTGGAACCTTCGACGTGTGGGGCAAGGGCACCAACCGTGACAGTGTCTAGCAGCCAGGTGCAGCTGGTGGAAATCT
GGCGGCGGAGTGGTGCAGCCTGGCAGAAGCCTGAGACTGAGCTGTGCCGCCAGCGGCTTCACCTTCACCAAGGCCT
GGATGCACTGGGTGCGCCAGGCCCTTGAAAGCAGCTGGAATGGGTGGCCAGATCAAGGACAAGAGCAACAGCTA
CGCCACCTACTACGCCGACAGCGTGAAGGGCCGGTTACCATCAGCCGGGACGACAGCAAGAACACCCTGTACCTG
CAGATGAACAGCCTGCGGGCCGAGGACACCGCCGTGTACTACTGTGCGGGCGTGTACTATGCCCTGAGCCCCCTTCA
TTACTGGGGCCAGGGAACCCTCGTGACCGTGTCTAGTTCGGACCGCCAGCACAAAGGGGCCATCGGTGTTCCCTCTGG
CCCCTTGACGAGAAGCACCAGCGAATCTACAGCCGCCCTGGGCTGCCTCGTGAAGGACTACTTTCCCGAGCCCGTG
ACCGTGTCTTGGAACCTCTGGCGCTCTGACAAGCGGCGTGACACCTTTCCAGCCGTGCTCCAGAGCAGCGGCCTGTA
CTCTCTGAGCAGCGTCGTGACAGTGCCAGCAGCAGCCTGGGCACCAAGACCTACACCTGTAACTGGAACCAAGC
CCAGCAACACCAAGGTGGACAAGCGGGTGGAAATCTAAGTACGGCCCTCCCTGCCCTCCTTGCCAGCCCTGAAGCT
GCCGGCGGACCCTCCGTGTTCTGTTCCCCCCAAAGCCCAAGGACACCCTGATGATCAGCCGGACCCCGAAGTGAC
CTGCGTGGTGGTGGATGTGTCCCAGGAAGATCCCGAGGTGCAGTTCAATTGGTACGTGGACGGCGTGGAAGTGCACA
ACGCCAAGACCAAGCCCAGAGAGGAACAGTTCAACAGCACCTACCGGGTGGTGTCCGTGCTGACCGTGCTGCACCA
GACTGGCTGAACGGCAAAGAGTACAAGTGCAAGGTGTCCAACAAGGGCCTGCCAGCTCCATCGAGAAAACCATC
AGCAAGGCCAAGGGCCAGCCCCGCGAGCCTCAAGTGTGTACCCTGCCCCCTAGCCAGGAAGAGATGACCAAGAACC
AGGTGTCCCTGAGCTGTGCCGTGAAAGGCTTCTACCCCAGCGACATTGCCGTGGAATGGGAGAGCAACGGCCAGCCC
GAGAACAATAACAAGACCACCCCCCTGTGCTGGACAGCGACGGCTCATTCTTCCTGGTGTCCAAGCTGACCGTGGA
CAAGAGCCGGTGGCAGGAAGGCAACGTGTTTCAGCTGCTCCGTGATGCACGAGGCCCTGCACAACCACTACACCCAG
AAGTCCCTGTCTCTGTCCCTGGGC 3 528
AGAGCCCACCTGGTGCAGTCTGGCACCGCCATGAAGAAACCAGGCGCCTCTGTGCGGGTGTCTCTGTCAGACAAGCG
GCTACACCTTCACCGCCACATCCTGTTCTGGTTCCGGCAGGCCCTGGCAGAGGACTGGAATGGGTGGGATGGATC
AAGCCCCAGTATGGCGCCGTGAACTTCGGCGGAGGCTTCCGGGATAGAGTGACCCTGACCCGGGACGTGTACCGCG
AGATCGCCTACATGGACATCCGGGGCCTGAAGCCCGATGACACCGCCGTGTACTACTGCGCCAGAGACAGAAGCTAC
GGCGACAGCAGCTGGGCTCTGGATGCTTGGGGCCAGGGCACAACCGTGGTGGTGTCTGCCGCCTCTACAAAGGGCCC
ATCGGTGTTCCCTCTGGCCCCCTTGACGAGAAGCACCAGCGAATCTACAGCCGCCNTGGGCTGCCTCGTGAAGGACT
ACTTTCCCGAGCCCGTGACCGTGTCTGGAACCTCTGGCGCTCTGACAAGCGGCGTGACACCTTTCCAGCCGTGCTC
CAGAGCAGCGGCCTGTACTCTCTGAGCAGCGTCGTGACAGTGCCAGCAGCAGCCTGGGCACCAAGACCTACACCTG
TAACGTGGACCAACAAGCCCAGCAACACCAAGGTGGACAAGCGGGTGGAAATCTAAGTACGGCCCTCCCTGCCCTCCTT
GCCAGCCCTGAAGCTGCCGGCGGACCCTCCGTGTTCTGTTCCCCCCAAAGCCCAAGGACACCCTGATGATCAGC
CGGACCCCGAAGTGACCTGCGTGGTGGTGGATGTGTCCCAGGAAGATCCCGAGGTGCAGTTCAATTGGTACGTGGA
CGGCGTGGAAAGTGCACAACGCCAAGACCAAGCCCAGAGAGGAACAGTTCAACAGCACCTACCGGGTGGTGTCCGTG
CTGACCGTGTGTCACCAGGACTGGCTGAACGGCAAAGAGTACAAGTGCAAGGTGTCCAACAAGGGCCTGCCAGCT
CCATCGAGAAAACCATCAGCAAGGCCAAGGGCCAGCCCCGCGAGCCTCAAGTGTATACCCTGCCCCCTTGCCAGGA
AGAGATGACCAAGAACCAGGTGTCCCTGTGGTGTCTCGTGAAAGGCTTCTACCCCAGCGACATTGCCGTGGAATGGG
AGAGCAACGGCCAGCCCGAGAACAATAACAAGACCACCCCCCTGTGCTGGACAGCGACGGCTCATTCTTCCTGTAC
TCCAAGCTGACCGTGGACAAGAGCCGGTGGCAGGAAGGCAACGTGTTTCAGCTGCTCCGTGATGCACGAGGCCCTGC

ACAACACTACACCCAGAAGTCCCTGTCTCTGTCCTGGGC 4 529

TACATCCACGTGACCCAGAGCCCCAGCAGCCTGTCCGTGTCCATCGGCGACAGAGTGACCATCAACTGCCAGACCTC
TCAGGGCGTGGGCAGCGACCTGCACTGGTATCAGCACAAGCCTGGCAGAGCCCCCAAGCTGCTGATCCACCACACA
AGCAGCGTGGAAGATGGCGTGCCAGCAGATTTTCCGGCAGCGGCTTCCACACCAGCTTCAACCTGACCATCAGCGA
TCTGCAGGCCGACGACATTGCCACCTACTATTGTCAGGTGCTGCAGTTCTTCCGGCAGAGGCAGCAGACTGCACATCA
AGCGTACGGTGGCCGCTCCCAGCGTGTTTCATCTTCCCACCTAGCGACGAGCAGCTGAAGTCCGGCACAGCCTCTGTC
GTGTGCCTGCTGAACAACCTTCTACCCCCGCGAGGCCAAAGTGCAGTGGAAGGTGGACAACGCCCTGCAGAGCGGCA
ACAGCCAGGAAAGCGTGACCGAGCAGGACAGCAAGGACTCCACCTACAGCCTGAGCAGCACCCCTGACACTGAGCAA
GGCCGACTACGAGAAGCACAAGGTGTACGCCTGCGAAGTGACCCACCAGGGCCTGTCTAGCCCCGTGACCAAGAGC
TTCAACCGGGGCGAGTGT Trispecific 1 530

GACATCGTGATGACCCAGACCCCCCTGAGCCTGAGCGTGACACCTGGACAGCCTGCCAGCATCAGCTGCAAGAGCA
16 N6/

GCCAGAGCCTGGTGCACCAGAACGCCCAGACCTACCTGAGCTGGTATCTGCAGAAGCCCCGGCCAGAGCCCCCAGTC
CD28sup ×

CCTGATCTACAAGGTGTCCAACAGATTCAGCGGCGTGCCCGACAGATTCTCCGGCAGCGGCTCTGGCACCGACTTCA
CD3mid_QQ

CCCTGAAGATCAGCCGGGTGGAAGCCGAGGACGTGGGCGTGTAATTGTGGCCAGGGCACCCAGTACCCCTTCACC
IgG4

TTTGGCAGCGGCACCAAGGTGGAATCAAGGACAAAACCCATACCGACATCCAGATGACCCAGAGCCCCAGCAGCC
FALA/409K_

TGTCTGCCAGCGTGGGCGACAGAGTGACCATCACCTGTCAGGCCAGCCAGAACATCTACGTGTGGCTGAACTGGTAT
DKTHT linker

CAGCAGAAGCCCCGCAAGGCCCCCAAGCTGCTGATCTACAAGGCCAGCAACCTGCACACCGGCGTGCCCAGCAGATT
TTCTGGCAGCGGCTCCGGCACCGACTTCACCTGACAATCAGCTCCCTGCAGCCCCGAGGACATTGCCACCTACTACT
GCCAGCAGGGCCAGACCTACCCCTACACCTTTGGCCAGGGCACCAAGCTGGAATCAAGGATAAGACCCACACCCG
TACGGTGGCCGCTCCCAGCGTGTTTCATCTTCCCACCTAGCGACGAGCAGCTGAAGTCCGGCACAGCCTCTGTCTGT
GCCTGCTGAACAACCTTCTACCCCCGCGAGGCCAAAGTGCAGTGGAAGGTGGACAACGCCCTGCAGAGCGGCAACAG
CCAGGAAAGCGTGACCGAGCAGGACAGCAAGGACTCCACCTACAGCCTGAGCAGCACCCCTGACACTGAGCAAGGCC
GACTACGAGAAGCACAAGGTGTACGCCTGCGAAGTGACCCACCAGGGCCTGTCTAGCCCCGTGACCAAGAGCTTCA
ACCGGGGCGAGTGT 2 531

CAGGTGCAGCTGGTGCAGTCTGGCGCCGAGGTCGTGAAACCTGGCGCCTCTGTGAAGGTGTCCTGCAAGGCCAGCGG
CTACACCTTTACCAGCTACTACATCCACTGGGTGCGCCAGGCCCTTGACAGGGACTGGAATGGATCGGCAGCATCT
ACCCCGGCAACGTGAACACCAACTACGCCCAGAAGTTCCAGGGCAGAGCCACCCTGACCGTGGACACCAGCATCAG
CACCGCCTACATGGAAGTGAAGCCGGCTGAGAAGCGACGACACCGCCGTGTACTACTGCACCCGGTCCCCTACGGCC
TGGATTGGAACCTCGACGTGTGGGGCAAGGGCACCAACCGTGACAGTGTCTAGCGACAAAACCCATACCCAGGTGCA
GCTGGTGGAACTCTGGCGGCGGAGTGGTGCAGCCTGGCAGAAGCCTGAGACTGAGCTGTGCCGCCAGCGGCTTCACT
TCACCAAGGCCTGGATGCACTGGGTGCGCCAGGCCCTTGAAAGCAGCTGGAATGGGTGGCCAGATCAAGGACAA
GAGCAACAGCTACGCCACCTACTACGCCGACAGCGTGAAGGGCCGGTTTACCATCAGCCGGGACGACAGCAAGAAC
ACCCTGTACCTGCAGATGAACAGCCTGCGGGCCGAGGACACCGCCGTGTACTACTGTCGGGGCGTGTACTATGCCCT
GAGCCCCTTCGATTACTGGGGCCAGGGAACCCCTCGTGACCGTGTCTAGTGATAAGACCCACACCGCCAGCACAAAGG
GCCATCGGTGTTCCCTCTGGCCCCTTGACAGCAGAAGCACCAAGCGAATCTACAGCCGCCCTGGGCTGCCTCGTGAAG
GACTACTTTCCCGAGCCCCGTGACCGTGTCTTGGAACCTCTGGCGCTCTGACAAGCGGCGTGACACCTTTCCAGCCGT
GCTCCAGAGCAGCGGCCTGTACTCTCTGAGCAGCGTCGTGACAGTGCCCAGCAGCAGCCTGGGCACCAAGACCTACA
CCTGTAACGTGGACCACAAGCCCAGCAACACCAAGGTGGACAAGCGGGTGAATCTAAGTACGGCCCTCCCTGCCCT
CCTTGCCCAGCCCCCTGAAGCTGCCGGCGGACCCTCCGTGTTCTGTTCCCCCCAAAGCCCAAGGACACCCTGATGAT
CAGCCGGACCCCCGAAGTGACCTGCGTGGTGGTGGATGTGTCCCAGGAAGATCCCAGAGTGCAGTTCAATTGGTACG
TGGACGGCGTGGAAGTGACACAACGCCAAGACCAAGCCCAGAGAGGAACAGTTCAACAGCACCTACCGGGTGGTGTCC
GTGCTGACCGTGTCTGCACCAGGACTGGCTGAACGGCAAAGAGTACAAGTGCAAGGTGTCCAACAAGGGCCTGCCCA
GCTCCATCGAGAAAACCATCAGCAAGGCCAAGGGCCAGCCCCGCGAGCCTCAAGTGTGTACCCTGCCCCCTAGCCA
GGAAGAGATGACCAAGAACCAGGTGTCCCTGAGCTGTGCCGTGAAAGGCTTCTACCCCAGCGACATTGCCGTGGAA
TGGGAGAGCAACGGCCAGCCCAGACAACACTACAAGACCACCCCCCTGTGCTGGACAGCGACGGCTCATTCTTCCT
GGTGTCCAAGCTGACCGTGGACAAGAGCCGGTGGCAGGAAGGCAACGTGTTACAGCTGCTCCGTGATGCACGAGGCC
CTGCACAACCACTACACCCAGAAGTCCCTGTCTCTGTCCCTGGGC 3 532

AGAGCCCACCTGGTGCAGTCTGGCACCGCCATGAAGAAACCAGGCGCCTCTGTGCGGGTGTCTGTGACACAAGCG
GCTACACCTTCACCGCCACATCCTGTTCTGGTTCCGGCAGGCCCTGGCAGAGGACTGGAATGGGTGGGATGGATC
AAGCCCCAGTATGGCGCCGTGAACCTCGGCGGAGGCTTCCGGGATAGAGTGACCCTGACCCGGGACGTGTACCGCG
AGATCGCCTACATGGACATCCGGGGCCTGAAGCCCGATGACACCGCCGTGTACTACTGCGCCAGAGACAGAAGCTAC
GGCGACAGCAGCTGGGCTCTGGATGCTTGGGGCCAGGGCACAACCGTGGTGGTGTCTGCCGCCTCTACAAAGGGCCC
ATCGGTGTTCCCTCTGGCCCCTTGACAGCAGAAGCACCAAGCGAATCTACAGCCGCCNTGGGCTGCCTCGTGAAGGACT
ACTTTCCCGAGCCCGTGACCGTGTCTTGGAACTCTGGCGCTCTGACAAGCGGCGTGACACCTTTCCAGCCGTGCTC
CAGAGCAGCGGCCTGTACTCTCTGAGCAGCGTCGTGACAGTGCCCAGCAGCAGCCTGGGCACCAAGACCTACACCTG
TAACGTGGACCACAAGCCCAGCAACACCAAGGTGGACAAGCGGGTGAATCTAAGTACGGCCCTCCCTGCCCTCCTT
GCCAGCCCCCTGAAGCTGCCGGCGGACCCTCCGTGTTCCCTGTTCCCCCAAAGCCCAAGGACACCCTGATGATCAGC

CGGACCCCGAAGTGACCTGCGTGGTGGATGTGTCCCAAGGATCCCGAGGTGCAGTTCAATTGGTACGTGGG
CGGCGTGGAAGTGCACAACGCCAAGACCAAGCCCAGAGAGGAACAGTTCAACAGCACCTACCGGGTGGTGTCCGTG
CTGACCGTGCTGCACCAGGACTGGCTGAACGGCAAAGAGTACAAGTGCAAGGTGTCCAACAAGGGCCTGCCAGCT
CCATCGAGAAAACCATCAGCAAGGCCAAGGGCCAGCCCCGCGAGCCTCAAGTGTATACCCTGCCCCCTTGCCAGGA
AGAGATGACCAAGAACCAGGTGTCCCTGTGGTGTCTCGTGAAAGGCTTCTACCCAGCGACATTGCCGTGGAATGGG
AGAGCAACGGCCAGCCCGAGAACAATAACAAGACCACCCCCCTGTGCTGGACAGCGACGGCTCATTCTTCCTGTAC
TCCAAGCTGACCGTGAGACAAGAGCCGGTGGCAGGAAGGCAACGTGTTACAGCTGCTCCGTGATGCACGAGGCCCTGC
ACAACCACTACACCCAGAAGTCCCTGTCTCTGTCCCTGGGC 4 533
TACATCCACGTGACCCAGAGCCCCAGCAGCCTGTCCGTGTCCATCGGCGACAGAGTGACCATCAACTGCCAGACCTC
TCAGGGCGTGGGCAGCGACCTGCACTGGTATCAGCACAAGCCTGGCAGAGCCCCCAAGCTGCTGATCCACCACACA
AGCAGCGTGGAAGATGGCGTGCCAGCAGATTTTCCGGCAGCGGCTTCCACACCAGCTTCAACCTGACCATCAGCGA
TCTGCAGGCCGACGACATTGCCACCTACTATTGTCAGGTGCTGCAGTTCTTCCGGCAGAGGCAGCAGACTGCACATCA
AGCGTACGGTGGCCGCTCCCAGCGTGTTCATCTTCCCACCTAGCGACGAGCAGCTGAAGTCCGGCACAGCCTCTGTC
GTGTGCCTGCTGAACAACCTTCTACCCCCGCGAGGGCCAAAGTGCAGTGGAAGGTGGACAACGCCCTGCAGAGCGGCA
ACAGCCAGGAAAGCGTGACCGAGCAGGACAGCAAGGACTCCACCTACAGCCTGAGCAGCACCTGACACTGAGCAA
GGCCGACTACGAGAAGCACAAGGTGTACGCCTGCGAAGTGACCCACCAGGGCCTGTCTAGCCCCGTGACCAAGAGC
TTCAACCGGGGCGAGTGT Trispecific 1 534
GACATCGTGATGACCCAGACCCCCCTGAGCCTGAGCGTGACACCTGGACAGCCTGCCAGCATCAGCTGCAAGAGCA
17 N6/
GCCAGAGCCTGGTGCACAACAACGCCAACACCTACCTGAGCTGGTATCTGCAGAAGCCCGGCCAGAGCCCCCAGTC
CD28sup ×
CCTGATCTACAAGGTGTCCAACAGATTCAGCGGCGTGCCCGACAGATTCTCCGGCAGCGGCTCTGGCACCGACTTCA
CD3mid
CCCTGAAGATCAGCCGGGTGGAAGCCGAGGACGTGGGCGTGTACTIONTGTGGCCAGGGCACCCAGTACCCCTTCACC
IgG4
TTTGGCAGCGGCACCAAGGTGGAAATCAAGGACAAAACCCATACCGACATCCAGATGACCCAGAGCCCCAGCAGCC
FALA/409K_
TGTCTGCCAGCGTGGGCGACAGAGTGACCATCACCTGTCAGGCCAGCCAGAACATCTACGTGTGGCTGAACTGGTAT
DKTHT linker
CAGCAGAAGCCCGGCAAGGCCCCCAAGCTGCTGATCTACAAGGCCAGCAACCTGCACACCGGCGTGCCCAGCAGAT
TTTCTGGCAGCGGCTCCGGCACCGACTTCACCCTGACAATCAGCTCCCTGCAGCCCGAGGACATTGCCACCTACTAC
TGCCAGCAGGGCCAGACCTACCCCTACACCTTTGGCCAGGGCACCAAGCTGGAAATCAAGGATAAGACCCACACCAG
TCAGCCCAAGGCTGCCCCCTCGGTCACTCTGTTCCCGCCCTCGAGTGAGGAGCTTCAAGCCAACAAGGCCACACTGG
TGTGTCTCATAAGTGACTTCTACCCGGGAGCCGTGACAGTGGCCTGGAAGGCAGATAGCAGCCCCGTCAAGGCGGG
AGTGGAGACCACCACACCCTCCAAACAAGCAACAACAAGTACGCGGCCAGCAGCTACCTGAGCCTGACGCCTGAG
CAGTGGAAAGTCCCACAGAAGCTACAGCTGCCAGGTACGCATGAAGGGAGCACCGTGGAGAAGACAGTGGCCCCTA
CAGAATGT 2 535
CAGGTGCAGCTGGTGCAGTCTGGCGCCGAGGTCTGTGAAACCTGGCGCCTCTGTGAAGGTGTCCTGCAAGGCCAGCGG
CTACACCTTTACCAGCTACTACATCCACTGGGTGCGCCAGGCCCCCTGGACAGGGACTGGAATGGATCGGCAGCATCT
ACCCCGGCAACGTGAACACCAACTACGCCCAGAAGTTCAGGGCAGAGCCACCCTGACCGTGGACACCAGCATCAG
CACCGCCTACATGGAAGTGCAGCGGTGAGAAAGCGACGACACCGCCGTGTACTACTGCACCCGGTCCCCTACGGCC
TGGATTGGAAGTTCGACGTGTGGGGCAAGGGCACCAACCGTGACAGTGTCTAGCGACAAAACCCATACCCAGGTGCA
GCTGGTGGAAATCTGGCGGCGGAGTGGTGCAGCCTGGCAGAAGCCTGAGACTGAGCTGTGCCGCCAGCGGCTTCACCT
TCACCAAGGCCTGGATGCACTGGGTGCGCCAGGCCCCCTGGAAAGCAGCTGGAATGGGTGGCCAGATCAAGGACAA
GAGCAACAGCTACGCCACCTACTACGCCGACAGCGTGAAGGGCCGTTTACCATCAGCCGGGACGACAGCAAGAAC
ACCCTGTACCTGCAGATGAACAGCCTGCGGGCCGAGGACACCGCCGTGTACTACTGTGCGGGCGTGTACTATGCCCT
GAGCCCCCTTCGATTACTGGGGCCAGGGAACCCTCGTGACCGTGTCTAGTGATAAGACCCACACCGCCAGCACAAAGG
GCCATCGGTGTTCCCTCTGGCCCCCTTGACGACAGAAGCACCAGCGAATCTACAGCCGCCCTGGGCTGCCTCGTGAAG
GACTACTTTCCCGAGCCCGTGACCGTGTCTGGAACCTCTGGCGCTCTGACAAGCGGCGTGCACACCTTTCCAGCCGT
GCTCCAGAGCAGCGGCCTGTACTCTCTGAGCAGCGTCTGTGACAGTGCCCAGCAGCAGCCTGGGCACCAAGACCTACA
CCTGTAACGTGGACCACAAGCCCAGCAACACCAAGGTGGACAAGCGGGTGGAAATCTAAGTACGGCCCTCCCTGCCCT
CCTTGCCCAGCCCCCTGAAGCTGCCGGCGGACCCTCCGTGTTCCCTGTTCCCCCAAGGCCAAGGACACCCTGATGAT
CAGCCGGACCCCCGAAGTGACCTGCGTGGTGGTGGATGTGTCCCAGGAAGATCCCAGAGTGCAGTTCAATTGGTACG
TGGACGGCGTGGAAGTGCACAACGCCAAGACCAAGCCCAGAGAGGAACAGTTCAACAGCACCTACCGGGTGGTGTCC
GTGCTGACCGTGCTGCACCAGGACTGGCTGAACGGCAAAGAGTACAAGTGCAAGGTGTCCAACAAGGGCCTGCCCA
GCTCCATCGAGAAAACCATCAGCAAGGCCAAGGGCCAGCCCCGCGAGCCTCAAGTGTGTACCCTGCCCCCTAGCCA
GGAAGAGATGACCAAGAACCAGGTGTCCCTGAGCTGTGCCGTGAAAGGCTTCTACCCAGCGACATTGCCGTGGAA
TGGGAGAGCAACGGCCAGCCCGAGAACAATAACAAGACCACCCCCCTGTGCTGGACAGCGACGGCTCATTCTTCCT
GGTGTCCAAGCTGACCGTGGACAAGAGCCGGTGGCAGGAAGGCAACGTGTTACAGCTGCTCCGTGATGCACGAGGCC
CTGCACAACCACTACACCCAGAAGTCCCTGTCTCTGTCCCTGGGC 3 536
AGAGCCCACCTGGTGCAGTCTGGCACCGCCATGAAGAAACCAGGCGCCTCTGTGCGGGTGTCTGTGACACAAGCG
GCTACACCTTCACCGCCCATCCTGTTCTGGTTCGGGCAGGCCCCCTGGCAGAGGACTGGAATGGGTGGGATGGATC
AAGCCCCAGTATGGCGCCGTGAACTTCGGCGGAGGCTTCCGGGATAGAGTGACCCTGACCCGGGACGTGTACCGCG

CGCTGCCTACATGGACATCCGGGGCCTGAAGCCCCGATGACACCGCCGCTGTACTACTGCGCCAGAGACAGAAGCTAC
GGCGACAGCAGCTGGGCTCTGGATGCTTGGGGCCAGGGCACAACCGTGGTGGTGTCTGCCGCCTCTACAAAGGGCCCC
ATCGGTGTTCCCTCTGGCCCCCTTGACAGCAGAAGCACCAGCGAATCTACAGCCGCCNTGGGCTGCCTCGTGAAGGACT
ACTTTCCCGAGCCCGTGACCGTGTCTTGAAGTCTGGCGCTCTGACAAGCGGCGTGACACCTTTCCAGCCGTGCTC
CAGAGCAGCGGCCTGTACTCTCTGAGCAGCGTCGTGACAGTGGCCAGCAGCAGCCTGGGCACCAAGACCTACACCTG
TAACGTGGACCACAAGCCCAGCAACACCAAGGTGGACAAGCGGGTGAATCTAAGTACGGCCCTCCCTGCCCTCCTT
GCCCAGCCCCCTGAAGCTGCCGGCGGACCCTCCGTGTTCCCTGTTCCCCCAAGCCCCAAGGACACCCTGATGATCAGC
CGGACCCCCGAAGTGACCTGCGTGGTGGTGGATGTGTCCCAGGAAGATCCCGAGGTGCAGTTCAATTGGTACGTGGA
CGGCGTGGAAGTGCACAACGCCAAGACCAAGCCCAGAGAGGAACAGTTCAACAGCACCTACCGGGTGGTGTCCGTG
CTGACCGTGCTGCACCAGGACTGGCTGAACGGCAAAGAGTACAAGTGCAAGGTGTCCAACAAGGGCCTGCCAGCT
CCATCGAGAAAACCATCAGCAAGGCCAAGGGCCAGCCCCGCGAGCCTCAAGTGTATACCCTGCCCCCTTGCCAGGA
AGAGATGACCAAGAACCAGGTGTCCCTGTGGTGTCTCGTGAAAGGCTTCTACCCAGCGACATTGCCGTGGAATGGG
AGAGCAACGGCCAGCCCGAGAACAACTACAAGACCACCCCCCTGTGCTGGACAGCGACGGCTCATTCTTCTGTAC
TCCAAGCTGACCGTGGAACAAGAGCCGGTGGCAGGAAGGCAACGTGTTACAGCTGCTCCGTGATGCACGAGGCCCTGC
ACAACCACTACACCCAGAAGTCCCTGTCTCTGTCCCTGGGC 4 537

TACATCCACGTGACCCAGAGCCCCAGCAGCCTGTCCGTGTCCATCGGCGACAGAGTGACCATCAACTGCCAGACCTC
TCAGGGCGTGGGCAGCGACCTGCACTGGTATCAGCACAAGCCTGGCAGAGCCCCCAAGCTGCTGATCCACCACACA
AGCAGCGTGGAAGATGGCGTGCCAGCAGATTTCCGGCAGCGGCTTCCACACCAGCTTCAACCTGACCATCAGCGA
TCTGCAGGCCGACGACATTGCCACCTACTATTGTCAGGTGCTGCAGTTCTTCGGCAGAGGCAGCAGACTGCACATCA
AGCGTACGGTGGCCGCTCCCAGCGTGTTCATCTTCCCACCTAGCGACGAGCAGCTGAAGTCCGGCACAGCCTCTGTC
GTGTGCCTGCTGAACAACCTTCTACCCCCGCGAGGCCAAAGTGCAAGTGGAAAGGTGGACAACGCCCTGCAGAGCGGCA
ACAGCCAGGAAAGCGTGACCGAGCAGGACAGCAAGGACTCCACCTACAGCCTGAGCAGCACCCCTGACACTGAGCAA
GGCCGACTACGAGAAGCACAAGGTGTACGCCTGCGAAGTGACCCACCAGGGCCTGTCTAGCCCCGTGACCAAGAGC
TTCAACCGGGGCGAGTGT Trispecific 1 538

GACATCGTGATGACCCAGACCCCCCTGAGCCTGAGCGTGACACCTGGACAGCCTGCCAGCATCAGCTGCAAGAGCA
19 N6/

GCCAGAGCCTGGTGCACCAGAACGCCAGACCTACCTGAGCTGGTATCTGCAGAAGCCCGGCCAGAGCCCCCAGTC
CD28sup ×

CCTGATCTACAAGGTGTCCAACAGATTCAGCGGCGTGCCCGACAGATTCTCCGGCAGCGGCTCTGGCACCGACTTCA
CD3mid_QQ

CCCTGAAGATCAGCCGGGTGGAAGCCGAGGACGTGGGCGTGTACTATTGTGGCCAGGGCACCCAGTACCCCTTCACC
IgG1_NNAS_

TTTGGCAGCGGCACCAAGGTGGAATCAAGGACAAAACCCATACCGACATCCAGATGACCCAGAGCCCCAGCAGCC
DKTHT linker

TGTCTGCCAGCGTGGGCGACAGAGTGACCATCACCTGTCAGGCCAGCCAGAACATCTACGTGTGGCTGAACTGGTAT
CAGCAGAAGCCCGGCAAGGCCCCCAAGCTGCTGATCTACAAGGCCAGCAACCTGCACACCGGCGTGCCAGCAGATT
TTCTGGCAGCGGCTCCGGCACCGACTTCACCTGACAATCAGCTCCCTGCAGCCCGAGGACATTGCCACCTACTACT
GCCAGCAGGGCCAGACCTACCCCTACACCTTTGGCCAGGGCACCAAGCTGGAAATCAAGGATAAGACCCACACCCG
TACGGTGGCCGCTCCCAGCGTGTTCATCTTCCCACCTAGCGACGAGCAGCTGAAGTCCGGCACAGCCTCTGTCTGT
GCCTGCTGAACAACCTTCTACCCCCGCGAGGCCAAAGTGCAAGTGGAAAGGTGGACAACGCCCTGCAGAGCGGCAACAG
CCAGGAAAGCGTGACCGAGCAGGACAGCAAGGACTCCACCTACAGCCTGAGCAGCACCCCTGACACTGAGCAAGGCC
GACTACGAGAAGCACAAGGTGTACGCCTGCGAAGTGACCCACCAGGGCCTGTCTAGCCCCGTGACCAAGAGCTTCA
ACCGGGGCGAGTGT 2 539

CAGGTGCAGCTGGTGCAGTCTGGCGCCGAGGTCTGTGAAACCTGGCGCCTCTGTGAAGGTGTCCTGCAAGGCCAGCGG
CTACACCTTTACCAGCTACTACATCCACTGGGTGCGCCAGGCCCTTGACAGGGACTGGAATGGATCGGCAGCATCT
ACCCCGGCAACGTGAACACCAACTACGCCCAGAAGTTCAGGGCAGAGCCACCCTGACCGTGGACACCAGCATCAG
CACCGCCTACATGGAAGTGAAGCGGCTGAGAAGCGACGACACCGCCGTGTACTACTGCACCCGGTCCCCTACGGCC
TGGATTGGAAGTTCGACGTGTGGGGCAAGGGCACCAACCGTGACAGTGTCTAGCGACAAAACCCATAACCCAGGTGCA
GCTGGTGGAAATCTGGCGGCGGAGTGGTGCAGCCTGGCAGAAGCCTGAGACTGAGCTGTGCCGCCAGCGGCTTCACT
TCACCAAGGCCTGGATGCACTGGGTGCGCCAGGCCCTTGAAAGCAGCTGGAATGGGTGGGCCAGATCAAGGACAA
GAGCAACAGCTACGCCACCTACTACGCCGACAGCGTGAAGGGCCGTTTACCATCAGCCGGGACGACAGCAAGAAC
ACCCTGTACCTGCAGATGAACAGCCTGCGGGCCGAGGACACCGCCGTGTACTACTGTCGGGGCGTGTACTATGCCCT
GAGCCCCCTTCGATTACTGGGGCCAGGGAACCCCTCGTGACCGTGTCTAGTGATAAGACCCACACCGCCAGCACAAAGG
GCCCCAGCGTGTTCCTCTGGCCCCCTAGCAGCAAGAGCACATCTGGCGGAACAGCCGCCCTGGGCTGCCTCGTGAAG
GACTACTTTCCCGAGCCCGTGACCGTGTCTTGAATTCTGGCGCCCTGACCAGCGGCGTGACACACCTTTCCAGCTGT
GCTGCAGTCCAGCGGCTGTACAGCCTGAGCAGCGTCGTGACAGTGGCCAGCAGCTCTCTGGGCACCCAGACCTACA
TCTGCAACGTGAACCACAAGCCCAGCAACACCAAGGTGGACAAGAAGGTGGAACCCAAGAGCTGCGACAAGACCCA
ACCTGTCCCCCTTGTCTTGGCCCCGAAGTGTGAGGAGGCCCTTCCGTGTTCCCTGTTCCCCCAAGCCCCAAGGACAC
CCTGATGATCAGCCGGACCCCCGAAGTGACCTGCGTGGTGGTGGATGTGTCCCACGAGGACCCTGAAGTGAAGTTCA
ATTGGTACGTGGACGGCGTGGAAGTGCACAACGCCAAGACCAAGCCAAGAGAGGAACAGTACAACAATGCCTCCCG
GGTGGTGTCCGTGCTGACCGTGCTGCACCAGGACTGGCTGAACGGCAAAGAGTACAAGTGCAAGGTGTCCAACAAG
GCCCTGCCTGCCCCCATCGAGAAAACCATCAGCAAGGCCAAGGGCCAGCCCCGCGAACCCAGGTGTGCACACTGC
CCCCAAGCAGGGACGAGCTGACCAAGAACCAGGTGTCCCTGAGCTGTGCCGTGAAAGGCTTCTACCCCTCCGATATC

CCGCTTGGATGGGAGAGCAACCGCCAGCCGAGAAACAACCTACAAGACCACCCCTGCTGTGCTGGACAGCGACGGCT
CATTCTTCCTGGTGTCCAAGCTGACAGTGGACAAGTCCCGGTGGCAGCAGGGCAACGTGTTTCAGCTGCTCCGTGATG
CACGAGGCCCTGCACAACCACTACACCCAGAAGTCCCTGAGCCTGAGCCCCGGC 3 540
AGAGCCCACCTGGTGCAGTCTGGCACCGCCATGAAGAAACCAGGCGCCTCTGTGCGGGTGTCTGTGTCAGACAAGCG
GCTACACCTTCACCGCCCATCCTGTTCTGGTTCCGGCAGGCCCTGGCAGAGGACTGGAATGGGTGGGATGGATC
AAGCCCCAGTATGGCGCCGTGAACTTCGGCGGAGGCTTCCGGGATAGAGTGACCCTGACCCGGGACGTGTACCGCG
AGATCGCCTACATGGACATCCGGGGCCTGAAGCCCGATGACACCGCCGTGTACTACTGCGCCAGAGACAGAAGCTA
CGGCGACAGCAGCTGGGCTCTGGATGCTTGGGGCCAGGGCACAACCGTGGTGGTGTCTGCCGCCTCTACAAAGGGCC
CATCGGTCTTCCCCCTGGCACCTCTCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGCCTGGTCAAGGAC
TACTTCCCCGAACCGGTGACGGTGTCTGTGGAACCTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTCT
ACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCCTGCCCTCCAGCAGCTTGGGCACCCAGACCTACATCT
GCAACGTGAATCACAAGCCCAGCAACACCAAGGTGGACAAGAAAGTTGAGCCCAAATCTTGTGACAAAACCTCACAC
ATGCCACCGTGGCCAGCACCTGAACTCCTGGGGGGACCGTCAGTCTTCTCTTCCCCCAAACCCCAAGGACACCC
TCATGATCTCCCGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAAC
TGGTATGTTGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACAATGCCTCCCGTG
TGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGCC
CTCCCAGCCCCCATCGAGAAAACCATCTCCAAGGCCAAAGGGCAGCCCCGAGAACCACAGGTGTACACCCTGCCCC
CATGCCGGGATGAGCTGACCAAGAATCAAGTCAGCCTGTGGTGCCTGGTAAAAGGCTTCTATCCCAGCGACATCGCC
GTGGAGTGGGAGAGCAATGGGCAGCCGAGAAACAACCTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCT
TCTTCTCTACTCAAACTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCAT
GAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCGGGT 4 541
TACATCCACGTGACCCAGAGCCCCAGCAGCCTGTCCGTGTCCATCGGCGACAGAGTGACCATCAACTGCCAGACCTC
TCAGGGCGTGGGCAGCGACCTGCACTGGTATCAGCACAAGCCTGGCAGAGCCCCCAAGCTGCTGATCCACCACACA
AGCAGCGTGGAAGATGGCGTGGCCAGCAGATTTTCCGGCAGCGGCTTCCACACCAGCTTCAACCTGACCATCAGCGA
TCTGCAGGCCGACGACATTGCCACCTACTATTGTGAGGTGCTGCAGTTCTTCCGGCAGAGGCAGCAGACTGCACATCA
AGCGTACGGTGGCCGCTCCCAGCGTGTTCATCTTCCCACCTAGCGACGAGCAGCTGAAGTCCGGCACAGCCTCTGTC
GTGTGCCTGCTGAACAACCTTCTACCCCCGCGAGGCCAAAGTGCAAGTGGAAAGGTGGACAACGCCCTGCAGAGCGGCA
ACAGCCAGGAAAGCGTGACCGAGCAGGACAGCAAGGACTCCACCTACAGCCTGAGCAGCACCCCTGACACTGAGCAA
GGCCGACTACGAGAAGCACAAGGTGTACGCCTGCGAAGTGACCCACCAGGGCCTGTCTAGCCCCGTGACCAAGAGC
TTCAACCGGGGGCAGTGT Trispecific 1 542
GACATCGTGATGACCCAGACCCCCCTGAGCCTGAGCGTGACACCTGGACAGCCTGCCAGCATCAGCTGCAAGAGCA
21 N6/
GCCAGAGCCTGGTGCACGACAACGCCAGACCTACCTGAGCTGGTATCTGCAGAAGCCCGGCCAGAGCCCCCAGTC
CD28sup ×
CCTGATCTACAAGGTGTCCAACAGATTACAGCGGCGTGCCCGACAGATTCTCCGGCAGCGGCTCTGGCACCGACTTCA
CD3mid_
CCCTGAAGATCAGCCGGGTGGAAGCCGAGGACGTGGGCGTGTACTATTGTGGCCAGGGCACCCAGTACCCCTTCACC
DNAQ IgG4
TTTGGCAGCGGCACCAAGGTGGAAATCAAGGACAAAACCCATACCGACATCCAGATGACCCAGAGCCCCAGCAGCC
FALA/409K_
TGTCTGCCAGCGTGGGCGACAGAGTGACCATCACCTGTCAGGCCAGCCAGAACATCTACGTGTGGCTGAACTGGTAT
DKTHT linker
CAGCAGAAGCCCGGCAAGGCCCCCAAGCTGCTGATCTACAAGGCCAGCAACCTGCACACCGGCGTGCCAGCAGAT
TTTCTGGCAGCGGCTCCGGCACCGACTTCACCCTGACAATCAGCTCCCTGCAGCCCGAGGACATTGCCACCTACTAC
TGCCAGCAGGGCCAGACCTACCCCTACACCTTTGGCCAGGGCACCAAGCTGGAAATCAAGGATAAGACCCACACCAG
TCAGCCCAAGGCTGCCCCCTCGGTCACTCTGTTCCCGCCCTCGAGTGAGGAGCTTCAAGCCAACAAGGCCACACTGG
TGTGTCTCATAAGTGACTTCTACCCGGGAGCCGTGACAGTGGCCTGGAAGGCAGATAGCAGCCCCGTCAAGGCGGG
AGTGGAGACCACCACACCCTCCAAACAAAGCAACAACAAGTACGCGGCCAGCAGCTACCTGAGCCTGACGCCTGAG
CAGTGGAAAGTCCCACAGAAGCTACAGCTGCCAGGTCACGCATGAAGGGAGCACCGTGGAGAAGACAGTGGCCCCTA
CAGAATGT 2 543
CAGGTGCAGCTGGTGCAGTCTGGCGCCGAGGTTCGTGAAACCTGGCGCCTCTGTGAAGGTGTCCTGCAAGGCCAGCGG
CTACACCTTTACCAGCTACTACATCCACTGGGTGCGCCAGGCCCTGGACAGGGACTGGAATGGATCGGCAGCATCT
ACCCCGGCAACGTGAACACCAACTACGCCCAGAAGTTCCAGGGCAGAGCCACCCTGACCGTGGACACCAGCATCAG
CACCGCCTACATGGAAGTGAAGCCGGCTGAGAAGCGACGACACCGCCGTGTACTACTGCACCCGGTCCCACTACGGCC
TGGATTGGAACCTTCGACGTGTGGGGCAAGGGCACCAACCGTGACAGTGTCTAGCGACAAAACCCATACCCAGGTGCA
GCTGGTGGAAATCTGGCGGCGGAGTGGTGCAGCCTGGCAGAAGCCTGAGACTGAGCTGTGCCGCCAGCGGCTTCACCT
TCACCAAGGCCTGGATGCACTGGGTGCGCCAGGCCCTGGAAAGCAGCTGGAATGGGTGGCCAGATCAAGGACAA
GAGCAACAGCTACGCCACCTACTACGCCGACAGCGTGAAGGGCCGGTTACCATCAGCCGGGACGACAGCAAGAAC
ACCCTGTACCTGCAGATGAACAGCCTGCGGGCCGAGGACACCGCCGTGTACTACTGTGCGGGCGTGTACTATGCCCT
GAGCCCCTTCGATTACTGGGGCCAGGGAACCCCTCGTGACCCTGTCTAGTGATAAGACCCACACCGCCAGCACAAAGG
GCCATCGGTGTTCCCTCTGGCCCCTTGACAGCAGAAGCACCAGCGAATCTACAGCCGCCCTGGGCTGCCTCGTGAAG
GACTACTTTCCCGAGCCCGTGACCCTGTCTGGAACCTCTGGCGCTCTGACAAGCGGCGTGCACACCTTTCCAGCCGT
GCTCCAGAGCAGCGGCTGTACTCTCTGAGCAGCGTCTGTGACAGTGCCCAGCAGCAGCCTGGGCACCAAGACCTACA

CCTGTAACGTGGACCAACAAGCCCCAGCAACCAAGGTGGACAAGCGGGTGGAATCTAAGTACGGCCCTCCCTGCCCC
CCTTGCCCAGCCCCTGAAGCTGCCGGCGGACCCTCCGTGTTCTCTGTTCCCCCAAAGCCCAAGGACACCCTGATGAT
CAGCCGGACCCCCGAAGTGACCTGCGTGGTGGTGGATGTGTCCCAGGAAGATCCCAGAGGTGCAGTTCAATTGGTACG
TGGACGGCGTGGAAGTGCAACAACGCCAAGACCAAGCCCAGAGAGGAACAGTTCAACAGCACCTACCGGGTGGTGTCC
GTGCTGACCGTGCTGCACCAGGACTGGCTGAACGGCAAAGAGTACAAGTGCAAGGTGTCCAACAAGGGCCTGCCCA
GCTCCATCGAGAAAACCATCAGCAAGGCCAAGGGCCAGCCCCGCGAGCCTCAAGTGTGTACCCTGCCCCCTAGCCA
GGAAGAGATGACCAAGAACCAGGTGTCCCTGAGCTGTGCCGTGAAAGGCTTCTACCCCAGCGACATTGCCGTGGAA
TGGGAGAGCAACGGCCAGCCCCGAGAACAATAAGACCACCCCCCTGTGCTGGACAGCGACGGCTCATTCTTCCT
GGTGTCCAAGCTGACCGTGGACAAGAGCCGGTGGCAGGAAGGCAACGTGTTACAGCTGCTCCGTGATGCACGAGGCC
CTGCACAACCACTACACCCAGAAGTCCCTGTCTCTGTCCCTGGGC 3 544

AGAGCCCACCTGGTGCAGTCTGGCACCGCCATGAAGAAACCAGGCGCCTCTGTGCGGGTGTCTGTGACACAAGCG
GCTACACCTTCACCGCCCACATCCTGTTCTGGTTCGCGCAGGCCCTGGCAGAGGACTGGAATGGGTGGGATGGATC
AAGCCCCAGTATGGCGCCGTGAACCTCGGCGGAGGCTTCCGGGATAGAGTGACCCTGACCCGGGACGTGTACC
AGATCGCCTACATGGACATCCGGGGCCTGAAGCCCGATGACACCGCCGTGTACTACTGCGCCAGAGACAGAAGCTAC
GGCGACAGCAGCTGGGCTCTGGATGCTTGGGGCCAGGGCACAACCGTGGTGGTGTCTGCCGCCTCTACAAAGGGCCC
ATCGGTGTTCCCTCTGGCCCCCTTGACAGCAGAAGCACCAGCGAATCTACAGCCGCCNTGGGCTGCCTCGTGAAGGACT
ACTTTCCCGAGCCCGTGACCGTGTCTCTGGAACCTCTGGCGCTCTGACAAGCGGCGTGACACCTTTCCAGCCGTGCTC
CAGAGCAGCGGCCTGTACTCTCTGAGCAGCGTCTGTGACAGTGGCCAGCAGCAGCCTGGGCACCAAGACCTACACCTG
TAACGTGGACCACAAGCCCAGCAACACCAAGGTGGACAAGCGGGTGAATCTAAGTACGGCCCTCCCTGCCCTCCTT
GCCCAGCCCCTGAAGCTGCCGGCGGACCCTCCGTGTTCCCTGTTCCCCCAAAGCCCAAGGACACCCTGATGATCAGC
CGGACCCCCGAAGTGACCTGCGTGGTGGTGGATGTGTCCCAGGAAGATCCCGAGGTGCAGTTCAATTGGTACGTGGA
CGGCGTGGAAGTGCAACAACGCCAAGACCAAGCCCAGAGAGGAACAGTTCAACAGCACCTACCGGGTGGTGTCCGTG
CTGACCGTGCTGCACCAGGACTGGCTGAACGGCAAAGAGTACAAGTGCAAGGTGTCCAACAAGGGCCTGCCAGCT
CCATCGAGAAAACCATCAGCAAGGCCAAGGGCCAGCCCCGCGAGCCTCAAGTGTATACCCTGCCCCCTTGCCAGGA
AGAGATGACCAAGAACCAGGTGTCCCTGTGGTGTCTCGTGAAAGGCTTCTACCCCAGCGACATTGCCGTGGAATGGG
AGAGCAACGGCCAGCCCGAGAACAATAAGACCACCCCCCTGTGCTGGACAGCGACGGCTCATTCTTCCTGTAC
TCCAAGCTGACCGTGGACAAGAGCCGGTGGCAGGAAGGCAACGTGTTACAGCTGCTCCGTGATGCACGAGGCCCTGC
ACAACCACTACACCCAGAAGTCCCTGTCTCTGTCCCTGGGC 4 545

TACATCCACGTGACCCAGAGCCCCAGCAGCCTGTCCGTGTCCATCGGCGACAGAGTGACCATCAACTGCCAGACCTC
TCAGGGCGTGGGCAGCGACCTGCACTGGTATCAGCACAAGCCTGGCAGAGCCCCCAAGCTGCTGATCCACCACACA
AGCAGCGTGGAAGATGGCGTGCCAGCAGATTTTCCGGCAGCGGCTTCCACACCAGCTTCAACCTGACCATCAGCGA
TCTGCAGGCCGACGACATTGCCACCTACTATTGTACAGGTGCTGCAGTTCTTCGGCAGAGGCAGCAGACTGCACATCA
AGCGTACGGTGGCCGCTCCCAGCGTGTTTCATCTTCCCACCTAGCGACGAGCAGCTGAAGTCCGGCACAGCCTCTGTC
GTGTGCCTGCTGAACAACCTTCTACCCCCGCGAGGCCAAAGTGCAAGTGGAAAGGTGGACAACGCCCTGCAGAGCGGCA
ACAGCCAGGAAAGCGTGACCGAGCAGGACAGCAAGGACTCCACCTACAGCCTGAGCAGCACCTTGACACTGAGCAA
GGCCGACTACGAGAAGCACAAGGTGTACGCCTGCGAAGTGACCCACCAGGGCCTGTCTAGCCCCGTGACCAAGAGC
TTCAACCGGGGCGAGTGT Trispecific 1 546

GACATCGTGATGACCCAGACCCCCCTGAGCCTGAGCGTGACACCTGGACAGCCTGCCAGCATCAGCTGCAAGAGCA
22 N6/
GCCAGAGCCTGGTGCACGAGAACCTGCAGACCTACCTGAGCTGGTATCTGCAGAAGCCCGGCCAGAGCCCCCAGTC
CD28sup ×
CCTGATCTACAAGGTGTCCAACAGATTCAGCGGCGTGCCCGACAGATTCTCCGGCAGCGGCTCTGGCACCGACTTCA
CD3mid_
CCCTGAAGATCAGCCGGGTGGAAGCCGAGGACGTGGGCGTGTAATATTGTGGCCAGGGCACCCAGTACCCCTTCACC
ENLQ IgG4
TTTGGCAGCGGCACCAAGGTGGAATCAAGGACAAAACCCATACCGACATCCAGATGACCCAGAGCCCCAGCAGCC
FALA/409K_
TGTCTGCCAGCGTGGGCGACAGAGTGACCATCACCTGTCAGGCCAGCCAGAACATCTACGTGTGGCTGAACTGGTAT
DKHT linker

CAGCAGAAGCCCGGCAAGGCCCCCAAGCTGCTGATCTACAAGGCCAGCAACCTGCACACCGGCGTGCCCAGCAGAT
TTTCTGGCAGCGGCTCCGGCACCGACTTCACCCTGACAATCAGCTCCCTGCAGCCCGAGGACATTGCCACCTACTAC
TGCCAGCAGGGCCAGACCTACCCCTACACCTTTGGCCAGGGCACCAAGCTGGAAATCAAGGATAAGACCCACACCCG
TACGGTGGCCGCTCCCAGCGTGTTTCATCTTCCCACCTAGCGACGAGCAGCTGAAGTCCGGCACAGCCTCTGTCTGT
GCCTGCTGAACAACCTTCTACCCCCGCGAGGCCAAAGTGCAAGTGGAAAGGTGGACAACGCCCTGCAGAGCGGCAACAG
CCAGGAAAGCGTGACCGAGCAGGACAGCAAGGACTCCACCTACAGCCTGAGCAGCACCTTGACACTGAGCAAGGCC
GACTACGAGAAGCACAAGGTGTACGCCTGCGAAGTGACCCACCAGGGCCTGTCTAGCCCCGTGACCAAGAGCTTCA
ACCGGGGCGAGTGT 2 547

CAGGTGCAGCTGGTGCAGTCTGGCGCCGAGGTCTGTGAAACCTGGCGCCTCTGTGAAGGTGTCTGTGCAAGGCCAGCGG
CTACACCTTTACCAGCTACTACATCCACTGGGTGCGCCAGGCCCTGGACAGGGACTGGAATGGATCGGCAGCATCT
ACCCCGGCAACGTGAACACCAACTACGCCCAGAAGTTCCAGGGCAGAGCCACCCTGACCGTGGACACCAGCATCAG
CACCGCCTACATGGAAGTGTGAGCCGGCTGAGAAGCGACGACACCGCCGTGTACTACTGCACCCGGTCCCCTACGGCC
TGGATTGGAACCTTCGACGTGTGGGGCAAGGGCACCAACCGTGACAGTGTCTAGCGACAAAACCCATACCCAGGTGCA
GCTGGTGGAAATCTGGCGGCGGAGTGGTGCAGCCTGGCAGAAGCCTGAGACTGAGCTGTGCCGCCAGCGGCTTACCT

TACCAAGGCCTGGATGCACTGGGTGCGCCAGGCCCTGGAAAAGCAGCTGGAATGGGTGGCCCGAGATCAAGGACAA
GAGCAACAGCTACGCCACCTACTACGCCGACAGCGTGAAGGGCCGGTTTACCATCAGCCGGGACGACAGCAAGAAC
ACCCTGTACCTGCAGATGAACAGCCTGCGGGCCGAGGACACCGCCGTGTACTACTGTGCGGGGCGTGTACTATGCCCT
GAGCCCCTTCGATTACTGGGGCCAGGGAACCCCTCGTGACCGTGTCTAGTGATAAGACCCACACCGCCAGCACAAAGG
GCCCATCGGTGTTCCCTCTGGCCCCTTGACGACAGAAGCACCAGCGAATCTACAGCCGCCCTGGGCTGCCTCGTGAAG
GACTACTTTCCCGAGCCCGTGACCGTGTCTGGAACCTCTGGCGCTCTGACAAGCGGCGTGCACACCTTTCCAGCCGT
GCTCCAGAGCAGCGGCCTGTACTCTCTGAGCAGCGTCGTGACAGTGCCCAGCAGCAGCCTGGGCACCAAGACCTACA
CCTGTAACGTGGACCACAAGCCCAGCAACACCAAGGTGGACAAGCGGGTGGAATCTAAGTACGGCCCTCCCTGCCCT
CCTTGCCCAGCCCCTGAAGCTGCCGGCGGACCCTCCGTGTTCCCTGTTCCCCCAAAGCCCAAGGACACCCTGATGAT
CAGCCGGACCCCCGAAGTGACCTGCGTGGTGGTGGATGTGTCCAGGAAGATCCCGAGGTGCAGTTCAATTGGTACG
TGGACGGCGTGGAAGTGACACAACGCCAAGACCAAGCCCAGAGAGGAACAGTTCAACAGCACCTACCGGGTGGTGTCC
GTGCTGACCGTGTCTGCACCAGGACTGGCTGAACGGCAAAGAGTACAAGTGCAAGGTGTCCAACAAGGGCCTGCCCA
GCTCCATCGAGAAAACCATCAGCAAGGCCAAGGGGCCAGCCCCGCGAGCCTCAAGTGTGTACCCTGCCCCCTAGCCA
GGAAGAGATGACCAAGAACCAGGTGTCCCTGAGCTGTGCCGTGAAAGGCTTCTACCCAGCGACATTGCCGTGGAA
TGGGAGAGCAACGGCCAGCCCGAGAACAATAAGACCACCCCCCTGTGCTGGACAGCGACGGCTCATTCTTCCT
GGTGTCCAAGCTGACCGTGGACAAGAGCCGGTGGCAGGAAGGCAACGTGTTACAGCTGCTCCGTGATGCACGAGGCC
CTGCACAACCACTACACCCAGAAGTCCCTGTCTCTGTCCCTGGGC 3 548

AGAGCCCACCTGGTGCAGTCTGGCACCGCCATGAAGAAACCAGGCGCCTCTGTGCGGGTGTCTGTGTCAGACAAGCG
GCTACACCTTCACCGCCACATCCTGTTCTGGTTCGGGCAGGCCCTGGCAGAGGACTGGAATGGGTGGGATGGATC
AAGCCCCAGTATGGCGCCGTGAACTTCGGCGGAGGCTTCCGGGATAGAGTGACCCTGACCCGGGACGTGTACC GCG
AGATCGCCTACATGGACATCCGGGGCCTGAAGCCCGATGACACCGCCGTGTACTACTGCGCCAGAGACAGAAGCTAC
GGCGACAGCAGCTGGGCTCTGGATGCTTGGGGCCAGGGCACAACCGTGGTGGTGTCTGCCGCCTCTACAAAGGGCCC
ATCGGTGTTCCCTCTGGCCCCTTGACGACAGAAGCACCAGCGAATCTACAGCCGCCNTGGGCTGCCTCGTGAAGGACT
ACTTTCCCGAGCCCGTGACCGTGTCTGGAACCTCTGGCGCTCTGACAAGCGGCGTGCACACCTTTCCAGCCGTGCTC
CAGAGCAGCGGCCTGTACTCTCTGAGCAGCGTCGTGACAGTGCCCAGCAGCAGCCTGGGCACCAAGACCTACACCTG
TAACGTGGACCACAAGCCCAGCAACACCAAGGTGGACAAGCGGGTGGAATCTAAGTACGGCCCTCCCTGCCCTCCTT
GCCAGCCCCTGAAGCTGCCGGCGGACCCTCCGTGTTCCCTGTTCCCCCAAAGCCCAAGGACACCCTGATGATCAGC
CGGACCCCCGAAGTGACCTGCGTGGTGGTGGATGTGTCCCAGGAAGATCCCGAGGTGCAGTTCAATTGGTACGTGGA
CGGCGTGGAAGTGACACAACGCCAAGACCAAGCCCAGAGAGGAACAGTTCAACAGCACCTACCGGGTGGTGTCCGTG
CTGACCGTGTCTGCACCAGGACTGGCTGAACGGCAAAGAGTACAAGTGCAAGGTGTCCAACAAGGGCCTGCCAGCT
CCATCGAGAAAACCATCAGCAAGGCCAAGGGCCAGCCCCGCGAGCCTCAAGTGTATACCCTGCCCCCTTGCCAGGA
AGAGATGACCAAGAACCAGGTGTCCCTGTGGTGTCTCGTGAAAGGCTTCTACCCAGCGACATTGCCGTGGAATGGG
AGAGCAACGGCCAGCCCGAGAACAACTACAAGACCACCCCCCTGTGCTGGACAGCGACGGCTCATTCTTCCTGTAC
TCCAAGCTGACCGTGGACAAGAGCCGGTGGCAGGAAGGCAACGTGTTACAGCTGCTCCGTGATGCACGAGGCCCTGC
ACAACCACTACACCCAGAAGTCCCTGTCTCTGTCCCTGGGC 4 549

TACATCCACGTGACCCAGAGCCCCAGCAGCCTGTCCGTGTCCATCGGCGACAGAGTGACCATCAACTGCCAGACCTC
TCAGGGCGTGGGCAGCGACCTGCACTGGTATCAGCACAAAGCCTGGCAGAGCCCCCAAGCTGCTGATCCACCACACA
AGCAGCGTGGAAGATGGCGTGCCAGCAGATTTTCCGGCAGCGGCTTCCACACCAGCTTCAACCTGACCATCAGCGA
TCTGCAGGCCGACGACATTGCCACCTACTATTGTACGGTGTCTGCAGTTCTTCCGGCAGAGGCAGCAGACTGCACATCA
AGCGTACGGTGGCCGCTCCCAGCGTGTTCATCTTCCCACCTAGCGACGAGCAGCTGAAGTCCGGCACAGCCTCTGTC
GTGTGCCTGCTGAACAACCTTCTACCCCCGCGAGGCCAAAGTGCAAGTGGAAAGGTGGACAACGCCCTGCAGAGCGGCA
ACAGCCAGGAAAGCGTGACCGAGCAGGACAGCAAGGACTCCACCTACAGCCTGAGCAGCACCCCTGACACTGAGCAA
GGCCGACTACGAGAAGCACAAGGTGTACGCCTGCGAAGTGACCCACCAGGGCCTGTCTAGCCCCGTGACCAAGAGC
TTCAACCGGGGCGAGTGT Trispecific 1 550

GACATCGTGATGACCCAGACCCCCCTGAGCCTGAGCGTGACACCTGGACAGCCTGCCAGCATCAGCTGCAAGAGCA
23 N6/

GCCAGAGCCTGGTGCACGAGAACCTGCGTACCTACCTGAGCTGGTATCTGCAGAAGCCCGGCCAGAGCCCCAGTCC
CD28sup ×

CTGATCTACAAGGTGTCCAACAGATTACAGCGGCGTGCCCGACAGATTCTCCGGCAGCGGCTCTGGCACCCGACTTCAC
CD3mid_

CCTGAAGATCAGCCGGGTGGAAGCCGAGGACGTGGGCGTGTACTATTGTGGCCAGGGCACCCAGTACCCCTTCACCT
ENLR IgG4

TTGGCAGCGGCACCAAGGTGGAAATCAAGGACAAAACCCATACCGACATCCAGATGACCCAGAGCCCCAGCAGCCT
FALA/409K_

GTCTGCCAGCGTGGGCGACAGAGTGACCATCACCTGTCAGGCCAGCCAGAACATCTACGTGTGGCTGAACTGGTATC
DKHT linker

AGCAGAAGCCCGCAAGGCCCCCAAGCTGCTGATCTACAAGGCCAGCAACCTGCACACCGGCGTGCCCAGCAGATT
TTCTGGCAGCGGCTCCGGCACCGACTTCACCCTGACAATCAGCTCCCTGCAGCCCGAGGACATTGCCACCTACTACT
GCCAGCAGGGCCAGACCTACCCCTACACCTTTGGCCAGGGCACCAAGCTGGAAATCAAGGATAAGACCCACACCCG
TACGGTGGCCGCTCCCAGCGTGTTCATCTTCCCACCTAGCGACGAGCAGCTGAAGTCCGGCACAGCCTCTGTCTGT
GCCTGCTGAACAACCTTCTACCCCCGCGAGGCCAAAGTGCAAGTGGAAAGGTGGACAACGCCCTGCAGAGCGGCAACAG
CCAGGAAAGCGTGACCGAGCAGGACAGCAAGGACTCCACCTACAGCCTGAGCAGCACCCCTGACACTGAGCAAGGCC
GACTACGAGAAGCACAAGGTGTACGCCTGCGAAGTGACCCACCAGGGCCTGTCTAGCCCCGTGACCAAGAGCTTCA

ACCGGCGGAGTGT 2 551

CAGGTGCAGCTGGTGCAGTCTGGCGCCGAGGTCTGTGAAACCTGGCGCCTCTGTGAAGGTGTCCTGCAAGGCCAGCGG
CTACACCTTTACCAGCTACTACATCCACTGGGTGCGCCAGGCCCTGGACAGGGACTGGAATGGATCGGCAGCATCT
ACCCCGGCAACGTGAACACCAACTACGCCCAGAAGTTCAGGGCAGAGCCACCCTGACCGTGGACACCAGCATCAG
CACCGCCTACATGGAAGTGAAGCCGGCTGAGAAGCGACGACACCGCCGTGTACTACTGCACCCGGTCCCACTACGGCC
TGGATTGGAACCTCGACGTGTGGGGCAAGGGCACCACCGTGACAGTGTCTAGCGACAAAACCCATACCCAGGTGCA
GCTGGTGGAAATCTGGCGGCGGAGTGGTGCAGCCTGGCAGAAGCCTGAGACTGAGCTGTGCCGCCAGCGGCTTCACCT
TCACCAAGGCCTGGATGCACTGGGTGCGCCAGGCCCTGGAAAGCAGCTGGAATGGGTGGCCAGATCAAGGACAA
GAGCAACAGCTACGCCACCTACTACGCCGACAGCGTGAAGGGCCGTTTACCATCAGCCGGGACGACAGCAAGAAC
ACCCTGTACCTGCAGATGAACAGCCTGCGGGCCGAGGACACCGCCGTGTACTACTGTGCGGGCGTGTACTATGCCCT
GAGCCCCTTCGATTACTGGGGCCAGGGAACCTCTGTGACCGTGTCTAGTGATAAGACCCACACCGCCAGCACAAAGG
GCCATCGGTGTTCCCTCTGGCCCCTTGACGACAGAAGCACCAGCGAATCTACAGCCGCCCTGGGCTGCCTCGTGAAG
GACTACTTTCCCGAGCCCGTGACCGTGTCTGGAACCTCTGGCGCTCTGACAAGCGGCGTGCACACCTTTCCAGCCGT
GCTCCAGAGCAGCGGCCTGTACTCTCTGAGCAGCGTCGTGACAGTGCCCAGCAGCAGCCTGGGCACCAAGACCTACA
CCTGTAACGTGGACCACAAGCCCAGCAACACCAAGGTGGACAAGCGGGTGGAAATCTAAGTACGGCCCTCCCTGCCCT
CCTTGCCCAGCCCCTGAAGCTGCCGGCGGACCCTCCGTGTTCCCTGTTCCCCCAAAGCCCAAGGACACCCTGATGAT
CAGCCGGACCCCCGAAGTGACCTGCGTGGTGGTGGATGTGTCCCAGGAAGATCCCAGAGGTGCAGTTCAATTGGTACG
TGGACGGCGTGGAAGTGCACAACGCCAAGACCAAGCCCAGAGAGGAACAGTTCAACAGCACCTACCGGGTGGTGTCC
GTGCTGACCGTGCTGCACCAGGACTGGCTGAACGGCAAAGAGTACAAGTGCAAGGTGTCCAACAAGGGCCTGCCCA
GCTCCATCGAGAAAACCATCAGCAAGGCCAAGGGCCAGCCCCGCGAGCCTCAAGTGTGTACCCTGCCCCCTAGCCA
GGAAGAGATGACCAAGAACCAGGTGTCCCTGAGCTGTGCCGTGAAAGGCTTCTACCCAGCGACATTGCCGTGGAA
TGGGAGAGCAACGGCCAGCCCAGAGAACAATAAGACCACCCCCCTGTGCTGGACAGCGACGGCTCATTCTTCCT
GGTGTCCAAGCTGACCGTGGACAAGAGCCGGTGGCAGGAAGGCAACGTGTTACAGTGTCTCCGTGATGCACGAGGCC
CTGCACAACCACTACACCCAGAAGTCCCTGTCTCTGTCCCTGGGC 3 552

AGAGCCCACCTGGTGCAGTCTGGCACCGCCATGAAGAAACCAGGCGCCTCTGTGCGGGTGTCTGTGACACAAGCG
GCTACACCTTCACCGCCACATCCTGTTCTGGTTCCGGCAGGCCCTGGCAGAGGACTGGAATGGGTGGGATGGATC
AAGCCCCAGTATGGCGCCGTGAACCTTCGGCGGAGGCTTCCGGGATAGAGTGACCCTGACCCGGGACGTGTACC
AGATCGCCTACATGGACATCCGGGGCCTGAAGCCCGATGACACCGCCGTGTACTACTGCGCCAGAGACAGAAGCTAC
GGCGACAGCAGCTGGGCTCTGGATGCTTGGGGCCAGGGCACAACCGTGGTGGTGTCTGCCGCCTCTACAAAGGGCCC
ATCGGTGTTCCCTCTGGCCCCCTTGACGACAGAAGCACCAGCGAATCTACAGCCGCCNTGGGCTGCCTCGTGAAGGACT
ACTTTCCCGAGCCCGTGACCGTGTCTCTGGAACCTCTGGCGCTCTGACAAGCGGCGTGCACACCTTTCCAGCCGTGCTC
CAGAGCAGCGCCTGTACTCTCTGAGCAGCGTCGTGACAGTGCCAGCAGCAGCCTGGGCACCAAGACCTACACCTG
TAACGTGGACCACAAGCCCAGCAACACCAAGGTGGACAAGCGGGTGGAAATCTAAGTACGGCCCTCCCTGCCCTCCTT
GCCAGCCCCTGAAGCTGCCGGCGGACCCTCCGTGTTCCCTGTTCCCCCAAAGCCCAAGGACACCCTGATGATCAGC
CGGACCCCCGAAGTGACCTGCGTGGTGGTGGATGTGTCCCAGGAAGATCCCAGGTGCAGTTCAATTGGTACGTGGA
CGGCGTGGAAAGTGCACAACGCCAAGACCAAGCCCAGAGAGGAACAGTTCAACAGCACCTACCGGGTGGTGTCCGTG
CTGACCGTGTCTGCACCAGGACTGGCTGAACGGCAAAGAGTACAAGTGCAAGGTGTCCAACAAGGGCCTGCCAGCT
CCATCGAGAAAACCATCAGCAAGGCCAAGGGCCAGCCCCGCGAGCCTCAAGTGTATACCCTGCCCCCTTGCCAGGA
AGAGATGACCAAGAACCAGGTGTCCCTGTGGTGTCTCGTGAAAGGCTTCTACCCAGCGACATTGCCGTGGAAATGGG
AGAGCAACGGCCAGCCCAGAGAACAATAAGACCACCCCCCTGTGCTGGACAGCGACGGCTCATTCTTCCTGTAC
TCCAAGCTGACCGTGGACAAGAGCCGGTGGCAGGAAGGCAACGTGTTACAGTGTCTCCGTGATGCACGAGGCCCTGC
ACAACCACTACACCCAGAAGTCCCTGTCTCTGTCCCTGGGC 4 553

TACATCCACGTGACCCAGAGCCCCAGCAGCCTGTCCGTGTCCATCGGCGACAGAGTGACCATCAACTGCCAGACCTC
TCAGGGCGTGGGCAGCGACCTGCACTGGTATCAGCACAAGCCTGGCAGAGCCCCCAAGCTGCTGATCCACCACACA
AGCAGCGTGGAAGATGGCGTGCCAGCAGATTTCCGGCAGCGGCTTCCACACCAGCTTCAACCTGACCATCAGCGA
TCTGCAGGCCGACGACATTGCCACCTACTATTGTCAGGTGCTGCAGTTCTTCCGGCAGAGGCAGCAGACTGCACATCA
AGCGTACGGTGGCCGCTCCCAGCGTGTTCATCTTCCCACCTAGCGACGAGCAGCTGAAGTCCGGCACAGCCTCTGTC
GTGTGCCTGCTGAACAACCTTCTACCCCCGCGAGGCCAAAGTGCAAGTGGAAAGGTGGACAACGCCCTGCAGAGCGGCA
ACAGCCAGGAAAGCGTGACCGAGCAGGACAGCAAGGACTCCACCTACAGCCTGAGCAGCACCTGACACTGAGCAA
GGCCGACTACGAGAAGCACAAGGTGTACGCCTGCGAAGTGACCCACCAGGGCCTGTCTAGCCCCGTGACCAAGAGC
TTCAACCGGGGCGAGTGT Trispecific 1 554

GACATCGTGATGACCCAGACCCCCCTGAGCCTGAGCGTGACACCTGGACAGCCTGCCAGCATCAGCTGCAAGAGCA
24 N6/
GCCAGAGCCTGGTGCACGAGAACCTGTTACCTACCTGAGCTGGTATCTGCAGAAGCCCGGCCAGAGCCCCCAGTCC
CD28sup ×
CTGATCTACAAGGTGTCCAACAGATTACAGCGGCGTGCCCGACAGATTCTCCGGCAGCGGCTCTGGCACCGACTTCAC
CD3mid_
CCTGAAGATCAGCCGGGTGGAAGCCGAGGACGTGGGCGTGTACTATTGTGGCCAGGGCACCCAGTACCCCTTCACCT
ENLF IgG4
TTGGCAGCGGCACCAAGGTGGAAATCAAGGACAAAACCCATACCGACATCCAGATGACCCAGAGCCCCAGCAGCCT
FALA/409K_
GTCTGCCAGCGTGGGCGACAGAGTGACCATCACCTGTCAGGCCAGCCAGAACATCTACGTGTGGCTGAACTGGTATC
DKTHT linker

AGCAAGCAAGCCGACAGGCCCCCAAGCTGTGATCTACAAGGCCACACCTGCACACCGCGCTGCCAGCAGATT
TTCTGGCAGCGGCTCCGGCACCGACTTCACCTTGACAATCAGCTCCCTGCAGCCCCGAGGACATTGCCACCTACTACT
GCCAGCAGGGCCAGACCTACCCCTACACCTTTGGCCAGGGCACCAAGCTGGAAATCAAGGATAAGACCCACACCCG
TACGGTGGCCGCTCCCAGCGTGTTTCATCTTCCACCTAGCGACGAGCAGCTGAAGTCCGGCACAGCCTCTGTCTGT
GCCTGCTGAACAACTTCTACCCCCGCGAGGCCAAAGTGCAGTGGAAGGTGGACAACGCCCTGCAGAGCGGCAACAG
CCAGGAAAGCGTGACCGAGCAGGACAGCAAGGACTCCACCTACAGCCTGAGCAGCACCCCTGACACTGAGCAAGGCC
GACTACGAGAAGCACAAAGGTGTACGCCTGCGAAGTGACCCACCAGGGCCTGTCTAGCCCCGTGACCAAGAGCTTCA
ACCGGGGCGAGTGT 2 555

CAGGTGCAGCTGGTGCAGTCTGGCGCCGAGGTCTGTGAAACCTGGCGCCTCTGTGAAGGTGTCCTGCAAGGCCAGCGG
CTACACCTTTACCAGCTACTACATCCACTGGGTGCGCCAGGCCCTTGACAGGGACTGGAATGGATCGGCAGCATCT
ACCCCGGCAACGTGAACACCAACTACGCCCAGAAGTTCAGGGCAGAGCCACCCTGACCGTGGACACCAGCATCAG
CACCGCCTACATGGAAGTGAAGCCGGCTGAGAAGCGACGACACCGCCGTGTACTACTGCACCCGGTCCCCTACGGCC
TGGATTGGAAGTTCGACGTGTGGGGCAAGGGCACCAACCGTGACAGTGTCTAGCGACAAAACCCATACCCAGGTGCA
GCTGGTGGAACTCTGGCGGCGGAGTGGTGCAGCCTGGCAGAAGCCTGAGACTGAGCTGTGCCGCCAGCGGCTTACCT
TCACCAAGGCCTGGATGCACTGGGTGCGCCAGGCCCTTGAAAGCAGCTGGAATGGGTGGCCCAGATCAAGGACAA
GAGCAACAGCTACGCCACCTACTACGCCGACAGCGTGAAGGGCCGTTTACCATCAGCCGGGACGACAGCAAGAAC
ACCCTGTACCTGCAGATGAACAGCCTGCGGGCCGAGGACACCGCCGTGTACTACTGTCCGGGCGTGTACTATGCCCT
GAGCCCCTTCGATTACTGGGGCCAGGGAACCTCGTGACCGTGTCTAGTGATAAGACCCACACCGCCAGCACAAAGG
GCCCATCGGTGTTCCCTCTGGCCCCTTGACAGCAGAAGCACCAAGCAGCAATCTACAGCCGCCCTGGGCTGCCTCGTGAAG
GACTACTTTCCCGAGCCCGTGACCGTGTCTTGGAAGTCTGGCGCTCTGACAAGCGGCGTGACACACCTTTCCAGCCGT
GCTCCAGAGCAGCGGCCTGTACTCTCTGAGCAGCGTCTGTGACAGTGCCCAGCAGCAGCCTGGGCACCAAGACCTACA
CCTGTAACGTGGACCACAAGCCCAGCAACACCAAGGTGGACAAGCGGGTGGAAATCTAAGTACGGCCCTCCCTGCCCT
CCTTGCCCAGCCCCTGAAGCTGCCGGCGGACCCTCCGTGTTCTGTTCCTGTTCCCCCAAAGCCCAAGGACACCCTGATGAT
CAGCCGGACCCCCGAAGTGACCTGCGTGGTGGTGGATGTGTCCAGGAAGATCCCAGAGTGCAGTTCAATTGGTACG
TGGACGGCGTGGAAGTGACAAACGCCAAGACCAAGCCCAGAGAGGAACAGTTCAACAGCACCTACCGGGTGGTGTCC
GTGCTGACCGTGTCTGCACCAGGACTGGCTGAACGGCAAAGAGTACAAGTGCAAGGTGTCCAACAAGGGCCTGCCCA
GCTCCATCGAGAAAACCATCAGCAAGGCCAAGGGCCAGCCCCGCGAGCCTCAAGTGTGTACCCTGCCCCCTAGCCA
GGAAGAGATGACCAAGAACCAGGTGTCCCTGAGCTGTGCCGTGAAAGGCTTCTACCCCAGCGACATTGCCGTGGAA
TGGGAGAGCAACGGCCAGCCCGAGAACAATAAGACCACCCCCCTGTGCTGGACAGCGACGGCTCATTCTTCCT
GGTGTCCAAGCTGACCGTGGACAAGAGCCGGTGGCAGGAAGGCAACGTGTTACAGCTGCTCCGTGATGCACGAGGCC
CTGCACAACCACTACACCCAGAAGTCCCTGTCTCTGTCCCTGGGC 3 556

AGAGCCCACCTGGTGCAGTCTGGCACCGCCATGAAGAAACCAGGCGCCTCTGTGCGGGTGTCTCTGTCAGACAAGCG
GCTACACCTTCACCGCCACATCCTGTTCTGGTTCCGGCAGGCCCTTGACAGAGGACTGGAATGGGTGGGATGGATC
AAGCCCCAGTATGGCGCCGTGAACCTCGGCGGAGGCTTCCGGGATAGAGTGACCCTGACCCGGGACGTGTACCGCG
AGATCGCCTACATGGACATCCGGGGCCTGAAGCCCGATGACACCGCCGTGTACTACTGCGCCAGAGACAGAAGCTAC
GGCGACAGCAGCTGGGCTCTGGATGCTTGGGGCCAGGGCACAAACCGTGGTGGTGTCTGCCGCCTCTACAAAGGGCCC
ATCGGTGTTCCCTCTGGCCCCTTGACAGCAGAAGCACCAAGCGAATCTACAGCCGCCNTGGGCTGCCTCGTGAAGGACT
ACTTTCCCGAGCCCGTGACCGTGTCTCTGGAAGTCTGGCGCTCTGACAAGCGGCGTGACACACCTTTCCAGCCGTGCTC
CAGAGCAGCGGCCTGTACTCTCTGAGCAGCGTCTGTGACAGTGCCCAGCAGCAGCCTGGGCACCAAGACCTACACCTG
TAACGTGGACCACAAGCCCAGCAACACCAAGGTGGACAAGCGGGTGGAAATCTAAGTACGGCCCTCCCTGCCCTCCTT
GCCAGCCCCTGAAGCTGCCGGCGGACCCTCCGTGTTCCCTGTTCCCCCAAAGCCCAAGGACACCCTGATGATCAGC
CGGACCCCCGAAGTGACCTGCGTGGTGGTGGATGTGTCCCAGGAAGATCCCGAGGTGCAGTTCAATTGGTACGTGGA
CGGCGTGGAAAGTGACAACGCCAAGACCAAGCCCAGAGAGGAACAGTTCAACAGCACCTACCGGGTGGTGTCCGTG
CTGACCGTGTCTGCACCAGGACTGGCTGAACGGCAAAGAGTACAAGTGCAAGGTGTCCAACAAGGGCCTGCCAGCT
CCATCGAGAAAACCATCAGCAAGGCCAAGGGCCAGCCCCGCGAGCCTCAAGTGTATACCCTGCCCCCTTGCCAGGA
AGAGATGACCAAGAACCAGGTGTCCCTGTGGTGTCTCGTGAAAGGCTTCTACCCCAGCGACATTGCCGTGGAAATGGG
AGAGCAACGGCCAGCCCGAGAACAATAAGACCACCCCCCTGTGCTGGACAGCGACGGCTCATTCTTCCTGTAC
TCCAAGCTGACCGTGGACAAGAGCCGGTGGCAGGAAGGCAACGTGTTACAGCTGCTCCGTGATGCACGAGGCCCTGC
ACAACCACTACACCCAGAAGTCCCTGTCTCTGTCCCTGGGC 4 557

TACATCCACGTGACCCAGAGCCCCAGCAGCCTGTCCGTGTCCATCGGCGACAGAGTGACCATCAACTGCCAGACCTC
TCAGGGCGTGGGCAGCGACCTGCACTGGTATCAGCACAAGCCTGGCAGAGCCCCCAAGCTGCTGATCCACCACACA
AGCAGCGTGGAAGATGGCGTGCCAGCAGATTTTCCGGCAGCGGCTTCCACACCAGCTTCAACCTGACCATCAGCGA
TCTGCAGGCCGACGACATTGCCACCTACTATTGTGAGGTGCTGCAGTTCTTCCGGCAGAGGCAGCAGACTGCACATCA
AGCGTACGGTGGCCGCTCCCAGCGTGTTTCATCTTCCACCTAGCGACGAGCAGCTGAAGTCCGGCACAGCCTCTGTC
GTGTGCCTGCTGAACAACTTCTACCCCCGCGAGGCCAAAGTGCAGTGGAAGGTGGACAACGCCCTGCAGAGCGGCA
ACAGCCAGGAAAGCGTGACCGAGCAGGACAGCAAGGACTCCACCTACAGCCTGAGCAGCACCCCTGACACTGAGCAA
GGCCGACTACGAGAAGCACAAAGGTGTACGCCTGCGAAGTGACCCACCAGGGCCTGTCTAGCCCCGTGACCAAGAGC
TTCAACCGGGGCGAGTGT Trispecific 1 558

GACATCGTGATGACCCAGACCCCCCTGAGCCTGAGCGTGACACCTGGACAGCCTGCCAGCATCAGCTGCAAGAGCA
25 N6_rw52/
GCCAGAGCCTGGTGCACGAGAACCTGCAGACCTACCTGAGCTGGTATCTGCAGAAGCCCGGCCAGAGCCCCCAGTC
CD28sup ×
CCTGATCTACAAGGTGTCCAACAGATTCAGCGGCGTGCCCGACAGATTCTCCGGCAGCGGCTCTGGCACCGACTTCA

CD3mid_

CCCTGAAGATCAGCCGGGTGGAAGCCGAGGACGTGGGCGTGCTACTATTGTGGCCAGGGCACCCAGTACCCCTTCACC
ENLQ_IgG4

TTTGGCAGCGGCACCAAGGTGGAATCAAGGACAAAACCCATACCGACATCCAGATGACCCAGAGCCCCAGCAGCC
FALA/409K_

TGTCTGCCAGCGTGGGCGACAGAGTGACCATCACCTGTCAGGCCAGCCAGAACATCTACGTGTGGCTGAACTGGTAT
DKTHT_linker

CAGCAGAAGCCCCGGCAAGGCCCCCAAGCTGCTGATCTACAAGGCCAGCAACCTGCACACCGGCGTGCCCAGCAGATT
TTCTGGCAGCGGCTCCGGCACCGACTTCACCCTGACAATCAGCTCCCTGCAGCCCCGAGGACATTGCCACCTACTACT
GCCAGCAGGGCCAGACCTACCCCTACACCTTTGGCCAGGGCACCAAGCTGGAATCAAGGATAAGACCCACACCCG
TACGGTGGCCGCTCCCAGCGTGTTCATCTTCCCACCTAGCGACGAGCAGCTGAAGTCCGGCACAGCCTCTGTCTGT
GCCTGCTGAACAACTTCTACCCCCGCGAGGCCAAAGTGCAGTGGAAGGTGGACAACGCCCTGCAGAGCGGCAACAG
CCAGGAAAGCGTGACCGAGCAGGACAGCAAGGACTCCACCTACAGCCTGAGCAGCACCCCTGACACTGAGCAAGGCC
GACTACGAGAAGCACAAAGGTGTACGCCTGCGAAGTGACCCACCAGGGCCTGTCTAGCCCCGTGACCAAGAGCTTCA
ACCGGGGCGAGTGT 2 559

CAGGTGCAGCTGGTGCAGTCTGGCGCCGAGGTGCTGAAACCTGGCGCCTCTGTGAAGGTGTCCTGCAAGGCCAGCGG
CTACACCTTTACCAGCTACTACATCCACTGGGTGCGCCAGGCCCTGGACAGGGACTGGAATGGATCGGCAGCATCT
ACCCCGGCAACGTGAACACCAACTACGCCCAGAAGTTCCAGGGCAGAGCCACCCTGACCGTGGACACCAGCATCAG
CACCGCCTACATGGAAGTGAAGCCGGCTGAGAAGCGACGACACCGCCGTGTACTACTGCACCCGGTCCCACTACGGCC
TGGATTGGAAGTTCGACGTGTGGGGCAAGGGCACCAACCGTGACAGTGTCTAGCGACAAAACCCATACCCAGGTGCA
GCTGGTGGAACTCTGGCGGCGGAGTGGTGCAGCCTGGCAGAAGCCTGAGACTGAGCTGTGCCGCCAGCGGCTTCACCT
TCACCAAGGCCTGGATGCACTGGGTGCGCCAGGCCCTGGAAAGCAGCTGGAATGGGTGGCCAGATCAAGGACAA
GAGCAACAGCTACGCCACCTACTACGCCGACAGCGTGAAGGGCCGGTTTACCATCAGCCGGGACGACAGCAAGAAC
ACCCTGTACCTGCAGATGAACAGCCTGCGGGCCGAGGACACCGCCGTGTACTACTGTCTGGGGCGTGTACTATGCCCT
GAGCCCCTTCGATTACTGGGGCCAGGGAACCCTCGTGACCGTGTCTAGTGATAAGACCCACACCGCCAGCACAAAGG
GCCATCGGTGTTCCCTCTGGCCCCTTGACGACAGAAGCACCAGCGAATCTACAGCCGCCCTGGGCTGCCTCGTGAAG
GACTACTTTCCCGAGCCCGTGACCGTGTCTGGAAGTCTGGCGCTCTGACAAGCGGCGTGCACACCTTTCCAGCCGT
GCTCCAGAGCAGCGGCTGTACTCTCTGAGCAGCGTCGTGACAGTGCCCAGCAGCAGCCTGGGCACCAAGACCTACA
CCTGTAACGTGGACCACAAGCCCAGCAACACCAAGGTGGACAAGCGGGTGGAATCTAAGTACGGCCCTCCCTGCCCT
CCTTGCCCAGCCCCCTGAAGCTGCCGGCGGACCCTCCGTGTTCCCTGTTCCCCCAAAGCCCAAGGACACCCTGATGAT
CAGCCGGACCCCCGAAGTGACCTGCGTGGTGGTGGATGTGTCCCAGGAAGATCCCAGAGGTGCAGTTCAATTGGTACG
TGGACGGCGTGGAAGTGCACAACGCCAAGACCAAGCCCAGAGAGGAACAGTTCAACAGCACCTACCGGGTGGTGTCC
GTGCTGACCGTGCTGCACCAGGACTGGCTGAACGGCAAAGAGTACAAGTGCAAGGTGTCCAACAAGGGCCTGCCCA
GCTCCATCGAGAAAACCATCAGCAAGGCCAAGGGCCAGCCCCGCGAGCCTCAAGTGTGTACCCTGCCCCCTAGCCA
GGAAGAGATGACCAAGAACCAGGTGTCCCTGAGCTGTGCCGTGAAAGGCTTCTACCCAGCGACATTGCCGTGGAA
TGGGAGAGCAACGGCCAGCCCGAGAACAATAAGACCACCCCCCTGTGCTGGACAGCGACGGCTCATTCTTCCT
GGTGTCCAAGCTGACCGTGGACAAGAGCCGGTGGCAGGAAGGCAACGTGTTTCAGCTGCTCCGTGATGCACGAGGCC
CTGCACAACCACTACACCCAGAAGTCCCTGTCTCTGTCCCTGGGC 3 560

AGAGCCCACCTGGTGCAGTCTGGCACCGCCATGAAGAAACCAGGCGCCTCTGTGCGGGTGTCTGTGACACAAGCG
GCTACACCTTCACCGCCACATCCTGTTCTGGTTCGGGCAGGCCCTGGCAGAGGACTGGAATGGGTGGGATGGATC
AAGCCCCAGTATGGCGCCACCAACTTCGGCGGAGGCTTCCGGGATAGAGTGACCCTGACCCGGGACGTGTACCGCG
AGATCGCCTACATGGACATCCGGGGCCTGAAGCCCGATGACACCGCCGTGTACTACTGCGCCAGAGACAGAAGCTAC
GGCGACAGCAGCTGGGCTCTGGATGCTTGGGGCCAGGGCACAAACCGTGGTGGTGTCTGCCGCCTCTACAAAGGGCCC
ATCGGTGTTCCCTCTGGCCCCTTGACGACAGAAGCACCAGCGAATCTACAGCCGCCCTGGGCTGCCTCGTGAAGGACT
ACTTTCCCGAGCCCGTGACCGTGTCTGGAAGTCTGGCGCTCTGACAAGCGGCGTGCACACCTTTCCAGCCGTGCTC
CAGAGCAGCGGCCTGTACTCTCTGAGCAGCGTCGTGACAGTGCCCAGCAGCAGCCTGGGCACCAAGACCTACACCTG
TAACGTGGACCACAAGCCCAGCAACACCAAGGTGGACAAGCGGGTGGAATCTAAGTACGGCCCTCCCTGCCCTCCTT
GCCAGCCCCCTGAAGCTGCCGGCGGACCCTCCGTGTTCCCTGTTCCCCCAAAGCCCAAGGACACCCTGATGATCAGC
CGGACCCCCGAAGTGACCTGCGTGGTGGTGGATGTGTCCCAGGAAGATCCCGAGGTGCAGTTCAATTGGTACGTGGA
CGGCGTGGAAAGTGCACAACGCCAAGACCAAGCCCAGAGAGGAACAGTTCAACAGCACCTACCGGGTGGTGTCCGTG
CTGACCGTGCTGCACCAGGACTGGCTGAACGGCAAAGAGTACAAGTGCAAGGTGTCCAACAAGGGCCTGCCAGCT
CCATCGAGAAAACCATCAGCAAGGCCAAGGGCCAGCCCCGCGAGCCTCAAGTGTATACCCTGCCCCCTTGCCAGGA
AGAGATGACCAAGAACCAGGTGTCCCTGTGGTGTCTCGTGAAAGGCTTCTACCCAGCGACATTGCCGTGGAATGGG
AGAGCAACGGCCAGCCCGAGAACAATAAGACCACCCCCCTGTGCTGGACAGCGACGGCTCATTCTTCCTGTAC
TCCAAGCTGACCGTGGACAAGAGCCGGTGGCAGGAAGGCAACGTGTTTCAGCTGCTCCGTGATGCACGAGGCCCTGC
ACAACCACTACACCCAGAAGTCCCTGTCTCTGTCCCTGGGC 4 561

TACATCCACGTGACCCAGAGCCCCAGCAGCCTGTCCGTGTCCATCGGCGACAGAGTGACCATCAACTGCCAGACCTC
TCAGGGCGTGGGCAGCGACCTGCACTGGTATCAGCACAAAGCCTGGCAGAGCCCCCAAGCTGCTGATCCACCACACA
AGCAGCTCCGAAGAGGGCGTGCCAGCAGATTTCCGGCAGCGGCTTCCACACCAGCTTCAACCTGACCATCAGCGA
TCTGCAGGCCGACGACATTGCCACCTACTATTGTCAGGTGCTGCAGTTCTTCCGGCAGAGGCAGCAGACTGCACATCA
AGCGTACGGTGGCCGCTCCCAGCGTGTTCATCTTCCCACCTAGCGACGAGCAGCTGAAGTCCGGCACAGCCTCTGTC
GTGTGCCTGCTGAACAACTTCTACCCCCGCGAGGCCAAAGTGCAGTGGAAGGTGGACAACGCCCTGCAGAGCGGCA
ACAGCCAGGAAAGCGTGACCGAGCAGGACAGCAAGGACTCCACCTACAGCCTGAGCAGCACCCCTGACACTGAGCAA

GGCCGACTCAGAAAGCACAGAGGTGTACGCTTGCGAAGTGACCCACCAGGGCCTGTCTAGCCCCGTGACCAAGAGC
TTCAACCGGGGCGAGTGT Trispecific 1 562
GACATCGTGATGACCCAGACCCCCCTGAGCCTGAGCGTGACACCTGGACAGCCTGCCAGCATCAGCTGCAAGAGCA
26 N6_rw52/
GCCAGAGCCTGGTGCACGAGAACCTGTTACCTACCTGAGCTGGTATCTGCAGAAGCCCGGCCAGAGCCCCCAGTCC
CD28sup ×
CTGATCTACAAGGTGTCCAACAGATTACAGCGGCGTGCCCGACAGATTCTCCGGCAGCGGCTCTGGCACCGACTTCAC
CD3mid_
CCTGAAGATCAGCCGGGTGGAAGCCGAGGACGTGGGCGTGTACTATTGTGGCCAGGGCACCCAGTACCCCTTCACCT
ENLF IgG4
TTGGCAGCGGCACCAAGGTGGAATCAAGGACAAAACCCATACCGACATCCAGATGACCCAGAGCCCCAGCAGCCT
FALA/409K_
GTCTGCCAGCGTGGGCGACAGAGTGACCATCACCTGTCAGGCCAGCCAGAACATCTACGTGTGGCTGAACTGGTATC
DKTHT linker
AGCAGAAGCCCGGCAAGGCCCCCAAGCTGCTGATCTACAAGGCCAGCAACCTGCACACCGGCGTGCCAGCAGATT
TTCTGGCAGCGGCTCCGGCACCGACTTCACCTTGACAATCAGCTCCCTGCAGCCCGAGGACATTGCCACCTACTACT
GCCAGCAGGGCCAGACCTACCCCTACACCTTTGGCCAGGGCACCAAGCTGGAAATCAAGGATAAGACCCACACCCG
TACGGTGGCCGCTCCCAGCGTGTTTCATCTTCCCACCTAGCGACGAGCAGCTGAAGTCCGGCACAGCCTCTGTCTGT
GCCTGCTGAACAACTTCTACCCCCGCGAGGCCAAAGTGCAAGTGGGAGGTGGACAACGCCCTGCAGAGCGGCCAACAG
CCAGGAAAGCGTGACCGAGCAGGACAGCAAGGACTCCACCTACAGCCTGAGCAGCACCCCTGACACTGAGCAAGGCC
GACTACGAGAAGCACAAAGGTGTACGCCTGCGAAGTGACCCACCAGGGCCTGTCTAGCCCCGTGACCAAGAGCTTCA
ACCGGGGCGAGTGT 2 563
CAGGTGCAGCTGGTGCAGTCTGGCGCCGAGGTTCGTGAAACCTGGCGCCTCTGTGAAGGTGTCCTGCAAGGCCAGCGG
CTACACCTTTACCAGCTACTACATCCACTGGGTGCGCCAGGCCCTTGACAGGGACTGGAATGGATCGGCAGCATCT
ACCCCGGCAACGTGAACACCAACTACGCCCAGAAGTTCAGGGCAGAGCCACCCTGACCGTGGACACCAGCATCAG
CACCGCCTACATGGAAGTGAAGCCGGCTGAGAAGCGACGACACCGCCGTGTACTACTGCACCCGGTCCCCTACGGCC
TGGATTGGAAGTTCGACGTGTGGGGCAAGGGCACCAACCGTGACAGTGTCTAGCGACAAAACCCATACCCAGGTGCA
GCTGGTGGAACTCTGGCGGCGGAGTGGTGCAGCCTGGCAGAAGCCTGAGACTGAGCTGTGCCGCCAGCGGCTTCACCT
TCACCAAGGCCTGGATGCACTGGGTGCGCCAGGCCCTTGAAAGCAGCTGGAATGGGTGGCCAGATCAAGGACAA
GAGCAACAGCTACGCCACCTACTACGCCGACAGCGTGAAGGGCCGTTTACCATCAGCCGGGACGACAGCAAGAAC
ACCCTGTACCTGCAGATGAACAGCCTGCGGGCCGAGGACACCGCCGTGTACTACTGTCCGGGCGTGTACTATGCCCT
GAGCCCCCTTCGATTACTGGGGCCAGGGAACCCTCGTGACCGTGTCTAGTGATAAGACCCACACCGCCAGCACAAAG
GCCATCGGTGTTCCCTCTGGCCCCTTGACGAGCAAGCACCAAGCGAATCTACAGCCGCCCTGGGCTGCCTCGTGAAG
GACTACTTTCCCGAGCCCGTGACCGTGTCTGGAAGTCTGGCGCTCTGACAAGCGGCGTGACACACCTTTCCAGCCGT
GCTCCAGAGCAGCGGCCTGTACTCTCTGAGCAGCGTCGTGACAGTGCCCAGCAGCAGCCTGGGCACCAAGACCTACA
CCTGTAACGTGGACCACAAGCCCAGCAACACCAAGGTGGACAAGCGGGTGGAAATCTAAGTACGGCCCTCCCTGCCCT
CCTTGCCCAGCCCCCTGAAGCTGCCGGCGGACCCTCCGTGTTCCCTGTTCCCCCAAAGCCCAAGGACACCCTGATGAT
CAGCCGGACCCCCGAAGTGACCTGCGTGGTGGTGGATGTGTCCAGGAAGATCCCGAGGTGCAGTTCAATTGGTACG
TGGACGGCGTGGAAGTGACAAACGCCAAGACCAAGCCCAGAGAGGAACAGTTCAACAGCACCTACCGGGTGGTGTCC
GTGCTGACCGTGCTGCACCAGGACTGGCTGAACGGCAAAGAGTACAAGTGCAAGGTGTCCAACAAGGGCCTGCCCA
GCTCCATCGAGAAAACCATCAGCAAGGCCAAGGGCCAGCCCCGCGAGCCTCAAGTGTGTACCCTGCCCCCTAGCCA
GGAAGAGATGACCAAGAACCAGGTGTCCCTGAGCTGTGCCGTGAAAGGCTTCTACCCAGCGACATTGCCGTGGAA
TGGGAGAGCAACGGCCAGCCCCGAGAACAACCTACAAGACCACCCCCCTGTGCTGGACAGCGACGGCTCATTCTTCCT
GGTGTCCAAGCTGACCGTGGACAAGAGCCGGTGGCAGGAAGGCAACGTGTTACAGTGCTCCGTGATGCACGAGGCC
CTGCACAACCACTACACCCAGAAGTCCCTGTCTCTGTCCCTGGGC 3 564
AGAGCCCACCTGGTGCAGTCTGGCACCGCCATGAAGAAACCAGGCGCCTCTGTGCGGGTGTCTGTGACACAAGCG
GCTACACCTTCACCGCCACATCCTGTTCTGGTTCCGGCAGGCCCTGGCAGAGGACTGGAATGGGTGGGATGGATC
AAGCCCCAGTATGGCGCCACCAACTTCGGCGGAGGCTTCCGGGATAGAGTGACCCTGACCCGGGACGTGTACCGCG
AGATCGCCTACATGGACATCCGGGGCCTGAAGCCCGATGACACCGCCGTGTACTACTGCGCCAGAGACAGAAGCTAC
GGCGACAGCAGCTGGGCTCTGGATGCTTGGGGCCAGGGCACAAACCGTGGTGGTGTCTGCCGCCTCTACAAAGGGCCC
ATCGGTGTTCCCTCTGGCCCCCTTGACGAGCAAGCACCAAGCGAATCTACAGCCGCCCTGGGCTGCCTCGTGAAGGACT
ACTTTCCCGAGCCCGTGACCGTGTCTGGAAGTCTGGCGCTCTGACAAGCGGCGTGACACACCTTTCCAGCCGTGCTC
CAGAGCAGCGGCCTGTACTCTCTGAGCAGCGTCGTGACAGTGCCCAGCAGCAGCCTGGGCACCAAGACCTACACCTG
TAACGTGGACCACAAGCCCAGCAACACCAAGGTGGACAAGCGGGTGGAAATCTAAGTACGGCCCTCCCTGCCCTCCTT
GCCAGCCCCCTGAAGCTGCCGGCGGACCCTCCGTGTTCCCTGTTCCCCCAAAGCCCAAGGACACCCTGATGATCAGC
CGGACCCCCGAAGTGACCTGCGTGGTGGTGGATGTGTCCAGGAAGATCCCGAGGTGCAGTTCAATTGGTACGTGGA
CGGCGTGGAAAGTGACAAACGCCAAGACCAAGCCCAGAGAGGAACAGTTCAACAGCACCTACCGGGTGGTGTCCGTG
CTGACCGTGCTGCACCAGGACTGGCTGAACGGCAAAGAGTACAAGTGCAAGGTGTCCAACAAGGGCCTGCCAGCT
CCATCGAGAAAACCATCAGCAAGGCCAAGGGCCAGCCCCGCGAGCCTCAAGTGTATACCCTGCCCCCTTGCCAGGA
AGAGATGACCAAGAACCAGGTGTCCCTGTGGTGTCTCGTGAAAGGCTTCTACCCAGCGACATTGCCGTGGAAATGGG
AGAGCAACGGCCAGCCCCGAGAACAACCTACAAGACCACCCCCCTGTGCTGGACAGCGACGGCTCATTCTTCCTGTAC
TCCAAGCTGACCGTGGACAAGAGCCGGTGGCAGGAAGGCAACGTGTTACAGTGCTCCGTGATGCACGAGGCCCTGC
ACAACCACTACACCCAGAAGTCCCTGTCTCTGTCCCTGGGC 4 565

TACATCGCTGACCGAGGCCACAGCCACAGCGCTGTCCTGTCCTGCGGCAGACAGTGCACCATCAACTGCCAGACCTC
TCAGGGCGTGGGCAGCGACCTGCACTGGTATCAGCACAAGCCTGGCAGAGCCCCCAAGCTGCTGATCCACCACACA
AGCAGCTCCGAAGAGGGCGTGCCAGCAGATTTTCCGGCAGCGGCTTCCACACCAGCTTCAACCTGACCATCAGCGA
TCTGCAGGCCGACGACATTGCCACCTACTATTGTCAGGTGCTGCAGTTCTTCCGGCAGAGGCAGCAGACTGCACATCA
AGCGTACGGTGGCCGCTCCCAGCGTGTTTCATCTTCCCACCTAGCGACGAGCAGCTGAAGTCCGGCACAGCCTCTGTC
GTGTGCCTGCTGAACAACCTTCTACCCCCGCGAGGCCAAAGTGCAGTGGAAGGTGGACAACGCCCTGCAGAGCGGCA
ACAGCCAGGAAAGCGTGACCGAGCAGGACAGCAAGGACTCCACCTACAGCCTGAGCAGCACCCCTGACACTGAGCAA
GGCCGACTACGAGAAGCACAAGGTGTACGCCTGCGAAGTGACCCACCAGGGCCTGTCTAGCCCCGTGACCAAGAGC
TTCAACCGGGGCGAGTGT Trispecific 1 566

GACATCGTGATGACCCAGACCCCCCTGAGCGTGACACCTGGACAGCCTGCCAGCATCAGCTGCAAGAGCA
27 N6_rw52/

GCCAGAGCCTGGTGACGAGAACCTGTTACCTACCTGAGCTGGTATCTGCAGAAGCCCGGCCAGAGCCCCAGTCC
CD28sup ×

CTGATCTACAAGGTGTCCAACAGATTACGCGGCGTGCCCGACAGATTCTCCGGCAGCGGCTCTGGCACCGACTTCAC
CD3mid_

CCTGAAGATCAGCCGGGTGGAAGCCGAGGACGTGGGCGTGTAATAATTGTGGCCAGGGCACCCAGTACCCCTTCACCT
ENLF

TTGGCAGCGGCACCAAGGTGGAATCAAGGACAAAACCCATACCGACATCCAGATGACCCAGAGCCCCAGCAGCCT
IgG1_NNAS_

GTCTGCCAGCGTGCGGACAGAGTGACCATCACCTGTCAGGCCAGCCAGAACATCTACGTGTGGCTGAACTGGTATC
DKTHT linker

AGCAGAAGCCCGGCAAGGCCCCCAAGCTGCTGATCTACAAGGCCAGCAACCTGCACACCGGCGTGCCAGCAGATT
TTCTGGCAGCGGCTCCGGCACCGACTTCACCCTGACAATCAGCTCCCTGCAGCCCCGAGGACATTGCCACCTACTACT
GCCAGCAGGGCCAGACCTACCCCTACACCTTTGGCCAGGGCACCAAGCTGGAAATCAAGGATAAGACCCACACCCG
TACGGTGGCCGCTCCCAGCGTGTTTCATCTTCCCACCTAGCGACGAGCAGCTGAAGTCCGGCACAGCCTCTGTCTGT
GCCTGCTGAACAACCTTCTACCCCCGCGAGGCCAAAGTGCAGTGGAAGGTGGACAACGCCCTGCAGAGCGGCAACAG
CCAGGAAAGCGTGACCGAGCAGGACAGCAAGGACTCCACCTACAGCCTGAGCAGCACCCCTGACACTGAGCAAGGCC
GACTACGAGAAGCACAAGGTGTACGCCTGCGAAGTGACCCACCAGGGCCTGTCTAGCCCCGTGACCAAGAGCTTCA
ACCGGGGCGAGTGT 2 567

CAGGTGCAGCTGGTGCACTCTGGCGCCGAGGTCGTGAAACCTGGCGCCTCTGTGAAGGTGTCCTGCAAGGCCAGCGG
CTACACCTTTACCAGCTACTACATCCACTGGGTGCGCCAGGCCCTGGACAGGGACTGGAATGGATCGGCAGCATCT
ACCCCGGCAACGTGAACACCAACTACGCCCAGAAGTTCCAGGGCAGAGCCACCCTGACCGTGGACACCAGCATCAG
CACCGCCTACATGGAAGTGAAGCCGGCTGAGAAGCGACGACACCGCCGTGTACTACTGCACCCGGTCCCACTACGGCC
TGGATTGGAATTCGACGTGTGGGGCAAGGGCACCAACCGTGACAGTGTCTAGCGACAAAACCCATACCCAGGTGCA
GCTGGTGGAAATCTGGCGGCGGAGTGGTGCAGCCTGGCAGAAGCCTGAGACTGAGCTGTGCCGCCAGCGGCTTCACCT
TCACCAAGGCCTGGATGCACTGGGTGCGCCAGGCCCTGGAAAGCAGCTGGAATGGGTGGGCCAGATCAAGGACAA
GAGCAACAGCTACGCCACCTACTACGCCGACAGCGTGAAGGGCCGGTTACCATCAGCCGGGACGACAGCAAGAAC
ACCCTGTACCTGCAGATGAACAGCCTGCGGGCCGAGGACACCGCCGTGTACTACTGTCGGGGCGTGTACTATGCCCT
GAGCCCCTTCGATTACTGGGGCCAGGGAACCCCTCGTGACCGTGTCTAGTGATAAGACCCACACCGCCAGCACAAAGG
GCCCCAGCGTGTCCCTCTGGCCCCCTAGCAGCAAGAGCACATCTGGCGGAACAGCCGCCCTGGGCTGCCTCGTGAAG
GACTACTTTCCCGAGCCCGTGACCGTGTCTGGAATTCTGGCGCCCTGACCAGCGGCGTGCACACCTTTCCAGCTGT
GCTGCAGTCCAGCGGCTGTACAGCCTGAGCAGCGTCGTGACAGTGCCCAGCAGCTCTCTGGGCACCCAGACCTACA
TCTGCAACGTGAACCACAAGCCCAGCAACACCAAGGTGGACAAGAAGGTGGAACCCAAGAGCTGCGACAAGACCCA
ACCTGTCCCCCTTGTCTGCCCCCGAAGTGTGAGGAGGCCCTTCCGTGTTCTGTTCCCCCACAAGCCCAAGGACAC
CCTGATGATCAGCCGGACCCCCGAAGTGACCTGCGTGGTGGTGGATGTGTCCCACGAGGACCCTGAAGTGAAGTTCA
ATTGGTACGTGGACGGCGTGGAAGTGCACAACGCCAAGACCAAGCCAAGAGAGGAACAGTACAACAATGCCTCCCG
GGTGGTGTCCGTGCTGACCGTGCTGCACCAGGACTGGCTGAACGGCAAAGAGTACAAGTGCAAGGTGTCCAACAAG
GCCCTGCCTGCCCCCATCGAGAAAACCATCAGCAAGGCCAAGGGCCAGCCCCGCGAACCCAGGTGTGCACACTGC
CCCCAAGCAGGGACGAGCTGACCAAGAACCAGGTGTCCCTGAGCTGTGCCGTGAAAGGCTTCTACCCCTCCGATATC
GCCGTGGAATGGGAGAGCAACGGCCAGCCCGAGAACAACCTACAAGACCACCCCCCTGTGCTGGACAGCGACGGCT
CATCTTCTCTGGTGTCCAAGCTGACAGTGGACAAGTCCCGGTGGCAGCAGGGCAACGTGTTACAGCTGCTCCGTGATG
CACGAGGCCCTGCACAACCACTACACCCAGAAGTCCCTGAGCCTGAGCCCCGGC 3 568

AGAGCCCACCTGGTGCACTCTGGCACCGCCATGAAGAAACCAGGCGCCTCTGTGCGGGTGTCTGTGACACAAGCG
GCTACACCTTCACCGCCACATCCTGTTCTGGTTCCGGCAGGCCCTGGCAGAGGACTGGAATGGGTGGGATGGATC
AAGCCCCAGTATGGCGCCACCAACTTCGGCGGAGGCTTCCGGGATAGAGTGACCCTGACCCGGGACGTGTACCGCG
AGATCGCCTACATGGACATCCGGGGCCTGAAGCCCGATGACACCGCCGTGTACTACTGCGCCAGAGACAGAAGCTA
CGGCGACAGCAGCTGGGCTCTGGATGCTTGGGGCCAGGGCACAAACCGTGGTGGTGTCTGCCGCTCTACAAAGGGCC
CATCGGTCTTCCCCCTGGCACCCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGCCTGGTCAAGGAC
TACTTCCCCGAACCGGTGACGGTGTCTGTGGAACCTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTCT
ACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTTGGGCACCCAGACCTACATCT
GCAACGTGAATCACAAGCCCAGCAACACCAAGGTGGACAAGAAAGTTGAGCCCAAATCTTGTGACAAAACCTCACAC
ATGCCACCGTGCCAGCACCTGAACTCCTGGGGGGACCGTCAGTCTTCTCTTCCCCCACAACCCCAAGGACACCC
TCATGATCTCCCGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAAC

TGGTATGTTGACGGCGTGGAGGTGCATAAATGCCAAGACAAAGCCGCGGAGGAGCAGTACAACAATGCCTCCCGTG
TGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGCC
CTCCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAACCACAGGTGTACACCCTGCCCC
CATGCCGGGATGAGCTGACCAAGAATCAAGTCAGCCTGTGGTGCCTGGTAAAAGGCTTCTATCCCAGCGACATCGCC
GTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAATAACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCT
TCTTCCTCTACTCAAACTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCAT
GAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCGGGT 4 569
TACATCCACGTGACCCAGAGCCCCAGCAGCCTGTCCGTGTCCATCGGGCAGAGAGTGACCATCAACTGCCAGACCTC
TCAGGGCGTGGGCAGCGACCTGCACTGGTATCAGCACAAGCCTGGCAGAGCCCCCAAGCTGCTGATCCACCACACA
AGCAGCTCCGAAGAGGGCGTGCCCAGCAGATTTCCGGCAGCGGCTTCCACACCAGCTTCAACCTGACCATCAGCGA
TCTGCAGGCCGACGACATTGCCACCTACTATTGTCAGGTGCTGCAGTTCTTCGGCAGAGGCAGCAGACTGCACATCA
AGCGTACGGTGGCCGCTCCCAGCGTGTTTCATCTTCCCACCTAGCGACGAGCAGCTGAAGTCCGGCACAGCCTCTGTC
GTGTGCCTGCTGAACAACCTTCTACCCCCGCGAGGCCAAAGTGCAAGTGGAAAGGTGGACAACGCCCTGCAGAGCGGCA
ACAGCCAGGAAAGCGTGACCGAGCAGGACAGCAAGGACTCCACCTACAGCCTGAGCAGCACCCTGACACTGAGCAA
GGCCGACTACGAGAAGCACAAGGTGTACGCCTGCGAAGTGACCCACCAGGGCCTGTCTAGCCCCGTGACCAAGAGC
TTCAACCGGGGCGAGTGT Trispecific 1 570
GACATCGTGATGACCCAGACCCCCCTGAGCCTGAGCGTGACACCTGGACAGCCTGCCAGCATCAGCTGCAAGAGCA
28 N6_FR3-03/
GCCAGAGCCTGGTGCACGAGAACCTGCAGACCTACCTGAGCTGGTATCTGCAGAAGCCCGGCCAGAGCCCCCAGTC
CD28sup ×
CCTGATCTACAAGGTGTCCAACAGATTCAGCGGCGTGCCCGACAGATTCTCCGGCAGCGGCTCTGGCACCGACTTCA
CD3mid_
CCCTGAAGATCAGCCGGGTGGAAGCCGAGGACGTGGGCGTGTAATGTGGCCAGGGCACCCAGTACCCCTTCACC
ENLQ IgG4
TTTGGCAGCGGCACCAAGGTGGAAATCAAGGACAAAACCCATACCGACATCCAGATGACCCAGAGCCCCAGCAGCC
FALA/409K_
TGTCTGCCAGCGTGGGCGACAGAGTGACCATCACCTGTCAGGCCAGCCAGAACATCTACGTGTGGCTGAACTGGTAT
DKTHT linker
CAGCAGAAGCCCGGCAAGGCCCCCAAGCTGCTGATCTACAAGGCCAGCAACCTGCACACCGGCGTGCCCAGCAGAT
TTTCTGGCAGCGGCTCCGGCACCGACTTCACCCTGACAATCAGCTCCCTGCAGCCCGAGGACATTGCCACCTACTAC
TGCCAGCAGGGCCAGACCTACCCCTACACCTTTGGCCAGGGCACCAAGCTGGAAATCAAGGATAAGACCCACACCCG
TACGGTGGCCGCTCCAGCGTGTTTCATCTTCCCACCTAGCGACGAGCAGCTGAAGTCCGGCACAGCCTCTGTCTGT
GCCTGCTGAACAACCTTCTACCCCCGCGAGGCCAAAGTGCAAGTGGAAAGGTGGACAACGCCCTGCAGAGCGGCAACAG
CCAGGAAAGCGTGACCGAGCAGGACAGCAAGGACTCCACCTACAGCCTGAGCAGCACCCTGACACTGAGCAAGGCC
GACTACGAGAAGCACAAGGTGTACGCCTGCGAAGTGACCCACCAGGGCCTGTCTAGCCCCGTGACCAAGAGCTTCA
ACCGGGGCGAGTGT 2 571
CAGGTGCAGCTGGTGCAGTCTGGCGCCGAGGTCTGTGAAACCTGGCGCCTCTGTGAAGGTGTCCTGCAAGGCCAGCGG
CTACACCTTTACCAGCTACTACATCCACTGGGTGCGCCAGGCCCTGGACAGGGACTGGAATGGATCGGCAGCATCT
ACCCCGGCAACGTGAACACCAACTACGCCCAGAAGTTCCAGGGCAGAGCCACCCTGACCGTGGACACCAGCATCAG
CACCGCCTACATGGAAGTGAAGCGGCTGAGAAGCGACGACACCGCCGTGTACTACTGCACCCGGTCCCACTACGGCC
TGGATTGGAACCTCGACGTGTGGGGCAAGGGCACCAACCGTGACAGTGTCTAGCGACAAAACCCATACCCAGGTGCA
GCTGGTGGAACTCTGGCGGCGGAGTGGTGCAGCCTGGCAGAAGCCTGAGACTGAGCTGTGCCGCCAGCGGCTTACCT
TCACCAAGGCCTGGATGCACTGGGTGCGCCAGGCCCTGGAAAGCAGCTGGAATGGGTGGCCCAGATCAAGGACAA
GAGCAACAGCTACGCCACCTACTACGCCGACAGCGTGAAGGGCCGTTTACCATCAGCCGGGACGACAGCAAGAAC
ACCCTGTACCTGCAGATGAACAGCCTGCGGGCCGAGGACACCGCCGTGTACTACTGTGCGGGCGTGTACTATGCCCT
GAGCCCCTTCGATTACTGGGGCCAGGGAACCCTCGTGACCGTGTCTAGTGATAAGACCCACACCGCCAGCACAAAGG
GCCATCGGTGTTCCCTCTGGCCCCTTGACAGCAGAAGCACCAAGCGAATCTACAGCCGCCCTGGGCTGCCTCGTGAAG
GACTACTTTCCCGAGCCCGTGACCGTGTCTGGAACCTCTGGCGCTCTGACAAGCGGCGTGACACACCTTTCCAGCCGT
GCTCCAGAGCAGCGGCTGTACTCTCTGAGCAGCGTCGTGACAGTGCCCAGCAGCAGCCTGGGCACCAAGACCTACA
CCTGTAACGTGGACCACAAGCCCAGCAACACCAAGGTGGACAAGCGGGTGGAACTTAAGTACGGCCCTCCCTGCCCT
CCTTGCCCAGCCCCTGAAGCTGCCGGCGGACCCTCCGTGTTCTGTTCCTGTTCCCCCAAGGCCAAGGACACCCTGATGAT
CAGCCGGACCCCCGAAGTGACCTGCGTGGTGGTGGATGTGTCCCAGGAAGATCCCAGAGTGCAGTTCAATTGGTACG
TGGACGGCGTGGAAGTGACACAACGCCAAGACCAAGCCCAGAGAGGAACAGTTCAACAGCACCTACCGGGTGGTGTCC
GTGCTGACCGTGCTGCACCAGGACTGGCTGAACGGCAAAGAGTACAAGTGCAAGGTGTCCAACAAGGGCCTGCCCA
GCTCCATCGAGAAAACCATCAGCAAGGCCAAGGGCCAGCCCCGCGAGCCTCAAGTGTGTACCCTGCCCCCTAGCCA
GGAAGAGATGACCAAGAACCAGGTGTCCCTGAGCTGTGCCGTGAAAGGCTTCTACCCAGCGACATTGCCGTGGAA
TGGGAGAGCAACGGCCAGCCCGAGAACAATAACAAGACCACCCCCCTGTGCTGGACAGCGACGGCTCATTCTTCCT
GGTGTCCAAGCTGACCGTGGACAAGAGCCGGTGGCAGGAAGGCAACGTGTTTCAGCTGCTCCGTGATGCACGAGGCC
CTGCACAACCACTACACCCAGAAGTCCCTGTCTCTGTCCCTGGGC 3 572
AGAGCCCACCTGGTGCAGTCTGGCACCGCCATGAAGAAACCAGGCGCCTCTGTGCGGGTGTCTGTGACACAAGCG
GCTACACCTTCACCGCCCACATCCTGTTCTGGTTCGGGCAGGCCCTGGCAGAGGACTGGAATGGGTGGGATGGATC
AAGCCCCAGTATGGCGCCGTGAACCTCGGCGGAGGCTTCCGGGATAGAGTGACCCTGACCCGGCAGCTGAGCCAGG
ACCCTGATGATCCGGATTGGGGCATCGCCTACATGGACATCCGGGGCCTGAAGCCCCGATGACACCGCCGTGTACTAC

TGCCGACAGACAGAAGCTACGGCGACAGCAGCTGGGCTCTGGATGCTTGGGGCCAGGGGCACAACCGTGGTGGTGT
CTGCCGCCTCTACAAAGGGCCCATCGGTGTTCCCTCTGGCCCCCTTGACAGCAGAAGCACCAGCGAATCTACAGCCGCC
NTGGGCTGCCTCGTGAAGGACTACTTTCCCGAGCCCGTGACCGTGTCTGGAAGTCTGGCGCTCTGACAAGCGGCGT
GCACACCTTTCCAGCCGTGCTCCAGAGCAGCGGCCTGTACTCTCTGAGCAGCGTCGTGACAGTGCCCAGCAGCAGCC
TGGGCACCAAGACCTACACCTGTAACGTGGACCACAAGCCCAGCAACACCAAGGTGGACAAGCGGGTGGAATCTAA
GTACGGCCCTCCCTGCCCTCCTTGCCCAGCCCTGAAGCTGCCGGCGGACCCTCCGTGTTCCCTGTTCCCCCAAAGC
CCAAGGACACCCTGATGATCAGCCGGACCCCCGAAGTGACCTGCGTGGTGGTGGATGTGTCCCAGGAAGATCCCGAG
GTGCAGTTCAATTGGTACGTGGACGGCGTGGAAGTGACAACGCCAAGACCAAGCCCAGAGAGGAACAGTTCAACA
GCACCTACCGGGTGGTGTCCGTGCTGACCGTGTGACCCAGGACTGGCTGAACGGCAAAGAGTACAAGTGCAAGGT
GTCCAACAAGGGCCTGCCAGCTCCATCGAGAAAACCATCAGCAAGGCCAAGGGCCAGCCCCGCGAGCCTCAAGTG
TATACCTTGCCCCCTTGCCAGGAAGAGATGACCAAGAACCAGGTGTCCCTGTGGTGTCTCGTGAAAGGCTTCTACCC
CAGCGACATTGCCGTGGAATGGGAGAGCAACGGCCAGCCCGAGAACAATAAGACCACCCCCCTGTGCTGGAC
AGCGACGGCTCATTCTTCCTGTACTCCAAGCTGACCGTGGACAAGAGCCGGTGGCAGGAAGGCAACGTGTTTCAGCTG
CTCCGTGATGCACGAGGCCCTGCACAACCACTACACCCAGAAGTCCCTGTCTGTCCCTGGGC 4 573
TACATCCACGTGACCCAGAGCCCCAGCAGCCTGTCCGTGTCCATCGGCGACAGAGTGACCATCAACTGCCAGACCTC
TCAGGGCGTGGGCAGCGACCTGCACTGGTATCAGCACAAGCCTGGCAGAGCCCCCAAGCTGCTGATCCACCACACA
AGCAGCGTGGAAGATGGCGTGCCAGCAGATTTTCCGGCAGCGGCTTCCACACCAGCTTCAACCTGACCATCAGCGA
TCTGCAGGCCGACGACATTGCCACCTACTATTGTCAGGTGCTGCAGTCTTTCGGCAGAGGCAGCAGACTGCACATCA
AGCGTACGGTGGCCGCTCCCAGCGTGTTTCATCTTCCCACCTAGCGACGAGCAGCTGAAGTCCGGCACAGCCTCTGTC
GTGTGCCTGCTGAACAACCTTCTACCCCCGCGAGGCCAAAGTGACGTGGAAGGTGGACAACGCCCTGCAGAGCGGCA
ACAGCCAGGAAAGCGTGACCGAGCAGGACAGCAAGGACTCCACCTACAGCCTGAGCAGCACCCCTGACACTGAGCAA
GGCCGACTACGAGAAGCACAAGGTGTACGCCTGCGAAGTGACCCACCAGGGCCTGTCTAGCCCCGTGACCAAGAGC
TTCAACCGGGGCGAGTGT Trispecific 1 574
GACATCGTGATGACCCAGACCCCCCTGAGCCTGAGCGTGACACCTGGACAGCCTGCCAGCATCAGCTGCAAGAGCA
29 N6_FR3-03/
GCCAGAGCCTGGTGCACGAGAACCTGTTCACCTACCTGAGCTGGTATCTGCAGAAGCCCGGCCAGAGCCCCAGTCC
CD28sup ×
CTGATCTACAAGGTGTCCAACAGATTACAGCGGCGTGCCCGACAGATTCTCCGGCAGCGGCTCTGGCACCGACTTCAC
CD3mid_
CCTGAAGATCAGCCGGGTGGAAGCCGAGGACGTGGGCGTGTAATTGTGGCCAGGGCACCCAGTACCCCTTCACCT
ENLF IgG4
TTGGCAGCGGCACCAAGGTGGAATCAAGGACAAAACCCATACCGACATCCAGATGACCCAGAGCCCCAGCAGCCT
FALA/409K_
GTCTGCCAGCGTGGGCGACAGAGTGACCATCACCTGTCAGGCCAGCCAGAACATCTACGTGTGGCTGAACTGGTATC
DKTHT linker
AGCAGAAGCCCGGCAAGGCCCCCAAGCTGCTGATCTACAAGGCCAGCAACCTGCACACCGGCGTGCCCAGCAGATT
TTCTGGCAGCGGCTCCGGCACCGACTTCACCTGACAATCAGCTCCCTGCAGCCCGAGGACATTGCCACCTACTACT
GCCAGCAGGGCCAGACCTACCCCTACACCTTTGGCCAGGGCACCAAGCTGGAAATCAAGGATAAGACCCACACCCG
TACGGTGGCCGCTCCCAGCGTGTTTCATCTTCCCACCTAGCGACGAGCAGCTGAAGTCCGGCACAGCCTCTGTCTGT
GCCTGCTGAACAACCTTCTACCCCCGCGAGGCCAAAGTGACGTGGAAGGTGGACAACGCCCTGCAGAGCGGCAACAG
CCAGGAAAGCGTGACCGAGCAGGACAGCAAGGACTCCACCTACAGCCTGAGCAGCACCCCTGACACTGAGCAAGGCC
GACTACGAGAAGCACAAGGTGTACGCCTGCGAAGTGACCCACCAGGGCCTGTCTAGCCCCGTGACCAAGAGCTTCA
ACCGGGGCGAGTGT 2 575
CAGGTGCAGCTGGTGCAGTCTGGCGCCGAGGTCTGTGAAACCTGGCGCCTCTGTGAAGGTGTCCTGCAAGGCCAGCGG
CTACACCTTTACCAGCTACTACATCCACTGGGTGCGCCAGGCCCTTGACAGGGACTGGAATGGATCGGCAGCATCT
ACCCCGGCAACGTGAACACCAACTACGCCCAGAAGTTCAGGGCAGAGCCACCCTGACCGTGGACACCAGCATCAG
CACCGCCTACATGGAAGTGAAGCCGGCTGAGAAGCGACGACACCGCCGTGTACTACTGCACCCGGTCCCCTACGGCC
TGGATTGGAACCTCGACGTGTGGGGCAAGGGCACCAACCGTGACAGTGTCTAGCGACAAAACCCATAACCCAGGTGCA
GCTGGTGGAACTCTGGCGGCGGAGTGGTGCAGCCTGGCAGAAGCCTGAGACTGAGCTGTGCCGCCAGCGGCTTCACCT
TCACCAAGGCCTGGATGCACTGGGTGCGCCAGGCCCTTGAAAGCAGCTGGAATGGGTGGCCCAGATCAAGGACAA
GAGCAACAGCTACGCCACCTACTACGCCGACAGCGTGAAGGGCCGTTTACCATCAGCCGGGACGACAGCAAGAAC
ACCCTGTACCTGCAGATGAACAGCCTGCGGGCCGAGGACACCGCCGTGTACTACTGTCGGGGCGTGTACTATGCCCT
GAGCCCCTTCGATTACTGGGGCCAGGGAACCCCTCGTGACCGTGTCTAGTGATAAGACCCACACCGCCAGCACAAAGG
GCCATCGGTGTTCCCTCTGGCCCCCTTGACAGCAGAAGCACCAGCGAATCTACAGCCGCCCTGGGCTGCCTCGTGAAG
GACTACTTTCCCGAGCCCGTGACCGTGTCTGGAAGTCTGGCGCTCTGACAAGCGGCGTGACACACCTTTCCAGCCGT
GCTCCAGAGCAGCGGCCTGTACTCTCTGAGCAGCGTCGTGACAGTGCCCAGCAGCAGCCTGGGCACCAAGACCTACA
CCTGTAACGTGGACCACAAGCCCAGCAACACCAAGGTGGACAAGCGGGTGGAAATCTAAGTACGGCCCTCCCTGCCCT
CCTTGCCCAGCCCCTGAAGCTGCCGGCGGACCCTCCGTGTTCCCTGTTCCCCCAAAGCCCAAGGACACCCTGATGAT
CAGCCGGACCCCCGAAGTGACCTGCGTGGTGGTGGATGTGTCCAGGAAGATCCCAGAGTGACGTTCAATTGGTACG
TGGACGGCGTGGAAGTGACACAACGCCAAGACCAAGCCCAGAGAGGAACAGTTCAACAGCACCTACCGGGTGGTGTCC
GTGCTGACCGTGTGTCACCAGGACTGGCTGAACGGCAAAGAGTACAAGTGCAAGGTGTCCAACAAGGGCCTGCCCA
GCTCCATCGAGAAAACCATCAGCAAGGCCAAGGGCCAGCCCCGCGAGCCTCAAGTGTGTACCCTGCCCCCTAGCCA
GGAAGAGATGACCAAGAACCAGGTGTCCCTGAGCTGTGCCGTGAAAGGCTTCTACCCAGCGACATTGCCGTGGAA

TGGAGGAGCAACGCGCCAGACGCCGAGAACAATACAAAGACCCACCCCTGTGCTGGACAGCGACGGCTCATTCTTCTT
GGTGTCCAAGCTGACCGTGGACAAGAGCCGGTGGCAGGAAGGCAACGTGTTCAGCTGCTCCGTGATGCACGAGGCC
CTGCACAACCACTACACCCAGAAGTCCCTGTCTCTGTCCCTGGGC 3 576
AGAGCCCACCTGGTGCAGTCTGGCACCGCCATGAAGAAACCAGGCGCCTCTGTGCGGGTGTCTGTGTCAGACAAGCG
GCTACACCTTCACCGCCCATCTCTGTTCTGGTTCCGGCAGGCCCTGGCAGAGGACTGGAATGGGTGGGATGGATC
AAGCCCCAGTATGGCGCCGTGAACTTCGGCGGAGGCTTCCGGGATAGAGTGACCCTGACCCGGCAGCTGAGCCAGG
ACCCTGATGATCCGGATTGGGGCATCGCTACATGGACATCCGGGGCCTGAAGCCCCGATGACACCGCCGTGTACTAC
TGCGCCAGAGACAGAAGCTACGGCGACAGCAGCTGGGCTCTGGATGCTTGGGGCCAGGGCACAACCGTGGTGGTGT
CTGCCGCCTCTACAAAGGGCCCATCGGTGTTCCCTCTGGCCCCCTTGACAGCAGAAGCACCAGCGAATCTACAGCCGCC
NTGGGCTGCCTCGTGAAGGACTACTTTCCCGAGCCCGTGACCGTGTCTTGGAACTCTGGCGCTCTGACAAGCGGCGT
GCACACCTTTCCAGCCGTGCTCCAGAGCAGCGGCCCTGTACTCTCTGAGCAGCGTCGTGACAGTGCCCAGCAGCAGCC
TGGGCACCAAGACCTACACCTGTAACTGGACCACAAGCCCAGCAACACCAAGGTGGACAAGCGGGTGGAACTCTAA
GTACGGCCCTCCCTGCCCTCCTTGCCCAGCCCTGAAGCTGCCGGCGGACCCTCCGTGTTCCCTGTTCCCCCAAAGC
CCAAGGACACCCCTGATGATCAGCCGGACCCCCGAAGTGACCTGCGTGGTGGTGGATGTGTCCCAGGAAGATCCCGAG
GTGCAGTTCAATTGGTACGTGGACGGCGTGGAAGTGACACAACGCCAAGACCAAGCCCAGAGAGGAACAGTTCAACA
GCACCTACCGGGTGGTGTCCGTGCTGACCGTGCTGCACCAGGACTGGCTGAACGGCAAAGAGTACAAGTGCAAGGT
GTCCAACAAGGGCCTGCCAGCTCCATCGAGAAAACCATCAGCAAGGCCAAGGGCCAGCCCCGCGAGCCTCAAGTG
TATACCCTGCCCCCTTGCCAGGAAGAGATGACCAAGAACCAGGTGTCCCTGTGGTGTCTCGTGAAAGGCTTCTACCC
CAGCGACATTGCCGTGGAATGGGAGAGCAACGGCCAGCCCGAGAACAACCTACAAGACCACCCCCCTGTGCTGGAC
AGCGACGGCTCATTCTTCTGTACTCCAAGCTGACCGTGGACAAGAGCCGGTGGCAGGAAGGCAACGTGTTCAGCTG
CTCCGTGATGCACGAGGCCCTGCACAACCACTACACCCAGAAGTCCCTGTCTCTGTCCCTGGGC 4 577
TACATCCACGTGACCCAGAGCCCCAGCAGCCTGTCCGTGTCCATCGGCGACAGAGTGACCATCAACTGCCAGACCTC
TCAGGGCGTGGGCAGCGACCTGCACTGGTATCAGCACAAGCCTGGCAGAGCCCCCAAGCTGCTGATCCACCACACA
AGCAGCGTGGAAGATGGCGTGCCAGCAGATTTTCCGGCAGCGGCTTCCACACCAGCTTCAACCTGACCATCAGCGA
TCTGCAGGCCGACGACATTGCCACCTACTATTGTGAGGTGCTGCAGTTCTTCGGCAGAGGCAGCAGACTGCACATCA
AGCGTACGGTGGCCGCTCCCAGCGTGTTTCATCTTCCCACCTAGCGACGAGCAGCTGAAGTCCGGCACAGCCTCTGTC
GTGTGCCTGCTGAACAACCTTCTACCCCCGCGAGGCCAAAGTGCAAGTGGAAAGGTGGACAACGCCCTGCAGAGCGGCA
ACAGCCAGGAAAGCGTGACCGAGCAGGACAGCAAGGACTCCACCTACAGCCTGAGCAGCACCCCTGACACTGAGCAA
GGCCGACTACGAGAAGCACAAGGTGTACGCCTGCGAAGTGACCCACCAGGGCCTGTCTAGCCCCGTGACCAAGAGC
TTCAACCGGGGCGAGTGT Trispecific 1 578
GACATCGTGATGACCCAGACCCCCCTGAGCCTGAGCGTGACACCTGGACAGCCTGCCAGCATCAGCTGCAAGAGCA
30 N6_FR3-03/
GCCAGAGCCTGGTGCACGAGAACCTGCAGACCTACCTGAGCTGGTATCTGCAGAAGCCCGGCCAGAGCCCCCAGTC
CD28sup ×
CCTGATCTACAAGGTGTCCAACAGATTACAGCGGCGTGCCCGACAGATTCTCCGGCAGCGGCTCTGGCACCGACTTCA
CD3mid_
CCCTGAAGATCAGCCGGGTGGAAGCCGAGGACGTGGGCGTGTAATTGTGGCCAGGGCACCCAGTACCCCTTCACC
ENLQIgG1_
TTTGGCAGCGGCACCAAGGTGGAATCAAGGACAAAACCCATACCGACATCCAGATGACCCAGAGCCCCAGCAGCC
NNAS_
TGTCTGCCAGCGTGGGCGACAGAGTGACCATCACCTGTCAGGCCAGCCAGAACATCTACGTGTGGCTGAACTGGTAT
DKTHT
CAGCAGAAGCCCGGCAAGGCCCCCAAGCTGCTGATCTACAAGGCCAGCAACCTGCACACCGGCGTGCCAGCAGAT
linker
TTTCTGGCAGCGGCTCCGGCACCGACTTCACCCTGACAATCAGCTCCCTGCAGCCCGAGGACATTGCCACCTACTAC
TGCCAGCAGGGCCAGACCTACCCCTACACCTTTGGCCAGGGCACCAAGCTGGAAATCAAGGATAAGACCCACACCCG
TACGGTGGCCGCTCCCAGCGTGTTTCATCTTCCCACCTAGCGACGAGCAGCTGAAGTCCGGCACAGCCTCTGTCTGT
GCCTGCTGAACAACCTTCTACCCCCGCGAGGCCAAAGTGCAAGTGGAAAGGTGGACAACGCCCTGCAGAGCGGCAACAG
CCAGGAAAGCGTGACCGAGCAGGACAGCAAGGACTCCACCTACAGCCTGAGCAGCACCCCTGACACTGAGCAAGGCC
GACTACGAGAAGCACAAGGTGTACGCCTGCGAAGTGACCCACCAGGGCCTGTCTAGCCCCGTGACCAAGAGCTTCA
ACCGGGGCGAGTGT 2 579
CAGGTGCAGCTGGTGCAGTCTGGCGCCGAGGTCGTGAAACCTGGCGCCTCTGTGAAGGTGTCTTGCAAGGCCAGCGG
CTACACCTTTACCAGCTACTACATCCACTGGGTGCGCCAGGCCCTGGACAGGGACTGGAATGGATCGGCAGCATCT
ACCCCGGCAACGTGAACACCAACTACGCCCAGAAGTTCCAGGGCAGAGCCACCCTGACCGTGGACACCAGCATCAG
CACCGCCTACATGGAAGTGAAGCCGGCTGAGAAGCGACGACACCGCCGTGTACTACTGCACCCGGTCCCACTACGGCC
TGGATTGGAACCTTCGACGTGTGGGGCAAGGGCACCAACCGTGACAGTGTCTAGCGACAAAACCCATACCCAGGTGCA
GCTGGTGGAACTCTGGCGGCGGAGTGGTGCAGCCTGGCAGAAGCCTGAGACTGAGCTGTGCCGCCAGCGGCTTACCT
TCACCAAGGCCTGGATGCACTGGGTGCGCCAGGCCCTGGAAAGCAGCTGGAATGGGTGGGCCAGATCAAGGACAA
GAGCAACAGCTACGCCACCTACTACGCCGACAGCGTGAAGGGCCGGTTACCATCAGCCGGGACGACAGCAAGAAC
ACCCTGTACCTGCAGATGAACAGCCTGCGGGCCGAGGACACCGCCGTGTACTACTGTCGGGGCGTGTACTATGCCCT
GAGCCCCTTCGATTACTGGGGCCAGGGAACCCCTCGTGACCGTGTCTAGTGATAAGACCCACACCGCCAGCACAAAGG
GCCCCAGCGTGTCCCTCTGGCCCCCTAGCAGCAAGAGCACATCTGGCGGAACAGCCGCCCTGGGCTGCCTCGTGAAG
GACTACTTTCCCGAGCCCGTGACCGTGTCTTGGAACTTCTGGCGCCCTGACCAGCGGCGTGACACACCTTTCCAGCTGT

CTGCTGATCCAGCGGCTGTACAGCCTGAGCAGCGTGGTGACAGTGGCCAGCAGCTCTCTTGGGCACCCAGACCTACA
TCTGCAACGTGAACCACAAGCCCAGCAACACCAAGGTGGACAAGAAGGTGGAACCCAAGAGCTGCGACAAGACCCA
ACCTGTCCCCCTTGTCTTGGCCCCGAAGTGTGGGAGGCCCTTCCGTGTTCTCTGTTCCCCCAAGGCCAAGGACAC
CCTGATGATCAGCCGGACCCCCGAAGTGACCTGCGTGGTGGTGGATGTGTCCCACGAGGACCCTGAAGTGAAGTTCA
ATTGGTACGTGGACGGCGTGGAAGTGCACAACGCCAAGACCAAGCCAAGAGAGGAACAGTACAACAATGCCTCCCG
GGTGGTGTCCGTGCTGACCGTGCTGCACCAGGACTGGCTGAACGGCAAAGAGTACAAGTGCAAGGTGTCCAACAAG
GCCCTGCCTGCCCCATCGAGAAAACCATCAGCAAGGCCAAGGGCCAGCCCCGCGAACCCAGGTGTGCACACTGC
CCCCAAGCAGGGACGAGCTGACCAAGAACCAGGTGTCCCTGAGCTGTGCCGTGAAAGGCTTCTACCCCTCCGATATC
GCCGTGGAATGGGAGAGCAACGGCCAGCCCGAGAACAATAACAAGACCACCCCCCTGTGCTGGACAGCGACGGCT
CATTCTTCTCTGGTGTCCAAGCTGACAGTGGACAAGTCCCGGTGGCAGCAGGGCAACGTGTTTACAGCTGCTCCGTGATG
CACGAGGCCCTGCACAACCACTACACCCAGAAGTCCCTGAGCCTGAGCCCCGGC 3 580

AGAGCCCACCTGGTGCAGTCTGGCACCGCCATGAAGAAACCAGGCGCCTCTGTGCGGGTGTCTGTGTCAGACAAGCG
GCTACACCTTCACCGCCCACATCCTGTTCTGGTTCGCGCAGGCCCTTGGCAGAGGACTGGAATGGGTGGGATGGATC
AAGCCCCAGTATGGCGCCGTGAACCTTCGGCGGAGGCTTCCGGGATAGAGTGACCCTGACCCGGCAGCTGAGCCAGG
ACCCTGATGATCCGGATTGGGGCATCGCCTACATGGACATCCGGGGCCTGAAGCCCCGATGACACCGCCGTGTACTAC
TGCGCCAGAGACAGAAGCTACGGCGACAGCAGCTGGGCTCTGGATGCTTGGGGCCAGGGCACAACCGTGGTGGTGT
CTGCCGCTCTACAAAGGGCCCATCGGTCTTCCCCCTGGCACCCCTCTCCAAGAGCACCTCTGGGGGCACAGCGGCC
CTGGGCTGCCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCTGGAAGTCAAGGCGCCCTGACCAGCGGCC
GCACACCTTCCCGGCTGTCTACAGTCTCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCT
TGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAACACCAAGGTGGACAAGAAAGTTGAGCCCCAA
TCTTGTGACAAAACCTACACATGCCACCGTGCCAGCACCTGAACTCCTGGGGGGACCGTCAGTCTTCTCTTCCC
CCAAAACCCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTACATGCGTGGTGGTGGACGTGAGCCACGAAG
ACCCTGAGGTCAAGTTCAACTGGTATGTTGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCA
GTACAACAATGCCTCCCGTGTGGTCAGCGTCTCACCCTGCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAGT
GCAAGGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAGCCAAAGGGCAGCCCCGAGAACC
ACAGGTGTACACCCTGCCCCCATGCCGGGATGAGCTGACCAAGAATCAAGTCAGCCTGTGGTGCCTGGTAAAAGGCT
TCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAATAACAAGACCACGCCTCCCGT
GCTGGACTCCGACGGCTCCTTCTTCTCTACTCAAAACTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCT
TCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCGGGT 4 581

TACATCCACGTGACCCAGAGCCCCAGCAGCCTGTCCGTGTCCATCGGCGACAGAGTGACCATCAACTGCCAGACCTC
TCAGGGCGTGGGCAGCGACCTGCACTGGTATCAGCACAAGCCTGGCAGAGCCCCCAAGCTGCTGATCCACCACACA
AGCAGCGTGGAAGATGGCGTGCCAGCAGATTTCCGGCAGCGGCTTCCACACCAGCTTCAACCTGACCATCAGCGA
TCTGCAGGCCGACGACATTGCCACCTACTATTGTCAGGTGCTGCAGTTCTTCCGGCAGAGGCAGCAGACTGCACATCA
AGCGTACGGTGGCCGCTCCAGCGTGTTTCTTCCACCTAGCGACGAGCAGCTGAAGTCCGGCACAGCCTCTGTC
GTGTGCCTGCTGAACAACCTTCTACCCCCGCGAGGGCCAAAGTGCAGTGGAAGGTGGACAACGCCCTGCAGAGCGGCA
ACAGCCAGGAAAGCGTGACCGAGCAGGACAGCAAGGACTCCACCTACAGCCTGAGCAGCACCCCTGACACTGAGCAA
GGCCGACTACGAGAAGCACAAGGTGTACGCCTGCGAAGTGACCCACCAGGGCCTGTCTAGCCCCGTGACCAAGAGC
TTCAACCGGGGCGAGTGT Trispecific 1 582

GACATCGTGATGACCCAGACCCCCCTGAGCCTGAGCGTGACACCTGGACAGCCTGCCAGCATCAGCTGCAAGAGCA
31 N6_FR3-03/
GCCAGAGCCTGGTGCACGAGAACCTGTTACCTACCTGAGCTGGTATCTGCAGAAGCCCGGCCAGAGCCCCCAGTCC
CD28sup ×
CTGATCTACAAGGTGTCCAACAGATTACAGCGGCGTGCCCGACAGATTCTCCGGCAGCGGCTCTGGCACCGACTTCAC
CD3mid_
CCTGAAGATCAGCCGGGTGGAAGCCGAGGACGTGGGCGTGTACTATTGTGGCCAGGGCACCCAGTACCCCTTCACCT
ENLF

TTGGCAGCGGCACCAAGGTGGAATCAAGGACAAAACCCATACCGACATCCAGATGACCCAGAGCCCCAGCAGCCT
IgG1_NNAS_
GTCTGCCAGCGTGGGCGACAGAGTGACCATCACCTGTCAGGCCAGCCAGAACATCTACGTGTGGCTGAACTGGTATC
DKTHT linker
AGCAGAAGCCCGGCAAGGCCCCCAAGCTGCTGATCTACAAGGCCAGCAACCTGCACACCGGCGTGCCAGCAGATT
TTCTGGCAGCGGCTCCGGCACCGACTTCACCCTGACAATCAGCTCCCTGCAGCCCGAGGACATTGCCACCTACTACT
GCCAGCAGGGCCAGACCTACCCCTACACCTTTGGCCAGGGCACCAAGCTGGAATCAAGGATAAGACCCACACCCG
TACGGTGGCCGCTCCCAGCGTGTTTCTTCCACCTAGCGACGAGCAGCTGAAGTCCGGCACAGCCTCTGTCTGTGT
GCCTGCTGAACAACCTTCTACCCCCGCGAGGGCCAAAGTGCAGTGGAAGGTGGACAACGCCCTGCAGAGCGGCAACAG
CCAGGAAAGCGTGACCGAGCAGGACAGCAAGGACTCCACCTACAGCCTGAGCAGCACCCCTGACACTGAGCAAGGCC
GACTACGAGAAGCACAAGGTGTACGCCTGCGAAGTGACCCACCAGGGCCTGTCTAGCCCCGTGACCAAGAGCTTCA
ACCGGGGCGAGTGT 2 583

CAGGTGCAGCTGGTGCAGTCTGGCGCCGAGGTGCTGAAACCTGGCGCCTCTGTGAAGGTGTCTGTGCAAGGCCAGCGG
CTACACCTTTACCAGCTACTACATCCACTGGGTGCGCCAGGCCCTTGGACAGGGACTGGAATGGATCGGCAGCATCT
ACCCCGGCAACGTGAACACCAACTACGCCCAGAAGTTCCAGGGCAGAGCCACCCTGACCGTGGACACCAGCATCAG
CACCGCCTACATGGAAGTGTGAGCCGGCTGAGAAGCGACGACACCGCCGTGTACTACTGCACCCGGTCCCCTACGGCC
TGGATTGGAACCTTCGACGTGTGGGGCAAGGGCACCAACCGTGACAGTGTCTAGCGACAAAACCCATACCCAGGTGCA

CTGGTGTGATCTGGCGCGGAGTGGTGTGACAGCTGGCAGAAGCCTGAGACTGAGCTGTGCCGCCAGCGGCTTCACTT
TCACCAAGGCCTGGATGCACTGGGTGCGCCAGGCCCTGGAAAGCAGCTGGAATGGGTGGCCCAGATCAAGGACAA
GAGCAACAGCTACGCCACCTACTACGCCGACAGCGTGAAGGGCCGGTTTACCATCAGCCGGGACGACAGCAAGAAC
ACCCTGTACCTGCAGATGAACAGCCTGCGGGCCGAGGACACCGCCGTGTACTACTGTTCGGGGCGTGTACTATGCCCT
GAGCCCCCTTCGATTACTGGGGCCAGGGAACCCCTCGTGACCGTGTCTAGTGATAAGACCCACACCGCCAGCACAAAGG
GCCCCAGCGTGTTCCCTCTGGCCCCCTAGCAGCAAGAGCACATCTGGCGGAACAGCCGCCCTGGGCTGCCTCGTGAAG
GACTACTTTCCCGAGCCCCGTGACCGTGTCTTGGGAATTCTGGCGCCCTGACCAGCGGCGTGCACACCTTTCCAGCTGT
GCTGCAGTCCAGCGGCTGTACAGCCTGAGCAGCGTCTGTGACAGTGCCCAGCAGCTCTCTGGGCACCCAGACCTACA
TCTGCAACGTGAACCACAAGCCCAGCAACACCAAGGTGGACAAGAAGGTGGAACCCAAGAGCTGCGACAAGACCCA
ACCTGTCCCCCTTGTCTGCCCCCGAACTGCTGGGAGGCCCTTCCGTGTTCTGTTCCCCCCAAAGCCCAAGGACAC
CCTGATGATCAGCCGGACCCCCGAAGTGACCTGCGTGGTGGTGGATGTGTCCCACGAGGACCTGAAGTGAAGTTCA
ATTGGTACGTGGACGGCGTGGAAGTGCACAACGCCAAGACCAAGCCAAGAGAGGAACAGTACAACAATGCCTCCCG
GGTGGTGTCCGTGCTGACCGTGTGTCACCAGGACTGGCTGAACGGCAAAGAGTACAAGTGCAAGGTGTCCAACAAG
GCCCTGCCTGCCCCCATCGAGAAAACCATCAGCAAGGCCAAGGGCCAGCCCCGCGAACCCAGGTGTGCACACTGC
CCCCAAGCAGGGACGAGCTGACCAAGAACCAGGTGTCCCTGAGCTGTGCCGTGAAAGGCTTCTACCCCTCCGATATC
GCCGTGGAATGGGAGAGCAACGGCCAGCCCGAGAACAACCTACAAGACCACCCCCCTGTGCTGGACAGCGACGGCT
CATCTTCTCTGGTGTCCAAGCTGACAGTGGACAAGTCCCGGTGGCAGCAGGGCAACGTGTTTACAGCTGCTCCGTGATG
CACGAGGCCCTGCACAACCACTACACCCAGAAGTCCCTGAGCCTGAGCCCCGGC 3 584

AGAGCCCACCTGGTGCAGTCTGGCACCCGCCATGAAGAAACCAGGCGCCTCTGTGCGGGTGTCTGTGTCAGACAAGCG
GCTACACCTTCACCGCCACATCCTGTTCTGGTTCGCGCAGGCCCTGGCAGAGGACTGGAATGGGTGGGATGGATC
AAGCCCCAGTATGGCGCCGTGAACTTCGGCGGAGGCTTCCGGGATAGAGTGACCCTGACCCGGCAGCTGAGCCAGG
ACCCTGATGATCCGGATTGGGGCATCGCTACATGGACATCCGGGGCCTGAAGCCCGATGACACCGCCGTGTACTAC
TGCGCCAGAGACAGAAGCTACGGCGACAGCAGCTGGGCTCTGGATGCTTGGGGCCAGGGCACAACCGTGGTGGTGT
CTGCCGCCTCTACAAAGGGCCCATCGGTCTTCCCCCTGGCACCCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCC
CTGGGCTGCCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCTGTGGAACCTCAGGCGCCCTGACCAGCGGCGT
GCACACCTTCCCGGCTGTCTACAGTCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCTCCAGCAGCT
TGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAACACCAAGGTGGACAAGAAAGTTGAGCCCAAA
TCTTGTGACAAAACCTCACACATGCCACCCGTGCCCAGCACCTGAACTCCTGGGGGGACCGTCACTCTTCTCTTCCC
CCCAAAACCCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTACATGCGTGGTGGTGGACGTGAGCCACGAAG
ACCCTGAGGTCAAGTTCAACTGGTATGTTGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCA
GTACAACAATGCCTCCCGTGTGGTTCAGCGTCTCACCCTGTCACCAGGACTGGCTGAATGGCAAGGAGTACAAGT
GCAAGGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAGCCAAAGGGCAGCCCCGAGAACC
ACAGGTGTACACCCTGCCCCCATGCCGGGATGAGCTGACCAAGAATCAAGTCAGCCTGTGGTGCCTGGTAAAAGGCT
TCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACCTACAAGACCACGCCTCCCGT
GCTGGACTCCGACGGCTCCTTCTTCTCTACTCAAACTCACCCTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCT
TCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCGGGT 4 585

TACATCCACGTGACCCAGAGCCCCAGCAGCCTGTCCGTGTCCATCGGCGACAGAGTGACCATCAACTGCCAGACCTC
TCAGGGCGTGGGCAGCGACCTGCACTGGTATCAGCACAAGCCTGGCAGAGCCCCCAAGCTGCTGATCCACCACACA
AGCAGCGTGGAAGATGGCGTGGCCAGCAGATTTTCCGGCAGCGGCTTCCACACCAGCTTCAACCTGACCATCAGCGA
TCTGCAGGCCGACGACATTGCCACCTACTATTGTCAGGTGCTGCAGTTCTTCGGCAGAGGCAGCAGACTGCACATCA
AGCGTACGGTGGCCGCTCCCAGCGTGTTTCTTCCCACCTAGCGACGAGCAGCTGAAGTCCGGCACAGCCTCTGTC
GTGTGCCTGCTGAACAACCTTCTACCCCCGCGAGGCCAAAGTGCAGTGGAAGGTGGACAACGCCCTGCAGAGCGGCA
ACAGCCAGGAAAGCGTGACCGAGCAGGACAGCAAGGACTCCACCTACAGCCTGAGCAGCACCCCTGACACTGAGCAA
GGCCGACTACGAGAAGCACAAGGTGTACGCCTGCGAAGTGACCCACCAGGGCCTGTCTAGCCCCGTGACCAAGAGC
TTCAACCGGGGCGAGTGT Trispecific 1 586

GACATCGTGATGACCCAGACCCCCCTGAGCCTGAGCGTGACACCTGGACAGCCTGCCAGCATCAGCTGCAAGAGCA
34 VRC01.23/
GCCAGAGCCTGGTGCACGAGAACCTGCAGACCTACCTGAGCTGGTATCTGCAGAAGCCCGGCCAGAGCCCCAGTC
CD28sup ×
CCTGATCTACAAGGTGTCCAACAGATTCAGCGGCGTGCCCGACAGATTCTCCGGCAGCGGCTCTGGCACCGACTTCA
CD3mid_
CCCTGAAGATCAGCCGGGTGGAAGCCGAGGACGTGGGCGTGTACTATTGTGGCCAGGGCACCCAGTACCCCTTCACC
ENLQ IgG4
TTTGGCAGCGGCACCAAGGTGGAATCAAGGACAAAACCCATACCGACATCCAGATGACCCAGAGCCCCAGCAGCC
FALA/409K_
TGTCTGCCAGCGTGGGCGACAGAGTGACCATCACCTGTCAGGCCAGCCAGAACATCTACGTGTGGCTGAACTGGTAT
DKTHT linker
CAGCAGAAGCCCGGCAAGGCCCCCAAGCTGCTGATCTACAAGGCCAGCAACCTGCACACCGGCGTGCCCAGCAGAT
TTTCTGGCAGCGGCTCCGGCACCGACTTCACCCTGACAATCAGTCCCTGCAGCCCGAGGACATTGCCACCTACTAC
TGCCAGCAGGGCCAGACCTACCCCTACACCTTTGGCCAGGGCACCAAGCTGGAATCAAGGATAAGACCCACACCCG
TACGGTGGCCGCTCCCAGCGTGTTTCTTCCCACCTAGCGACGAGCAGCTGAAGTCCGGCACAGCCTCTGTCTGT
GCCTGCTGAACAACCTTCTACCCCCGCGAGGCCAAAGTGCAGTGGAAGGTGGACAACGCCCTGCAGAGCGGCAACAG
CCAGGAAAGCGTGACCGAGCAGGACAGCAAGGACTCCACCTACAGCCTGAGCAGCACCCCTGACACTGAGCAAGGCC

GACTACGAGAAGCGTGTACGCCTGCGAAGTGACCCACCAGGGCCTGTCTAGCCCCGTGACCAAGAGCTTCA
ACCGGGGCGAGTGT 2 587
CAGGTGCAGCTGGTGCAGTCTGGCGCCGAGGTCTGTGAAACCTGGCGCCTCTGTGAAGGTGTCCTGCAAGGCCAGCGG
CTACACCTTTACCAGCTACTACATCCACTGGGTGCGCCAGGCCCTGGACAGGGACTGGAATGGATCGGCAGCATCT
ACCCCGGCAACGTGAACACCAACTACGCCCAGAAGTTCAGGGCAGAGCCACCCTGACCGTGGACACCAGCATCAG
CACCGCCTACATGGAAGTGAAGCCGGCTGAGAAGCGACGACACCGCCGTGTACTACTGCACCCGGTCCCACTACGGCC
TGGATTGGAAGTTCGACGTGTGGGGCAAGGGCACCAACCGTGACAGTGTCTAGCGACAAAACCCATACCCAGGTGCA
GCTGGTGGAAATCTGGCGGCGGAGTGGTGCAGCCTGGCAGAAGCCTGAGACTGAGCTGTGCCGCCAGCGGCTTCACCT
TCACCAAGGCCTGGATGCACTGGGTGCGCCAGGCCCTGGAAAGCAGCTGGAATGGGTGGCCAGATCAAGGACAA
GAGCAACAGCTACGCCACCTACTACGCCGACAGCGTGAAGGGCCGGTTCACCATCAGCCGGGACGACAGCAAGAAC
ACCCTGTACCTGCAGATGAACAGCCTGCGGGCCGAGGACACCGCCGTGTACTACTGTGCGGGCGTGTACTATGCCCT
GAGCCCCTTCGATTACTGGGGCCAGGGAACCTCGTGACCGTGTCTAGTGATAAGACCCACACCGCCAGCACAAAGG
GCCATCGGTGTTCCCTCTGGCCCCTTGACGACAGAAGCACCAGCGAATCTACAGCCGCCCTGGGCTGCCTCGTGAAG
GACTACTTTCCCGAGCCCGTGACCGTGTCTGGAAGTCTGGCGCTCTGACAAGCGGCGTGACACACCTTTCCAGCCGT
GCTCCAGAGCAGCGGCCTGTACTCTCTGAGCAGCGTCTGTGACAGTGCCCAGCAGCAGCCTGGGCACCAAGACCTACA
CCTGTAACGTGGACCACAAGCCCAGCAACACCAAGGTGGACAAGCGGGTGGAAATCTAAGTACGGCCCTCCCTGCCCT
CCTTGCCCAGCCCCCTGAAGCTGCCGGCGGACCCTCCGTGTTCCCTGTTCCCCCAAAGCCCAAGGACACCCTGATGAT
CAGCCGGACCCCCGAAGTGACCTGCGTGGTGGTGGATGTGTCCCAGGAAGATCCCAGAGTGCAGTTCAATTGGTACG
TGGACGGCGTGGAAAGTGACAAACGCCAAGACCAAGCCCAGAGAGGAACAGTTCAACAGCACCTACCGGGTGGTGTCC
GTGCTGACCGTGTCTGCACCAGGACTGGCTGAACGGCAAAGAGTACAAGTGCAAGGTGTCCAACAAGGGCCTGCCCA
GCTCCATCGAGAAAACCATCAGCAAGGCCAAGGGCCAGCCCCGCGAGCCTCAAGTGTGTACCCTGCCCCCTAGCCA
GGAAGAGATGACCAAGAACCAGGTGTCCCTGAGCTGTGCCGTGAAAGGCTTCTACCCAGCGACATTGCCGTGGAA
TGGGAGAGCAACGGCCAGCCCAGACAACACTACAAGACCACCCCCCTGTGCTGGACAGCGACGGCTCATTCTTCCT
GGTGTCCAAGCTGACCGTGGACAAGAGCCGGTGGCAGGAAGGCAACGTGTTACAGTGTCTCCGTGATGCACGAGGCC
CTGCACAACCACTACACCCAGAAGTCCCTGTCTCTGTCCCTGGGC 3 588

CAGGTGCAGCTGGTGCAGTCTGGCGGCCAGATGAAGAAACCCGGCGAGAGCATGCGGATCAGCTGCAGAGCCAGCG
GCTACGAGTTCATCGACTGCACCCTGAACTGGATCAGACTGGCCCCTGGCAAGCGGCCTGAGTGGATGGGATGGCTG
AAGCCTAGATGGGGAGCCGTGAACTACGCCAGACCTCTGCAGGGCAGAGTGACCATGACCCGGCAGCTGAGCCAGG
ACCCTGATGATCCGGATTGGGGCACCGCCTTCCCTGGAAGTGCAGGAGCCTGACCGTGGATGATACCGCCGTGTACTTC
TGCACCCGGGGCAAGAACTGCGACTACAACCTGGGACTTCGAGCACTGGGGCAGAGGCACCCCTGTGATCGTGTCAA
GCGCGTCGACCAAGGGCCCATCGGTGTTCCCTCTGGCCCCTTGACGACAGAAGCACCAGCGAATCTACAGCCGCCNTG
GGCTGCCTCGTGAAGGACTACTTTCCCGAGCCCGTGACCGTGTCTGGAAGTCTGGCGNTNTGACAAGCGGCGTGCA
CACCTTTCCAGCCGTGCTCCAGAGCAGCGGCCTGTACTCTCTGAGCAGCGTCGTGACAGTGCCCAGCAGCAGCCTGG
GCACCAAGACCTACACCTGTAACGTGGACCACAAGCCCAGCAACACCAAGGTGGACAAGCGGGTGGAAATCTAAGTAC
GGCCCTCCCTGCCCTCCTTGCCCAGCCCCCTGAAGCTGCCGGCGGACCCTCCGTGTTCCCTGTTCCCCCAAAGCCCA
GGACACCCTGATGATCAGCCGGACCCCCGAAGTGACCTGCGTGGTGGTGGATGTGTCCCAGGAAGATCCCAGAGGTG
CAGTTCAATTGGTACGTGGACGGCGTGGAAAGTGACAAACGCCAAGACCAAGCCCAGAGAGGAACAGTTCAACAGCA
CCTACCGGGTGGTGTCCGTGCTGACCGTGTCTGCACCAGGACTGGCTGAACGGCAAAGAGTACAAGTGCAAGGTGTCC
AACAAGGGCCTGCCAGCTCCATCGAGAAAACCATCAGCAAGGCCAAGGGCCAGCCCCGCGAGCCTCAAGTGTATA
CCCTGCCCCCTTGCCAGGAAGAGATGACCAAGAACCAGGTGTCCCTGTGGTGTCTCGTGAAAGGCTTCTACCCCAGC
GACATTGCCGTGGAATGGGAGAGCAACGGCCAGCCCGAGAACAACTACAAGACCACCCCCCTGTGCTGGACAGCG
ACGGCTCATTCTTCCTGTACTCCAAGCTGACCGTGGACAAGAGCCGGTGGCAGGAAGGCAACGTGTTACAGTGTCTCC
GTGATGCACGAGGCCCTGCACAACCACTACACCCAGAAGTCCCTGTCTCTGTCCCTGGGC 4 589

CTGACACAGAGCCCTGGCACCCCTGTCACTGAGCCCAGGCGAGACAGCCATCATCAGCTGCCGGACAAGCCAGTACG
GCAGCCTGGCCTGGTATCAGCAGAGGCCTGGACAGGGCCCCAGACTCGTGATCTACAGCGGCAGCACAAAGAGCCGC
CGAATCCCCGATAGATTACAGCGGCTCCAGATGGGGACCCGACTACAACCTGACCATCAGCAACCTGGAAAGCGGC
GACTTCGGCGTGTACTACTGCCAGCAGTACGAGTTCTTCGGCCAGGGCACCAAGGTGCAGGTGGACATCAAGCGTAC
GGTGGCCGCTCCAGCGTGTTTCATCTTCCCACCTAGCGACGAGCAGCTGAAGTCCGGCACAGCCTCTGTCTGTGCC
TGCTGAACAACCTTCTACCCCCGCGAGGCCAAAGTGACGTGGAAGGTGGACAACGCCCTGCAGAGCGGCAACAGCCAG
GAAAGCGTGACCGAGCAGGACAGCAAGGACTCCACCTACAGCCTGAGCAGCACCCCTGACACTGAGCAAGGCCGACT
ACGAGAAGCACAAGGTGTACGCCTGCGAAGTGACCCACCAGGGCCTGTCTAGCCCCGTGACCAAGAGCTTCAACCG
GGGCGAGTGT Trispecific 1 590

GACATCGTGATGACCCAGACCCCCCTGAGCCTGAGCGTGACACCTGGACAGCCTGCCAGCATCAGCTGCAAGAGCA
35 VRC01.23/
GCCAGAGCCTGGTGCACGAGAACCTGTTACCTACCTGAGCTGGTATCTGCAGAAGCCCGGCCAGAGCCCCAGTCC
CD28sup ×
CTGATCTACAAGGTGTCCAACAGATTACAGCGGCGTGCCGACAGATTCTCCGGCAGCGGCTCTGGCACCGACTTCAC
CD3mid_
CCTGAAGATCAGCCGGGTGGAAGCCGAGGACGTGGGCGTGTACTATTGTGGCCAGGGCACCCAGTACCCCTTCACCT
ENLF IgG4
TTGGCAGCGGCACCAAGGTGGAAATCAAGGACAAAACCCATACCGACATCCAGATGACCCAGAGCCCCAGCAGCCT
FALA/409K_
GTCTGCCAGCGTGGGCGACAGAGTGACCATCACCTGTCAGGCCAGCCAGAACATCTACGTGTGGCTGAACTGGTATC

DKHTT linker

AGCAGAAGCCCGGCAAGGCCCAAGCTGCTGATCTACAAGGCCAGCAACCTGCACACCGGCGTGCCCAGCAGATT
TTCTGGCAGCGGCTCCGGCACCGACTTCACCTGACAATCAGCTCCCTGCAGCCCGAGGACATTGCCACCTACTACT
GCCAGCAGGGCCAGACCTACCCCTACACCTTTGGCCAGGGCACCAAGCTGGAATCAAGGATAAGACCCACACCCG
TACGGTGGCCGCTCCCAGCGTGTTTCATCTTCCACCTAGCGACGAGCAGCTGAAGTCCGGCACAGCCTCTGTCTGT
GCCTGCTGAACAACCTTCTACCCCCGCGAGGCCAAAGTGCAGTGGAAGGTGGACAACGCCCTGCAGAGCGGCAACAG
CCAGGAAAGCGTGACCGAGCAGGACAGCAAGGACTCCACCTACAGCCTGAGCAGCACCCCTGACACTGAGCAAGGCC
GACTACGAGAAGCACAAAGGTGTACGCCTGCGAAGTGACCCACCAGGGCCTGTCTAGCCCCGTGACCAAGAGCTTCA
ACCGGGGCGAGTGT 2 591

CAGGTGCAGCTGGTGCAGTCTGGCGCCGAGGTCTGTGAAACCTGGCGCCTCTGTGAAGGTGTCCTGCAAGGCCAGCGG
CTACACCTTTACCAGCTACTACATCCACTGGGTGCGCCAGGCCCTTGACAGGGACTGGAATGGATCGGCAGCATCT
ACCCCGGCAACGTGAACACCAACTACGCCCAGAAGTTCAGGGCAGAGCCACCCTGACCGTGGACACCAGCATCAG
CACCGCCTACATGGAAGTGAAGCCGGCTGAGAAGCGACGACACCGCCGTGTACTACTGCACCCGGTCCCCTACGGCC
TGGATTGGAACCTCGACGTGTGGGGCAAGGGCACCAACCGTGACAGTGTCTAGCGACAAAACCCATACCCAGGTGCA
GCTGGTGGAACTCTGGCGGCGGAGTGGTGCAGCCTGGCAGAAGCCTGAGACTGAGCTGTGCCGCCAGCGGCTTACCT
TCACCAAGGCCTGGATGCACTGGGTGCGCCAGGCCCTTGAAAGCAGCTGGAATGGGTGGCCAGATCAAGGACAA
GAGCAACAGCTACGCCACCTACTACGCCGACAGCGTGAAGGGCCGTTTACCATCAGCCGGGACGACAGCAAGAAC
ACCCTGTACCTGCAGATGAACAGCCTGCGGGCCGAGGACACCGCCGTGTACTACTGTCGGGGCGTGTACTATGCCCT
GAGCCCCCTTCGATTACTGGGGCCAGGGAACCCCTCGTGACCGTGTCTAGTGATAAGACCCACACCGCCAGCACAAAGG
GCCATCGGTGTTCCCTCTGGCCCCTTGACAGCAGAAGCACCAGCGAATCTACAGCCGCCCTGGGCTGCCTCGTGAAG
GACTACTTTCCCGAGCCCGTGACCGTGTCTGGAAGTCTGGCGCTCTGACAAGCGGCGTGACACCTTTCCAGCCGT
GCTCCAGAGCAGCGGCCTGTACTCTCTGAGCAGCGTCTGTGACAGTGCCCAGCAGCAGCCTGGGCACCAAGACCTACA
CCTGTAACGTGGACCACAAGCCCAGCAACACCAAGGTGGACAAGCGGGTGAATCTAAGTACGGCCCTCCCTGCCCT
CCTTGCCCAGCCCCTGAAGCTGCCGGCGGACCCTCCGTGTTCTGTTCCCCCAAAGCCCAAGGACACCCTGATGAT
CAGCCGGACCCCCGAAGTGACCTGCGTGGTGGTGGATGTGTCCAGGAAGATCCCAGAGTGCAGTTCAATTGGTACG
TGGACGGCGTGGAAGTGACAAACGCCAAGACCAAGCCCAGAGAGGAACAGTTCAACAGCACCTACCGGGTGGTGTCC
GTGCTGACCGTGTCTGCACCAGGACTGGCTGAACGGCAAAGAGTACAAGTGCAAGGTGTCCAACAAGGGCCTGCCCA
GCTCCATCGAGAAAACCATCAGCAAGGCCAAGGGCCAGCCCCGCGAGCCTCAAGTGTGTACCCTGCCCCCTAGCCA
GGAAGAGATGACCAAGAACCAGGTGTCCCTGAGCTGTGCCGTGAAAGGCTTCTACCCAGCGACATTGCCGTGGAA
TGGGAGAGCAACGGCCAGCCCGAGAACAATAAGACCACCCCCCTGTGCTGGACAGCGACGGCTCATTCTTCCT
GGTGTCCAAGCTGACCGTGGACAAGAGCCGGTGGCAGGAAGGCAACGTGTTACAGCTGCTCCGTGATGCACGAGGCC
CTGCACAACCACTACACCCAGAAGTCCCTGTCTCTGTCCCTGGGC 3 592

CAGGTGCAGCTGGTGCAGTCTGGCGGCCAGATGAAGAAACCCGGCGAGAGCATGCGGATCAGCTGCAGAGCCAGCG
GCTACGAGTTCATCGACTGCACCCTGAAGTGGATCAGACTGGCCCCTGGCAAGCGGCCTGAGTGGATGGGATGGCTG
AAGCCTAGATGGGGAGCCGTGAAGTACGCCAGACCTCTGCAGGGCAGAGTGACCATGACCCGGCAGCTGAGCCAGG
ACCCTGATGATCCGGATTGGGGCACCGCCTTCCCTGGAAGTGGCGAGCCTGACCGTGGATGATACCGCCGTGTACTTC
TGACCCCGGGGCAAGAACTGCGACTACAACTGGGACTTCGAGCACTGGGGCAGAGGCACCCCTGTGATCGTGTCAA
GCGCGTCGACCAAGGGCCCATCGGTGTTCCCTCTGGCCCCTTGACAGCAGAAGCACCAGCGAATCTACAGCCGCCNTG
GGCTGCCTCGTGAAGGACTACTTTCCCGAGCCCGTGACCGTGTCTGGAAGTCTGGCGNTNTGACAAGCGGCGTGCA
CACCTTTCCAGCCGTGCTCCAGAGCAGCGGCCTGTACTCTCTGAGCAGCGTCTGTGACAGTGCCCAGCAGCAGCCTGG
GCACCAAGACCTACACCTGTAACGTGGACCACAAGCCCAGCAACACCAAGGTGGACAAGCGGGTGGAACTTAAGTA
CGGCCCTCCCTGCCCTCCTTGCCCAGCCCCTGAAGCTGCCGGCGGACCCTCCGTGTTCCCTGTTCCCCCAAAGCCCA
AGGACACCCTGATGATCAGCCGGACCCCCGAAGTGACCTGCGTGGTGGTGGATGTGTCCAGGAAGATCCCGAGGTG
CAGTTCAATTGGTACGTGGACGGCGTGGAAGTGACAACGCCAAGACCAAGCCCAGAGAGGAACAGTTCAACAGCA
CCTACCGGGTGGTGTCCGTGCTGACCGTGTGACCAAGGACTGGCTGAACGGCAAAGAGTACAAGTGCAAGGTGTCC
AACAAGGGCCTGCCAGCTCCATCGAGAAAACCATCAGCAAGGCCAAGGGCCAGCCCCGCGAGCCTCAAGTGTATA
CCCTGCCCCCTTGCCAGGAAGAGATGACCAAGAACCAGGTGTCCCTGTGGTGTCTCGTGAAAGGCTTCTACCCAGC
GACATTGCCGTGGAATGGGAGAGCAACGGCCAGCCCGAGAACAATAAGACCACCCCCCTGTGCTGGACAGCG
ACGGCTCATTCTTCTGTACTCCAAGCTGACCGTGGACAAGAGCCGGTGGCAGGAAGGCAACGTGTTACAGCTGCTCC
GTGATGCACGAGGCCCTGCACAACCACTACACCCAGAAGTCCCTGTCTCTGTCCCTGGGC 4 593

CTGACACAGAGCCCTGGCACCCCTGTCACTGAGCCCAGGCGAGACAGCCATCATCAGCTGCCGGACAAGCCAGTACG
GCAGCCTGGCCTGGTATCAGCAGAGGCCTGGACAGGCCCCAGACTCGTGATCTACAGCGGCAGCACAAAGAGCCGC
CGGAATCCCCGATAGATTACAGCGGCTCCAGATGGGGACCCGACTACAACCTGACCATCAGCAACCTGGAAAGCGGC
GACTTCGGCGTGTACTACTGCCAGCAGTACGAGTTCTTCGGCCAGGGCACCAAGGTGCAGGTGGACATCAAGCGTAC
GGTGGCCGCTCCAGCGTGTTTCATCTTCCACCTAGCGACGAGCAGCTGAAGTCCGGCACAGCCTCTGTCTGTGCC
TGCTGAACAACCTTCTACCCCCGCGAGGCCAAAGTGCAGTGGAAGGTGGACAACGCCCTGCAGAGCGGCAACAGCCAG
GAAAGCGTGACCGAGCAGGACAGCAAGGACTCCACCTACAGCCTGAGCAGCACCCCTGACACTGAGCAAGGCCGACT
ACGAGAAGCACAAAGGTGTACGCCTGCGAAGTGACCCACCAGGGCCTGTCTAGCCCCGTGACCAAGAGCTTCAACCG
GGGCGAGTGT

EXAMPLES

[0640] The Examples that follow are illustrative of specific embodiments of the disclosure, and various uses thereof. They are set forth for explanatory purposes only, and should not be construed as limiting the scope of the invention in any way.

Example 1: Development of Trispecific HER2/CD28xCD3 Antibodies and Variant Anti-CD3 Binding Sites

[0641] Immuno-oncology is a promising, emerging therapeutic approach to disease management in cancer. The immune system is the first line of defense against cancer development and progression. There is now large evidence that T cells are able to control tumor growth and prolong the survival of cancer patients in both early and late stages of disease. However, T cells specific for tumors can be limited in a number of ways preventing them from controlling the disease.

[0642] In order to remove the limitations on T cells induced by uncontrolled tumors, novel antibodies were developed in the trispecific antibody format depicted in FIG. 1A to specifically activate the T cells to engage HER2 expressing cancer cells. These novel trispecific antibodies are able to bind to three targets: HER2, CD3, and CD28. Anti-HER2 and anti-CD3 binding sites were further optimized for high affinity binding and reduction in potential manufacturing liabilities.

[0643] HER2 amplification and overexpression can be found in molecular subtypes of breast cancer, and also in gastric, ovarian, lung and prostate carcinomas. Optimal activation of T cells requires two factors: (1) Antigen recognition and (2) Co-stimulation. Using the trispecific HER2/CD28xCD3 trispecific binding proteins described herein, Signal 1 is provided by an agonist anti-CD3 binding site, and Signal 2 is provided by an agonist anti-CD28 binding site (see, e.g., FIG. 1D). It is thought that the trispecific antibodies described in the subsequent Examples recruit T cells to the tumor via HER2 and activate the engaged T cells by binding to CD3 and CD28. The resulting activation induces the killing potential of the immune cells against the nearby tumor cells.

Materials and Methods

Production and Characterization of Antibodies

[0644] Trispecific antibody variants were produced by transient transfection of expression plasmids into Expi293 cells. 5 days after transfection, the supernatant from transfected cells was collected, quantified and normalized by absorbance at 280 nm on Nano Drop. The binding of supernatant to corresponding antigens were determined by ELISA and the absorbance of parental HER2 WT tri Ab was set as 1.0. The fold changes of other variants were calculated by dividing the corresponding absorbance to that of parental Ab.

[0645] Trispecific antibody variants were purified using protein A affinity purification followed by SEC purification. The binding of purified antibodies to corresponding antigens were determined by ELISA. The EC50 were determined based on the binding curve generated by Graphpad Prism7.

Results

[0646] Trispecific Ab variants were produced with several mutations in the binding arms in order to mitigate potential manufacturing liabilities, e.g., deamidation sites. A binding ELISA assay was performed to assess binding of the indicated trispecific antibodies to each of the three targets: HER2, CD3, and CD28. In FIG. 1B, HER2/CD3xCD28 trispecific antibodies with the indicated anti-HER2 or anti-CD3 variants were compared to parental Trispecific Ab. Introducing some sets of mutations (e.g., 32/33 QQ and 33/35QQ) into the VL domain of the anti-CD3 binding site led to dramatically reduced binding to CD3, whereas 32/35 QQ mutations retained near wild-type binding. MS peptide analyses showed that binding sites with the DNAQ mutations in CDR-L1 (SEQ ID NO:63) were still subject to greater than 15% deamidation, whereas ENLQ (SEQ ID NO:281), ENLF (SEQ ID NO:282), and ENLR (SEQ ID NO:283) led to less than 5% deamidation. Importantly, these variants also retained binding to CD3.

[0647] In addition, binding curves for the indicated antibodies binding to human HER2, human CD28, and CD3 are provided in FIG. 1C. The EC50 values of selected trispecific antibody variants are provided in Table E.

TABLE-US-00012 TABLE E A binding ELISA assay was performed on purified trispecific antibodies to determine their binding affinities for HER2, human CD3, and human CD28. Binding Affinity (ELISA)(nM) EC50 Human Human Trispecific antibody HER2 CD3 CD28 HER2 (WT-trastuzumab)/ 162.3 566.4 1321 CD28supxCD3mid (32/35 QQ (LC); DKTHT linkers on HC/LC) IgG4 FALA HER2 (30R/55Q/102E + 93.66 364.8 871.9 LC-WT-trastuzumab)/ CD28supxCD3mid (32/35 QQ (LC); DKTHT linkers on HC/LC) IgG4 FALA HER2-30R/55Q/102E/ 83.89 3222 1024 CD28supxCD3mid (32/33/35QSQ) DKTHT linker IgG4 FALA HER2 (30R/55Q/102E + 111.2 725.7 1053 LC-WT-trastuzumab)/ CD28supxCD3mid (DNAQ (LC); DKTHT linkers on HC/LC) IgG4 FALA HER2 (30R/55Q/102E + 111.5 412.5 1345 LC-WT-trastuzumab)/ CD28supxCD3mid (32/35QQ (LC); L1 linker) IgG4 FALA HER230R/55Q/102E/ 123.9 81.53 878.8 CD28supxCD3mid (32/33/3435 ENLR (LC); DKTHT linkers on HC/LC) IgG4 FALA HER2 (30R/56A/102S + 516.0 5494 3631 LC-WT-trastuzumab)/ CD28supxCD3mid (32/35QQ185E) IgG4 FALA HER2-30R/55Q/102E + 1540 10616 2036 LC-30Q/CD28supxCD3mid (32/35QQ) 185S L1 linker IgG4 FALA HER2-30R/55Q/102E/ 467.0 19382 1814 CD28supxCD3mid (32/33/35QSQ) 185S L1 linker IgG4 FALA HER2-30R/55Q/102E/ 478.6 19756 1739 CD28supxCD3mid (32/33/35QSQ) 185E L1 linker IgG4 FALA HER2/CD28supxCD3mid 228.9 671.2 752 DKTHT linkers on HC/LC) IgG4 FALA HER2/CD28supxCD3mid 195.9 773.3 1466 (32/33/3435 ENLF (LC); DKTHT linkers on HC/LC) IgG4 FALA HER2/CD28supxCD3mid 212.1 10558 2405 (32/33/3435 ENLQ (LC); DKTHT linkers on HC/LC) IgG4 FALA HER2/CD28supxCD3mid 166.2 381.9 1051 (32/33/3435 ENLR (LC); DKTHT linkers on HC/LC) IgG4 FALA anti-Her2/CD3/3CD28 176.1 516.2 870.6 IgG4 FALA

[0648] Without wishing to be bound by theory, as depicted in FIG. 1D, it is believed that HER2/CD3/CD28 trispecific antibodies recruit T cells to cancer cells through the anti-HER2 and anti-CD3/CD28 arms. Further, it is believed that engaged T cells are activated by the anti-CD28/CD3 arms. Killing of cancer cells is believed, without wishing to be bound by theory, to occur through T cell mediated mechanisms (e.g., Perform, granzyme). Without wishing to be bound to theory, it is contemplated that similar mechanisms may allow for killing of other types of tumors by substituting antigen binding sites that recognize other tumor target proteins.

Example 2: Development of Trispecific CD38/CD3xCD28 Antibodies

[0649] Trispecific CD38/CD3xCD28 antibodies were developed and characterized for binding to CD38, CD3 and CD28 polypeptides.

Materials and Methods

Generation of CD38 CD28xCD3 trispecific antibodies

[0650] A panel of anti-CD38, anti-CD3, and anti-CD28 antibodies, as well as human IgG4 Fc domains were used to generate CD38/CD28xCD3 trispecific antibodies in the trispecific antibody format depicted in FIG. 2A.

[0651] Trispecific binding proteins were produced by transient transfection of 4 expression plasmids into Expi293 cells using ExpiFectamine™ 293 Transfection Kit (Thermo Fisher Scientific) according to manufacturer's protocol. Briefly, 25% (w/w) of each plasmid was diluted into Opti-MEM, mixed with pre-diluted ExpiFectamine reagent for 20-30 minutes at room temperature (RT), and added into Expi293 cells (2.5×10^6 cells/ml). An optimization of transfection to determine the best ratio of plasmids was often used in order to produce the trispecific binding protein with good yield and purity.

[0652] 4-5 days post transfection, the supernatant from transfected cells was collected and filtered through 0.45 µm filter unit (Nalgene). The trispecific binding protein in the supernatant was purified using a 3-step procedure. First, protein A affinity purification was used, and the bound Ab was eluted using "IgG Elution Buffer" (Thermo Fisher Scientific). Second, product was dialyzed against PBS (pH7.4) overnight with 2 changes of PBS buffer. Any precipitate was cleared by filtration through 0.45 µm filter unit (Nalgene) before next step. Third, size-exclusion chromatography (SEC) purification (Hiload 16/600 Superdex 200 pg, or Hiload 26/600 Superdex 200 pg, GE Healthcare) was used to remove aggregates and different species in the prep. The fractions were analyzed on reduced and non-reduced SDS-PAGE to identify the fractions that contained the monomeric trispecific binding protein before combining them. The purified antibody can be aliquoted and stored at -80° C. long term.

ELISA Binding Assay

[0653] Binding affinities to each target antigen by the CD38/CD28xCD3 T cell engagers were measured by ELISA. Briefly, each antigen was used to coat the 96-well Immuno Plate (Thermo Fisher Scientific) overnight at 4° C. using 200 ng/well in PBS (pH7.4) of each antigen. The coated plate was blocked using 5% skim milk+2% BSA in PBS for one hour at RT, followed by washing with PBS+0.25% Tween 20 three times (Aqua Max 400, Molecular Devices). Serial dilution of antibodies (trispecific and control Abs) were prepared and added onto the ELISA plates (100 µl/well in duplicate), incubated at room temperature (RT) for one hour, followed by washing 5 times with PBS+0.25% Tween 20. After washing, the HRP conjugated secondary anti-human Fab (1:5000, Cat. No. 109-035-097, Jackson ImmunoResearch Inc) was added to each well and incubated at RT for 30 minutes. After washing 5 times with PBS+0.25% Tween 20, 100 µl of TMB Microwell Peroxidase Substrate (KPL, Gaithersburg, MD, USA) was added to each well. The reaction was terminated by adding 50 µl 1M H.sub.2SO.sub.4, and OD450 was measured using SpectraMax M5 (Molecular Devices) and analyzed using SoftMax Pro6.3 software (Molecular Devices). The final data was transferred to GraphPad Prism software (GraphPad Software, CA, USA), and plotted. EC50 was calculated using the same software.

Measurement of Trispecific Antibody Binding Using SPR

[0654] Human CD38-His antigens were used (Cambridge Biologics, Cambridge, MA) for full kinetic analysis. Kinetic characterization of purified antibodies was performed using SPR technology on a BIACORE 3000 (GE Healthcare). A capture assay using human IgG1 specific antibody capture and orientation of the investigated antibodies was used. For capture of Fc containing protein constructs the human antibody capture kit (GE Healthcare) was used. For capture of His tagged antigen, anti-His antibody capture kit (GE Healthcare) was used. The capture antibody was immobilized via primary amine groups (11000 RU) on a research grade CM5 chip (GE Life Sciences) using standard procedures. The analyzed antibody was captured at a flow rate of 10 µL/min with an adjusted RU value that would result in maximal analyte binding signal of typically 30 RU. Binding kinetics were measured against the trispecific antibodies. Assay buffer HBS EP (10 mM HEPES, pH 7.4, 150 mM NaCl, 3 mM EDTA, and 0.005% Surfactant P20) was used at a flow rate of 30 µl/min. Chip surfaces were regenerated with the regeneration solution of the respective capture kit. Kinetic parameters were analyzed and calculated in the BIA evaluation program package v4.1 using a flow cell without captured antibody as reference and the 1:1 Langmuir binding model with mass transfer.

Daratumumab Competition Binding Assay

[0655] For Daratumumab competition binding assay, Daratumumab was amine coupled to the active surface of CM5 chip. Reference surface was left blank and used to subtract any non-specific binding of injected molecules. Recombinant CD38-His (Sino Biological, Part #10818-H08H) was injected over the Daratumumab surface followed by injection of test antibodies. If a monospecific anti-CD38 antibody recognized an epitope on CD38 which was different from that of Daratumumab, injection of the antibody resulted in an increased SPR signal. If an antibody recognized an overlapping epitope as Daratumumab, injection of the antibody did not increase SPR signal.

Results

[0656] The binding affinities of selected CD38/CD28sup x CD3mid_ENLQ DKTHT IgG4 FALA trispecific antibodies with alternative anti-CD38 binding domains for human CD38 were determined by SPR. The association rate constant (K.sub.On), dissociation rate constant (K.sub.Off), and the K.sub.D of the selected trispecific antibodies are provided in Table A. The selected trispecific antibodies showed various degrees of affinities against human CD38 antigen.

TABLE-US-00013 TABLE A Binding characteristics of selected CD38/CD28sup x CD3mid_ENLQ DKTHT IgG4 FALA trispecific antibodies with alternative anti-CD38 binding domains for human CD38 determined by SPR. Anti-CD38 binding domain k.sub.on (M.sup.-1s.sup.-1) k.sub.off (s.sup.-1) K.sub.D (M) CD38VH1 5.55E+05 1.58E-03 2.85E-09 CD38hhy992 1.35E+06 1.75E-04 1.29E-10 CD38hyb6284 7.85E+05 5.12E-04 6.52E-10 CD38hyb5739 9.80E+05 5.46E-03 5.57E-09 CD38hhy1195 1.27E+06 1.80E-02 1.42E-08 CD38hhy1370 3.76E+05 3.29E-04 8.76E-10

[0657] The binding affinities of selected CD38/CD28sup x CD3mid_ENLQ DKTHT IgG4 FALA trispecific antibodies with alternative anti-CD38 binding domains for human CD3, human CD28, human CD38 and cynomolgus monkey CD38 were

then determined by ELISA as described above. As shown in FIGS. 2B-2E, the selected CD38/CD28sup x CD3mid_ENLQ DKTHT IgG4 FALA trispecific antibodies with alternative anti-CD38 binding domains showed various affinities to human (FIG. 2B) and cynomolgus monkey CD38 (FIG. 2C), but similar affinity to human CD3 (FIG. 2D) and CD28 (FIG. 2E). EC50 values were then calculated by GraphPad Prism 7.02 using variable slope model with four-parameter logistic curve. The EC50 values of the selected trispecific antibodies for human CD3, human CD28, human CD38 and cynomolgus monkey CD38 are provided in Table B. Control antibody was a human IgG4 isotype control.

TABLE-US-00014 TABLE B EC50 values of selected CD38/CD28sup x CD3mid_ENLQ DKTHT IgG4 FALA trispecific antibodies with alternative anti-CD38 binding domains for human CD3, human CD28, human CD38 and cynomolgus monkey CD38. Anti-CD38 EC50 (pM) binding domain hCD38 Cyno CD38 hCD3 hCD28 CD38VH1 7244 2128 6742 725 CD38hhy992 229 912 33593 809 CD38hyb6284 253 290 8222 711 CD38hyb5739 984 1628 10791 825 CD38hhy1195 102537 37701 7631 697 CD38hhy1370 587 553 24968 1257

[0658] An SPR competition assay was carried out to determine whether anti-CD38 antibodies hhy6284, hhy992, hhy5379, or hhy1195 (tested in monospecific antibody format) compete with Daratumumab for binding to CD38. Following CD38 injection over Daratumumab (immobilized on SPR sensor chip), the test antibodies (or Daratumumab) were injected over the Daratumumab/CD38 complex. As shown in FIG. 3, injection of Hyb6264, hhy992, Hyb5379, and Hhy1195 increased SPR signal, indicating that these antibodies recognized the epitopes on CD38 which are different from the epitope which Daratumumab recognizes. As expected, injection of free Daratumumab (a competitive binding control) did not increase the SPR signal.

[0659] Binding of anti-CD38 antibodies to human or cynomolgus CD38 polypeptides is summarized in Table B2.

TABLE-US-00015 TABLE B2 Summary of anti-CD38 binding characteristics to human or cynomolgus CD38. ELISA ELISA FACS FACS SPR SPR huCD38 cynoCD38 huCD38 cynoCD38 huCD38 cynoCD38 Name EC50 nM EC50 nM EC50 nM EC50 nM KD M KD M AntiCD38_hyb_5739 0.12 0.09 0.3 0.5 AntiCD38_hyb_6284 0.11 0.13 0.4 0.7

AntiCD38_hhy_992 0.09 0.08 100 288 3.65E-10 6.12E-09 AntiCD38_hhy_1195 1.4 0.86 38 15 4.00E-08 2.60E-08

[0660] Anti-CD38 antibodies were also tested for competitive binding to daratumumab in SPR assay. For daratumumab competition binding assay, daratumumab was amine coupled to the active surface of CM5 chip. Reference surface was left blank and used to subtract any non-specific binding of injected molecules. Recombinant CD38-His (Sino Biological, Part #10818-H08H) was injected over the daratumumab surface followed by injection of test antibodies. If an antibody recognizes an epitope on CD38 which is different from that of daratumumab, injection of the antibody will result in an increased SPR signal. If an antibody recognizes an overlapping epitope as daratumumab, injection of the antibody will not increase SPR signal. According to the results of these assays the tested antibodies hhy992, hyb6284, hhy1195 and hhy1370 did not compete with daratumumab.

Example 3: Trispecific CD38/CD3xCD28 Antibodies Promote Lysis of Human Multiple Myeloma and Lymphoma Tumor Cells

[0661] An in vitro cell lysis assay was used to determine whether trispecific CD38/CD3xCD28 antibodies had anti-tumor cell activity using human multiple myeloma and lymphoma cells.

Materials and Methods

In Vitro Killing Assay Against Tumor Cells Using Human T Cells

[0662] Target tumor cells were labeled with the membrane dye PKH-26 (Sigma) and co-cultured for 24 hours with human PBMC or enriched CD8 T cells as effector cells at E:T ratio of 10:1 (E:T=3:1 using enriched CD8 T cells) in the presence of indicated concentrations of tri-specific or relevant control antibodies. Peripheral blood mononuclear cells were isolated from normal human donors by Ficoll separation, and autologous CD8+ or pan-T cells were enriched using kits from Miltenyi Biotech (San Diego, CA). The extent of cell lysis in the target cells was determined by staining with a LIVE/DEAD™ Fixable Violet Dead Cell Stain Kit (Life Technologies) and measured by the number of dead cells in the labelled target cell population by running the samples on an LSRFortessa instrument (BD Biosciences) followed by analysis using the Flowjo software (Treestar).

In Vitro Killing Assay Against Tumor Cells Using Human T Cells in the Presence of Daratumumab

[0663] 5 nM Daratumumab or isotype control antibodies were pre-incubated with PKH-26 labeled target tumor cells (10.sup.5 cells/well) for 30 minutes, followed by addition of trispecific TCEs at indicated concentrations, and human PBMCs (E:T=10:1). 24 hours later, the extent of cell lysis in the target cells was determined by staining with a LIVE/DEAD™ Fixable Violet Dead Cell Stain Kit (Life Technologies) and measured by the number of dead cells in the labelled target cell population by running the samples on an LSRFortessa instrument (BD Biosciences) followed by analysis using the Flowjo software (Treestar).

Results

[0664] The in vitro cell killing activity of CD38/CD28sup x CD3mid_ENLQ DKTHT IgG4 FALA trispecific antibodies with alternative anti-CD38 binding domains was determined using a human multiple myeloma cell line NCI-H929 that expresses both CD38 and CD28. The assay was carried out in the presence of 5 nM Daratumumab or isotype control antibodies (present during the assay period). As shown in FIGS. 4A-4B, all tested trispecific antibodies led to cell lysis in a concentration-dependent manner in the presence and absence of Daratumumab. The EC50 values were then calculated in the presence and absence of Daratumumab (Table C). The cell killing activities of trispecific antibodies CD38/CD28sup x CD3mid_ENLQ DKTHT IgG4 FALA with the CD38VH1 or CD38hhy1370 anti-CD38 binding domains were reduced by Daratumumab, while trispecific antibodies with the CD38hyb5739, CD38hyb6284, or CD38hhy1195 anti-CD38 binding domains exhibited between 3-8 fold reductions in cell killing activity in the presence of Daratumumab (Table C).

TABLE-US-00016 TABLE C In vitro killing activity against human multiple myeloma cell line NCI-H929 (CD38+/CD28+)

by CD38/CD28sup x CD3mid_ENLQ DKTHT IgG4 FALA trispecific antibodies with alternative anti-CD38 binding domains in the presence of Daratumumab. EC50 Anti-CD38 binding domains (pM) CD38VH1 CD38hhy992 CD38hyb5739 CD38hyb6284 CD38hhy1195 CD38hhy1370 With 29.82 125.8 9.115 33.65 89.27 255.4 Dara With 1.063 13.43 2.736 4.37 16.97 9.599 human IgG1

[0665] In addition, an in vitro cell lysis assay was used to measure the cell killing activity of selected CD38/CD28sup x CD3mid_ENLQ DKTHT IgG4 FALA trispecific antibodies with alternative anti-CD38 binding domains using a human lymphoma cell line OCI-LY19 that expresses CD38 but not CD28. The assay was carried out in the presence of 5 nM Daratumumab or isotype control antibodies which were present in the assay period. As shown in FIGS. 5A-5B, all tested trispecific led to cell lysis in a concentration-dependent manner in the presence and absence of Daratumumab. The EC50 values were then calculated in the presence and absence of Daratumumab (Table D). The cell killing activity of CD38/CD28sup x CD3mid_ENLQ DKTHT IgG4 FALA trispecific antibodies with CD38VH1 anti-CD38 binding domain was reduced by about 24 fold by Daratumumab, while trispecific antibodies with the CD38hhy992, CD38hyb5739, CD38hyb6284, CD38hhy1195, or CD38hhy1370 anti-CD38 binding domains also exhibited reductions in cell killing activity in the presence of Daratumumab (Table D).

TABLE-US-00017 TABLE D In vitro killing activity against human lymphoma cell line OCI-LY19 (CD38+/CD28-) by selected CD38/CD28sup x CD3mid_ENLQ DKTHT IgG4 FALA trispecific antibodies with alternative anti-CD38 binding domains in the presence of Daratumumab. EC50 Anti-CD38 binding domains (pM) CD38VH1 CD38hhy992 CD38hyb5739 CD38hyb6284 CD38hhy1195 CD38hhy1370 With 135.9 133.3 219.1 81.05 715.2 209.8 Dara With 5.662 57.32 60.97 42.07 296.4 58.54 human IgG1

Example 4: CD38/CD28xCD3 Trispecific Antibodies Promote CMV-Specific Immune Response

[0666] As part of adaptive immunity, T cell immunity plays a crucial role in controlling viral infection and cancer, possibly eliminating infected cells and malignant cells which result in clearance of viral infection or cure of cancer. In chronic infectious diseases such as Herpes viral infection (HSV, CMV, EBV, etc.), HIV, and HBV viruses establish their persistence in humans by various mechanisms including immune suppression, T cell exhaustion, and latency establishment. Nevertheless, viral infection generally induces viral antigen specific immunity including antigen specific CD8 T cells that can readily recognize infected cells for controlling or killing through cytokine release or cytotoxic T cell (CTL) mediated killing processes. Thus, viral antigen specific T cell activation and/or amplification in vivo and/or ex vivo provide therapeutic strategies against chronic viral infections.

[0667] Anti-CD38/CD28xCD3 trispecific antibodies were developed and evaluated for their potential in activating T cells, and promoting proliferation and/or amplification of antigen specific T cells. These trispecific Abs can effectively expand CD4 and CD8 effector and memory populations, including antigen specific CD8 T central memory and effector memory cells in vitro. Specifically, in vitro expansion of CMV and EBV specific CD8 central memory and effector memory cells were demonstrated. The anti-CD38/CD28xCD3 trispecific antibodies described herein exhibited novel properties by engaging CD3/CD28/CD38, providing signaling pathways to stimulate and expand T cells, which may offer an effective strategy treating chronic infectious diseases such as HSV, CMV, EBV, HIV-1, and HBV infections.

[0668] In this Example, the ability of CD38/CD28xCD3 trispecific antibodies to promote activation and expansion of CMV-specific T cells was determined.

Materials and Methods

In Vitro T Cell Proliferation Measurement

[0669] T cells were isolated from human PBMC donors by negative selection using a magnetic Pan T Cell Isolation Kit (Miltenyi Biotec GmbH, Germany). Antibodies were coated onto 96-well cell culture plates by preparing the antibodies in sterile PBS and dispensing 50 μ L into each well (350 ng/well). The plates were then incubated at 37° C. for at least 2 hours and then washed with sterile PBS. The untouched T cells were added to the antibody-coated plates (5 \times 10^{sup.5} cells/mL) and incubated at 37° C. for multiple days. The cells were passaged with new cell culture media onto fresh antibody-coated plates on Day 4. In certain experiments with 7 days incubation, only fresh medium was added without changing to fresh antibody-coated plate. The cells were collected at specific time points and cell numbers calculated using CountBright™ counting beads.

In Vitro T Cell Proliferation Assay and T Cell Subset Determination

[0670] Peripheral blood mononuclear cells were isolated from blood of healthy human donors collected by Research Blood Components, LLC (Boston, MA). The PBMCs were added to antibody-coated plates (350 ng/well) (5 \times 10^{sup.5} cells/mL), as previously described above, and incubated at 37° C. for 3 and 7 days. The cells were collected at specific time points and analyzed by flow cytometry for T cell subsets: naïve (CCR7+ CD45RO-), T.sub.cm (CCR7+ CD45RO+), T.sub.cm (CCR7- CD45RO+), Tregs (CD4+ Foxp3+ CD25hi). CMV pp65-specific and EBV BMLF-specific CD8+ T cells were detected using fluorescent-conjugated pentamer restricted to the PBMC donors' HLA/viral peptide (A*02:01/NLVPMTATV, SEQ ID NO:284), (A*02:01/GLCTLVAML, SEQ ID NO:285), respectively (ProImmune, Oxford, UK). PBMC was obtained from HemaCare (Van Nuys, CA) for donors with known CMV or EBV infection. PMBC from donors negative for the restricting HLA type was used as negative control. Staining was done as per manufacturer's protocol.

Quantification of CMV-Specific T-Cells

[0671] As indicated above Peripheral blood mononuclear cells (PBMCs) were isolated from blood of known CMV-infected human donors and added to plates containing the trispecific antibody or control antibody. The plates were incubated at 37° C. The cells were collected at specific time points and analyzed by flow cytometry.

Results

[0672] CD38/CD28sup x CD3mid_ENLQ DKTHT IgG4 FALA trispecific antibodies with alternative anti-CD38 binding

domains ΔVH1CD38 (control), CD38VH1, CD38hhy992, CD38hyb5739, CD38hyb6284, CD38hhy1195, and CD38hhy1370 were tested as described above using PBMCs isolated from CMV-infected human donor D (FIGS. 6A-6J) and CMV-infected human donor E (FIGS. 7A-7J). All tested CD38 trispecific Abs activated and promoted the proliferation of CMV-specific T cells, leading to increases in CMV-specific CD8⁺ T cells (cells/well) with different potency and kinetics in a dose response manner over the 7 day experiment (CMV Donor D, FIGS. 6A-6B; CMV Donor E, FIGS. 7A-7B). In addition, all tested CD38 trispecific Abs promoted the amplification (cells/well) of CMV-specific central memory (T.sub.cm) (CMV Donor D, FIGS. 6C-6D; CMV Donor E, FIGS. 7C-7D) and effector memory (T.sub.cm) CD8⁺ T cells (CMV Donor D, FIGS. 6E-6F; CMV Donor E, FIGS. 7E-7F), which were both amplified dramatically in 7 days. FIGS. 6G-6J (CMV Donor D) and FIGS. 7G-7J (CMV Donor E) provide time courses showing the percent of CMV-specific T.sub.cm and T.sub.cm cells at days 0, 3, and 7 of the 7-day experiments described above.

[0673] Taken together, these data indicate that CD38/CD28xCD3 trispecific antibodies promote activation and expansion of CMV-specific T cells, such as CMV-specific CD8⁺ T cells, CMV-specific effector memory (T.sub.cm) CD8⁺ T cells, and CMV-specific central memory (T.sub.cm) CD8⁺ T cells.

Example 5: CD38/CD28xCD3 Trispecific Antibodies Promote EBV-Specific Immune Response

[0674] Next, the ability of CD38/CD28xCD3 trispecific antibodies to promote activation and expansion of Epstein-Barr virus (EBV)-specific T cells was determined.

Materials and Methods

Quantification of EBV-Specific T-Cells

[0675] As indicated above, peripheral blood mononuclear cells (PBMCs) were isolated from blood of known EBV-infected human donors and added to plates containing the trispecific antibody or control antibody. The plates were incubated at 37° C. for up to 11 days. The cells were collected at specific time points and analyzed by flow cytometry.

Results

[0676] CD38/CD28sup x CD3mid_ENLQ DKTHT IgG4 FALA trispecific antibodies with alternative anti-CD38 binding domains ΔVH1CD38 (control), CD38VH1, CD38hhy992, CD38hyb5739, CD38hyb6284, CD38hhy1195, and CD38hhy1370 were also tested as described above using PBMCs isolated from EBV-infected donor C (FIGS. 8A-8J) and EBV-infected donor D (FIGS. 9A-12). All tested CD38 trispecific Abs activated T cells and promoted the proliferation of EBV-specific T cells, leading to increases in EBV-specific CD8⁺ T cells (cells/well) with different potency and kinetics in a dose response manner over the 7 day experiment (EBV Donor C, FIGS. 8A-8B; EBV Donor D, FIGS. 9A-9B). In addition, all tested CD38 trispecific Abs promoted the amplification (cells/well) of EBV-specific central memory (T.sub.cm) (EBV Donor C, FIGS. 8C-8D; EBV Donor D, FIGS. 9C-9D) and effector memory (T.sub.cm) CD8⁺ T cells (EBV Donor C, FIGS. 8E-8F; EBV Donor D, FIGS. 9E-9F), which were both amplified dramatically in 7 days. FIGS. 8G-8J (EBV Donor C) and FIGS. 9G-12 (EBV Donor D) provide time courses showing the percent of EBV-specific T.sub.cm and T.sub.cm cells at days 0, 3, and 7 of the 7-day experiments described above.

[0677] Taken together, these data indicate that CD38/CD28xCD3 trispecific antibodies promote activation and expansion of EBV-specific T cells, such as EBV-specific CD8⁺ T cells, EBV-specific effector memory (T.sub.cm) CD8⁺ T cells, and EBV-specific central memory (T.sub.cm) CD8⁺ T cells.

Example 6: Anti-Tumor Effects of Her2/CD28 x CD3 Trispecific Antibody in Tumor-Bearing Mice

[0678] In this Example, the Her2/CD28 x CD3 trispecific antibody was tested for anti-tumor effects in a ZR-75-1 tumor bearing Nod scid gamma (NSG) mouse model engrafted with in vitro expanded T cells.

Materials and Methods

[0679] NSG mice were divided into 5 groups of 10 mice each. On Day 0, ZR-75-1 human breast cancer cells were implanted into the mammary fat pad with 50% matrigel into each mouse at 5 million cells/mouse. On Days 17/18, expansion of human CD3⁺ T cells was begun. Randomization of mice occurred on Day 24 when tumors were approximately 150 mm^{sup.3}. On Day 25, all mice were engrafted with in vitro expanded human CD3⁺ T cells at 10 million cells in 300 μL/mouse (1QW, 1 IP injection).

[0680] Starting on Day 25, one group of mice received doses of vehicle alone (8% w/v sucrose, 0.05% w/v polysorbate 80, 10 mM histidine, pH 5.5), while the other 4 groups received Her2/CD28 x CD3 trispecific antibody, both at 10 mL/kg. Groups receiving trispecific antibody were dosed at 100, 10, 1, or 0.1 μg/kg. Antibody or vehicle was administered 1QW intravenously in 2 doses (e.g., Days 25 and 32). Blood and tumor tissue was collected on Day 38 or 39.

Results

[0681] Her2/CD28 x CD3 trispecific antibody (binding protein #2 from Table 1, corresponding to SEQ ID Nos: 104-107) was compared to vehicle control for its effects on human breast tumor growth in the NSG mouse model engrafted with in vitro expanded human T cells described above. Treatment with Her2/CD28 x CD3 trispecific antibody at the highest dose (100 ug/kg) led to the most significant inhibition of tumor growth and regression, although the 10 ug/kg dose also showed anti-tumor effects (FIGS. 13A & 13D). No significant body weight loss was observed (FIG. 13B). Individual tumor volumes over time from each trispecific antibody treatment group are provided in FIG. 13C.

[0682] Next, the effect of trispecific antibody treatment on individual immune cell subsets was examined. Human CD45⁺, human CD8⁺, and human CD4⁺ cell populations were measured by flow cytometry, as well as mouse CD45⁺ cells (FIGS. 14A-14C). Highest dose (100 ug/kg) of trispecific antibody led to depletion of human CD4⁺ cells, and this effect was dose dependent (FIGS. 14B & 14C). Counts of human CD8⁺ cells were largely unaffected by trispecific antibody administration.

[0683] The effect of trispecific antibody treatment on tumor infiltrating lymphocytes (TILs) was also assessed by immunohistochemical (IHC) staining for human CD45, CD4, and CD8. Using H&E staining, tumors from the low dose groups (1 ug/kg or 0.1 ug/kg trispecific antibody) were generally of comparable size as the vehicle control group. As shown

in FIGS. 15A-15C, human TILs were increased in the group receiving the low dose of Her2/CD28 x CD3 trispecific antibody, but human TILs were sparse in the high dose group. IHC images were also examined quantitatively (FIGS. 16A-16C). These results indicated significant reductions in CD45+ and CD8+ cells in the higher trispecific antibody dose groups (100 ug/kg and 10 ug/kg).

[0684] Compared to vehicle control, tumors from the high dose trispecific antibody treatment groups (100 ug/kg or 10 ug/kg) were characterized by sparse TILs. Moderate to large numbers of CD45+, CD4+, or CD8+ human TILs were observed in the 1 ug/kg and 0.1 ug/kg trispecific antibody treatment groups. These TILs were mostly present at the tumor edges but occasionally extended deeper into the tumor core.

[0685] In conclusion, these results demonstrate that treatment of ZR-75-1 breast tumor bearing NSG mice engrafted with in vitro activated T cells using 2 intravenous doses of HER2-targeting, T cell-engaging trispecific antibody at 100 ug/kg or 10 ug/kg resulted in significant reductions in tumor volume and, concomitantly, a significant decrease in TILs. At the 1 ug/kg trispecific antibody dose, there was a marginal and inconsistent trend for increased TILs as compared to vehicle control.

Example 7: Effect of Anti-HER2 and Anti-CD3 Antigen Binding Domain Sequences in Her2/CD28 x CD3 Trispecific Antibody on Cancer Cell Killing

[0686] This Example describes the effect of anti-Her2 and anti-CD3 variable domain sequences on target cell killing. In this Example, a Her2/CD28 x CD3 trispecific antibody (“control”) with wild-type trastuzumab antigen binding domain and an anti-CD3 antigen binding domain without 32/35 QQ mutations in the V.sub.L domain (see Example 1) was compared with Her2/CD28 x CD3 trispecific antibodies #1-6 from Table 1, corresponding to SEQ ID Nos: 100-103, 104-107, 286-289, 290-293, 294-297, and 298-301, respectively.

Materials and Methods

[0687] CD8+ T cells were isolated from human PBMCs from healthy donor using a magnetic bead isolation kit (Miltenyi Biotec). The T cells were used as effector cells against breast cancer cell lines expressing various levels of HER2 at 3:1 (Effector:Target) ratio. The cells were incubated with experimental or control trispecific antibody for 2 days before flow cytometry acquisition using viability dye (Invitrogen) and PKH26 target cell staining (Sigma). Mean EC50 for target cell lysis was calculated from 2-3 PBMC donors for each trispecific Ab.

Results

[0688] All trispecific antibodies were characterized for in vitro cell lysis of three HER2+ breast cancer target cell lines: HCC1954, BT20, and MDA-MB-231. HCC1954 breast cancer cells were found to express high levels of HER2, as assessed by flow cytometry (up to ~150,000 receptors/cell), IHC (3+), or the HercepTest HER2 expression assay (3+) (FIG. 17A). BT20 breast cancer cells were found to express intermediate levels of HER2, as assessed by flow cytometry (~60,000 receptors/cell), IHC (1+), or the HercepTest HER2 expression assay (1+) (FIG. 17C). MDA-MB-231 breast cancer cells were found to express low levels of HER2, as assessed by flow cytometry (~9,000 receptors/cell), IHC (0+), or the HercepTest HER2 expression assay (0) (FIG. 17E). Results of the cell killing assays targeting HCC1954, BT20, or MDA-MB-231 are shown in FIGS. 17B, 17D, and 17F, respectively, comparing binding protein #2 vs. control or binding proteins #1 and #5 vs. control. The results demonstrated that the Her2/CD28 x CD3 trispecific antibodies having 30R/55Q/102E mutations in the anti-HER2 arm and 32/35 QQ mutations in the VL domain of the anti-CD3 arm showed improved target cell killing against all three cell lines, particularly at lower antibody concentrations.

[0689] Mean EC50 (pM) for in vitro cell killing was determined for all trispecific antibodies targeting the three breast cancer cell lines noted above (HCC1954, BT20, and MDA-MB-231) as well as the gastric cancer cell lines OE19 (high HER2 expression) and GSU (intermediate HER2 expression). Generally, the Her2/CD28 x CD3 trispecific antibodies having mutations in the anti-HER2 arm and in the VL domain of the anti-CD3 arm showed a lower EC50 (and thus superior cell killing) against all three breast cancer cell lines (FIG. 18A) and both gastric cancer cell lines (FIG. 18B). These results demonstrate that, while all trispecific antibodies are able to induce cell killing of HER2+ cells, the mutated trispecific antibodies consistently displayed improved cell killing efficacy against multiple target cell types.

Claims

1. A binding protein comprising four polypeptide chains that form three antigen binding sites, wherein a first polypeptide chain comprises a structure represented by the formula:

V.sub.L2-L.sub.1-V.sub.L1-L.sub.2-C.sub.L [I] and a second polypeptide chain comprises a structure represented by the formula:

V.sub.H1-L.sub.3-V.sub.H2-L.sub.4-C.sub.H1-hinge-C.sub.H2-C.sub.H3 [II] and a third polypeptide chain comprises a structure represented by the formula:

V.sub.H3-C.sub.H1-hinge-C.sub.H2-C.sub.H3 [III] and a fourth polypeptide chain comprises a structure represented by the formula:

V.sub.L3-C.sub.L [IV] wherein: V.sub.L1 is a first immunoglobulin light chain variable domain; V.sub.L2 is a second immunoglobulin light chain variable domain; V.sub.L3 is a third immunoglobulin light chain variable domain; V.sub.H1 is a first immunoglobulin heavy chain variable domain; V.sub.H2 is a second immunoglobulin heavy chain variable domain; V.sub.H3 is a third immunoglobulin heavy chain variable domain; C.sub.L is an immunoglobulin light chain constant domain; C.sub.H1 is an immunoglobulin C.sub.H1 heavy chain constant domain; C.sub.H2 is an immunoglobulin C.sub.H2 heavy chain constant domain; C.sub.H3 is an immunoglobulin C.sub.H3 heavy chain constant domain; hinge is an immunoglobulin hinge region connecting the C.sub.H1 and C.sub.H2 domains; and L.sub.1, L.sub.2, L.sub.3 and L.sub.4 are amino acid linkers; wherein the polypeptide of formula I and the polypeptide of formula II form a cross-over light chain-

heavy chain pair; and wherein V.sub.H1 and V.sub.L1 form a first antigen binding site; wherein V.sub.H2 and V.sub.L2 form a second antigen binding site that binds a CD3 polypeptide, wherein the V.sub.H2 domain comprises a CDR-H1 sequence comprising the amino acid sequence of GFTFTKAW (SEQ ID NO:55), a CDR-H2 sequence comprising the amino acid sequence of IKDKSNSYAT (SEQ ID NO:56), and a CDR-H3 sequence comprising the amino acid sequence of RGVYYALSPFDY (SEQ ID NO:57), and the V.sub.L2 domain comprises a CDR-L1 sequence comprising the amino acid sequence of QSLVHX.sub.1NX.sub.2X.sub.3TY, wherein X.sub.1 is E or Q, X.sub.2 is A or L, and X.sub.3 is Q, R, or F (SEQ ID NO:180), a CDR-L2 sequence comprising the amino acid sequence of KVS (SEQ ID NO:64), and a CDR-L3 sequence comprising the amino acid sequence of GQGTQYPFT (SEQ ID NO:65); and wherein V.sub.H3 and V.sub.L3 form a third antigen binding site that binds a HER2 polypeptide.

2. The binding protein of claim 1, wherein the first binding site binds a CD28 polypeptide.

3. The binding protein of claim 2, wherein the V.sub.H1 domain comprises a CDR-H1 sequence comprising the amino acid sequence of GYTFTSY (SEQ ID NO:49), a CDR-H2 sequence comprising the amino acid sequence of IYPGNVNT (SEQ ID NO:50), and a CDR-H3 sequence comprising the amino acid sequence of TRSHYGLDWNFDV (SEQ ID NO:51), and the V.sub.L1 domain comprises a CDR-L1 sequence comprising the amino acid sequence of QNIYVW (SEQ ID NO:52), a CDR-L2 sequence comprising the amino acid sequence of KAS (SEQ ID NO:53), and a CDR-L3 sequence comprising the amino acid sequence of QQGQTPY (SEQ ID NO:54).

4. The binding protein of claim 3, wherein the V.sub.H1 domain comprises the amino acid sequence of QVQLVQSGAEVVKPGASVKVCKASGYTFTSYIHVVRQAPGQGLEWIGSIYPGNVNT
NYAQKFQGRATLTVDTSISTAYMELSRSLRSDDTAVYYCTRSHYGLDWNFDVWGKGTT VTVSS (SEQ ID NO:91), and/or the V.sub.L1 domain comprises the amino acid sequence of
DIQMTQSPSSLSASVGDRVTITCQASQNIYVWLNWYQKPKGKAPKLLIYKASNLHTGVP
SRFSGSGSGTDFTLTISLQPEDATYYCQQGQTPYPTFGQGTKLEIK (SEQ ID NO:92).

5. The binding protein of claim 1, wherein the CDR-L1 sequence of the V.sub.L2 domain comprises an amino acid sequence selected from the group consisting of QSLVHQNAQTY (SEQ ID NO:59), QSLVHENLQTY (SEQ ID NO:60), QSLVHENLFTY (SEQ ID NO:61), and QSLVHENLRTY (SEQ ID NO:62).

6. The binding protein of claim 5, wherein the V.sub.H2 domain comprises the amino acid sequence of QVQLVESGGGVVQPGRSLRLSCAASGFTFTKAWMHVVRQAPGKQLEWVAQIKDKSNS YATYYADSVKGRF
TISRDDSKNTLYLQMNSLRAEDTAVYYCRGVYYALSPFDYWGGQ TLTVTVSS (SEQ ID NO:93) or
QVQLVESGGGVVQPGRSLRLSCAASGFTFTKAWMHVVRQAPGKQLEWVAQIKDKSNS
YATYYASSVKGRFTISRDD SKNTLYLQMNSLRAEDTAVYYCRGVYYALSPFDYWGGQ TLTVTVSS (SEQ ID NO:595), and/or the V.sub.L2 domain comprises an amino acid sequence selected from the group consisting of
DIVMTQTPLSLSVTPGQPASISCKSSQSLVHQNAQTYLSWY LQKPGQSPQSLIYKVS NRF
SGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCGQGTQYPFTFGSGTKVEIK (SEQ ID NO:95),
DIVMTQTPLSLSVTPGQPASISCKSSQSLVHENLQTYLSWY LQKPGQSPQSLIYKVS NRF
GVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCGQGTQYPFTFGSGTKVEIK (SEQ ID NO:96),
DIVMTQTPLSLSVTPGQPASISCKSSQSLVHENLFTYLSWY LQKPGQSPQSLIYKVS NRF
GVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCGQGTQYPFTFGSGTKVEIK (SEQ ID NO:97), and
DIVMTQTPLSLSVTPGQPASISCKSSQSLVHENLRTYLSWY LQKPGQSPQSLIYKVS NRF
GVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCGQGTQYPFTFGSGTKVEIK (SEQ ID NO:98).

7-11. (canceled)

12. The binding protein of claim 1, wherein the HER2 polypeptide is a human HER2 polypeptide.

13. The binding protein of claim 12, wherein: (a) the V.sub.H3 domain comprises a CDR-H1 sequence comprising the amino acid sequence of GFNIKDTY (SEQ ID NO:1) or GFNIRDTY (SEQ ID NO:2), a CDR-H2 sequence comprising the amino acid sequence of IYPTNGYT (SEQ ID NO:3), IYPTQGYT (SEQ ID NO:4), or IYPTNAYT (SEQ ID NO:5), and a CDR-H3 sequence comprising the amino acid sequence of SRWGGDGFYAMDY (SEQ ID NO:6), SRWGGE GFYAMDY (SEQ ID NO:7), or SRWGGSGFYAMDY (SEQ ID NO:8), and the V.sub.L3 domain comprises a CDR-L1 sequence comprising the amino acid sequence of QDVNTA (SEQ ID NO:9) or QDVQTA (SEQ ID NO:10), a CDR-L2 sequence comprising the amino acid sequence of SAS (SEQ ID NO:11), and a CDR-L.sub.3 sequence comprising the amino acid sequence of QQHYTTP (SEQ ID NO:12); (b) the V.sub.H3 domain comprises a CDR-H1 sequence comprising the amino acid sequence of GFNIKDTY (SEQ ID NO:1), a CDR-H2 sequence comprising the amino acid sequence of IYPTNGYT (SEQ ID NO:3), and a CDR-H3 sequence comprising the amino acid sequence of SRWGGDGFYAMDY (SEQ ID NO:6), and the V.sub.L3 domain comprises a CDR-L1 sequence comprising the amino acid sequence of QDVNTA (SEQ ID NO:9), a CDR-L2 sequence comprising the amino acid sequence of SAS (SEQ ID NO:11), and a CDR-L3 sequence comprising the amino acid sequence of QQHYTTP (SEQ ID NO:12); (c) the V.sub.H3 domain comprises a CDR-H1 sequence comprising the amino acid sequence of GFNIRDTY (SEQ ID NO:2), a CDR-H2 sequence comprising the amino acid sequence of IYPTQGYT (SEQ ID NO:4), and a CDR-H3 sequence comprising the amino acid sequence of SRWGGE GFYAMDY (SEQ ID NO:7), and the V.sub.L3 domain comprises a CDR-L1 sequence comprising the amino acid sequence of QDVNTA (SEQ ID NO:9), a CDR-L2 sequence comprising the amino acid sequence of SAS (SEQ ID NO:11), and a CDR-L3 sequence comprising the amino acid sequence of QQHYTTP (SEQ ID NO:12); (d) the V.sub.H3 domain comprises a CDR-H1 sequence comprising the amino acid sequence of GFNIRDTY (SEQ ID NO:2), a CDR-H2 sequence comprising the amino acid sequence of IYPTNAYT (SEQ ID NO:5), and a CDR-H3 sequence comprising the amino acid sequence of SRWGGSGFYAMDY (SEQ ID NO:8), and the V.sub.L3 domain comprises a CDR-L1 sequence comprising the amino acid sequence of QDVNTA (SEQ ID NO:9), a CDR-L2 sequence comprising the amino acid sequence of SAS (SEQ ID NO:11), and a CDR-L3 sequence

comprising the amino acid sequence of QQHYTTP (SEQ ID NO:12); (e) the V.sub.H3 domain comprises a CDR-H1 sequence comprising the amino acid sequence of GFNIRDY (SEQ ID NO:2), a CDR-H2 sequence comprising the amino acid sequence of IYPTQGYT (SEQ ID NO:4), and a CDR-H3 sequence comprising the amino acid sequence of SRWGGSGFYAMDY (SEQ ID NO:8), and the V.sub.L3 domain comprises a CDR-L1 sequence comprising the amino acid sequence of QDVNTA (SEQ ID NO:9), a CDR-L2 sequence comprising the amino acid sequence of SAS (SEQ ID NO:11), and a CDR-L3 sequence comprising the amino acid sequence of QQHYTTP (SEQ ID NO:12); (f) the V.sub.H3 domain comprises a CDR-H1 sequence comprising the amino acid sequence of GFNIRDY (SEQ ID NO:2), a CDR-H2 sequence comprising the amino acid sequence of IYPTNAYT (SEQ ID NO:5), and a CDR-H3 sequence comprising the amino acid sequence of SRWGEGFYAMDY (SEQ ID NO:7), and the V.sub.L3 domain comprises a CDR-L1 sequence comprising the amino acid sequence of QDVNTA (SEQ ID NO:9), a CDR-L2 sequence comprising the amino acid sequence of SAS (SEQ ID NO:11), and a CDR-L3 sequence comprising the amino acid sequence of QQHYTTP (SEQ ID NO:12); or (g) the V.sub.H3 domain comprises a CDR-H1 sequence comprising the amino acid sequence of GFNIKDY (SEQ ID NO:1), a CDR-H2 sequence comprising the amino acid sequence of IYPTNGYT (SEQ ID NO:3), and a CDR-H3 sequence comprising the amino acid sequence of SRWGGDGFYAMDY (SEQ ID NO:6), and the V.sub.L3 domain comprises a CDR-L1 sequence comprising the amino acid sequence of QDVQTA (SEQ ID NO:10), a CDR-L2 sequence comprising the amino acid sequence of SAS (SEQ ID NO:11), and a CDR-L3 sequence comprising the amino acid sequence of QQHYTTP (SEQ ID NO:12).

14. The binding protein of claim 13, wherein: (a) the V.sub.H3 domain comprises the amino acid sequence of EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYT RYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGT LTVSS (SEQ ID NO:72), EVQLVESGGGLVQPGGSLRL SCAASGFNIRDYIHWVRQAPGKGLEWVARIYPTQGYTR YADSVKGRF TISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGEGFYAMDYWGQGT L VTVSS (SEQ ID NO:73), EVQLVESGGGLVQPGGSLRLSCAASGFNIRDYIHWVRQAPGKGLEWVARIYPTQGYTR YADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGSGFYAMDYWGQGT L VTVSS (SEQ ID NO:74), EVQLVESGGGLVQPGGSLRLSCAASGFNIRDYIHWVRQAPGKGLEWVARIYPTNAYTR YADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGSGFYAMDYWGQGT L VTVSS (SEQ ID NO:75), or EVQLVESGGGLVQPGGSLRLSCAASGFNIRDYIHWVRQAPGKGLEWVARIYPTNAYTR YADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGEGFYAMDYWGQGT L VTVSS (SEQ ID NO:76), and/or the V.sub.L3 domain comprises the amino acid sequence of DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVP SRFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIK (SEQ ID NO:77) or DIQMTQSPSSLSASVGDRVTITCRASQDVQTA VAWYQQKPGKAPKLLIYSASFLYSGVP SRFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIK (SEQ ID NO:78); (b) the V.sub.H3 domain comprises the amino acid sequence of EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYT RYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGT LTVSS (SEQ ID NO:72), and/or the V.sub.L3 domain comprises the amino acid sequence of DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVP SRFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIK (SEQ ID NO:77); (c) the V.sub.H3 domain comprises the amino acid sequence of EVQLVESGGGLVQPGGSLRLSCAASGFNIRDYIHWVRQAPGKGLEWVARIYPTQGYTR YADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGEGFYAMDYWGQGT L VTVSS (SEQ ID NO:73), and/or the V.sub.L3 domain comprises the amino acid sequence of DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVP SRFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIK (SEQ ID NO:77); (d) the V.sub.H3 domain comprises the amino acid sequence of EVQLVESGGGLVQPGGSLRLSCAASGFNIRDYIHWVRQAPGKGLEWVARIYPTNAYTR YADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGSGFYAMDYWGQGT L VTVSS (SEQ ID NO:75), and/or the V.sub.L3 domain comprises the amino acid sequence of DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVP SRFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIK (SEQ ID NO:77); (e) the V.sub.H3 domain comprises the amino acid sequence of EVQLVESGGGLVQPGGSLRLSCAASGFNIRDYIHWVRQAPGKGLEWVARIYPTQGYTR YADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGSGFYAMDYWGQGT L VTVSS (SEQ ID NO:74), and/or the V.sub.L3 domain comprises the amino acid sequence of DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVP SRFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIK (SEQ ID NO:77); (f) the V.sub.H3 domain comprises the amino acid sequence of EVQLVESGGGLVQPGGSLRLSCAASGFNIRDYIHWVRQAPGKGLEWVARIYPTNAYTR YADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGEGFYAMDYWGQGT L VTVSS (SEQ ID NO:76), and/or the V.sub.L3 domain comprises the amino acid sequence of DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVP SRFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIK (SEQ ID NO:77); or (g) the V.sub.H3 domain

that is at least 95% identical to the amino acid sequence of SEQ ID NO:290; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO:291 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:291; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO:292 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:292; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO:293 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:293; or (k) the first polypeptide chain comprises the amino acid sequence of SEQ ID NO:294 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:294; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO:295 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:295; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO:296 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:296; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO:297 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:297.

16. The binding protein of claim 1, wherein at least one of L.sub.1, L.sub.2, L.sub.3 or L.sub.4 is independently 0 amino acids in length.

17. The binding protein of claim 1, wherein (a) L.sub.1, L.sub.2, L.sub.3 and L.sub.4 each independently are zero amino acids in length or comprise a sequence selected from the group consisting of GGGGSGGGGS (SEQ ID NO:69), GGGGSGGGSGGGGS (SEQ ID NO:70), S, RT, TKGPS (SEQ ID NO:68), GQPKAAP (SEQ ID NO:67), and GGS GSSGSGG (SEQ ID NO:71); or (b) L.sub.1, L.sub.2, L.sub.3 and L.sub.4 each independently comprise a sequence selected from the group consisting of GGGGSGGGGS (SEQ ID NO:69), GGGGSGGGSGGGGS (SEQ ID NO:70), S, RT, TKGPS (SEQ ID NO:68), GQPKAAP (SEQ ID NO:67), and GGS GSSGSGG (SEQ ID NO:71).

18. The binding protein of claim 1, wherein L.sub.1 comprises the sequence GQPKAAP (SEQ ID NO:67), L.sub.2 comprises the sequence TKGPS (SEQ ID NO:68), L.sub.3 comprises the sequence S, and L.sub.4 comprises the sequence RT.

19. The binding protein of claim 1, wherein at least one of L.sub.1, L.sub.2, L.sub.3 or L.sub.4 comprises the sequence DKTHT (SEQ ID NO:66).

20. The binding protein of claim 19, wherein L.sub.1, L.sub.2, L.sub.3 and L.sub.4 each independently comprise the sequence DKTHT (SEQ ID NO:66).

21. The binding protein of claim 1, wherein the hinge-C.sub.H2-C.sub.H3 domains of the second and the third polypeptide chains are human IgG4 hinge-C.sub.H2-C.sub.H3 domains, and wherein the hinge-C.sub.H2-C.sub.H3 domains each comprise amino acid substitutions at positions corresponding to positions 234 and 235 of human IgG4 according to EU Index, wherein the amino acid substitutions are F234A and L235A.

22. The binding protein of claim 1, wherein the hinge-C.sub.H2-C.sub.H3 domains of the second and the third polypeptide chains are human IgG4 hinge-C.sub.H2-C.sub.H3 domains, and wherein the hinge-C.sub.H2-C.sub.H3 domains each comprise amino acid substitutions at positions corresponding to positions 233-236 of human IgG4 according to EU Index, wherein the amino acid substitutions are E233P, F234V, L235A, and a deletion at 236.

23. The binding protein of claim 1, wherein the hinge-C.sub.H2-C.sub.H3 domains of the second and the third polypeptide chains are human IgG4 hinge-C.sub.H2-C.sub.H3 domains, and wherein the hinge-C.sub.H2-C.sub.H3 domains each comprise amino acid substitutions at positions corresponding to positions 228 and 409 of human IgG4 according to EU Index, wherein the amino acid substitutions are S228P and R409K.

24. The binding protein of claim 1, wherein the hinge-C.sub.H2-C.sub.H3 domains of the second and the third polypeptide chains are human IgG1 hinge-C.sub.H2-C.sub.H3 domains, and wherein the hinge-C.sub.H2-C.sub.H3 domains each comprise amino acid substitutions at positions corresponding to positions 234, 235, and 329 of human IgG1 according to EU Index, wherein the amino acid substitutions are L234A, L235A, and P329A.

25. The binding protein of claim 1, wherein the hinge-C.sub.H2-C.sub.H3 domains of the second and the third polypeptide chains are human IgG1 hinge-C.sub.H2-C.sub.H3 domains, and wherein the hinge-C.sub.H2-C.sub.H3 domains each comprise amino acid substitutions at positions corresponding to positions 298, 299, and 300 of human IgG1 according to EU Index, wherein the amino acid substitutions are S298N, T299A, and Y300S.

26. The binding protein of claim 1, wherein the hinge-C.sub.H2-C.sub.H3 domain of the second polypeptide chain comprises amino acid substitutions at positions corresponding to positions 349, 366, 368, and 407 of human IgG1 or IgG4 according to EU Index, wherein the amino acid substitutions are Y349C, T366S, L368A, and Y407V; and wherein the hinge-C.sub.H2-C.sub.H3 domain of the third polypeptide chain comprises amino acid substitutions at positions corresponding to positions 354 and 366 of human IgG1 or IgG4 according to EU Index, wherein the amino acid substitutions are S354C and T366W.

27. The binding protein of claim 1, wherein the hinge-C.sub.H2-C.sub.H3 domain of the second polypeptide chain comprises amino acid substitutions at positions corresponding to positions 354 and 366 of human IgG1 or IgG4 according to EU Index, wherein the amino acid substitutions are S354C and T366W; and wherein the hinge-C.sub.H2-C.sub.H3 domain of the third polypeptide chain comprises amino acid substitutions at positions corresponding to positions 349, 366, 368, and 407 of human IgG1 or IgG4 according to EU Index, wherein the amino acid substitutions are Y349C, T366S, L368A, and Y407V.

28. An isolated nucleic acid molecule comprising a nucleotide sequence encoding the binding protein of claim 1.

29. An expression vector comprising the nucleic acid molecule of claim 28.

30. An isolated host cell comprising the nucleic acid molecule of claim 28.

31. The isolated host cell of claim 30, wherein the host cell is a mammalian or insect cell.

32. A pharmaceutical composition comprising the binding protein of claim 1 and a pharmaceutically acceptable carrier.

33-85. (canceled)

86. A vector system comprising one or more vectors encoding a first, second, third, and fourth polypeptide chain of a binding

protein of claim 1.

87. The vector system of claim 86, wherein the vector system comprises a first vector encoding the first polypeptide chain of the binding protein, a second vector encoding the second polypeptide chain of the binding protein, a third vector encoding the third polypeptide chain of the binding protein, and a fourth vector encoding the fourth polypeptide chain of the binding protein.

88. A kit of polynucleotides, comprising: (a) a first polynucleotide comprising the polynucleotide sequence of SEQ ID NO:189, a second polynucleotide comprising the polynucleotide sequence of SEQ ID NO:190, a third polynucleotide comprising the polynucleotide sequence of SEQ ID NO:191, and a fourth polynucleotide comprising the polynucleotide sequence of SEQ ID NO:192; (b) a first polynucleotide comprising the polynucleotide sequence of SEQ ID NO:193, a second polynucleotide comprising the polynucleotide sequence of SEQ ID NO:194, a third polynucleotide comprising the polynucleotide sequence of SEQ ID NO:195, and a fourth polynucleotide comprising the polynucleotide sequence of SEQ ID NO:196; (c) a first polynucleotide comprising the polynucleotide sequence of SEQ ID NO:201, a second polynucleotide comprising the polynucleotide sequence of SEQ ID NO:202, a third polynucleotide comprising the polynucleotide sequence of SEQ ID NO:203, and a fourth polynucleotide comprising the polynucleotide sequence of SEQ ID NO:204; (d) a first polynucleotide comprising the polynucleotide sequence of SEQ ID NO:217, a second polynucleotide comprising the polynucleotide sequence of SEQ ID NO:218, a third polynucleotide comprising the polynucleotide sequence of SEQ ID NO:219, and a fourth polynucleotide comprising the polynucleotide sequence of SEQ ID NO:220; (e) a first polynucleotide comprising the polynucleotide sequence of SEQ ID NO:225, a second polynucleotide comprising the polynucleotide sequence of SEQ ID NO:226, a third polynucleotide comprising the polynucleotide sequence of SEQ ID NO:227, and a fourth polynucleotide comprising the polynucleotide sequence of SEQ ID NO:228; (f) a first polynucleotide comprising the polynucleotide sequence of SEQ ID NO:229, a second polynucleotide comprising the polynucleotide sequence of SEQ ID NO:230, a third polynucleotide comprising the polynucleotide sequence of SEQ ID NO:231, and a fourth polynucleotide comprising the polynucleotide sequence of SEQ ID NO:232; (g) a first polynucleotide comprising the polynucleotide sequence of SEQ ID NO:233, a second polynucleotide comprising the polynucleotide sequence of SEQ ID NO:234, a third polynucleotide comprising the polynucleotide sequence of SEQ ID NO:235, and a fourth polynucleotide comprising the polynucleotide sequence of SEQ ID NO:236; or (h) a first polynucleotide comprising the polynucleotide sequence of SEQ ID NO:241, a second polynucleotide comprising the polynucleotide sequence of SEQ ID NO:242, a third polynucleotide comprising the polynucleotide sequence of SEQ ID NO:243, and a fourth polynucleotide comprising the polynucleotide sequence of SEQ ID NO:244.

89. The kit of claim 88, wherein the first, second, third, and fourth polynucleotides are present on one or more expression vectors.

90-128. (canceled)

129. A binding protein comprising four polypeptide chains that form three antigen binding sites, wherein a first polypeptide chain comprises a structure represented by the formula:

V.sub.L2-L.sub.1-V.sub.L1-L.sub.2-C.sub.L [I] and a second polypeptide chain comprises a structure represented by the formula:

V.sub.H1-L.sub.3-V.sub.H2-L.sub.4-C.sub.H1-hinge-C.sub.H2-C.sub.H3 [II] and a third polypeptide chain comprises a structure represented by the formula:

V.sub.H3-C.sub.H1-hinge-C.sub.H2-C.sub.H3 [III] and a fourth polypeptide chain comprises a structure represented by the formula:

V.sub.L3-C.sub.L [IV] wherein: V.sub.L1 is a first immunoglobulin light chain variable domain; V.sub.L2 is a second immunoglobulin light chain variable domain; V.sub.L3 is a third immunoglobulin light chain variable domain; V.sub.H1 is a first immunoglobulin heavy chain variable domain; V.sub.H2 is a second immunoglobulin heavy chain variable domain; V.sub.H3 is a third immunoglobulin heavy chain variable domain; C.sub.L is an immunoglobulin light chain constant domain; C.sub.H1 is an immunoglobulin C.sub.H1 heavy chain constant domain; C.sub.H2 is an immunoglobulin C.sub.H2 heavy chain constant domain; C.sub.H3 is an immunoglobulin C.sub.H3 heavy chain constant domain; hinge is an immunoglobulin hinge region connecting the C.sub.H1 and C.sub.H2 domains; and L.sub.1, L.sub.2, L.sub.3 and L.sub.4 are amino acid linkers; wherein the polypeptide of formula I and the polypeptide of formula II form a cross-over light chain-heavy chain pair; wherein V.sub.H1 and V.sub.L1 form a first antigen binding site that binds a CD28 polypeptide, wherein the V.sub.H1 domain comprises a CDR-H1 sequence comprising the amino acid sequence of GYTFTSYY (SEQ ID NO:49), a CDR-H2 sequence comprising the amino acid sequence of IYPGNVNT (SEQ ID NO:50), and a CDR-H3 sequence comprising the amino acid sequence of TRSHYGLDWNFDV (SEQ ID NO:51), and the V.sub.L1 domain comprises a CDR-L1 sequence comprising the amino acid sequence of QNIYVW (SEQ ID NO:52), a CDR-L2 sequence comprising the amino acid sequence of KAS (SEQ ID NO:53), and a CDR-L3 sequence comprising the amino acid sequence of QQGQTYPY (SEQ ID NO:54); wherein V.sub.H2 and V.sub.L2 form a second antigen binding site that binds a CD3 polypeptide, wherein the V.sub.H2 domain comprises a CDR-H1 sequence comprising the amino acid sequence of GFTFTKAW (SEQ ID NO:55), a CDR-H2 sequence comprising the amino acid sequence of IKDKSNSYAT (SEQ ID NO:56), and a CDR-H3 sequence comprising the amino acid sequence of RGVYYALSPFDY (SEQ ID NO:57), and the V.sub.L2 domain comprises a CDR-L1 sequence comprising the amino acid sequence of QSLVHQNAQTY (SEQ ID NO:59), a CDR-L2 sequence comprising the amino acid sequence of KVS (SEQ ID NO:64), and a CDR-L3 sequence comprising the amino acid sequence of GQGTQYPFT (SEQ ID NO:65); and wherein V.sub.H3 and V.sub.L3 form a third antigen binding site that binds a HER2 polypeptide wherein the V.sub.H3 domain comprises a CDR-H1 sequence comprising the amino acid sequence of GFNIRDY (SEQ ID NO:2), a CDR-H2 sequence comprising the amino acid sequence of IYPTQGYT (SEQ ID NO:4), and

a CDR-H3 sequence comprising the amino acid sequence of SRWGGEFGFYAMDY (SEQ ID NO:7), and the V.sub.L3 domain comprises a CDR-L1 sequence comprising the amino acid sequence of QDVNTA (SEQ ID NO:9), a CDR-L2 sequence comprising the amino acid sequence of SAS (SEQ ID NO:11), and a CDR-L3 sequence comprising the amino acid sequence of QQHYTTP (SEQ ID NO:12).

130. The binding protein of claim 129, wherein: the V.sub.H1 domain comprises the amino acid sequence of QVQLVQSGAEVVKPGASVKVSKASGYTFTSYIHVWRQAPGQGLEWIGSIYPGNVNTNYAQKFQGRATLTVDTSISTAYMELSRSLRSDDTAVYYCTRSHYGLDWNFDVWGKGTT VTVSS (SEQ ID NO:91), and the V.sub.L1 domain comprises the amino acid sequence of DIQMTQSPSSLSASVGDRVTITCQASQNIYVWLNWYQKPGKAPKLLIYKASNLHTGVP SRFSGSGSGTDFTLTISLQPEDATYYCQQGQTYPTFGQGTKLEIK (SEQ ID NO:92); the V.sub.H2 domain comprises the amino acid sequence of QVQLVESGGGVVQPGRSLRLSCAASGFTFTKAWMHWRQAPGKQLEWVAQIKDKSNSYATYYADSVKGRFTISRDDSKNTLYLQMNSLRAEDTAVYYCRGVYYALSPFDYWGQG TLVTVSS (SEQ ID NO:93); and the V.sub.L2 domain comprises the amino acid sequence of DIVMTQTPLSLSVTPGQPASISCKSSQSLVHQNATYLSWYLVQKPGQSPQSLIYKVSNRFGSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCGQGQTQYPFTFGSGTKVEIK (SEQ ID NO:95); and the V.sub.H3 domain comprises the amino acid sequence of EVQLVESGGGLVQPGGSLRLSCAASGFNIRDITYIHWRQAPGKQLEWVARIYPTQGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGEFGFYAMDYWGQGT LTVTVSS (SEQ ID NO:73), and the V.sub.L3 domain comprises the amino acid sequence of DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQKPGKAPKLLIYSASFLYSGVPSRFSGSRSGTDFTLTISLQPEDFATYYCQQHYTTPPTFGQGTKVEIK (SEQ ID NO:77).

131. The binding protein of claim 129, wherein the first polypeptide chain comprises the amino acid sequence of SEQ ID NO:104 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:104; the second polypeptide chain comprises the amino acid sequence of SEQ ID NO:105 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:105; the third polypeptide chain comprises the amino acid sequence of SEQ ID NO:106 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:106; and the fourth polypeptide chain comprises the amino acid sequence of SEQ ID NO:107 or an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:107.

132. The binding protein of claim 129, wherein L.sub.1, L.sub.2, L.sub.3 and L.sub.4 each independently comprise the sequence DKTHT (SEQ ID NO:66).

133. The binding protein of claim 129, wherein the hinge-C.sub.H2-C.sub.H3 domains of the second and the third polypeptide chains are human IgG4 hinge-C.sub.H2-C.sub.H3 domains, and wherein the hinge-C.sub.H2-C.sub.H3 domains each comprise amino acid substitutions at positions corresponding to positions 234 and 235 of human IgG4 according to EU Index, wherein the amino acid substitutions are F234A and L235A.

134. The binding protein of claim 129, wherein the hinge-C.sub.H2-C.sub.H3 domains of the second and the third polypeptide chains are human IgG4 hinge-C.sub.H2-C.sub.H3 domains, and wherein the hinge-C.sub.H2-C.sub.H3 domains each comprise amino acid substitutions at positions corresponding to positions 228 and 409 of human IgG4 according to EU Index, wherein the amino acid substitutions are S228P and R409K.

135. The binding protein of claim 129, wherein the hinge-C.sub.H2-C.sub.H3 domain of the second polypeptide chain comprises amino acid substitutions at positions corresponding to positions 349, 366, 368, and 407 of human IgG1 or IgG4 according to EU Index, wherein the amino acid substitutions are Y349C, T366S, L368A, and Y407V; and wherein the hinge-C.sub.H2-C.sub.H3 domain of the third polypeptide chain comprises amino acid substitutions at positions corresponding to positions 354 and 366 of human IgG1 or IgG4 according to EU Index, wherein the amino acid substitutions are S354C and T366W.

136. The binding protein of claim 129, wherein the hinge-C.sub.H2-C.sub.H3 domain of the second polypeptide chain comprises amino acid substitutions at positions corresponding to positions 354 and 366 of human IgG1 or IgG4 according to EU Index, wherein the amino acid substitutions are S354C and T366W; and wherein the hinge-C.sub.H2-C.sub.H3 domain of the third polypeptide chain comprises amino acid substitutions at positions corresponding to positions 349, 366, 368, and 407 of human IgG1 or IgG4 according to EU Index, wherein the amino acid substitutions are Y349C, T366S, L368A, and Y407V.
